02383000000000493000450099100020000070000020000270600020000470100020000609100090
00081300020000171510021000370350010000584800034000680300021001029300005001231170
00800128085000500136935001000141031000300151032000200154036000600156042000200162
20000020016406500090016612200030017504800140017804800140019204800240020604900260
02300490026002560490033002820490033003150490034003480490031003820490033004130490
03500446043007200481043007200553043007200625540038800697540040201085540039601487
541000601883#1#0#i#1#20100917#Jornal de Pediatria#J. Pediatr. (Rio J.)#0021-7557
#Sociedade Brasileira de Pediatria#J. Pediatr. (Rio J.)#JPED#vancouv#decs#0021-7
557#86#4#20104#1#0#20100800#16#^les^hSumario#^lpt^hSumário#^len^hTable of Conten
ts#^lpt^cJPED010^tEditoriais#^len^cJPED010^tEditorials#^lpt^cJPED030^tArtigos Or
iginais#^len^cJPED030^tOriginal Articles#^lpt^cJPED100^tArtigos de Revisão#^len^
cJPED100^tReview Articles#^lpt^cJPED160^tComunicação Breve#^len^cJPED160^tBrief 
Communication#^les^tJ. Pediatr. (Rio J.)^vvol.86^nno.4^cPorto Alegre^mjul./ago.^
a2010#^lpt^tJ. Pediatr. (Rio J.)^vvol.86^nno.4^cPorto Alegre^mjul./ago.^a2010#^l
en^tJ. Pediatr. (Rio J.)^vvol.86^nno.4^cPorto Alegre^mJuly/Aug.^a2010#^t<a rel="
license" href="http://creativecommons.org/licenses/by-nc/3.0/"><img alt="Creativ
e Commons License" style="border-width:0" src="http://i.creativecommons.org/l/by
-nc/3.0/80x15.png" /></a> Todo el contenido de esta revista, excepto dónde está 
identificado, est&#225; bajo una <a rel="license" href="http://creativecommons.o
rg/licenses/by-nc/3.0/">Licencia Creative Commons</a>^les#^t<a rel="license" hre
f="http://creativecommons.org/licenses/by-nc/3.0/"><img alt="Creative Commons Li
cense" style="border-width:0" src="http://i.creativecommons.org/l/by-nc/3.0/80x1
5.png" /></a> Todo o conteúdo deste periódico, exceto onde est&#225 identificado
, est&#225; licenciado sob uma <a rel="license" href="http://creativecommons.org
/licenses/by-nc/3.0/">Licen&#231;a Creative Commons</a>^lpt#^t<a rel="license" h
ref="http://creativecommons.org/licenses/by-nc/3.0/"><img alt="Creative Commons 
License" style="border-width:0" src="http://i.creativecommons.org/l/by-nc/3.0/80
x15.png" /></a> All the contents of this journal, except where otherwise noted, 
is licensed under a <a rel="license" href="http://creativecommons.org/licenses/b
y-nc/3.0/">Creative Commons Attribution License</a>^len#BY-NC##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v86n4#V:\Scielo\serial\jped\v86n4\markup\a01v86n4.htm#S#o#1#1#text#1#20
110126#175315#a01v86n4.htm#59##
00923000000000409000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030002100104
03100030012503200020012806500090013001400110013903500100015012300020016001200730
01620120062002350100036002970700065003330700092003981170008004900720002004980020
01300500#v86n4#V:\Scielo\serial\jped\v86n4\markup\a01v86n4.htm#S#h#2#1#text#1#ed
#pt#br1.1#1#4.0#ND#01#JPED010#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f255^l256#0
021-7557#1#Fator de impacto 2009: uma nova realidade para o Jornal de Pediatria^
lpt#2009 impact factor: a new reality for Jornal de Pediatria^len#^rND^1A01 A02^
nRenato S.^sProcianoy#Universidade Federal do Rio Grande do Sul^iA01^cPorto Aleg
re^sRS#UFRGS^iA02^1Hospital de Clínicas de Porto Alegre^2Serviço de Neonatologia
^cPorto Alegre^sRS#vancouv#8#a01v86n4.htm##
00951000000000409000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030002100104
03100030012503200020012806500090013001400110013903500100015012300020016001200870
01620120076002490100036003250700065003610700092004261170008005180720002005260020
01300528#v86n4#V:\Scielo\serial\jped\v86n4\markup\a01v86n4.htm#S#f#3#1#text#1#ed
#pt#br1.1#1#4.0#ND#01#JPED010#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f255^l256#0
021-7557#1#<b>Fator de impacto 2009</b>: <b>uma nova realidade para o Jornal de 
Pediatria</b>^lpt#<b>2009 impact factor</b>: <b>a new reality for Jornal de Pedi
atria</b>^len#^rND^1A01 A02^nRenato S.^sProcianoy#Universidade Federal do Rio Gr
ande do Sul^iA01^cPorto Alegre^sRS#UFRGS^iA02^1Hospital de Clínicas de Porto Ale
gre^2Serviço de Neonatologia^cPorto Alegre^sRS#vancouv#8#a01v86n4.htm##
01042000000000421000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030002100119
03100030014003200020014306500090014501400110015403500100016512300020017501200730
01770120062002500100035003120700067003470700094004141170008005080720002005160020
01300518008008900531#v86n4#V:\Scielo\serial\jped\v86n4\markup\a01v86n4.htm#S#l#4
#1#text#1#^mjul./ago.^a2010#ed#pt#br1.1#1#4.0#01#JPED010#nd#J. Pediatr. (Rio J.)
#86#4#20100800#^f255^l256#0021-7557#1#Fator de impacto 2009: uma nova realidade 
para o Jornal de Pediatria^lpt#2009 impact factor: a new reality for Jornal de P
ediatria^len#^rND^1A01 A02^nRenato S^sProcianoy#^iA01^1Universidade Federal do R
io Grande do Sul^cPorto Alegre^sRS#^iA02^1UFRGS^2Hospital de Clínicas de Porto A
legre^3Serviço de Neonatologia^cPorto Alegre^sRS#vancouv#8#a01v86n4.htm#Internet
^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572010000400001
##
00312000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704008300070002001300153#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#5#1#text#47#<p align="right"><font si
ze="2" face="Verdana"><b>EDITORIAL</b></font></p>     ^cY#a01v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#6#2#text#47#<p>&nbsp;</p>     ^cY#a01
v86n4.htm##
00360000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704013100070002001300201#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#7#3#text#47#<p><font size="4" face="V
erdana"><b>Fator de impacto 2009: uma nova realidade    para o Jornal de Pediatr
ia</b></font></p>     ^cY#a01v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#8#4#text#47#<p>&nbsp;</p>     ^cY#a01
v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#9#5#text#47#<p>&nbsp;</p>     ^cY#a01
v86n4.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704007900071002001300150#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#10#6#text#47#<p><font size="2" face="
Verdana"><b>Renato S. Procianoy</b></font></p>     ^cY#a01v86n4.htm##
00540000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704031000071002001300381#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#11#7#text#47#<p><font size="2" face="
Verdana">Professor titular, Pediatria, Universidade Federal    do Rio Grande do 
Sul (UFRGS), Porto Alegre, RS, Chefe, Servi&ccedil;o de Neonatologia,    Hospita
l de Cl&iacute;nicas de Porto Alegre (HCPA), UFRGS, Porto Alegre, RS,    Editor-
Chefe, Jornal de Pediatria</font></p>     ^cY#a01v86n4.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704012300071002001300194#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#12#8#text#47#<p><font size="2" face="
Verdana"><a name="topo"></a><a href="#correspondence">Correspond&ecirc;ncia</a><
/font></p>     ^cY#a01v86n4.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#13#9#text#47#<p>&nbsp;</p>     ^cY#a0
1v86n4.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#14#10#text#47#<p>&nbsp;</p>     ^cY#a
01v86n4.htm##
00905000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704067400072002001300746#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#15#11#text#47#<p><font face="Verdana"
 size="2">A edi&ccedil;&atilde;o de um peri&oacute;dico    m&eacute;dico cient&i
acute;fico &eacute; uma tarefa dif&iacute;cil. Existem    dois clientes a serem 
atendidos, leitores e autores, sendo que os interesses    e objetivos de ambos f
requentemente s&atilde;o n&atilde;o coincidentes. Os leitores,    cl&iacute;nico
s ou pesquisadores, desejam artigos que lhes possam ser &uacute;teis.    Por out
ro lado, os autores querem ter seus artigos publicados em revistas com    grande
 visibilidade e reconhecimento cient&iacute;fico, o que possibilitar&aacute;    
uma ampla divulga&ccedil;&atilde;o de suas investiga&ccedil;&otilde;es.</font></
p>     ^cY#a01v86n4.htm##
02207000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704197600072002001302048#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#16#12#text#47#<p><font face="Verdana"
 size="2">Tendo em vista essa situa&ccedil;&atilde;o, como    avaliar a import&a
circ;ncia de um peri&oacute;dico m&eacute;dico cient&iacute;fico    no mundo atu
al? O que julgar como importante? Algumas respostas poss&iacute;veis    incluem 
o n&uacute;mero de exemplares em cada tiragem, o n&uacute;mero de acessos    on-
line, o impacto que os artigos publicados naquele peri&oacute;dico causam    sob
re a pr&aacute;tica m&eacute;dica di&aacute;ria ou o n&uacute;mero de vezes    q
ue os artigos daquele peri&oacute;dico s&atilde;o citados por outros artigos.   
 Imagina-se que todos os crit&eacute;rios citados sejam importantes. Entretanto,
    alguns &oacute;bices ocorrem. O n&uacute;mero de exemplares em cada tiragem 
   &eacute; uma medida que est&aacute; em extin&ccedil;&atilde;o. Muitos peri&oa
cute;dicos    s&atilde;o disponibilizados somente on-line, e a tend&ecirc;ncia f
utura &eacute;    que existam menos revistas impressas em virtude dos altos cust
os da impress&atilde;o    e distribui&ccedil;&atilde;o e da quest&atilde;o ecol&
oacute;gica. A contabiliza&ccedil;&atilde;o    dos acessos on-line &eacute; de d
if&iacute;cil controle, e as informa&ccedil;&otilde;es    obtidas nem sempre s&a
tilde;o confi&aacute;veis. Al&eacute;m disso, a popula&ccedil;&atilde;o    que a
cessa as revistas on-line &eacute; muito heterog&ecirc;nea e nem sempre    &eacu
te; o principal alvo dos autores que publicam naquele peri&oacute;dico.    O imp
acto sobre a pr&aacute;tica di&aacute;ria dos artigos publicados &eacute;    ime
nsur&aacute;vel e muitas vezes ocorre num per&iacute;odo n&atilde;o imediato    
ao da publica&ccedil;&atilde;o. Dessa forma, no mundo atual, a &uacute;nica    m
edida confi&aacute;vel existente que apresenta resultado em curto prazo &eacute;
    o n&uacute;mero de cita&ccedil;&otilde;es dos artigos publicados por um peri
&oacute;dico    feitas por outros artigos cient&iacute;ficos. Isso se chama fato
r de impacto.</font></p>     ^cY#a01v86n4.htm##
01066000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704083500072002001300907#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#17#13#text#47#<p><font face="Verdana"
 size="2">O fator de impacto &eacute; definido como a raz&atilde;o    entre o n&
uacute;mero de cita&ccedil;&otilde;es, em um dado ano, de artigos    publicados 
em uma revista nos 2 anos precedentes e o n&uacute;mero total de    artigos publ
icados na mesma revista nesses 2 anos. Assim, a an&aacute;lise do    fator de im
pacto permite medir a import&acirc;ncia dos artigos publicados em    uma revista
 em um per&iacute;odo de tempo de 2 anos ap&oacute;s a sua publica&ccedil;&atild
e;o.    Apesar de muito criticado, o fator de impacto ainda &eacute; muito utili
zado    na avalia&ccedil;&atilde;o de um peri&oacute;dico cient&iacute;fico<SUP>
1</SUP>:    quanto mais alto &eacute; o fator de impacto, maior &eacute; o prest
&iacute;gio    da revista na comunidade cient&iacute;fica internacional.</font><
/p>     ^cY#a01v86n4.htm##
00656000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704042500072002001300497#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#18#14#text#47#<p><font face="Verdana"
 size="2">Em 2007, ao anunciar que o Jornal de Pediatria    estava sendo inclu&i
acute;do na base dados da Thomson Reuters (ISI) e que passaria    a ter seu fato
r de impacto medido, salientei que o fator de impacto do Jornal    de Pediatria 
permitiria avaliar a import&acirc;ncia da produ&ccedil;&atilde;o    cient&iacute
;fica brasileira no cen&aacute;rio internacional2<SUP>2</SUP>.</font></p>     ^c
Y#a01v86n4.htm##
00794000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704056300072002001300635#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#19#15#text#47#<p><font face="Verdana"
 size="2">O fator de impacto &eacute; divulgado no Journal    Citation Reports (
JCR), que engloba mais de 10.000 peri&oacute;dicos de ci&ecirc;ncias    e ci&eci
rc;ncias sociais. Na &aacute;rea m&eacute;dica cl&iacute;nica, est&atilde;o    i
nclu&iacute;dos 17 peri&oacute;dicos brasileiros; na &aacute;rea pedi&aacute;tri
ca,    est&atilde;o indexados 94 peri&oacute;dicos, de pelo menos 16 pa&iacute;s
es    diferentes, sendo que o Jornal de Pediatria &eacute; a &uacute;nica revist
a    pedi&aacute;trica latino-americana.</font></p>     ^cY#a01v86n4.htm##
00839000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704060800072002001300680#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#20#16#text#47#<p><font face="Verdana"
 size="2">O primeiro fator de impacto do Jornal de Pediatria    (fator de impact
o de 2009), divulgado no final de junho de 2010, &eacute; de    1,382, o que col
oca o nosso peri&oacute;dico na 48ª posi&ccedil;&atilde;o entre    os peri&oacut
e;dicos pedi&aacute;tricos internacionais e na quarta posi&ccedil;&atilde;o    e
ntre os peri&oacute;dicos m&eacute;dicos cl&iacute;nicos brasileiros. Esse    fa
to comprova a pujan&ccedil;a da pesquisa m&eacute;dica brasileira, em especial  
  a pedi&aacute;trica, como j&aacute; havia sido reportado anteriormente<SUP>3</
SUP>.</font></p>     ^cY#a01v86n4.htm##
01206000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704097500072002001301047#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#21#17#text#47#<p><font face="Verdana"
 size="2">Uma das raz&otilde;es do sucesso do Jornal de    Pediatria &eacute; a 
diversidade dos artigos publicados. Os temas abordados    nos artigos publicados
 no nosso peri&oacute;dico incluem desde cuidados prim&aacute;rios,    como alei
tamento materno, at&eacute; pesquisa translacional, assim como estudos    observ
acionais e cl&iacute;nicos randomizados<SUP>4-7</SUP>. Nosso &uacute;nico    com
prometimento tem sido sempre com a qualidade cient&iacute;fica do material    ac
eito para publica&ccedil;&atilde;o. Estamos cumprindo o compromisso assumido    
quando fui empossado como editor do Jornal de Pediatria, em mar&ccedil;o de    2
002, quando foi dito que o Jornal de Pediatria deveria fazer a ponte entre    a 
pesquisa b&aacute;sica e a pr&aacute;tica cl&iacute;nica na &aacute;rea pedi&aac
ute;trica,    trazendo sempre novos conhecimentos e procurando informar o leitor
 sobre o que    h&aacute; de mais atual<SUP>8</SUP>.</font></p>     ^cY#a01v86n4
.htm##
01116000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704088500072002001300957#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#22#18#text#47#<p><font face="Verdana"
 size="2">Esse excelente resultado se deve ao trabalho    e empenho de in&uacute
;meras pessoas: dos editores associados e executivos,    que tiveram participa&c
cedil;&atilde;o ativa ao longo dos anos; do Conselho    Editorial, que sempre re
spondeu prontamente &agrave;s nossas demandas; dos presidentes    da Sociedade B
rasileira de Pediatria Lincoln Marcelo Silveira Freire, Diocl&eacute;cio    Camp
os Jr. e Eduardo da Silva Vaz, que sempre nos apoiaram em todas as decis&otilde;
es;    da diretoria da Sociedade Brasileira de Pediatria, que deu o suporte nece
ss&aacute;rio    ao desenvolvimento da revista; dos revisores independentes dos 
artigos, que    sempre responderam &agrave; solicita&ccedil;&atilde;o de colabor
a&ccedil;&atilde;o;    e, em especial, dos pesquisadores, que submeteram excelen
tes artigos para publica&ccedil;&atilde;o.</font></p>     ^cY#a01v86n4.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704019900072002001300271#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#23#19#text#47#<p><font face="Verdana"
 size="2">Dessa forma, espera-se que o crescimento cient&iacute;fico    e o reco
nhecimento internacional do Jornal de Pediatria estejam apenas se iniciando.</fo
nt></p>     ^cY#a01v86n4.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#24#20#text#47#<p>&nbsp;</p>     ^cY#a
01v86n4.htm##
00308000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007700072002001300149#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#25#21#text#47#<p><font size="3" face=
"Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#a01v86n4.htm##
00378000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704013300074002001300207#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a01v86n4.htm#S#p#26#22#text#47#1#<p><font 
size="2" face="Verdana">1. Garfield E. The history and meaning of the    journal
 impact factor. JAMA. 2006;295:90-3.    ^cY#a01v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#27#23#text#47#</font></p>     ^cY#a01
v86n4.htm##
00370000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704012500074002001300199#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a01v86n4.htm#S#p#28#24#text#47#2#<p><font 
size="2" face="Verdana">2. Procianoy RS. The journal impact factor today.    J P
ediatr (Rio J). 2007;83:487.    ^cY#a01v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#29#25#text#47#</font></p>     ^cY#a01
v86n4.htm##
00387000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704014200074002001300216#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a01v86n4.htm#S#p#30#26#text#47#3#<p><font 
size="2" face="Verdana">3. Piccoli N, Procianoy RS. Brazilian scientific    jour
nals: an overview. Eur Sci Edit 2007;33:73-4.    ^cY#a01v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#31#27#text#47#</font></p>     ^cY#a01
v86n4.htm##
00465000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704022000074002001300294#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a01v86n4.htm#S#p#32#28#text#47#4#<p><font 
size="2" face="Verdana">4. Parizoto GM, Parada CM, Ven&acirc;ncio SI,    Carvalh
aes MA. Trends and patterns of exclusive breastfeeding for under-6-month-old    
children. J Pediatr (Rio J). 2009;85:201-8.    ^cY#a01v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#33#29#text#47#</font></p>     ^cY#a01
v86n4.htm##
00475000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704023000074002001300304#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a01v86n4.htm#S#p#34#30#text#47#5#<p><font 
size="2" face="Verdana">5. Passoni CR, Coelho CA. Ascorbic acid supplementation 
   has a cytoprotective effect on secondary biliary cirrhosis: experimental stud
y    in young rats. J Pediatr (Rio J). 2008;84:522-8.    ^cY#a01v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#35#31#text#47#</font></p>     ^cY#a01
v86n4.htm##
00532000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704028700074002001300361#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a01v86n4.htm#S#p#36#32#text#47#6#<p><font 
size="2" face="Verdana">6. Almeida MF, Guinsburg R, Martinez FE, Procianoy    RS
, Leone CR, Marba ST, et al. Perinatal factors associated with early deaths    o
f preterm infants born in Brazilian Network on Neonatal Research centers. J    P
ediatr (Rio J). 2008;84:300-7.    ^cY#a01v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#37#33#text#47#</font></p>     ^cY#a01
v86n4.htm##
00557000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704031200074002001300386#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a01v86n4.htm#S#p#38#34#text#47#7#<p><font 
size="2" face="Verdana">7. Moraes MA, Bonatto RC, Carpi MF, Ricchetti    SM,&nbs
p; Padovani CR,&nbsp; Fioretto JR. Comparison between intermittent mandatory    
ventilation and synchronized intermittent mandatory ventilation with pressure   
 support in children. J Pediatr (Rio J). 2009;85:15-20.    ^cY#a01v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#39#35#text#47#</font></p>     ^cY#a01
v86n4.htm##
00359000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704011400074002001300188#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a01v86n4.htm#S#p#40#36#text#47#8#<p><font 
size="2" face="Verdana">8. Procianoy RS. Commitment to quality. J Pediatr    (Ri
o J). 2002;78:83.    ^cY#a01v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#41#37#text#47#</font></p>     ^cY#a01
v86n4.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#42#38#text#47#<p>&nbsp;</p>     ^cY#a
01v86n4.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#43#39#text#47#<p>&nbsp;</p>     ^cY#a
01v86n4.htm##
00411000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704018000072002001300252#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#44#40#text#47#<p><font size="2" face=
"Verdana"><a name="correspondence"></a><a href="#topo"><img src="/img/revistas/j
ped/v86n4/seta.gif" border="0"></a>    <b> Correspond&ecirc;ncia:</b>    ^cY#a01
v86n4.htm##
00265000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003400072002001300106#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#45#41#text#47#<br>   Renato S. Procia
noy    ^cY#a01v86n4.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004100072002001300113#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#46#42#text#47#<BR>   Rua Silva Jardim
, 1155/701    ^cY#a01v86n4.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704004700072002001300119#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#47#43#text#47#<BR>   CEP 90450-071 - 
Porto Alegre, RS    ^cY#a01v86n4.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704009700072002001300169#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#48#44#text#47#<BR>   E-mail: <A href=
mailto:renatosp@terra.com.br>renatosp@terra.com.br</A></font></p>     ^cY#a01v86
n4.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#49#45#text#47#<p>&nbsp;</p>     ^cY#a
01v86n4.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#50#46#text#47#<p>&nbsp;</p>     ^cY#a
01v86n4.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704019200072002001300264#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a01v86n4.htm#S#p#51#47#text#47#<p><font size="2" face=
"Verdana">Conflitos de interesse: N&atilde;o foram declarados    conflitos de in
teresse associados &agrave; publica&ccedil;&atilde;o deste editorial.</font></p>
     ^cY#a01v86n4.htm##
00480000000000265000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100019000720120058000910300
00500149065000900154064000500163031000400168014000500172865000900177002001300186
035001000199801000500209#v86n4#V:\Scielo\serial\jped\v86n4\markup\a01v86n4.htm#S
#c#52#1#text#8#1#^rND^sGarfield^nE.#The history and meaning of the journal impac
t factor.^len#JAMA#20060000#2006#295#90-3#20100800#a01v86n4.htm#0098-7484#JAMA##
00483000000000265000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100020000720120036000920300
01800128065000900146064000500155031000300160014000400163865000900167002001300176
035001000189801001800199#v86n4#V:\Scielo\serial\jped\v86n4\markup\a01v86n4.htm#S
#c#53#2#text#8#2#^rND^sProcianoy^nRS#The journal impact factor today^len#J Pedia
tr (Rio J)#20070000#2007#83#487#20100800#a01v86n4.htm#0021-7557#J Pediatr (Rio J
)##
00481000000000265000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100017000720100020000890120
04700109030001300156710000200169065000900171064000500180031000300185014000500188
865000900193002001300202#v86n4#V:\Scielo\serial\jped\v86n4\markup\a01v86n4.htm#S
#c#54#3#text#8#3#^rND^sPiccoli^nN#^rND^sProcianoy^nRS#Brazilian scientific journ
als: an overview^len#Eur Sci Edit#2#20070000#2007#33#73-4#20100800#a01v86n4.htm#
#
00623000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100019000720100017000910100
01900108010002100127012008200148030001800230065000900248064000500257031000300262
014000600265865000900271002001300280035001000293801001800303#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a01v86n4.htm#S#c#55#4#text#8#4#^rND^sParizoto^nGM#^rND^sPa
rada^nCM#^rND^sVenâncio^nSI#^rND^sCarvalhaes^nMA#Trends and patterns of exclusiv
e breastfeeding for under-6-month-old children^len#J Pediatr (Rio J)#20090000#20
09#85#201-8#20100800#a01v86n4.htm#0021-7557#J Pediatr (Rio J)##
00603000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100018000720100017000900120
12700107030001800234065000900252064000500261031000300266014000600269865000900275
002001300284035001000297801001800307#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
1v86n4.htm#S#c#56#5#text#8#5#^rND^sPassoni^nCR#^rND^sCoelho^nCA#Ascorbic acid su
pplementation has a cytoprotective effect on secondary biliary cirrhosis: experi
mental study in young rats^len#J Pediatr (Rio J)#20080000#2008#84#522-8#20100800
#a01v86n4.htm#0021-7557#J Pediatr (Rio J)##
00740000000000337000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100018000720100019000900100
01900109010002000128010001600148010001600164810000600180012012500186030001800311
06500090032906400050033803100030034301400060034686500090035200200130036103500100
0374801001800384#v86n4#V:\Scielo\serial\jped\v86n4\markup\a01v86n4.htm#S#c#57#6#
text#8#6#^rND^sAlmeida^nMF#^rND^sGuinsburg^nR#^rND^sMartinez^nFE#^rND^sProcianoy
^nRS#^rND^sLeone^nCR#^rND^sMarba^nST#et al#Perinatal factors associated with ear
ly deaths of preterm infants born in Brazilian Network on Neonatal Research cent
ers^len#J Pediatr (Rio J)#20080000#2008#84#300-7#20100800#a01v86n4.htm#0021-7557
#J Pediatr (Rio J)##
00742000000000325000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100017000720100018000890100
01600107010002000123010001900143010001900162012014400181030001800325065000900343
06400050035203100030035701400060036086500090036600200130037503500100038880100180
0398#v86n4#V:\Scielo\serial\jped\v86n4\markup\a01v86n4.htm#S#c#58#7#text#8#7#^rN
D^sMoraes^nMA#^rND^sBonatto^nRC#^rND^sCarpi^nMF#^rND^sRicchetti^nSM#^rND^sPadova
ni^nCR#^rND^sFioretto^nJR#Comparison between intermittent mandatory ventilation 
and synchronized intermittent mandatory ventilation with pressure support in chi
ldren^len#J Pediatr (Rio J)#20090000#2009#85#15-20#20100800#a01v86n4.htm#0021-75
57#J Pediatr (Rio J)##
00472000000000265000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100020000720120026000920300
01800118065000900136064000500145031000300150014000300153865000900156002001300165
035001000178801001800188#v86n4#V:\Scielo\serial\jped\v86n4\markup\a01v86n4.htm#S
#c#59#8#text#8#8#^rND^sProcianoy^nRS#Commitment to quality^len#J Pediatr (Rio J)
#20020000#2002#78#83#20100800#a01v86n4.htm#0021-7557#J Pediatr (Rio J)##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v86n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#o#1#1#text#1#20
110126#175320#a02v86n4.htm#93##
00855000000000397000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000400087121000300091049000800094158000300102030002100105
03100030012603200020012906500090013101400110014003500100015112300020016101200780
0163012008000241010002500321070008700346117000800433072000300441002001300444#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#h#2#1#text#1#ed#pt#br1.1#1#
4.0#TAB#02#JPED010#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f256^l258#0021-7557#1#
Assistência médica de qualidade para a anemia falciforme: já chegamos lá?^lpt#To
ward high quality medical care for sickle cell disease: are we there yet?^len#^r
ND^1A01^nJane^sHankins#St. Jude Children's Research Hospital^iA01^1Department of
 Hematology^cMemphis^sTN^pEUA#vancouv#19#a02v86n4.htm##
00883000000000397000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000400087121000300091049000800094158000300102030002100105
03100030012603200020012906500090013101400110014003500100015112300020016101200920
0163012009400255010002500349070008700374117000800461072000300469002001300472#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#f#3#1#text#1#ed#pt#br1.1#1#
4.0#TAB#02#JPED010#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f256^l258#0021-7557#1#
<b>Assistência médica de qualidade para a anemia falciforme</b>: <b>já chegamos 
lá?</b>^lpt#<b>Toward high quality medical care for sickle cell disease</b>: <b>
are we there yet?</b>^len#^rND^1A01^nJane^sHankins#St. Jude Children's Research 
Hospital^iA01^1Department of Hematology^cMemphis^sTN^pEUA#vancouv#19#a02v86n4.ht
m##
00988000000000421000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101038000400105121000300109049000800112158000300120
03000210012303100030014403200020014706500090014901400110015803500100016912300020
01790120078001810120080002590100025003390700089003641170008004530720003004610020
01300464008008900477#v86n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#l#4
#1#text#1#^mjul./ago.^a2010#ed#pt#br1.1#1#4.0#tab#02#JPED010#nd#J. Pediatr. (Rio
 J.)#86#4#20100800#^f256^l258#0021-7557#1#Assistência médica de qualidade para a
 anemia falciforme: já chegamos lá?^lpt#Toward high quality medical care for sic
kle cell disease: are we there yet?^len#^rND^1A01^nJane^sHankins#^iA01^1St. Jude
 Children's Research Hospital^2Department of Hematology^cMemphis^sTN^pEUA#vancou
v#19#a02v86n4.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&p
id=S0021-75572010000400002##
00312000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704008300070002001300153#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#5#1#text#70#<p align="right"><font si
ze="2" face="Verdana"><b>EDITORIAL</b></font></p>     ^cY#a02v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#6#2#text#70#<p>&nbsp;</p>     ^cY#a02
v86n4.htm##
00389000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704016000070002001300230#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#7#3#text#70#<p><font size="4" face="V
erdana"><b>Assist&ecirc;ncia m&eacute;dica de qualidade para a anemia falciforme
: j&aacute; chegamos l&aacute;?</b></font></p>     ^cY#a02v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#8#4#text#70#<p>&nbsp;</p>     ^cY#a02
v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#9#5#text#70#<p>&nbsp;</p>     ^cY#a02
v86n4.htm##
00302000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704007200071002001300143#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#10#6#text#70#<p><font size="2" face="
Verdana"><b>Jane Hankins</b></font></p>     ^cY#a02v86n4.htm##
00393000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704016300071002001300234#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#11#7#text#70#<p><font size="2" face="
Verdana">MD, MS, Assistant member, Department of Hematology,    St. Jude Childre
n's Research Hospital, Memphis, TN, EUA</font></p>     ^cY#a02v86n4.htm##
00363000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704013300071002001300204#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#12#8#text#70#<p><font size="2" face="
Verdana"><a name="topo" id="topo"></a><a href="#correspondence">Correspond&ecirc
;ncia</a></font></p>     ^cY#a02v86n4.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#13#9#text#70#<p>&nbsp;</p>     ^cY#a0
2v86n4.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#14#10#text#70#<p>&nbsp;</p>     ^cY#a
02v86n4.htm##
01248000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704101700072002001301089#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#15#11#text#70#<P><font face="Verdana"
 size="2">A anemia falciforme, um dos dist&uacute;rbios    de um &uacute;nico ge
ne mais comuns no mundo, afeta aproximadamente 280.000    nascidos vivos por ano
 em todo o mundo. Essa doen&ccedil;a e a talassemia juntas    s&atilde;o respons
&aacute;veis por 3,4% de todas as mortes de crian&ccedil;as    menores de 5 anos
<SUP>1</SUP>. Beb&ecirc;s falc&ecirc;micos t&ecirc;m risco    particularmente au
mentado de morte prematura por causa da perda precoce da fun&ccedil;&atilde;o   
 filtradora do ba&ccedil;o<SUP>2,3</SUP>. Isso coloca esses beb&ecirc;s vulner&a
acute;veis    em alto risco de adquirirem infec&ccedil;&otilde;es invasivas caus
adas por organismos    encapsulados, especialmente o pneumococo. Al&eacute;m dis
so, o sequestro espl&ecirc;nico    &eacute; uma importante complica&ccedil;&atil
de;o relacionada &agrave; anemia    falciforme, que, se n&atilde;o reconhecida e
 tratada precocemente, pode levar    a colapso circulat&oacute;rio e &oacute;bit
o<SUP>4</SUP>.</font></P>     ^cY#a02v86n4.htm##
01665000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704143400072002001301506#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#16#12#text#70#<P><font face="Verdana"
 size="2">Apesar do risco aumentado de complica&ccedil;&otilde;es    fatais no i
n&iacute;cio da vida, as taxas de mortalidade de pacientes com anemia    falcifo
rme diminu&iacute;ram significativamente nas &uacute;ltimas 4 d&eacute;cadas.   
 A redu&ccedil;&atilde;o mais significativa ocorreu nos primeiros 5 anos de vida
,    com uma mudan&ccedil;a cont&iacute;nua em dire&ccedil;&atilde;o &agrave; mo
rtalidade    mais tardia<SUP>5</SUP>. Essa tend&ecirc;ncia importante de sobrevi
da aumentada    entre crian&ccedil;as pode ser atribu&iacute;da a medidas simple
s, como diagn&oacute;stico    precoce, seguido de tratamento profil&aacute;tico 
e orienta&ccedil;&atilde;o    antecipat&oacute;ria. O primeiro e mais fundamenta
l desses passos &eacute; a    implementa&ccedil;&atilde;o de programas de triage
m neonatal. A identifica&ccedil;&atilde;o    de uma popula&ccedil;&atilde;o jove
m em risco permitiu o uso direcionado de    penicilina profil&aacute;tica e imun
iza&ccedil;&atilde;o especial com vacina&ccedil;&atilde;o    contra <i>Streptoco
ccus pneumoniae</i>, <i>Haemophilus influenzae</i> e <i>Meningococcus    meningi
tidis</i>. Essas estrat&eacute;gias b&aacute;sicas de sa&uacute;de p&uacute;blic
a    tiveram um impacto positivo no desfecho global dos pacientes pedi&aacute;tr
icos    com anemia falciforme n&atilde;o somente nos EUA, mas tamb&eacute;m no r
esto    do mundo<SUP>6,7</SUP>.</font></P>     ^cY#a02v86n4.htm##
01603000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704137200072002001301444#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#17#13#text#70#<P><font face="Verdana"
 size="2">Estat&iacute;sticas recentes de uma coorte de    Dallas, Texas, EUA, m
ostram que as chances de crian&ccedil;as com anemia falciforme    morrerem antes
 dos 5 anos de idade s&atilde;o menores do que 1%<SUP>8</SUP>.    Isso represent
a uma grande mudan&ccedil;a se comparado aos anos 60 e 70, quando    n&atilde;o 
se esperava que muitas crian&ccedil;as com anemia falciforme chegassem    &agrav
e; idade adulta e o seu risco de sepse era de 20 a 30 vezes maior do que    aque
le da popula&ccedil;&atilde;o em geral<SUP>9,10</SUP>. Neste n&uacute;mero    do
 Jornal de Pediatria, Fernandes e seus colegas demonstram elegantemente que    a
 implementa&ccedil;&atilde;o de um programa de triagem neonatal organizado,    c
entralizado e bem elaborado, seguido do emprego diligente de padr&otilde;es    c
l&iacute;nicos b&aacute;sicos, &eacute; capaz de impactar e modificar o curso   
 natural da anemia falciforme em crian&ccedil;as jovens. As taxas de sobrevida  
  de crian&ccedil;as de Minas Gerais com anemia falciforme menores de 5 anos s&a
tilde;o    compar&aacute;veis &agrave;quelas da Am&eacute;rica do Norte, da Euro
pa e do    Caribe apesar da exist&ecirc;ncia relativamente recente do programa b
rasileiro    de triagem neonatal de hemoglobinopatias (<a href=/img/revistas/jpe
d/v86n4/4a02t1.gif>Tabela    1</a>)<SUP>11</SUP>.</font></P>     ^cY#a02v86n4.ht
m##
01761000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704153000072002001301602#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#18#14#text#70#<P align=left><font fac
e="Verdana" size="2"> No futuro, mais melhorias s&atilde;o    esperadas no progr
ama brasileiro de anemia falciforme. No estudo de Fernandes,    os autores desco
briram que a taxa de imuniza&ccedil;&atilde;o especial (vacinas    contra o pneu
mococo e o meningococo) era muito baixa entre os casos fatais (somente    40% da
s crian&ccedil;as que morreram haviam sido imunizadas), e, em 31% dos    pacient
es, a causa do &oacute;bito foi sequestro espl&ecirc;nico agudo. Isso    ressalt
a a necessidade de um maior esfor&ccedil;o para se alcan&ccedil;ar a    imuniza&
ccedil;&atilde;o total contra organismos encapsulados. Al&eacute;m disso,    mai
s investimento na educa&ccedil;&atilde;o dos familiares sobre as complica&ccedil
;&otilde;es    da anemia falciforme poderia ter prevenido os casos fatais de seq
uestro espl&ecirc;nico.    Uma maior &ecirc;nfase na educa&ccedil;&atilde;o dos 
profissionais de sa&uacute;de    que trabalham nas unidades b&aacute;sicas de sa
&uacute;de sobre a anemia falciforme    provavelmente melhoraria o desfecho de m
uitas outras crian&ccedil;as com anemia    falciforme. Considerando-se que 58% d
as fam&iacute;lias que perderam uma crian&ccedil;a    com anemia falciforme em M
inas Gerais tinham uma renda mensal de at&eacute;    R$ 100,00, a taxa de mortal
idade relativamente baixa observada no estudo de    Fernandes mostra que diagn&o
acute;stico adequado e assist&ecirc;ncia m&eacute;dica    podem prevenir a morta
lidade mesmo em um contexto de extrema pobreza.</font></P>     ^cY#a02v86n4.htm#
#
01406000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704117500072002001301247#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#19#15#text#70#<P><font face="Verdana"
 size="2">Outro potencial modificador da doen&ccedil;a    que pode ter um impact
o na sua hist&oacute;ria natural e reduzir a mortalidade    precoce &eacute; a t
erapia com hidroxiureia. A hidroxiureia parece ter prevenido    mortes entre adu
ltos com anemia falciforme nos EUA e na Gr&eacute;cia<SUP>12,13</SUP>.    Devido
 &agrave; facilidade de administra&ccedil;&atilde;o e ao baixo custo,    a terap
ia com hidroxiureia pode ser adotada e usada em pa&iacute;ses em desenvolvimento
.    A factibilidade do seu uso, incluindo o custo do monitoramento cont&iacute;
nuo    da toxicidade e da efic&aacute;cia, pode ser um problema para regi&otilde
;es    com poucos recursos, mas, com um planejamento adequado e a implementa&cce
dil;&atilde;o    de infraestrutura b&aacute;sica, pode ser feito. A terapia com 
hidroxiureia    tem o potencial de reduzir as taxas de mortalidade de crian&cced
il;as pequenas    com anemia falciforme por causa do poss&iacute;vel papel que e
xerce na prote&ccedil;&atilde;o    de &oacute;rg&atilde;os e do seu comprovado e
feito na redu&ccedil;&atilde;o    de epis&oacute;dios vaso-oclusivos agudos<SUP>
14,15</SUP>.</font></P>     ^cY#a02v86n4.htm##
01382000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704115100072002001301223#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#20#16#text#70#<P><font face="Verdana"
 size="2">Para finalizar, &eacute; importante notar que    a cria&ccedil;&atilde
;o de um programa que seja respons&aacute;vel por diagnosticar    e tratar a ane
mia falciforme de maneira bem-sucedida no contexto de uma economia    emergente 
exige esfor&ccedil;os substanciais de seus organizadores e apoio governamental  
  prolongado. Apesar dos obst&aacute;culos naturais para se estabelecer essa inf
raestrutura    m&eacute;dica, assim como o significativo baixo n&iacute;vel soci
oecon&ocirc;mico    da maioria dos pacientes, os &oacute;bitos podem ser preveni
dos e os desfechos    melhorados atrav&eacute;s dessa iniciativa. A experi&ecirc
;ncia do Brasil pode    servir como exemplo para muitos outros pa&iacute;ses em 
situa&ccedil;&atilde;o    socioecon&ocirc;mica parecida. Como profissionais resp
ons&aacute;veis pelo tratamento    da anemia falciforme, j&aacute; vencemos um l
ongo caminho, e, embora ainda n&atilde;o    tenhamos alcan&ccedil;ado a meta de 
excel&ecirc;ncia em cuidados m&eacute;dicos    para todos os pacientes com anemi
a falciforme, a estrada para diante pode ser    seguida com sucesso.</font></P> 
    ^cY#a02v86n4.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#21#17#text#70#<P>&nbsp;</P>     ^cY#a
02v86n4.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007400072002001300146#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#22#18#text#70#<P><font size="3" face=
"Verdana"><b>Agradecimentos</b></font></P>     ^cY#a02v86n4.htm##
00518000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704028700072002001300359#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#23#19#text#70#<P><font face="Verdana"
 size="2">A autora agradece ao Dr. Charles Quinn pelas    informa&ccedil;&otilde
;es adicionais sobre a sobrevida da Coorte Neonatal de    Dallas e aos Drs. Winf
red Wang e Vani Shanker pelos &uacute;teis coment&aacute;rios    sobre o editori
al.</font></p>      ^cY#a02v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#24#20#text#70#<p>&nbsp;</p>       ^cY
#a02v86n4.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007900072002001300151#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#25#21#text#70#<p><font size="3" face=
"Verdana"><b>Refer&ecirc;ncias</b></font></p>       ^cY#a02v86n4.htm##
00427000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704018200074002001300256#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#p#26#22#text#70#1#<p><font 
size="2" face="Verdana">1. Modell B, Darlison M. Global epidemiology of haemoglo
bin disorders and derived service indicators. Bull World Health Organ. 2008;86:4
80-7.    ^cY#a02v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#27#23#text#70#</font></p>         ^cY
#a02v86n4.htm##
00399000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704015400074002001300228#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#p#28#24#text#70#2#<p><font 
size="2" face="Verdana">2. Pearson HA, Spencer RP, Cornelius EA. Functional aspl
enia in sickle-cell anemia. N Engl J Med. 1969;281:923-6.    ^cY#a02v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#29#25#text#70#</font></p>         ^cY
#a02v86n4.htm##
00542000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704029700074002001300371#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#p#30#26#text#70#3#<p><font 
size="2" face="Verdana">3. Brown AK, Sleeper LA, Miller ST, Pegelow CH, Gill FM,
 Waclawiw MA. Reference values and hematologic changes from birth to 5 years in 
patients with sickle cell disease. Cooperative Study of Sickle Cell Disease. Arc
h Pediatr Adolesc Med. 1994;148:796-804.    ^cY#a02v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#31#27#text#70#</font></p>         ^cY
#a02v86n4.htm##
00443000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704019800074002001300272#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#p#32#28#text#70#4#<p><font 
size="2" face="Verdana">4. Kinney TR, Ware RE, Schultz WH, Filston HC. Long-term
 management of splenic sequestration in children with sickle cell disease. J Ped
iatr. 1990;117:194-9.    ^cY#a02v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#33#29#text#70#</font></p>         ^cY
#a02v86n4.htm##
00388000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704014300074002001300217#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#p#34#30#text#70#5#<p><font 
size="2" face="Verdana">5. Hassell KL. Population estimates of sickle cell disea
se in the U.S. Am J Prev Med. 2010;38:S512-21.    ^cY#a02v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#35#31#text#70#</font></p>         ^cY
#a02v86n4.htm##
00449000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704020400074002001300278#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#p#36#32#text#70#6#<p><font 
size="2" face="Verdana">6. King L, Fraser R, Forbes M, Grindley M, Ali S, Reid M
. Newborn sickle cell disease screening: the Jamaican experience (1995-2006). J 
Med Screen. 2007;14:117-22.    ^cY#a02v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#37#33#text#70#</font></p>         ^cY
#a02v86n4.htm##
00431000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704018600074002001300260#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#p#38#34#text#70#7#<p><font 
size="2" face="Verdana">7. Rahimy MC, Gangbo A, Ahouignan G, Alihonou E. Newborn
 screening for sickle cell disease in the Republic of Benin. J Clin Pathol. 2009
;62:46-8.    ^cY#a02v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002500072002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#39#35#text#70# </font></p>         ^c
Y#a02v86n4.htm##
00431000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704018600074002001300260#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#p#40#36#text#70#8#<p><font 
size="2" face="Verdana">8. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improve
d survival of children and adolescents with sickle cell disease. Blood. 2010;115
:3447-52.    ^cY#a02v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#41#37#text#70#</font></p>         ^cY
#a02v86n4.htm##
00381000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704013600074002001300210#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#p#42#38#text#70#9#<p><font 
size="2" face="Verdana">9. Kabins SA, Lerner C. Fulminant pneumococcemia and sic
kle cell anemia. JAMA. 1970;211:467-71.    ^cY#a02v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#43#39#text#70#</font></p>         ^cY
#a02v86n4.htm##
00392000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704014600075002001300221#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#p#44#40#text#70#10#<p><font
 size="2" face="Verdana">10. Robinson MG, Watson RJ. Pneumococcal meningitis in 
sickle-cell anemia. N Engl J Med. 1966;274:1006-8.    ^cY#a02v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#45#41#text#70#</font></p>         ^cY
#a02v86n4.htm##
00464000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704021800075002001300293#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#p#46#42#text#70#11#<p><font
 size="2" face="Verdana">11. Fernandes AP, Janu&aacute;rio JN, Cangussu CB, de M
acedo DL, Viana MB. Mortality of children with sickle cell disease: a population
 study. J Pediatr (Rio J). 2010;86:279-84.    ^cY#a02v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#47#43#text#70#</font></p>         ^cY
#a02v86n4.htm##
00513000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704026700075002001300342#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#p#48#44#text#70#12#<p><font
 size="2" face="Verdana">12. Steinberg MH, Barton F, Castro O, Pegelow CH, Balla
s SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult
 sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;2
89:1645-51.    ^cY#a02v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#49#45#text#70#</font></p>         ^cY
#a02v86n4.htm##
00582000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704033600075002001300411#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#p#50#46#text#70#13#<p><font
 size="2" face="Verdana">13. Voskaridou E, Christoulas D, Bilalis A, Plata E, Va
rvagiannis K, Stamatopoulos G, et al. The effect of prolonged administration of 
hydroxyurea on morbidity and mortality in adult patients with sickle cell syndro
mes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115:2354-63.
    ^cY#a02v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#51#47#text#70#</font></p>         ^cY
#a02v86n4.htm##
00551000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704030500075002001300380#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#p#52#48#text#70#14#<p><font
 size="2" face="Verdana">14. Charache S, Terrin ML, Moore RD, Dover GJ, Barton F
B, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in
 sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Si
ckle Cell Anemia. N Engl J Med. 1995;332:1317-22.    ^cY#a02v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#53#49#text#70#</font></p>         ^cY
#a02v86n4.htm##
00494000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704024800075002001300323#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#p#54#50#text#70#15#<p><font
 size="2" face="Verdana">15. Hankins JS, Helton KJ, McCarville MB, Li CS, Wang W
C, Ware RE. Preservation of spleen and brain function in children with sickle ce
ll anemia treated with hydroxyurea. Pediatr Blood Cancer. 2008;50:293-7.    ^cY#
a02v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#55#51#text#70#</font></p>         ^cY
#a02v86n4.htm##
00447000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704020100075002001300276#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#p#56#52#text#70#16#<p><font
 size="2" face="Verdana">16. Lee A, Thomas P, Cupidore L, Serjeant B, Serjeant G
. Improved survival in homozygous sickle cell disease: lessons from a cohort stu
dy. BMJ. 1995;311:1600-2.    ^cY#a02v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#57#53#text#70#</font></p>         ^cY
#a02v86n4.htm##
00459000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704021300075002001300288#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#p#58#54#text#70#17#<p><font
 size="2" face="Verdana">17. Powars DR, Chan LS, Hiti A, Ramicone E, Johnson C. 
Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients. 
Medicine (Baltimore). 2005;84:363-76.    ^cY#a02v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#59#55#text#70#</font></p>         ^cY
#a02v86n4.htm##
00511000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704026500075002001300340#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#p#60#56#text#70#18#<p><font
 size="2" face="Verdana">18. Gill FM, Sleeper LA, Weiner SJ, Brown AK, Bellevue 
R, Grover R, et al. Clinical events in the first decade in a cohort of infants w
ith sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood. 1995;8
6:776-83.    ^cY#a02v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#61#57#text#70#</font></p>         ^cY
#a02v86n4.htm##
00498000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000300072704025200075002001300327#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#p#62#58#text#70#19#<p><font
 size="2" face="Verdana">19. Telfer P, Coen P, Chakravorty S, Wilkey O, Evans J,
 Newell H, et al. Clinical outcomes in children with sickle cell disease living 
in England: a neonatal cohort in East London. Haematologica. 2007;92:905-12.    
^cY#a02v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#63#59#text#70#</font></p>     ^cY#a02
v86n4.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#64#60#text#70#<p>&nbsp;</p>     ^cY#a
02v86n4.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#65#61#text#70#<p>&nbsp;</p>     ^cY#a
02v86n4.htm##
00411000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704018000072002001300252#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#66#62#text#70#<p><font size="2" face=
"Verdana"><a name="correspondence"></a><a href="#topo"><img src="/img/revistas/j
ped/v86n4/seta.gif" border="0"></a>    <b> Correspond&ecirc;ncia:</b>    ^cY#a02
v86n4.htm##
00261000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003000072002001300102#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#67#63#text#70#<br>   Jane S. Hankins 
   ^cY#a02v86n4.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005200072002001300124#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#68#64#text#70#<BR>   St. Jude Childre
n's Research Hospital    ^cY#a02v86n4.htm##
00281000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704005000072002001300122#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#69#65#text#70#<BR>   262 Danny Thomas
 St., Mail Stop 800    ^cY#a02v86n4.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704003800072002001300110#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#70#66#text#70#<BR>   Memphis, TN 3810
5 - EUA    ^cY#a02v86n4.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704010100072002001300173#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#71#67#text#70#<BR>   E-mail: <A href=
mailto:jane.hankins@stjude.org>jane.hankins@stjude.org</A></font></p>     ^cY#a0
2v86n4.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#72#68#text#70#<p>&nbsp;</p>     ^cY#a
02v86n4.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#73#69#text#70#<p>&nbsp;</p>     ^cY#a
02v86n4.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704019200072002001300264#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a02v86n4.htm#S#p#74#70#text#70#<p><font size="2" face=
"Verdana">Conflitos de interesse: N&atilde;o foram declarados    conflitos de in
teresse associados &agrave; publica&ccedil;&atilde;o deste editorial.</font></p>
     ^cY#a02v86n4.htm##
00568000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100016000730100018000890120
08000107030002400187065000900211064000500220031000300225014000600228865000900234
002001300243035001000256801002400266#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
2v86n4.htm#S#c#75#1#text#19#1#^rND^sModell^nB#^rND^sDarlison^nM#Global epidemiol
ogy of haemoglobin disorders and derived service indicators^len#Bull World Healt
h Organ#20080000#2008#86#480-7#20100800#a02v86n4.htm#0042-9686#Bull World Health
 Organ##
00547000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100018000730100018000910100
02000109012004600129030001300175065000900188064000500197031000400202014000600206
865000900212002001300221035001000234801001300244#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a02v86n4.htm#S#c#76#2#text#19#2#^rND^sPearson^nHA#^rND^sSpencer^nRP#^r
ND^sCornelius^nEA#Functional asplenia in sickle-cell anemia^len#N Engl J Med#196
90000#1969#281#923-6#20100800#a02v86n4.htm#0028-4793#N Engl J Med##
00756000000000325000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100016000730100018000890100
01700107010001800124010001500142010001900157012014600176030002500322065000900347
06400050035603100040036101400080036586500090037300200130038203500100039580100250
0405#v86n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#c#77#3#text#19#3#^r
ND^sBrown^nAK#^rND^sSleeper^nLA#^rND^sMiller^nST#^rND^sPegelow^nCH#^rND^sGill^nF
M#^rND^sWaclawiw^nMA#Reference values and hematologic changes from birth to 5 ye
ars in patients with sickle cell disease. Cooperative Study of Sickle Cell Disea
se^len#Arch Pediatr Adolesc Med#19940000#1994#148#796-804#20100800#a02v86n4.htm#
1072-4710#Arch Pediatr Adolesc Med##
00606000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100017000730100015000900100
01800105010001800123012008700141030001000228065000900238064000500247031000400252
014000600256865000900262002001300271035001000284801001000294#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a02v86n4.htm#S#c#78#4#text#19#4#^rND^sKinney^nTR#^rND^sWar
e^nRE#^rND^sSchultz^nWH#^rND^sFilston^nHC#Long-term management of splenic seques
tration in children with sickle cell disease^len#J Pediatr#19900000#1990#117#194
-9#20100800#a02v86n4.htm#0022-3476#J Pediatr##
00470000000000253000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100019000730120060000920300
01500152710000200167065000900169064000500178031000300183014000800186865000900194
002001300203#v86n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#c#79#5#text
#19#5#^rND^sHassell^nKL.#Population estimates of sickle cell disease in the U.S.
^len#Am J Prev Med.#2#20100000#2010#38#S512-21#20100800#a02v86n4.htm##
00619000000000313000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100014000730100016000870100
01600103010001800119010001300137010001400150012007900164030001400243710000200257
065000900259064000500268031000300273014000700276865000900283002001300292#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#c#80#6#text#19#6#^rND^sKing^nL#
^rND^sFraser^nR#^rND^sForbes^nM#^rND^sGrindley^nM#^rND^sAli^nS#^rND^sReid^nM#New
born sickle cell disease screening: the Jamaican experience (1995-2006)^len#J Me
d Screen.#2#20070000#2007#14#117-22#20100800#a02v86n4.htm##
00565000000000289000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100017000730100016000900100
01900106010001800125012007100143030001500214710000200229065000900231064000500240
031000300245014000500248865000900253002001300262#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a02v86n4.htm#S#c#81#7#text#19#7#^rND^sRahimy^nMC#^rND^sGangbo^nA#^rND^
sAhouignan^nG#^rND^sAlihonou^nE#Newborn screening for sickle cell disease in the
 Republic of Benin^len#J Clin Pathol.#2#20090000#2009#62#46-8#20100800#a02v86n4.
htm##
00591000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100016000730100017000890100
01800106010002000124012007500144030000600219065000900225064000500234031000400239
014000800243865000900251002001300260035001000273801000600283#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a02v86n4.htm#S#c#82#8#text#19#8#^rND^sQuinn^nCT#^rND^sRoge
rs^nZR#^rND^sMcCavit^nTL#^rND^sBuchanan^nGR.#Improved survival of children and a
dolescents with sickle cell disease^len#Blood#20100000#2010#115#3447-52#20100800
#a02v86n4.htm#0006-4971#Blood##
00505000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080003000681180002000710100017000730100017000900120
05300107030000500160065000900165064000500174031000400179014000700183865000900190
002001300199035001000212801000500222#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
2v86n4.htm#S#c#83#9#text#19#9#^rND^sKabins^nSA#^rND^sLerner^nC.#Fulminant pneumo
coccemia and sickle cell anemia.^len#JAMA#19700000#1970#211#467-71#20100800#a02v
86n4.htm#0098-7484#JAMA##
00490000000000265000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100019000750100017000940120
05000111030001400161710000200175065000900177064000500186031000400191014000700195
865000900202002001300211#v86n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S
#c#84#10#text#19#10#^rND^sRobinson^nMG#^rND^sWatson^nRJ#Pneumococcal meningitis 
in sickle-cell anemia^len#N Engl J Med.#2#19660000#1966#274#1006-8#20100800#a02v
86n4.htm##
00646000000000313000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100020000750100019000950100
01900114010002000133010001600153012007100169030001800240065000900258064000500267
031000300272014000700275865000900282002001300291035001000304801001800314#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#c#85#11#text#19#11#^rND^sFernan
des^nAP#^rND^sJanuário^nJN#^rND^sCangussu^nCB#^rND^sde Macedo^nDL#^rND^sViana^nM
B#Mortality of children with sickle cell disease: a population study^len#J Pedia
tr (Rio J)#20100000#2010#86#279-84#20100800#a02v86n4.htm#0021-7557#J Pediatr (Ri
o J)##
00718000000000337000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100020000750100016000950100
01600111010001800127010001700145010001600162810000600178012012800184030000500312
06500090031706400050032603100040033101400080033586500090034300200130035203500100
0365801000500375#v86n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#c#86#12
#text#19#12#^rND^sSteinberg^nMH#^rND^sBarton^nF#^rND^sCastro^nO#^rND^sPegelow^nC
H#^rND^sBallas^nSK#^rND^sKutlar^nA#et al#Effect of hydroxyurea on mortality and 
morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treat
ment^len#JAMA#20030000#2003#289#1645-51#20100800#a02v86n4.htm#0098-7484#JAMA##
00788000000000337000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100020000750100021000950100
01700116010001500133010002200148010002300170810000600193012018100199030000600380
06500090038606400050039503100040040001400080040486500090041200200130042103500100
0434801000600444#v86n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#c#87#13
#text#19#13#^rND^sVoskaridou^nE#^rND^sChristoulas^nD#^rND^sBilalis^nA#^rND^sPlat
a^nE#^rND^sVarvagiannis^nK#^rND^sStamatopoulos^nG#et al#The effect of prolonged 
administration of hydroxyurea on morbidity and mortality in adult patients with 
sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)^len#Blo
od#20100000#2010#115#2354-63#20100800#a02v86n4.htm#0006-4971#Blood##
00732000000000325000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100018000750100017000930100
01600110010001600126010001700142010001700159810000600176012016000182030001400342
71000020035606500090035806400050036703100040037201400080037686500090038400200130
0393#v86n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#c#88#14#text#19#14#
^rND^sCharache^nS#^rND^sTerrin^nML#^rND^sMoore^nRD#^rND^sDover^nGJ#^rND^sBarton^
nFB#^rND^sEckert^nSV#et al#Effect of hydroxyurea on the frequency of painful cri
ses in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea
 in Sickle Cell Anemia^len#N Engl J Med.#2#19950000#1995#332#1317-22#20100800#a0
2v86n4.htm##
00663000000000313000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100018000750100017000930100
02100110010001300131010001500144010001500159012010700174030002100281710000200302
065000900304064000500313031000300318014000600321865000900327002001300336#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#c#89#15#text#19#15#^rND^sHankin
s^nJS#^rND^sHelton^nKJ#^rND^sMcCarville^nMB#^rND^sLi^nCS#^rND^sWang^nWC#^rND^sWa
re^nRE#Preservation of spleen and brain function in children with sickle cell an
emia treated with hydroxyurea^len#Pediatr Blood Cancer#2#20080000#2008#50#293-7#
20100800#a02v86n4.htm##
00623000000000313000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100013000750100016000880100
01800104010001800122010001900140012008500159030000400244065000900248064000500257
031000400262014000700266865000900273002001300282035001000295801000400305#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#c#90#16#text#19#16#^rND^sLee^nA
#^rND^sThomas^nP#^rND^sCupidore^nL#^rND^sSerjeant^nB#^rND^sSerjeant^nG.#Improved
 survival in homozygous sickle cell disease: lessons from a cohort study^len#BMJ
#19950000#1995#311#1600-2#20100800#a02v86n4.htm#0959-8138#BMJ##
00652000000000313000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100017000750100015000920100
01400107010001800121010001800139012008300157030002100240065000900261064000500270
031000300275014000700278865000900285002001300294035001000307801002100317#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#c#91#17#text#19#17#^rND^sPowars
^nDR#^rND^sChan^nLS#^rND^sHiti^nA#^rND^sRamicone^nE#^rND^sJohnson^nC.#Outcome of
 sickle cell anemia: a 4-decade observational study of 1056 patients^len#Medicin
e (Baltimore)#20050000#2005#84#363-76#20100800#a02v86n4.htm#0025-7974#Medicine (
Baltimore)##
00717000000000337000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100015000750100018000900100
01700108010001600125010001800141010001600159810000600175012013000181030000600311
06500090031706400050032603100030033101400070033486500090034100200130035003500100
0363801000600373#v86n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#c#92#18
#text#19#18#^rND^sGill^nFM#^rND^sSleeper^nLA#^rND^sWeiner^nSJ#^rND^sBrown^nAK#^r
ND^sBellevue^nR#^rND^sGrover^nR#et al#Clinical events in the first decade in a c
ohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Dise
ase^len#Blood#19950000#1995#86#776-83#20100800#a02v86n4.htm#0006-4971#Blood##
00712000000000337000450000400060000070200480000670500020005470600020005670000030
00587010003000617090005000647080003000691180003000720100016000750100014000910100
02100105010001600126010001500142010001600157810000600173012011100179030001400290
06500090030406400050031303100030031801400070032186500090032800200130033703500100
0350801001400360#v86n4#V:\Scielo\serial\jped\v86n4\markup\a02v86n4.htm#S#c#93#19
#text#19#19#^rND^sTelfer^nP#^rND^sCoen^nP#^rND^sChakravorty^nS#^rND^sWilkey^nO#^
rND^sEvans^nJ#^rND^sNewell^nH#et al#Clinical outcomes in children with sickle ce
ll disease living in England: a neonatal cohort in East London^len#Haematologica
#20070000#2007#92#905-12#20100800#a02v86n4.htm#0390-6078#Haematologica##
00271000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670910009000690920007000780020013000857030
00300098#v86n4#V:\Scielo\serial\jped\v86n4\markup\a03v86n4.htm#S#o#1#1#text#1#20
110126#175324#a03v86n4.htm#35##
00867000000000397000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030002100104
03100030012503200020012806500090013001400110013903500100015012300020016001200790
0162012006500241010003000306070011000336117000800446072000200454002001300456#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a03v86n4.htm#S#h#2#1#text#1#ed#pt#br1.1#1#
4.0#ND#03#JPED010#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f259^l260#0021-7557#1#D
iagnóstico de alergia intestinal ao leite de vaca, nunca uma tarefa fácil^lpt#Di
agnosis of cow milk allergy in the gut, never an easy task^len#^rND^1A01^nJon A.
^sVanderhoof#Harvard Medical School^iA01^1Children's Hospital^2Division of Gastr
oenterology and Nutrition^cBoston^sMA^pEUA#vancouv#4#a03v86n4.htm##
00881000000000397000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670710003000690400003000720010006000750420
00200081120000400083038000300087121000300090049000800093158000300101030002100104
03100030012503200020012806500090013001400110013903500100015012300020016001200860
0162012007200248010003000320070011000350117000800460072000200468002001300470#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a03v86n4.htm#S#f#3#1#text#1#ed#pt#br1.1#1#
4.0#ND#03#JPED010#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f259^l260#0021-7557#1#<
b>Diagnóstico de alergia intestinal ao leite de vaca, nunca uma tarefa fácil</b>
^lpt#<b>Diagnosis of cow milk allergy in the gut, never an easy task</b>^len#^rN
D^1A01^nJon A.^sVanderhoof#Harvard Medical School^iA01^1Children's Hospital^2Div
ision of Gastroenterology and Nutrition^cBoston^sMA^pEUA#vancouv#4#a03v86n4.htm#
#
00984000000000409000450000400060000070200480000670500020005470600020005670000020
00587010002000607090005000627080002000670640018000690710003000870400003000900010
00600093042000200099120000400101121000300105049000800108158000300116030002100119
03100030014003200020014306500090014501400110015403500100016512300020017501200790
01770120065002560100029003210700112003501170008004620720002004700020013004720080
08900485#v86n4#V:\Scielo\serial\jped\v86n4\markup\a03v86n4.htm#S#l#4#1#text#1#^m
jul./ago.^a2010#ed#pt#br1.1#1#4.0#03#JPED010#nd#J. Pediatr. (Rio J.)#86#4#201008
00#^f259^l260#0021-7557#1#Diagnóstico de alergia intestinal ao leite de vaca, nu
nca uma tarefa fácil^lpt#Diagnosis of cow milk allergy in the gut, never an easy
 task^len#^rND^1A01^nJon A^sVanderhoof#^iA01^1Harvard Medical School^2Children's
 Hospital^3Division of Gastroenterology and Nutrition^cBoston^sMA^pEUA#vancouv#4
#a03v86n4.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S
0021-75572010000400003##
00312000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704008300070002001300153#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#5#1#text#27#<p align="right"><font si
ze="2" face="Verdana"><b>EDITORIAL</b></font></p>     ^cY#a03v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#6#2#text#27#<p>&nbsp;</p>     ^cY#a03
v86n4.htm##
00377000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704014800070002001300218#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#7#3#text#27#<p><font size="4" face="V
erdana"><b>Diagn&oacute;stico de alergia intestinal ao leite de vaca, nunca uma 
tarefa f&aacute;cil</b></font></p>     ^cY#a03v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#8#4#text#27#<p>&nbsp;</p>     ^cY#a03
v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000500062708000300067704002200070002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#9#5#text#27#<p>&nbsp;</p>     ^cY#a03
v86n4.htm##
00307000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704007700071002001300148#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#10#6#text#27#<p><font size="2" face="
Verdana"><b>Jon A. Vanderhoof</b></font></p>     ^cY#a03v86n4.htm##
00395000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704016500071002001300236#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#11#7#text#27#<p><font size="2" face="
Verdana">MD, Division of Gastroenterology and Nutrition,    Children's Hospital,
 Harvard Medical School, Boston (MA), EUA</font></p>     ^cY#a03v86n4.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#12#8#text#27#<p>&nbsp;</p>     ^cY#a0
3v86n4.htm##
00252000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000500063708000300068704002200071002001300093#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#13#9#text#27#<p>&nbsp;</p>     ^cY#a0
3v86n4.htm##
01978000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704174700072002001301819#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#14#10#text#27#<p><font size="2" face=
"Verdana">O artigo de Lins et al.<SUP>1</SUP> &eacute; um estudo importante porq
ue ressalta v&aacute;rios fatores-chave da alergia &agrave; prote&iacute;na do l
eite de vaca. Os pesquisadores identificaram, com base na hist&oacute;ria, 66 pa
cientes com rea&ccedil;&otilde;es adversas &agrave; prote&iacute;na do leite de 
vaca. Essas rea&ccedil;&otilde;es inclu&iacute;am uma variedade de sintomas cut&
acirc;neos, gastrointestinais e sist&ecirc;micos. Mediram-se os n&iacute;veis de
 imunoglobulina E (IgE) s&eacute;rica total e espec&iacute;fica, incluindo antic
ase&iacute;na, anti &#946;-lactoglobulina e anti &#945;-lactalbumina. Os pacient
es foram orientados a seguir uma dieta de exclus&atilde;o do leite de vaca por p
elo menos 2 semanas, utilizando f&oacute;rmula de prote&iacute;na de soja. Ap&oa
cute;s a resolu&ccedil;&atilde;o dos sintomas, um teste de desafio com prote&iac
ute;na do leite de vaca foi realizado em ambiente hospitalar, com consultas sema
nais de acompanhamento por 4 semanas consecutivas ap&oacute;s o teste, per&iacut
e;odo durante o qual os pacientes continuaram a consumir leite de vaca. Aproxima
damente metade dos pacientes n&atilde;o apresentou rea&ccedil;&atilde;o positiva
 &agrave; prote&iacute;na do leite de vaca. Naqueles que tiveram rea&ccedil;&ati
lde;o positiva, uma rea&ccedil;&atilde;o tardia foi comum, ocorrendo em 77% dos 
casos. Os pacientes apresentaram rea&ccedil;&atilde;o at&eacute; a terceira sema
na de consumo de prote&iacute;na do leite de vaca. Os n&iacute;veis de IgE espec
&iacute;fica de duas subfra&ccedil;&otilde;es de prote&iacute;na de leite de vac
a foram elevados em somente uma porcentagem muito pequena dos pacientes com resu
ltado de teste positivo.</FONT></P>     ^cY#a03v86n4.htm##
01419000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704118800072002001301260#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#15#11#text#27#<P><font face="Verdana"
 size="2">A conclus&atilde;o &oacute;bvia do artigo &eacute;    que muitas crian
&ccedil;as nas quais se considera que os sintomas est&atilde;o    relacionados &
agrave; alergia ao leite de vaca provavelmente t&ecirc;m outras    causas para s
eus sintomas. Outras conclus&otilde;es n&atilde;o t&atilde;o &oacute;bvias,    m
as igualmente importantes, a serem lembradas incluem a observa&ccedil;&atilde;o 
   de que a maioria dos casos de alergia ao leite de vaca na primeira inf&acirc;
ncia    n&atilde;o &eacute; mediada pela IgE. Esse tipo de alergia &eacute; cara
cterizado    por hipersensibilidade tardia, como foi elegantemente exemplificado
 pela recidiva    bastante tardia dos sintomas ap&oacute;s o teste (at&eacute; 3
 semanas). Portanto,&nbsp;    n&atilde;o se pode diagnosticar ou excluir a alerg
ia ao leite de vaca de maneira    confi&aacute;vel com base em teste cut&acirc;n
eo ou dosagem dos anticorpos IgE    espec&iacute;fica em beb&ecirc;s e crian&cce
dil;as pequenas. Da mesma forma,    um teste oral deve ser realizado com um per&
iacute;odo prolongado de observa&ccedil;&atilde;o,    at&eacute; 4 semanas, como
 os autores demonstraram.</font></P>     ^cY#a03v86n4.htm##
00821000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704059000072002001300662#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#16#12#text#27#<P><font face="Verdana"
 size="2">Sabe-se que a alergia ao leite de vaca em beb&ecirc;s    tem uma resol
u&ccedil;&atilde;o relativamente precoce em muitos casos, geralmente    durante 
o primeiro ano de vida<SUP>2</SUP>. Portanto, &eacute; poss&iacute;vel    que os
 pesquisadores tenham subestimado a porcentagem de beb&ecirc;s realmente    al&e
acute;rgicos ao leite de vaca, j&aacute; que alguns podem ter se livrado    da a
lergia antes da realiza&ccedil;&atilde;o do teste. N&atilde;o temos como    sabe
r, mas o n&uacute;mero desses casos provavelmente &eacute; pequeno.</font></P>  
   ^cY#a03v86n4.htm##
01565000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704133400072002001301406#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#17#13#text#27#<P><font face="Verdana"
 size="2">A import&acirc;ncia dessas observa&ccedil;&otilde;es    dever&aacute; 
crescer nos pr&oacute;ximos anos, pois o espectro da alergia &agrave;    prote&i
acute;na do leite de vaca parece estar aumentando. A observa&ccedil;&atilde;o   
 de que a esofagite eosinof&iacute;lica &eacute; uma doen&ccedil;a al&eacute;rgi
ca    e a resposta ao tratamento com dieta mesmo fora da primeira inf&acirc;ncia
 aumentar&atilde;o    a necessidade de melhores crit&eacute;rios e m&eacute;todo
s diagn&oacute;sticos    para alergia alimentar<SUP>3</SUP>. Atualmente, estamos
 limitados &agrave; biopsia    repetitiva para avaliar tanto a sensibilidade ali
mentar quanto as respostas    terap&ecirc;uticas. Parece que a alergia ao leite 
de vaca pode causar constipa&ccedil;&atilde;o    depois dos primeiros dois anos 
de vida, assim como sangramento retal em pr&eacute;-escolares    quase tanto qua
nto em beb&ecirc;s<SUP>4</SUP>. Igualmente, a avalia&ccedil;&atilde;o    da rea&
ccedil;&atilde;o &agrave; interven&ccedil;&atilde;o alimentar pode ser    dif&ia
cute;cil, e as caracter&iacute;sticas histol&oacute;gicas, mesmo que presentes, 
   s&atilde;o inespec&iacute;ficas. Para dist&uacute;rbios como esses, os testes
    tradicionais para validar o diagn&oacute;stico ser&atilde;o ainda mais dif&i
acute;ceis.</font></P>     ^cY#a03v86n4.htm##
01067000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704083600072002001300908#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#18#14#text#27#<P><font face="Verdana"
 size="2">A alergia ao leite de vaca provou ser uma causa    relativamente comum
 de uma variedade de manifesta&ccedil;&otilde;es cut&acirc;neas    e gastrointes
tinais em beb&ecirc;s e crian&ccedil;as pequenas. O diagn&oacute;stico    dessa 
condi&ccedil;&atilde;o permanece dif&iacute;cil; assim, a confirma&ccedil;&atild
e;o    com um teste de desafio com leite &eacute; ideal para evitar excesso de t
ratamento    complexo e de alto custo. Quando o teste de desafio com leite de va
ca &eacute;    realizado, deve ser feito com a compreens&atilde;o de que provave
lmente se est&aacute;    lidando com uma alergia n&atilde;o relacionada &agrave;
 IgE, sendo necess&aacute;rio    um per&iacute;odo de monitoramento prolongado c
om observa&ccedil;&atilde;o cuidadosa    de uma s&eacute;rie de sintomas.</font>
</P>     ^cY#a03v86n4.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#19#15#text#27#<P>&nbsp;</P>     ^cY#a
03v86n4.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704007900072002001300151#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#20#16#text#27#<p><font size="3" face=
"Verdana"><b>Refer&ecirc;ncias</b></font></p>       ^cY#a03v86n4.htm##
00438000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704019300074002001300267#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a03v86n4.htm#S#p#21#17#text#27#1#<p><font 
size="2" face="Verdana">1. Lins MG, Horowitz MR, Silva GAP, Motta ME. Oral food 
challenge test to confirm the diagnosis of cow's milk allergy. J Pediatr (Rio J)
. 2010;86:285-9.    ^cY#a03v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#22#18#text#27#</font></p>         ^cY
#a03v86n4.htm##
00409000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704016400074002001300238#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a03v86n4.htm#S#p#23#19#text#27#2#<p><font 
size="2" face="Verdana">2. Vanderhoof JA, Young RJ. Allergic disorders of the ga
strointestinal tract. Curr Opin Clin Nutr Metab Care. 2001;4:553-6.    ^cY#a03v8
6n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002400072002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#24#20#text#27#</font></p>         ^cY
#a03v86n4.htm##
00399000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704015400074002001300228#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a03v86n4.htm#S#p#25#21#text#27#3#<p><font 
size="2" face="Verdana">3. Chehade M, Aceves SS. Food allergy and eosinphilic es
ophagitis. Curr Opin Allergy Clin Immunol. 2010;10:231-7.    ^cY#a03v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#26#22#text#27#</font></p>     ^cY#a03
v86n4.htm##
00393000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069888000200072704014800074002001300222#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a03v86n4.htm#S#p#27#23#text#27#4#<p><font 
size="2" face="Verdana">4. Troncone R, Discepolo    V. Colon in food allergy. J 
Pediatr Gastroenterol Nutr. 2009;48 Suppl 2:S89-91.    ^cY#a03v86n4.htm##
00251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002000072002001300092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#28#24#text#27#</font></p>     ^cY#a03
v86n4.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#29#25#text#27#<p>&nbsp;</p>     ^cY#a
03v86n4.htm##
00253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704002200072002001300094#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#30#26#text#27#<p>&nbsp;</p>     ^cY#a
03v86n4.htm##
00375000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000500064708000300069704014400072002001300216#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a03v86n4.htm#S#p#31#27#text#27#<p><font size="2" face=
"Verdana">Conflitos de interesse: Vice-presidente, Global    Medical Affairs, Me
ad Johnson Nutrition.</font></p>     ^cY#a03v86n4.htm##
00608000000000301000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100015000720100019000870100
01700106010001600123012007600139030001800215065000900233064000500242031000300247
014000600250865000900256002001300265035001000278801001800288#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a03v86n4.htm#S#c#32#1#text#4#1#^rND^sLins^nMG#^rND^sHorowi
tz^nMR#^rND^sSilva^nGAP#^rND^sMotta^nME#Oral food challenge test to confirm the 
diagnosis of cow's milk allergy^len#J Pediatr (Rio J)#20100000#2010#86#285-9#201
00800#a03v86n4.htm#0021-7557#J Pediatr (Rio J)##
00506000000000265000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100021000720100016000930120
05300109030003200162710000200194065000900196064000500205031000200210014000600212
865000900218002001300227#v86n4#V:\Scielo\serial\jped\v86n4\markup\a03v86n4.htm#S
#c#33#2#text#4#2#^rND^sVanderhoof^nJA#^rND^sYoung^nRJ#Allergic disorders of the 
gastrointestinal tract^len#Curr Opin Clin Nutr Metab Care.#2#20010000#2001#4#553
-6#20100800#a03v86n4.htm##
00496000000000265000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100017000720100017000890120
04500106030003200151710000200183065000900185064000500194031000300199014000600202
865000900208002001300217#v86n4#V:\Scielo\serial\jped\v86n4\markup\a03v86n4.htm#S
#c#34#3#text#4#3#^rND^sChehade^nM#^rND^sAceves^nSS#Food allergy and eosinphilic 
esophagitis^len#Curr Opin Allergy Clin Immunol.#2#20100000#2010#10#231-7#2010080
0#a03v86n4.htm##
00502000000000277000450000400060000070200480000670500020005470600020005670000030
00587010002000617090005000637080002000681180002000700100018000720100020000900120
02600110030003000136710000200166065000900168064000500177031000300182032001000185
014000700195865000900202002001300211#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
3v86n4.htm#S#c#35#4#text#4#4#^rND^sTroncone^nR#^rND^sDiscepolo^nV.#Colon in food
 allergy^len#J Pediatr Gastroenterol Nutr.#2#20090000#2009#48#^sSuppl 2#S89-91#2
0100800#a03v86n4.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#o#1#1#article#1
#20110126#175337#a04v86n4.htm#290##
04731000000000649000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000210011303100030013403200020013706500090013901400110014803500100015901200780
01690120071002470100033003180100028003510700051003790831743004300850010021730850
03802183085002502221085002002246085002202266085002502288085002802313083151702341
08500100385808500360386808500250390408500200392908500220394908500240397108500260
39951170008040210720003040291120009040321110009040411140009040501130009040590020
01304068#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#h#2#1#article#1
#ra#pt#br1.1#1#4.0#ILUS#TAB#04#JPED100#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f2
61^l270#0021-7557#Atrofia muscular espinhal: diagnóstico, tratamento e perspecti
vas futuras^lpt#Spinal muscular atrophy: diagnosis, treatment and future prospec
ts^len#^rND^1A01^nMariana T. C.^sBaioni#^rND^1A01^nCelia R.^sAmbiel#Universidade
 Estadual de Maringá^iA01^cMaringá^sPR#^lpt^aOBJETIVO: Relatar as recentes desco
bertas genéticas e moleculares, juntamente com as perspectivas futuras, para o t
ratamento da atrofia muscular espinhal, auxiliando, dessa forma, os profissionai
s da área da saúde a fazerem um rápido diagnóstico e proporcionarem um suporte t
erapêutico correto e precoce. FONTES DOS DADOS: As informações foram coletadas a
 partir de artigos científicos publicados nas duas últimas décadas, pesquisados 
nas bases de dados SciELO, PubMed e MEDLINE. SÍNTESE DOS DADOS: A atrofia muscul
ar espinhal é uma doença neurodegenerativa com herança genética autossômica rece
ssiva. É causada por uma deleção homozigótica do gene de sobrevivência do motone
urônio. Essa alteração genética resulta na redução dos níveis da proteína de sob
revivência do motoneurônio, levando à degeneração de motoneurônios alfa da medul
a espinhal, o que resulta em fraqueza e paralisia muscular proximal progressiva 
simétrica. Sabe-se que alguns cuidados básicos referentes à nutrição, respiração
 e fisioterapia podem ser importantes para retardar o progresso da doença e prol
ongar a vida dos pacientes. Vários medicamentos estão sendo testados, alguns nov
os, outros já conhecidos, como o ácido valproico, sendo que a paralisia pode ser
 estacionada, mas não revertida. CONCLUSÕES: A atrofia muscular espinhal é uma d
esordem de difícil diagnóstico, por ser pouco conhecida, e de tratamento ainda i
ncerto. Os tratamentos farmacológicos e as terapias de suporte existentes ainda 
não são capazes de recuperar os motoneurônios ou as células musculares que já fo
ram perdidos, mas têm o objetivo de retardar o progresso da doença e melhorar a 
função muscular residual dos pacientes, bem como oferecer uma melhor qualidade e
 expectativa de vida.#^ddecs^i1#^tm^lpt^kAtrofia muscular espinhal^i1#^tm^lpt^km
otoneurônio^i1#^tm^lpt^kterapia^i1#^tm^lpt^kgene SMN1^i1#^tm^lpt^kproteína SMN^i
1#^tm^lpt^kácido valproico^i1#^len^aOBJECTIVE: To report on recent genetic and m
olecular discoveries and on future prospects for the treatment of spinal muscula
r atrophy (SMA), thereby helping healthcare professionals to make a quick diagno
sis and provide appropriate and timely therapeutic support. SOURCES: Information
 was collected from scientific articles published in the last 2 decades, retriev
ed from the databases SciELO, PubMed, and MEDLINE. SUMMARY OF THE FINDINGS: SMA 
is a neurodegenerative disorder with autosomal recessive genetic heredity. It is
 caused by a homozygous deletion of the survival motor neuron (SMN1) gene. This 
genetic alteration results in reduced levels of the SMN protein, leading to dege
neration of alpha motor neurons of the spinal cord and resulting in muscle weakn
ess and progressive symmetrical proximal paralysis. It is known that basic nutri
tional and respiratory care and physiotherapy can be important to delaying disea
se progression and prolonging patients' lives. Several drugs are being tested, s
ome new, others, such as valproic acid, already known; paralysis can be halted, 
but not reversed. CONCLUSIONS: SMA is a difficult to diagnose disorder, because 
it is little known, and treatment is uncertain. Pharmacological treatments and s
upportive therapies are not yet able to recover motor neurons or muscle cells th
at have already been lost, but are aimed at delaying disease progression and imp
roving patients' residual muscle function, as well as offering better quality of
 life and life expectancy.#^ddecs^i2#^tm^len^kSpinal muscular atrophy^i2#^tm^len
^kmotor neuron^i2#^tm^len^ktherapy^i2#^tm^len^kSMN1 gene^i2#^tm^len^kSMN protein
^i2#^tm^len^kvalproic acid^i2#vancouv#51#20090826#26.08.09#20091014#14.10.09#a04
v86n4.htm##
04826000000000649000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000210011303100030013403200020013706500090013901400110014803500100015901200920
01690120085002610100033003460100028003790700051004070831771004580850010022290850
03802239085002502277085002002302085002202322085002502344085002802369083155602397
08500100395308500360396308500250399908500200402408500220404408500240406608500260
40901170008041160720003041241120009041271110009041361140009041451130009041540020
01304163#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#f#3#1#article#1
#ra#pt#br1.1#1#4.0#ILUS#TAB#04#JPED100#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f2
61^l270#0021-7557#<b>Atrofia muscular espinhal</b>: <b>diagnóstico, tratamento e
 perspectivas futuras</b>^lpt#<b>Spinal muscular atrophy</b>: <b>diagnosis, trea
tment and future prospects</b>^len#^rND^1A01^nMariana T. C.^sBaioni#^rND^1A01^nC
elia R.^sAmbiel#Universidade Estadual de Maringá^iA01^cMaringá^sPR#^lpt^a<b>OBJE
TIVO: </b>Relatar as recentes descobertas genéticas e moleculares, juntamente co
m as perspectivas futuras, para o tratamento da atrofia muscular espinhal, auxil
iando, dessa forma, os profissionais da área da saúde a fazerem um rápido diagnó
stico e proporcionarem um suporte terapêutico correto e precoce. <b>FONTES DOS D
ADOS: </b>As informações foram coletadas a partir de artigos científicos publica
dos nas duas últimas décadas, pesquisados nas bases de dados SciELO, PubMed e ME
DLINE. <b>SÍNTESE DOS DADOS: </b>A atrofia muscular espinhal é uma doença neurod
egenerativa com herança genética autossômica recessiva. É causada por uma deleçã
o homozigótica do gene de sobrevivência do motoneurônio. Essa alteração genética
 resulta na redução dos níveis da proteína de sobrevivência do motoneurônio, lev
ando à degeneração de motoneurônios alfa da medula espinhal, o que resulta em fr
aqueza e paralisia muscular proximal progressiva simétrica. Sabe-se que alguns c
uidados básicos referentes à nutrição, respiração e fisioterapia podem ser impor
tantes para retardar o progresso da doença e prolongar a vida dos pacientes. Vár
ios medicamentos estão sendo testados, alguns novos, outros já conhecidos, como 
o ácido valproico, sendo que a paralisia pode ser estacionada, mas não revertida
. <b>CONCLUSÕES:</b> A atrofia muscular espinhal é uma desordem de difícil diagn
óstico, por ser pouco conhecida, e de tratamento ainda incerto. Os tratamentos f
armacológicos e as terapias de suporte existentes ainda não são capazes de recup
erar os motoneurônios ou as células musculares que já foram perdidos, mas têm o 
objetivo de retardar o progresso da doença e melhorar a função muscular residual
 dos pacientes, bem como oferecer uma melhor qualidade e expectativa de vida.#^d
decs^i1#^tm^lpt^kAtrofia muscular espinhal^i1#^tm^lpt^kmotoneurônio^i1#^tm^lpt^k
terapia^i1#^tm^lpt^kgene SMN1^i1#^tm^lpt^kproteína SMN^i1#^tm^lpt^kácido valproi
co^i1#^len^a<b>OBJECTIVE: </b>To report on recent genetic and molecular discover
ies and on future prospects for the treatment of spinal muscular atrophy (SMA), 
thereby helping healthcare professionals to make a quick diagnosis and provide a
ppropriate and timely therapeutic support. <b>SOURCES: </b>Information was colle
cted from scientific articles published in the last 2 decades, retrieved from th
e databases SciELO, PubMed, and MEDLINE. <b>SUMMARY OF THE FINDINGS: </b>SMA is 
a neurodegenerative disorder with autosomal recessive genetic heredity. It is ca
used by a homozygous deletion of the survival motor neuron (SMN<sub>1</sub>) gen
e. This genetic alteration results in reduced levels of the SMN protein, leading
 to degeneration of alpha motor neurons of the spinal cord and resulting in musc
le weakness and progressive symmetrical proximal paralysis. It is known that bas
ic nutritional and respiratory care and physiotherapy can be important to delayi
ng disease progression and prolonging patients' lives. Several drugs are being t
ested, some new, others, such as valproic acid, already known; paralysis can be 
halted, but not reversed. <b>CONCLUSIONS:</b> SMA is a difficult to diagnose dis
order, because it is little known, and treatment is uncertain. Pharmacological t
reatments and supportive therapies are not yet able to recover motor neurons or 
muscle cells that have already been lost, but are aimed at delaying disease prog
ression and improving patients' residual muscle function, as well as offering be
tter quality of life and life expectancy.#^ddecs^i2#^tm^len^kSpinal muscular atr
ophy^i2#^tm^len^kmotor neuron^i2#^tm^len^ktherapy^i2#^tm^len^kSMN1 gene^i2#^tm^l
en^kSMN protein^i2#^tm^len^kvalproic acid^i2#vancouv#51#20090826#26.08.09#200910
14#14.10.09#a04v86n4.htm##
04862000000000673000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000300117049000800120
15800030012803000210013103100030015203200020015506500090015701400110016603500100
01770120078001870120071002650100032003360100027003680700053003950831743004480850
01002191085003802201085002502239085002002264085002202284085002502306085002802331
08315170235908500100387608500360388608500250392208500200394708500220396708500240
39890850026040131170008040390720003040471120009040501110009040591140009040681130
00904077002001304086008008904099#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86
n4.htm#S#l#4#1#article#1#^mjul./ago.^a2010#ra#pt#br1.1#1#4.0#ilus#tab#04#JPED100
#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f261^l270#0021-7557#Atrofia muscular esp
inhal: diagnóstico, tratamento e perspectivas futuras^lpt#Spinal muscular atroph
y: diagnosis, treatment and future prospects^len#^rND^1A01^nMariana T. C^sBaioni
#^rND^1A01^nCelia R^sAmbiel#^iA01^1Universidade Estadual de Maringá^cMaringá^sPR
#^lpt^aOBJETIVO: Relatar as recentes descobertas genéticas e moleculares, juntam
ente com as perspectivas futuras, para o tratamento da atrofia muscular espinhal
, auxiliando, dessa forma, os profissionais da área da saúde a fazerem um rápido
 diagnóstico e proporcionarem um suporte terapêutico correto e precoce. FONTES D
OS DADOS: As informações foram coletadas a partir de artigos científicos publica
dos nas duas últimas décadas, pesquisados nas bases de dados SciELO, PubMed e ME
DLINE. SÍNTESE DOS DADOS: A atrofia muscular espinhal é uma doença neurodegenera
tiva com herança genética autossômica recessiva. É causada por uma deleção homoz
igótica do gene de sobrevivência do motoneurônio. Essa alteração genética result
a na redução dos níveis da proteína de sobrevivência do motoneurônio, levando à 
degeneração de motoneurônios alfa da medula espinhal, o que resulta em fraqueza 
e paralisia muscular proximal progressiva simétrica. Sabe-se que alguns cuidados
 básicos referentes à nutrição, respiração e fisioterapia podem ser importantes 
para retardar o progresso da doença e prolongar a vida dos pacientes. Vários med
icamentos estão sendo testados, alguns novos, outros já conhecidos, como o ácido
 valproico, sendo que a paralisia pode ser estacionada, mas não revertida. CONCL
USÕES: A atrofia muscular espinhal é uma desordem de difícil diagnóstico, por se
r pouco conhecida, e de tratamento ainda incerto. Os tratamentos farmacológicos 
e as terapias de suporte existentes ainda não são capazes de recuperar os motone
urônios ou as células musculares que já foram perdidos, mas têm o objetivo de re
tardar o progresso da doença e melhorar a função muscular residual dos pacientes
, bem como oferecer uma melhor qualidade e expectativa de vida.#^ddecs^i1#^tm^lp
t^kAtrofia muscular espinhal^i1#^tm^lpt^kmotoneurônio^i1#^tm^lpt^kterapia^i1#^tm
^lpt^kgene SMN1^i1#^tm^lpt^kproteína SMN^i1#^tm^lpt^kácido valproico^i1#^len^aOB
JECTIVE: To report on recent genetic and molecular discoveries and on future pro
spects for the treatment of spinal muscular atrophy (SMA), thereby helping healt
hcare professionals to make a quick diagnosis and provide appropriate and timely
 therapeutic support. SOURCES: Information was collected from scientific article
s published in the last 2 decades, retrieved from the databases SciELO, PubMed, 
and MEDLINE. SUMMARY OF THE FINDINGS: SMA is a neurodegenerative disorder with a
utosomal recessive genetic heredity. It is caused by a homozygous deletion of th
e survival motor neuron (SMN1) gene. This genetic alteration results in reduced 
levels of the SMN protein, leading to degeneration of alpha motor neurons of the
 spinal cord and resulting in muscle weakness and progressive symmetrical proxim
al paralysis. It is known that basic nutritional and respiratory care and physio
therapy can be important to delaying disease progression and prolonging patients
' lives. Several drugs are being tested, some new, others, such as valproic acid
, already known; paralysis can be halted, but not reversed. CONCLUSIONS: SMA is 
a difficult to diagnose disorder, because it is little known, and treatment is u
ncertain. Pharmacological treatments and supportive therapies are not yet able t
o recover motor neurons or muscle cells that have already been lost, but are aim
ed at delaying disease progression and improving patients' residual muscle funct
ion, as well as offering better quality of life and life expectancy.#^ddecs^i2#^
tm^len^kSpinal muscular atrophy^i2#^tm^len^kmotor neuron^i2#^tm^len^ktherapy^i2#
^tm^len^kSMN1 gene^i2#^tm^len^kSMN protein^i2#^tm^len^kvalproic acid^i2#vancouv#
51#20090826#26.08.09#20091014#14.10.09#a04v86n4.htm#Internet^ihttp://www.scielo.
br/scielo.php?script=sci_arttext&pid=S0021-75572010000400004##
00331000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704009800074002001300172#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#5#1#article#235#<p align="right"><fon
t size="2" face="Verdana"><b>ARTIGO DE REVIS&Atilde;O</b></font></p>     ^cY#a04
v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#6#2#article#235#<p>&nbsp;</p>     ^cY
#a04v86n4.htm##
00376000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704014300074002001300217#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#7#3#article#235#<p><font size="4" fac
e="Verdana"><b>Atrofia muscular espinhal: diagn&oacute;stico,    tratamento e pe
rspectivas futuras</b></font></p>     ^cY#a04v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#8#4#article#235#<p>&nbsp;</p>     ^cY
#a04v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#9#5#article#235#<p>&nbsp;</p>     ^cY
#a04v86n4.htm##
00361000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012700075002001300202#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#10#6#article#235#<p> <font size="2" f
ace="Verdana"><b>Mariana T. C. Baioni<sup>I</sup>; Celia R.    Ambiel<sup>II</su
p></b></font> </p>     ^cY#a04v86n4.htm##
00388000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704015400075002001300229#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#11#7#article#235#<p><font size="2" fa
ce="Verdana"><sup>I</sup>Especialista, Fisiologia Humana,    Universidade Estadu
al de Maring&aacute; (UEM), Maring&aacute;, PR    ^cY#a04v86n4.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012400075002001300199#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#12#8#article#235#<br>   <sup>II</sup>
Doutora, Biologia Celular, Professora, Fisiologia Humana, UEM,    Maring&aacute;
, PR</font></p>     ^cY#a04v86n4.htm##
00357000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012300075002001300198#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#13#9#article#235#<p><font size="2" fa
ce="Verdana"><a name="topo"></a><a href="#correspondence">Correspond&ecirc;ncia<
/a></font></p>     ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#14#10#article#235#<p>&nbsp;</p>     ^
cY#a04v86n4.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#15#11#article#235#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a04v86n4.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006600076002001300142#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#16#12#article#235#<p><font size="2" f
ace="Verdana"><b>RESUMO</b></font></p>     ^cY#a04v86n4.htm##
00642000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040700076002001300483#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#17#13#article#235#<p><font size="2" f
ace="Verdana"> <b>OBJETIVO: </b> Relatar as recentes descobertas    gen&eacute;t
icas e moleculares, juntamente com as perspectivas futuras, para    o tratamento
 da atrofia muscular espinhal, auxiliando, dessa forma, os profissionais    da &
aacute;rea da sa&uacute;de a fazerem um r&aacute;pido diagn&oacute;stico    e pr
oporcionarem um suporte terap&ecirc;utico correto e precoce.    ^cY#a04v86n4.htm
##
00473000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023800076002001300314#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#18#14#article#235#<br>   <b>FONTES DO
S DADOS: </b> As informa&ccedil;&otilde;es foram coletadas a partir    de artigo
s cient&iacute;ficos publicados nas duas &uacute;ltimas d&eacute;cadas,    pesqu
isados nas bases de dados SciELO, PubMed e MEDLINE.    ^cY#a04v86n4.htm##
01340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704110500076002001301181#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#19#15#article#235#<br>   <b>S&Iacute;
NTESE DOS DADOS: </b>A atrofia muscular espinhal &eacute; uma doen&ccedil;a    n
eurodegenerativa com heran&ccedil;a gen&eacute;tica autoss&ocirc;mica recessiva.
    &Eacute; causada por uma dele&ccedil;&atilde;o homozig&oacute;tica do gene d
e    sobreviv&ecirc;ncia do motoneur&ocirc;nio. Essa altera&ccedil;&atilde;o gen
&eacute;tica    resulta na redu&ccedil;&atilde;o dos n&iacute;veis da prote&iacu
te;na de sobreviv&ecirc;ncia    do motoneur&ocirc;nio, levando &agrave; degenera
&ccedil;&atilde;o de motoneur&ocirc;nios    alfa da medula espinhal, o que resul
ta em fraqueza e paralisia muscular proximal    progressiva sim&eacute;trica. Sa
be-se que alguns cuidados b&aacute;sicos referentes    &agrave; nutri&ccedil;&at
ilde;o, respira&ccedil;&atilde;o e fisioterapia podem    ser importantes para re
tardar o progresso da doen&ccedil;a e prolongar a vida    dos pacientes. V&aacut
e;rios medicamentos est&atilde;o sendo testados, alguns    novos, outros j&aacut
e; conhecidos, como o &aacute;cido valproico, sendo que    a paralisia pode ser 
estacionada, mas n&atilde;o revertida.    ^cY#a04v86n4.htm##
00854000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061900076002001300695#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#20#16#article#235#<br>   <b>CONCLUS&O
tilde;ES:</b> A atrofia muscular espinhal &eacute; uma desordem    de dif&iacute
;cil diagn&oacute;stico, por ser pouco conhecida, e de tratamento    ainda incer
to. Os tratamentos farmacol&oacute;gicos e as terapias de suporte    existentes 
ainda n&atilde;o s&atilde;o capazes de recuperar os motoneur&ocirc;nios    ou as
 c&eacute;lulas musculares que j&aacute; foram perdidos, mas t&ecirc;m    o obje
tivo de retardar o progresso da doen&ccedil;a e melhorar a fun&ccedil;&atilde;o 
   muscular residual dos pacientes, bem como oferecer uma melhor qualidade e exp
ectativa    de vida.</font></p>     ^cY#a04v86n4.htm##
00448000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021300076002001300289#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#21#17#article#235#<p><font size="2" f
ace="Verdana"><b>Palavras-chave: </b> Atrofia muscular espinhal,    motoneur&oci
rc;nio, terapia, gene SMN1, prote&iacute;na SMN, &aacute;cido valproico.</font><
/p> <hr size="1" noshade>     ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#22#18#article#235#<p>&nbsp;</p>     ^
cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#23#19#article#235#<p>&nbsp;</p>     ^
cY#a04v86n4.htm##
00319000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008400076002001300160#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#24#20#article#235#<p><font size="3" f
ace="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#a04v86n4.htm##
00788000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055300076002001300629#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#25#21#article#235#<p><font size="2" f
ace="Verdana">A atrofia muscular espinhal (AME) &eacute; uma    doen&ccedil;a ne
urodegenerativa com heran&ccedil;a gen&eacute;tica autoss&ocirc;mica    recessiv
a. &Eacute; a principal desordem fatal com esse car&aacute;ter gen&eacute;tico  
  depois da fibrose c&iacute;stica (1:6.000), com uma incid&ecirc;ncia de 1:6.00
0    a 1:10.000 nascimentos<SUP>1</SUP>. A frequ&ecirc;ncia de indiv&iacute;duos
    portadores (heterozigotos) da doen&ccedil;a &eacute; de um para cada 40 a 60
    indiv&iacute;duos<SUP>2</SUP>.</font></p>     ^cY#a04v86n4.htm##
00767000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053200076002001300608#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#26#22#article#235#<p><font size="2" f
ace="Verdana">A doen&ccedil;a &eacute; causada por uma dele&ccedil;&atilde;o    
ou muta&ccedil;&atilde;o homozig&oacute;tica do gene 1 de sobreviv&ecirc;ncia   
 do motoneur&ocirc;nio (SMN<SUB>1</SUB>), localizado na regi&atilde;o telom&eacu
te;rica    do cromossomo 5q13, sendo que o n&uacute;mero de c&oacute;pias de um 
gene semelhante    a ele (SMN<SUB>2</SUB>), localizado na regi&atilde;o centrom&
eacute;rica, &eacute;    o principal determinante da severidade da doen&ccedil;a
<SUP>3</SUP>.</font></p>     ^cY#a04v86n4.htm##
00956000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072100076002001300797#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#27#23#article#235#<p><font size="2" f
ace="Verdana">Essa altera&ccedil;&atilde;o gen&eacute;tica    no gene SMN<SUB>1<
/SUB> &eacute; respons&aacute;vel pela redu&ccedil;&atilde;o    dos n&iacute;vei
s da prote&iacute;na de sobreviv&ecirc;ncia do motoneur&ocirc;nio    (SMN). O ge
ne SMN<SUB>2</SUB> n&atilde;o compensa completamente a aus&ecirc;ncia    da expr
ess&atilde;o do SMN<SUB>1</SUB> porque produz apenas 25% da prote&iacute;na    S
MN<SUP>4</SUP>. A falta da prote&iacute;na SMN leva &agrave; degenera&ccedil;&at
ilde;o    de motoneur&ocirc;nios alfa (&#945;) localizados no corno anterior da 
medula    espinhal, o que resulta em fraqueza e paralisia muscular proximal prog
ressiva    e sim&eacute;trica<SUP>2</SUP>.</font></p>     ^cY#a04v86n4.htm##
00842000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060700076002001300683#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#28#24#article#235#<p><font face="Verd
ana" size="2">A classifica&ccedil;&atilde;o cl&iacute;nica    da AME &eacute; da
da pela idade de in&iacute;cio e m&aacute;xima fun&ccedil;&atilde;o    motora ad
quirida, sendo ent&atilde;o dividida em: 1) severa (tipo I, AME aguda    ou doen
&ccedil;a de Werdnig-Hoffmann); 2) intermedi&aacute;ria (tipo II ou AME    cr&oc
irc;nica); 3) branda (tipo III, AME juvenil ou doen&ccedil;a de Kugelberg-Weland
er);    e 4) tipo IV (AME adulta)<SUP>3</SUP>. Outros autores<SUP>5-7</SUP> clas
sificam    a AME em apenas tr&ecirc;s categorias: severa, intermedi&aacute;ria e
 branda.</font></p>     ^cY#a04v86n4.htm##
00787000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055200076002001300628#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#29#25#article#235#<p><font face="Verd
ana" size="2">A AME &eacute; uma desordem de dif&iacute;cil    diagn&oacute;stic
o e de tratamento ainda incerto. Seu diagn&oacute;stico &eacute;    dado pela ev
id&ecirc;ncia, tanto eletrofisiol&oacute;gica como histol&oacute;gica,    de des
nerva&ccedil;&atilde;o do m&uacute;sculo<SUP>3</SUP>. Para confirmar o    diagn&
oacute;stico, &eacute; feita atualmente uma an&aacute;lise molecular,    que &ea
cute; dada pela detec&ccedil;&atilde;o da aus&ecirc;ncia do &eacute;xon    7 do 
gene SMN<SUB>1</SUB><SUP>2</SUP>.</font></p>     ^cY#a04v86n4.htm##
01013000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077800076002001300854#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#30#26#article#235#<p><font face="Verd
ana" size="2">Por ser uma doen&ccedil;a neurodegenerativa progressiva,    o paci
ente acometido pela AME necessita de v&aacute;rios cuidados especiais,    que po
dem estacionar o progresso da doen&ccedil;a e prolongar a vida do mesmo.    Assi
m, este artigo de revis&atilde;o bibliogr&aacute;fica teve por objetivo    descr
ever o perfil cl&iacute;nico e laboratorial dos pacientes portadores de    AME, 
bem como relatar as recentes descobertas gen&eacute;ticas e moleculares,    junt
amente com as perspectivas futuras para o tratamento dessa patologia, auxiliando
,    dessa forma, os profissionais da &aacute;rea da sa&uacute;de a fazerem um r
&aacute;pido    diagn&oacute;stico e proporcionarem um suporte terap&ecirc;utico
 correto e precoce.</font></p>     ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#31#27#article#235#<p>&nbsp;</p>     ^
cY#a04v86n4.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007500076002001300151#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#32#28#article#235#<p><font size="3" f
ace="Verdana"><b>Desenvolvimento</b></font></p>     ^cY#a04v86n4.htm##
00336000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010100076002001300177#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#33#29#article#235#<p><font size="2" f
ace="Verdana"><b><i>Classifica&ccedil;&atilde;o da AME</i></b></font></p>     ^c
Y#a04v86n4.htm##
00451000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021600076002001300292#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#34#30#article#235#<p><font face="Verd
ana" size="2">A AME pode ser classificada em quatro tipos,    de acordo com a id
ade de in&iacute;cio da doen&ccedil;a e a m&aacute;xima fun&ccedil;&atilde;o    
motora adquirida.</font></p>     ^cY#a04v86n4.htm##
01492000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704125700076002001301333#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#35#31#article#235#<p><font face="Verd
ana" size="2">AME tipo I: (tamb&eacute;m denominada AME severa,    doen&ccedil;a
 de Werdnig-Hoffmann ou AME aguda) se caracteriza pelo in&iacute;cio    precoce 
(de 0 a 6 meses de idade), pela falta de habilidade de sentar sem apoio    e pel
a curta expectativa de vida (menor que 2 anos)<SUP>3</SUP>. Crian&ccedil;as    a
ssim diagnosticadas t&ecirc;m pouco controle da cabe&ccedil;a, com choro e    to
sse fracos. Antes de completar 1 ano de idade, n&atilde;o s&atilde;o mais    cap
azes de engolir e se alimentar. A fraqueza de tronco e membros normalmente    se
 dirige para os m&uacute;sculos intercostais, o que dificulta o desenvolvimento 
   normal do ciclo respirat&oacute;rio. Apesar dos m&uacute;sculos intercostais 
   serem afetados, o diafragma inicialmente &eacute; poupado. O risco de mortali
dade    precoce est&aacute; usualmente associado com disfun&ccedil;&atilde;o bul
bar    e complica&ccedil;&otilde;es respirat&oacute;rias<SUP>8</SUP>. Apesar de 
essas    crian&ccedil;as apresentarem historicamente uma curta expectativa de vi
da (menos    de 2 anos), gra&ccedil;as &agrave; melhora dos cuidados cl&iacute;n
icos nos    &uacute;ltimos anos, tem sido observado um aumento da sobreviv&ecirc
;ncia<SUP>9</SUP>.</font></p>     ^cY#a04v86n4.htm##
01197000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704096200076002001301038#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#36#32#article#235#<p><font face="Verd
ana" size="2">AME tipo II: (ou AME cr&ocirc;nica) &eacute;    sintom&aacute;tica
 por volta dos 6 a 18 meses de vida, mas pode se manifestar    mais precocemente
. Alguns pacientes assim classificados conseguem sentar sozinhos    enquanto out
ros o fazem somente quando posicionados<SUP>3</SUP>. Os pacientes    melhor dese
nvolvidos conseguem ficar em p&eacute; quando apoiados, entretanto,    n&atilde;
o adquirem a habilidade de andar independentemente. A fraqueza bulbar,    combin
ada com dificuldade de engolir, pode levar a baixo ganho de peso em algumas    c
rian&ccedil;as. Al&eacute;m disso, esses pacientes podem ter dificuldades para  
  tossir e limpar secre&ccedil;&otilde;es provenientes da traqueia, ter tremores
    finos (chamados de miofascicula&ccedil;&otilde;es) e ser acometidos por esco
liose    e contraturas ao longo dos anos<SUP>8</SUP>. A expectativa de vida gira
 em torno    de 10 a 40 anos<SUP>3,8</SUP>.</font></p>     ^cY#a04v86n4.htm##
01409000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704117400076002001301250#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#37#33#article#235#<p><font face="Verd
ana" size="2">AME tipo III: (tamb&eacute;m chamada de AME juvenil    ou doen&cce
dil;a de Kugelberg-Welander) aparece ap&oacute;s os 18 meses, por&eacute;m    a 
idade de in&iacute;cio varia muito. De acordo com Wirth et al.<SUP>10</SUP>,    
o aparecimento da doen&ccedil;a antes dos 3 anos de idade &eacute; classificado 
   como AME tipo IIIa, enquanto que, ap&oacute;s essa idade, &eacute; reconhecid
o    como AME tipo IIIb. O que difere as duas &eacute; a preserva&ccedil;&atilde
;o    da capacidade de andar, sendo que os indiv&iacute;duos com o tipo IIIa s&a
tilde;o    capazes de andar at&eacute; os 20 anos, enquanto os pacientes do tipo
 IIIb da    mesma idade permanecem com essa habilidade durante a vida toda<SUP>1
1</SUP>.    Dificuldades de engolir, tossir ou hipoventila&ccedil;&atilde;o notu
rna s&atilde;o    menos frequentes do que nos pacientes com o tipo II, mas podem
 ocorrer. Com    o passar dos anos, esses indiv&iacute;duos podem desenvolver es
coliose. A principal    caracter&iacute;stica desses pacientes &eacute; que eles
 conseguem andar independentemente,    e a expectativa de vida &eacute; indefini
da<SUP>3</SUP>.</font></p>     ^cY#a04v86n4.htm##
00887000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065200076002001300728#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#38#34#article#235#<p><font face="Verd
ana" size="2">AME tipo IV: n&atilde;o existe um consenso quanto    &agrave; idad
e de in&iacute;cio desse tipo de AME. Russman<SUP>3</SUP> descreve    que ela se
 desenvolve ap&oacute;s os 10 anos de idade, enquanto Wang et al.<SUP>8</SUP>   
 relatam que o in&iacute;cio da fraqueza ocorre normalmente na segunda ou tercei
ra    d&eacute;cada de vida ou por volta dos 30 anos. O preju&iacute;zo motor &e
acute;    suave e n&atilde;o ocorrem problemas de degluti&ccedil;&atilde;o ou re
spirat&oacute;rios.    Esses indiv&iacute;duos conseguem andar normalmente e pos
suem uma expectativa    de vida normal<SUP>3,8</SUP>.</font></p>     ^cY#a04v86n
4.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#39#35#article#235#<p><font face="Verd
ana" size="2"><b><i>Aspectos cl&iacute;nicos da AME</i></b></font></p>     ^cY#a
04v86n4.htm##
00765000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053000076002001300606#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#40#36#article#235#<p><font face="Verd
ana" size="2">Como ocorre perda progressiva apenas dos motoneur&ocirc;nios    &#
945;, a fun&ccedil;&atilde;o prejudicada &eacute; apenas a da motricidade,    fi
cando os neur&ocirc;nios sensoriais intactos. Essa perda de fun&ccedil;&atilde;o
    leva &agrave; fraqueza e &agrave; atrofia sim&eacute;trica progressiva dos m
&uacute;sculos    volunt&aacute;rios proximais de pernas, bra&ccedil;os e, event
ualmente, de m&uacute;sculos    do tronco durante o progresso da doen&ccedil;a<S
UP>8</SUP>.</font></p>     ^cY#a04v86n4.htm##
01182000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704094700076002001301023#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#41#37#article#235#<p><font face="Verd
ana" size="2">V&aacute;rios aspectos cl&iacute;nicos incomuns    s&atilde;o obse
rvados na AME. Um deles &eacute; o padr&atilde;o de distribui&ccedil;&atilde;o  
  da fraqueza muscular, que &eacute; mais compat&iacute;vel com uma desordem mio
p&aacute;tica    do que neurog&ecirc;nica<SUP>12</SUP>. Os m&uacute;sculos proxi
mais est&atilde;o    mais envolvidos que os distais, as pernas s&atilde;o mais a
fetadas que os bra&ccedil;os,    e estes s&atilde;o mais acometidos do que face 
e diafragma<SUP>8,12</SUP>. Ou    seja, n&atilde;o ocorre uma distribui&ccedil;&
atilde;o homog&ecirc;nea da fraqueza    e atrofia muscular. Quase sempre, a seve
ridade da fraqueza est&aacute; relacionada    com a idade de in&iacute;cio, send
o que a crian&ccedil;a com o tipo mais grave    da doen&ccedil;a (AME tipo I) po
de parecer normal ao nascimento, mas no decorrer    de poucos meses apresenta fr
aqueza muscular<SUP>8</SUP>.</font></p>     ^cY#a04v86n4.htm##
00638000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040300076002001300479#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#42#38#article#235#<p><font face="Verd
ana" size="2">Adicionalmente, o curso cl&iacute;nico da AME    para os indiv&iac
ute;duos que sobrevivem al&eacute;m da inf&acirc;ncia mostra    que a perda de f
or&ccedil;a muscular &eacute; normalmente mais not&aacute;vel    no in&iacute;ci
o da doen&ccedil;a, e depois a pot&ecirc;ncia muscular residual    pode se estab
ilizar durante meses a anos<SUP>12,13</SUP>.</font></p>     ^cY#a04v86n4.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010400076002001300180#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#43#39#article#235#<p><font face="Verd
ana" size="2"><b><i>Base gen&eacute;tica molecular da AME</i></b></font></p>    
 ^cY#a04v86n4.htm##
01076000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084100076002001300917#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#44#40#article#235#<p><font face="Verd
ana" size="2">Estudos gen&eacute;ticos revelam que a AME &eacute;    causada pel
a aus&ecirc;ncia do gene SMN<SUB>1</SUB>, localizado na por&ccedil;&atilde;o    
telom&eacute;rica do cromossomo 5<SUP>12,14,15</SUP>. Esse gene foi identificado
    em 1995 por Lefebvre et al.<SUP>16</SUP>; cont&eacute;m nove &eacute;xons qu
e    codificam a prote&iacute;na SMN. Todos os pacientes ret&ecirc;m ao menos um
a    c&oacute;pia de um gene muito semelhante a ele, o SMN<SUB>2</SUB>, que est&
aacute;    localizado na parte centrom&eacute;rica desse mesmo cromossomo. A aus
&ecirc;ncia    de SMN<SUB>1</SUB> &eacute; causada pela sua dele&ccedil;&atilde;
o ou, ent&atilde;o,    devido a uma convers&atilde;o g&ecirc;nica que transforma
 SMN<SUB>1</SUB> em    SMN<SUB>2</SUB><SUP>7</SUP> (<a href=#522f1 >Figura 1</a>
).</font></p>     ^cY#a04v86n4.htm##
00308000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007300076002001300149#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#45#41#article#235#<p><font face="Verd
ana" size="2"><a name="522f1"></a></font></p>     ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#46#42#article#235#<p>&nbsp;</p>     ^
cY#a04v86n4.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011500076002001300191#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#47#43#article#235#<p align="center"><
font face="Verdana" size="2"><img src="/img/revistas/jped/v86n4/4a04f1.gif"></fo
nt></p>     ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#48#44#article#235#<p>&nbsp;</p>     ^
cY#a04v86n4.htm##
00827000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704059200076002001300668#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#49#45#article#235#<p><font face="Verd
ana" size="2">O gene SMN<SUB>1</SUB> &eacute; respons&aacute;vel    pela s&iacut
e;ntese completa da prote&iacute;na SMN. No entanto, o gene SMN<SUB>2</SUB>    n
&atilde;o &eacute; capaz de sintetiz&aacute;-la totalmente, sendo respons&aacute
;vel    por parte de sua produ&ccedil;&atilde;o. SMN<SUB>2</SUB> produz 10 a 25%
 da    prote&iacute;na funcional, enquanto os outros 75% d&atilde;o origem a uma
 prote&iacute;na    truncada e inst&aacute;vel (SMN&#8710;7), que &eacute; rapid
amente degradada    (<a href=#522f1 >Figura 1</a>)<SUP>10,15,17,18</SUP>.</font>
</p>     ^cY#a04v86n4.htm##
01357000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704112200076002001301198#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#50#46#article#235#<p><font face="Verd
ana" size="2">Outro ponto importante a ser destacado &eacute;    o fato de que a
 quantidade de c&oacute;pias intactas de SMN<SUB>2</SUB> &eacute;    determinant
e para a severidade da doen&ccedil;a. Na <a href=#522f2 >Figura 2</a>,    est&aa
cute; esquematizado o gen&oacute;tipo de indiv&iacute;duos n&atilde;o-afetados  
  e afetados pela AME, caracterizando os pacientes tipos I, II e III. Est&aacute
;    tamb&eacute;m representada a quantidade de prote&iacute;na SMN sintetizada,
    de acordo com cada gen&oacute;tipo. Em consequ&ecirc;ncia do aumento no n&ua
cute;mero    de c&oacute;pias de SMN<SUB>2</SUB>, &eacute; produzida uma quantid
ade maior    da prote&iacute;na SMN funcional, o que reduz a severidade da doen&
ccedil;a<SUP>5,7,10,19</SUP>.    Tamb&eacute;m se pode observar, na mesma figura
, o fato de que eventos de convers&atilde;o    g&ecirc;nica s&atilde;o respons&a
acute;veis pelos fen&oacute;tipos mais suaves    da doen&ccedil;a, enquanto os d
e dele&ccedil;&atilde;o do gene SMN<SUB>1</SUB>    d&atilde;o origem &agrave;s f
ormas mais graves da AME<SUP>7,20,21</SUP>.</font></p>     ^cY#a04v86n4.htm##
00308000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007300076002001300149#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#51#47#article#235#<p><font face="Verd
ana" size="2"><a name="522f2"></a></font></p>     ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#52#48#article#235#<p>&nbsp;</p>     ^
cY#a04v86n4.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011500076002001300191#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#53#49#article#235#<p align="center"><
font face="Verdana" size="2"><img src="/img/revistas/jped/v86n4/4a04f2.gif"></fo
nt></p>     ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#54#50#article#235#<p>&nbsp;</p>     ^
cY#a04v86n4.htm##
00963000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072800076002001300804#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#55#51#article#235#<p><font face="Verd
ana" size="2">A prote&iacute;na SMN est&aacute; amplamente    distribu&iacute;da
 em todas as c&eacute;lulas do corpo<SUP>18,22</SUP>. Est&aacute;    presente ta
nto no citoplasma quanto no n&uacute;cleo da c&eacute;lula, sendo    que, no n&u
acute;cleo, se une a determinadas estruturas envolvidas com a remo&ccedil;&atild
e;o    de sequ&ecirc;ncias n&atilde;o-codificantes (&iacute;ntrons) do pr&eacute
;-RNAm    &#091;&aacute;cido ribonucleico (<i>ribonucleic acid</i>) mensageiro&#
093;.    Adicionalmente, parece que a SMN tamb&eacute;m tem participa&ccedil;&at
ilde;o    na regula&ccedil;&atilde;o da transcri&ccedil;&atilde;o e na express&a
tilde;o    de determinados genes<SUP>18,10</SUP>.</font></p>     ^cY#a04v86n4.ht
m##
01712000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704147700076002001301553#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#56#52#article#235#<p><font face="Verd
ana" size="2">Apesar dos avan&ccedil;os no conhecimento da    bioqu&iacute;mica 
da SMN, n&atilde;o est&aacute; claro como sua redu&ccedil;&atilde;o    em todos 
os tipos celulares causa especificamente degenera&ccedil;&atilde;o    dos motone
ur&ocirc;nios &#945;. Isso levanta a quest&atilde;o da possibilidade    de a SMN
 apresentar uma fun&ccedil;&atilde;o adicional restrita a esses neur&ocirc;nios.
    Nesse contexto, estudos imuno-histoqu&iacute;micos t&ecirc;m localizado a SM
N    em dendritos, cones de implanta&ccedil;&atilde;o e ax&ocirc;nios de motoneu
r&ocirc;nios,    sugerindo um papel no transporte de RNA ao longo dos ax&ocirc;n
ios<SUP>10</SUP>.    Adicionalmente, tem sido observado que os motoneur&ocirc;ni
os de camundongos    e peixes-zebra SMN-<i>knockout</i> mostram falhas em alcan&
ccedil;ar a placa    motora, apresentando ax&ocirc;nio com ramifica&ccedil;&otil
de;es aberrantes,    indicando uma forte evid&ecirc;ncia de um importante papel 
da SMN no desenvolvimento    morfol&oacute;gico e na migra&ccedil;&atilde;o axon
al<SUP>23</SUP>. Por outro    lado, a prote&iacute;na SMN tamb&eacute;m &eacute;
 encontrada p&oacute;s-sinapticamente    na jun&ccedil;&atilde;o neuromuscular e
 dentro das bandas Z do m&uacute;sculo    estriado, indicando que a patog&ecirc;
nese n&atilde;o envolve exclusivamente    o corpo celular do motoneur&ocirc;nio,
 podendo afetar tamb&eacute;m a pr&oacute;pria    fibra muscular<SUP>24</SUP>.</
font></p>     ^cY#a04v86n4.htm##
00800000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056500076002001300641#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#57#53#article#235#<p><font face="Verd
ana" size="2">Casos de indiv&iacute;duos com aus&ecirc;ncia    completa da prote
&iacute;na SMN, isto &eacute;, pacientes com AME e que apresentam    tamb&eacute
;m aus&ecirc;ncia do gene SMN<SUB>2</SUB>, nunca foram reportados.    Isto porqu
e, provavelmente, esse gen&oacute;tipo seja incompat&iacute;vel com    a vida, p
odendo a prote&iacute;na SMN ter um papel essencial durante o desenvolvimento   
 embrion&aacute;rio<SUP>19,25,26</SUP> ou apresentar uma fun&ccedil;&atilde;o   
 moduladora na apoptose neuronal<SUP>27</SUP>.</font></p>     ^cY#a04v86n4.htm##
00320000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008500076002001300161#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#58#54#article#235#<p><font face="Verd
ana" size="2"><b><i>Diagn&oacute;stico</i></b></font></p>     ^cY#a04v86n4.htm##
00561000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032600076002001300402#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#59#55#article#235#<p><font face="Verd
ana" size="2">Por ser uma desordem neurol&oacute;gica de baixa    incid&ecirc;nc
ia, o diagn&oacute;stico da AME &eacute; dif&iacute;cil. Entretanto,    pelo fat
o da AME evoluir progressivamente, a rapidez em se estabelecer um diagn&oacute;s
tico    preciso &eacute; imprescind&iacute;vel.</font></p>     ^cY#a04v86n4.htm#
#
00635000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040000076002001300476#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#60#56#article#235#<p><font face="Verd
ana" size="2">A manifesta&ccedil;&atilde;o de sinais cl&iacute;nicos    caracter
&iacute;sticos na crian&ccedil;a, como hipotonia, paresia, arreflexia    e miofa
scicula&ccedil;&otilde;es, devem ser investigados com cautela<SUP>1</SUP>,    um
a vez que esses sinais cl&iacute;nicos podem estar presentes em outras neuropato
logias    (<a href=#522t1 >Tabela 1</a>).</font></p>     ^cY#a04v86n4.htm##
00308000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007300076002001300149#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#61#57#article#235#<p><font face="Verd
ana" size="2"><a name="522t1"></a></font></p>     ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#62#58#article#235#<p>&nbsp;</p>     ^
cY#a04v86n4.htm##
00350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011500076002001300191#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#63#59#article#235#<p align="center"><
font face="Verdana" size="2"><img src="/img/revistas/jped/v86n4/4a04t1.gif"></fo
nt></p>     ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#64#60#article#235#<p>&nbsp;</p>     ^
cY#a04v86n4.htm##
00618000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038300076002001300459#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#65#61#article#235#<p><font face="Verd
ana" size="2"> Por outro lado, como as doen&ccedil;as neuromusculares    s&atild
e;o as principais causas de hipotonia na inf&acirc;ncia<sup>28</sup>    e, dentr
e elas, as que acometem as crian&ccedil;as com maior frequ&ecirc;ncia    s&atild
e;o a AME e as distrofias<sup>28,29</sup>, a <a href=/img/revistas/jped/v86n4/4a
04t2.gif>Tabela    2</a></font></p>     ^cY#a04v86n4.htm##
00630000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039500076002001300471#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#66#62#article#235#<p><font face="Verd
ana" size="2"><SUP>30</SUP> apresenta um resumo dos principais    aspectos que a
s diferenciam. Contudo, &eacute; preciso enfatizar que nem sempre    todos os as
pectos aqui descritos estar&atilde;o presentes nos pacientes, visto    que estes
 variam de acordo com o est&aacute;gio da doen&ccedil;a em que cada    indiv&iac
ute;duo se encontra ao ser avaliado.</font></p>     ^cY#a04v86n4.htm##
00770000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053500076002001300611#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#67#63#article#235#<p><font face="Verd
ana" size="2">De uma forma geral, o diagn&oacute;stico da AME    &eacute; dado p
ela evid&ecirc;ncia de desnerva&ccedil;&atilde;o muscular, constatada    na elet
romiografia e na bi&oacute;psia muscular<SUP>3</SUP>. Como exame confirmat&oacut
e;rio,    &eacute; feita tamb&eacute;m uma an&aacute;lise molecular, que &eacute
; dada    pela detec&ccedil;&atilde;o da aus&ecirc;ncia do &eacute;xon 7 do gene
 SMN<SUB>1</SUB>,    independente de sua classifica&ccedil;&atilde;o cl&iacute;n
ica<SUP>2</SUP>.</font></p>     ^cY#a04v86n4.htm##
00655000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042000076002001300496#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#68#64#article#235#<p><font face="Verd
ana" size="2">A creatinofosfoquinase (CPK) pode estar normal    ou reduzida em a
t&eacute; cinco vezes<SUP>1</SUP>. A dosagem s&eacute;rica da    CPK pode difere
nciar uma doen&ccedil;a neurog&ecirc;nica, como &eacute; o caso    da AME, de do
en&ccedil;as miop&aacute;ticas, como as distrofias, nas quais as    les&otilde;e
s musculares fazem com que os n&iacute;veis da CPK se elevem.</font></p>     ^cY
#a04v86n4.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007500076002001300151#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#69#65#article#235#<p><font face="Verd
ana" size="2"><i>Eletromiografia</i></font></p>     ^cY#a04v86n4.htm##
00515000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028000076002001300356#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#70#66#article#235#<p><font face="Verd
ana" size="2">Atrav&eacute;s da eletromiografia, pode-se distinguir    se o acom
etimento &eacute; do neur&ocirc;nio motor, de ra&iacute;zes ou nervos    perif&e
acute;ricos, da jun&ccedil;&atilde;o mioneural ou da fibra muscular<SUP>29</SUP>
.</font></p>     ^cY#a04v86n4.htm##
00937000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070200076002001300778#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#71#67#article#235#<p><font face="Verd
ana" size="2">A AME possui uma evid&ecirc;ncia eletrofisiol&oacute;gica    de de
snerva&ccedil;&atilde;o, com averigua&ccedil;&atilde;o intacta de condu&ccedil;&
atilde;o    dos nervos motor e sensorial<SUP>1,10</SUP>. S&atilde;o observados p
otenciais    de fibrila&ccedil;&atilde;o no repouso em casos de desnerva&ccedil;
&atilde;o,    seja ela localizada tanto no corno anterior quanto no nervo perif&
eacute;rico,    bem como s&atilde;o ainda encontrados potenciais de unidade moto
ra de dura&ccedil;&atilde;o    e amplitude aumentadas e pode haver redu&ccedil;&
atilde;o da velocidade de condu&ccedil;&atilde;o    motora nas formas mais preco
ces da AME<SUP>1</SUP>.</font></p>     ^cY#a04v86n4.htm##
00318000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008300076002001300159#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#72#68#article#235#<p><font face="Verd
ana" size="2"><i>Bi&oacute;psia muscular</i></font></p>     ^cY#a04v86n4.htm##
00939000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070400076002001300780#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#73#69#article#235#<p><font face="Verd
ana" size="2">Em pacientes com AME, podem ser encontradas diversas    altera&cce
dil;&otilde;es musculares. Algumas altera&ccedil;&otilde;es histopatol&oacute;gi
cas    s&atilde;o caracter&iacute;sticas, como a presen&ccedil;a de fibras muscu
lares    atr&oacute;ficas, tanto do tipo I quanto do tipo II, hipertrofia de fib
ras tipo    I ou agrupamento de tipo de fibras<SUP>1,10</SUP>. Entretanto, essas
 altera&ccedil;&otilde;es    podem tamb&eacute;m ser encontradas em outros casos
 de desnerva&ccedil;&atilde;o<SUP>31</SUP>.    Dessa forma, esse tipo de exame n
&atilde;o pode ser confirmat&oacute;rio para    AME, e sim mais um dado cl&iacut
e;nico a ser considerado.</font></p>     ^cY#a04v86n4.htm##
00589000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035400076002001300430#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#74#70#article#235#<p><font face="Verd
ana" size="2">Nas formas de evolu&ccedil;&atilde;o mais lenta,    a interposi&cc
edil;&atilde;o de altera&ccedil;&otilde;es miop&aacute;ticas secund&aacute;rias,
    como fibras angulares, n&uacute;cleos centrais, fendas e desarranjo miofibri
lar,    aumenta com a evolu&ccedil;&atilde;o da doen&ccedil;a<SUP>32</SUP>.</fon
t></p>     ^cY#a04v86n4.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010200076002001300178#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#75#71#article#235#<p><font face="Verd
ana" size="2"><i>Investiga&ccedil;&atilde;o gen&eacute;tica</i></font></p>     ^
cY#a04v86n4.htm##
00816000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058100076002001300657#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#76#72#article#235#<p><font face="Verd
ana" size="2">Os estudos de gen&eacute;tica molecular s&atilde;o    definitivos 
para o diagn&oacute;stico da AME e poderiam at&eacute; mesmo ser    os &uacute;n
icos realizados. Atrav&eacute;s de uma investiga&ccedil;&atilde;o    gen&eacute;
tica, detecta-se a aus&ecirc;ncia completa do &eacute;xon 7 do gene    SMN<SUB>1
</SUB> (com ou sem dele&ccedil;&atilde;o do &eacute;xon 8)<SUP>2,8</SUP>.    Com
o o gene SMN<SUB>2</SUB> n&atilde;o possui esse &eacute;xon, sua aus&ecirc;ncia 
   determina tamb&eacute;m a nulidade do gene SMN<SUB>1</SUB>.</font></p>     ^c
Y#a04v86n4.htm##
00669000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043400076002001300510#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#77#73#article#235#<p><font face="Verd
ana" size="2">Se o paciente com suspeita de ter AME possuir    uma c&oacute;pia 
do gene SMN<SUB>1</SUB>, neste caso, deve-se investigar se    essa c&oacute;pia 
remanescente cont&eacute;m muta&ccedil;&otilde;es brandas,    como muta&ccedil;&
otilde;es pontuais, inser&ccedil;&otilde;es e dele&ccedil;&otilde;es,    promove
ndo uma disfun&ccedil;&atilde;o homozig&oacute;tica desse gene<SUP>8</SUP>.</fon
t></p>     ^cY#a04v86n4.htm##
00669000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043400076002001300510#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#78#74#article#235#<p><font face="Verd
ana" size="2">O diagn&oacute;stico gen&eacute;tico-molecular    &eacute; mais pr
eciso e menos invasivo que os outros dois exames descritos,    por&eacute;m n&at
ilde;o est&aacute; amplamente dispon&iacute;vel no Brasil.    &Eacute; enfatizad
o que a pesquisa de dele&ccedil;&atilde;o no gene SMN &eacute;    capaz de dirim
ir situa&ccedil;&otilde;es de d&uacute;vida diagn&oacute;stica<SUP>1</SUP>.</fon
t></p>     ^cY#a04v86n4.htm##
01028000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704079300076002001300869#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#79#75#article#235#<p><font face="Verd
ana" size="2">Alternativamente, Kolb et al.<SUP>33</SUP> desenvolveram    uma t&
eacute;cnica de medida da pr&oacute;pria prote&iacute;na SMN em c&eacute;lulas  
  mononucleares (linf&oacute;citos e mon&oacute;citos), obtidas de amostras sang
u&iacute;neas    de pacientes com AME. Como esperado, os n&iacute;veis da prote&
iacute;na SMN    apresentaram-se significativamente reduzidos nos pacientes em r
ela&ccedil;&atilde;o    aos indiv&iacute;duos controles. Os autores<SUP>33</SUP>
 enfatizam que esse    ensaio poder&aacute; ser usado futuramente no acompanhame
nto de testes cl&iacute;nicos    que buscam aumentar o n&iacute;vel do RNAm e/ou
 da pr&oacute;pria prote&iacute;na    SMN, mas n&atilde;o seria a melhor escolha
 para o diagn&oacute;stico da AME.</font></p>     ^cY#a04v86n4.htm##
00312000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007700076002001300153#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#80#76#article#235#<p><font face="Verd
ana" size="2"><b><i>Tratamento</i></b></font></p>     ^cY#a04v86n4.htm##
00690000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045500076002001300531#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#81#77#article#235#<p><font face="Verd
ana" size="2">Pelo fato de estarmos diante de uma patologia    neurodegenerativa
 progressiva, a AME necessita de v&aacute;rios cuidados especiais,    que podem 
estacionar o progresso da doen&ccedil;a e prolongar a vida do indiv&iacute;duo. 
   Esses cuidados abrangem principalmente a terapia de suporte, j&aacute; que,  
  infelizmente, ainda n&atilde;o existe tratamento farmacol&oacute;gico para a  
  doen&ccedil;a.</font></p>     ^cY#a04v86n4.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007800076002001300154#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#82#78#article#235#<p><font face="Verd
ana" size="2"><i>Terapia de suporte</i></font></p>     ^cY#a04v86n4.htm##
00644000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040900076002001300485#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#83#79#article#235#<p><font face="Verd
ana" size="2">Envolve uma equipe multidisciplinar respons&aacute;vel    por prol
ongar e melhorar a qualidade de vida dos pacientes<SUP>24</SUP>. Os    cuidados 
abrangem suporte tanto respirat&oacute;rio quanto nutricional, al&eacute;m    de
 cuidados ortop&eacute;dicos e fisioterap&ecirc;uticos, para que a crian&ccedil;
a    n&atilde;o tenha um preju&iacute;zo postural.</font></p>     ^cY#a04v86n4.h
tm##
00309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007400076002001300150#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#84#80#article#235#<p><font face="Verd
ana" size="2">a) Cuidados respirat&oacute;rios:    ^cY#a04v86n4.htm##
00458000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022300076002001300299#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#85#81#article#235#<BR>   Doen&ccedil;
as pulmonares s&atilde;o a principal causa de morbimortalidade nos    pacientes 
com AME tipos I e II e podem ocorrer em uma pequena parte dos pacientes    com A
ME tipo III<SUP>8</SUP>.</font></p>     ^cY#a04v86n4.htm##
01003000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076800076002001300844#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#86#82#article#235#<p><font face="Verd
ana" size="2">Por causa da gravidade da fraqueza muscular e    pelo fato de fica
rem sempre deitados ou se levantarem muito pouco, esses pacientes    apresentam 
uma capacidade limitada de tossir e limpar secre&ccedil;&otilde;es    presentes 
nas vias a&eacute;reas inferiores. Em consequ&ecirc;ncia disso, podem    ocorrer
 infec&ccedil;&otilde;es recorrentes, que exacerbam a fraqueza muscular    (prin
cipalmente dos m&uacute;sculos respirat&oacute;rios)<SUP>8</SUP>, podendo    tam
b&eacute;m resultar em atelectasia e colapso pulmonar<SUP>24</SUP>. Al&eacute;m 
   disso, essas crian&ccedil;as podem apresentar hipoventila&ccedil;&atilde;o no
turna    e subdesenvolvimento dos pulm&otilde;es e parede tor&aacute;cica<SUP>8,
24</SUP>.</font></p>     ^cY#a04v86n4.htm##
01090000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704085500076002001300931#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#87#83#article#235#<p><font face="Verd
ana" size="2">Os cuidados ao paciente incluem um r&aacute;pido    acesso &agrave
;s interven&ccedil;&otilde;es cl&iacute;nicas especiais e suporte    respirat&oa
cute;rio quando necess&aacute;rio (incluindo desde ventila&ccedil;&atilde;o    n
&atilde;o invasiva at&eacute; traqueostomia e ventila&ccedil;&atilde;o mec&acirc
;nica).    T&eacute;cnicas de limpeza das vias a&eacute;reas e de mobiliza&ccedi
l;&atilde;o    das secre&ccedil;&otilde;es s&atilde;o muito &uacute;teis e inclu
em fisioterapia    pulmonar e drenagem postural. Tamb&eacute;m deve ter um r&aac
ute;pido acesso    &agrave; antibioticoterapia, al&eacute;m de o paciente fazer 
parte de uma rotina    de imuniza&ccedil;&otilde;es, abrangendo diversas vacinas
 contra agentes que    podem causar infec&ccedil;&otilde;es pulmonares graves<SU
P>8,24,34</SUP>.</font></p>     ^cY#a04v86n4.htm##
00816000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058100076002001300657#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#88#84#article#235#<p><font face="Verd
ana" size="2">Tanto a atrofia quanto a hipotonia musculares    exercem influ&eci
rc;ncia direta no comprometimento respirat&oacute;rio e motor    de pacientes co
m AME. Neste contexto, a fisioterapia se destaca dentro da equipe    multidiscip
linar, atuando na preven&ccedil;&atilde;o e no tratamento de deformidades    &oa
cute;sseas e nos dist&uacute;rbios respirat&oacute;rios, dando sua contribui&cce
dil;&atilde;o    na preven&ccedil;&atilde;o do progresso dessa doen&ccedil;a e n
a melhoria da    qualidade de vida dos pacientes<SUP>13</SUP>.</font></p>     ^c
Y#a04v86n4.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006600076002001300142#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#89#85#article#235#<p><font face="Verd
ana" size="2">b) Cuidados nutricionais:    ^cY#a04v86n4.htm##
00885000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065000076002001300726#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#90#86#article#235#<BR>   As crian&cce
dil;as com AME podem apresentar v&aacute;rios problemas gastrointestinais,    co
mo refluxo gastroesof&aacute;gico, constipa&ccedil;&atilde;o, distens&atilde;o  
  abdominal e esvaziamento g&aacute;strico retardado<SUP>8,24</SUP>. O refluxo  
  &eacute; um fator determinante de morbimortalidade, pois pode estar associado 
   com aspira&ccedil;&atilde;o silenciosa, o que pode resultar em pneumonia por 
   aspira&ccedil;&atilde;o e agravar ainda mais o quadro. Alimentos muito gordur
osos    devem ser evitados, pois estes atrasam o esvaziamento g&aacute;strico e 
aumentam    o risco de ocorrer refluxo<SUP>8</SUP>.</font></p>     ^cY#a04v86n4.
htm##
00744000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050900076002001300585#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#91#87#article#235#<p><font face="Verd
ana" size="2">A constipa&ccedil;&atilde;o, que tem origem multifatorial,    pode
 ocorrer em consequ&ecirc;ncia da motilidade anormal do trato gastrointestinal, 
   ingest&atilde;o reduzida de alimentos ricos em fibras e de &aacute;gua, al&ea
cute;m    da baixa tonicidade dos m&uacute;sculos da parede abdominal<SUP>8,34</
SUP>.    Adicionalmente, a redu&ccedil;&atilde;o dos movimentos intestinais ness
es pacientes    pode acarretar distens&atilde;o abdominal<SUP>8</SUP>.</font></p
>     ^cY#a04v86n4.htm##
00682000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044700076002001300523#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#92#88#article#235#<p><font face="Verd
ana" size="2">Os cuidados ao paciente incluem um tratamento    farmacol&oacute;g
ico para o refluxo gastroesof&aacute;gico, envolvendo neutralizantes    para o &
aacute;cido g&aacute;strico e/ou inibidores da secre&ccedil;&atilde;o    g&aacut
e;strica, como os inibidores da bomba de pr&oacute;tons e os bloqueadores    da 
histamina<SUP>8</SUP>, al&eacute;m dos agentes pr&oacute;-cin&eacute;ticos<SUP>2
4</SUP>.</font></p>     ^cY#a04v86n4.htm##
00789000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055400076002001300630#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#93#89#article#235#<p><font face="Verd
ana" size="2">A avalia&ccedil;&atilde;o da alimenta&ccedil;&atilde;o    por um n
utricionista pode ser realizada. Vale destacar que os pacientes com    AME podem
 ter uma massa gorda aceit&aacute;vel para seu corpo, entretanto podem    ser cl
assificados como tendo um peso abaixo do normal, baseado no crit&eacute;rio    p
eso/altura, em consequ&ecirc;ncia da sua reduzida massa corporal. Isto poderia  
  levar a uma recomenda&ccedil;&atilde;o diet&eacute;tica inapropriada, o que   
 acarretaria obesidade<SUP>8</SUP>.</font></p>     ^cY#a04v86n4.htm##
00586000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035100076002001300427#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#94#90#article#235#<p><font face="Verd
ana" size="2">Em casos graves, em que a crian&ccedil;a n&atilde;o    consegue se
 alimentar por via enteral, uma suplementa&ccedil;&atilde;o cal&oacute;rica    v
ia parenteral deve ser considerada para evitar o catabolismo muscular, principal
mente    em crian&ccedil;as com estoque reduzido de gordura<SUP>8</SUP>.</font><
/p>     ^cY#a04v86n4.htm##
00307000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007200076002001300148#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#95#91#article#235#<p><font face="Verd
ana" size="2">c) Cuidados ortop&eacute;dicos:    ^cY#a04v86n4.htm##
01040000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080500076002001300881#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#96#92#article#235#<BR>   Os principai
s problemas decorrentes da limita&ccedil;&atilde;o da fun&ccedil;&atilde;o    mo
tora de tronco e membros provocada pela fraqueza muscular incluem a deformidade 
   postural (escoliose), limita&ccedil;&atilde;o da mobilidade e da execu&ccedil
;&atilde;o    de atividades di&aacute;rias, risco aumentado de dor, osteopenia e
 fraturas<SUP>4,8,24</SUP>.    Iannaccone<SUP>34</SUP> relata que a escoliose &e
acute; rara antes do primeiro    ano, assim, n&atilde;o &eacute; normalmente vis
ta em crian&ccedil;as com AME    tipo I, mas &eacute; comum em pacientes com AME
 tipo II e menos comum nos indiv&iacute;duos    tipo III. Devido &agrave; fraque
za dos m&uacute;sculos paraespinhais, a escoliose    progride lentamente e deve 
ser monitorada com periodicidade<SUP>24</SUP>.</font></p>     ^cY#a04v86n4.htm##
00880000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064500076002001300721#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#97#93#article#235#<p><font face="Verd
ana" size="2">O paciente com AME do tipo I tamb&eacute;m apresenta    dificuldad
es relacionadas com a limita&ccedil;&atilde;o de controle da cabe&ccedil;a,    p
ostura e alinhamento. Nos pacientes do tipo II, contraturas, disfun&ccedil;&atil
de;o    respirat&oacute;ria e escoliose caracterizam os principais problemas. J&
aacute;    a combina&ccedil;&atilde;o de fraqueza muscular proximal e preju&iacu
te;zo de    equil&iacute;brio nos pacientes com AME tipo III resultam na ocorr&e
circ;ncia    de quedas frequentes e fadiga anormal durante a execu&ccedil;&atild
e;o de atividade    f&iacute;sica<SUP>8</SUP>.</font></p>     ^cY#a04v86n4.htm##
00760000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052500076002001300601#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#98#94#article#235#<p><font face="Verd
ana" size="2">As interven&ccedil;&otilde;es que podem ser feitas    para evitar 
piores consequ&ecirc;ncias s&atilde;o o controle postural, controle    de dores 
e contraturas, adapta&ccedil;&atilde;o das atividades di&aacute;rias,    mobilid
ade com cadeira de rodas ou andador, &oacute;rteses nos membros e terapias    qu
e incentivem o desenvolvimento da mobilidade, prolongando a sobreviv&ecirc;ncia 
   dessas crian&ccedil;as, al&eacute;m de aliviar o peso da doen&ccedil;a<SUP>8<
/SUP>.</font></p>     ^cY#a04v86n4.htm##
00910000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067500076002001300751#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#99#95#article#235#<p><font face="Verd
ana" size="2">Exerc&iacute;cios regulares, como a nata&ccedil;&atilde;o    ou ou
tros esportes adaptados, s&atilde;o importantes para recuperar a auto-estima    
dessas crian&ccedil;as, introduzi-las num contexto social, al&eacute;m de serem 
   importantes para a manuten&ccedil;&atilde;o da forma f&iacute;sica. Swoboda  
  et al.<SUP>13</SUP> relatam que a pr&aacute;tica de exerc&iacute;cios regulare
s    pode ser ben&eacute;fica para desenvolver m&uacute;sculos e articula&ccedil
;&otilde;es,    aumentar a densidade &oacute;ssea, melhorar a motilidade intesti
nal, al&eacute;m    de prover uma sensa&ccedil;&atilde;o geral de bem-estar.</fo
nt></p>     ^cY#a04v86n4.htm##
01086000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704085000077002001300927#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#100#96#article#235#<p><font face="Ver
dana" size="2">Grondard et al.<SUP>35</SUP> estudaram os benef&iacute;cios    da
 pr&aacute;tica de exerc&iacute;cios regulares em ratos mutantes com AME do    t
ipo II e obtiveram resultados positivos em suas avalia&ccedil;&otilde;es. Eles  
  notaram que os ratos mutantes que eram for&ccedil;ados a correr em uma roda   
 apresentavam um aumento expressivo do tempo de sobreviv&ecirc;ncia em rela&cced
il;&atilde;o    aos ratos n&atilde;o-treinados, al&eacute;m de observarem uma re
du&ccedil;&atilde;o    da morte dos motoneur&ocirc;nios medulares. Tais resultad
os sugerem que a pr&aacute;tica    regular de exerc&iacute;cios f&iacute;sicos d
everia estar associada &agrave;    terapia farmacol&oacute;gica, para testar a p
ossibilidade de efeitos ben&eacute;ficos    cumulativos contra o progresso da do
en&ccedil;a.</font></p>     ^cY#a04v86n4.htm##
00526000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704029000077002001300367#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#101#97#article#235#<p><font face="Ver
dana" size="2">Finalmente, Oskoui &amp; Kaufmann<SUP>24</SUP>    alertam que dev
eriam ser feitas modifica&ccedil;&otilde;es dentro da casa onde    essas crian&c
cedil;as moram a fim de garantir sua seguran&ccedil;a e permitir    sua independ
&ecirc;ncia.</font></p>     ^cY#a04v86n4.htm##
00316000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704008000077002001300157#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#102#98#article#235#<p><font face="Ver
dana" size="2"><i>Farmacol&oacute;gico</i></font></p>     ^cY#a04v86n4.htm##
01004000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704076800077002001300845#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#103#99#article#235#<p><font face="Ver
dana" size="2">Infelizmente, nenhum tratamento farmacol&oacute;gico    para a AM
E encontra-se hoje dispon&iacute;vel. No entanto, em virtude do progresso    no 
entendimento das bases gen&eacute;ticas e da fisiopatologia da AME, tentativas  
  em potencial para o seu tratamento est&atilde;o emergindo<SUP>36,37</SUP>. Alg
umas    drogas que est&atilde;o sendo testadas no tratamento de pacientes com AM
E t&ecirc;m    como alvo terap&ecirc;utico o gene SMN<SUB>2</SUB>. Estrat&eacute
;gias que aumentam    a transcri&ccedil;&atilde;o desse gene ou que estabilizam 
a prote&iacute;na    formada a partir dele parecem promissoras<SUP>37,38</SUP>. 
A seguir, est&atilde;o    descritas algumas drogas com essa perspectiva terap&ec
irc;utica.</font></p>     ^cY#a04v86n4.htm##
00330000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009300078002001300171#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#104#100#article#235#<p><font face="Ve
rdana" size="2">a) Drogas inibidoras da enzima histona desacetilase:    ^cY#a04v
86n4.htm##
00690000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704045300078002001300531#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#105#101#article#235#<BR>   Essa class
e de drogas tem sido investigada no tratamento da AME devido a sua    habilidade
 em ativar a transcri&ccedil;&atilde;o do gene SMN<SUB>2</SUB>, pois    quando a
 histona encontra-se acetilada (histona desacetilase inibida), os fatores    de 
transcri&ccedil;&atilde;o passam a ter uma maior acessibilidade a v&aacute;rios 
   genes (dentre eles o SMN<SUB>2</SUB>), favorecendo a transcri&ccedil;&atilde;
o    dos mesmos.</font></p>     ^cY#a04v86n4.htm##
00878000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704064100078002001300719#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#106#102#article#235#<p><font face="Ve
rdana" size="2">Drogas clinicamente conhecidas, como o &aacute;cido    valproico
, o butirato de s&oacute;dio e o fenilbutirato s&atilde;o exemplos    de compost
os que apresentam uma a&ccedil;&atilde;o inibidora sobre a enzima    histona des
acetilase. Essa propriedade as tornam candidatas em potencial para    o tratamen
to da AME, principalmente o &aacute;cido valproico<SUP>17,38,39</SUP>    e o fen
ilbutirato<SUP>40</SUP>, que apresentam uma melhor capacidade de penetra&ccedil;
&atilde;o    no SNC, aliada ao fato de terem seu perfil farmacocin&eacute;tico e
 de seguran&ccedil;a    j&aacute; descritos.</font></p>     ^cY#a04v86n4.htm##
01396000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704115900078002001301237#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#107#103#article#235#<p><font face="Ve
rdana" size="2">O &aacute;cido valproico &eacute; o inibidor    da histona desac
etilase mais investigado em testes pr&eacute;-cl&iacute;nicos    e cl&iacute;nic
os em que &eacute; analisada sua efic&aacute;cia no tratamento    da AME<SUP>17,
38,39</SUP>. A efic&aacute;cia do &aacute;cido valproico em induzir    aumento n
os n&iacute;veis da prote&iacute;na SMN foi demonstrada em culturas    de fibrob
lastos de pacientes com AME I<SUP>17,39</SUP>, fatias de hipocampo<SUP>39</SUP> 
   e em culturas de motoneur&ocirc;nios<SUP>38</SUP> de ratos apresentando um mo
delo    de AME I. Nos estudos <i>in vivo</i>, a administra&ccedil;&atilde;o de &
aacute;cido    valproico no bebedouro de camundongos com modelo de AME III, al&e
acute;m de    elevar os n&iacute;veis da prote&iacute;na SMN na medula espinhal,
 tamb&eacute;m    induziu melhora na fun&ccedil;&atilde;o motora, com potenciais
 motores evocados    maiores, menor degenera&ccedil;&atilde;o dos neur&ocirc;nio
s da medula espinhal    e uma melhor inerva&ccedil;&atilde;o da jun&ccedil;&atil
de;o neuromuscular quando    comparados com os animais SMA controles<SUP>41</SUP
>.</font></p>     ^cY#a04v86n4.htm##
01729000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704149200078002001301570#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#108#104#article#235#<p><font face="Ve
rdana" size="2">A partir desses estimulantes resultados pr&eacute;-cl&iacute;nic
os,    iniciaram-se as investiga&ccedil;&otilde;es cl&iacute;nicas. Os estudos c
l&iacute;nicos    realizados por Tsai et al.<SUP>42</SUP> e Weihl et al.<SUP>43<
/SUP> com pequeno    n&uacute;mero de pacientes, n&atilde;o-randomizados e sem p
lacebo-controlados    demonstraram uma modesta melhora na for&ccedil;a muscular 
e na fun&ccedil;&atilde;o    subjetiva. As doses do &aacute;cido valproico utili
zadas nesses estudos s&atilde;o    aquelas preconizadas para o tratamento da epi
lepsia (15 a 50 mg/kg/dia). Recentemente,    foi publicado por Swoboda et al.<SU
P>44</SUP> o primeiro estudo cl&iacute;nico    fase II com &aacute;cido valproic
o administrado (15 a 50 mg/kg/dia) a 42 pacientes    portadores de AME tipo I, I
I ou III, com idade de 2 a 31 anos. Os resultados    s&atilde;o, de certa forma,
 inconclusivos, devido provavelmente &agrave; heterogeneidade    da amostra, ond
e n&atilde;o foi poss&iacute;vel observar uma interfer&ecirc;ncia    clara da dr
oga no progresso da doen&ccedil;a, al&eacute;m de alguns pacientes    apresentar
em ganho de peso e deple&ccedil;&atilde;o de carnitina. Os pr&oacute;prios    au
tores<SUP>44</SUP> enfatizam a necessidade de ensaios cl&iacute;nicos randomizad
os,    placebo-controlados e duplo-cegos, a fim de permitirem uma investiga&cced
il;&atilde;o    mais apurada da efic&aacute;cia do &aacute;cido valproico no tra
tamento da AME.</font></p>     ^cY#a04v86n4.htm##
01103000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704086600078002001300944#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#109#105#article#235#<p><font face="Ve
rdana" size="2">Por outro lado, um trabalho ainda no prelo da    revista Neurolo
gy of Disease, executado por Rak et al.<SUP>38</SUP>, mostra    que culturas de 
motoneur&ocirc;nios de camundongos portadores de AME I, tratadas    com &aacute;
cido valproico, tamb&eacute;m aumentam a express&atilde;o da prote&iacute;na    
SMN. Por&eacute;m, inesperadamente, foi constatada uma redu&ccedil;&atilde;o    
da excitabilidade dos terminais axonais, decorrentes de uma a&ccedil;&atilde;o  
  inibit&oacute;ria da droga nos canais de Ca<SUP sa>+2</SUP sa> voltagem-depend
entes    e, possivelmente, em outros canais adicionais que contribuem para a exc
itabilidade    dos motoneur&ocirc;nios. A partir desses achados, os autores adve
rtem que o    &aacute;cido valproico poderia agravar alguns sintomas da doen&cce
dil;a no paciente    com AME.</font></p>     ^cY#a04v86n4.htm##
00656000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704041900078002001300497#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#110#106#article#235#<p><font face="Ve
rdana" size="2">Outras drogas que est&atilde;o em fase de estudo    pr&eacute;-c
l&iacute;nico e cl&iacute;nico s&atilde;o a hidroxiureia<SUP>37,45</SUP>    e as
 quinazolonas<SUP>37</SUP>, que t&ecirc;m a capacidade de ativar a transcri&cced
il;&atilde;o    do gene SMN<SUB>2</SUB> atrav&eacute;s de mecanismos que n&atild
e;o interferem    na atividade da enzima histona desacetilase.</font></p>     ^c
Y#a04v86n4.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010100078002001300179#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#111#107#article#235#<p><font face="Ve
rdana" size="2">b) Drogas estabilizadoras da prote&iacute;na    SMN&#8710;7:    
^cY#a04v86n4.htm##
01026000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704078900078002001300867#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#112#108#article#235#<BR>   Pertencem 
a esse grupo, o indoprofeno<SUP>46</SUP> (anti-inflamat&oacute;rio    n&atilde;o
-esteroidal) e alguns antibi&oacute;ticos aminoglicos&iacute;deos,    como a ami
cacina e a tobramicina<SUP>47</SUP>. Essas drogas t&ecirc;m a habilidade    de a
umentar a efici&ecirc;ncia do processo de tradu&ccedil;&atilde;o da prote&iacute
;na    derivada do gene SMN<SUB>2</SUB>, resultando em uma prote&iacute;na mais 
est&aacute;vel.    Infelizmente, tanto o indoprofeno quanto os aminoglicos&iacut
e;deos t&ecirc;m    uma pobre penetra&ccedil;&atilde;o no SNC<SUP>37</SUP>. A s&
iacute;ntese de    compostos que ret&ecirc;m essa atividade estabilizadora e que
 sejam capazes    de atravessar a barreira hematoencef&aacute;lica &eacute; agua
rdada com grande    expectativa.</font></p>     ^cY#a04v86n4.htm##
00375000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704013800078002001300216#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#113#109#article#235#<p><font face="Ve
rdana" size="2"><b><i>Perspectivas futuras para o diagn&oacute;stico    e o trat
amento da AME</i></b></font></p>     ^cY#a04v86n4.htm##
00828000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704059100078002001300669#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#114#110#article#235#<p><font face="Ve
rdana" size="2">Existem ainda v&aacute;rias inc&oacute;gnitas    sobre a AME que
 precisam ser solucionadas. Wang et al.<SUP>8</SUP> preconizam    que, em vista 
dos avan&ccedil;os terap&ecirc;uticos recentes, &eacute; poss&iacute;vel    que 
no futuro a AME possa ser tratada mais eficientemente em pacientes pr&eacute;-si
ntom&aacute;ticos,    diagnosticados t&atilde;o brevemente quanto o in&iacute;ci
o do desenvolvimento    da doen&ccedil;a, bem como que a interrup&ccedil;&atilde
;o do progresso se inicie    antes mesmo de a fraqueza se tornar aparente.</font
></p>     ^cY#a04v86n4.htm##
01210000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704097300078002001301051#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#115#111#article#235#<p><font face="Ve
rdana" size="2">Dados preliminares de estudos eletrofisiol&oacute;gicos    que i
ncluem a estima&ccedil;&atilde;o de unidades motoras em crian&ccedil;as    com A
ME sugerem que a perda de motoneur&ocirc;nios &eacute; mais significante    no p
er&iacute;odo p&oacute;s-natal para a maioria dos pacientes<SUP>13</SUP>.    Por
 isso, seria necess&aacute;rio o estabelecimento de exames para diagn&oacute;sti
co    neonatal, ou at&eacute; mesmo para a detec&ccedil;&atilde;o pr&eacute;-nat
al    da AME, a fim de se antecipar o acesso a cuidados m&eacute;dicos especiais
.    Wirth et al.<SUP>10</SUP> relatam que, em fam&iacute;lias com risco de ter 
uma    crian&ccedil;a com AME, poderia ser oferecido um diagn&oacute;stico pr&ea
cute;-natal    atrav&eacute;s da an&aacute;lise de amostras da vilosidade cori&o
circ;nica (10ª    e 12ª semana de gesta&ccedil;&atilde;o) ou do fluido amni&oacu
te;tico (14ª e    16ª semana de gesta&ccedil;&atilde;o).</font></p>     ^cY#a04v
86n4.htm##
00953000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704071600078002001300794#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#116#112#article#235#<p><font face="Ve
rdana" size="2">No Brasil, o Centro de Estudos do Genoma Humano,    na Universid
ade de S&atilde;o Paulo (CEGH-USP), oferece um diagn&oacute;stico    pr&eacute;-
natal a casais que j&aacute; tiveram um filho com AME, j&aacute;    que estes co
rrem um risco de 25% em cada gesta&ccedil;&atilde;o de ter outro    filho com a 
mesma doen&ccedil;a. N&atilde;o se deve interpretar um diagn&oacute;stico    de 
doen&ccedil;a gen&eacute;tica positivo como fator determinante para se interromp
er    a gesta&ccedil;&atilde;o, e sim apenas como chave para a introdu&ccedil;&a
tilde;o    de uma terap&ecirc;utica antes mesmo que o beb&ecirc; desenvolva sint
omas relacionados    com a enfermidade.</font></p>     ^cY#a04v86n4.htm##
00954000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704071700078002001300795#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#117#113#article#235#<p><font face="Ve
rdana" size="2">Assim, tamb&eacute;m vale comentar que de nada    adianta um dia
gn&oacute;stico pr&eacute;-natal se n&atilde;o houver uma terap&ecirc;utica    a
dequada, que tenha uma resposta positiva sem provocar efeitos colaterais delet&e
acute;rios    tanto para a gestante como para o seu filho. No entanto, isto ser&
aacute; poss&iacute;vel    apenas a partir do momento em que houver um projeto u
niversal para rec&eacute;m-nascidos,    infra-estrutura necess&aacute;ria para i
nclu&iacute;-los em ensaios cl&iacute;nicos,    al&eacute;m da regulamenta&ccedi
l;&atilde;o &eacute;tica aprovada para tratamento    dessas crian&ccedil;as pr&e
acute;-sintom&aacute;ticas<SUP>24</SUP>.</font></p>     ^cY#a04v86n4.htm##
01428000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704119100078002001301269#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#118#114#article#235#<p><font face="Ve
rdana" size="2">Da mesma forma, a utiliza&ccedil;&atilde;o das    c&eacute;lulas
-tronco vem sendo estudada como fonte celular promissora para    o tratamento de
 desordens relacionadas com a perda dessas c&eacute;lulas exclusivas,    como &e
acute; o caso da AME<SUP>48</SUP>. &Eacute; importante destacar que existem    v
&aacute;rios obst&aacute;culos que os pesquisadores devem superar a fim de    co
mprovarem a utiliza&ccedil;&atilde;o eficaz das c&eacute;lulas-tronco. Dentre   
 eles, podemos citar: a produ&ccedil;&atilde;o de uma grande quantidade de moton
eur&ocirc;nios    diferenciados obtidos das c&eacute;lulas-tronco<SUP>49</SUP>; 
a perman&ecirc;ncia    de c&eacute;lulas parcialmente diferenciadas no sistema n
ervoso ap&oacute;s    seu implante; as c&eacute;lulas t&ecirc;m que ter a capaci
dade de estender seus    ax&ocirc;nios e criar sinapses; e, por &uacute;ltimo, t
odas elas devem resultar    em uma recupera&ccedil;&atilde;o funcional significa
tiva<SUP>24</SUP>. Assim,    num futuro n&atilde;o t&atilde;o pr&oacute;ximo, as
 c&eacute;lulas-tronco poder&atilde;o    ser utilizadas na recupera&ccedil;&atil
de;o de desordens neuromusculares.</font></p>     ^cY#a04v86n4.htm##
00571000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704033400078002001300412#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#119#115#article#235#<p><font face="Ve
rdana" size="2">Finalmente, subst&acirc;ncias com a&ccedil;&atilde;o    neuropro
tetora (como a cardiotrofina-1)<SUP>50</SUP>, bem como a convers&atilde;o    gen
&eacute;tica do gene SMN<SUB>2</SUB> em SMN<SUB>1</SUB><SUP>51</SUP>, tamb&eacut
e;m    s&atilde;o propostas terap&ecirc;uticas em estudo.</font></p>     ^cY#a04
v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#120#116#article#235#<p>&nbsp;</p>    
 ^cY#a04v86n4.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009400078002001300172#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#121#117#article#235#<p><font size="3"
 face="Verdana"><b>Considera&ccedil;&otilde;es finais</b></font></p>     ^cY#a04
v86n4.htm##
00832000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704059500078002001300673#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#122#118#article#235#<p><font size="2"
 face="Verdana">Tanto o acompanhamento m&eacute;dico quanto os    cuidados palia
tivos s&atilde;o importantes durante toda a vida dos pacientes    com AME. Tais 
cuidados abrangem suporte tanto respirat&oacute;rio quanto nutricional,    al&ea
cute;m de cuidados ortop&eacute;dicos e fisioterap&ecirc;uticos para que    a cr
ian&ccedil;a n&atilde;o tenha um preju&iacute;zo postural. Al&eacute;m destes,  
  tamb&eacute;m podemos citar tratamentos farmacol&oacute;gicos, que ainda est&a
tilde;o    em estudo, tanto com drogas novas como drogas j&aacute; conhecidas.</
font></p>     ^cY#a04v86n4.htm##
00963000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704072600078002001300804#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#123#119#article#235#<p><font face="Ve
rdana" size="2">N&atilde;o se deve esperar que os tratamentos    farmacol&oacute
;gicos em estudo possam recuperar os motoneur&ocirc;nios ou as    c&eacute;lulas
 musculares que j&aacute; foram perdidas por causa da atrofia.    Em vez disso, 
o objetivo &eacute; retardar o progresso da doen&ccedil;a e melhorar    a fun&cc
edil;&atilde;o muscular residual dos pacientes com AME. Infelizmente,    a paral
isia pode ser estacionada, mas n&atilde;o revertida. Entretanto, atrav&eacute;s 
   dos cuidados m&eacute;dicos e de reabilita&ccedil;&atilde;o, muitos pacientes
    com AME podem desfrutar completamente e de forma produtiva suas vidas e freq
uentemente    ter uma expectativa de vida normal.</font></p>     ^cY#a04v86n4.ht
m##
00828000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704059100078002001300669#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#124#120#article#235#<p><font face="Ve
rdana" size="2">Finalmente, outro ponto importante a ser ressaltado    &eacute; 
que, pelo fato da AME ser uma desordem de origem gen&eacute;tica recessiva,    o
 aconselhamento gen&eacute;tico &eacute; um componente essencial para as fam&iac
ute;lias    desses pacientes. Atrav&eacute;s do aconselhamento gen&eacute;tico, 
os pais,    que s&atilde;o portadores da AME, devem ser motivados a terem cautel
a em planejar    futuras gesta&ccedil;&otilde;es, visto que o risco de se ter fi
lhos com a mesma    heran&ccedil;a gen&eacute;tica n&atilde;o se extingue.</font
></p>     ^cY#a04v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#125#121#article#235#<p>&nbsp;</p>    
 ^cY#a04v86n4.htm##
00314000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704007700078002001300155#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#126#122#article#235#<p><font size="3"
 face="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#a04v86n4.htm##
00435000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704018400080002001300264#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#127#123#article#235#1#<p>
<font size="2" face="Verdana">1. Ara&uacute;jo AP, Ramos VG, Cabello PH. Dificul
dades    diagn&oacute;sticas na atrofia muscular espinhal. Arq Neuropsiquiatr. 2
005;63:145-9.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#128#124#article#235#</font></p>     ^
cY#a04v86n4.htm##
00383000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704013200080002001300212#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#129#125#article#235#2#<p>
<font size="2" face="Verdana">2. Prior TW. Spinal muscular atrophy diagnostics. 
   J Child Neurol. 2007;22:952-6. Review.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#130#126#article#235#</font></p>     ^
cY#a04v86n4.htm##
00418000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704016700080002001300247#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#131#127#article#235#3#<p>
<font size="2" face="Verdana">3. Russman BS. Spinal muscular atrophy: clinical  
  classifications and disease heterogeneity. J Child Neurol. 2007;22:946-51.    
^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#132#128#article#235#</font></p>     ^
cY#a04v86n4.htm##
00511000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704026000080002001300340#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#133#129#article#235#4#<p>
<font size="2" face="Verdana">4. Shanmugarajan S, Swoboda KJ, Iannaccone ST,    
Ries WL, Maria BL, Reddy SV. Congenital bone fractures in spinal muscular atroph
y:    functional role for SMN protein in bone remodeling. J Child Neurol. 2007;2
2:967-73.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#134#130#article#235#</font></p>     ^
cY#a04v86n4.htm##
00561000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704031000080002001300390#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#135#131#article#235#5#<p>
<font size="2" face="Verdana">5. Feldk&ouml;tter M, Schwarzer V, Wirth R, Wienke
r    TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time ligh
tCycler    PCR: fast and reliable carrier testing and prediction of severity of 
spinal    muscular atrophy. Am J Hum Genet. 2002;70:358-68.    ^cY#a04v86n4.htm#
#
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#136#132#article#235#</font></p>     ^
cY#a04v86n4.htm##
00456000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704020500080002001300285#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#137#133#article#235#6#<p>
<font size="2" face="Verdana">6. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai  
  CH, Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl  
  Acad Sci U S A. 2001;98:9808-13.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#138#134#article#235#</font></p>     ^
cY#a04v86n4.htm##
00510000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704025900080002001300339#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#139#135#article#235#7#<p>
<font size="2" face="Verdana">7. Campbell L, Potter A, Ignatius J, Dubowitz    V
, Davies K. Genomic variation and gene conversion in spinal muscular atrophy:   
 implications for disease process and clinical phenotype. Am J Hum Genet. 1997;6
1:40-50.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#140#136#article#235#</font></p>     ^
cY#a04v86n4.htm##
00471000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704022000080002001300300#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#141#137#article#235#8#<p>
<font size="2" face="Verdana">8. Wang CH, Finkel RS, Bertini ES, Schroth M,    S
imonds A, Wong B, et al. Consensus statement for standard of care in spinal    m
uscular atrophy. J Child Neurol. 2007;22:1027-49.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#142#138#article#235#</font></p>     ^
cY#a04v86n4.htm##
00460000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704020900080002001300289#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#143#139#article#235#9#<p>
<font size="2" face="Verdana">9. Oskoui M, Levy G, Garland CJ, Gray JM, O'Hagen 
   J, De Vivo DC, et al. The changing natural history of spinal muscular atrophy
    type 1. Neurology. 2007;69:1931-6.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#144#140#article#235#</font></p>     ^
cY#a04v86n4.htm##
00422000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017000081002001300251#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#145#141#article#235#10#<p
><font size="2" face="Verdana">10. Wirth B, Brichta L, Hahnen E. Spinal muscular
    atrophy: from gene to therapy. Semin Pediatr Neurol. 2006;13:121-31. Review.
    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#146#142#article#235#</font></p>     ^
cY#a04v86n4.htm##
00521000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026900081002001300350#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#147#143#article#235#11#<p
><font size="2" face="Verdana">11. Zerres K, Rudnik-Sch&ouml;neborn S. Natural  
  history in proximal spinal muscular atrophy. Clinical analysis of 445 patients
    and suggestions for a modification of existing classifications. Arch Neurol.
    1995;52:518-23.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#148#144#article#235#</font></p>     ^
cY#a04v86n4.htm##
00391000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704013900081002001300220#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#149#145#article#235#12#<p
><font size="2" face="Verdana">12. Sumner CJ. Molecular mechanisms of spinal    
muscular atrophy. J Child Neurol. 2007;22:979-89.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#150#146#article#235#</font></p>     ^
cY#a04v86n4.htm##
00471000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021900081002001300300#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#151#147#article#235#13#<p
><font size="2" face="Verdana">13. Swoboda KJ, Kissel JT, Crawford TO, Bromberg 
   MB, Acsadi G, D'Anjou G, et al. Perspectives on clinical trials in spinal mus
cular    atrophy. J Child Neurol. 2007;22:957-66.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#152#148#article#235#</font></p>     ^
cY#a04v86n4.htm##
00496000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024400081002001300325#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#153#149#article#235#14#<p
><font size="2" face="Verdana">14. Heier CR, Gogliotti RG, DiDonato CJ. SMN    t
ranscript stability: could modulation of messenger RNA degradation provide    a 
novel therapy for spinal muscular atrophy? J Child Neurol. 2007;22:1013-8.    ^c
Y#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#154#150#article#235#</font></p>     ^
cY#a04v86n4.htm##
00463000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021100081002001300292#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#155#151#article#235#15#<p
><font size="2" face="Verdana">15. Meldrum C, Scott C, Swoboda KJ. Spinal muscul
ar    atrophy genetic counseling access and genetic knowledge: parents' perspest
ives.    J Child Neurol. 2007;22:1019-26.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#156#152#article#235#</font></p>     ^
cY#a04v86n4.htm##
00488000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023600081002001300317#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#157#153#article#235#16#<p
><font size="2" face="Verdana">16. Lefebvre S, B&uuml;rglen L, Reboullet S,    C
lermont O, Burlet P, Viollet L, et al. Identification and characterization    of
 a spinal muscular atrophy-determining gene. Cell. 1995;80:155-65.    ^cY#a04v86
n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#158#154#article#235#</font></p>     ^
cY#a04v86n4.htm##
00479000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022700081002001300308#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#159#155#article#235#17#<p
><font size="2" face="Verdana">17. Sumner CJ, Huynh TN, Markowitz JA, Perhac    
JS, Hill B, Coovet DD, et al. Valproic acid increases SMN levels in spinal muscu
lar    atrophy patient cells. Ann Neurol. 2003;54:647-54.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#160#156#article#235#</font></p>     ^
cY#a04v86n4.htm##
00462000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021000081002001300291#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#161#157#article#235#18#<p
><font size="2" face="Verdana">18. Burghes AH, Beattie CE. Spinal muscular atrop
hy:    why do low levels of survival motor neuron protein make motor neurons sic
k?    Nat Rev Neurosci. 2009;10:597-609.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#162#158#article#235#</font></p>     ^
cY#a04v86n4.htm##
00562000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031000081002001300391#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#163#159#article#235#19#<p
><font size="2" face="Verdana">19. Monani UR, Sendtner M, Coovert DD, Parsons   
 DW, Andreassi C, Le TT, et al. The human centromeric survival motor neuron gene
    (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse w
ith    spinal muscular atrophy. Hum Mol Genet. 2000;9:333-9.    ^cY#a04v86n4.htm
##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#164#160#article#235#</font></p>     ^
cY#a04v86n4.htm##
00406000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704015400081002001300235#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#165#161#article#235#20#<p
><font size="2" face="Verdana">20. Burghes AH. When is a deletion not a deletion
?    When it is converted. Am J Hum Genet. 1997;61:9-15. Review.    ^cY#a04v86n4
.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#166#162#article#235#</font></p>     ^
cY#a04v86n4.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028100081002001300362#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#167#163#article#235#21#<p
><font size="2" face="Verdana">21. McAndrew PE, Parsons DW, Simard LR, Rochette 
   C, Ray PN, Mendell JR, et al. Identification of proximal spinal muscular atro
phy    carriers and patients by analysis of SMNT and SMNC gene copy number. Am J
 Hum    Genet. 1997;60:1411-22.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#168#164#article#235#</font></p>     ^
cY#a04v86n4.htm##
00475000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022300081002001300304#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#169#165#article#235#22#<p
><font size="2" face="Verdana">22. Coovert DD, Le TT, McAndrew PE, Strasswimmer 
   J, Crawford TO, Mendell JR, et al. The survival motor neuron protein in spina
l    muscular atrophy. Hum Mol Genet. 1997;6:1205-14.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#170#166#article#235#</font></p>     ^
cY#a04v86n4.htm##
00503000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025100081002001300332#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#171#167#article#235#23#<p
><font size="2" face="Verdana">23. McWhorter ML, Monani UR, Burghes AH, Beattie 
   CE. Knockdown of the survival motor neuron (Smn) protein in zebrafish causes 
   defects in motor axon outgrowth and pathfinding. J Cell Biol. 2003;162:919-31
.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#172#168#article#235#</font></p>     ^
cY#a04v86n4.htm##
00389000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704013700081002001300218#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#173#169#article#235#24#<p
><font size="2" face="Verdana">24. Oskoui M, Kaufmann P. Spinal muscular atrophy
.    Neurotherapeutics. 2008;5:499-506. Review.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#174#170#article#235#</font></p>     ^
cY#a04v86n4.htm##
00402000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704015000081002001300231#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#175#171#article#235#25#<p
><font size="2" face="Verdana">25. Kolb SJ, Battle DJ, Dreyfuss G. Molecular    
functions of the SMN complex. J Child Neurol. 2007;22:990-4.    ^cY#a04v86n4.htm
##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#176#172#article#235#</font></p>     ^
cY#a04v86n4.htm##
00453000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020100081002001300282#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#177#173#article#235#26#<p
><font size="2" face="Verdana">26. Beattie CE, Carrel TL, Mcwhorter ML. Fishing 
   for a mechanism: using zebrafish to understand spinal muscular atrophy. J Chi
ld    Neurol. 2007;22:995-1003.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#178#174#article#235#</font></p>     ^
cY#a04v86n4.htm##
00467000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021500081002001300296#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#179#175#article#235#27#<p
><font size="2" face="Verdana">27. Kerr DA, Nery JP, Traystman RJ, Chau BN,    H
ardwick JM. Survival motor neuron protein modulates neuron-specific apoptosis.  
  Proc Natl Acad Sci U S A. 2000;97:13312-17.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#180#176#article#235#</font></p>     ^
cY#a04v86n4.htm##
00376000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704012400081002001300205#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#181#177#article#235#28#<p
><font size="2" face="Verdana">28. Diz MA, Diz MC. Hipotonia na inf&acirc;ncia. 
   An Prod Acad Doc. 2007;1:184-9.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#182#178#article#235#</font></p>     ^
cY#a04v86n4.htm##
00385000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704013300081002001300214#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#183#179#article#235#29#<p
><font size="2" face="Verdana">29. Reed UC. Doen&ccedil;as neuromusculares.    J
 Pediatr (Rio J). 2002;78 Suppl 1:S89-S103.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#184#180#article#235#</font></p>     ^
cY#a04v86n4.htm##
00593000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034100081002001300422#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#185#181#article#235#30#<p
><font size="2" face="Verdana">30. ABRAME &#150; Associa&ccedil;&atilde;o Brasil
eira    de Amiotrofia Espinhal. Diferen&ccedil;as entre Atrofias e Distrofias. <
A href=http://www.atrofiaespinhal.org/oque_atrofia_distrofia.php target="_blank"
>http://www.atrofiaespinhal.org/oque_atrofia_distrofia.php</A>.    Acessado em: 
12/05/2008.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#186#182#article#235#</font></p>     ^
cY#a04v86n4.htm##
00458000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020600081002001300287#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#187#183#article#235#31#<p
><font size="2" face="Verdana">31. Pons R, Andreetta F, Wang CH, Vu TH, Bonilla 
   E, DiMauro S, et al. Mitochondrial myopathy simulating spinal muscular atroph
y.    Pediatr Neurol. 1996;15:153-8.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#188#184#article#235#</font></p>     ^
cY#a04v86n4.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027100081002001300352#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#189#185#article#235#32#<p
><font size="2" face="Verdana">32. Mastaglia FL, Walton JN. Histological and    
histochemical changes in skeletal muscle from cases of chronic juvenile and    e
arly adult spinal muscular atrophy (the Kugelberg-Welander syndrome). J Neurol  
  Sci. 1971;12:15-44.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#190#186#article#235#</font></p>     ^
cY#a04v86n4.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023800081002001300319#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#191#187#article#235#33#<p
><font size="2" face="Verdana">33. Kolb SJ, Gubitz AK, Olszewski RF Jr, Ottinger
    E, Sumner CJ, Fischbeck KH, et al. A novel cell imunoassay to measure surviv
al    of motor neurons protein in blood cells. BMC Neurol. 2006;6:6.    ^cY#a04v
86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#192#188#article#235#</font></p>     ^
cY#a04v86n4.htm##
00391000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704013900081002001300220#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#193#189#article#235#34#<p
><font size="2" face="Verdana">34. Iannaccone ST. Modern management of spinal   
 muscular atrophy. J Child Neurol. 2007;22:974-8.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#194#190#article#235#</font></p>     ^
cY#a04v86n4.htm##
00502000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025000081002001300331#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#195#191#article#235#35#<p
><font size="2" face="Verdana">35. Grondard C, Biondi O, Armand AS, L&eacute;col
le    S, Della Gaspera BD, Pariset C, et al. Regular exercise prolongs survival 
in    a type 2 spinal muscular atrophy model mouse. J Neurosci. 2005;25:7615-22.
    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#196#192#article#235#</font></p>     ^
cY#a04v86n4.htm##
00452000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020000081002001300281#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#197#193#article#235#36#<p
><font size="2" face="Verdana">36. Lunke S, El-Osta A. The emerging role of    e
pigenetic modifications and chromatin remodeling in spinal muscular atrophy.    
J Neurochem. 2009;109:1557-69.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#198#194#article#235#</font></p>     ^
cY#a04v86n4.htm##
00396000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704014400081002001300225#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#199#195#article#235#37#<p
><font size="2" face="Verdana">37. Sumner CJ. Therapeutics development for spina
l    muscular atrophy. NeuroRx. 2006;3:235-45. Review.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#200#196#article#235#</font></p>     ^
cY#a04v86n4.htm##
00467000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021500081002001300296#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#201#197#article#235#38#<p
><font size="2" face="Verdana">38. Rak K, Lechner BD, Schneider C, Drexl H,    S
endtner M, Jablonka S. Valproic acid blocks excitability in SMA type I mouse    
motor neurons. Neurobiol Dis. 2009;36:477-87.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#202#198#article#235#</font></p>     ^
cY#a04v86n4.htm##
00532000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028000081002001300361#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#203#199#article#235#39#<p
><font size="2" face="Verdana">39. Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl 
   FA, Raschke H, Blumcke I, et al. Valproic acid increases the SMN2 protein lev
el:    a well-known drug as a potential therapy for spinal muscular atrophy. Hum
 Mol    Genet. 2003;12:2481-9.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#204#200#article#235#</font></p>     ^
cY#a04v86n4.htm##
00486000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023400081002001300315#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#205#201#article#235#40#<p
><font size="2" face="Verdana">40. Brahe C, Vitali T, Tiziano FD, Angelozzi    C
, Pinto AM, Borgo F, et al. Phenylbutyrate increases SMN gene expression in    s
pinal muscular atrophy patients. Eur J Hum Genet. 2005;13:256-9.    ^cY#a04v86n4
.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#206#202#article#235#</font></p>     ^
cY#a04v86n4.htm##
00448000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019600081002001300277#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#207#203#article#235#41#<p
><font size="2" face="Verdana">41. Tsai LK, Tsai MS, Ting CH, Li H. Multiple    
therapeutic effects of valproic acid in spinal muscular atrophy model mice.    J
 Mol Med. 2008;86:1243-54.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#208#204#article#235#</font></p>     ^
cY#a04v86n4.htm##
00429000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017700081002001300258#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#209#205#article#235#42#<p
><font size="2" face="Verdana">42. Tsai LK, Yang CC, Hwu WL, Li H. Valproic    a
cid treatment in six patients with spinal muscular atrophy. Eur J Neurol. 2007;1
4:e8-9.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#210#206#article#235#</font></p>     ^
cY#a04v86n4.htm##
00459000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020700081002001300288#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#211#207#article#235#43#<p
><font size="2" face="Verdana">43. Weihl CC, Connolly AM, Pestronk A. Valproate 
   may improve strength and function in patients with type III/IV spinal muscle 
   atrophy. Neurology. 2006;67:500-1.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#212#208#article#235#</font></p>     ^
cY#a04v86n4.htm##
00470000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021800081002001300299#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#213#209#article#235#44#<p
><font size="2" face="Verdana">44. Swoboda KJ, Scott CB, Reyna SP, Prior TW,    
LaSalle B, Sorenson Sl, et al. Phase II open label study of valproic acid in    
spinal muscular atrophy. PLoS One. 2009;4:e5268.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#214#210#article#235#</font></p>     ^
cY#a04v86n4.htm##
00468000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021600081002001300297#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#215#211#article#235#45#<p
><font size="2" face="Verdana">45. Liang WC, You CY, Chang JG, Chen YC, Chang   
 YF, Wang HY, et al. The effect of hydroxyurea in spinal muscular atrophy cells 
   and patients. J Neurol Sci. 2008;268:87-94.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#216#212#article#235#</font></p>     ^
cY#a04v86n4.htm##
00508000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025600081002001300337#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#217#213#article#235#46#<p
><font size="2" face="Verdana">46. Lunn MR, Root DE, Martino AM, Flaherty SP,   
 Kelley BP, Coovert DD, et al. Indoprofen upregulates the survival motor neuron 
   protein through a cyclooxygenase-independent mechanism. Chem Biol. 2004;11:14
89-93.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#218#214#article#235#</font></p>     ^
cY#a04v86n4.htm##
00527000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027500081002001300356#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#219#215#article#235#47#<p
><font size="2" face="Verdana">47. Wolstencroft EC, Mattis V, Bajer AA, Young   
 PJ, Lorson CL. A non-sequence-specific requirement for SMN protein activity:   
 the role of aminoglycosides in inducing elevated SMN protein levels. Hum Mol   
 Genet. 2005;14:1199-210.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#220#216#article#235#</font></p>     ^
cY#a04v86n4.htm##
00504000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025200081002001300333#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#221#217#article#235#48#<p
><font size="2" face="Verdana">48. Lee H, Shamy GA, Elkabetz Y, Schofield CM,   
 Harrsion NL, Panagiotakos G, et al. Directed differentiation and transplantatio
n    of human embryonic stem cell-derived motoneurons. Stem Cells. 2007;25:1931-
9.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#222#218#article#235#</font></p>     ^
cY#a04v86n4.htm##
00440000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018800081002001300269#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#223#219#article#235#49#<p
><font size="2" face="Verdana">49. Nayak MS, Kim YS, Goldman M, Keirstead HS,   
 Kerr DA. Cellular therapies in motor neuron diseases. Biochim Biophys Acta.    
2006;1762:1128-38.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#224#220#article#235#</font></p>     ^
cY#a04v86n4.htm##
00510000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025800081002001300339#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#225#221#article#235#50#<p
><font size="2" face="Verdana">50. Lesbordes JC, Cifuentes-Diaz C, Miroglio    A
, Joshi V, Bordet T, Kahn A, et al. Therapeutic benefits of cardiotrophin-1    g
ene transfer in a mouse model of spinal muscular atrophy. Hum Mol Genet. 2003;12
:1233-9.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#226#222#article#235#</font></p>     ^
cY#a04v86n4.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022100081002001300302#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#p#227#223#article#235#51#<p
><font size="2" face="Verdana">51. DiMatteo D, Callahan S, Kmiec EB. Genetic    
conversion of an SMN2 gene to SMN1: a novel approach to the treatment of spinal 
   muscular atrophy. Exp Cell Res. 2008;314:878-86.    ^cY#a04v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#228#224#article#235#</font></p>     ^
cY#a04v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#229#225#article#235#<p>&nbsp;</p>    
 ^cY#a04v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#230#226#article#235#<p>&nbsp;</p>    
 ^cY#a04v86n4.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018000078002001300258#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#231#227#article#235#<p><font size="2"
 face="Verdana"><a name="correspondence"></a><a href="#topo"><img src="/img/revi
stas/jped/v86n4/seta.gif" border="0"></a>    <b> Correspond&ecirc;ncia:</b>    ^
cY#a04v86n4.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#232#228#article#235#<br>   Celia Regi
na Ambiel    ^cY#a04v86n4.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004600078002001300124#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#233#229#article#235#<BR>   Rua Carlos
 Roberto Seghezzi 668    ^cY#a04v86n4.htm##
00287000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005000078002001300128#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#234#230#article#235#<BR>   CEP 87140-
000 - Pai&ccedil;andu, PR    ^cY#a04v86n4.htm##
00322000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008500078002001300163#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#235#231#article#235#<BR>   E-mail: <A
 href=mailto:crasilva@uem.br>crasilva@uem.br</A></font></p>     ^cY#a04v86n4.htm
##
00339000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010200078002001300180#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#236#232#article#235#<p><font size="2"
 face="Verdana">Artigo submetido em 26.08.09, aceito em 14.10.09.</font></p>    
 ^cY#a04v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#237#233#article#235#<p>&nbsp;</p>    
 ^cY#a04v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#238#234#article#235#<p>&nbsp;</p>    
 ^cY#a04v86n4.htm##
00403000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704016600078002001300244#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a04v86n4.htm#S#p#239#235#article#235#<p><font size="2"
 face="Verdana"> N&atilde;o foram declarados conflitos de interesse    associado
s &agrave; publica&ccedil;&atilde;o deste artigo.</font></p>     ^cY#a04v86n4.ht
m##
00570000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100016000940100
01800110012005900128030001900187065000900206064000500215031000300220014000600223
865000900229002001300238035001000251801001900261#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a04v86n4.htm#S#c#240#1#article#51#1#^rND^sAraújo^nAP#^rND^sRamos^nVG#^
rND^sCabello^nPH#Dificuldades diagnósticas na atrofia muscular espinhal^lpt#Arq 
Neuropsiquiatr#20050000#2005#63#145-9#20100800#a04v86n4.htm#0004-282X#Arq Neurop
siquiatr##
00451000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770120040000940300
01600134710000200150065000900152064000500161031000300166014000600169865000900175
002001300184#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#241#2#art
icle#51#2#^rND^sPrior^nTW.#Spinal muscular atrophy diagnostics^len#J Child Neuro
l.#2#20070000#2007#22#952-6#20100800#a04v86n4.htm##
00494000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770120081000950300
01600176710000200192065000900194064000500203031000300208014000700211865000900218
002001300227#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#242#3#art
icle#51#3#^rND^sRussman^nBS#Spinal muscular atrophy: clinical classifications an
d disease heterogeneity.^len#J Child Neurol.#2#20070000#2007#22#946-51#20100800#
a04v86n4.htm##
00707000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100023000770100018001000100
02100118010001500139010001600154010001600170012010900186030001500295065000900310
06400050031903100030032401400070032786500090033400200130034303500100035680100150
0366#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#243#4#article#51#
4#^rND^sShanmugarajan^nS#^rND^sSwoboda^nKJ#^rND^sIannaccone^nST#^rND^sRies^nWL#^
rND^sMaria^nBL#^rND^sReddy^nSV#Congenital bone fractures in spinal muscular atro
phy: functional role for SMN protein in bone remodeling^len#J Child Neurol#20070
000#2007#22#967-73#20100800#a04v86n4.htm#0883-0738#J Child Neurol##
00732000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100019000970100
01500116010001800131010001600149012016700165030001500332065000900347064000500356
031000300361014000700364865000900371002001300380035001000393801001500403#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#244#5#article#51#5#^rND^sFeld
kötter^nM#^rND^sSchwarzer^nV#^rND^sWirth^nR#^rND^sWienker^nTF#^rND^sWirth^nB.#Qu
antitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast an
d reliable carrier testing and prediction of severity of spinal muscular atrophy
^len#Am J Hum Genet#20020000#2002#70#358-68#20100800#a04v86n4.htm#0002-9297#Am J
 Hum Genet##
00618000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100019000930100
01500112010001500127010001500142010001200157012006000169030002600229710000200255
065000900257064000500266031000300271014000800274865000900282002001300291#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#245#6#article#51#6#^rND^sChan
g^nJG#^rND^sHsieh-Li^nHM#^rND^sJong^nYJ#^rND^sWang^nNM#^rND^sTsai^nCH#^rND^sLi^n
H#Treatment of spinal muscular atrophy by sodium butyrate^len#Proc Natl Acad Sci
 U S A.#2#20010000#2001#98#9808-13#20100800#a04v86n4.htm##
00689000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100016000950100
01800111010001800129010001700147012012600164030001500290065000900305064000500314
031000300319014000600322865000900328002001300337035001000350801001500360#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#246#7#article#51#7#^rND^sCamp
bell^nL#^rND^sPotter^nA#^rND^sIgnatius^nJ#^rND^sDubowitz^nV#^rND^sDavies^nK.#Gen
omic variation and gene conversion in spinal muscular atrophy: implications for 
disease process and clinical phenotype^len#Am J Hum Genet#19970000#1997#61#40-50
#20100800#a04v86n4.htm#0002-9297#Am J Hum Genet##
00678000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100017000920100
01800109010001700127010001700144010001400161810000600175012007200181030001500253
06500090026806400050027703100030028201400080028586500090029300200130030203500100
0315801001500325#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#247#8
#article#51#8#^rND^sWang^nCH#^rND^sFinkel^nRS#^rND^sBertini^nES#^rND^sSchroth^nM
#^rND^sSimonds^nA#^rND^sWong^nB#et al#Consensus statement for standard of care i
n spinal muscular atrophy^len#J Child Neurol#20070000#2007#22#1027-49#20100800#a
04v86n4.htm#0883-0738#J Child Neurol##
00663000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100014000930100
01800107010001500125010001700140010001800157810000600175012006800181030001000249
06500090025906400050026803100030027301400070027686500090028300200130029203500100
0305801001000315#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#248#9
#article#51#9#^rND^sOskoui^nM#^rND^sLevy^nG#^rND^sGarland^nCJ#^rND^sGray^nJM#^rN
D^sO'Hagen^nJ#^rND^sDe Vivo^nDC#et al#The changing natural history of spinal mus
cular atrophy type 1.^len#Neurology#20070000#2007#69#1931-6#20100800#a04v86n4.ht
m#0028-3878#Neurology##
00565000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01600111012005000127030002100177065000900198064000500207031000300212032000700215
865000900222002001300231035001000244801002100254#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a04v86n4.htm#S#c#249#10#article#51#10#^rND^sWirth^nB#^rND^sBrichta^nL#
^rND^sHahnen^nE#Spinal muscular atrophy: from gene to therapy^len#Semin Pediatr 
Neurol#20060000#2006#13#121-31#20100800#a04v86n4.htm#1071-9091#Semin Pediatr Neu
rol##
00635000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100028000950120
15400123030001200277065000900289064000500298031000300303014000700306865000900313
002001300322035001000335801001200345#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
4v86n4.htm#S#c#250#11#article#51#11#^rND^sZerres^nK#^rND^sRudnik-Schöneborn^nS.#
Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 pa
tients and suggestions for a modification of existing classifications^len#Arch N
eurol#19950000#1995#52#518-23#20100800#a04v86n4.htm#0003-9942#Arch Neurol##
00500000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790120052000960300
01500148065000900163064000500172031000300177014000700180865000900187002001300196
035001000209801001500219#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S
#c#251#12#article#51#12#^rND^sSumner^nCJ#Molecular mechanisms of spinal muscular
 atrophy^len#J Child Neurol#20070000#2007#22#979-89#20100800#a04v86n4.htm#0883-0
738#J Child Neurol##
00644000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01900114010001900133010001600152010001700168810000600185012006300191030001600254
71000020027006500090027206400050028103100030028601400070028986500090029600200130
0305#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#252#13#article#51
#13#^rND^sSwoboda^nKJ#^rND^sKissel^nJT#^rND^sCrawford^nTO#^rND^sBromberg^nMB#^rN
D^sAcsadi^nG#^rND^sD'Anjou^nG#et al#Perspectives on clinical trials in spinal mu
scular atrophy^len#J Child Neurol.#2#20070000#2007#22#957-66#20100800#a04v86n4.h
tm##
00606000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100020000950100
02000115012012900135030001600264710000200280065000900282064000500291031000300296
014000700299865000900306002001300315#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
4v86n4.htm#S#c#253#14#article#51#14#^rND^sHeier^nCR#^rND^sGogliotti^nRG#^rND^sDi
Donato^nCJ.#SMN transcript stability: could modulation of messenger RNA degradat
ion provide a novel therapy for spinal muscular atrophy?^len#J Child Neurol.#2#2
0070000#2007#22#1013-8#20100800#a04v86n4.htm##
00571000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960100
01800111012009900129030001600228710000200244065000900246064000500255031000300260
014000800263865000900271002001300280#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
4v86n4.htm#S#c#254#15#article#51#15#^rND^sMeldrum^nC#^rND^sScott^nC#^rND^sSwobod
a^nKJ#Spinal muscular atrophy genetic counseling access and genetic knowledge: p
arents' perspestives^len#J Child Neurol.#2#20070000#2007#22#1019-26#20100800#a04
v86n4.htm##
00680000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01900114010001800133010001600151010001700167810000600184012008600190030000500276
06500090028106400050029003100030029501400070029886500090030500200130031403500100
0327801000500337#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#255#1
6#article#51#16#^rND^sLefebvre^nS#^rND^sBürglen^nL#^rND^sReboullet^nS#^rND^sCler
mont^nO#^rND^sBurlet^nP#^rND^sViollet^nL#et al#Identification and characterizati
on of a spinal muscular atrophy-determining gene^len#Cell#19950000#1995#80#155-6
5#20100800#a04v86n4.htm#0092-8674#Cell##
00682000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
02000112010001700132010001400149010001700163810000600180012008000186030001100266
06500090027706400050028603100030029101400070029486500090030100200130031003500100
0323801001100333#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#256#1
7#article#51#17#^rND^sSumner^nCJ#^rND^sHuynh^nTN#^rND^sMarkowitz^nJA#^rND^sPerha
c^nJS#^rND^sHill^nB#^rND^sCoovet^nDD#et al#Valproic acid increases SMN levels in
 spinal muscular atrophy patient cells^len#Ann Neurol#20030000#2003#54#647-54#20
100800#a04v86n4.htm#0364-5134#Ann Neurol##
00553000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970120
10500115030001800220710000200238065000900240064000500249031000300254014000800257
865000900265002001300274#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S
#c#257#18#article#51#18#^rND^sBurghes^nAH#^rND^sBeattie^nCE#Spinal muscular atro
phy: why do low levels of survival motor neuron protein make motor neurons sick?
^len#Nat Rev Neurosci.#2#20090000#2009#10#597-609#20100800#a04v86n4.htm##
00732000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
01800114010001800132010001900150010001300169810000600182012015700188030001500345
71000020036006500090036206400050037103100020037601400060037886500090038400200130
0393#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#258#19#article#51
#19#^rND^sMonani^nUR#^rND^sSendtner^nM#^rND^sCoovert^nDD#^rND^sParsons^nDW#^rND^
sAndreassi^nC#^rND^sLe^nTT#et al#The human centromeric survival motor neuron gen
e (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse wit
h spinal muscular atrophy^len#Hum Mol Genet.#2#20000000#2000#9#333-9#20100800#a0
4v86n4.htm##
00473000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120060000970300
01600157710000200173065000900175064000500184031000300189014000500192865000900197
002001300206#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#259#20#ar
ticle#51#20#^rND^sBurghes^nAH#When is a deletion not a deletion? When it is conv
erted^len#Am J Hum Genet.#2#19970000#1997#61#9-15#20100800#a04v86n4.htm##
00703000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
01700116010001800133010001400151010001800165810000600183012012300189030001600312
71000020032806500090033006400050033903100030034401400080034786500090035500200130
0364#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#260#21#article#51
#21#^rND^sMcAndrew^nPE#^rND^sParsons^nDW#^rND^sSimard^nLR#^rND^sRochette^nC#^rND
^sRay^nPN#^rND^sMendell^nJR#et al#Identification of proximal spinal muscular atr
ophy carriers and patients by analysis of SMNT and SMNC gene copy number^len#Am 
J Hum Genet.#2#19970000#1997#60#1411-22#20100800#a04v86n4.htm##
00648000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100013000970100
01900110010002200129010001900151010001800170810000600188012006500194030001500259
71000020027406500090027606400050028503100020029001400080029286500090030000200130
0309#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#261#22#article#51
#22#^rND^sCoovert^nDD#^rND^sLe^nTT#^rND^sMcAndrew^nPE#^rND^sStrasswimmer^nJ#^rND
^sCrawford^nTO#^rND^sMendell^nJR#et al#The survival motor neuron protein in spin
al muscular atrophy^len#Hum Mol Genet.#2#19970000#1997#6#1205-14#20100800#a04v86
n4.htm##
00630000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100017000990100
01800116010001800134012012600152030001300278710000200291065000900293064000500302
031000400307014000700311865000900318002001300327#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a04v86n4.htm#S#c#262#23#article#51#23#^rND^sMcWhorter^nML#^rND^sMonani
^nUR#^rND^sBurghes^nAH#^rND^sBeattie^nCE#Knockdown of the survival motor neuron 
(Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfindin
g.^len#J Cell Biol.#2#20030000#2003#162#919-31#20100800#a04v86n4.htm##
00474000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100019000950120
02800114030001800142710000200160065000900162064000500171031000200176014000800178
865000900186002001300195#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S
#c#263#24#article#51#24#^rND^sOskoui^nM#^rND^sKaufmann^nP.#Spinal muscular atrop
hy^len#Neurotherapeutics#2#20080000#2008#5#499-506#20100800#a04v86n4.htm##
00514000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01900111012004300130030001600173710000200189065000900191064000500200031000300205
014000600208865000900214002001300223#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
4v86n4.htm#S#c#264#25#article#51#25#^rND^sKolb^nSJ#^rND^sBattle^nDJ#^rND^sDreyfu
ss^nG.#Molecular functions of the SMN complex^len#J Child Neurol.#2#20070000#200
7#22#990-4#20100800#a04v86n4.htm##
00562000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
02000114012008400134030001600218710000200234065000900236064000500245031000300250
014000900253865000900262002001300271#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
4v86n4.htm#S#c#265#26#article#51#26#^rND^sBeattie^nCE#^rND^sCarrel^nTL#^rND^sMcw
horter^nML#Fishing for a mechanism: using zebrafish to understand spinal muscula
r atrophy.^len#J Child Neurol.#2#20070000#2007#22#995-1003#20100800#a04v86n4.htm
##
00612000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100015000940100
02000109010001500129010001900144012007100163030002600234710000200260065000900262
064000500271031000300276014000900279865000900288002001300297#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a04v86n4.htm#S#c#266#27#article#51#27#^rND^sKerr^nDA#^rND^
sNery^nJP#^rND^sTraystman^nRJ#^rND^sChau^nBN#^rND^sHardwick^nJM#Survival motor n
euron protein modulates neuron-specific apoptosis.^len#Proc Natl Acad Sci U S A.
#2#20000000#2000#97#13312-17#20100800#a04v86n4.htm##
00465000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100015000930120
02600108030001800134710000200152065000900154064000500163031000200168014000700170
865000900177002001300186#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S
#c#267#28#article#51#28#^rND^sDiz^nMA#^rND^sDiz^nMC.#Hipotonia na infância^lpt#A
n Prod Acad Doc.#2#20070000#2007#1#184-9.#20100800#a04v86n4.htm##
00504000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790120028000940300
01800122065000900140064000500149031000300154032001000157014000900167865000900176
002001300185035001000198801001800208#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
4v86n4.htm#S#c#268#29#article#51#29#^rND^sReed^nUC#Doenças neuromusculares^lpt#J
 Pediatr (Rio J)#20020000#2002#78#^sSuppl 1#S89-S103#20100800#a04v86n4.htm#0021-
7557#J Pediatr (Rio J)##
00485000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170045000790180043001240370
05800167110000900225109001100234865000900245002001300254#v86n4#V:\Scielo\serial\
jped\v86n4\markup\a04v86n4.htm#S#c#269#30#article#51#30#Associação Brasileira de
 Amiotrofia Espinhal#Diferenças entre Atrofias e Distrofias^lpt#http://www.atrof
iaespinhal.org/oque_atrofia_distrofia.php#20080512#12/05/2008#20100800#a04v86n4.
htm##
00631000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100019000930100
01500112010001300127010001700140010001700157810000600174012006200180030001600242
71000020025806500090026006400050026903100030027401400060027786500090028300200130
0292#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#270#31#article#51
#31#^rND^sPons^nR#^rND^sAndreetta^nF#^rND^sWang^nCH#^rND^sVu^nTH#^rND^sBonilla^n
E#^rND^sDiMauro^nS#et al#Mitochondrial myopathy simulating spinal muscular atrop
hy^len#Pediatr Neurol.#2#19960000#1996#15#153-8#20100800#a04v86n4.htm##
00610000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100017000990120
16700116030001400283710000200297065000900299064000500308031000300313014000600316
865000900322002001300331#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S
#c#271#32#article#51#32#^rND^sMastaglia^nFL#^rND^sWalton^nJN#Histological and hi
stochemical changes in skeletal muscle from cases of chronic juvenile and early 
adult spinal muscular atrophy (the Kugelberg-Welander syndrome)^len#J Neurol Sci
.#2#19710000#1971#12#15-44#20100800#a04v86n4.htm##
00663000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
02300111010001800134010001700152010002000169810000600189012008800195030001200283
71000020029506500090029706400050030603100020031101400020031386500090031500200130
0324#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#272#33#article#51
#33#^rND^sKolb^nSJ#^rND^sGubitz^nAK#^rND^sOlszewski^nRF Jr#^rND^sOttinger^nE#^rN
D^sSumner^nCJ#^rND^sFischbeck^nKH#et al#A novel cell imunoassay to measure survi
val of motor neurons protein in blood cells^len#BMC Neurol.#2#20060000#2006#6#6#
20100800#a04v86n4.htm##
00500000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790120049001000300
01500149065000900164064000500173031000300178014000600181865000900187002001300196
035001000209801001500219#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S
#c#273#34#article#51#34#^rND^sIannaccone^nST#Modern management of spinal muscula
r atrophy^len#J Child Neurol#20070000#2007#22#974-8#20100800#a04v86n4.htm#0883-0
738#J Child Neurol##
00668000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01700113010001700130010002400147010001700171810000600188012008700194030001200281
71000020029306500090029506400050030403100030030901400080031286500090032000200130
0329#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#274#35#article#51
#35#^rND^sGrondard^nC#^rND^sBiondi^nO#^rND^sArmand^nAS#^rND^sLécolle^nS#^rND^sDe
lla Gaspera^nBD#^rND^sPariset^nC#et al#Regular exercise prolongs survival in a t
ype 2 spinal muscular atrophy model mouse^len#J Neurosci.#2#20050000#2005#25#761
5-22#20100800#a04v86n4.htm##
00543000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100018000940120
10200112030001300214710000200227065000900229064000500238031000400243014000800247
865000900255002001300264#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S
#c#275#36#article#51#36#^rND^sLunke^nS#^rND^sEl-Osta^nA.#The emerging role of ep
igenetic modifications and chromatin remodeling in spinal muscular atrophy^len#J
 Neurochem.#2#20090000#2009#109#1557-69#20100800#a04v86n4.htm##
00462000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790120057000960300
00800153710000200161065000900163064000500172031000200177014000700179865000900186
002001300195#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#276#37#ar
ticle#51#37#^rND^sSumner^nCJ#Therapeutics development for spinal muscular atroph
y^len#NeuroRx#2#20060000#2006#3#235-45#20100800#a04v86n4.htm##
00629000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100013000790100018000920100
01900110010001500129010001800144010001800162012007200180030001500252710000200267
065000900269064000500278031000300283014000700286865000900293002001300302#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#277#38#article#51#38#^rND^sRa
k^nK#^rND^sLechner^nBD#^rND^sSchneider^nC#^rND^sDrexl^nH#^rND^sSendtner^nM#^rND^
sJablonka^nS#Valproic acid blocks excitability in SMA type I mouse motor neurons
^len#Neurobiol Dis.#2#20090000#2009#36#477-87#20100800#a04v86n4.htm##
00703000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01600113010002300129010001700152010001700169810000600186012012100192030001500313
71000020032806500090033006400050033903100030034401400080034786500090035500200130
0364#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#278#39#article#51
#39#^rND^sBrichta^nL#^rND^sHofmann^nY#^rND^sHahnen^nE#^rND^sSiebzehnrubl^nFA#^rN
D^sRaschke^nH#^rND^sBlumcke^nI#et al#Valproic acid increases the SMN2 protein le
vel: a well-known drug as a potential therapy for spinal muscular atrophy^len#Hu
m Mol Genet.#2#20030000#2003#12#2481-9.#20100800#a04v86n4.htm##
00659000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
01800110010001900128010001600147010001500163810000600178012008500184030001700269
71000020028606500090028806400050029703100030030201400060030586500090031100200130
0320#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#279#40#article#51
#40#^rND^sBrahe^nC#^rND^sVitali^nT#^rND^sTiziano^nFD#^rND^sAngelozzi^nC#^rND^sPi
nto^nAM#^rND^sBorgo^nF#et al#Phenylbutyrate increases SMN gene expression in spi
nal muscular atrophy patients^len#Eur J Hum Genet.#2#20050000#2005#13#256-9#2010
0800#a04v86n4.htm##
00574000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100015000940100
01500109010001200124012008800136030001100224710000200235065000900237064000500246
031000300251014000800254865000900262002001300271#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a04v86n4.htm#S#c#280#41#article#51#41#^rND^sTsai^nLK#^rND^sTsai^nMS#^r
ND^sTing^nCH#^rND^sLi^nH#Multiple therapeutic effects of valproic acid in spinal
 muscular atrophy model mice^len#J Mol Med.#2#20080000#2008#86#1243-54#20100800#
a04v86n4.htm##
00558000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100015000940100
01400109010001200123012007300135030001400208710000200222065000900224064000500233
031000300238014000500241865000900246002001300255#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a04v86n4.htm#S#c#281#42#article#51#42#^rND^sTsai^nLK#^rND^sYang^nCC#^r
ND^sHwu^nWL#^rND^sLi^nH#Valproic acid treatment in six patients with spinal musc
ular atrophy^len#Eur J Neurol.#2#20070000#2007#14#e8-9#20100800#a04v86n4.htm##
00597000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100019000950100
01900114012009900133030001000232065000900242064000500251031000300256014000600259
865000900265002001300274035001000287801001000297#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a04v86n4.htm#S#c#282#43#article#51#43#^rND^sWeihl^nCC#^rND^sConnolly^n
AM#^rND^sPestronk^nA.#Valproate may improve strength and function in patients wi
th type III/IV spinal muscle atrophy^len#Neurology#20060000#2006#67#500-1#201008
00#a04v86n4.htm#0028-3878#Neurology##
00642000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01600113010001600129010001700145010001900162810000600181012007400187030000900261
71000020027006500090027206400050028103100020028601400060028886500090029400200130
0303#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#283#44#article#51
#44#^rND^sSwoboda^nKJ#^rND^sScott^nCB#^rND^sReyna^nSP#^rND^sPrior^nTW#^rND^sLaSa
lle^nB#^rND^sSorenson^nSl#et al#Phase II open label study of valproic acid in sp
inal muscular atrophy^len#PLoS One#2#20090000#2009#4#e5268#20100800#a04v86n4.htm
##
00641000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100014000950100
01600109010001500125010001600140010001500156810000600171012007600177030001400253
71000020026706500090026906400050027803100040028301400060028786500090029300200130
0302#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#284#45#article#51
#45#^rND^sLiang^nWC#^rND^sYou^nCY#^rND^sChang^nJG#^rND^sChen^nYC#^rND^sChang^nYF
#^rND^sWang^nHY#et al#The effect of hydroxyurea in spinal muscular atrophy cells
 and patients^len#J Neurol Sci.#2#20080000#2008#268#87-94#20100800#a04v86n4.htm#
#
00681000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100015000940100
01800109010001900127010001700146010001800163810000600181012010800187030001100295
71000020030606500090030806400050031703100030032201400080032586500090033300200130
0342#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#285#46#article#51
#46#^rND^sLunn^nMR#^rND^sRoot^nDE#^rND^sMartino^nAM#^rND^sFlaherty^nSP#^rND^sKel
ley^nBP#^rND^sCoovert^nDD#et al#Indoprofen upregulates the survival motor neuron
 protein through a cyclooxygenase-independent mechanism^len#Chem Biol.#2#2004000
0#2004#11#1489-93#20100800#a04v86n4.htm##
00668000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790100016001020100
01600118010001600134010001700150012013400167030001500301710000200316065000900318
064000500327031000300332014000900335865000900344002001300353#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a04v86n4.htm#S#c#286#47#article#51#47#^rND^sWolstencroft^n
EC#^rND^sMattis^nV#^rND^sBajer^nAA#^rND^sYoung^nPJ#^rND^sLorson^nCL#A non-sequen
ce-specific requirement for SMN protein activity: the role of aminoglycosides in
 inducing elevated SMN protein levels^len#Hum Mol Genet.#2#20050000#2005#14#1199
-210#20100800#a04v86n4.htm##
00677000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100013000790100016000920100
01800108010002000126010001900146010002200165810000600187012009800193030001200291
71000020030306500090030506400050031403100030031901400070032286500090032900200130
0338#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#287#48#article#51
#48#^rND^sLee^nH#^rND^sShamy^nGA#^rND^sElkabetz^nY#^rND^sSchofield^nCM#^rND^sHar
rsion^nNL#^rND^sPanagiotakos^nG#et al#Directed differentiation and transplantati
on of human embryonic stem cell-derived motoneurons^len#Stem Cells.#2#20070000#2
007#25#1931-9#20100800#a04v86n4.htm##
00584000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100014000950100
01700109010002000126010001500146012004800161030002200209710000200231065000900233
064000500242031000500247014000800252865000900260002001300269#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a04v86n4.htm#S#c#288#49#article#51#49#^rND^sNayak^nMS#^rND
^sKim^nYS#^rND^sGoldman^nM#^rND^sKeirstead^nHS#^rND^sKerr^nDA#Cellular therapies
 in motor neuron diseases^len#Biochim Biophys Acta.#2#20060000#2006#1762#1128-38
#20100800#a04v86n4.htm##
00683000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100024000990100
01800123010001500141010001600156010001400172810000600186012010200192030001500294
71000020030906500090031106400050032003100030032501400070032886500090033500200130
0344#v86n4#V:\Scielo\serial\jped\v86n4\markup\a04v86n4.htm#S#c#289#50#article#51
#50#^rND^sLesbordes^nJC#^rND^sCifuentes-Diaz^nC#^rND^sMiroglio^nA#^rND^sJoshi^nV
#^rND^sBordet^nT#^rND^sKahn^nA#et al#Therapeutic benefits of cardiotrophin-1 gen
e transfer in a mouse model of spinal muscular atrophy^len#Hum Mol Genet.#2#2003
0000#2003#12#1233-9#20100800#a04v86n4.htm##
00581000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970100
01600115012010900131030001400240710000200254065000900256064000500265031000400270
014000700274865000900281002001300290#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
4v86n4.htm#S#c#290#51#article#51#51#^rND^sDiMatteo^nD#^rND^sCallahan^nS#^rND^sKm
iec^nEB#Genetic conversion of an SMN2 gene to SMN1: a novel approach to the trea
tment of spinal muscular atrophy^len#Exp Cell Res.#2#20080000#2008#314#878-86#20
100800#a04v86n4.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#o#1#1#article#1
#20110126#175418#a05v86n4.htm#333##
04491000000000661000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002100108
03100030012903200020013206500090013401400110014303500100015401200520016401200550
02160100033002710100032003040100039003360100029003750700083004040700051004870700
08900538083145200627085001002079085003502089085002202124085002502146085002002171
08500240219108314120221508500100362708500370363708500210367408500250369508500210
37200850024037411170008037650720003037731120009037761110011037851140009037961130
01103805002001303816#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#h#2
#1#article#1#ra#pt#br1.1#1#4.0#TAB#05#JPED100#nd#J. Pediatr. (Rio J.)#86#4#20100
800#^f271^l278#0021-7557#Atividade física na criança com diabetes tipo 1^lpt#Phy
sical activity in children with type 1 diabetes^len#^rND^1A01^nCristiane P.^sMic
ulis#^rND^1A02^nLuis P.^sMascarenhas#^rND^1A03^nMargaret C. S.^sBoguszewski#^rND
^1A03^nWagner de^sCampos#Universidade Federal do Paraná^iA01^1Departamento de Ed
ucação Física^cCuritiba^sPR#UFPR^iA02^1Departamento de Pediatria^cCuritiba^sPR#U
FPR^iA03^1Unidade de Endocrinologia Pediátrica^2Departamento de Pediatria^cCurit
iba^sPR#^lpt^aOBJETIVO: Abordar os aspectos práticos da realização segura de ati
vidade física e esportes em crianças e adolescentes portadores de diabetes tipo 
1. FONTES DOS DADOS: A pesquisa dos artigos foi conduzida em fontes de dados nac
ionais (SciELO) e internacionais (PubMed/MEDLINE), assim como nas próprias refer
ências dos artigos encontrados, adotando como limites: artigos publicados nos úl
timos 10 anos, preferencialmente conduzidos em crianças e adolescentes com diabe
tes tipo 1, sendo em sua maioria estudos experimentais e meta-análises sobre ati
vidade física. SÍNTESE DOS DADOS: Com o metabolismo aeróbico, os músculos esquel
éticos consomem maior quantidade de glicose para gerar energia, o que diminui a 
gliconeogênese hepática, levando a uma diminuição na glicemia e aumentando o ris
co de hipoglicemia. A reposição de carboidratos antes, durante e após o exercíci
o em quantidade adequada e a redução da dose de insulina de ação rápida (pré-ref
eição) são os principais aliados da criança e adolescente com diabetes tipo 1 pa
ra evitar a ocorrência da hipoglicemia severa. CONCLUSÕES: Para a reposição de c
arboidratos e a redução da dose de insulina, deve-se considerar o tipo, a duraçã
o e a intensidade da atividade física, bem como o horário de sua realização. A p
articipação em diversos esportes, coletivos e individuais, e em atividades físic
as de intensidades variadas é possível, sendo muito recomendado no tratamento do
 diabetes infantil.#^ddecs^i1#^tm^lpt^kDiabetes melito tipo 1^i1#^tm^lpt^kexercí
cio^i1#^tm^lpt^khipoglicemia^i1#^tm^lpt^kcriança^i1#^tm^lpt^kadolescente^i1#^len
^aOBJECTIVE: To discuss the practical aspects of safe physical activity and spor
ts participation in children and adolescents with type 1 diabetes mellitus. SOUR
CES: A literature search was conducted using national (SciELO) and international
 (PubMed/MEDLINE) databases and the reference lists of the articles found, adopt
ing the following limits: articles on physical activity published in the last 10
 years, preferably conducted in children and adolescents with type 1 diabetes. M
ost studies had an experimental design or were meta-analyses. SUMMARY OF THE FIN
DINGS: Skeletal muscle glucose uptake is greater during aerobic metabolism in or
der to generate energy for muscle contraction, which suppresses hepatic gluconeo
genesis and thus promotes a decrease in blood glucose levels and increased risk 
of hypoglycemia. Adequate carbohydrate replacement before, during, and after exe
rcise and reduction of preprandial rapid-acting insulin doses are the main allie
s in avoiding severe hypoglycemic events among diabetic children and adolescents
. CONCLUSIONS: Type, duration, and intensity of physical activity must be consid
ered when planning carbohydrate replacement and insulin dose reduction, as must 
the timing of exercise. Nonetheless, physical activity and participation in many
 individual and team sports is possible and highly recommended in the treatment 
of type 1 diabetes in children and adolescents.#^ddecs^i2#^tm^len^kType 1 diabet
es mellitus^i2#^tm^len^kexercise^i2#^tm^len^khypoglycemia^i2#^tm^len^kchildren^i
2#^tm^len^kadolescents^i2#vancouv#76#20100121#21.01.2010#20100224#24.02.2010#a05
v86n4.htm##
04561000000000661000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002100108
03100030012903200020013206500090013401400110014303500100015401200590016401200620
02230100033002850100032003180100039003500100029003890700083004180700051005010700
08900552083148000641085001002121085003502131085002202166085002502188085002002213
08500240223308314400225708500100369708500370370708500210374408500250376508500210
37900850024038111170008038350720003038431120009038461110011038551140009038661130
01103875002001303886#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#f#3
#1#article#1#ra#pt#br1.1#1#4.0#TAB#05#JPED100#nd#J. Pediatr. (Rio J.)#86#4#20100
800#^f271^l278#0021-7557#<b>Atividade física na criança com diabetes tipo 1</b>^
lpt#<b>Physical activity in children with type 1 diabetes</b>^len#^rND^1A01^nCri
stiane P.^sMiculis#^rND^1A02^nLuis P.^sMascarenhas#^rND^1A03^nMargaret C. S.^sBo
guszewski#^rND^1A03^nWagner de^sCampos#Universidade Federal do Paraná^iA01^1Depa
rtamento de Educação Física^cCuritiba^sPR#UFPR^iA02^1Departamento de Pediatria^c
Curitiba^sPR#UFPR^iA03^1Unidade de Endocrinologia Pediátrica^2Departamento de Pe
diatria^cCuritiba^sPR#^lpt^a<b>OBJETIVO: </b>Abordar os aspectos práticos da rea
lização segura de atividade física e esportes em crianças e adolescentes portado
res de diabetes tipo 1. <b>FONTES DOS DADOS: </b>A pesquisa dos artigos foi cond
uzida em fontes de dados nacionais (SciELO) e internacionais (PubMed/MEDLINE), a
ssim como nas próprias referências dos artigos encontrados, adotando como limite
s: artigos publicados nos últimos 10 anos, preferencialmente conduzidos em crian
ças e adolescentes com diabetes tipo 1, sendo em sua maioria estudos experimenta
is e meta-análises sobre atividade física. <b>SÍNTESE DOS DADOS: </b>Com o metab
olismo aeróbico, os músculos esqueléticos consomem maior quantidade de glicose p
ara gerar energia, o que diminui a gliconeogênese hepática, levando a uma diminu
ição na glicemia e aumentando o risco de hipoglicemia. A reposição de carboidrat
os antes, durante e após o exercício em quantidade adequada e a redução da dose 
de insulina de ação rápida (pré-refeição) são os principais aliados da criança e
 adolescente com diabetes tipo 1 para evitar a ocorrência da hipoglicemia severa
. <b>CONCLUSÕES:</b> Para a reposição de carboidratos e a redução da dose de ins
ulina, deve-se considerar o tipo, a duração e a intensidade da atividade física,
 bem como o horário de sua realização. A participação em diversos esportes, cole
tivos e individuais, e em atividades físicas de intensidades variadas é possível
, sendo muito recomendado no tratamento do diabetes infantil.#^ddecs^i1#^tm^lpt^
kDiabetes melito tipo 1^i1#^tm^lpt^kexercício^i1#^tm^lpt^khipoglicemia^i1#^tm^lp
t^kcriança^i1#^tm^lpt^kadolescente^i1#^len^a<b>OBJECTIVE: </b>To discuss the pra
ctical aspects of safe physical activity and sports participation in children an
d adolescents with type 1 diabetes mellitus. <b>SOURCES: </b>A literature search
 was conducted using national (SciELO) and international (PubMed/MEDLINE) databa
ses and the reference lists of the articles found, adopting the following limits
: articles on physical activity published in the last 10 years, preferably condu
cted in children and adolescents with type 1 diabetes. Most studies had an exper
imental design or were meta-analyses. <b>SUMMARY OF THE FINDINGS: </b>Skeletal m
uscle glucose uptake is greater during aerobic metabolism in order to generate e
nergy for muscle contraction, which suppresses hepatic gluconeogenesis and thus 
promotes a decrease in blood glucose levels and increased risk of hypoglycemia. 
Adequate carbohydrate replacement before, during, and after exercise and reducti
on of preprandial rapid-acting insulin doses are the main allies in avoiding sev
ere hypoglycemic events among diabetic children and adolescents. <b>CONCLUSIONS:
</b> Type, duration, and intensity of physical activity must be considered when 
planning carbohydrate replacement and insulin dose reduction, as must the timing
 of exercise. Nonetheless, physical activity and participation in many individua
l and team sports is possible and highly recommended in the treatment of type 1 
diabetes in children and adolescents.#^ddecs^i2#^tm^len^kType 1 diabetes mellitu
s^i2#^tm^len^kexercise^i2#^tm^len^khypoglycemia^i2#^tm^len^kchildren^i2#^tm^len^
kadolescents^i2#vancouv#76#20100121#21.01.2010#20100224#24.02.2010#a05v86n4.htm#
#
04625000000000685000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000400108121000300112049000800115158000300123
03000210012603100030014703200020015006500090015201400110016103500100017201200520
01820120055002340100032002890100031003210100038003520100029003900700085004190700
05300504070009100557083145200648085001002100085003502110085002202145085002502167
08500200219208500240221208314120223608500100364808500370365808500210369508500250
37160850021037410850024037621170008037860720003037941120009037971110011038061140
00903817113001103826002001303837008008903850#v86n4#V:\Scielo\serial\jped\v86n4\m
arkup\a05v86n4.htm#S#l#4#1#article#1#^mjul./ago.^a2010#ra#pt#br1.1#1#4.0#tab#05#
JPED100#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f271^l278#0021-7557#Atividade fís
ica na criança com diabetes tipo 1^lpt#Physical activity in children with type 1
 diabetes^len#^rND^1A01^nCristiane P^sMiculis#^rND^1A02^nLuis P^sMascarenhas#^rN
D^1A03^nMargaret C. S^sBoguszewski#^rND^1A03^nWagner de^sCampos#^iA01^1Universid
ade Federal do Paraná^2Departamento de Educação Física^cCuritiba^sPR#^iA02^1UFPR
^2Departamento de Pediatria^cCuritiba^sPR#^iA03^1UFPR^2Unidade de Endocrinologia
 Pediátrica^3Departamento de Pediatria^cCuritiba^sPR#^lpt^aOBJETIVO: Abordar os 
aspectos práticos da realização segura de atividade física e esportes em criança
s e adolescentes portadores de diabetes tipo 1. FONTES DOS DADOS: A pesquisa dos
 artigos foi conduzida em fontes de dados nacionais (SciELO) e internacionais (P
ubMed/MEDLINE), assim como nas próprias referências dos artigos encontrados, ado
tando como limites: artigos publicados nos últimos 10 anos, preferencialmente co
nduzidos em crianças e adolescentes com diabetes tipo 1, sendo em sua maioria es
tudos experimentais e meta-análises sobre atividade física. SÍNTESE DOS DADOS: C
om o metabolismo aeróbico, os músculos esqueléticos consomem maior quantidade de
 glicose para gerar energia, o que diminui a gliconeogênese hepática, levando a 
uma diminuição na glicemia e aumentando o risco de hipoglicemia. A reposição de 
carboidratos antes, durante e após o exercício em quantidade adequada e a reduçã
o da dose de insulina de ação rápida (pré-refeição) são os principais aliados da
 criança e adolescente com diabetes tipo 1 para evitar a ocorrência da hipoglice
mia severa. CONCLUSÕES: Para a reposição de carboidratos e a redução da dose de 
insulina, deve-se considerar o tipo, a duração e a intensidade da atividade físi
ca, bem como o horário de sua realização. A participação em diversos esportes, c
oletivos e individuais, e em atividades físicas de intensidades variadas é possí
vel, sendo muito recomendado no tratamento do diabetes infantil.#^ddecs^i1#^tm^l
pt^kDiabetes melito tipo 1^i1#^tm^lpt^kexercício^i1#^tm^lpt^khipoglicemia^i1#^tm
^lpt^kcriança^i1#^tm^lpt^kadolescente^i1#^len^aOBJECTIVE: To discuss the practic
al aspects of safe physical activity and sports participation in children and ad
olescents with type 1 diabetes mellitus. SOURCES: A literature search was conduc
ted using national (SciELO) and international (PubMed/MEDLINE) databases and the
 reference lists of the articles found, adopting the following limits: articles 
on physical activity published in the last 10 years, preferably conducted in chi
ldren and adolescents with type 1 diabetes. Most studies had an experimental des
ign or were meta-analyses. SUMMARY OF THE FINDINGS: Skeletal muscle glucose upta
ke is greater during aerobic metabolism in order to generate energy for muscle c
ontraction, which suppresses hepatic gluconeogenesis and thus promotes a decreas
e in blood glucose levels and increased risk of hypoglycemia. Adequate carbohydr
ate replacement before, during, and after exercise and reduction of preprandial 
rapid-acting insulin doses are the main allies in avoiding severe hypoglycemic e
vents among diabetic children and adolescents. CONCLUSIONS: Type, duration, and 
intensity of physical activity must be considered when planning carbohydrate rep
lacement and insulin dose reduction, as must the timing of exercise. Nonetheless
, physical activity and participation in many individual and team sports is poss
ible and highly recommended in the treatment of type 1 diabetes in children and 
adolescents.#^ddecs^i2#^tm^len^kType 1 diabetes mellitus^i2#^tm^len^kexercise^i2
#^tm^len^khypoglycemia^i2#^tm^len^kchildren^i2#^tm^len^kadolescents^i2#vancouv#7
6#20100121#21.01.2010#20100224#24.02.2010#a05v86n4.htm#Internet^ihttp://www.scie
lo.br/scielo.php?script=sci_arttext&pid=S0021-75572010000400005##
00333000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704010000074002001300174#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#5#1#article#253#<p align="right"><fon
t size="2" face="Verdana"><b>ARTIGO DE REVIS&Atilde;O</b></font>  </p>     ^cY#a
05v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#6#2#article#253#<p>&nbsp;</p>     ^cY
#a05v86n4.htm##
00357000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704012400074002001300198#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#7#3#article#253#<p><font size="4" fac
e="Verdana"><b>Atividade f&iacute;sica na crian&ccedil;a    com diabetes tipo 1<
/b></font></p>     ^cY#a05v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#8#4#article#253#<p>&nbsp;</p>     ^cY
#a05v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#9#5#article#253#<p>&nbsp;</p>     ^cY
#a05v86n4.htm##
00439000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704020500075002001300280#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#10#6#article#253#<p><font size="2" fa
ce="Verdana"><b>Cristiane P. Miculis<sup>I</sup>; Luis P.    Mascarenhas<sup>II<
/sup>; Margaret C. S. Boguszewski<sup>III</sup>; Wagner de    Campos<sup>IV</sup
></b></font></p>     ^cY#a05v86n4.htm##
00451000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704021700075002001300292#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#11#7#article#253#<p><font size="2" fa
ce="Verdana"><sup>I</sup>Mestre, Educa&ccedil;&atilde;o F&iacute;sica,    Depart
amento de Educa&ccedil;&atilde;o F&iacute;sica, Universidade Federal do    Paran
&aacute; (UFPR), Curitiba, PR    ^cY#a05v86n4.htm##
00354000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012000075002001300195#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#12#8#article#253#<br>   <sup>II</sup>
Doutorando, Sa&uacute;de da Crian&ccedil;a, Departamento de Pediatria,    UFPR, 
Curitiba, PR    ^cY#a05v86n4.htm##
00387000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704015300075002001300228#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#13#9#article#253#<br>   <sup>III</sup
>Doutora, Professora associada, Departamento de Pediatria, Unidade    de Endocri
nologia Pedi&aacute;trica, UFPR, Curitiba, PR    ^cY#a05v86n4.htm##
00377000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014200076002001300218#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#14#10#article#253#<br>   <sup>IV</sup
>Doutor, Professor titular, Departamento de Educa&ccedil;&atilde;o    F&iacute;s
ica, UFPR, Curitiba, PR</font></p>     ^cY#a05v86n4.htm##
00368000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013300076002001300209#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#15#11#article#253#<p><font size="2" f
ace="Verdana"><a name="topo" id="topo"></a><a href="#correspondence">Correspond&
ecirc;ncia</a></font></p>     ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#16#12#article#253#<p>&nbsp;</p>     ^
cY#a05v86n4.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#17#13#article#253#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a05v86n4.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006600076002001300142#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#18#14#article#253#<p><font size="2" f
ace="Verdana"><b>RESUMO</b></font></p>     ^cY#a05v86n4.htm##
00474000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023900076002001300315#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#19#15#article#253#<p><font size="2" f
ace="Verdana"> <b>OBJETIVO: </b> Abordar os aspectos pr&aacute;ticos    da reali
za&ccedil;&atilde;o segura de atividade f&iacute;sica e esportes em    crian&cce
dil;as e adolescentes portadores de diabetes tipo 1.    ^cY#a05v86n4.htm##
00725000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049000076002001300566#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#20#16#article#253#<br>   <b>FONTES DO
S DADOS: </b> A pesquisa dos artigos foi conduzida em fontes de    dados naciona
is (SciELO) e internacionais (PubMed/MEDLINE), assim como nas pr&oacute;prias   
 refer&ecirc;ncias dos artigos encontrados, adotando como limites: artigos publi
cados    nos &uacute;ltimos 10 anos, preferencialmente conduzidos em crian&ccedi
l;as    e adolescentes com diabetes tipo 1, sendo em sua maioria estudos experim
entais    e meta-an&aacute;lises sobre atividade f&iacute;sica.    ^cY#a05v86n4.
htm##
00951000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071600076002001300792#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#21#17#article#253#<br>   <b>S&Iacute;
NTESE DOS DADOS: </b>Com o metabolismo aer&oacute;bico, os m&uacute;sculos    es
quel&eacute;ticos consomem maior quantidade de glicose para gerar energia,    o 
que diminui a gliconeog&ecirc;nese hep&aacute;tica, levando a uma diminui&ccedil
;&atilde;o    na glicemia e aumentando o risco de hipoglicemia. A reposi&ccedil;
&atilde;o    de carboidratos antes, durante e ap&oacute;s o exerc&iacute;cio em 
quantidade    adequada e a redu&ccedil;&atilde;o da dose de insulina de a&ccedil
;&atilde;o    r&aacute;pida (pr&eacute;-refei&ccedil;&atilde;o) s&atilde;o os pr
incipais aliados    da crian&ccedil;a e adolescente com diabetes tipo 1 para evi
tar a ocorr&ecirc;ncia    da hipoglicemia severa.    ^cY#a05v86n4.htm##
00771000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053600076002001300612#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#22#18#article#253#<br>   <b>CONCLUS&O
tilde;ES:</b> Para a reposi&ccedil;&atilde;o de carboidratos e a    redu&ccedil;
&atilde;o da dose de insulina, deve-se considerar o tipo, a dura&ccedil;&atilde;
o    e a intensidade da atividade f&iacute;sica, bem como o hor&aacute;rio de su
a    realiza&ccedil;&atilde;o. A participa&ccedil;&atilde;o em diversos esportes
,    coletivos e individuais, e em atividades f&iacute;sicas de intensidades var
iadas    &eacute; poss&iacute;vel, sendo muito recomendado no tratamento do diab
etes    infantil.</font></p>     ^cY#a05v86n4.htm##
00421000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018600076002001300262#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#23#19#article#253#<p><font size="2" f
ace="Verdana"><b>Palavras-chave: </b> Diabetes melito tipo    1, exerc&iacute;ci
o, hipoglicemia, crian&ccedil;a, adolescente.</font></p> <hr size="1" noshade>  
   ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#24#20#article#253#<p>&nbsp;</p>     ^
cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#25#21#article#253#<p>&nbsp;</p>     ^
cY#a05v86n4.htm##
00319000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008400076002001300160#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#26#22#article#253#<p><font size="3" f
ace="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#a05v86n4.htm##
00765000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053000076002001300606#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#27#23#article#253#<p><font face="Verd
ana" size="2">O diabetes tipo 1 (DM1) &eacute; uma doen&ccedil;a    autoimune ca
racterizada pela perda progressiva das c&eacute;lulas beta-pancre&aacute;ticas  
  que ir&aacute; culminar com a interrup&ccedil;&atilde;o da produ&ccedil;&atild
e;o    de insulina e consequentemente desequil&iacute;brio metab&oacute;lico gra
ve<SUP>1,2</SUP>.    Estima-se que, no per&iacute;odo de diagn&oacute;stico, ape
nas 10 a 20% das    c&eacute;lulas beta-pancre&aacute;ticas sejam funcionantes<S
UP>3</SUP>.</font></p>     ^cY#a05v86n4.htm##
00703000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046800076002001300544#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#28#24#article#253#<p><font face="Verd
ana" size="2">A preval&ecirc;ncia do DM1 vem aumentando consideravelmente    em 
todo o mundo, sendo mais acentuada nos pa&iacute;ses n&oacute;rdicos e muito    
baixa nos pa&iacute;ses asi&aacute;ticos<SUP>4</SUP>. No Brasil, n&atilde;o    e
xistem dados nacionais sobre a incid&ecirc;ncia/preval&ecirc;ncia de DM1, mas,  
  de acordo com estudos regionais, a incid&ecirc;ncia varia de 7,6 a 12/100.000 
   pessoas-ano<SUP>5-7</SUP>.</font></p>     ^cY#a05v86n4.htm##
00778000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054300076002001300619#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#29#25#article#253#<p><font face="Verd
ana" size="2">As complica&ccedil;&otilde;es microvasculares    e macrovasculares
 s&atilde;o comumente encontradas em pacientes com DM1 com    dura&ccedil;&atild
e;o em torno de 15 a 20 anos<SUP>8</SUP>, sendo incomuns antes    dos 10 anos de
 idade<SUP>9</SUP>. Por&eacute;m, as doen&ccedil;as microvasculares    como reti
nopatia e nefropatia diab&eacute;ticas s&atilde;o altamente influenciadas    pel
o controle glic&ecirc;mico e podem ser encontradas em adolescentes portadores   
 de DM1<SUP>10,11</SUP>.</font></p>     ^cY#a05v86n4.htm##
00589000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035400076002001300430#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#30#26#article#253#<p><font face="Verd
ana" size="2">Por outro lado, a ocorr&ecirc;ncia de doen&ccedil;as    cardiovasc
ulares (DCV) acontece principalmente na idade adulta<SUP>12</SUP>,    e a preven
&ccedil;&atilde;o do desenvolvimento dessas comorbidades pode ser    o maior ben
ef&iacute;cio da pr&aacute;tica regular de atividade f&iacute;sica    (AF).</fon
t></p>     ^cY#a05v86n4.htm##
00941000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070600076002001300782#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#31#27#article#253#<p><font face="Verd
ana" size="2">A influ&ecirc;ncia da AF sobre os n&iacute;veis    de hemoglobina 
glicada (HbA1c) de crian&ccedil;as portadoras de DM1 parece ser    em favor de u
m melhor controle glic&ecirc;mico, sendo que a maioria dos estudos    encontrou 
uma diminui&ccedil;&atilde;o significante nos n&iacute;veis de HbA1c    ap&oacut
e;s um programa de AF regular<SUP>13,14</SUP>. Al&eacute;m disso, estudos    exp
erimentais comprovam a melhora significativa do perfil lip&iacute;dico, da    pr
ess&atilde;o arterial e da composi&ccedil;&atilde;o corporal, fatores de risco  
  tradicionais para o desenvolvimento de DCV, em crian&ccedil;as e adolescentes 
   com DM1<SUP>15,16</SUP>.</font></p>     ^cY#a05v86n4.htm##
00645000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041000076002001300486#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#32#28#article#253#<p><font face="Verd
ana" size="2">Entretanto, mesmo com a comprovada a&ccedil;&atilde;o    preventiv
a da AF, seja ela recreativa ou esportiva<SUP>14,17-20</SUP>, a maioria    das c
rian&ccedil;as e adolescentes com DM1 permanece abaixo dos n&iacute;veis    de A
F recomendada<SUP>21-23</SUP>, aumentando ainda mais o risco de desenvolver    p
recocemente doen&ccedil;as micro e macrovasculares.</font></p>     ^cY#a05v86n4.
htm##
00642000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040700076002001300483#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#33#29#article#253#<p><font face="Verd
ana" size="2">O objetivo desta revis&atilde;o foi abordar os    aspectos pr&aacu
te;ticos da realiza&ccedil;&atilde;o segura de AF e esportes    em crian&ccedil;
as e adolescentes portadores de DM1, bem como o papel da hipoglicemia    como ba
rreira para um estilo de vida ativo fisicamente e quais as atividades    e espor
tes indicados para essa popula&ccedil;&atilde;o.</font></p>     ^cY#a05v86n4.htm
##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#34#30#article#253#<p>&nbsp;</p>     ^
cY#a05v86n4.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010500076002001300181#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#35#31#article#253#<p><font size="3" f
ace="Verdana"><b>Por que fazer exerc&iacute;cio f&iacute;sico?</b></font></p>   
  ^cY#a05v86n4.htm##
00789000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055400076002001300630#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#36#32#article#253#<p><font face="Verd
ana" size="2">Crian&ccedil;as e adolescentes portadores de    DM1 apresentam mai
or risco para desenvolver doen&ccedil;as microvasculares (retinopatia,    nefrop
atia e neuropatia diab&eacute;ticas)<SUP>10,24</SUP> e cardiovasculares<SUP>12,2
5</SUP>.    Estudos recentes mostram que &eacute; poss&iacute;vel verificar a pr
esen&ccedil;a    de sinais de doen&ccedil;a arterial ateroscler&oacute;tica<SUP>
26,27</SUP>,    de retinopatia e de nefropatia diab&eacute;ticas j&aacute; na pr
imeira inf&acirc;ncia<SUP>24</SUP>.</font></p>     ^cY#a05v86n4.htm##
01001000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076600076002001300842#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#37#33#article#253#<p><font face="Verd
ana" size="2">Os principais fatores de risco para o desenvolvimento    dessas do
en&ccedil;as s&atilde;o a falta de um controle glic&ecirc;mico adequado<SUP>10</
SUP>    (<a href=/img/revistas/jped/v86n4/4a05t1.gif>Tabela 1</a>), dislipidemia
, obesidade,    press&atilde;o arterial elevada e inatividade f&iacute;sica<SUP>
28-32</SUP>.    Tais fatores s&atilde;o pass&iacute;veis de preven&ccedil;&atild
e;o atrav&eacute;s    de uma alimenta&ccedil;&atilde;o balanceada e pr&oacute;pr
ia para crian&ccedil;as    e adolescentes com DM1, assiduidade na aplica&ccedil;
&atilde;o das doses de    insulina e da mensura&ccedil;&atilde;o da glicemia de 
ponta de dedo e manuten&ccedil;&atilde;o    de um estilo de vida ativo<SUP>10,13
</SUP>.</font></p>     ^cY#a05v86n4.htm##
01077000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084200076002001300918#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#38#34#article#253#<p><font face="Verd
ana" size="2">Apesar dos benef&iacute;cios &agrave; sa&uacute;de    proporcionad
os pela AF regular, de intensidade moderada a vigorosa por 30 a    60 min<SUP>34
,35</SUP>, a maioria dos jovens n&atilde;o segue essa recomenda&ccedil;&atilde;o
<SUP>31,36</SUP>.    Considerando que os n&iacute;veis de AF e de aptid&atilde;o
 cardiorrespirat&oacute;ria    tendem a diminuir com a idade<SUP>37,38</SUP>, in
centivar e oferecer oportunidades    para a pr&aacute;tica de uma AF desde a inf
&acirc;ncia poder&aacute; promover    a manuten&ccedil;&atilde;o de um estilo de
 vida ativo at&eacute; a vida adulta<SUP>39</SUP>,    assim como melhorar os n&i
acute;veis de glicemia de jejum e de sensibilidade    &agrave; insulina, princip
almente em crian&ccedil;as e adolescentes que apresentam    DM1<SUP>16,40,41</SU
P>.</font></p>     ^cY#a05v86n4.htm##
01311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704107600076002001301152#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#39#35#article#253#<p><font face="Verd
ana" size="2">A AF aer&oacute;bia utiliza como principais fontes    de energia o
 glicog&ecirc;nio muscular e hep&aacute;tico, a glicose sangu&iacute;nea    e os
 &aacute;cidos graxos livres, dependendo da dura&ccedil;&atilde;o e intensidade 
   da atividade<SUP>42</SUP>. Para que sejam alcan&ccedil;ados os benef&iacute;c
ios    mencionados, a literatura recomenda que a AF aer&oacute;bia seja feita a 
uma    intensidade moderada a vigorosa &#091;40-85% do consumo m&aacute;ximo de 
oxig&ecirc;nio    (VO<SUB>2</SUB>m&aacute;x) ou 55-90% da frequ&ecirc;ncia card&
iacute;aca am&aacute;xima    (FCm&aacute;x)&#093;, com frequ&ecirc;ncia de tr&ec
irc;s a cinco vezes por semana,    durante 20-60 min<SUP>43</SUP>, preconizando 
de 5 a 10 min de atividades aer&oacute;bias    de baixa intensidade para o aquec
imento e 5 a 10 min de exerc&iacute;cios de    flexibilidade ap&oacute;s a ativi
dade, podendo ser associada, ainda, a realiza&ccedil;&atilde;o    ao menos duas 
vezes por semana de exerc&iacute;cio de fortalecimento muscular<SUP>34</SUP>.</f
ont></p>     ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#40#36#article#253#<p>&nbsp;</p>     ^
cY#a05v86n4.htm##
00317000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008200076002001300158#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#41#37#article#253#<p><font size="3" f
ace="Verdana"><b>O medo da hipoglicemia</b></font></p>     ^cY#a05v86n4.htm##
00676000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044100076002001300517#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#42#38#article#253#<p><font face="Verd
ana" size="2">Um dos maiores problemas da realiza&ccedil;&atilde;o    da AF em c
rian&ccedil;as portadoras de DM1 &eacute; a ocorr&ecirc;ncia frequente    de hip
oglicemia durante ou at&eacute; mesmo ap&oacute;s v&aacute;rias horas    do t&ea
cute;rmino do exerc&iacute;cio<SUP>44,45</SUP>, o que acaba desencorajando    a 
realiza&ccedil;&atilde;o de uma AF regular por essas crian&ccedil;as<SUP>44</SUP
>.</font></p>     ^cY#a05v86n4.htm##
00798000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056300076002001300639#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#43#39#article#253#<p><font face="Verd
ana" size="2">A hipoglicemia ocorre por hiperinsuliniza&ccedil;&atilde;o    ex&o
acute;gena pr&eacute;-exerc&iacute;cio aer&oacute;bico, pela taxa inadequada    
de insulina/glucagon ou pelo aumento da sensibilidade &agrave; insulina<SUP>45</
SUP>.    Com o metabolismo aer&oacute;bico, os m&uacute;sculos esquel&eacute;tic
os consomem    maior quantidade de glicose para gerar energia, o que diminui a g
liconeog&ecirc;nese    hep&aacute;tica<SUP>46</SUP>, levando a uma diminui&ccedi
l;&atilde;o na glicemia    sangu&iacute;nea.</font></p>     ^cY#a05v86n4.htm##
01050000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704081500076002001300891#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#44#40#article#253#<p><font face="Verd
ana" size="2">O diab&eacute;tico, por consequ&ecirc;ncia da    utiliza&ccedil;&a
tilde;o de insulina ex&oacute;gena, n&atilde;o apresenta par&acirc;metros    fis
iol&oacute;gicos para inibi&ccedil;&atilde;o da a&ccedil;&atilde;o insul&iacute;
nica,    e a sensibilidade &agrave; sua a&ccedil;&atilde;o perdura durante a rea
liza&ccedil;&atilde;o    de exerc&iacute;cios f&iacute;sicos<SUP>45</SUP>. J&aac
ute; no indiv&iacute;duo    sem diabetes ocorreria uma supress&atilde;o da produ
&ccedil;&atilde;o e libera&ccedil;&atilde;o    de insulina pelo p&acirc;ncreas d
urante o exerc&iacute;cio f&iacute;sico, estimulando    a libera&ccedil;&atilde;
o hep&aacute;tica de glicose pelo aumento do glucagon,    gerando assim uma esta
bilidade glic&ecirc;mica plasm&aacute;tica<SUP>46</SUP>.</font></p>     ^cY#a05v
86n4.htm##
00637000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040200076002001300478#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#45#41#article#253#<p><font face="Verd
ana" size="2">Apesar do risco de hipoglicemia, a AF &eacute;    recomendada para
 crian&ccedil;as com DM1<SUP>47,48</SUP>. Segundo Hoffman<SUP>49</SUP>,    com u
m regime adequado de insulina e com um plano alimentar individualizado,    crian
&ccedil;as com DM1 podem usufruir dos benef&iacute;cios f&iacute;sicos    e psic
ossociais promovidos pelo exerc&iacute;cio.</font></p>     ^cY#a05v86n4.htm##
00721000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048600076002001300562#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#46#42#article#253#<p><font face="Verd
ana" size="2">Assim, ap&oacute;s definir qual tipo, intensidade    e dura&ccedil
;&atilde;o da AF a ser realizada, &eacute; necess&aacute;rio reduzir    entre 25
 a 75% a dose de insulina pr&eacute;-refei&ccedil;&atilde;o<SUP>50</SUP>    e of
erecer &agrave; crian&ccedil;a reposi&ccedil;&atilde;o de carboidrato simples<SU
P>51</SUP>.    Entretanto, mesmo com todos esses cuidados, &eacute; poss&iacute;
vel ocorrer    epis&oacute;dio de hipoglicemia.</font></p>     ^cY#a05v86n4.htm#
#
00964000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072900076002001300805#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#47#43#article#253#<p><font face="Verd
ana" size="2">Dessa forma, o seguinte procedimento deve ser    realizado<SUP>49<
/SUP>: ao observar sintomas de hipoglicemia (isto &eacute;,    fraqueza, tontura
, tremor, sonol&ecirc;ncia, sudorese, fome, confus&atilde;o,    agressividade), 
testar o n&iacute;vel glic&ecirc;mico. Se for confirmada a hipoglicemia,    ofer
ecer 15 g de carboidrato simples, aguardar 15 min e repetir o teste de glicemia.
    Caso o n&iacute;vel de glicemia ainda n&atilde;o esteja normalizado, repetir
    o carboidrato. Contudo, quando a crian&ccedil;a n&atilde;o &eacute; capaz de
    ingerir o carboidrato, deve-se aplicar glucagon (1 mg) intramuscular para re
alizar    um atendimento emergencial<SUP>52</SUP>.</font></p>     ^cY#a05v86n4.h
tm##
00879000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064400076002001300720#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#48#44#article#253#<p><font face="Verd
ana" size="2">Os efeitos da AF sobre os fatores de risco cardiovasculares    e m
etab&oacute;licos certamente superam a adversidade da poss&iacute;vel hipoglicem
ia<SUP>13,15</SUP>.    Herbst et al.<SUP>47</SUP> relataram que a AF regular &ea
cute; o fator que mais    influencia o controle da glicemia sem, no entanto, aum
entar o risco de hipoglicemia    em crian&ccedil;as com DM1. Neste mesmo sentido
, alguns estudos t&ecirc;m comprovado    que a AF regular, seja ela cont&iacute;
nua ou intermitente<SUP>41</SUP>, n&atilde;o    eleva o risco de hipoglicemia em
 crian&ccedil;as e adolescentes<SUP>13</SUP>.</font></p>     ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#49#45#article#253#<p>&nbsp;</p>     ^
cY#a05v86n4.htm##
00360000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012500076002001300201#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#50#46#article#253#<p><font size="3" f
ace="Verdana"><b>Como evitar a hipoglicemia durante uma atividade    f&iacute;si
ca</b></font></p>     ^cY#a05v86n4.htm##
00533000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029800076002001300374#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#51#47#article#253#<p><font face="Verd
ana" size="2">A literatura coloca que dois fatores s&atilde;o    essenciais para
 prevenir a ocorr&ecirc;ncia de hipoglicemia no decorrer da pr&aacute;tica    de
 AF durante a inf&acirc;ncia e adolesc&ecirc;ncia. Esses fatores s&atilde;o    d
iscutidos a seguir.</font></p>     ^cY#a05v86n4.htm##
00341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010600076002001300182#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#52#48#article#253#<p><font face="Verd
ana" size="2"><b><i>Reposi&ccedil;&atilde;o de carboidratos</i></b></font></p>  
   ^cY#a05v86n4.htm##
00708000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047300076002001300549#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#53#49#article#253#<p><font face="Verd
ana" size="2">O primeiro cuidado anterior &agrave; realiza&ccedil;&atilde;o    d
e qualquer AF fica a cargo da reposi&ccedil;&atilde;o de carboidratos (CHO),    
que deve ser realizada de acordo com a glicemia sangu&iacute;nea avaliada pr&eac
ute;-exerc&iacute;cio    (<a href=/img/revistas/jped/v86n4/4a05t2.gif>Tabela 2</
a>), podendo indicar    se o exerc&iacute;cio dever ser adiado ou at&eacute; mes
mo contraindicado<SUP>53-55</SUP>.</font></p>     ^cY#a05v86n4.htm##
00880000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064500076002001300721#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#54#50#article#253#<p><font face="Verd
ana" size="2">Quando a AF n&atilde;o for previamente programada,    a reposi&cce
dil;&atilde;o de CHO &eacute; a principal medida para evitar a ocorr&ecirc;ncia 
   de hipoglicemia<SUP>51</SUP>. Contudo, essa reposi&ccedil;&atilde;o deve ser 
   suficiente apenas para evitar essa complica&ccedil;&atilde;o, pois se for em 
   excesso pode levar ao ganho de peso, que seria indesejado e diminuiria os efe
itos    ben&eacute;ficos do exerc&iacute;cio<SUP>10,57</SUP>. Al&eacute;m disso,
 a quantidade    de CHO que deve ser ingerida varia de acordo com a dura&ccedil;
&atilde;o e intensidade    da AF<SUP>51</SUP>.</font></p>     ^cY#a05v86n4.htm##
00962000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072700076002001300803#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#55#51#article#253#<p><font face="Verd
ana" size="2">Para atividades de intensidade leve (&lt; 50%    VO<SUB>2</SUB>max
) e com dura&ccedil;&atilde;o entre 30 e 60 min, a reposi&ccedil;&atilde;o    de
 CHO deve ser feita de acordo com a glicemia sangu&iacute;nea pr&eacute; e    p&
oacute;s-exerc&iacute;cio. J&aacute; para atividades de intensidade moderada    
(50-75% VO<SUB>2</SUB>max) ou alta (&gt; 75% VO<SUB>2</SUB>max), com dura&ccedil
;&atilde;o    <u>&gt;</u> 60 min, a reposi&ccedil;&atilde;o de CHO pode ser nece
ss&aacute;ria    antes, durante e ap&oacute;s. Neste caso, deve-se repor de 1 a 
1,5 g de CHO/kg    de peso corporal/hora de AF e verificar a glicemia sempre ant
es de oferecer    o carboidrato<SUP>54,55</SUP>.</font></p>     ^cY#a05v86n4.htm
##
00343000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010800076002001300184#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#56#52#article#253#<p><font face="Verd
ana" size="2"><b><i>Redu&ccedil;&atilde;o da dose de insulina</i></b></font></p>
     ^cY#a05v86n4.htm##
00876000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064100076002001300717#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#57#53#article#253#<p><font face="Verd
ana" size="2">A altera&ccedil;&atilde;o da dose de insulina    dever ser vista c
om cuidado e seguir a orienta&ccedil;&atilde;o m&eacute;dica,    uma vez que exi
stem muitas contradi&ccedil;&otilde;es quanto &agrave; redu&ccedil;&atilde;o    
da dose de insulina, n&atilde;o havendo um consenso internacional ou nacional<SU
P>58</SUP>.    Contudo, o que a maioria dos pesquisadores recomenda &eacute; uma
 redu&ccedil;&atilde;o    individualizada, de acordo com a intensidade, dura&cce
dil;&atilde;o e hor&aacute;rio    da AF, bem como do tipo de insulina ministrada
 pr&eacute;-exerc&iacute;cio<SUP>55</SUP>.</font></p>     ^cY#a05v86n4.htm##
00913000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067800076002001300754#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#58#54#article#253#<p><font face="Verd
ana" size="2">Assim, a redu&ccedil;&atilde;o da dose de insulina    regular deve
 ser feita quando o exerc&iacute;cio &eacute; realizado de 2 a 3    horas ap&oac
ute;s sua administra&ccedil;&atilde;o, enquanto se deve priorizar    a redu&cced
il;&atilde;o da dose de insulina de a&ccedil;&atilde;o r&aacute;pida    (pr&eacu
te;-refei&ccedil;&atilde;o) quando o exerc&iacute;cio for conduzido    ap&oacute
;s 1 hora de sua aplica&ccedil;&atilde;o. Nos casos de AF no final    da tarde, 
&eacute; a dose da insulina de a&ccedil;&atilde;o r&aacute;pida pr&eacute;-refei
&ccedil;&atilde;o    noturna que dever&aacute; ser reduzida<SUP>48,55,59</SUP>.<
/font></p>     ^cY#a05v86n4.htm##
00617000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038200076002001300458#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#59#55#article#253#<p><font face="Verd
ana" size="2">A Sociedade Brasileira de Diabetes<SUP>56</SUP>    aconselha a red
u&ccedil;&atilde;o da dose de insulina de acordo com a intensidade    e dura&cce
dil;&atilde;o do exerc&iacute;cio f&iacute;sico, baseado nos dados    do estudo 
de Rabasa-Lhoret et al.<SUP>50</SUP> (ver <a href=/img/revistas/jped/v86n4/4a05t
3.gif>Tabela    3</a>).</font></p>     ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#60#56#article#253#<p>&nbsp;</p>     ^
cY#a05v86n4.htm##
00366000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013100076002001300207#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#61#57#article#253#<p><font size="3" f
ace="Verdana"><b>Altera&ccedil;&otilde;es glic&ecirc;micas    durante o exerc&ia
cute;cio</b></font></p>     ^cY#a05v86n4.htm##
00519000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028400076002001300360#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#62#58#article#253#<p><font face="Verd
ana" size="2">O comportamento da glicemia no decorrer da pr&aacute;tica    de ex
erc&iacute;cios f&iacute;sicos varia de acordo com o tipo da atividade    e sua 
intensidade, portanto discutiremos sobre trabalhos aer&oacute;bio e anaer&oacute
;bio.</font></p>     ^cY#a05v86n4.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#63#59#article#253#<p><font face="Verd
ana" size="2"><b><i>Atividade f&iacute;sica cont&iacute;nua    moderada</i></b><
/font></p>     ^cY#a05v86n4.htm##
01194000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704095900076002001301035#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#64#60#article#253#<p><font face="Verd
ana" size="2">A AF cont&iacute;nua moderada &eacute; eficaz    na redu&ccedil;&a
tilde;o da glicemia sangu&iacute;nea em pacientes com DM1 por    aumentar o cons
umo de glicose pelos m&uacute;sculos esquel&eacute;ticos<SUP>45</SUP>.    Nesses
 indiv&iacute;duos, os mecanismos fisiol&oacute;gicos de contrarregula&ccedil;&a
tilde;o    hormonal s&atilde;o alterados<SUP>45,60</SUP>. Normalmente, ao inicia
r uma AF,    a queda na glicemia sangu&iacute;nea inibe a secre&ccedil;&atilde;o
 pancre&aacute;tica    de insulina para que ocorra um aumento da produ&ccedil;&a
tilde;o hep&aacute;tica    de glicose, equilibrando assim o consumo e a produ&cc
edil;&atilde;o de glicose<SUP>54</SUP>.    Entretanto, em pacientes com DM1, com
o n&atilde;o h&aacute; produ&ccedil;&atilde;o    end&oacute;gena de insulina, o 
organismo &eacute; incapaz de controlar sua disponibilidade,    aumentando o ris
co de ocorrer hipoglicemia<SUP>60</SUP>.</font></p>     ^cY#a05v86n4.htm##
00710000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047500076002001300551#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#65#61#article#253#<p><font face="Verd
ana" size="2">Al&eacute;m disso, o exerc&iacute;cio aer&oacute;bio    aumenta a 
sensibilidade &agrave; insulina, exacerbando sua a&ccedil;&atilde;o    quando ad
ministrada antes do in&iacute;cio da AF<SUP>61</SUP>. Assim, nesse    tipo de ex
erc&iacute;cio, devem-se seguir com extrema aten&ccedil;&atilde;o    as recomend
a&ccedil;&otilde;es para reposi&ccedil;&atilde;o de CHO e redu&ccedil;&atilde;o 
   na dose de insulina<SUP>62</SUP>.</font></p>     ^cY#a05v86n4.htm##
00353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011800076002001300194#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#66#62#article#253#<p><font face="Verd
ana" size="2"><b><i>Atividade f&iacute;sica cont&iacute;nua    vigorosa</i></b><
/font></p>     ^cY#a05v86n4.htm##
00758000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052300076002001300599#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#67#63#article#253#<p><font face="Verd
ana" size="2">Ao contr&aacute;rio do exerc&iacute;cio cont&iacute;nuo    leve a 
moderado, no exerc&iacute;cio de alta intensidade a ocorr&ecirc;ncia    de hipog
licemia &eacute; menos comum<SUP>41</SUP>, pois em indiv&iacute;duos    com DM1 
os mecanismos reguladores da glicemia independentes da insulina est&atilde;o    
preservados. Logo, &eacute; a libera&ccedil;&atilde;o de catecolaminas que ir&aa
cute;    controlar a produ&ccedil;&atilde;o hep&aacute;tica de glicose<SUP>54</S
UP>.</font></p>     ^cY#a05v86n4.htm##
00673000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043800076002001300514#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#68#64#article#253#<p><font face="Verd
ana" size="2">As catecolaminas (epinefrina, norepinefrina,    dopamina) exibem e
feitos excitat&oacute;rios e inibit&oacute;rios do sistema    nervoso perif&eacu
te;rico e a&ccedil;&otilde;es no sistema nervoso central (SNC),    al&eacute;m d
a modula&ccedil;&atilde;o da fun&ccedil;&atilde;o end&oacute;crina,    como a se
cre&ccedil;&atilde;o de insulina e a taxa de glicogen&oacute;lise<SUP>63</SUP>.<
/font></p>     ^cY#a05v86n4.htm##
00962000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072700076002001300803#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#69#65#article#253#<p><font face="Verd
ana" size="2">Nesse tipo de exerc&iacute;cio, a principal preocupa&ccedil;&atild
e;o    n&atilde;o &eacute; a hipoglicemia p&oacute;s-exerc&iacute;cio, mas sim a
 hiperglicemia,    pois os mecanismos mediados pela insulina n&atilde;o est&atil
de;o presentes.    Logo, a reposi&ccedil;&atilde;o de carboidrato extra ou redu&
ccedil;&atilde;o    na dose de insulina podem resultar na exacerba&ccedil;&atild
e;o da hiperglicemia    p&oacute;s-exerc&iacute;cio de alta intensidade<SUP>54</
SUP>. Caso esse tipo    de atividade seja o de escolha para a crian&ccedil;a ou 
adolescente, talvez    haja necessidade de aplicar uma dose de insulina logo ap&
oacute;s o t&eacute;rmino    da AF<SUP>64</SUP>.</font></p>     ^cY#a05v86n4.htm
##
00354000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011900076002001300195#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#70#66#article#253#<p><font face="Verd
ana" size="2"><b><i>Exerc&iacute;cio intermitente moderado    a vigoroso</i></b>
</font></p>     ^cY#a05v86n4.htm##
00837000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060200076002001300678#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#71#67#article#253#<p><font face="Verd
ana" size="2">Estudos recentes sugerem que esse tipo de exerc&iacute;cio    seja
 o ideal para crian&ccedil;as e adolescentes portadores de DM1<SUP>41,65-67</SUP
>.    Al&eacute;m de imitarem a maioria das atividades comuns &agrave;s crian&cc
edil;as,    como futebol, v&ocirc;lei, pega-pega, etc., esse tipo de exerc&iacut
e;cio parece    equilibrar a glicemia durante e ap&oacute;s sua realiza&ccedil;&
atilde;o, de    modo a reduzir a ocorr&ecirc;ncia hipoglicemia (AF de intensidad
e moderada)    sem exacerbar a hiperglicemia (AF de intensidade alta)<SUP>54</SU
P>.</font></p>     ^cY#a05v86n4.htm##
00944000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070900076002001300785#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#72#68#article#253#<p><font face="Verd
ana" size="2">O exerc&iacute;cio intenso intermitente gera    menor decl&iacute;
nio da glicose sangu&iacute;nea por estimular respostas hormonais    e metab&oac
ute;licas antagonistas &agrave; diminui&ccedil;&atilde;o da glicemia.    Esse ti
po de AF eleva os n&iacute;veis de lactato sangu&iacute;neo, o que pode    contr
ibuir para atenuar o decl&iacute;nio da glicemia por inibir a a&ccedil;&atilde;o
    da insulina, seja ela end&oacute;gena ou ex&oacute;gena, na recupera&ccedil;
&atilde;o    da glicose pelos m&uacute;sculos perif&eacute;ricos<SUP>68</SUP> e 
por proporcionar    a produ&ccedil;&atilde;o de glicose via gliconeog&ecirc;nese
 hep&aacute;tica<SUP>69</SUP>.</font></p>     ^cY#a05v86n4.htm##
00543000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030800076002001300384#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#73#69#article#253#<p><font face="Verd
ana" size="2">Al&eacute;m disso, o aumento das catecolaminas    em resposta ao e
xerc&iacute;cio intenso intermitente estimula a produ&ccedil;&atilde;o    hep&aa
cute;tica de glicose, ao mesmo tempo em que inibe o consumo da glicose    mediad
o pela insulina<SUP>70</SUP>.</font></p>     ^cY#a05v86n4.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009300076002001300169#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#74#70#article#253#<p><font face="Verd
ana" size="2"><b><i>Exerc&iacute;cio resistido</i></b></font></p>     ^cY#a05v86
n4.htm##
00765000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053000076002001300606#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#75#71#article#253#<p><font face="Verd
ana" size="2">N&atilde;o s&oacute; a pr&aacute;tica regular    de AF aer&oacute;
bia &eacute; indicada para crian&ccedil;as e adolescentes com    DM1, mas tamb&e
acute;m &eacute; recomendada<SUP>33,35</SUP> a realiza&ccedil;&atilde;o    de ex
erc&iacute;cios resistidos, duas a tr&ecirc;s vezes por semana, com objetivo    
de manter e/ou aumentar a for&ccedil;a muscular, aumentar o gasto energ&eacute;t
ico,    reduzir o tecido adiposo visceral e melhorar a densidade &oacute;ssea<SU
P>54</SUP>.</font></p>     ^cY#a05v86n4.htm##
00650000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704041500076002001300491#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#76#72#article#253#<p><font face="Verd
ana" size="2">Segundo Andersen<SUP>71</SUP>, o exerc&iacute;cio    de resist&eci
rc;ncia pode ser uma alternativa para o treinamento de pacientes    com DM1 e po
rtadores de complica&ccedil;&otilde;es microvasculares em membros    inferiores 
(neuropatia perif&eacute;rica, p&eacute; diab&eacute;tico) que n&atilde;o    con
seguem realizar exerc&iacute;cios com impacto articular.</font></p>     ^cY#a05v
86n4.htm##
01175000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704094000076002001301016#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#77#73#article#253#<p><font face="Verd
ana" size="2">Contudo, para esse tipo de atividade, ainda n&atilde;o    existem 
recomenda&ccedil;&otilde;es espec&iacute;ficas quanto &agrave; redu&ccedil;&atil
de;o    da dose de insulina e/ou reposi&ccedil;&atilde;o de CHO, nem sobre seus 
efeitos    em pacientes com DM1<SUP>40</SUP>. Mosher et al.<SUP>14</SUP> demonst
raram em    crian&ccedil;as com DM1 que o exerc&iacute;cio de resist&ecirc;ncia 
em combina&ccedil;&atilde;o    com exerc&iacute;cio aer&oacute;bio foi capaz de 
melhorar a aptid&atilde;o cardiorrespirat&oacute;ria,    a for&ccedil;a muscular
, o perfil lip&iacute;dico e o controle da glicemia.    Al&eacute;m disso, nesse
 estudo apenas um indiv&iacute;duo apresentou hipoglicemia.    Por outro lado, n
o estudo de Ramalho et al.<SUP>72</SUP>, n&atilde;o se observaram    efeitos do 
exerc&iacute;cio de resist&ecirc;ncia sobre o perfil lip&iacute;dico    e o cont
role glic&ecirc;mico.</font></p>     ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#78#74#article#253#<p>&nbsp;</p>     ^
cY#a05v86n4.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011100076002001300187#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#79#75#article#253#<p><font size="3" f
ace="Verdana"><b>O esporte e a crian&ccedil;a com diabetes    tipo 1</b></font><
/p>     ^cY#a05v86n4.htm##
00755000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052000076002001300596#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#80#76#article#253#<p><font face="Verd
ana" size="2">Os in&uacute;meros benef&iacute;cios promovidos    pelo exerc&iacu
te;cio f&iacute;sico regular superam o risco de ocorrer hipoglicemia    durante 
sua realiza&ccedil;&atilde;o<SUP>13,15</SUP>. Seguindo-se corretamente    as ori
enta&ccedil;&otilde;es sobre a redu&ccedil;&atilde;o da dose de insulina,    a r
eposi&ccedil;&atilde;o de CHO e o tipo de atividade que ser&aacute; praticado,  
  diminuem-se consideravelmente os epis&oacute;dios de hipoglicemia<SUP>49</SUP>
.</font></p>     ^cY#a05v86n4.htm##
00679000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044400076002001300520#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#81#77#article#253#<p><font face="Verd
ana" size="2">Herbst et al.<SUP>47</SUP> relataram que a AF    regular &eacute; 
o fator que mais influencia o controle da glicemia sem, no    entanto, aumentar 
o risco de hipoglicemia em crian&ccedil;as com DM1. Da mesma    forma, alguns es
tudos t&ecirc;m comprovado que a AF regular, seja ela cont&iacute;nua    ou inte
rmitente<SUP>41,66,73</SUP>, n&atilde;o aumenta o risco de hipoglicemia<SUP>13</
SUP>.</font></p>     ^cY#a05v86n4.htm##
01065000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083000076002001300906#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#82#78#article#253#<p><font face="Verd
ana" size="2">Nesta linha de racioc&iacute;nio, os melhores    tipos de AF seria
m aquelas em que ocorre um aumento progressivo do esfor&ccedil;o    f&iacute;sic
o e por um tempo prolongado de est&iacute;mulo<SUP>74</SUP>. Sendo    assim, div
ersos esportes coletivos (futebol, v&ocirc;lei, basquete, handebol,    nata&cced
il;&atilde;o, t&ecirc;nis de quadra) e individuais, como lutas marciais    (jud&
ocirc;, jiu-jitsu), surfe, corrida, caminhada e ciclismo, se enquadram    dentro
 das recomenda&ccedil;&otilde;es para crian&ccedil;as e adolescentes diab&eacute
;ticos<SUP>23,75</SUP>.    A escolha da AF depender&aacute; da habilidade de cad
a indiv&iacute;duo, do    objetivo que quer alcan&ccedil;ar com o exerc&iacute;c
io e, principalmente,    do seu gosto pela atividade em quest&atilde;o.</font></
p>     ^cY#a05v86n4.htm##
01496000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704126100076002001301337#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#83#79#article#253#<p><font face="Verd
ana" size="2">Da mesma forma, o tipo de AF e/ou esporte escolhido    deve estar 
de acordo com a faixa et&aacute;ria da crian&ccedil;a, de modo que    a pr&aacut
e;tica de esportes na primeira inf&acirc;ncia deve ter como objetivo    principa
l a brincadeira, caminhada de curta dist&acirc;ncia, corrida, pular,    nadar e 
dar cambalhotas. Entre os 6 e 9 anos, pode-se introduzir a competi&ccedil;&atild
e;o    com regras flex&iacute;veis e as atividades esportivas podem ser gin&aacu
te;stica    ol&iacute;mpica, nata&ccedil;&atilde;o, ciclismo, skate e esportes c
oletivos.    A partir dos 10 ou 12 anos, esportes como futebol, nata&ccedil;&ati
lde;o, t&ecirc;nis,    v&ocirc;lei, gin&aacute;stica art&iacute;stica, dan&ccedi
l;a e esportes aqu&aacute;ticos    podem ser introduzidos e direcionados para a 
competi&ccedil;&atilde;o, visando    adquirir e aprimorar as habilidades individ
uais<SUP>76</SUP>. Contudo, em alguns    esportes, como corridas automotivas, pa
raquedismo, escalada, mergulho e alpinismo,    a mensura&ccedil;&atilde;o e a co
rre&ccedil;&atilde;o da glicemia sangu&iacute;nea    tornam-se dif&iacute;ceis e
 menos confi&aacute;veis, sendo desaconselhada a    pr&aacute;tica desse tipo de
 esporte<SUP>57</SUP>.</font></p>     ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#84#80#article#253#<p>&nbsp;</p>     ^
cY#a05v86n4.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#85#81#article#253#<p><font size="3" f
ace="Verdana"><b>Conclus&atilde;o</b></font></p>     ^cY#a05v86n4.htm##
01162000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704092700076002001301003#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#86#82#article#253#<p><font face="Verd
ana" size="2">Primeiramente, destaca-se que a atividade aer&oacute;bia,    de in
tensidade moderada e intercalada com per&iacute;odos de alta intensidade    &eac
ute; eficaz na diminui&ccedil;&atilde;o da ocorr&ecirc;ncia de hipoglicemia,    
e que a participa&ccedil;&atilde;o em esportes &eacute; poss&iacute;vel e segura
    para crian&ccedil;as e adolescentes com diabetes tipo 1. Contudo, sugere-se 
   cautela em seguir as recomenda&ccedil;&otilde;es vigentes sobre a redu&ccedil
;&atilde;o    das doses de insulina de a&ccedil;&atilde;o r&aacute;pida por caus
a dos diferentes    tipos de insulina dispon&iacute;veis no mercado. Al&eacute;m
 disso, por haver    poucos estudos controlados, randomizados e duplo-cegos na p
opula&ccedil;&atilde;o    pedi&aacute;trica, a adequa&ccedil;&atilde;o da dose d
e insulina deve ser individualizada    e discutida com o m&eacute;dico endocrino
logista.</font></p>     ^cY#a05v86n4.htm##
00889000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065400076002001300730#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#87#83#article#253#<p><font face="Verd
ana" size="2">Estimular a participa&ccedil;&atilde;o de pacientes    portadores 
de DM1 em esporte recreativo ou de competi&ccedil;&atilde;o, seja    individual 
ou coletivo, &eacute; essencial para o controle dos perfis metab&oacute;lico    
e lip&iacute;dico, da press&atilde;o arterial, bem como de outros fatores, como 
   bem-estar, alta autoestima e autoconfian&ccedil;a. Desta forma, pode ser poss
&iacute;vel    diminuir a morbimortalidade associada &agrave;s complica&ccedil;&
otilde;es do    diabetes, melhorando concomitantemente a qualidade de vida de no
ssos pacientes    pedi&aacute;tricos portadores de DM1.</font></p>     ^cY#a05v8
6n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#88#84#article#253#<p>&nbsp;</p>     ^
cY#a05v86n4.htm##
00312000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007700076002001300153#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#89#85#article#253#<p><font size="3" f
ace="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#a05v86n4.htm##
00378000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704012900078002001300207#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#90#86#article#253#1#<p><f
ont size="2" face="Verdana">1. Silink M. Childhood diabetes: a global perspectiv
e.    Horm Res. 2002;57 Suppl 1:1-5.    ^cY#a05v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#91#87#article#253#</font></p>     ^cY
#a05v86n4.htm##
00464000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021500078002001300293#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#92#88#article#253#2#<p><f
ont size="2" face="Verdana">2. Fernandes AP, Pace AE, Zanetti ML, Foss MC,    Do
nadi EA. Fatores imunogen&eacute;ticos associados ao diabetes mellitus do    tip
o 1. Rev Lat Am Enfermagem. 2005;13:743-9.    ^cY#a05v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#93#89#article#253#</font></p>     ^cY
#a05v86n4.htm##
00463000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021400078002001300292#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#94#90#article#253#3#<p><f
ont size="2" face="Verdana">3. Knip M, Veijola R, Virtanen SM, Hy&ouml;ty    H, 
Vaarala O, Åkerblom HK. Environmental triggers and determinants of type 1    dia
betes. Diabetes. 2005;54 Suppl 2:S125-36.    ^cY#a05v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#95#91#article#253#</font></p>     ^cY
#a05v86n4.htm##
00502000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025300078002001300331#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#96#92#article#253#4#<p><f
ont size="2" face="Verdana">4. Karvonen M, Viik-Kajander M, Moltchanova E,    Li
bman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwid
e.    Diabetes Mondiale (DiaMond) Project Group. Diabetes Care. 2000;23:1516-26.
    ^cY#a05v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#97#93#article#253#</font></p>     ^cY
#a05v86n4.htm##
00477000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022800078002001300306#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#98#94#article#253#5#<p><f
ont size="2" face="Verdana">5. Ferreira SR, Franco LJ, Vivolo MA, Negrato    CA,
 Simoes AC, Ventureli CR. Population-based incidence of IDDM in the state    of 
S&atilde;o Paulo, Brazil. Diabetes Care. 1993;16:701-4.    ^cY#a05v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#99#95#article#253#</font></p>     ^cY
#a05v86n4.htm##
00454000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704020400079002001300283#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#100#96#article#253#6#<p><
font size="2" face="Verdana">6. Lisb&ocirc;a HR, Graebin R, Butzke L, Rodrigues 
   CS. Incidence of type 1 diabetes mellitus in Passo Fundo, RS, Brazil. Braz J 
   Med Biol Res. 1998;31:1553-6.    ^cY#a05v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#101#97#article#253#</font></p>     ^c
Y#a05v86n4.htm##
00506000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704025600079002001300335#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#102#98#article#253#7#<p><
font size="2" face="Verdana">7. Negrato CA, Dias JP, Teixeira MF, Dias A,    Sal
gado MH, Lauris JR, et al. Temporal trends in incidence of type 1 diabetes    be
tween 1986 and 2006 in Brazil. J Endocrinol Invest. 2009. &#091;ahead of print&#
093;    ^cY#a05v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#103#99#article#253#</font></p>     ^c
Y#a05v86n4.htm##
00546000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704029500080002001300375#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#104#100#article#253#8#<p>
<font size="2" face="Verdana">8. Effect of intensive diabetes treatment on    ca
rotid artery wall thickness in the epidemiology of diabetes interventions    and
 complications. Epidemiology of Diabetes Interventions and Complications    (EDI
C) Research Group. Diabetes. 1999;48:383-90.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#105#101#article#253#</font></p>     ^
cY#a05v86n4.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704022200080002001300302#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#106#102#article#253#9#<p>
<font size="2" face="Verdana">9. Asmal AC, Dayal B, Jialal I, Leary WP, Omar    
MA, Pillay NL, et al. Non-insulin-dependent diabetes mellitus with early onset  
  in Blacks and Indians. S Afr Med J. 1981;60:93-6.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#107#103#article#253#</font></p>     ^
cY#a05v86n4.htm##
00545000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029300081002001300374#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#108#104#article#253#10#<p
><font size="2" face="Verdana">10. The effect of intensive treatment of diabetes
    on the development and progression of long-term complications in insulin-dep
endent    diabetes mellitus. The Diabetes Control And Complications Trial Resear
ch Group.    N Engl J Med. 1993;329:977-86.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#109#105#article#253#</font></p>     ^
cY#a05v86n4.htm##
00478000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022600081002001300307#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#110#106#article#253#11#<p
><font size="2" face="Verdana">11. The absence of a glycemic threshold for the  
  development of long-term complications: the perspective of the Diabetes Contro
l    and Complications Trial. Diabetes. 1996;45:1289-98.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#111#107#article#253#</font></p>     ^
cY#a05v86n4.htm##
00501000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024900081002001300330#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#112#108#article#253#12#<p
><font size="2" face="Verdana">12. Skrivarhaug T, Bangstad HJ, Stene LC, Sandvik
    L, Hanssen KF, Joner G. Long-term mortality in a nationwide cohort of childh
ood-onset    type 1 diabetic patients in Norway. Diabetologia. 2006;49:298-305. 
   ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#113#109#article#253#</font></p>     ^
cY#a05v86n4.htm##
00474000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022200081002001300303#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#114#110#article#253#13#<p
><font size="2" face="Verdana">13. Bernardini AL, Vanelli M, Chiari G, Iovane   
 B, Gelmetti C, Vitale R, et al. Adherence to physical activity in young people 
   with type 1 diabetes. Acta Biomed. 2004;75:153-7.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#115#111#article#253#</font></p>     ^
cY#a05v86n4.htm##
00516000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026400081002001300345#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#116#112#article#253#14#<p
><font size="2" face="Verdana">14. Mosher PE, Nash MS, Perry AC, LaPerriere    A
R, Goldberg RB. Aerobic circuit exercise training: effect on adolescents with   
 well-controlled insulin-dependent diabetes mellitus. Arch Phys Med Rehabil.    
1998;79:652-7.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#117#113#article#253#</font></p>     ^
cY#a05v86n4.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023300081002001300314#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#118#114#article#253#15#<p
><font size="2" face="Verdana">15. Khawali C, Andriolo A, Ferreira SR. Benef&iac
ute;cios    da atividade f&iacute;sica no perfil lip&iacute;dico de pacientes co
m diabetes    tipo 1. Arq Bras Endocrinol Metab. 2003;47:49-54.    ^cY#a05v86n4.
htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#119#115#article#253#</font></p>     ^
cY#a05v86n4.htm##
00457000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020500081002001300286#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#120#116#article#253#16#<p
><font size="2" face="Verdana">16. Lehmann R, Kaplan V, Bingisser R, Bloch KE,  
  Spinas GA. Impact of physical activity on cardiovascular risk factors in IDDM.
    Diabetes Care. 1997;20:1603-11.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#121#117#article#253#</font></p>     ^
cY#a05v86n4.htm##
00498000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024600081002001300327#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#122#118#article#253#17#<p
><font size="2" face="Verdana">17. Heyman E, Toutain C, Delamarche P, Berthon   
 P, Briard D, Youssef H, et al. Exercise training and cardiovascular risk factor
s    in type 1 diabetic adolescent girls. Pediatr Exerc Sci. 2007;19:408-19.    
^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#123#119#article#253#</font></p>     ^
cY#a05v86n4.htm##
00508000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025600081002001300337#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#124#120#article#253#18#<p
><font size="2" face="Verdana">18. Laaksonen DE, Atalay M, Niskanen LK, Mustonen
    J, Sen CK, Lakka TA, et al. Aerobic exercise and the lipid profile in type I
    diabetic men: a randomized controlled trial. Med Sci Sports Exerc. 2000;32:1
541-8.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#125#121#article#253#</font></p>     ^
cY#a05v86n4.htm##
00569000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031700081002001300398#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#126#122#article#253#19#<p
><font size="2" face="Verdana">19. Rigla M, S&aacute;nchez-Quesada JL, Ord&oacut
e;&ntilde;ez-Llanos    J, Prat T, Caix&agrave;s A, Jorba O, et al. Effect of phy
sical exercise on lipoprotein(a)    and low-density lipoprotein modifications in
 type 1 and type 2 diabetic patients.    Metabolism. 2000;49:640-7.    ^cY#a05v8
6n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#127#123#article#253#</font></p>     ^
cY#a05v86n4.htm##
00592000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034000081002001300421#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#128#124#article#253#20#<p
><font size="2" face="Verdana">20. Sideravi&#269;i&#363;t&#279; S, Gaili&#363;ni
ene    A, Visagurskiene K, Vizbaraite D. The effect of long-term swimming progra
m on    body composition, aerobic capacity and blood lipids in 14-19-year aged h
ealthy    girls and girls with type 1 diabetes mellitus. Medicina (Kaunas). 2006
;42:661-6.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#129#125#article#253#</font></p>     ^
cY#a05v86n4.htm##
00607000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704035500081002001300436#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#130#126#article#253#21#<p
><font size="2" face="Verdana">21. Herbst A, Kordonouri O, Schwab KO, Schmidt   
 F, Holl RW; DPV Initiative of the German Working Group for Pediatric Diabetolog
y    Germany. Impact of physical activity on cardiovascular risk factors in chil
dren    with type 1 diabetes: a multicenter study of 23,251 patients. Diabetes C
are.    2007;30:2098-100.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#131#127#article#253#</font></p>     ^
cY#a05v86n4.htm##
00575000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032300081002001300404#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#132#128#article#253#22#<p
><font size="2" face="Verdana">22. Margeirsdottir HD, Larsen JR, Brunborg C,    
Overby NC, Dahl-Jørgensen K; Norwegian Study Group for Childhood Diabetes. High 
   prevalence of cardiovascular risk factors in children and adolescents with ty
pe    1 diabetes: a population-based study. Diabetologia. 2008;51:554-61.    ^cY
#a05v86n4.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#133#129#article#253# </font></p>     
^cY#a05v86n4.htm##
00516000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026400081002001300345#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#134#130#article#253#23#<p
><font size="2" face="Verdana">23. Valerio G, Spagnuolo MI, Lombardi F, Spadaro 
   R, Siano M, Franzese A. Physical activity and sports participation in childre
n    and adolescents with type 1 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2
007;17:376-82.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#135#131#article#253#</font></p>     ^
cY#a05v86n4.htm##
00560000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030800081002001300389#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#136#132#article#253#24#<p
><font size="2" face="Verdana">24. Majaliwa ES, Munubhi E, Ramaiya K, Mpembeni  
  R, Sanyiwa A, Mohn A, et al. Survey on acute and chronic complications in chil
dren    and adolescents with type 1 diabetes at Muhimbili National Hospital in D
ar es    Salaam, Tanzania. Diabetes Care. 2007;30:2187-92.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#137#133#article#253#</font></p>     ^
cY#a05v86n4.htm##
00494000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024200081002001300323#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#138#134#article#253#25#<p
><font size="2" face="Verdana">25. Sellers EA, Yung G, Dean HJ. Dyslipidemia    
and other cardiovascular risk factors in a Canadian First Nation pediatric popul
ation    with type 2 diabetes mellitus. Pediatr Diabetes. 2007;8:384-90.    ^cY#
a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#139#135#article#253#</font></p>     ^
cY#a05v86n4.htm##
00563000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031100081002001300392#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#140#136#article#253#26#<p
><font size="2" face="Verdana">26. McGill HC Jr, McMahan AC, Malcom GT, Oalmann 
   MC, Strong JP. Relation of glycohemoglobin and adiposity to atherosclerosis  
  in youth. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Rese
arch    Group. Arterioscler Thromb Vasc Biol. 1995;15:431-40.    ^cY#a05v86n4.ht
m##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#141#137#article#253#</font></p>     ^
cY#a05v86n4.htm##
00465000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021300081002001300294#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#142#138#article#253#27#<p
><font size="2" face="Verdana">27. McGill HC Jr, McMahan CA, Herderick EE, Malco
m    GT, Tracy RE, Strong JP. Origin of atherosclerosis in childhood and adolesc
ence.    Am J Clin Nutr. 2000;72:1307S-15S.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#143#139#article#253#</font></p>     ^
cY#a05v86n4.htm##
00510000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025800081002001300339#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#144#140#article#253#28#<p
><font size="2" face="Verdana">28. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda
    Y, Mas JL, et al. International prevalence, recognition, and treatment of ca
rdiovascular    risk factors in outpatients with atherothrombosis. JAMA. 2006;29
5:180-9.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#145#141#article#253#</font></p>     ^
cY#a05v86n4.htm##
00674000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704042200081002001300503#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#146#142#article#253#29#<p
><font size="2" face="Verdana">29. Grundy SM, Becker D, Clark LT, Cooper RS,    
Denke MA, Howard J, et al. Third report of the National Cholesterol Education   
 Program (NCEP) expert panel on detection, evaluation, and treatment of high    
blood cholesterol in adults (Adult Treatment Panel III) final report. National  
  Institutes of Health. National Heart, Lung, and Blood Institute. NIH Publicati
on,    2002.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#147#143#article#253#</font></p>     ^
cY#a05v86n4.htm##
00472000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022000081002001300301#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#148#144#article#253#30#<p
><font size="2" face="Verdana">30. Hancox RJ, Milne BJ, Poulton R. Association  
  between child and adolescent television viewing and adult health: a longitudin
al    birth cohort study. Lancet. 2004;364:257-62.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#149#145#article#253#</font></p>     ^
cY#a05v86n4.htm##
00572000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032000081002001300401#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#150#146#article#253#31#<p
><font size="2" face="Verdana">31. Ribeiro RQ, Lotufo PA, Lamounier JA, Oliveira
    RG, Soares JF, Botter DA. Fatores adicionais de risco cardiovascular associa
dos    ao excesso de peso em crian&ccedil;as e adolescentes. O Estudo do Cora&cc
edil;&atilde;o    de Belo Horizonte. Arq Bras Cardiol. 2006;86:408-18.    ^cY#a0
5v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#151#147#article#253#</font></p>     ^
cY#a05v86n4.htm##
00537000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028500081002001300366#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#152#148#article#253#32#<p
><font size="2" face="Verdana">32. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum  
  A, Lanas F, et al. Effect of potentially modifiable risk factors associated   
 with myocardial infarction in 52 countries (the INTERHEART study): case-control
    study. Lancet. 2004;364:937-52.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#153#149#article#253#</font></p>     ^
cY#a05v86n4.htm##
00407000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704015500081002001300236#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#154#150#article#253#33#<p
><font size="2" face="Verdana">33. American Diabetes Association. Standards    o
f medical care in diabetes - 2008. Diabetes Care. 2008;31:S12-54.    ^cY#a05v86n
4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#155#151#article#253#</font></p>     ^
cY#a05v86n4.htm##
00566000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031400081002001300395#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#156#152#article#253#34#<p
><font size="2" face="Verdana">34. Haskell WL, Lee IM, Pate RR, Powell KE, Blair
    SN, Franklin BA, et al. Physical activity and public health: updated recomme
ndation    for adults from the American College of Sports Medicine and the Ameri
can Heart    Association. Med Sci Sports Exerc. 2007;39:1423-34.    ^cY#a05v86n4
.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#157#153#article#253#</font></p>     ^
cY#a05v86n4.htm##
00528000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027600081002001300357#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#158#154#article#253#35#<p
><font size="2" face="Verdana">35. Kohrt WM, Bloomfield SA, Little KD, Nelson   
 ME, Yingling VR. American College of Sports Medicine. American College of Sport
s    Medicine Position Stand: physical activity and bone health. Med Sci Sports 
Exerc.    2004;36:1985-96.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#159#155#article#253#</font></p>     ^
cY#a05v86n4.htm##
00724000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704047200081002001300553#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#160#156#article#253#36#<p
><font size="2" face="Verdana">36. Center for Disease Control. US Department    
Of Health And Human Services. Physical activity and good nutrition: essential   
 elements to prevent chronic diseases and obesity. Atlanta (GA): National Center
    for Chronic Disease Prevention and Health Promotion. <A href=http://www.cdc.
gov/nccdphp/publications/aag/pdf/dnpa.pdf target="_blank">http://www.cdc.gov/ncc
dphp/publications/aag/pdf/dnpa.pdf</A>.    Acesso: 21/02/2008.    ^cY#a05v86n4.h
tm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#161#157#article#253#</font></p>     ^
cY#a05v86n4.htm##
00481000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022900081002001300310#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#162#158#article#253#37#<p
><font size="2" face="Verdana">37. Kimm SY, Glynn NW, Kriska AM, Barton BA,    K
ronsberg SS, Daniels SR, et al. Decline in physical activity in black and white 
   girls during adolescence. N Engl J Med. 2002;347:709-15.    ^cY#a05v86n4.htm#
#
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#163#159#article#253#</font></p>     ^
cY#a05v86n4.htm##
00474000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022200081002001300303#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#164#160#article#253#38#<p
><font size="2" face="Verdana">38. Twisk JW, Kemper HC, van Mechelen W. Tracking
    of activity and fitness and the relationship with cardiovascular disease ris
k    factors. Med Sci Sports Exerc. 2000;32:1455-61.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#165#161#article#253#</font></p>     ^
cY#a05v86n4.htm##
00466000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021400081002001300295#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#166#162#article#253#39#<p
><font size="2" face="Verdana">39. Yang X, Telama R, Viikari J, Raitakari OT.   
 Risk of obesity in relation to physical activity tracking from youth to adultho
od.    Med Sci Sports Exerc. 2006;38:919-25.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#167#163#article#253#</font></p>     ^
cY#a05v86n4.htm##
00528000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027600081002001300357#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#168#164#article#253#40#<p
><font size="2" face="Verdana">40. de Angelis K, da Pureza DY, Flores LJ, Rodrig
ues    B, Melo KF, Schaan BD, et al. Efeitos fisiol&oacute;gicos do treinamento 
f&iacute;sico    em pacientes portadores de diabetes tipo 1. Arq Bras Endocrinol
 Metabol. 2006;50:1005-13.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#169#165#article#253#</font></p>     ^
cY#a05v86n4.htm##
00514000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026200081002001300343#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#170#166#article#253#41#<p
><font size="2" face="Verdana">41. Guelfi KJ, Jones TW, Fournier PA. The decline
    in blood glucose levels is less with intermittent high-intensity compared wi
th    moderate exercise in individuals with type 1 diabetes. Diabetes Care. 2005
;28:1289-94.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#171#167#article#253#</font></p>     ^
cY#a05v86n4.htm##
00482000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023000081002001300311#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#172#168#article#253#42#<p
><font size="2" face="Verdana">42. Corigliano G, Iazzetta N, Corigliano M, Strol
lo    F. Blood glucose changes in diabetic children and adolescents engaged in m
ost    common sports activities. Acta Biomed. 2006;77:26-33.    ^cY#a05v86n4.htm
##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#173#169#article#253#</font></p>     ^
cY#a05v86n4.htm##
00466000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021400081002001300295#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#174#170#article#253#43#<p
><font size="2" face="Verdana">43. Zinman B, Ruderman N, Campaigne BN, Devlin   
 JT, Schneider SH. American Diabetes Association. Physical activity/exercise    
and diabetes. Diabetes Care. 2004;27:S13-54.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#175#171#article#253#</font></p>     ^
cY#a05v86n4.htm##
00486000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023400081002001300315#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#176#172#article#253#44#<p
><font size="2" face="Verdana">44. Tsalikian E, Mauras N, Beck RW, Tamborlane   
 WV, Janz KF, Chase HP, et al. Impact of exercise on overnight glycemic control 
   in children with type 1 mellitus. J Pediatr. 2005;147:528-34.    ^cY#a05v86n4
.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#177#173#article#253#</font></p>     ^
cY#a05v86n4.htm##
00409000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704015700081002001300238#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#178#174#article#253#45#<p
><font size="2" face="Verdana">45. Giannini C, Mohn A, Chiarelli F. Physical    
exercise and diabetes during childhood. Acta Biomed. 2006;77:18-25.    ^cY#a05v8
6n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#179#175#article#253#</font></p>     ^
cY#a05v86n4.htm##
00488000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023600081002001300317#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#180#176#article#253#46#<p
><font size="2" face="Verdana">46. Wojtaszewski JF, Hansen BF, Gade J, Kiens    
B, Markuns JF, Goodyear LJ, et al. Insulin signaling and insulin sensitivity    
after exercise in human skeletal muscle. Diabetes. 2000;49:325-31.    ^cY#a05v86
n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#181#177#article#253#</font></p>     ^
cY#a05v86n4.htm##
00499000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024700081002001300328#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#182#178#article#253#47#<p
><font size="2" face="Verdana">47. Herbst A, Bachran R, Kapellen T, Holl RW.    
Effects of regular physical activity on control of glycemia in pediatric patient
s    with type 1 diabetes mellitus. Arch Pediatr Adolesc Med. 2006;160:573-7.   
 ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#183#179#article#253#</font></p>     ^
cY#a05v86n4.htm##
00447000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019500081002001300276#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#184#180#article#253#48#<p
><font size="2" face="Verdana">48. Toni S, Reali MF, Barni F, Lenzi L, Festini  
  F. Managing insulin therapy during exercise in type 1 diabetes mellitus. Acta 
   Biomed. 2006;77:34-40.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#185#181#article#253#</font></p>     ^
cY#a05v86n4.htm##
00441000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018900081002001300270#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#186#182#article#253#49#<p
><font size="2" face="Verdana">49. Hoffman RP. Practical management of type    1
 diabetes mellitus in adolescent patients: challenges and goals. Treat Endocrino
l.    2004;3:27-39.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#187#183#article#253#</font></p>     ^
cY#a05v86n4.htm##
00602000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704035000081002001300431#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#188#184#article#253#50#<p
><font size="2" face="Verdana">50. Rabasa-Lhoret R, Bourque J, Ducros F, Chiasso
n    JL. Guidelines for premeal insulin dose reduction for postprandial exercise
    of different intensities and durations in type 1 diabetic subjects treated i
ntensively    with a basal-bolus insulin regimen (ultralente-lispro). Diabetes C
are. 2001;24:625-30.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#189#185#article#253#</font></p>     ^
cY#a05v86n4.htm##
00489000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023700081002001300318#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#190#186#article#253#51#<p
><font size="2" face="Verdana">51. Grimm JJ, Ybarra J, Bern&eacute; C, Muchnick 
   S, Golay A. A new table for prevention of hypoglycaemia during physical activ
ity    in type 1 diabetic patients. Diabetes Metab. 2004;30:465-70.    ^cY#a05v8
6n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#191#187#article#253#</font></p>     ^
cY#a05v86n4.htm##
00451000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019900081002001300280#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#192#188#article#253#52#<p
><font size="2" face="Verdana">52. Chiarelli F, Verrotti A, Catino M, Sabatino  
  G, Pinelli L. Hypoglycaemia in children with type 1 diabetes mellitus. Acta   
 Paediatr Suppl.1999;88:31-4.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#193#189#article#253#</font></p>     ^
cY#a05v86n4.htm##
00427000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017500081002001300256#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#194#190#article#253#53#<p
><font size="2" face="Verdana">53. De Feo P, Di Loreto C, Ranchelli A, Fatone   
 C, Gambelunghe G, Lucidi P, et al. Exercise and diabetes. Acta Biomed. 2006;77:
14-7.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#195#191#article#253#</font></p>     ^
cY#a05v86n4.htm##
00442000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019000081002001300271#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#196#192#article#253#54#<p
><font size="2" face="Verdana">54. Gulve EA. Exercise and glycemic control in   
 diabetes: benefits, challenges, and adjustments to pharmacotherapy. Phys Ther. 
   2008;88:1297-321.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#197#193#article#253#</font></p>     ^
cY#a05v86n4.htm##
00447000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019500081002001300276#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#198#194#article#253#55#<p
><font size="2" face="Verdana">55. Robertson K, Adolfsson P, Riddell MC, Scheine
r    G, Hanas R. Exercise in children and adolescents with diabetes. Pediatric D
iabetes.    2008;9:65-77.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#199#195#article#253#</font></p>     ^
cY#a05v86n4.htm##
00560000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030800081002001300389#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#200#196#article#253#56#<p
><font size="2" face="Verdana">56. Sociedade Brasileira de Diabetes. Protocolo  
  hiper/hipoglicemias x corrida para atletas com diabetes. <A href=http://www.di
abetes.org.br/protocolos/protativfis.php target="_blank">http://www.diabetes.org
.br/protocolos/protativfis.php</A>.    Acesso: 13/03/2009.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#201#197#article#253#</font></p>     ^
cY#a05v86n4.htm##
00575000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032300081002001300404#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#202#198#article#253#57#<p
><font size="2" face="Verdana">57. Ferriss JB, Webb D, Chaturvedi N, Fuller    J
H, Idzior-Walus B. EURODIAB Prospective Complications Group. Weight gain is    a
ssociated with improved glycaemic control but with adverse changes in plasma    
lipids and blood pressure in Type 1 diabetes. Diabet Med. 2006;23:557-64.    ^cY
#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#203#199#article#253#</font></p>     ^
cY#a05v86n4.htm##
00434000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018200081002001300263#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#204#200#article#253#58#<p
><font size="2" face="Verdana">58. Ramalho AC, Soares S. O papel do exerc&iacute
;cio    no tratamento do diabetes melito tipo 1. Arq Bras Endocrinol Metabol. 20
08;52:260-7.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#205#201#article#253#</font></p>     ^
cY#a05v86n4.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023300081002001300314#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#206#202#article#253#59#<p
><font size="2" face="Verdana">59. Tuominen JA, Karonen SL, Melamies L, Bolli   
 G, Koivisto VA. Exercise-induced hypoglycaemia in IDDM patients treated with   
 a short-acting insulin analogue. Diabetologia. 1995;38:106-11.    ^cY#a05v86n4.
htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#207#203#article#253#</font></p>     ^
cY#a05v86n4.htm##
00535000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028300081002001300364#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#208#204#article#253#60#<p
><font size="2" face="Verdana">60. Tansey MJ, Tsalikian E, Beck RW, Mauras N,   
 Buckingham BA, Weinzimer SA, et al. The effects of aerobic exercise on glucose 
   and counterregulatory hormone concentrations in children with type 1 diabetes
.    Diabetes Care. 2006;29:20-5.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#209#205#article#253#</font></p>     ^
cY#a05v86n4.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028100081002001300362#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#210#206#article#253#61#<p
><font size="2" face="Verdana">61. Goulet ED, M&eacute;lan&ccedil;on MO, Auberti
n-Leheudre    M, Dionne IJ. Aerobic training improves insulin sensitivity 72-120
 h after the    last exercise session in younger but not in older women. Eur J A
ppl Physiol.    2005;95:146-52.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#211#207#article#253#</font></p>     ^
cY#a05v86n4.htm##
00598000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034600081002001300427#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#212#208#article#253#62#<p
><font size="2" face="Verdana">62. Sociedade Brasileira de Diabetes. Tratamento 
   e acompanhamento do diabetes mellitus: diretrizes da sociedade brasileira de 
   diabetes, 2007. <A href=http://www.diabetes.org.br/educacao/livrosonline.php 
target="_blank">http://www.diabetes.org.br/educacao/livrosonline.php</A>.    Ace
sso: 23/06/2008.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#213#209#article#253#</font></p>     ^
cY#a05v86n4.htm##
00584000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033200081002001300413#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#214#210#article#253#63#<p
><font size="2" face="Verdana">63. Purdon C, Brousson M, Nyveen SL, Miles PD,   
 Halter JB, Vranic M, et al. The roles of insulin and catecholamines in the gluc
oregulatory    response during intense exercise and early recovery in insulin-de
pendent diabetic    and control subjects. J Clin Endocrinol Metab. 1993;76:566-7
3.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#215#211#article#253#</font></p>     ^
cY#a05v86n4.htm##
00471000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021900081002001300300#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#216#212#article#253#64#<p
><font size="2" face="Verdana">64. Marliss EB, Vranic M. Intense execise has    
unique effects on both insulin release and its roles in glucoregulation: implica
tions    for diabetes. Diabetes. 2002;51:S271-83.    ^cY#a05v86n4.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#217#213#article#253# </font></p>     
^cY#a05v86n4.htm##
00507000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025500081002001300336#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#218#214#article#253#65#<p
><font size="2" face="Verdana">65. Bussau VA, Ferreira LD, Jones TW, Fournier   
 PA. The 10-s maximal sprint: a novel approach to counter an exercise-mediated  
  fall in glycemia in individuals with type 1 diabetes. Diabetes Care. 2006;29:6
01-6.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#219#215#article#253#</font></p>     ^
cY#a05v86n4.htm##
00501000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024900081002001300330#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#220#216#article#253#66#<p
><font size="2" face="Verdana">66. Guelfi KJ, Jones TW, Fournier PA. Intermitent
    high-intensity exercise does not increase the risk of early postexercise hyp
oglycemia    in individuals with type 1 diabetes. Diabetes Care. 2005;28:416-8. 
   ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#221#217#article#253#</font></p>     ^
cY#a05v86n4.htm##
00565000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031300081002001300394#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#222#218#article#253#67#<p
><font size="2" face="Verdana">67. Guelfi KJ, Ratnam N, Smythe GA, Jones TW,    
Fournier PA. Effect of intermittent high-intensity compared with continuous    m
oderate exercise on glucose production and utilization in individuals with    ty
pe 1 diabetes. Am J Physiol Endocrinol Metab. 2007;292:E865-70.    ^cY#a05v86n4.
htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#223#219#article#253#</font></p>     ^
cY#a05v86n4.htm##
00507000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025500081002001300336#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#224#220#article#253#68#<p
><font size="2" face="Verdana">68. Vettor R, Lombardi AM, Fabris R, Pagano C,   
 Cusin I, Rohner-Jeanrenaud F, et al. Lactate infusion in anesthetized rats prod
uces    insulin resistance in heart and skeletal muscles. Metabolism. 1997;46:68
4-90.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#225#221#article#253#</font></p>     ^
cY#a05v86n4.htm##
00511000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025900081002001300340#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#226#222#article#253#69#<p
><font size="2" face="Verdana">69. Miller BF, Fattor JA, Jacobs KA, Horning    M
A, Navazio F, Lindinger MI, et al. Lactate and glucose interactions during    re
st and exercise in men: effect of exogenous lactate infusion. J Physiol. 2002;54
4:963-75.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#227#223#article#253#</font></p>     ^
cY#a05v86n4.htm##
00513000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026100081002001300342#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#228#224#article#253#70#<p
><font size="2" face="Verdana">70. Kreisman SH, Halter JB, Vranic M, Marliss    
EB. Combined infusion of epinephrine and norepinephrine during moderate exercise
    reproduces the glucoregulatory response of intense exercise. Diabetes. 2003;
52:1347-54.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#229#225#article#253#</font></p>     ^
cY#a05v86n4.htm##
00388000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704013600081002001300217#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#230#226#article#253#71#<p
><font size="2" face="Verdana">71. Andersen H. Muscular endurance in long-term  
  IDDM patients. Diabetes Care. 1998;21:604-9.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#231#227#article#253#</font></p>     ^
cY#a05v86n4.htm##
00544000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029200081002001300373#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#232#228#article#253#72#<p
><font size="2" face="Verdana">72. Ramalho AC, de Lourdes Lima M, Nunes F, Cambu
&iacute;    Z, Barbosa C, Andrade A, et al. The effect of resistance versus aero
bic training    on metabolic control in patients with type-1 diabetes mellitus. 
Diabetes Res    Clin Pract. 2006;72:271-6.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#233#229#article#253#</font></p>     ^
cY#a05v86n4.htm##
00457000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020500081002001300286#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#234#230#article#253#73#<p
><font size="2" face="Verdana">73. Ruzic L, Sporis G, Matkovic BR. High volume-l
ow    intensity exercise camp and glycemic control in diabetic children. J Paedi
atr    Child Health. 2008;44:122-8.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#235#231#article#253#</font></p>     ^
cY#a05v86n4.htm##
00379000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704012700081002001300208#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#236#232#article#253#74#<p
><font size="2" face="Verdana">74. Dorchy H, Poortmans J. Sport and the diabetic
    child. Sports Med. 1989;7:248-62.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#237#233#article#253#</font></p>     ^
cY#a05v86n4.htm##
00363000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704011100081002001300192#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#238#234#article#253#75#<p
><font size="2" face="Verdana">75. Gallen I. Exercise in Type 1 diabetes. Diabet
    Med. 2003;20:2-5.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#239#235#article#253#</font></p>     ^
cY#a05v86n4.htm##
00445000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019300081002001300274#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#p#240#236#article#253#76#<p
><font size="2" face="Verdana">76. Green L, Adeyanju M. Exercise and fitness    
guidelines for elementary and middle school children. The Elementary School    J
ournal. 1991;91:437-44.    ^cY#a05v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#241#237#article#253#</font></p>     ^
cY#a05v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#242#238#article#253#<p>&nbsp;</p>    
 ^cY#a05v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#243#239#article#253#<p>&nbsp;</p>    
 ^cY#a05v86n4.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018000078002001300258#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#244#240#article#253#<p><font size="2"
 face="Verdana"><a name="correspondence"></a><a href="#topo"><img src="/img/revi
stas/jped/v86n4/seta.gif" border="0"></a>    <b> Correspond&ecirc;ncia:</b>    ^
cY#a05v86n4.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003800078002001300116#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#245#241#article#253#<br>   Cristiane 
Petra Miculis    ^cY#a05v86n4.htm##
00356000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011900078002001300197#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#246#242#article#253#<BR>   Centro de 
Estudos no Esporte e Exerc&iacute;cio, Departamento de Educa&ccedil;&atilde;o   
 F&iacute;sica    ^cY#a05v86n4.htm##
00289000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005200078002001300130#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#247#243#article#253#<BR>   Universida
de Federal do Paran&aacute;    ^cY#a05v86n4.htm##
00290000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005300078002001300131#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#248#244#article#253#<BR>   Rua Cora&c
cedil;&atilde;o de Maria, 92    ^cY#a05v86n4.htm##
00280000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004300078002001300121#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#249#245#article#253#<BR>   BR 116, Km
 95 - Curitiba, PR    ^cY#a05v86n4.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003500078002001300113#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#250#246#article#253#<BR>   Tel.: (41)
 3360.4336    ^cY#a05v86n4.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#251#247#article#253#<BR>   Fax: (41) 
3360.4336    ^cY#a05v86n4.htm##
00332000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009500078002001300173#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#252#248#article#253#<BR>   E-mail: <A
 href=mailto:crispetra@uol.com.br>crispetra@uol.com.br</A></font></p>     ^cY#a0
5v86n4.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010600078002001300184#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#253#249#article#253#<p><font size="2"
 face="Verdana">Artigo submetido em 21.01.2010, aceito em 24.02.2010.</font></p>
     ^cY#a05v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#254#250#article#253#<p>&nbsp;</p>    
 ^cY#a05v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#255#251#article#253#<p>&nbsp;</p>    
 ^cY#a05v86n4.htm##
00390000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704015300078002001300231#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#256#252#article#253#<p><font face="Ve
rdana" size="2">N&atilde;o foram declarados conflitos de interesse    associados
 &agrave; publica&ccedil;&atilde;o deste artigo.    ^cY#a05v86n4.htm##
00357000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012000078002001300198#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a05v86n4.htm#S#p#257#253#article#253#<br>   Este traba
lho foi realizado na Universidade Federal do Paran&aacute; (UFPR),    Curitiba, 
PR.</font></p>     ^cY#a05v86n4.htm##
00469000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770120045000930300
01000138710000200148065000900150064000500159031000300164032001000167014000400177
865000900181002001300190#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S
#c#258#1#article#76#1#^rND^sSilink^nM#Childhood diabetes: a global perspective^l
en#Horm Res.#2#20020000#2002#57#^sSuppl 1#1-5#20100800#a05v86n4.htm##
00645000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100015000970100
01800112010001500130010001700145012007000162030002200232065000900254064000500263
031000300268014000600271865000900277002001300286035001000299801002200309#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#259#2#article#76#2#^rND^sFern
andes^nAP#^rND^sPace^nAE#^rND^sZanetti^nML#^rND^sFoss^nMC#^rND^sDonadi^nEA#Fator
es imunogenéticos associados ao diabetes mellitus do tipo 1.^lpt#Rev Lat Am Enfe
rmagem#20050000#2005#13#743-9#20100800#a05v86n4.htm#0104-1169#Rev Lat Am Enferma
gem##
00664000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100017000910100
01900108010001500127010001700142010001900159012006300178030000900241065000900250
06400050025903100030026403200100026701400080027786500090028500200130029403500100
0307801000900317#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#260#3
#article#76#3#^rND^sKnip^nM#^rND^sVeijola^nR#^rND^sVirtanen^nSM#^rND^sHyöty^nH#^
rND^sVaarala^nO#^rND^sÅkerblom^nHK#Environmental triggers and determinants of ty
pe 1 diabetes^len#Diabetes#20040000#2005#54#^sSuppl 2#S125-36#20100800#a05v86n4.
htm#0012-1797#Diabetes##
00700000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100023000950100
02100118010001600139010001700155010002100172012009600193030001400289065000900303
06400050031203100030031701400080032086500090032800200130033703500100035080100140
0360#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#261#4#article#76#
4#^rND^sKarvonen^nM#^rND^sViik-Kajander^nM#^rND^sMoltchanova^nE#^rND^sLibman^nI#
^rND^sLaPorte^nR#^rND^sTuomilehto^nJ.#Incidence of childhood type 1 diabetes wor
ldwide. Diabetes Mondiale (DiaMond) Project Group^len#Diabetes Care#20000000#200
0#23#1516-26#20100800#a05v86n4.htm#0149-5992#Diabetes Care##
00667000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100017000960100
01700113010001800130010001700148010002000165012007300185030001400258065000900272
06400050028103100030028601400060028986500090029500200130030403500100031780100140
0327#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#262#5#article#76#
5#^rND^sFerreira^nSR#^rND^sFranco^nLJ#^rND^sVivolo^nMA#^rND^sNegrato^nCA#^rND^sS
imoes^nAC#^rND^sVentureli^nCR#Population-based incidence of IDDM in the state of
 São Paulo, Brazil^len#Diabetes Care#19930000#1993#16#701-4#20100800#a05v86n4.ht
m#0149-5992#Diabetes Care##
00575000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940100
01600111010002000127012006900147030002100216710000200237065000900239064000500248
031000300253014000700256865000900263002001300272#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a05v86n4.htm#S#c#263#6#article#76#6#^rND^sLisbôa^nHR#^rND^sGraebin^nR#
^rND^sButzke^nL#^rND^sRodrigues^nCS#Incidence of type 1 diabetes mellitus in Pas
so Fundo, RS, Brazil^len#Braz J Med Biol Res.#2#19980000#1998#31#1553-6#20100800
#a05v86n4.htm##
00668000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100015000950100
01900110010001400129010001800143010001700161810000600178012008400184030002000268
065000900288064000500297865000900302002001300311035001000324801002000334#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#264#7#article#76#7#^rND^sNegr
ato^nCA#^rND^sDias^nJP#^rND^sTeixeira^nMF#^rND^sDias^nA#^rND^sSalgado^nMH#^rND^s
Lauris^nJR#et al#Temporal trends in incidence of type 1 diabetes between 1986 an
d 2006 in Brazil^len#J Endocrinol Invest#19990000#2009#20100800#a05v86n4.htm#039
1-4097#J Endocrinol Invest##
00625000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750120220000770300009002970650
00900306064000500315031000300320014000700323865000900330002001300339035001000352
801000900362#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#265#8#art
icle#76#8#Effect of intensive diabetes treatment on carotid artery wall thicknes
s in the epidemiology of diabetes interventions and complications. Epidemiology 
of Diabetes Interventions and Complications (EDIC) Research Group^len#Diabetes#1
9990000#1999#48#383-90#20100800#a05v86n4.htm#0012-1797#Diabetes##
00646000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100015000930100
01600108010001600124010001500140010001700155810000600172012008300178030001300261
71000020027406500090027606400050028503100030029001400050029386500090029800200130
0307#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#266#9#article#76#
9#^rND^sAsmal^nAC#^rND^sDayal^nB#^rND^sJialal^nI#^rND^sLeary^nWP#^rND^sOmar^nMA#
^rND^sPillay^nNL#et al#Non-insulin-dependent diabetes mellitus with early onset 
in Blacks and Indians^len#S Afr Med J.#2#19810000#1981#60#93-6#20100800#a05v86n4
.htm##
00596000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760120212000790300014002917100
00200305065000900307064000500316031000400321014000700325865000900332002001300341
#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#267#10#article#76#10#
The effect of intensive treatment of diabetes on the development and progression
 of long-term complications in insulin-dependent diabetes mellitus. The Diabetes
 Control And Complications Trial Research Group^len#N Engl J Med.#2#19930000#199
3#329#977-86#20100800#a05v86n4.htm##
00560000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760120152000790300009002310650
00900240064000500249031000300254014000800257865000900265002001300274035001000287
801000900297#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#268#11#ar
ticle#76#11#The absence of a glycemic threshold for the development of long-term
 complications: the perspective of the Diabetes Control and Complications Trial^
len#Diabetes#19960000#1996#45#1289-98#20100800#a05v86n4.htm#0012-1797#Diabetes##
00695000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100019001000100
01600119010001700135010001800152010001500170012010100185030001300286065000900299
06400050030803100030031301400080031686500090032400200130033303500100034680100130
0356#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#269#12#article#76
#12#^rND^sSkrivarhaug^nT#^rND^sBangstad^nHJ#^rND^sStene^nLC#^rND^sSandvik^nL#^rN
D^sHanssen^nKF#^rND^sJoner^nG#Long-term mortality in a nationwide cohort of chil
dhood-onset type 1 diabetic patients in Norway^len#Diabetologia#20060000#2006#49
#298-305#20100800#a05v86n4.htm#0012-186X#Diabetologia##
00647000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100017001000100
01600117010001600133010001800149010001600167810000600183012007200189030001300261
71000020027406500090027606400050028503100030029001400060029386500090029900200130
0308#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#270#13#article#76
#13#^rND^sBernardini^nAL#^rND^sVanelli^nM#^rND^sChiari^nG#^rND^sIovane^nB#^rND^s
Gelmetti^nC#^rND^sVitale^nR#et al#Adherence to physical activity in young people
 with type 1 diabetes^len#Acta Biomed.#2#20040000#2004#75#153-7#20100800#a05v86n
4.htm##
00657000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960100
01600111010002100127010001900148012011800167030002300285710000200308065000900310
064000500319031000300324014000600327865000900333002001300342#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a05v86n4.htm#S#c#271#14#article#76#14#^rND^sMosher^nPE#^rN
D^sNash^nMS#^rND^sPerry^nAC#^rND^sLaPerriere^nAR#^rND^sGoldberg^nRB#Aerobic circ
uit exercise training: effect on adolescents with well-controlled insulin-depend
ent diabetes mellitus^len#Arch Phys Med Rehabil.#2#19980000#1998#79#652-7#201008
00#a05v86n4.htm##
00644000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
01900114012008700133030002600220065000900246064000500255031000300260014000600263
865000900269002001300278035001000291801005300301#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a05v86n4.htm#S#c#272#15#article#76#15#^rND^sKhawali^nC#^rND^sAndriolo^
nA#^rND^sFerreira^nSR#Benefícios da atividade física no perfil lipídico de pacie
ntes com diabetes tipo 1^lpt#Arq Bras Endocrinol Metab#20030000#2003#47#49-54#20
100800#a05v86n4.htm#0004-2730#Arquivos Brasileiros de Endocrinologia & Metabolog
ia##
00601000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01900112010001600131010001700147012007100164030001500235710000200250065000900252
064000500261031000300266014000800269865000900277002001300286#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a05v86n4.htm#S#c#273#16#article#76#16#^rND^sLehmann^nR#^rN
D^sKaplan^nV#^rND^sBingisser^nR#^rND^sBloch^nKE#^rND^sSpinas^nGA#Impact of physi
cal activity on cardiovascular risk factors in IDDM^len#Diabetes Care.#2#1997000
0#1997#20#1603-11#20100800#a05v86n4.htm##
00671000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
02000112010001700132010001600149010001700165810000600182012009000188030001900278
71000020029706500090029906400050030803100030031301400070031686500090032300200130
0332#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#274#17#article#76
#17#^rND^sHeyman^nE#^rND^sToutain^nC#^rND^sDelamarche^nP#^rND^sBerthon^nP#^rND^s
Briard^nD#^rND^sYoussef^nH#et al#Exercise training and cardiovascular risk facto
rs in type 1 diabetic adolescent girls^len#Pediatr Exerc Sci.#2#20070000#2007#19
#408-19#20100800#a05v86n4.htm##
00681000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100016000990100
01900115010001800134010001400152010001600166810000600182012009700188030002200285
71000020030706500090030906400050031803100030032301400070032686500090033300200130
0342#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#275#18#article#76
#18#^rND^sLaaksonen^nDE#^rND^sAtalay^nM#^rND^sNiskanen^nLK#^rND^sMustonen^nJ#^rN
D^sSen^nCK#^rND^sLakka^nTA#et al#Aerobic exercise and the lipid profile in type 
I diabetic men: a randomized controlled trial^len#Med Sci Sports Exerc.#2#200000
00#2000#32#1541-8#20100800#a05v86n4.htm##
00741000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100026000940100
02400120010001400144010001600158010001500174810000600189012013100195030001100326
06500090033706400050034603100030035101400060035486500090036000200130036903500100
0382801001100392#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#276#1
9#article#76#19#^rND^sRigla^nM#^rND^sSánchez-Quesada^nJL#^rND^sOrdóñez-Llanos^nJ
#^rND^sPrat^nT#^rND^sCaixàs^nA#^rND^sJorba^nO#et al#Effect of physical exercise 
on lipoprotein(a) and low-density lipoprotein modifications in type 1 and type 2
 diabetic patients^len#Metabolism#20000000#2000#49#640-7#20100800#a05v86n4.htm#0
026-0495#Metabolism##
00714000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100038000790100026001170100
02300143010002000166012017300186030001800359710000200377065000900379064000500388
031000300393014000600396865000900402002001300411#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a05v86n4.htm#S#c#277#20#article#76#20#^rND^sSideravi&#269;i&#363;t&#27
9;^nS#^rND^sGaili&#363;niene^nA#^rND^sVisagurskiene^nK#^rND^sVizbaraite^nD#The e
ffect of long-term swimming program on body composition, aerobic capacity and bl
ood lipids in 14-19-year aged healthy girls and girls with type 1 diabetes melli
tus^len#Medicina (Kaunas)#2#20060000#2006#42#661-6#20100800#a05v86n4.htm##
00756000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100020000950100
01700115010001700132010001500149011007700164012013600241030001500377710000200392
065000900394064000500403031000300408014000900411865000900420002001300429#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#278#21#article#76#21#^rND^sHe
rbst^nA#^rND^sKordonouri^nO#^rND^sSchwab^nKO#^rND^sSchmidt^nF#^rND^sHoll^nRW#DPV
 Initiative of the German Working Group for Pediatric Diabetology Germany#Impact
 of physical activity on cardiovascular risk factors in children with type 1 dia
betes: a multicenter study of 23,251 patients^len#Diabetes Care.#2#20070000#2007
#30#2098-100#20100800#a05v86n4.htm##
00759000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100025000790100017001040100
01800121010001700139010002400156011004500180012012600225030001300351065000900364
06400050037303100030037801400070038186500090038800200130039703500100041080100130
0420#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#279#22#article#76
#22#^rND^sMargeirsdottir^nHD#^rND^sLarsen^nJR#^rND^sBrunborg^nC#^rND^sOverby^nNC
#^rND^sDahl-Jørgensen^nK#Norwegian Study Group for Childhood Diabetes#High preva
lence of cardiovascular risk factors in children and adolescents with type 1 dia
betes: a population-based study^len#Diabetologia#20080000#2008#51#554-61#2010080
0#a05v86n4.htm#0012-186X#Diabetologia##
00678000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100020000960100
01800116010001700134010001500151010001800166012010500184030002700289710000200316
065000900318064000500327031000300332014000700335865000900342002001300351#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#280#23#article#76#23#^rND^sVa
lerio^nG#^rND^sSpagnuolo^nMI#^rND^sLombardi^nF#^rND^sSpadaro^nR#^rND^sSiano^nM#^
rND^sFranzese^nA#Physical activity and sports participation in children and adol
escents with type 1 diabetes mellitus^len#Nutr Metab Cardiovasc Dis.#2#20070000#
2007#17#376-82#20100800#a05v86n4.htm##
00763000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
01700115010001800132010001700150010001400167810000600181012015300187030001400340
06500090035406400050036303100030036801400080037186500090037900200130038803500100
0401801001400411#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#281#2
4#article#76#24#^rND^sMajaliwa^nES#^rND^sMunubhi^nE#^rND^sRamaiya^nK#^rND^sMpemb
eni^nR#^rND^sSanyiwa^nA#^rND^sMohn^nA#et al#Survey on acute and chronic complica
tions in children and adolescents with type 1 diabetes at Muhimbili National Hos
pital in Dar es Salaam, Tanzania^len#Diabetes Care#20070000#2007#30#2187-92#2010
0800#a05v86n4.htm#0149-5992#Diabetes Care##
00601000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100014000970100
01500111012013300126030001700259710000200276065000900278064000500287031000200292
014000700294865000900301002001300310#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
5v86n4.htm#S#c#282#25#article#76#25#^rND^sSellers^nEA#^rND^sYung^nG#^rND^sDean^n
HJ#Dyslipidemia and other cardiovascular risk factors in a Canadian First Nation
 pediatric population with type 2 diabetes mellitus^len#Pediatr Diabetes#2#20070
000#2007#8#384-90#20100800#a05v86n4.htm##
00704000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100018000990100
01700117010001800134010001700152012015400169030003100323710000200354065000900356
064000500365031000300370014000700373865000900380002001300389#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a05v86n4.htm#S#c#283#26#article#76#26#^rND^sMcGill^nHC Jr#
^rND^sMcMahan^nAC#^rND^sMalcom^nGT#^rND^sOalmann^nMC#^rND^sStrong^nJP#Relation o
f glycohemoglobin and adiposity to atherosclerosis in youth. Pathobiological Det
erminants of Atherosclerosis in Youth (PDAY) Research Group^len#Arterioscler Thr
omb Vasc Biol.#2#19950000#1995#15#431-40#20100800#a05v86n4.htm##
00627000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100018000990100
02000117010001700137010001600154010001700170012005900187030001600246710000200262
065000900264064000500273031000300278014001000281865000900291002001300300#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#284#27#article#76#27#^rND^sMc
Gill^nHC Jr#^rND^sMcMahan^nCA#^rND^sHerderick^nEE#^rND^sMalcom^nGT#^rND^sTracy^n
RE#^rND^sStrong^nJP#Origin of atherosclerosis in childhood and adolescence^len#A
m J Clin Nutr.#2#20000000#2000#72#1307S-15S#20100800#a05v86n4.htm##
00707000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
01600110010001700126010001500143010001400158810000600172012012500178030000500303
06500090030806400050031703100040032201400060032686500090033200200130034103500100
0354801000500364#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#285#2
8#article#76#28#^rND^sBhatt^nDL#^rND^sSteg^nPG#^rND^sOhman^nEM#^rND^sHirsch^nAT#
^rND^sIkeda^nY#^rND^sMas^nJL#et al#International prevalence, recognition, and tr
eatment of cardiovascular risk factors in outpatients with atherothrombosis^len#
JAMA#20060000#2006#295#180-9#20100800#a05v86n4.htm#0098-7484#JAMA##
00799000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160017000790160016000960160
01600112016001700128016001600145016001600161810000600177018020000183062009000383
065000900473064000500482865000900487002001300496#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a05v86n4.htm#S#c#286#29#article#76#29#^rND^sGrundy^nSM#^rND^sBecker^nD
#^rND^sClark^nLT#^rND^sCooper^nRS#^rND^sDenke^nMA#^rND^sHoward^nJ#et al#Third re
port of the National Cholesterol Education Program (NCEP) expert panel on detect
ion, evaluation, and treatment of high blood cholesterol in adults (Adult Treatm
ent Panel III) final report^len#National Institutes of Health. National Heart, L
ung, and Blood Institute. NIH Publication#20020000#2002#20100800#a05v86n4.htm##
00606000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01700112012011600129030000700245065000900252064000500261031000400266014000700270
865000900277002001300286035001000299801000700309#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a05v86n4.htm#S#c#287#30#article#76#30#^rND^sHancox^nRJ#^rND^sMilne^nBJ
#^rND^sPoulton^nR#Association between child and adolescent television viewing an
d adult health: a longitudinal birth cohort study^len#Lancet#20040000#2004#364#2
57-62#20100800#a05v86n4.htm#0099-5355#Lancet##
00746000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
02000114010001900134010001700153010001700170012014300187030001700330065000900347
06400050035603100030036101400070036486500090037100200130038003500100039380100170
0403#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#288#31#article#76
#31#^rND^sRibeiro^nRQ#^rND^sLotufo^nPA#^rND^sLamounier^nJA#^rND^sOliveira^nRG#^r
ND^sSoares^nJF#^rND^sBotter^nDA#Fatores adicionais de risco cardiovascular assoc
iados ao excesso de peso em crianças e adolescentes. O Estudo do Coração de Belo
 Horizonte^lpt#Arq Bras Cardiol#20060000#2006#86#408-18#20100800#a05v86n4.htm#00
66-782X#Arq Bras Cardiol##
00733000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
01600110010001400126010001600140010001500156810000600171012014700177030000700324
06500090033106400050034003100040034501400070034986500090035600200130036503500100
0378801000700388#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#289#3
2#article#76#32#^rND^sYusuf^nS#^rND^sHawken^nS#^rND^sOunpuu^nS#^rND^sDans^nT#^rN
D^sAvezum^nA#^rND^sLanas^nF#et al#Effect of potentially modifiable risk factors 
associated with myocardial infarction in 52 countries (the INTERHEART study): ca
se-control study^len#Lancet#20040000#2004#364#937-52#20100800#a05v86n4.htm#0099-
5355#Lancet##
00493000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760120049000790300014001280650
00900142064000500151031000300156014000700159865000900166002001300175011001500188
035001000203801001400213#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S
#c#290#33#article#76#33#Standards of medical care in diabetes - 2008^len#Diabete
s Care#20080000#2008#31#S12-54#20100800#a05v86n4.htm#^rND^sYusuf^nS#0149-5992#Di
abetes Care##
00736000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100014000970100
01500111010001700126010001600143010001900159810000600178012015500184030002200339
71000020036106500090036306400050037203100030037701400080038086500090038800200130
0397#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#291#34#article#76
#34#^rND^sHaskell^nWL#^rND^sLee^nIM#^rND^sPate^nRR#^rND^sPowell^nKE#^rND^sBlair^
nSN#^rND^sFranklin^nBA#et al#Physical activity and public health: updated recomm
endation for adults from the American College of Sports Medicine and the America
n Heart Association^len#Med Sci Sports Exerc.#2#20070000#2007#39#1423-34#2010080
0#a05v86n4.htm##
00710000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100021000950100
01700116010001700133010002000150012012700170030002100297065000900318064000500327
031000300332014000800335865000900343002001300352035001000365801002100375#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#292#35#article#76#35#^rND^sKo
hrt^nWM#^rND^sBloomfield^nSA#^rND^sLittle^nKD#^rND^sNelson^nME#^rND^sYingling^nV
R.#American College of Sports Medicine. American College of Sports Medicine Posi
tion Stand: physical activity and bone health^len#Med Sci Sports Exerc#20040000#
2004#36#1985-96#20100800#a05v86n4.htm#0195-9131#Med Sci Sports Exerc##
00672000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170071000790180101001500660
01200251062006800263037005700331110000900388109001100397865000900408002001300417
#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#293#36#article#76#36#
US Department Of Health And Human Services^dCenter for Disease Control#Physical 
activity and good nutrition: essential elements to prevent chronic diseases and 
obesity^len#Atlanta^eGA#National Center for Chronic Disease Prevention and Healt
h Promotion#http://www.cdc.gov/nccdphp/publications/aag/pdf/dnpa.pdf#20080221#21
/02/2008#20100800#a05v86n4.htm##
00654000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
01700110010001700127010002000144010001800164810000600182012007700188030001400265
71000020027906500090028106400050029003100040029501400070029986500090030600200130
0315#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#294#37#article#76
#37#^rND^sKimm^nSY#^rND^sGlynn^nNW#^rND^sKriska^nAM#^rND^sBarton^nBA#^rND^sKrons
berg^nSS#^rND^sDaniels^nSR#et al#Decline in physical activity in black and white
 girls during adolescence^len#N Engl J Med.#2#20020000#2002#347#709-15#20100800#
a05v86n4.htm##
00583000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
02300112012009900135030002200234710000200256065000900258064000500267031000300272
014000800275865000900283002001300292#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
5v86n4.htm#S#c#295#38#article#76#38#^rND^sTwisk^nJW#^rND^sKemper^nHC#^rND^svan M
echelen^nW.#Tracking of activity and fitness and the relationship with cardiovas
cular disease risk factors^len#Med Sci Sports Exerc.#2#20000000#2000#32#1455-61#
20100800#a05v86n4.htm##
00592000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100016000930100
01700109010002000126012008600146030002200232710000200254065000900256064000500265
031000300270014000700273865000900280002001300289#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a05v86n4.htm#S#c#296#39#article#76#39#^rND^sYang^nX#^rND^sTelama^nR#^r
ND^sViikari^nJ#^rND^sRaitakari^nOT#Risk of obesity in relation to physical activ
ity tracking from youth to adulthood^len#Med Sci Sports Exerc.#2#20060000#2006#3
8#919-25#20100800#a05v86n4.htm##
00734000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100020000990100
01700119010001900136010001500155010001700170810000600187012009000193030002800283
06500090031106400050032003100030032501400080032886500090033600200130034503500100
0358801002800368#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#297#4
0#article#76#40#^rND^sde Angelis^nK#^rND^sda Pureza^nDY#^rND^sFlores^nLJ#^rND^sR
odrigues^nB#^rND^sMelo^nKF#^rND^sSchaan^nBD#et al#Efeitos fisiológicos do treina
mento físico em pacientes portadores de diabetes tipo 1^len#Arq Bras Endocrinol 
Metabol#20060000#2006#50#1005-13#20100800#a05v86n4.htm#0004-2730#Arq Bras Endocr
inol Metabol##
00655000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01900112012014900131030001400280065000900294064000500303031000300308014000800311
865000900319002001300328035001000341801001400351#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a05v86n4.htm#S#c#298#41#article#76#41#^rND^sGuelfi^nKJ#^rND^sJones^nTW
#^rND^sFournier^nPA#The decline in blood glucose levels is less with intermitten
t high-intensity compared with moderate exercise in individuals with type 1 diab
etes^len#Diabetes Care#20050000#2005#28#1289-94#20100800#a05v86n4.htm#0149-5992#
Diabetes Care##
00608000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100018000990100
02000117010001700137012010400154030001300258710000200271065000900273064000500282
031000300287014000600290865000900296002001300305#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a05v86n4.htm#S#c#299#42#article#76#42#^rND^sCorigliano^nG#^rND^sIazzet
ta^nN#^rND^sCorigliano^nM#^rND^sStrollo^nF#Blood glucose changes in diabetic chi
ldren and adolescents engaged in most common sports activities^len#Acta Biomed.#
2#20060000#2006#77#26-33#20100800#a05v86n4.htm##
00622000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
02000113010001700133010002000150011003000170012004500200030001500245710000200260
065000900262064000500271031000300276014000700279865000900286002001300295#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#300#43#article#76#43#^rND^sZi
nman^nB#^rND^sRuderman^nN#^rND^sCampaigne^nBN#^rND^sDevlin^nJT#^rND^sSchneider^n
SH#American Diabetes Association#Physical activity/exercise and diabetes.^len#Di
abetes Care.#2#20040000#2004#27#S13-54#20100800#a05v86n4.htm##
00688000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01500114010002100129010001500150010001600165810000600181012008600187030001000273
06500090028306400050029203100040029701400070030186500090030800200130031703500100
0330801001000340#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#301#4
4#article#76#44#^rND^sTsalikian^nE#^rND^sMauras^nN#^rND^sBeck^nRW#^rND^sTamborla
ne^nWV#^rND^sJanz^nKF#^rND^sChase^nHP#et al#Impact of exercise on overnight glyc
emic control in children with type 1 mellitus^len#J Pediatr#20050000#2005#147#52
8-34#20100800#a05v86n4.htm#0022-3476#J Pediatr##
00521000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100014000970100
02000111012005200131030001300183710000200196065000900198064000500207031000300212
014000600215865000900221002001300230#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
5v86n4.htm#S#c#302#45#article#76#45#^rND^sGiannini^nC#^rND^sMohn^nA#^rND^sChiare
lli^nF.#Physical exercise and diabetes during childhood^len#Acta Biomed.#2#20060
000#2006#77#18-25#20100800#a05v86n4.htm##
00689000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790100017001020100
01400119010001500133010001800148010001900166810000600185012008600191030000900277
06500090028606400050029503100030030001400070030386500090031000200130031903500100
0332801000900342#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#303#4
6#article#76#46#^rND^sWojtaszewski^nJF#^rND^sHansen^nBF#^rND^sGade^nJ#^rND^sKien
s^nB#^rND^sMarkuns^nJF#^rND^sGoodyear^nLJ#et al#Insulin signaling and insulin se
nsitivity after exercise in human skeletal muscle^len#Diabetes#20000000#2000#49#
325-31#20100800#a05v86n4.htm#0012-1797#Diabetes##
00626000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01800112010001500130012011600145030002600261710000200287065000900289064000500298
031000400303014000700307865000900314002001300323#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a05v86n4.htm#S#c#304#47#article#76#47#^rND^sHerbst^nA#^rND^sBachran^nR
#^rND^sKapellen^nT#^rND^sHoll^nRW#Effects of regular physical activity on contro
l of glycemia in pediatric patients with type 1 diabetes mellitus^len#Arch Pedia
tr Adolesc Med.#2#20060000#2006#160#573-7.#20100800#a05v86n4.htm##
00592000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100016000930100
01500109010001500124010001700139012007300156030001300229710000200242065000900244
064000500253031000300258014000700261865000900268002001300277#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a05v86n4.htm#S#c#305#48#article#76#48#^rND^sToni^nS#^rND^s
Reali^nMF#^rND^sBarni^nF#^rND^sLenzi^nL#^rND^sFestini^nF#Managing insulin therap
y during exercise in type 1 diabetes mellitus^len#Acta Biomed.#2#20060000#2006#7
7#34-40.#20100800#a05v86n4.htm##
00513000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790120098000980300
01700196710000200213065000900215064000500224031000200229014000600231865000900237
002001300246#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#306#49#ar
ticle#76#49#^rND^sHoffman^nRP.#Practical management of type 1 diabetes mellitus 
in adolescent patients: challenges and goals^len#Treat Endocrinol#2#20040000#200
4#3#27-39#20100800#a05v86n4.htm##
00496000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790100017001020100
01600119010002000135030001500155710000200170065000900172064000500181031000300186
014000700189865000900196002001300205#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
5v86n4.htm#S#c#307#50#article#76#50#^rND^sRabasa-Lhoret^nR#^rND^sBourque^nJ#^rND
^sDucros^nF#^rND^sChiasson^nJL.#Diabetes Care.#2#20010000#2001#24#625-30#2010080
0#a05v86n4.htm##
00626000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01500111010001800126010001500144012010100159030001600260710000200276065000900278
064000500287031000300292014000700295865000900302002001300311#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a05v86n4.htm#S#c#308#51#article#76#51#^rND^sGrimm^nJJ#^rND
^sYbarra^nJ#^rND^sBerné^nC#^rND^sMuchnick^nS#^rND^sGolay^nA#A new table for prev
ention of hypoglycaemia during physical activity in type 1 diabetic patients^len
#Diabetes Metab.#2#20040000#2004#30#465-70#20100800#a05v86n4.htm##
00597000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
01600116010001800132010001800150012006000168030002100228710000200249065000900251
064000500260031000300265014000500268865000900273002001300282#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a05v86n4.htm#S#c#309#52#article#76#52#^rND^sChiarelli^nF#^
rND^sVerrotti^nA#^rND^sCatino^nM#^rND^sSabatino^nG#^rND^sPinelli^nL.#Hypoglycaem
ia in children with type 1 diabetes mellitus^len#Acta Paediatr Suppl.#2#19990000
#1999#88#31-4#20100800#a05v86n4.htm##
00494000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100019000950100
01900114010001600133010002100149010001600170810000600186012002600192865000900218
002001300227#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#310#53#ar
ticle#76#53#^rND^sDe Feo^nP#^rND^sDi Loreto^nC#^rND^sRanchelli^nA#^rND^sFatone^n
C#^rND^sGambelunghe^nG#^rND^sLucidi^nP#et al#Exercise and diabetes^len#20100800#
a05v86n4.htm##
00543000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120104000950300
01000199065000900209064000500218031000300223014000900226865000900235002001300244
035001000257801001000267#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S
#c#311#54#article#76#54#^rND^sGulve^nEA#Exercise and glycemic control in diabete
s: benefits, challenges, and adjustments to pharmacotherapy^len#Phys Ther#200800
00#2008#88#1297-321#20100800#a05v86n4.htm#0031-9023#Phys Ther##
00590000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100019000980100
01800117010001800135010001500153012005500168030001900223710000200242065000900244
064000500253031000200258014000600260865000900266002001300275#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a05v86n4.htm#S#c#312#55#article#76#55#^rND^sRobertson^nK#^
rND^sAdolfsson^nP#^rND^sRiddell^nMC#^rND^sScheiner^nG#^rND^sHanas^nR#Exercise in
 children and adolescents with diabetes^len#Pediatric Diabetes#2#20080000#2008#9
#65-77#20100800#a05v86n4.htm##
00496000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170033000790180070001120370
05400182110000900236109001100245865000900256002001300265#v86n4#V:\Scielo\serial\
jped\v86n4\markup\a05v86n4.htm#S#c#313#56#article#76#56#Sociedade Brasileira de 
Diabetes#Protocolo hiper/hipoglicemias x corrida para atletas com diabetes^lpt#h
ttp://www.diabetes.org.br/protocolos/protativfis.php#20090313#13/03/2009#2010080
0#a05v86n4.htm##
00757000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100014000970100
02000111010001700131010002200148011004100170012014200211030001100353065000900364
06400050037303100030037801400070038186500090038800200130039703500100041080100110
0420#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#314#57#article#76
#57#^rND^sFerriss^nJB#^rND^sWebb^nD#^rND^sChaturvedi^nN#^rND^sFuller^nJH#^rND^sI
dzior-Walus^nB#EURODIAB Prospective Complications Group#Weight gain is associate
d with improved glycaemic control but with adverse changes in plasma lipids and 
blood pressure in Type 1 diabetes^len#Diabet Med#20060000#2006#23#557-64#2010080
0#a05v86n4.htm#0742-3071#Diabet Med##
00568000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970120
06600113030002800179065000900207064000500216031000300221014000600224865000900230
002001300239035001000252801002800262#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
5v86n4.htm#S#c#315#58#article#76#58#^rND^sRamalho^nAC#^rND^sSoares^nS#O papel do
 exercí­cio no tratamento do diabetes melito tipo 1^lpt#Arq Bras Endocrinol Meta
bol#20080000#2008#52#260-7#20100800#a05v86n4.htm#0004-2730#Arq Bras Endocrinol M
etabol##
00661000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
01800116010001500134010001900149012009700168030001300265065000900278064000500287
031000300292014000700295865000900302002001300311035001000324801001300334#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#316#59#article#76#59#^rND^sTu
ominen^nJA#^rND^sKaronen^nSL#^rND^sMelamies^nL#^rND^sBolli^nG#^rND^sKoivisto^nVA
#Exercise-induced hypoglycaemia in IDDM patients treated with a short-acting ins
ulin analogue^len#Diabetologia#19950000#1995#38#106-11#20100800#a05v86n4.htm#001
2-186X#Diabetologia##
00738000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100019000960100
01500115010001600130010002100146010002000167810000600187012012500193030001400318
06500090033206400050034103100030034601400050034986500090035400200130036303500100
0376801001400386#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#317#6
0#article#76#60#^rND^sTansey^nMJ#^rND^sTsalikian^nE#^rND^sBeck^nRW#^rND^sMauras^
nN#^rND^sBuckingham^nBA#^rND^sWeinzimer^nSA#et al#The effects of aerobic exercis
e on glucose and counterregulatory hormone concentrations in children with type 
1 diabetes^len#Diabetes Care#20060000#2006#29#20-5#20100800#a05v86n4.htm#0149-59
92#Diabetes Care##
00680000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100019000960100
02700115010001700142012012500159030001900284065000900303064000500312031000300317
014000700320865000900327002001300336035001000349801001900359#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a05v86n4.htm#S#c#318#61#article#76#61#^rND^sGoulet^nED#^rN
D^sMélançon^nMO#^rND^sAubertin-Leheudre^nM#^rND^sDionne^nIJ#Aerobic training imp
roves insulin sensitivity 72-120 h after the last exercise session in younger bu
t not in older women^len#Eur J Appl Physiol#20050000#2005#95#146-52#20100800#a05
v86n4.htm#0301-5548#Eur J Appl Physiol##
00532000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170033000790180107001120370
05300219110000900272109001100281865000900292002001300301#v86n4#V:\Scielo\serial\
jped\v86n4\markup\a05v86n4.htm#S#c#319#62#article#76#62#Sociedade Brasileira de 
Diabetes#Tratamento e acompanhamento do diabetes mellitus: diretrizes da socieda
de brasileira de diabetes, 2007^lpt#http://www.diabetes.org.br/educacao/livroson
line.php#20080623#23/06/2008#20100800#a05v86n4.htm##
00797000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01700113010001600130010001700146010001600163810000600179012017000185030002400355
06500090037906400050038803100030039301400070039686500090040300200130041203500100
0425801002400435#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#320#6
3#article#76#63#^rND^sPurdon^nC#^rND^sBrousson^nM#^rND^sNyveen^nSL#^rND^sMiles^n
PD#^rND^sHalter^nJB#^rND^sVranic^nM#et al#The roles of insulin and catecholamine
s in the glucoregulatory response during intense exercise and early recovery in 
insulin-dependent diabetic and control subjects^len#J Clin Endocrinol Metab#1993
0000#1993#76#566-73#20100800#a05v86n4.htm#0021-972X#J Clin Endocrinol Metab##
00589000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970120
12300113030000900236065000900245064000500254031000300259014000800262865000900270
002001300279035001000292801000900302#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
5v86n4.htm#S#c#321#64#article#76#64#^rND^sMarliss^nEB#^rND^sVranic^nM#Intense ex
ecise has unique effects on both insulin release and its roles in glucoregulatio
n: implications for diabetes^len#Diabetes#20020000#2002#51#S271-83#20100800#a05v
86n4.htm#0012-1797#Diabetes##
00666000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100019000960100
01600115010001900131012013100150030001400281065000900295064000500304031000300309
014000600312865000900318002001300327035001000340801001400350#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a05v86n4.htm#S#c#322#65#article#76#65#^rND^sBussau^nVA#^rN
D^sFerreira^nLD#^rND^sJones^nTW#^rND^sFournier^nPA#The 10-s maximal sprint: a no
vel approach to counter an exercise-mediated fall in glycemia in individuals wit
h type 1 diabetes^len#Diabetes Care#20060000#2006#29#601-6#20100800#a05v86n4.htm
#0149-5992#Diabetes Care##
00642000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01900112012013800131030001400269065000900283064000500292031000300297014000600300
865000900306002001300315035001000328801001400338#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a05v86n4.htm#S#c#323#66#article#76#66#^rND^sGuelfi^nKJ#^rND^sJones^nTW
#^rND^sFournier^nPA#Intermitent high-intensity exercise does not increase the ri
sk of early postexercise hypoglycemia in individuals with type 1 diabetes^len#Di
abetes Care#20050000#2005#28#416-8#20100800#a05v86n4.htm#0149-5992#Diabetes Care
##
00705000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01700112010001600129010001900145012015900164030003000323710000200353065000900355
064000500364031000400369014000800373865000900381002001300390#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a05v86n4.htm#S#c#324#67#article#76#67#^rND^sGuelfi^nKJ#^rN
D^sRatnam^nN#^rND^sSmythe^nGA#^rND^sJones^nTW#^rND^sFournier^nPA#Effect of inter
mittent high-intensity compared with continuous moderate exercise on glucose pro
duction and utilization in individuals with type 1 diabetes^len#Am J Physiol End
ocrinol Metab#2#20070000#2007#292#E865-70#20100800#a05v86n4.htm##
00710000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100019000950100
01600114010001600130010001500146010002700161810000600188012010000194030001100294
06500090030506400050031403100030031901400070032286500090032900200130033803500100
0351801001100361#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#325#6
8#article#76#68#^rND^sVettor^nR#^rND^sLombardi^nAM#^rND^sFabris^nR#^rND^sPagano^
nC#^rND^sCusin^nI#^rND^sRohner-Jeanrenaud^nF#et al#Lactate infusion in anestheti
zed rats produces insulin resistance in heart and skeletal muscles^len#Metabolis
m#19970000#1997#46#684-90#20100800#a05v86n4.htm#0026-0495#Metabolism##
00683000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01700113010001800130010001700148010002000165810000600185012010700191030001000298
71000020030806500090031006400050031903100040032401400070032886500090033500200130
0344#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#326#69#article#76
#69#^rND^sMiller^nBF#^rND^sFattor^nJA#^rND^sJacobs^nKA#^rND^sHorning^nMA#^rND^sN
avazio^nF#^rND^sLindinger^nMI#et al#Lactate and glucose interactions during rest
 and exercise in men: effect of exogenous lactate infusion^len#J Physiol#2#20020
000#2002#544#963-75#20100800#a05v86n4.htm##
00667000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
01600115010001800131012014100149030000900290065000900299064000500308031000300313
014000800316865000900324002001300333035001000346801000900356#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a05v86n4.htm#S#c#327#70#article#76#70#^rND^sKreisman^nSH#^
rND^sHalter^nJB#^rND^sVranic^nM#^rND^sMarliss^nEB#Combined infusion of epinephri
ne and norepinephrine during moderate exercise reproduces the glucoregulatory re
sponse of intense exercise^len#Diabetes#20030000#2003#52#1347-54#20100800#a05v86
n4.htm#0012-1797#Diabetes##
00496000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120050000970300
01400147065000900161064000500170031000300175014000600178865000900184002001300193
035001000206801001400216#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S
#c#328#71#article#76#71#^rND^sAndersen^nH#Muscular endurance in long-term IDDM p
atients^len#Diabetes Care#19980000#1998#21#604-9#20100800#a05v86n4.htm#0149-5992
#Diabetes Care##
00751000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100025000970100
01500122010001700137010001700154010001700171810000600188012011600194030002400310
06500090033406400050034303100030034801400060035186500090035700200130036603500100
0379801002400389#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S#c#329#7
2#article#76#72#^rND^sRamalho^nAC#^rND^sde Lourdes Lima^nM#^rND^sNunes^nF#^rND^s
Cambuí­^nZ#^rND^sBarbosa^nC#^rND^sAndrade^nA#et al#The effect of resistance vers
us aerobic training on metabolic control in patients with type-1 diabetes mellit
us^len#Diabetes Res Clin Pract#20060000#2006#72#271-6#20100800#a05v86n4.htm#0168
-8227#Diabetes Res Clin Pract##
00608000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
01900110012008600129030002400215065000900239064000500248031000300253014000600256
865000900262002001300271035001000284801002400294#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a05v86n4.htm#S#c#330#73#article#76#73#^rND^sRuzic^nL#^rND^sSporis^nG#^
rND^sMatkovic^nBR#High volume-low intensity exercise camp and glycemic control i
n diabetic children^len#J Paediatr Child Health#20080000#2008#44#122-8#20100800#
a05v86n4.htm#1034-4810#J Paediatr Child Health##
00502000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100019000950120
03300114030001100147065000900158064000500167031000200172014000700174865000900181
002001300190035001000203801001100213#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
5v86n4.htm#S#c#331#74#article#76#74#^rND^sDorchy^nH#^rND^sPoortmans^nJ#Sport and
 the diabetic child^len#Sports Med#19890000#1989#7#248-62#20100800#a05v86n4.htm#
0112-1642#Sports Med##
00468000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120032000950300
01100127065000900138064000500147031000300152014000400155865000900159002001300168
035001000181801001100191#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S
#c#332#75#article#76#75#^rND^sGallen^nI#Exercise in Type 1 diabetes^len#Diabet M
ed#20030000#2003#20#2-5#20100800#a05v86n4.htm#0742-3071#Diabet Med##
00534000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100018000940120
07800112030003000190710000200220065000900222064000500231031000300236014000700239
865000900246002001300255#v86n4#V:\Scielo\serial\jped\v86n4\markup\a05v86n4.htm#S
#c#333#76#article#76#76#^rND^sGreen^nL#^rND^sAdeyanju^nM#Exercise and fitness gu
idelines for elementary and middle school children^len#The Elementary School Jou
rnal#2#19910000#1991#91#437-44#20100800#a05v86n4.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#o#1#1#article#1
#20110126#175435#a06v86n4.htm#193##
05573000000000721000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090038000400094121000300098049000800101158000300109
03000210011203100030013303200020013606500090013801400110014703500100015824100090
01680120082001770120071002590100052003300100032003820100035004140100035004490100
03200484070005300516070008500569070009400654070008900748083182700837085001002664
08500300267408500240270408500360272808500300276408317730279408500100456708500190
45770850024045960850022046200850034046420850028046760580053047040600034047571170
00804791072000304799112000904802111000904811114000904820113000904829002001304838
#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#h#2#1#article#1#oa#pt#b
r1.1#1#4.0#GRA#TAB#06#JPED030#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f279^l284#0
021-7557#^tpr^i01#Mortalidade de crianças com doença falciforme: um estudo de ba
se populacional^lpt#Mortality of children with sickle cell disease: a population
 study^len#^rND^1A01 A02^nAna Paula Pinheiro Chagas^sFernandes#^rND^1A03^nJosé N
élio^sJanuário#^rND^1A02^nCamila Blanco^sCangussu#^rND^1A02^nDaniela Lino de^sMa
cedo#^rND^1A04^nMarcos Borato^sViana#Núcleo de Ações e Pesquisa em Apoio Diagnós
tico^iA01#Universidade Federal de Minas Gerais^iA02^1Faculdade de Medicina^cBelo
 Horizonte^sMG#Universidade Federal de Minas Gerais^iA03^1Departamento de Clínic
a Médica^cBelo Horizonte^sMG#Universidade Federal de Minas Gerais^iA04^1Departam
ento de Pediatria^cBelo Horizonte^sMG#^lpt^aOBJETIVO: Caracterizar os óbitos das
 crianças com doença falciforme (DF) triadas no estado de Minas Gerais e acompan
hadas na Fundação Hemominas. MÉTODOS: Coorte de crianças diagnosticadas pelo Pro
grama de Triagem Neonatal de Minas Gerais (março/1998 - fevereiro/2005). Os óbit
os foram identificados pela busca ativa das crianças ausentes nas consultas agen
dadas nos hemocentros. Dados clínicos e epidemiológicos foram coletados dos docu
mentos de óbito, banco de dados da triagem neonatal, prontuários médicos e em en
trevistas com as famílias. RESULTADOS: Foram triadas 1.833.030 crianças no perío
do, sendo 1.396 com DF (1:1.300). Ocorreram 78 óbitos: 63 em crianças com genóti
po SS, 12 em crianças com genótipo SC e três em crianças com genótipo S/&#946;+ 
talassemia. Cinquenta e seis crianças (71,8%) morreram antes dos 2 anos de idade
; 59 morreram em hospitais e 18 no domicílio ou trânsito. Causas de óbito pelo a
testado (n = 78): 38,5% infecção; 16,6% sequestro esplênico agudo; 9% outras cau
sas; 15,4% sem assistência médica; e 20,5% indeterminada. Segundo as entrevistas
 (n = 52), o sequestro esplênico foi responsável por quase 1/3 dos óbitos, contr
astando com a porcentagem de apenas 14% registrada nos atestados de óbito. As pr
obabilidades de sobrevida aos 5 anos (erro padrão da média) para crianças SS, SC
 e S&#946;+ talassemia foram: 89,4 (1,4), 97,7 (0,7) e 94,7% (3,0), respectivame
nte (SS versus SC, p < 0,0001). CONCLUSÕES: Mesmo em um programa de triagem neon
atal com rigoroso controle do tratamento, a probabilidade de óbito em crianças c
om genótipo SS ainda é elevada. Os óbitos com causa indeterminada indicam dificu
ldades no reconhecimento da DF e das suas complicações. Esforços educativos diri
gidos a profissionais da saúde e familiares devem ser incrementados para diminui
r a mortalidade pela DF.#^ddecs^i1#^tm^lpt^kAnemia falciforme^i1#^tm^lpt^kmortal
idade^i1#^tm^lpt^kfatores socioeconômicos^i1#^tm^lpt^ksistemas de saúde^i1#^len^
aOBJECTIVE: To describe the deaths of children with sickle cell disease (SCD) in
 Minas Gerais, Brazil, and followed up at the Fundação Hemominas. METHODS: Cohor
t of children diagnosed by the Neonatal Screening Program in Minas Gerais (March
/1998 - February/2005). Deaths were identified by searching for children who did
 not attend scheduled consultations at hemocenters. Clinical and epidemiological
 data were abstracted from death certificates, the newborn screening database, i
ndividual medical records, and from interviews with families. RESULTS: During th
e period, 1,833,030 newborns were screened; 1,396 had SCD (1:1,300). There were 
78 deaths: 63 with SS genotype, 12 with SC genotype, and three with S&#946;+thal
assemia genotype. Fifty-six children (71.8%) died before 2 years of age; 59 died
 in hospitals and 18 at home or during transportation. Causes of death according
 to certificates (n = 78): infections, 38.5%; acute splenic sequestration, 16.6%
; other causes, 9%; did not receive medical care, 15.4%; and not identified on c
ertificates, 20.5%. According to interviews (n = 52), acute splenic sequestratio
n was responsible for one third of deaths, in contrast with 14% recorded on deat
h certificates. Survival probabilities at 5y (SEM) for children with SS, SC, and
 S&#946;+thalassemia were 89.4 (1.4), 97.7 (0.7), and 94.7% (3.0), respectively 
(SS vs. SC, p < 0.0001). CONCLUSIONS: Even with a carefully controlled newborn s
creening program, the probability of SS children dying was still found to be hig
h. Causes not identified on death certificates may indicate difficulties recogni
zing SCD and its complications. Educational campaigns directed at health profess
ionals and SCD patients' families should be boosted in order to decrease SCD mor
tality.#^ddecs^i2#^tm^len^kAnemia^i2#^tm^len^ksickle cell^i2#^tm^len^kmortality^
i2#^tm^len^ksocioeconomic factors^i2#^tm^len^khealth services^i2#Nacional de Des
envolvimento Científico e Tecnológico#MCT/CNPq/MS-SCTIE-DECIT nº 026/20#vancouv#
30#20091228#28.12.09#20100310#10.03.10#a06v86n4.htm##
05772000000000721000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090038000400094121000300098049000800101158000300109
03000210011203100030013303200020013606500090013801400110014703500100015824100090
01680120096001770120085002730100052003580100032004100100035004420100035004770100
03200512070005300544070008500597070009400682070008900776083188700865085001002752
08500300276208500240279208500360281608500300285208318260288208500100470808500190
47180850024047370850022047610850034047830850028048170580053048450600092048981170
00804990072000304998112000905001111000905010114000905019113000905028002001305037
#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#f#3#1#article#1#oa#pt#b
r1.1#1#4.0#GRA#TAB#06#JPED030#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f279^l284#0
021-7557#^tpr^i01#<b>Mortalidade de crianças com doença falciforme</b>: <b>um es
tudo de base populacional</b>^lpt#<b>Mortality of children with sickle cell dise
ase</b>: <b>a population study</b>^len#^rND^1A01 A02^nAna Paula Pinheiro Chagas^
sFernandes#^rND^1A03^nJosé Nélio^sJanuário#^rND^1A02^nCamila Blanco^sCangussu#^r
ND^1A02^nDaniela Lino de^sMacedo#^rND^1A04^nMarcos Borato^sViana#Núcleo de Ações
 e Pesquisa em Apoio Diagnóstico^iA01#Universidade Federal de Minas Gerais^iA02^
1Faculdade de Medicina^cBelo Horizonte^sMG#Universidade Federal de Minas Gerais^
iA03^1Departamento de Clínica Médica^cBelo Horizonte^sMG#Universidade Federal de
 Minas Gerais^iA04^1Departamento de Pediatria^cBelo Horizonte^sMG#^lpt^a<b>OBJET
IVO: </b>Caracterizar os óbitos das crianças com doença falciforme (DF) triadas 
no estado de Minas Gerais e acompanhadas na Fundação Hemominas. <b>MÉTODOS: </b>
Coorte de crianças diagnosticadas pelo Programa de Triagem Neonatal de Minas Ger
ais (março/1998 - fevereiro/2005). Os óbitos foram identificados pela busca ativ
a das crianças ausentes nas consultas agendadas nos hemocentros. Dados clínicos 
e epidemiológicos foram coletados dos documentos de óbito, banco de dados da tri
agem neonatal, prontuários médicos e em entrevistas com as famílias. <b>RESULTAD
OS: </b>Foram triadas 1.833.030 crianças no período, sendo 1.396 com DF (1:1.300
). Ocorreram 78 óbitos: 63 em crianças com genótipo SS, 12 em crianças com genót
ipo SC e três em crianças com genótipo S/&#946;<sup>+</sup> talassemia. Cinquent
a e seis crianças (71,8%) morreram antes dos 2 anos de idade; 59 morreram em hos
pitais e 18 no domicílio ou trânsito. Causas de óbito pelo atestado (n = 78): 38
,5% infecção; 16,6% sequestro esplênico agudo; 9% outras causas; 15,4% sem assis
tência médica; e 20,5% indeterminada. Segundo as entrevistas (n = 52), o sequest
ro esplênico foi responsável por quase 1/3 dos óbitos, contrastando com a porcen
tagem de apenas 14% registrada nos atestados de óbito. As probabilidades de sobr
evida aos 5 anos (erro padrão da média) para crianças SS, SC e S&#946;<sup>+</su
p> talassemia foram: 89,4 (1,4), 97,7 (0,7) e 94,7% (3,0), respectivamente (SS <
i>versus</i> SC, p &lt; 0,0001). <b>CONCLUSÕES: </b>Mesmo em um programa de tria
gem neonatal com rigoroso controle do tratamento, a probabilidade de óbito em cr
ianças com genótipo SS ainda é elevada. Os óbitos com causa indeterminada indica
m dificuldades no reconhecimento da DF e das suas complicações. Esforços educati
vos dirigidos a profissionais da saúde e familiares devem ser incrementados para
 diminuir a mortalidade pela DF.#^ddecs^i1#^tm^lpt^kAnemia falciforme^i1#^tm^lpt
^kmortalidade^i1#^tm^lpt^kfatores socioeconômicos^i1#^tm^lpt^ksistemas de saúde^
i1#^len^a<b>OBJECTIVE: </b>To describe the deaths of children with sickle cell d
isease (SCD) in Minas Gerais, Brazil, and followed up at the Fundação Hemominas.
 <b>METHODS: </b>Cohort of children diagnosed by the Neonatal Screening Program 
in Minas Gerais (March/1998 - February/2005). Deaths were identified by searchin
g for children who did not attend scheduled consultations at hemocenters. Clinic
al and epidemiological data were abstracted from death certificates, the newborn
 screening database, individual medical records, and from interviews with famili
es. <b>RESULTS: </b>During the period, 1,833,030 newborns were screened; 1,396 h
ad SCD (1:1,300). There were 78 deaths: 63 with SS genotype, 12 with SC genotype
, and three with S&#946;<sup>+</sup>thalassemia genotype. Fifty-six children (71
.8%) died before 2 years of age; 59 died in hospitals and 18 at home or during t
ransportation. Causes of death according to certificates (n = 78): infections, 3
8.5%; acute splenic sequestration, 16.6%; other causes, 9%; did not receive medi
cal care, 15.4%; and not identified on certificates, 20.5%. According to intervi
ews (n = 52), acute splenic sequestration was responsible for one third of death
s, in contrast with 14% recorded on death certificates. Survival probabilities a
t 5y (SEM) for children with SS, SC, and S&#946;<sup>+</sup>thalassemia were 89.
4 (1.4), 97.7 (0.7), and 94.7% (3.0), respectively (SS vs. SC, p &lt; 0.0001). <
b>CONCLUSIONS: </b>Even with a carefully controlled newborn screening program, t
he probability of SS children dying was still found to be high. Causes not ident
ified on death certificates may indicate difficulties recognizing SCD and its co
mplications. Educational campaigns directed at health professionals and SCD pati
ents' families should be boosted in order to decrease SCD mortality.#^ddecs^i2#^
tm^len^kAnemia^i2#^tm^len^ksickle cell^i2#^tm^len^kmortality^i2#^tm^len^ksocioec
onomic factors^i2#^tm^len^khealth services^i2#Nacional de Desenvolvimento Cientí
fico e Tecnológico#<span style='font-size:10.0pt;font-family:Verdana'>MCT/CNPq/M
S-SCTIE-DECIT nº 026/20</span>#vancouv#30#20091228#28.12.09#20100310#10.03.10#a0
6v86n4.htm##
05840000000000745000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000400108038000400112121000300116049000800119
15800030012703000210013003100030015103200020015406500090015601400110016503500100
01762410009001860120082001950120071002770100052003480100032004000100035004320100
03500467010003200502070005500534070008700589070009600676070009100772083189900863
08500100276208500300277208500240280208500360282608500300286208318290289208500100
47210850019047310850024047500850022047740850034047960850028048300580053048580600
03404911117000804945072000304953112000904956111000904965114000904974113000904983
002001304992008008905005#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S
#l#4#1#article#1#^mjul./ago.^a2010#oa#pt#br1.1#1#4.0#gra#tab#06#JPED030#nd#J. Pe
diatr. (Rio J.)#86#4#20100800#^f279^l284#0021-7557#^tpr^i01#Mortalidade de crian
ças com doença falciforme: um estudo de base populacional^lpt#Mortality of child
ren with sickle cell disease: a population study^len#^rND^1A01 A02^nAna Paula Pi
nheiro Chagas^sFernandes#^rND^1A03^nJosé Nélio^sJanuário#^rND^1A02^nCamila Blanc
o^sCangussu#^rND^1A02^nDaniela Lino de^sMacedo#^rND^1A04^nMarcos Borato^sViana#^
iA01^1Núcleo de Ações e Pesquisa em Apoio Diagnóstico#^iA02^1Universidade Federa
l de Minas Gerais^2Faculdade de Medicina^cBelo Horizonte^sMG#^iA03^1Universidade
 Federal de Minas Gerais^2Departamento de Clínica Médica^cBelo Horizonte^sMG#^iA
04^1Universidade Federal de Minas Gerais^2Departamento de Pediatria^cBelo Horizo
nte^sMG#^lpt^aOBJETIVO: Caracterizar os óbitos das crianças com doença falciform
e (DF) triadas no estado de Minas Gerais e acompanhadas na Fundação Hemominas. M
ÉTODOS: Coorte de crianças diagnosticadas pelo Programa de Triagem Neonatal de M
inas Gerais (março/1998 - fevereiro/2005). Os óbitos foram identificados pela bu
sca ativa das crianças ausentes nas consultas agendadas nos hemocentros. Dados c
línicos e epidemiológicos foram coletados dos documentos de óbito, banco de dado
s da triagem neonatal, prontuários médicos e em entrevistas com as famílias. RES
ULTADOS: Foram triadas 1.833.030 crianças no período, sendo 1.396 com DF (1:1.30
0). Ocorreram 78 óbitos: 63 em crianças com genótipo SS, 12 em crianças com genó
tipo SC e três em crianças com genótipo S/&#946;+ talassemia. Cinquenta e seis c
rianças (71,8 por cento) morreram antes dos 2 anos de idade; 59 morreram em hosp
itais e 18 no domicílio ou trânsito. Causas de óbito pelo atestado (n = 78): 38,
5 por cento infecção; 16,6 por cento sequestro esplênico agudo; 9 por cento outr
as causas; 15,4 por cento sem assistência médica; e 20,5 por cento indeterminada
. Segundo as entrevistas (n = 52), o sequestro esplênico foi responsável por qua
se 1/3 dos óbitos, contrastando com a porcentagem de apenas 14 por cento registr
ada nos atestados de óbito. As probabilidades de sobrevida aos 5 anos (erro padr
ão da média) para crianças SS, SC e S&#946;+ talassemia foram: 89,4 (1,4), 97,7 
(0,7) e 94,7 por cento (3,0), respectivamente (SS versus SC, p < 0,0001). CONCLU
SÕES: Mesmo em um programa de triagem neonatal com rigoroso controle do tratamen
to, a probabilidade de óbito em crianças com genótipo SS ainda é elevada. Os óbi
tos com causa indeterminada indicam dificuldades no reconhecimento da DF e das s
uas complicações. Esforços educativos dirigidos a profissionais da saúde e famil
iares devem ser incrementados para diminuir a mortalidade pela DF.#^ddecs^i1#^tm
^lpt^kAnemia falciforme^i1#^tm^lpt^kmortalidade^i1#^tm^lpt^kfatores socioeconômi
cos^i1#^tm^lpt^ksistemas de saúde^i1#^len^aOBJECTIVE: To describe the deaths of 
children with sickle cell disease (SCD) in Minas Gerais, Brazil, and followed up
 at the Fundação Hemominas. METHODS: Cohort of children diagnosed by the Neonata
l Screening Program in Minas Gerais (March/1998 - February/2005). Deaths were id
entified by searching for children who did not attend scheduled consultations at
 hemocenters. Clinical and epidemiological data were abstracted from death certi
ficates, the newborn screening database, individual medical records, and from in
terviews with families. RESULTS: During the period, 1,833,030 newborns were scre
ened; 1,396 had SCD (1:1,300). There were 78 deaths: 63 with SS genotype, 12 wit
h SC genotype, and three with S&#946;+thalassemia genotype. Fifty-six children (
71.8 percent) died before 2 years of age; 59 died in hospitals and 18 at home or
 during transportation. Causes of death according to certificates (n = 78): infe
ctions, 38.5 percent; acute splenic sequestration, 16.6 percent; other causes, 9
 percent; did not receive medical care, 15.4 percent; and not identified on cert
ificates, 20.5 percent. According to interviews (n = 52), acute splenic sequestr
ation was responsible for one third of deaths, in contrast with 14 percent recor
ded on death certificates. Survival probabilities at 5y (SEM) for children with 
SS, SC, and S&#946;+thalassemia were 89.4 (1.4), 97.7 (0.7), and 94.7 percent (3
.0), respectively (SS vs. SC, p < 0.0001). CONCLUSIONS: Even with a carefully co
ntrolled newborn screening program, the probability of SS children dying was sti
ll found to be high. Causes not identified on death certificates may indicate di
fficulties recognizing SCD and its complications. Educational campaigns directed
 at health professionals and SCD patients' families should be boosted in order t
o decrease SCD mortality.#^ddecs^i2#^tm^len^kAnemia^i2#^tm^len^ksickle cell^i2#^
tm^len^kmortality^i2#^tm^len^ksocioeconomic factors^i2#^tm^len^khealth services^
i2#Nacional de Desenvolvimento Científico e Tecnológico#MCT/CNPq/MS-SCTIE-DECIT 
nº 026/20#vancouv#30#20091228#28.12.09#20100310#10.03.10#a06v86n4.htm#Internet^i
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572010000400006##
00323000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704009000074002001300164#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#5#1#article#159#<p align="right"><fon
t size="2" face="Verdana"><b>ARTIGO ORIGINAL</b></font> </p>     ^cY#a06v86n4.ht
m##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#6#2#article#159#<p>&nbsp;</p>     ^cY
#a06v86n4.htm##
00387000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704015400074002001300228#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#7#3#article#159#<p><font size="4" fac
e="Verdana"><b>Mortalidade de crian&ccedil;as com doen&ccedil;a    falciforme: u
m estudo de base populacional</b></font></p>     ^cY#a06v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#8#4#article#159#<p>&nbsp;</p>     ^cY
#a06v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#9#5#article#159#<p>&nbsp;</p>     ^cY
#a06v86n4.htm##
00512000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704027800075002001300353#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#10#6#article#159#<p><font size="2" fa
ce="Verdana"><b>Ana Paula Pinheiro Chagas Fernandes<sup>I</sup>;    Jos&eacute; 
N&eacute;lio Janu&aacute;rio<sup>II</sup>; Camila Blanco Cangussu<sup>III</sup>;
    Daniela Lino de Macedo<sup>III</sup>; Marcos Borato Viana<sup>IV</sup></b></
font></p>     ^cY#a06v86n4.htm##
00464000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704023000075002001300305#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#11#7#article#159#<p><font size="2" fa
ce="Verdana"><sup>I</sup>N&uacute;cleo de A&ccedil;&otilde;es    e Pesquisa em A
poio Diagn&oacute;stico (NUPAD), Faculdade de Medicina, Universidade    Federal 
de Minas Gerais (UFMG), Belo Horizonte, MG    ^cY#a06v86n4.htm##
00416000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704018200075002001300257#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#12#8#article#159#<br>   <sup>II</sup>
NUPAD, Faculdade de Medicina, UFMG, Belo Horizonte, MG, Professor    assistente,
 Departamento de Cl&iacute;nica M&eacute;dica, UFMG, Belo Horizonte,    MG    ^c
Y#a06v86n4.htm##
00382000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704014800075002001300223#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#13#9#article#159#<br>   <sup>III</sup
>NUPAD, Faculdade de Medicina, UFMG, Belo Horizonte, MG, Acad&ecirc;mica,    Cur
so de Medicina, UFMG, Belo Horizonte, MG    ^cY#a06v86n4.htm##
00404000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016900076002001300245#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#14#10#article#159#<br>   <sup>IV</sup
>NUPAD, Faculdade de Medicina, UFMG, Belo Horizonte, MG, Professor    titular, D
epartamento de Pediatria, UFMG, Belo Horizonte, MG</font></p>     ^cY#a06v86n4.h
tm##
00368000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013300076002001300209#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#15#11#article#159#<p><font size="2" f
ace="Verdana"><a name="topo" id="topo"></a><a href="#correspondence">Correspond&
ecirc;ncia</a></font></p>     ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#16#12#article#159#<p>&nbsp;</p>     ^
cY#a06v86n4.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#17#13#article#159#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a06v86n4.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006600076002001300142#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#18#14#article#159#<p><font size="2" f
ace="Verdana"><b>RESUMO</b></font></p>     ^cY#a06v86n4.htm##
00469000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023400076002001300310#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#19#15#article#159#<p><font size="2" f
ace="Verdana"><b>OBJETIVO: </b> Caracterizar os &oacute;bitos    das crian&ccedi
l;as com doen&ccedil;a falciforme (DF) triadas no estado de Minas    Gerais e ac
ompanhadas na Funda&ccedil;&atilde;o Hemominas.    ^cY#a06v86n4.htm##
00752000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051700076002001300593#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#20#16#article#159#<br>   <b>M&Eacute;
TODOS: </b> Coorte de crian&ccedil;as diagnosticadas pelo Programa    de Triagem
 Neonatal de Minas Gerais (mar&ccedil;o/1998 &#150; fevereiro/2005). Os    &oacu
te;bitos foram identificados pela busca ativa das crian&ccedil;as ausentes    na
s consultas agendadas nos hemocentros. Dados cl&iacute;nicos e epidemiol&oacute;
gicos    foram coletados dos documentos de &oacute;bito, banco de dados da triag
em neonatal,    prontu&aacute;rios m&eacute;dicos e em entrevistas com as fam&ia
cute;lias.    ^cY#a06v86n4.htm##
01386000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704115100076002001301227#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#21#17#article#159#<br>   <b>RESULTADO
S: </b>Foram triadas 1.833.030 crian&ccedil;as no per&iacute;odo,    sendo 1.396
 com DF (1:1.300). Ocorreram 78 &oacute;bitos: 63 em crian&ccedil;as    com gen&
oacute;tipo SS, 12 em crian&ccedil;as com gen&oacute;tipo SC e tr&ecirc;s    em 
crian&ccedil;as com gen&oacute;tipo S/&#946;<sup>+</sup> talassemia. Cinquenta  
  e seis crian&ccedil;as (71,8%) morreram antes dos 2 anos de idade; 59 morreram
    em hospitais e 18 no domic&iacute;lio ou tr&acirc;nsito. Causas de &oacute;b
ito    pelo atestado (n = 78): 38,5% infec&ccedil;&atilde;o; 16,6% sequestro esp
l&ecirc;nico    agudo; 9% outras causas; 15,4% sem assist&ecirc;ncia m&eacute;di
ca; e 20,5%    indeterminada. Segundo as entrevistas (n = 52), o sequestro espl&
ecirc;nico    foi respons&aacute;vel por quase 1/3 dos &oacute;bitos, contrastan
do com a porcentagem    de apenas 14% registrada nos atestados de &oacute;bito. 
As probabilidades de    sobrevida aos 5 anos (erro padr&atilde;o da m&eacute;dia
) para crian&ccedil;as    SS, SC e S&#946;<sup>+</sup> talassemia foram: 89,4 (1
,4), 97,7 (0,7) e 94,7%    (3,0), respectivamente (SS <i>versus</i> SC, p < 0,00
01).    ^cY#a06v86n4.htm##
00747000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051200076002001300588#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#22#18#article#159#<br>   <b>CONCLUS&O
tilde;ES: </b> Mesmo em um programa de triagem neonatal com rigoroso    controle
 do tratamento, a probabilidade de &oacute;bito em crian&ccedil;as com    gen&oa
cute;tipo SS ainda &eacute; elevada. Os &oacute;bitos com causa indeterminada   
 indicam dificuldades no reconhecimento da DF e das suas complica&ccedil;&otilde
;es.    Esfor&ccedil;os educativos dirigidos a profissionais da sa&uacute;de e f
amiliares    devem ser incrementados para diminuir a mortalidade pela DF.</font>
</p>     ^cY#a06v86n4.htm##
00425000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019000076002001300266#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#23#19#article#159#<p><font size="2" f
ace="Verdana"><b>Palavras-chave: </b> Anemia falciforme, mortalidade,    fatores
 socioecon&ocirc;micos, sistemas de sa&uacute;de.</font></p> <hr size="1" noshad
e>     ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#24#20#article#159#<p>&nbsp;</p>     ^
cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#25#21#article#159#<p>&nbsp;</p>     ^
cY#a06v86n4.htm##
00319000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008400076002001300160#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#26#22#article#159#<p><font size="3" f
ace="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#a06v86n4.htm##
01008000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077300076002001300849#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#27#23#article#159#<p><font size="2" f
ace="Verdana">A doen&ccedil;a falciforme (DF) &eacute; uma    desordem gen&eacut
e;tica de grande import&acirc;ncia cl&iacute;nica e epidemiol&oacute;gica    cuj
a caracter&iacute;stica principal &eacute; a heran&ccedil;a do gene da globina  
  beta S (gene &#946;<sup>s</sup>). Este gene determina a presen&ccedil;a da hem
oglobina    variante S nas hem&aacute;cias. Os fen&ocirc;menos vaso-oclusivos e 
a hem&oacute;lise    cr&ocirc;nica s&atilde;o os principais determinantes das ma
nifesta&ccedil;&otilde;es    cl&iacute;nicas da DF. Apesar de a altera&ccedil;&a
tilde;o principal estar restrita    aos eritr&oacute;citos do sangue, trata-se d
e doen&ccedil;a sist&ecirc;mica    que pode acometer qualquer &oacute;rg&atilde;
o<SUP>1</SUP>.</font></p>     ^cY#a06v86n4.htm##
01006000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077100076002001300847#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#28#24#article#159#<p><font face="Verd
ana" size="2">No Brasil, a DF &eacute; um importante problema    de sa&uacute;de
 p&uacute;blica. Estima-se que o n&uacute;mero de indiv&iacute;duos    com tra&c
cedil;o falciforme seja de 7.200.000, com preval&ecirc;ncia na popula&ccedil;&at
ilde;o    geral entre 2 e 8%<SUP>2</SUP>. Em Minas Gerais (MG) a incid&ecirc;nci
a do tra&ccedil;o    falciforme &eacute; de 3,3%, e a da DF &eacute; de, aproxim
adamente, 1:1.400    rec&eacute;m-nascidos triados, tendo como base o Programa E
stadual de Triagem    Neonatal (PETN-MG), que implantou a triagem para hemoglobi
nopatias em mar&ccedil;o    de 1998. O PETN-MG abrange todos os munic&iacute;pio
s do estado, e sua cobertura    &eacute; de 94% dos rec&eacute;m-nascidos vivos<
SUP>3</SUP>.</font></p>     ^cY#a06v86n4.htm##
00915000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068000076002001300756#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#29#25#article#159#<p><font face="Verd
ana" size="2">Embora a DF determine elevadas morbidade e mortalidade,    princip
almente nos primeiros 5 anos de vida<SUP>4-9</SUP>, a mortalidade das    crian&c
cedil;as com DF nos primeiros 10 anos de vida tem diminu&iacute;do<SUP>10-14</SU
P>.    Em 1970, a mediana de sobrevida, para cidad&atilde;os estadunidenses com 
a forma    homozig&oacute;tica (SS), era de 20 anos<SUP>15</SUP>. Ap&oacute;s a 
implanta&ccedil;&atilde;o    dos programas de diagn&oacute;stico neonatal, educa
&ccedil;&atilde;o e aten&ccedil;&atilde;o    integral ao paciente, a crian&ccedi
l;a SS passou a apresentar 85% de chance    de sobrevida aos 20 anos<SUP>4</SUP>
.</font></p>     ^cY#a06v86n4.htm##
00912000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067700076002001300753#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#30#26#article#159#<p><font face="Verd
ana" size="2">Apesar de a maioria dos gen&oacute;tipos da DF    determinar dimin
ui&ccedil;&atilde;o da expectativa de vida, a anemia falciforme,    estado de ho
mozigose para hemoglobina S, representa o gen&oacute;tipo mais comum    e a apre
senta&ccedil;&atilde;o cl&iacute;nica mais grave da doen&ccedil;a. V&aacute;rios
    estudos mostram maior incid&ecirc;ncia de &oacute;bitos e menor sobrevida en
tre    pacientes com anemia falciforme<SUP>4,9,16,17</SUP>. Dentre as principais
 causas    de &oacute;bito na primeira d&eacute;cada de vida est&atilde;o as inf
ec&ccedil;&otilde;es    e o sequestro espl&ecirc;nico agudo<SUP>4,16-23</SUP>.</
font></p>     ^cY#a06v86n4.htm##
00845000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061000076002001300686#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#31#27#article#159#<p><font face="Verd
ana" size="2">Este estudo teve como objetivo conhecer mais    detalhadamente as 
causas e circunst&acirc;ncias dos &oacute;bitos ocorridos    em crian&ccedil;as 
com DF triadas pelo PETN-MG. A utiliza&ccedil;&atilde;o de    uma coorte de base
 populacional &eacute; in&eacute;dita no Brasil. A compreens&atilde;o    dos div
ersos determinantes do evento &oacute;bito pode favorecer o planejamento    de p
ol&iacute;ticas p&uacute;blicas e outras a&ccedil;&otilde;es que possam    contr
ibuir para reduzir a morbimortalidade e melhorar a qualidade de vida das    pess
oas com DF.</font></p>     ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#32#28#article#159#<p>&nbsp;</p>     ^
cY#a06v86n4.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007400076002001300150#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#33#29#article#159#<p><font size="3" f
ace="Verdana"><b>M&eacute;todos</b></font></p>     ^cY#a06v86n4.htm##
00580000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034500076002001300421#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#34#30#article#159#<p><font face="Verd
ana" size="2">A popula&ccedil;&atilde;o estudada constituiu-se    de crian&ccedi
l;as diagnosticadas com DF pelo PETN-MG, acompanhadas nos hemocentros    da Fund
a&ccedil;&atilde;o Hemominas, que evolu&iacute;ram para &oacute;bito    no per&i
acute;odo de 1º de mar&ccedil;o de 1998 a 28 de fevereiro de 2005.</font></p>   
  ^cY#a06v86n4.htm##
00963000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072800076002001300804#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#35#31#article#159#<p><font face="Verd
ana" size="2">O PETN-MG realiza a triagem para DF e outras    hemoglobinopatias 
desde mar&ccedil;o de 1998. Todos os 853 munic&iacute;pios    do estado est&atil
de;o cadastrados no programa, sendo a cobertura deste de 94%    dos nascidos viv
os. As amostras de sangue dos rec&eacute;m-nascidos s&atilde;o    coletadas no q
uinto dia de vida em papel-filtro e encaminhadas ao laborat&oacute;rio    de tri
agem neonatal do N&uacute;cleo de A&ccedil;&otilde;es e Pesquisa em Apoio    Dia
gn&oacute;stico (NUPAD) da Faculdade de Medicina da Universidade Federal    de M
inas Gerais (UFMG), Belo Horizonte (MG), que responde pela coordena&ccedil;&atil
de;o    t&eacute;cnica e operacional do programa.</font></p>     ^cY#a06v86n4.ht
m##
00801000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056600076002001300642#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#36#32#article#159#<p><font face="Verd
ana" size="2">A informa&ccedil;&atilde;o do &oacute;bito resulta    da investiga
&ccedil;&atilde;o do motivo do n&atilde;o comparecimento &agrave;    consulta ag
endada no hemocentro. As a&ccedil;&otilde;es de busca ativa do NUPAD    abrangem
 a totalidade dos pacientes triados com DF em acompanhamento na Funda&ccedil;&at
ilde;o    Hemominas, n&atilde;o sendo necess&aacute;rio, portanto, processo de a
mostragem.    &Eacute; seguro afirmar que todos os &oacute;bitos ocorridos no pe
r&iacute;odo    do estudo foram contabilizados.</font></p>     ^cY#a06v86n4.htm#
#
00822000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058700076002001300663#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#37#33#article#159#<p><font face="Verd
ana" size="2">Os dados foram extra&iacute;dos do banco de dados    do PETN-MG, d
e documentos de &oacute;bito, do banco de dados do Sistema &Uacute;nico    de Sa
&uacute;de (DATASUS) e do Instituto Brasileiro de Geografia e Estat&iacute;stica
    (IBGE), de prontu&aacute;rios m&eacute;dicos dos ambulat&oacute;rios da Fund
a&ccedil;&atilde;o    Hemominas e em entrevista com familiares e/ou cuidadores d
a crian&ccedil;a.    Dos 78 documentos de &oacute;bito foram extra&iacute;dos os
 dados referentes    &agrave;s causas, data e local do &oacute;bito.</font></p> 
    ^cY#a06v86n4.htm##
00872000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063700076002001300713#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#38#34#article#159#<p><font face="Verd
ana" size="2">O banco de dados do NUPAD foi a fonte das informa&ccedil;&otilde;e
s    sobre a localiza&ccedil;&atilde;o das fam&iacute;lias e avalia&ccedil;&atil
de;o    da ades&atilde;o ao protocolo de acompanhamento, pois todas as consultas
 feitas    nos hemocentros geram uma c&oacute;pia do atendimento que &eacute; re
metida    ao Setor de Controle e Tratamento do NUPAD. O estudo, por ser retrospe
ctivo,    n&atilde;o incluiu coleta espec&iacute;fica de dados para avaliar ades
&atilde;o    a medidas profil&aacute;ticas contra infec&ccedil;&atilde;o (vacina
s especiais    e antibi&oacute;ticos).</font></p>     ^cY#a06v86n4.htm##
01524000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704128900076002001301365#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#39#35#article#159#<p><font face="Verd
ana" size="2">A entrevista foi realizada com o respons&aacute;vel    pela crian&
ccedil;a a partir de roteiro semiestruturado durante o ano de 2006    e ap&oacut
e;s transcorridos de 1 a 8 anos desde a ocorr&ecirc;ncia do &oacute;bito.    Foi
 necess&aacute;rio que a pesquisadora APPCF visitasse pessoalmente 41 munic&iacu
te;pios,    percorrendo cerca de 10 mil quil&ocirc;metros. Apesar de muito esfor
&ccedil;o,    24 fam&iacute;lias n&atilde;o foram localizadas, principalmente aq
uelas nas    quais o &oacute;bito da crian&ccedil;a havia ocorrido mais de 5 ano
s antes;    duas fam&iacute;lias se recusaram a participar da entrevista. Ela te
ve dura&ccedil;&atilde;o    mediana de 25 minutos e abordou quatro aspectos: 1) 
as circunst&acirc;ncias    relacionadas ao evento &oacute;bito; 2) o acompanhame
nto para DF e a ocorr&ecirc;ncia    de outros eventos agudos; 3) condi&ccedil;&a
tilde;o socioecon&ocirc;mica e cultural;    e 4) impress&otilde;es sobre as expe
ri&ecirc;ncias vividas com a crian&ccedil;a    com DF. A realiza&ccedil;&atilde;
o da entrevista foi condicionada &agrave; leitura    e assinatura de um termo de
 consentimento que abrangeu os objetivos, os procedimentos    e os poss&iacute;v
eis benef&iacute;cios e custos oriundos do estudo.</font></p>     ^cY#a06v86n4.h
tm##
00493000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025800076002001300334#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#40#36#article#159#<p><font face="Verd
ana" size="2">Os dados dos prontu&aacute;rios da Funda&ccedil;&atilde;o    Hemom
inas foram digitados em um banco de dados que utiliza o programa Access    da Mi
crosoft, constru&iacute;do especificamente para a pesquisa.</font></p>     ^cY#a
06v86n4.htm##
01053000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704081800076002001300894#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#41#37#article#159#<p><font face="Verd
ana" size="2">Para a an&aacute;lise estat&iacute;stica, as    compara&ccedil;&ot
ilde;es das frequ&ecirc;ncias entre vari&aacute;veis nominais    foram feitas ut
ilizando-se o teste de qui-quadrado, sem corre&ccedil;&atilde;o    de continuida
de, ou teste exato de Fisher, quando necess&aacute;rio. As curvas    de sobrevid
a foram baseadas no m&eacute;todo de Kaplan-Meier, e as compara&ccedil;&otilde;e
s    entre curvas foram feitas pelo teste de <i>logrank</i>. Todos os 78 &oacute
;bitos    ocorridos, independentemente de relacionados ou n&atilde;o &agrave; DF
, foram    considerados eventos adversos. As crian&ccedil;as vivas em 15/02/2005
 (n = 1.318)    foram "censuradas" nessa data. Consideraram-se significativos os
 testes com    probabilidade de erro alfa <u>&lt;</u> 0,05.</font></p>     ^cY#a
06v86n4.htm##
00580000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034500076002001300421#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#42#38#article#159#<p><font face="Verd
ana" size="2">A pesquisa foi aprovada pelos Comit&ecirc;s de    &Eacute;tica em 
Pesquisa da UFMG e da Funda&ccedil;&atilde;o Hemominas e foi    selecionada para
 financiamento pelo Conselho Nacional de Desenvolvimento Cient&iacute;fico    e 
Tecnol&oacute;gico pelo edital MCT/CNPq/MS-SCTIE-DECIT nº 026/20.</font></p>    
  ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#43#39#article#159#<p>&nbsp;</p>     ^
cY#a06v86n4.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007000076002001300146#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#44#40#article#159#<p><font size="3" f
ace="Verdana"><b>Resultados</b></font></p>     ^cY#a06v86n4.htm##
00753000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051800076002001300594#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#45#41#article#159#<p><font size="2" f
ace="Verdana">No per&iacute;odo estudado, 1.833.030 rec&eacute;m-nascidos    for
am triados pelo PETN-MG, e 1.396 crian&ccedil;as tiveram perfil hemoglob&iacute;
nico    compat&iacute;vel com DF: 764 com gen&oacute;tipo SS ou S&#946;<sup>0</S
UP>-talassemia,    555 com hemoglobinopatia SC, 10 com hemoglobinopatia SD e 67 
com S&#946;<sup>+</sup>    talassemia (incid&ecirc;ncia de 1:1.313 para todas as
 formas, 1:2.400 para SS/S&#946;<sup>0</sup>-talassemia    e 1:3.300 para SC).</
font></p>      ^cY#a06v86n4.htm##
00637000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040200076002001300478#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#46#42#article#159#<p><font face="Verd
ana" size="2">Em 7 anos, ocorreram 78 &oacute;bitos. Desses,    41 ocorreram em 
crian&ccedil;as do g&ecirc;nero masculino (52%) e 37 em pacientes    do feminino
 (48%). A maioria das crian&ccedil;as que faleceram residia em &aacute;rea    ur
bana (78%) e em munic&iacute;pios de pequeno porte, com popula&ccedil;&atilde;o 
   de at&eacute; 50.000 habitantes (56,4%).</font></p>     ^cY#a06v86n4.htm##
00759000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052400076002001300600#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#47#43#article#159#<p><font face="Verd
ana" size="2">A mediana da idade &agrave; coleta do sangue    para a triagem foi
 de 9 dias, sendo que 75% das crian&ccedil;as foram triadas    at&eacute; os 18 
dias de vida. A mediana de idade &agrave; primeira consulta    no hemocentro foi
 de 2,1 meses. Tr&ecirc;s crian&ccedil;as faleceram antes da    realiza&ccedil;&
atilde;o da primeira consulta no hemocentro, com 19, 55 e 57    dias de vida. Em
 dois casos a causa do &oacute;bito foi septicemia e em um caso    foi indetermi
nada.</font></p>     ^cY#a06v86n4.htm##
00560000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032500076002001300401#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#48#44#article#159#<p><font face="Verd
ana" size="2">A <a href=#687f1 >Figura 1</a> mostra a distribui&ccedil;&atilde;o
    dos &oacute;bitos segundo a faixa et&aacute;ria. A maioria dos &oacute;bitos
    (71,8%) ocorreu em crian&ccedil;as de at&eacute; 2 anos de idade. A mediana 
   de idade ao &oacute;bito foi de 13,7 meses.</font></p>     ^cY#a06v86n4.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#49#45#article#159#<p><a name="687f1">
</a></p>     ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#50#46#article#159#<p>&nbsp;</p>     ^
cY#a06v86n4.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007800076002001300154#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#51#47#article#159#<p align="center"><
img src="/img/revistas/jped/v86n4/4a06f1.gif"></p>     ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#52#48#article#159#<p>&nbsp;</p>     ^
cY#a06v86n4.htm##
00522000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028700076002001300363#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#53#49#article#159#<p><font size="2" f
ace="Verdana"> De acordo com o perfil hemoglob&iacute;nico    detectado na triag
em neonatal, 63 &oacute;bitos ocorreram em crian&ccedil;as    SS/S&#946;<sup>0</
sup> (80,8%), 12 em SC (15,4%) e tr&ecirc;s em S&#946;<sup>+</sup>    talassemia
 (3,8%).</font></p>     ^cY#a06v86n4.htm##
00579000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704034400076002001300420#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#54#50#article#159#<p><font face="Verd
ana" size="2">Segundo a informa&ccedil;&atilde;o do documento    de notifica&cce
dil;&atilde;o do &oacute;bito, houve preval&ecirc;ncia de &oacute;bitos    hospi
talares (59); entretanto, ocorreram 15 &oacute;bitos domiciliares, tr&ecirc;s   
 em tr&acirc;nsito e um na unidade b&aacute;sica de sa&uacute;de.</font></p>    
 ^cY#a06v86n4.htm##
00636000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040100076002001300477#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#55#51#article#159#<p><font face="Verd
ana" size="2">A infec&ccedil;&atilde;o (incluindo pneumonia    e septicemia) foi
 a principal <i>causa mortis</i> registrada no documento de    &oacute;bito, seg
uida pelo sequestro espl&ecirc;nico agudo. Foi considerada    como desconhecida 
a causa de &oacute;bito em cujo registro constava "sem assist&ecirc;ncia    m&ea
cute;dica" (<a href=#687f2 >Figura 2</a>).</font></p>     ^cY#a06v86n4.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#56#52#article#159#<p><a name="687f2">
</a></p>     ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#57#53#article#159#<p>&nbsp;</p>     ^
cY#a06v86n4.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007800076002001300154#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#58#54#article#159#<p align="center"><
img src="/img/revistas/jped/v86n4/4a06f2.gif"></p>     ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#59#55#article#159#<p>&nbsp;</p>     ^
cY#a06v86n4.htm##
00835000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060000076002001300676#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#60#56#article#159#<p><font face="Verd
ana" size="2">Em rela&ccedil;&atilde;o &agrave;s crian&ccedil;as    das fam&iacu
te;lias entrevistadas (n = 52) ocorreram algumas discord&acirc;ncias    entre as
 causas de &oacute;bito documentadas e as relatadas ou sugeridas pela    entrevi
sta. O sequestro espl&ecirc;nico, por exemplo, foi a causa de sete dos    52 &oa
cute;bitos (13,5%) quando se considerou a informa&ccedil;&atilde;o do    documen
to de &oacute;bito, mas, quando foram considerados os dados da entrevista,    o 
sequestro espl&ecirc;nico passou a responder por 16 dos 52 &oacute;bitos (30,8%)
.</font></p>     ^cY#a06v86n4.htm##
01225000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704099000076002001301066#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#61#57#article#159#<p><font size="2" f
ace="Verdana">A <a href=#687f3 >Figura 3</a> mostra as curvas    de sobrevida da
s crian&ccedil;as com hemoglobinopatia SS/S&#946;<sup>0</sup>-talassemia,    SC,
 SD e S&#946;<sup>+</sup> talassemia. A curva de sobrevida das crian&ccedil;as  
  SS/S&#946;<sup>0</sup>-talassemia &eacute; significativamente inferior &agrave
;quela    das crian&ccedil;as SC (p &lt; 0,0001). A curva de sobrevida das crian
&ccedil;as    SS/S&#946;<sup>0</sup>-talassemia n&atilde;o difere significativam
ente daquelas    correspondentes &agrave;s crian&ccedil;as S&#946;<sup>+</sup> t
alassemia e SD    (p = 0,21 e p = 0,36, respectivamente). Constatou-se, ainda, q
ue no decorrer    dos primeiros 5 anos de vida, as crian&ccedil;as SS/S&#946;<su
p>0</sup>-talassemia    apresentaram maior queda na probabilidade de sobrevida e
m compara&ccedil;&atilde;o    com as crian&ccedil;as SC e S&#946;<sup>+</sup> ta
lassemia (<a href=/img/revistas/jped/v86n4/4a06t1.gif>Tabela    1</a>).</font></
p>     ^cY#a06v86n4.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#62#58#article#159#<p><a name="687f3">
</a></p>     ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#63#59#article#159#<p>&nbsp;</p>     ^
cY#a06v86n4.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007800076002001300154#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#64#60#article#159#<p align="center"><
img src="/img/revistas/jped/v86n4/4a06f3.gif"></p>     ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#65#61#article#159#<p>&nbsp;</p>     ^
cY#a06v86n4.htm##
00491000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025600076002001300332#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#66#62#article#159#<p align=left><font
 face="Verdana" size="2"> Considerando o total de consultas    agendadas nos hem
ocentros para as 78 crian&ccedil;as que faleceram (580 consultas),    houve 77,3
% de comparecimento e 22,7% de n&atilde;o comparecimento.</font></p>     ^cY#a06
v86n4.htm##
01948000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704171300076002001301789#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#67#63#article#159#<p><font face="Verd
ana" size="2">De acordo com os dados apurados nas entrevistas    (n = 52), 57,7%
 das crian&ccedil;as foram atendidas nas primeiras 6 horas ap&oacute;s    o in&i
acute;cio dos sintomas relacionados ao evento que determinou o &oacute;bito,    
71,2%, em at&eacute; 24 horas e 17,3% faleceram sem receber assist&ecirc;ncia   
 m&eacute;dica. O &oacute;bito, nesse grupo, ocorreu nas primeiras 12 horas do  
  in&iacute;cio dos sintomas em 55,8% dos casos e em 67,3%, nas primeiras 24 hor
as.    Febre, dor, v&ocirc;mito e prostra&ccedil;&atilde;o foram, pelo relato da
s fam&iacute;lias,    os sintomas iniciais mais frequentemente relacionados ao e
vento &oacute;bito.    Os hospitais foram o primeiro servi&ccedil;o de sa&uacute
;de procurado por 19    fam&iacute;lias (36,5%), seguidos pelas unidades b&aacut
e;sicas de sa&uacute;de,    procuradas por 12 (23%), e as unidades de pronto ate
ndimento, por seis (11,5%).    O uso regular da profilaxia com antibi&oacute;tic
o foi relatado por 43 fam&iacute;lias    (82,7%), e o uso regular do &aacute;cid
o f&oacute;lico, por 47 (90,4%). O uso    regular dos imunobiol&oacute;gicos esp
eciais foi relatado por 21 fam&iacute;lias    (40,4%). Quanto &agrave; evolu&cce
dil;&atilde;o cl&iacute;nica anterior ao &oacute;bito,    65% das crian&ccedil;a
s j&aacute; haviam sido internadas pelo menos uma vez,    sendo que 19% foram in
ternadas mais de tr&ecirc;s vezes. A crise &aacute;lgica    j&aacute; tinha acon
tecido em 67,3% das crian&ccedil;as antes do &oacute;bito    e o sequestro espl&
ecirc;nico agudo j&aacute; havia ocorrido em 14 crian&ccedil;as    (27%), sendo 
que em duas essa intercorr&ecirc;ncia havia acontecido mais de    uma vez.</font
></p>     ^cY#a06v86n4.htm##
00995000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076000076002001300836#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#68#64#article#159#<p><font face="Verd
ana" size="2">Quanto &agrave; situa&ccedil;&atilde;o socioecon&ocirc;mica    das
 fam&iacute;lias entrevistadas (n = 52), 58% das fam&iacute;lias tinham renda   
 <i>per capita </i>mensal de at&eacute; R$ 100,00 e, em 20% dos casos, de at&eac
ute;    R$ 50,00. O valor m&iacute;nimo da renda <i>per capita</i> foi 0 e o m&a
acute;ximo    foi de R$ 380,00. O valor do sal&aacute;rio-m&iacute;nimo na ocasi
&atilde;o    da pesquisa era de R$ 350,00. A m&eacute;dia do n&uacute;mero de pe
ssoas por    fam&iacute;lia foi de 5,6. Quanto &agrave; escolaridade dos pais, 7
6,8% das    m&atilde;es e 86,8% dos pais tinham o ensino fundamental incompleto,
 sendo que    13,5% das m&atilde;es e 19% dos pais n&atilde;o eram alfabetizados
.</font></p>     ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#69#65#article#159#<p>&nbsp;</p>     ^
cY#a06v86n4.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#70#66#article#159#<p><font size="3" f
ace="Verdana"><b>Discuss&atilde;o</b></font></p>     ^cY#a06v86n4.htm##
00848000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061300076002001300689#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#71#67#article#159#<p><font face="Verd
ana" size="2">A casu&iacute;stica estudada no presente estudo    reflete a reali
dade global de sa&uacute;de das crian&ccedil;as mineiras com    DF, porque a cob
ertura do PETN-MG atinge, em m&eacute;dia, 94% de todos os rec&eacute;m-nascidos
    e 100% dos munic&iacute;pios do estado. Todos os &oacute;bitos de crian&cced
il;as    triadas com DF e em acompanhamento nos hemocentros foram informados, se
ndo que    os casos representam a totalidade dos &oacute;bitos ocorridos nesse g
rupo de    crian&ccedil;as no per&iacute;odo, o que configura um estudo com base
 populacional.</font></p>     ^cY#a06v86n4.htm##
00764000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052900076002001300605#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#72#68#article#159#<p><font face="Verd
ana" size="2">Neste estudo, assim como em outros, n&atilde;o    houve diferen&cc
edil;a significativa na incid&ecirc;ncia dos &oacute;bitos entre    os g&ecirc;n
eros na faixa et&aacute;ria estudada<SUP>4,23</SUP>. A maior incid&ecirc;ncia   
 de &oacute;bitos (80,8%) entre os pacientes com Hb SS, que representa o gen&oac
ute;tipo    mais comum e a apresenta&ccedil;&atilde;o cl&iacute;nica mais grave 
da doen&ccedil;a,    tamb&eacute;m foi constatada em outros trabalhos<SUP>4,9,16
,17</SUP>.</font></p>     ^cY#a06v86n4.htm##
01188000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704095300076002001301029#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#73#69#article#159#<p><font face="Verd
ana" size="2">A distribui&ccedil;&atilde;o por faixa et&aacute;ria    em que oco
rreu o &oacute;bito evidenciou uma concentra&ccedil;&atilde;o nos    primeiros 2
 anos de vida, semelhante ao relatado por outros autores<SUP>4,16,19,21</SUP>.  
  Segundo publica&ccedil;&atilde;o do Centers for Disease Control and Prevention
    (CDC), com dados do acompanhamento das crian&ccedil;as com DF provenientes d
os    programas de triagem neonatal de tr&ecirc;s estados estadunidenses, a medi
ana    da idade ao &oacute;bito foi de 22 meses<SUP>24</SUP>. A elevada mortalid
ade    nos primeiros 5 anos de vida poderia ser explicada pela maior incid&ecirc
;ncia    de eventos agudos graves na inf&acirc;ncia. Tr&ecirc;s crian&ccedil;as 
faleceram    com menos de 2 meses de idade, antes da realiza&ccedil;&atilde;o da
 primeira    consulta, por causas que, provavelmente, n&atilde;o se relacionaram
 ao diagn&oacute;stico    de base.</font></p>     ^cY#a06v86n4.htm##
01167000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704093200076002001301008#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#74#70#article#159#<p><font face="Verd
ana" size="2">Embora prevalecessem os &oacute;bitos hospitalares,    &eacute; im
portante ressaltar que quase 1/4 deles ocorreu no domic&iacute;lio    ou em tr&a
circ;nsito para uma unidade de sa&uacute;de. Alguns fatores, como    resid&ecirc
;ncia em &aacute;rea rural, dificuldade de transporte at&eacute;    a unidade de
 sa&uacute;de e dificuldade da fam&iacute;lia na identifica&ccedil;&atilde;o    
de situa&ccedil;&otilde;es de risco para a crian&ccedil;a, parecem ter contribu&
iacute;do    para esse quadro. Um estudo realizado na Inglaterra relatou sete &o
acute;bitos    domiciliares em um grupo de 11 pacientes com DF e idade abaixo de
 20 anos. Os    autores enfatizaram que a agilidade no reconhecimento do evento 
agudo e a busca    por atendimento m&eacute;dico devem contrapor-se &agrave; rap
idez da evolu&ccedil;&atilde;o    dos sinais e sintomas graves da doen&ccedil;a<
SUP>25</SUP>.</font></p>     ^cY#a06v86n4.htm##
01603000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704136800076002001301444#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#75#71#article#159#<p><font face="Verd
ana" size="2">A infec&ccedil;&atilde;o foi a principal causa    de &oacute;bito 
no presente estudo, seguida pelo sequestro espl&ecirc;nico agudo.    Dados semel
hantes foram publicados por outros autores<SUP>4,17-21,26,27</SUP>.    Entretant
o, &eacute; elevado o n&uacute;mero de &oacute;bitos com causa indeterminada    
e desconhecida. O &oacute;bito por causa indeterminada pode sugerir certa dificu
ldade    da equipe de sa&uacute;de em reconhecer a DF e suas complica&ccedil;&ot
ilde;es    agudas, j&aacute; que a maior parte desses registros foi proveniente 
de &oacute;bitos    hospitalares. A causa de &oacute;bito desconhecida se relaci
onou, em sua maioria,    aos &oacute;bitos sem assist&ecirc;ncia m&eacute;dica. 
A compara&ccedil;&atilde;o    entre os dados dos documentos de &oacute;bito e os
 das 52 entrevistas evidenciou    discord&acirc;ncias, principalmente em rela&cc
edil;&atilde;o &agrave; identifica&ccedil;&atilde;o    do sequestro espl&ecirc;n
ico agudo como causa do &oacute;bito. &Eacute; interessante    destacar a aparen
te dificuldade no reconhecimento do sequestro espl&ecirc;nico    pelas equipes d
e sa&uacute;de, pois se trata de um dos principais eventos agudos    graves da D
F na inf&acirc;ncia, cuja hist&oacute;ria e apresenta&ccedil;&atilde;o    cl&iac
ute;nica s&atilde;o muito evidentes<SUP>26</SUP>.</font></p>     ^cY#a06v86n4.ht
m##
00779000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054400076002001300620#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#76#72#article#159#<p><font size="2" f
ace="Verdana">A an&aacute;lise da curva de sobrevida mostrou    que, nos primeir
os 5 anos de vida, as crian&ccedil;as SS/S&#946;<sup>0</SUP>-talassemia    apres
entaram maior queda na probabilidade de sobrevida em compara&ccedil;&atilde;o   
 com as crian&ccedil;as SC. A falta de signific&acirc;ncia estat&iacute;stica   
 na compara&ccedil;&atilde;o com os grupos S&#946;<sup>+</SUP> talassemia e SD  
  provavelmente &eacute; devida ao n&uacute;mero reduzido de indiv&iacute;duos  
  nessas duas categorias.</font></p>     ^cY#a06v86n4.htm##
01589000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704135400076002001301430#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#77#73#article#159#<p><font size="2" f
ace="Verdana">A taxa geral de mortalidade para menores de 5    anos em Minas Ger
ais foi de 30,4 por mil no ano de 2000<SUP>28</SUP>, o que,    descontada a taxa
 de mortalidade neonatal precoce, resulta numa estimativa de    18 por 1.000 par
a efeito de compara&ccedil;&atilde;o com a probabilidade estimada    de sobrevid
a aos 5 anos no presente estudo. Para as crian&ccedil;as SS, essa    estimativa 
foi de 106 por 1.000 (10,6%), ou seja, cerca de seis vezes superior    &agrave; 
do estado. A curva de sobrevida das 310 crian&ccedil;as SS que faziam    parte d
o estudo de coorte na Jamaica mostrou mortalidade de 6% no primeiro ano    de vi
da<SUP>5</SUP>. A estimativa de &oacute;bito aos 6 anos de idade para crian&cced
il;as    SS/S&#946;<sup>0</SUP>-talassemia na coorte de Dallas foi de 5%<SUP>29<
/SUP>.    Ressalve-se, entretanto, que a &aacute;rea abrangida se restringiu ao 
nordeste    do Texas e que a inclus&atilde;o no estudo s&oacute; ocorreu ap&oacu
te;s o comparecimento    para uma primeira consulta no Comprehensive Sicke Cell 
Center (mediana de 4,2    meses) e n&atilde;o ap&oacute;s o diagn&oacute;stico l
aboratorial do rec&eacute;m-nascido    (sensibilidade pr&oacute;xima a 100%), o 
que, evidentemente, subestima o c&aacute;lculo    da probabilidade de &oacute;bi
to na popula&ccedil;&atilde;o real.</font></p>     ^cY#a06v86n4.htm##
01614000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704137900076002001301455#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#78#74#article#159#<p><font face="Verd
ana" size="2">O atendimento m&eacute;dico, na maioria dos casos,    ocorreu nas 
primeiras 6 horas do in&iacute;cio dos sintomas. N&atilde;o houve,    portanto, 
grande atraso na busca pelo atendimento. As unidades b&aacute;sicas    de sa&uac
ute;de foram respons&aacute;veis por 23% desses atendimentos, o que    pode ser 
explicado pelo grande n&uacute;mero de crian&ccedil;as residindo em    munic&iac
ute;pios de pequeno porte. A alta ades&atilde;o &agrave; profilaxia    com antib
i&oacute;ticos deve ser considerada com ceticismo, pois estudo espec&iacute;fico
    realizado no Hemocentro de MG evidenciou que os n&iacute;veis de ades&atilde
;o    s&atilde;o bem mais baixos que esse valor<SUP>30</SUP>. Pode-se concluir q
ue    as principais dificuldades encontradas que poderiam ter contribu&iacute;do
 para    o &oacute;bito estariam relacionadas ao atendimento em si, ou seja, &ag
rave;    capacita&ccedil;&atilde;o da equipe de sa&uacute;de para o atendimento 
aos eventos    agudos da DF e aos recursos dispon&iacute;veis na unidade de sa&u
acute;de procurada    para as a&ccedil;&otilde;es necess&aacute;rias. Outro fato
r que deve ser considerado    &eacute; a rapidez da evolu&ccedil;&atilde;o de de
terminados quadros cl&iacute;nicos.    A reduzida escolaridade dos pais e a baix
a renda familiar constitu&iacute;ram    entraves adicionais.</font></p>     ^cY#
a06v86n4.htm##
01122000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704088700076002001300963#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#79#75#article#159#<p><font face="Verd
ana" size="2">A principal limita&ccedil;&atilde;o do estudo    foi seu car&aacut
e;ter retrospectivo, pois o protocolo de acompanhamento cl&iacute;nico    utiliz
ado possu&iacute;a finalidades de assist&ecirc;ncia e n&atilde;o de pesquisa.   
 A aus&ecirc;ncia de entrevistas em 1/3 dos casos decorreu tamb&eacute;m do fato
    de se tratar de uma coorte retrospectiva, pois a localiza&ccedil;&atilde;o d
as    fam&iacute;lias &eacute; dificultada com o passar dos anos. Como a finalid
ade    principal das entrevistas era conhecer como ocorreram os &oacute;bitos, a
crescentando    ao estudo um car&aacute;ter qualitativo mais refinado e humano d
o que a simples    inspe&ccedil;&atilde;o dos atestados e registros m&eacute;dic
os, consideramos    que a aus&ecirc;ncia de 26 entrevistas &#150; em 78 &#150; n
&atilde;o comprometeu os objetivos    almejados.</font></p>     ^cY#a06v86n4.htm
##
01001000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076600076002001300842#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#80#76#article#159#<p><font face="Verd
ana" size="2">Diante dos resultados deste estudo, percebe-se    que na DF o fato
r social se associa fortemente ao determinante biol&oacute;gico,    contribuindo
 de maneira decisiva para o aumento da morbidade e mortalidade da    doen&ccedil
;a. Assim, a problem&aacute;tica da DF n&atilde;o se limita apenas    a quest&ot
ilde;es t&eacute;cnicas, mas &eacute;, tamb&eacute;m, uma quest&atilde;o    pol&
iacute;tica e social. O programa de aten&ccedil;&atilde;o integral &agrave;    p
essoa com DF, do Minist&eacute;rio da Sa&uacute;de, representa uma meta a ser   
 conquistada pelos pacientes, familiares e profissionais envolvidos com o objeti
vo    de melhorar a atual condi&ccedil;&atilde;o de vida e sa&uacute;de dessas p
essoas.</font></p>     ^cY#a06v86n4.htm##
01353000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704111800076002001301194#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#81#77#article#159#<p><font face="Verd
ana" size="2">Conclui-se que, mesmo em um programa de triagem    neonatal com ri
goroso controle do tratamento, a probabilidade de &oacute;bito    aos 5 anos em 
crian&ccedil;as SS nos 7 primeiros anos do PETN-MG foi bem maior    que a mortal
idade geral. Os &oacute;bitos com causa indeterminada indicam dificuldades    no
 reconhecimento da DF e suas complica&ccedil;&otilde;es. Esfor&ccedil;os educati
vos    dirigidos a profissionais de sa&uacute;de e familiares devem ser incremen
tados    para diminuir a mortalidade e morbidade causadas pela DF. A capacita&cc
edil;&atilde;o    das Unidades B&aacute;sicas de Sa&uacute;de deve ser priorizad
a, pois interven&ccedil;&otilde;es    simples, como a triagem neonatal, o uso da
 penicilina profil&aacute;tica, as    imuniza&ccedil;&otilde;es e as pr&aacute;t
icas educativas, t&ecirc;m grande    impacto na sa&uacute;de p&uacute;blica. Mui
tos &oacute;bitos seriam evitados    pela educa&ccedil;&atilde;o e melhora das c
ondi&ccedil;&otilde;es sociais, econ&ocirc;micas    e culturais das fam&iacute;l
ias que possuem crian&ccedil;as com DF.</font></p>     ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#82#78#article#159#<p>&nbsp;</p>     ^
cY#a06v86n4.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007400076002001300150#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#83#79#article#159#<p><font size="3" f
ace="Verdana"><b>Agradecimentos</b></font></p>     ^cY#a06v86n4.htm##
00480000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024500076002001300321#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#84#80#article#159#<p><font face="Verd
ana" size="2">A todas as fam&iacute;lias que, apesar do sofrimento    que envolv
e a perda de uma crian&ccedil;a, dispuseram-se a contar o que aconteceu    &agra
ve; &eacute;poca do &oacute;bito de seu filho.</font></p>     ^cY#a06v86n4.htm##
00455000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022000076002001300296#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#85#81#article#159#<p><font face="Verd
ana" size="2">Ao Conselho Nacional de Desenvolvimento Cient&iacute;fico    e Tec
nol&oacute;gico (CNPq) que, pelo edital MCT/CNPq/MS-SCTIE-DECIT nº 026/20,    fi
nanciou este projeto.</font></p>     ^cY#a06v86n4.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019500076002001300271#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#86#82#article#159#<p><font face="Verd
ana" size="2">Ao NUPAD-UFMG, em especial aos membros do Setor    de Controle e T
ratamento, pela dedica&ccedil;&atilde;o profissional e suporte    ao estudo.</fo
nt></p>     ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#87#83#article#159#<p>&nbsp;</p>     ^
cY#a06v86n4.htm##
00312000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007700076002001300153#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#88#84#article#159#<p><font size="3" f
ace="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#a06v86n4.htm##
00376000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704012700078002001300205#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#89#85#article#159#1#<p><f
ont size="2" face="Verdana">1. Serjeant GR. Sickle cell disease. 2nd ed.    Oxfo
rd: Oxford University Press; 1992.    ^cY#a06v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#90#86#article#159#</font></p>     ^cY
#a06v86n4.htm##
00403000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704015400078002001300232#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#91#87#article#159#2#<p><f
ont size="2" face="Verdana">2. Can&ccedil;ado RD, Jesus JA. A doen&ccedil;a    f
alciforme no Brasil. Rev Bras Hematol Hemoter. 2007;29:204-6.    ^cY#a06v86n4.ht
m##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#92#88#article#159#</font></p>     ^cY
#a06v86n4.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027400078002001300352#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#93#89#article#159#3#<p><f
ont size="2" face="Verdana">3. Januario J. Incid&ecirc;ncia da doen&ccedil;a    
falciforme em um milh&atilde;o de nascidos vivos em Minas Gerais (1998-2001)    
&#091;disserta&ccedil;&atilde;o&#093;. Belo Horizonte: Universidade Federal de M
inas Gerais;    2002.    ^cY#a06v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#94#90#article#159#</font></p>     ^cY
#a06v86n4.htm##
00492000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024300078002001300321#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#95#91#article#159#4#<p><f
ont size="2" face="Verdana">4. Leikin SL, Gallagher D, Kinney TR, Sloane    D, K
lug P, Rida W. Mortality in children and adolescents with sickle cell disease.  
  Cooperative Study of Sickle Cell Disease. Pediatrics. 1989;84:500-8.    ^cY#a0
6v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#96#92#article#159#</font></p>     ^cY
#a06v86n4.htm##
00419000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704017000078002001300248#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#97#93#article#159#5#<p><f
ont size="2" face="Verdana">5. Serjeant GR. Natural history and determinants    
of clinical severity of sickle cell disease. Curr Opin Hematol. 1995;2:103-8.   
 ^cY#a06v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#98#94#article#159#</font></p>     ^cY
#a06v86n4.htm##
00455000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020600078002001300284#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#99#95#article#159#6#<p><f
ont size="2" face="Verdana">6. Lee A, Thomas P, Cupidore L, Serjeant B, Serjeant
    G. Improved survival in homozygous sickle cell disease: lessons from a cohor
t    study. BMJ. 1995;311:1600-2.    ^cY#a06v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#100#96#article#159#</font></p>     ^c
Y#a06v86n4.htm##
00471000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704022100079002001300300#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#101#97#article#159#7#<p><
font size="2" face="Verdana">7. Koko J, Dufillot D, M'Ba-Meyo J, Gahouma D,    K
ani F. Mortality of children with sickle cell disease in a pediatric department 
   in Central Africa. Arch Pediatr. 1998;5:965-9.    ^cY#a06v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#102#98#article#159#</font></p>     ^c
Y#a06v86n4.htm##
00494000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704024400079002001300323#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#103#99#article#159#8#<p><
font size="2" face="Verdana">8. Thomas C, Lemerle S, Bernaudin F, Feingold    J,
 Guillou-Bataille M, Reinert P. Sickle cell anemia: study of the pediatric    mo
rtality in Ile de France from 1985 to 1992. Arch Pediatr. 1996;3:445-51.    ^cY#
a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#104#100#article#159#</font></p>     ^
cY#a06v86n4.htm##
00492000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704024100080002001300321#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#105#101#article#159#9#<p>
<font size="2" face="Verdana">9. Platt OS, Brambilla DJ, Rosse WF, Milner PF,   
 Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectanc
y    and risk factors for early death. N Engl J Med. 1994;330:1639-44.    ^cY#a0
6v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#106#102#article#159#</font></p>     ^
cY#a06v86n4.htm##
00430000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017800081002001300259#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#107#103#article#159#10#<p
><font size="2" face="Verdana">10. Bainbridge R, Higgs DR, Maude GH, Serjeant   
 GR. Clinical presentation of homozygous sickle cell disease. J Pediatr. 1985;10
6:881-5.    ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#108#104#article#159#</font></p>     ^
cY#a06v86n4.htm##
00440000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018800081002001300269#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#109#105#article#159#11#<p
><font size="2" face="Verdana">11. Powars D, Chan LS, Schroeder WA. The variable
    expression of sickle cell disease is genetically determined. Semin Hematol. 
   1990;27:360-76.    ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#110#106#article#159#</font></p>     ^
cY#a06v86n4.htm##
00445000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019300081002001300274#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#111#107#article#159#12#<p
><font size="2" face="Verdana">12. Vichinsky E, Hurst D, Earles A, Kleman K,    
Lubin B. Newborn screening for sickle cell disease: effect on mortality. Pediatr
ics.    1988;81:749-55.    ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#112#108#article#159#</font></p>     ^
cY#a06v86n4.htm##
00446000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019400081002001300275#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#113#109#article#159#13#<p
><font size="2" face="Verdana">13. Zarkowsky HS, Gallagher D, Gill FM, Wang    W
C, Falletta JM, Lande WM, et al. Bacteremia in sickle hemoglobinopathies. J    P
ediatr. 1986;109:579-85.    ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#114#110#article#159#</font></p>     ^
cY#a06v86n4.htm##
00458000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020600081002001300287#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#115#111#article#159#14#<p
><font size="2" face="Verdana">14. Yanni E, Grosse SD, Yang Q, Olney RS. Trends 
   in pediatric sickle cell disease-related mortality in the United States, 1983
-2002.    J Pediatr. 2009;154:541-5.    ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#116#112#article#159#</font></p>     ^
cY#a06v86n4.htm##
00376000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704012400081002001300205#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#117#113#article#159#15#<p
><font size="2" face="Verdana">15. Scott RB. Health care priority and sickle    
cell anemia. JAMA. 1970;214:731-4.    ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#118#114#article#159#</font></p>     ^
cY#a06v86n4.htm##
00412000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016000081002001300241#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#119#115#article#159#16#<p
><font size="2" face="Verdana">16. Thomas AN, Pattison C, Serjeant GR. Causes   
 of death in sickle-cell disease in Jamaica. Br Med J. 1982;285:633-5.    ^cY#a0
6v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#120#116#article#159#</font></p>     ^
cY#a06v86n4.htm##
00467000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021500081002001300296#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#121#117#article#159#17#<p
><font size="2" face="Verdana">17. Manci EA, Culberson DE, Yang YM, Gardner    T
M, Powell R, Haynes J Jr, et al. Causes of death in sickle cell disease: an    a
utopsy study. Br J Haematol. 2003;123:359-65.    ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#122#118#article#159#</font></p>     ^
cY#a06v86n4.htm##
00448000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019600081002001300277#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#123#119#article#159#18#<p
><font size="2" face="Verdana">18. Seeler RA. Deaths in children with sickle    
cell anemia. A clinical analysis of 19 fatal instances in Chicago. Clin Pediatr 
   (Phila). 1972;11:634-7.    ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#124#120#article#159#</font></p>     ^
cY#a06v86n4.htm##
00512000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026000081002001300341#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#125#121#article#159#19#<p
><font size="2" face="Verdana">19. Diggs L. Anatomic lesions in sickle cell    d
isease. In: Abramson H, Bertles JH, Wethers D, editors. Sickle cell disease:    
diagnosis, management, education and research. Saint Louis: CV Mosby; 1973.    p
. 189-229.    ^cY#a06v86n4.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#126#122#article#159# </font></p>     
^cY#a06v86n4.htm##
00471000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021900081002001300300#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#127#123#article#159#20#<p
><font size="2" face="Verdana">20. Miller ST, Sleeper LA, Pegelow CH, Enos LE,  
  Wang WC, Weiner SJ, et al. Prediction of adverse outcomes in children with sic
kle    cell disease. N Engl J Med. 2000;342:83-9.    ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#128#124#article#159#</font></p>     ^
cY#a06v86n4.htm##
00526000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027400081002001300355#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#129#125#article#159#21#<p
><font size="2" face="Verdana">21. Gill FM, Sleeper LA, Weiner SJ, Brown AK,    
Bellevue R, Grover R, et al. Clinical events in the first decade in a cohort    
of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease.  
  Blood. 1995;86:776-83.    ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#130#126#article#159#</font></p>     ^
cY#a06v86n4.htm##
00456000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020400081002001300285#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#131#127#article#159#22#<p
><font size="2" face="Verdana">22. Rogers DW, Clarke JM, Cupidore L, Ramlal    A
M, Sparke BR, Serjeant GR. Early deaths in Jamaican children with sickle cell   
 disease. Br Med J. 1978;1:1515-6.    ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#132#128#article#159#</font></p>     ^
cY#a06v86n4.htm##
00489000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023700081002001300318#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#133#129#article#159#23#<p
><font size="2" face="Verdana">23. Shankar SM, Arbogast PG, Mitchel E, Cooper   
 WO, Wang WC, Griffin MR. Medical care utilization and mortality in sickle cell 
   disease: a population-based study. Am J Hematol. 2005;80:262-70.    ^cY#a06v8
6n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#134#130#article#159#</font></p>     ^
cY#a06v86n4.htm##
00540000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028800081002001300369#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#135#131#article#159#24#<p
><font size="2" face="Verdana">24. Centers for Disease Control and Prevention   
 (CDC). Mortality among children with sickle cell disease identified by newborn 
   screening during 1990-1994 &#150; California, Illinois, and New York. MMWR Mo
rb Mortal    Wkly Rep. 1998;47:169-72.    ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#136#132#article#159#</font></p>     ^
cY#a06v86n4.htm##
00444000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019200081002001300273#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#137#133#article#159#25#<p
><font size="2" face="Verdana">25. Gray A, Anionwu EN, Davies SC, Brozovic M.   
 Patterns of mortality in sickle cell disease in the United Kingdom. J Clin Path
ol.    1991;44:459-63.    ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#138#134#article#159#</font></p>     ^
cY#a06v86n4.htm##
00464000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021200081002001300293#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#139#135#article#159#26#<p
><font size="2" face="Verdana">26. Resende PV, Viana MB, Murao M, Chaves AC,    
Ribeiro AC. Acute splenic sequestration in a cohort of children with sickle    c
ell anemia. J Pediatr (RJ). 2009;85:163-9.    ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#140#136#article#159#</font></p>     ^
cY#a06v86n4.htm##
00530000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027800081002001300359#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#141#137#article#159#27#<p
><font size="2" face="Verdana">27. Van-Dunem JC, Alves JG, Bernardino L, Figueir
oa    JN, Braga C, Nascimento Mde L, et al. Factors associated with sickle cell 
disease    mortality among hospitalized Angolan children and adolescents. West A
fr J Med.    2007;26:269-73.    ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#142#138#article#159#</font></p>     ^
cY#a06v86n4.htm##
00556000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030400081002001300385#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#143#139#article#159#28#<p
><font size="2" face="Verdana">28. Programa das Na&ccedil;&otilde;es Unidas    p
ara o Desenvolvimento. Atlas do Desenvolvimento Humano no Brasil. Bras&iacute;li
a:    PNUD-Brasil; 2002. <A href=http://www.pnud.org.br/atlas target="_blank">ht
tp://www.pnud.org.br/atlas</A>.    Acesso: 23/05/2006.    ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#144#140#article#159#</font></p>     ^
cY#a06v86n4.htm##
00404000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704015200081002001300233#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#145#141#article#159#29#<p
><font size="2" face="Verdana">29. Quinn CT, Rogers ZR, Buchanan GR. Survival   
 of children with sickle cell disease. Blood. 2004;103:4023-7.    ^cY#a06v86n4.h
tm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#146#142#article#159#</font></p>     ^
cY#a06v86n4.htm##
00477000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022500081002001300306#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#p#147#143#article#159#30#<p
><font size="2" face="Verdana">30. Bitar&atilde;es EL, Oliveira BM, Viana MB.   
 Compliance with antibiotic prophylaxis in children with sickle cell anemia:    
a prospective study. J Pediatr (Rio J). 2008;84:316-22.    ^cY#a06v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#148#144#article#159#</font></p>     ^
cY#a06v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#149#145#article#159#<p>&nbsp;</p>    
 ^cY#a06v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#150#146#article#159#<p>&nbsp;</p>    
 ^cY#a06v86n4.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018000078002001300258#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#151#147#article#159#<p><font size="2"
 face="Verdana"><a name="correspondence"></a><a href="#topo"><img src="/img/revi
stas/jped/v86n4/seta.gif" border="0"></a>    <b> Correspond&ecirc;ncia:</b>    ^
cY#a06v86n4.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003500078002001300113#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#152#148#article#159#<br>   Marcos Bor
ato Viana     ^cY#a06v86n4.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010500078002001300183#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#153#149#article#159#<BR>   Faculdade 
de Medicina, Departamento de Pediatria, Universidade Federal de Minas    Gerais 
    ^cY#a06v86n4.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004200078002001300120#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#154#150#article#159#<BR>   Av. Alfred
o Balena, 190/267    ^cY#a06v86n4.htm##
00286000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004900078002001300127#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#155#151#article#159#<BR>   CEP 30130-
100 - Belo Horizonte, MG    ^cY#a06v86n4.htm##
00273000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003600078002001300114#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#156#152#article#159#<BR>   Tel.: (31)
 3409.9772     ^cY#a06v86n4.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#157#153#article#159#<BR>   Fax: (31) 
3409.9770    ^cY#a06v86n4.htm##
00326000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008900078002001300167#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#158#154#article#159#<BR>   E-mail: <A
 href=mailto:vianamb@gmail.com>vianamb@gmail.com</A></font></p>     ^cY#a06v86n4
.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010200078002001300180#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#159#155#article#159#<p><font size="2"
 face="Verdana">Artigo submetido em 28.12.09, aceito em 10.03.10.</font></p>    
 ^cY#a06v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#160#156#article#159#<p>&nbsp;</p>    
 ^cY#a06v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#161#157#article#159#<p>&nbsp;</p>    
 ^cY#a06v86n4.htm##
00391000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704015400078002001300232#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#162#158#article#159#<p><font size="2"
 face="Verdana"> N&atilde;o foram declarados conflitos de interesse    associado
s &agrave; publica&ccedil;&atilde;o deste artigo.    ^cY#a06v86n4.htm##
00746000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704050900078002001300587#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a06v86n4.htm#S#p#163#159#article#159#<br>   Apoio: N&u
acute;cleo de A&ccedil;&otilde;es e Pesquisa em Apoio Diagn&oacute;stico    (NUP
AD), Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG),    Belo
 Horizonte, MG; Conselho Nacional de Desenvolvimento Cient&iacute;fico e    Tecn
ol&oacute;gico (CNPq) &#150; o &uacute;ltimo autor &eacute; bolsista 2 do &oacut
e;rg&atilde;o    de fomento &agrave; pesquisa; pesquisa financiada parcialmente 
pelo CNPq atrav&eacute;s    do edital MCT/CNPq/MS-SCTIE-DECIT nº 026/20.</font><
/p>     ^cY#a06v86n4.htm##
00431000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160019000770180024000960630
00200120066000700122062002400129065000900153064000500162865000900167002001300176
#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#c#164#1#article#30#1#^r
ND^sSerjeant^nGR#Sickle cell disease^len#2#Oxford#Oxford University Press#199200
00#1992#20100800#a06v86n4.htm##
00483000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100016000950120
03400111030002500145710000200170065000900172064000500181031000300186014000600189
865000900195002001300204#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S
#c#165#2#article#30#2#^rND^sCançado^nRD#^rND^sJesus^nJA#A doença falciforme no B
rasil^lpt#Rev Bras Hematol Hemoter#2#20070000#2007#29#204-6#20100800#a06v86n4.ht
m##
00532000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160018000770180095000950510
01200190066001500202062003700217065000900254064000500263865000900268002001300277
#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#c#166#3#article#30#3#^r
ND^sJanuario^nJ#Incidência da doença falciforme em um milhão de nascidos vivos e
m Minas Gerais (1998-2001)^lpt#dissertação#Belo Horizonte#Universidade Federal d
e Minas Gerais#20020000#2002#20100800#a06v86n4.htm##
00686000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100019000940100
01700113010001600130010001400146010001400160012010900174030001100283065000900294
06400050030303100030030801400060031186500090031700200130032603500100033980100110
0349#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#c#167#4#article#30#
4#^rND^sLeikin^nSL#^rND^sGallagher^nD#^rND^sKinney^nTR#^rND^sSloane^nD#^rND^sKlu
g^nP#^rND^sRida^nW#Mortality in children and adolescents with sickle cell diseas
e: Cooperative Study of Sickle Cell Disease^len#Pediatrics#19890000#1989#84#500-
8#20100800#a06v86n4.htm#0031-4005#Pediatrics##
00533000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770120081000960300
01800177065000900195064000500204031000200209014000600211865000900217002001300226
035001000239801001800249#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S
#c#168#5#article#30#5#^rND^sSerjeant^nGR#Natural history and determinants of cli
nical severity of sickle cell disease^len#Curr Opin Hematol#19950000#1995#2#103-
8#20100800#a06v86n4.htm#1065-6251#Curr Opin Hematol##
00624000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100013000770100016000900100
01800106010001800124010001800142012008500160030000400245065000900249064000500258
031000400263014000700267865000900274002001300283035001000296801000400306#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#c#169#6#article#30#6#^rND^sLee^
nA#^rND^sThomas^nP#^rND^sCupidore^nL#^rND^sSerjeant^nB#^rND^sSerjeant^nG#Improve
d survival in homozygous sickle cell disease: lessons from a cohort study^len#BM
J#19950000#1995#311#1600-2#20100800#a06v86n4.htm#0959-8138#BMJ##
00648000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100018000910100
01900109010001700128010001400145012009500159030001300254065000900267064000500276
031000200281014000600283865000900289002001300298035001000311801001300321#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#c#170#7#article#30#7#^rND^sKoko
^nJ#^rND^sDufillot^nD#^rND^sM'Ba-Meyo^nJ#^rND^sGahouma^nD#^rND^sKani^nF#Mortalit
y of children with sickle cell disease in a pediatric department in Central Afri
ca^len#Arch Pediatr#19980000#1998#5#965-9#20100800#a06v86n4.htm#0096-6630#Arch P
ediatr##
00689000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100017000930100
01900110010001800129010002600147010001700173012009200190030001300282065000900295
06400050030403100020030901400070031186500090031800200130032703500100034080100130
0350#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#c#171#8#article#30#
8#^rND^sThomas^nC#^rND^sLemerle^nS#^rND^sBernaudin^nF#^rND^sFeingold^nJ#^rND^sGu
illou-Bataille^nM#^rND^sReinert^nP#Sickle cell anemia: study of the pediatric mo
rtality in Ile de France from 1985 to 1992^len#Arch Pediatr#19960000#1996#3#445-
51#20100800#a06v86n4.htm#0096-6630#Arch Pediatr##
00697000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100020000930100
01600113010001700129010001600146010002000162810000600182012008700188030001300275
06500090028806400050029703100040030201400080030686500090031400200130032303500100
0336801001300346#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#c#172#9
#article#30#9#^rND^sPlatt^nOS#^rND^sBrambilla^nDJ#^rND^sRosse^nWF#^rND^sMilner^n
PF#^rND^sCastro^nO#^rND^sSteinberg^nMH#et al#Mortality in sickle cell disease: L
ife expectancy and risk factors for early death^len#N Engl J Med#19940000#1994#3
30#1639-44#20100800#a06v86n4.htm#0028-4793#N Engl J Med##
00588000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100016000990100
01600115010001900131012006000150030001000210065000900220064000500229031000400234
014000600238865000900244002001300253035001000266801001000276#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a06v86n4.htm#S#c#173#10#article#30#10#^rND^sBainbridge^nR#
^rND^sHiggs^nDR#^rND^sMaude^nGH#^rND^sSerjeant^nGR#Clinical presentation of homo
zygous sickle cell disease^len#J Pediatr#19850000#1985#106#881-5#20100800#a06v86
n4.htm#0022-3476#J Pediatr##
00581000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
02000110012007700130030001400207065000900221064000500230031000300235014000700238
865000900245002001300254035001000267801001400277#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a06v86n4.htm#S#c#174#11#article#30#11#^rND^sPowars^nD#^rND^sChan^nLS#^
rND^sSchroeder^nWA#The variable expression of sickle cell disease is genetically
 determined^len#Semin Hematol#19900000#1990#27#360-76#20100800#a06v86n4.htm#0037
-1963#Semin Hematol##
00619000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100015000980100
01600113010001600129010001500145012006700160030001100227065000900238064000500247
031000300252014000700255865000900262002001300271035001000284801001100294#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#c#175#12#article#30#12#^rND^sVi
chinsky^nE#^rND^sHurst^nD#^rND^sEarles^nA#^rND^sKleman^nK#^rND^sLubin^nB#Newborn
 screening for sickle cell disease: effect on mortality^len#Pediatrics#19880000#
1988#81#749-55#20100800#a06v86n4.htm#0031-4005#Pediatrics##
00648000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100019000990100
01500118010001500133010001900148010001600167810000600183012004400189030001000233
06500090024306400050025203100040025701400070026186500090026800200130027703500100
0290801001000300#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#c#176#1
3#article#30#13#^rND^sZarkowsky^nHS#^rND^sGallagher^nD#^rND^sGill^nFM#^rND^sWang
^nWC#^rND^sFalletta^nJM#^rND^sLande^nWM#et al#Bacteremia in sickle hemoglobinopa
thies^len#J Pediatr#19860000#1986#109#579-85#20100800#a06v86n4.htm#0022-3476#J P
ediatr##
00613000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01400111010001600125012009400141030001000235065000900245064000500254031000400259
014000600263865000900269002001300278035001000291801001000301#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a06v86n4.htm#S#c#177#14#article#30#14#^rND^sYanni^nE#^rND^
sGrosse^nSD#^rND^sYang^nQ#^rND^sOlney^nRS#Trends in pediatric sickle cell diseas
e-related mortality in the United States, 1983-2002^len#J Pediatr#20090000#2009#
154#541-5#20100800#a06v86n4.htm#0022-3476#J Pediatr##
00475000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120048000950300
00500143065000900148064000500157031000400162014000600166865000900172002001300181
035001000194801000500204#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S
#c#178#15#article#30#15#^rND^sScott^nRB#Health care priority and sickle cell ane
mia^len#JAMA#19700000#1970#214#731-4#20100800#a06v86n4.htm#0098-7484#JAMA##
00551000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
01900114012005400133030000900187065000900196064000500205031000400210014000600214
865000900220002001300229035001000242801000900252#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a06v86n4.htm#S#c#179#16#article#30#16#^rND^sThomas^nAN#^rND^sPattison^
nC#^rND^sSerjeant^nGR#Causes of death in sickle-cell disease in Jamaica^len#Br M
ed J#19820000#1982#285#633-5#20100800#a06v86n4.htm#0007-1447#Br Med J##
00673000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100020000950100
01500115010001800130010001600148010001900164810000600183012006100189030001400250
06500090026406400050027303100040027801400070028286500090028900200130029803500100
0311801001400321#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#c#180#1
7#article#30#17#^rND^sManci^nEA#^rND^sCulberson^nDE#^rND^sYang^nYM#^rND^sGardner
^nTM#^rND^sPowell^nR#^rND^sHaynes Jr^nJ#et al#Causes of death in sickle cell dis
ease: an autopsy study^len#Br J Haematol#20030000#2003#123#359-65#20100800#a06v8
6n4.htm#0007-1048#Br J Haematol##
00560000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790120101000960300
02100197065000900218064000500227031000300232014000600235865000900241002001300250
035001000263801002100273#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S
#c#181#18#article#30#18#^rND^sSeeler^nRA#Deaths in children with sickle cell ane
mia: A clinical analysis of 19 fatal instances in Chicago^len#Clin Pediatr (Phil
a)#19720000#1972#11#634-7#20100800#a06v86n4.htm#0009-9228#Clin Pediatr (Phila)##
00617000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790120044000940160
01800138016001800156016001700174018007100191066001200262062000900274014000800283
065000900291064000500300865000900305002001300314#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a06v86n4.htm#S#c#182#19#article#30#19#^rND^sDiggs^nL#Anatomic lesions 
in sickle cell disease^len#^rED^sAbramson^nH#^rED^sBertles^nJH#^rED^sWethers^nD#
Sickle cell disease: diagnosis, management, education and research^len#Saint Lou
is#CV Mosby#189-229#19730000#1973#20100800#a06v86n4.htm##
00676000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
01800114010001500132010001500147010001700162810000600179012007200185030001300257
06500090027006400050027903100040028401400050028886500090029300200130030203500100
0315801001300325#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#c#183#2
0#article#30#20#^rND^sMiller^nST#^rND^sSleeper^nLA#^rND^sPegelow^nCH#^rND^sEnos^
nLE#^rND^sWang^nWC#^rND^sWeiner^nSJ#et al#Prediction of adverse outcomes in chil
dren with sickle cell disease^len#N Engl J Med#20000000#2000#342#83-9#20100800#a
06v86n4.htm#0028-4793#N Engl J Med##
00721000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100018000940100
01700112010001600129010001800145010001600163810000600179012013000185030000600315
06500090032106400050033003100030033501400070033886500090034500200130035403500100
0367801000600377#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#c#184#2
1#article#30#21#^rND^sGill^nFM#^rND^sSleeper^nLA#^rND^sWeiner^nSJ#^rND^sBrown^nA
K#^rND^sBellevue^nR#^rND^sGrover^nR#et al#Clinical events in the first decade in
 a cohort of infants with sickle cell disease: Cooperative Study of Sickle Cell 
Disease^len#Blood#19950000#1995#86#776-83#20100800#a06v86n4.htm#0006-4971#Blood#
#
00646000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01800113010001700131010001700148010001900165012006300184030000900247065000900256
06400050026503100020027001400070027286500090027900200130028803500100030180100090
0311#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#c#185#22#article#30
#22#^rND^sRogers^nDW#^rND^sClarke^nJM#^rND^sCupidore^nL#^rND^sRamlal^nAM#^rND^sS
parke^nBR#^rND^sSerjeant^nGR#Early deaths in Jamaican children with sickle cell 
disease^len#Br Med J#19780000#1978#1#1515-6#20100800#a06v86n4.htm#0007-1447#Br M
ed J##
00683000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
01700116010001700133010001500150010001800165012009200183030001300275065000900288
06400050029703100030030201400070030586500090031200200130032103500100033480100130
0344#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#c#186#23#article#30
#23#^rND^sShankar^nSM#^rND^sArbogast^nPG#^rND^sMitchel^nE#^rND^sCooper^nWO#^rND^
sWang^nWC#^rND^sGriffin^nMR#Medical care utilization and mortality in sickle cel
l disease: a population-based study^len#Am J Hematol#20050000#2005#80#262-70#201
00800#a06v86n4.htm#0361-8609#Am J Hematol##
00636000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760110043000790120140001220300
02600262065000900288064000500297031000300302014000700305865000900312002001300321
035001000334801002600344#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S
#c#187#24#article#30#24#Centers for Disease Control and Prevention#Mortality amo
ng children with sickle cell disease identified by newborn screening during 1990
-1994 - California, Illinois, and New York^len#MMWR Morb Mortal Wkly Rep#1998000
0#1998#47#169-72#20100800#a06v86n4.htm#0149-2195#MMWR Morb Mortal Wkly Rep##
00603000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100018000930100
01700111010001800128012007100146030001400217065000900231064000500240031000300245
014000700248865000900255002001300264035001000277801001400287#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a06v86n4.htm#S#c#188#25#article#30#25#^rND^sGray^nA#^rND^s
Anionwu^nEN#^rND^sDavies^nSC#^rND^sBrozovic^nM#Patterns of mortality in sickle c
ell disease in the United Kingdom^len#J Clin Pathol#19910000#1991#44#459-63#2010
0800#a06v86n4.htm#0021-9746#J Clin Pathol##
00607000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01500113010001700128010001800145012008000163030001500243710000200258065000900260
064000500269031000300274014000600277865000900283002001300292#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a06v86n4.htm#S#c#189#26#article#30#26#^rND^sResende^nPV#^r
ND^sViana^nMB#^rND^sMurao^nM#^rND^sChaves^nAC#^rND^sRibeiro^nAC#Acute splenic se
questration in a cohort of children with sickle cell anemia^len#J Pediatr (RJ)#2
#20090000#2009#85#163-9#20100800#a06v86n4.htm##
00734000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100016000990100
02000115010002000135010001500155010002400170810000600194012011000200030001500310
06500090032506400050033403100030033901400070034286500090034900200130035803500100
0371801001500381#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#c#190#2
7#article#30#27#^rND^sVan-Dunem^nJC#^rND^sAlves^nJG#^rND^sBernardino^nL#^rND^sFi
gueiroa^nJN#^rND^sBraga^nC#^rND^sNascimento Mde^nL#et al#Factors associated with
 sickle cell disease mortality among hospitalized Angolan children and adolescen
ts^len#West Afr J Med#20070000#2007#26#269-73#20100800#a06v86n4.htm#0189-160X#We
st Afr J Med##
00536000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760180097000790660009001760620
01200185065000900197064000500206037002900211110000900240109001100249865000900260
002001300269#v86n4#V:\Scielo\serial\jped\v86n4\markup\a06v86n4.htm#S#c#191#28#ar
ticle#30#28#Programa das Nações Unidas para o Desenvolvimento. Atlas do Desenvol
vimento Humano no Brasil^lpt#Brasília#PNUD-Brasil#20020000#2002#http://www.pnud.
org.br/atlas#20060523#23/05/2006#20100800#a06v86n4.htm##
00540000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100017000950100
01900112012005000131030000600181065000900187064000500196031000400201014000700205
865000900212002001300221035001000234801000600244#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a06v86n4.htm#S#c#192#29#article#30#29#^rND^sQuinn^nCT#^rND^sRogers^nZR
#^rND^sBuchanan^nGR#Survival of children with sickle cell disease^len#Blood#2004
0000#2004#103#4023-7#20100800#a06v86n4.htm#0006-4971#Blood##
00615000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100019000980100
01600117012010000133030001800233065000900251064000500260031000300265014000700268
865000900275002001300284035001000297801001800307#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a06v86n4.htm#S#c#193#30#article#30#30#^rND^sBitarães^nEL#^rND^sOliveir
a^nBM#^rND^sViana^nMB#Compliance with antibiotic prophylaxis in children with si
ckle cell anemia: a prospective study^len#J Pediatr (Rio J)#20080000#2008#84#316
-22#20100800#a06v86n4.htm#0021-7557#J Pediatr (Rio J)##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#o#1#1#article#1
#20110126#175452#a07v86n4.htm#175##
04974000000000697000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090038000400094121000300098049000800101158000300109
03000210011203100030013303200020013606500090013801400110014703500100015801201100
01680120076002780100040003540100030003940100042004240100047004660700116005130700
14700629070005300776083154200829085001002371085003902381085003402420085003002454
08500210248408500240250508314530252908500100398208500340399208500360402608500310
40620850019040930850024041121170008041360720003041441120009041471110011041561140
00904167113001104176058006204187060001404249002001304263#v86n4#V:\Scielo\serial\
jped\v86n4\markup\a07v86n4.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#GRA#TAB#07#JP
ED030#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f285^l289#0021-7557#Teste de desenc
adeamento alimentar oral na confirmação diagnóstica da alergia à proteína do lei
te de vaca^lpt#Oral food challenge test to confirm the diagnosis of cow's milk a
llergy^len#^rND^1A01^nMaria das Graças Moura^sLins#^rND^nMárcia Raquel^sHorowitz
#^rND^1A02^nGiselia Alves Pontes da^sSilva#^rND^1A03^nMaria Eugênia Farias Almei
da^sMotta#Universidade Federal de Pernambuco^iA01^1Programa de Pós-Graduação em 
Saúde da Criança e do Adolescente^cRecife^sPE#Universidade Federal de Pernambuco
^iA02^1Departamento Materno Infantil^2Programa de Pós-Graduação em Saúde da Cria
nça e do Adolescente^cRecife^sPE#UFPE^iA03^1Departamento Materno Infantil^cRecif
e^sPE#^lpt^aOBJETIVO: Verificar a prevalência de alergia à proteína do leite de 
vaca em crianças com sintomas atribuídos à ingestão do leite de vaca. MÉTODOS: F
oram estudadas 65 crianças com sintomas atribuídos à ingestão do leite de vaca. 
A definição diagnóstica ocorreu após teste de desencadeamento alimentar oral abe
rto, realizado no mínimo 15 dias após dieta de exclusão e ausência de sintomas, 
com período de observação de até 4 semanas após o teste. Considerou-se caso (ale
rgia à proteína do leite de vaca positiva; n = 35) criança com reaparecimento do
 sintoma que motivou a realização do teste, e comparação (alergia à proteína do 
leite de vaca negativa; n = 30) aquela sem sintomas após o período de observação
 do teste. RESULTADOS: A mediana de idade foi 5 meses (P 25-75% 2-9 meses) no gr
upo caso e 7 meses (P 25-75% 4-11 meses) no grupo comparação (p = 0,05). O teste
 não confirmou alergia à proteína do leite de vaca em 46,8% dos pacientes com si
ntomas atribuídos à ingestão de leite de vaca. Reação tardia ocorreu em 77,1% (2
7/35) dos casos com teste positivo, sendo 18/27 na primeira, 3/27 na segunda e 6
/27 na terceira semana de observação. Encontrou-se associação estatística signif
icante entre manifestações cutâneas e teste positivo (p = 0,04), mas não com sin
tomas digestivos e respiratórios. CONCLUSÃO: Os resultados corroboram a necessid
ade do teste de desencadeamento alimentar oral para determinar os pacientes que 
realmente têm alergia à proteína do leite de vaca e se beneficiarão com dieta de
 exclusão de leite de vaca.#^ddecs^i1#^tm^lpt^kHipersensibilidade a leite^i1#^tm
^lpt^kcondições patológicas^i1#^tm^lpt^ksinais e sintomas^i1#^tm^lpt^klactente^i
1#^tm^lpt^kpré-escolar^i1#^len^aOBJECTIVE: To determine the prevalence of cow's 
milk protein allergy in children with symptoms attributed to cow's milk intake. 
METHODS: Sixty-five children with symptoms attributed to cow's milk intake were 
studied. Diagnosis was established after an open oral food challenge test carrie
d out at least 15 days after an elimination diet and absence of symptoms, with a
 follow-up period of up to 4 weeks after the test. The children who remained asy
mptomatic after this period were considered negative for cow's milk protein alle
rgy (n = 30), while those whose symptoms reappeared were considered positive (n 
= 35). RESULTS: The median age was 5 months (P 25-75% 2-9 months) in the case gr
oup and 7 months (P 25-75% 4-11 months) in the comparison group (p = 0.05). The 
test did not confirm cow's milk protein allergy in 46.8% of the patients with sy
mptoms attributed to cow's milk intake. A delayed reaction occurred in 77.1% (27
/35) of the cases testing positive, 18/27 in the first week, 3/27 in the second 
week, and 6/27 in the third week of follow-up. A statistically significant assoc
iation was found between cutaneous manifestations and positive test result (p = 
0.04). However, there was no association with digestive and respiratory symptoms
. CONCLUSION: Our results confirm the need of an oral food challenge test to det
ermine which patients really have cow's milk protein allergy and may therefore b
enefit from a diet free of cow's milk.#^ddecs^i2#^tm^len^kMilk hypersensitivity^
i2#^tm^len^kpathological conditions^i2#^tm^len^ksigns and symptoms^i2#^tm^len^ki
nfant^i2#^tm^len^kpreschooler^i2#vancouv#34#20100126#26.01.2010#20100419#19.04.2
010#Conselho Nacional de Desenvolvimento Científico e Tecnológico#475291/2006-9#
a07v86n4.htm##
05102000000000697000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090038000400094121000300098049000800101158000300109
03000210011203100030013303200020013606500090013801400110014703500100015801201170
01680120083002850100040003680100030004080100042004380100047004800700116005270700
14700643070005300790083157000843085001002413085003902423085003402462085003002496
08500210252608500240254708314810257108500100405208500340406208500360409608500310
41320850019041630850024041821170008042060720003042141120009042171110011042261140
00904237113001104246058006204257060007204319002001304391#v86n4#V:\Scielo\serial\
jped\v86n4\markup\a07v86n4.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#GRA#TAB#07#JP
ED030#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f285^l289#0021-7557#<b>Teste de des
encadeamento alimentar oral na confirmação diagnóstica da alergia à proteína do 
leite de vaca</b>^lpt#<b>Oral food challenge test to confirm the diagnosis of co
w's milk allergy</b>^len#^rND^1A01^nMaria das Graças Moura^sLins#^rND^nMárcia Ra
quel^sHorowitz#^rND^1A02^nGiselia Alves Pontes da^sSilva#^rND^1A03^nMaria Eugêni
a Farias Almeida^sMotta#Universidade Federal de Pernambuco^iA01^1Programa de Pós
-Graduação em Saúde da Criança e do Adolescente^cRecife^sPE#Universidade Federal
 de Pernambuco^iA02^1Departamento Materno Infantil^2Programa de Pós-Graduação em
 Saúde da Criança e do Adolescente^cRecife^sPE#UFPE^iA03^1Departamento Materno I
nfantil^cRecife^sPE#^lpt^a<b>OBJETIVO: </b>Verificar a prevalência de alergia à 
proteína do leite de vaca em crianças com sintomas atribuídos à ingestão do leit
e de vaca. <b>MÉTODOS: </b>Foram estudadas 65 crianças com sintomas atribuídos à
 ingestão do leite de vaca. A definição diagnóstica ocorreu após teste de desenc
adeamento alimentar oral aberto, realizado no mínimo 15 dias após dieta de exclu
são e ausência de sintomas, com período de observação de até 4 semanas após o te
ste. Considerou-se caso (alergia à proteína do leite de vaca positiva; n = 35) c
riança com reaparecimento do sintoma que motivou a realização do teste, e compar
ação (alergia à proteína do leite de vaca negativa; n = 30) aquela sem sintomas 
após o período de observação do teste. <b>RESULTADOS: </b>A mediana de idade foi
 5 meses (P 25-75% 2-9 meses) no grupo caso e 7 meses (P 25-75% 4-11 meses) no g
rupo comparação (p = 0,05). O teste não confirmou alergia à proteína do leite de
 vaca em 46,8% dos pacientes com sintomas atribuídos à ingestão de leite de vaca
. Reação tardia ocorreu em 77,1% (27/35) dos casos com teste positivo, sendo 18/
27 na primeira, 3/27 na segunda e 6/27 na terceira semana de observação. Encontr
ou-se associação estatística significante entre manifestações cutâneas e teste p
ositivo (p = 0,04), mas não com sintomas digestivos e respiratórios. <b>CONCLUSÃ
O: </b>Os resultados corroboram a necessidade do teste de desencadeamento alimen
tar oral para determinar os pacientes que realmente têm alergia à proteína do le
ite de vaca e se beneficiarão com dieta de exclusão de leite de vaca.#^ddecs^i1#
^tm^lpt^kHipersensibilidade a leite^i1#^tm^lpt^kcondições patológicas^i1#^tm^lpt
^ksinais e sintomas^i1#^tm^lpt^klactente^i1#^tm^lpt^kpré-escolar^i1#^len^a<b>OBJ
ECTIVE: </b>To determine the prevalence of cow's milk protein allergy in childre
n with symptoms attributed to cow's milk intake. <b>METHODS: </b>Sixty-five chil
dren with symptoms attributed to cow's milk intake were studied. Diagnosis was e
stablished after an open oral food challenge test carried out at least 15 days a
fter an elimination diet and absence of symptoms, with a follow-up period of up 
to 4 weeks after the test. The children who remained asymptomatic after this per
iod were considered negative for cow's milk protein allergy (n = 30), while thos
e whose symptoms reappeared were considered positive (n = 35). <b>RESULTS: </b>T
he median age was 5 months (P 25-75% 2-9 months) in the case group and 7 months 
(P 25-75% 4-11 months) in the comparison group (p = 0.05). The test did not conf
irm cow's milk protein allergy in 46.8% of the patients with symptoms attributed
 to cow's milk intake. A delayed reaction occurred in 77.1% (27/35) of the cases
 testing positive, 18/27 in the first week, 3/27 in the second week, and 6/27 in
 the third week of follow-up. A statistically significant association was found 
between cutaneous manifestations and positive test result (p = 0.04). However, t
here was no association with digestive and respiratory symptoms. <b>CONCLUSION: 
</b>Our results confirm the need of an oral food challenge test to determine whi
ch patients really have cow's milk protein allergy and may therefore benefit fro
m a diet free of cow's milk.#^ddecs^i2#^tm^len^kMilk hypersensitivity^i2#^tm^len
^kpathological conditions^i2#^tm^len^ksigns and symptoms^i2#^tm^len^kinfant^i2#^
tm^len^kpreschooler^i2#vancouv#34#20100126#26.01.2010#20100419#19.04.2010#Consel
ho Nacional de Desenvolvimento Científico e Tecnológico#<span style='font-size:1
0.0pt;font-family:Verdana'>475291/2006-9</span>#a07v86n4.htm##
05175000000000721000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000400108038000400112121000300116049000800119
15800030012703000210013003100030015103200020015406500090015601400110016503500100
01760120110001860120076002960100040003720100030004120100042004420100047004840700
11800531070014900649070005500798083157800853085001002431085003902441085003402480
08500300251408500210254408500240256508314810258908500100407008500340408008500360
41140850031041500850019041810850024042001170008042240720003042321120009042351110
01104244114000904255113001104264058006204275060001404337002001304351008008904364
#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#l#4#1#article#1#^mjul./
ago.^a2010#oa#pt#br1.1#1#4.0#gra#tab#07#JPED030#nd#J. Pediatr. (Rio J.)#86#4#201
00800#^f285^l289#0021-7557#Teste de desencadeamento alimentar oral na confirmaçã
o diagnóstica da alergia à proteína do leite de vaca^lpt#Oral food challenge tes
t to confirm the diagnosis of cow's milk allergy^len#^rND^1A01^nMaria das Graças
 Moura^sLins#^rND^nMárcia Raquel^sHorowitz#^rND^1A02^nGiselia Alves Pontes da^sS
ilva#^rND^1A03^nMaria Eugênia Farias Almeida^sMotta#^iA01^1Universidade Federal 
de Pernambuco^2Programa de Pós-Graduação em Saúde da Criança e do Adolescente^cR
ecife^sPE#^iA02^1Universidade Federal de Pernambuco^2Departamento Materno Infant
il^3Programa de Pós-Graduação em Saúde da Criança e do Adolescente^cRecife^sPE#^
iA03^1UFPE^2Departamento Materno Infantil^cRecife^sPE#^lpt^aOBJETIVO: Verificar 
a prevalência de alergia à proteína do leite de vaca em crianças com sintomas at
ribuídos à ingestão do leite de vaca. MÉTODOS: Foram estudadas 65 crianças com s
intomas atribuídos à ingestão do leite de vaca. A definição diagnóstica ocorreu 
após teste de desencadeamento alimentar oral aberto, realizado no mínimo 15 dias
 após dieta de exclusão e ausência de sintomas, com período de observação de até
 4 semanas após o teste. Considerou-se caso (alergia à proteína do leite de vaca
 positiva; n = 35) criança com reaparecimento do sintoma que motivou a realizaçã
o do teste, e comparação (alergia à proteína do leite de vaca negativa; n = 30) 
aquela sem sintomas após o período de observação do teste. RESULTADOS: A mediana
 de idade foi 5 meses (P 25-75 por cento 2-9 meses) no grupo caso e 7 meses (P 2
5-75 por cento 4-11 meses) no grupo comparação (p = 0,05). O teste não confirmou
 alergia à proteína do leite de vaca em 46,8 por cento dos pacientes com sintoma
s atribuídos à ingestão de leite de vaca. Reação tardia ocorreu em 77,1 por cent
o (27/35) dos casos com teste positivo, sendo 18/27 na primeira, 3/27 na segunda
 e 6/27 na terceira semana de observação. Encontrou-se associação estatística si
gnificante entre manifestações cutâneas e teste positivo (p = 0,04), mas não com
 sintomas digestivos e respiratórios. CONCLUSÃO: Os resultados corroboram a nece
ssidade do teste de desencadeamento alimentar oral para determinar os pacientes 
que realmente têm alergia à proteína do leite de vaca e se beneficiarão com diet
a de exclusão de leite de vaca.#^ddecs^i1#^tm^lpt^kHipersensibilidade a leite^i1
#^tm^lpt^kcondições patológicas^i1#^tm^lpt^ksinais e sintomas^i1#^tm^lpt^klacten
te^i1#^tm^lpt^kpré-escolar^i1#^len^aOBJECTIVE: To determine the prevalence of co
w's milk protein allergy in children with symptoms attributed to cow's milk inta
ke. METHODS: Sixty-five children with symptoms attributed to cow's milk intake w
ere studied. Diagnosis was established after an open oral food challenge test ca
rried out at least 15 days after an elimination diet and absence of symptoms, wi
th a follow-up period of up to 4 weeks after the test. The children who remained
 asymptomatic after this period were considered negative for cow's milk protein 
allergy (n = 30), while those whose symptoms reappeared were considered positive
 (n = 35). RESULTS: The median age was 5 months (P 25-75 percent 2-9 months) in 
the case group and 7 months (P 25-75 percent 4-11 months) in the comparison grou
p (p = 0.05). The test did not confirm cow's milk protein allergy in 46.8 percen
t of the patients with symptoms attributed to cow's milk intake. A delayed react
ion occurred in 77.1 percent (27/35) of the cases testing positive, 18/27 in the
 first week, 3/27 in the second week, and 6/27 in the third week of follow-up. A
 statistically significant association was found between cutaneous manifestation
s and positive test result (p = 0.04). However, there was no association with di
gestive and respiratory symptoms. CONCLUSION: Our results confirm the need of an
 oral food challenge test to determine which patients really have cow's milk pro
tein allergy and may therefore benefit from a diet free of cow's milk.#^ddecs^i2
#^tm^len^kMilk hypersensitivity^i2#^tm^len^kpathological conditions^i2#^tm^len^k
signs and symptoms^i2#^tm^len^kinfant^i2#^tm^len^kpreschooler^i2#vancouv#34#2010
0126#26.01.2010#20100419#19.04.2010#Conselho Nacional de Desenvolvimento Científ
ico e Tecnológico#475291/2006-9#a07v86n4.htm#Internet^ihttp://www.scielo.br/scie
lo.php?script=sci_arttext&pid=S0021-75572010000400007##
00323000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704009000074002001300164#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#5#1#article#137#<p align="right"><fon
t size="2" face="Verdana"><b>ARTIGO ORIGINAL</b></font> </p>     ^cY#a07v86n4.ht
m##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#6#2#article#137#<p>&nbsp;</p>     ^cY
#a07v86n4.htm##
00439000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704020600074002001300280#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#7#3#article#137#<p><font size="4" fac
e="Verdana"><b>Teste de desencadeamento alimentar oral na    confirma&ccedil;&at
ilde;o diagn&oacute;stica da alergia &agrave; prote&iacute;na    do leite de vac
a</b></font></p>     ^cY#a07v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#8#4#article#137#<p>&nbsp;</p>     ^cY
#a07v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#9#5#article#137#<p>&nbsp;</p>     ^cY
#a07v86n4.htm##
00486000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704025200075002001300327#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#10#6#article#137#<p><font size="2" fa
ce="Verdana"><b>Maria das Gra&ccedil;as Moura Lins<sup>I</sup>;  M&aacute;rcia R
aquel Horowitz<sup>II</sup>; Giselia Alves Pontes da Silva<sup>III</sup>;  Maria
 Eug&ecirc;nia Farias Almeida Motta<sup>IV</sup></b></font></p>     ^cY#a07v86n4
.htm##
00457000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704022300075002001300298#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#11#7#article#137#<p><font size="2" fa
ce="Verdana"><sup>I</sup>Doutoranda, Programa de P&oacute;s-Gradua&ccedil;&atild
e;o    em Sa&uacute;de da Crian&ccedil;a e do Adolescente, Universidade Federal 
de    Pernambuco (UFPE), Recife, PE    ^cY#a07v86n4.htm##
00337000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704010300075002001300178#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#12#8#article#137#<br>   <sup>II</sup>
Acad&ecirc;mica, Medicina,    UFPE, Recife, PE, Bolsista, PIBIC/FACEPE/CNPq    ^
cY#a07v86n4.htm##
00474000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704024000075002001300315#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#13#9#article#137#<br>   <sup>III</sup
>Doutora, Medicina, Professora    associada e coordenadora, Programa de P&oacute
;s-Gradua&ccedil;&atilde;o em    Sa&uacute;de da Crian&ccedil;a e do Adolescente
, Departamento Materno Infantil,    UFPE, Recife, PE    ^cY#a07v86n4.htm##
00364000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012900076002001300205#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#14#10#article#137#<br>   <sup>IV</sup
>Doutora, Medicina, Professora    adjunta, Departamento Materno Infantil, UFPE, 
Recife, PE</font></p>     ^cY#a07v86n4.htm##
00368000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013300076002001300209#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#15#11#article#137#<p><font size="2" f
ace="Verdana"><a name="topo" id="topo"></a><a href="#correspondence">Correspond&
ecirc;ncia</a></font></p>     ^cY#a07v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#16#12#article#137#<p>&nbsp;</p>     ^
cY#a07v86n4.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#17#13#article#137#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a07v86n4.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006600076002001300142#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#18#14#article#137#<p><font size="2" f
ace="Verdana"><b>RESUMO</b></font></p>     ^cY#a07v86n4.htm##
00476000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024100076002001300317#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#19#15#article#137#<p><font size="2" f
ace="Verdana"> <b>OBJETIVO: </b> Verificar a preval&ecirc;ncia    de alergia &ag
rave; prote&iacute;na do leite de vaca em crian&ccedil;as com    sintomas atribu
&iacute;dos &agrave; ingest&atilde;o do leite de vaca.    ^cY#a07v86n4.htm##
01081000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084600076002001300922#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#20#16#article#137#<br>   <b>M&Eacute;
TODOS: </b> Foram estudadas 65 crian&ccedil;as com sintomas atribu&iacute;dos   
 &agrave; ingest&atilde;o do leite de vaca. A defini&ccedil;&atilde;o diagn&oacu
te;stica    ocorreu ap&oacute;s teste de desencadeamento alimentar oral aberto, 
realizado    no m&iacute;nimo 15 dias ap&oacute;s dieta de exclus&atilde;o e aus
&ecirc;ncia    de sintomas, com per&iacute;odo de observa&ccedil;&atilde;o de at
&eacute; 4    semanas ap&oacute;s o teste. Considerou-se caso (alergia &agrave; 
prote&iacute;na    do leite de vaca positiva; n = 35) crian&ccedil;a com reapare
cimento do sintoma    que motivou a realiza&ccedil;&atilde;o do teste, e compara
&ccedil;&atilde;o    (alergia &agrave; prote&iacute;na do leite de vaca negativa
; n = 30) aquela    sem sintomas ap&oacute;s o per&iacute;odo de observa&ccedil;
&atilde;o do teste.    ^cY#a07v86n4.htm##
01002000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076700076002001300843#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#21#17#article#137#<br>   <b>RESULTADO
S: </b>A mediana de idade foi 5 meses (P 25-75% 2-9 meses) no grupo    caso e 7 
meses (P 25-75% 4-11 meses) no grupo compara&ccedil;&atilde;o (p =    0,05). O t
este n&atilde;o confirmou alergia &agrave; prote&iacute;na do leite    de vaca e
m 46,8% dos pacientes com sintomas atribu&iacute;dos &agrave; ingest&atilde;o   
 de leite de vaca. Rea&ccedil;&atilde;o tardia ocorreu em 77,1% (27/35) dos caso
s    com teste positivo, sendo 18/27 na primeira, 3/27 na segunda e 6/27 na terc
eira    semana de observa&ccedil;&atilde;o. Encontrou-se associa&ccedil;&atilde;
o estat&iacute;stica    significante entre manifesta&ccedil;&otilde;es cut&acirc
;neas e teste positivo    (p = 0,04), mas n&atilde;o com sintomas digestivos e r
espirat&oacute;rios.    ^cY#a07v86n4.htm##
00553000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031800076002001300394#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#22#18#article#137#<br>   <b>CONCLUS&A
tilde;O: </b> Os resultados corroboram a necessidade do teste de    desencadeame
nto alimentar oral para determinar os pacientes que realmente t&ecirc;m    alerg
ia &agrave; prote&iacute;na do leite de vaca e se beneficiar&atilde;o com    die
ta de exclus&atilde;o de leite de vaca.</font></p>     ^cY#a07v86n4.htm##
00460000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022500076002001300301#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#23#19#article#137#<p><font size="2" f
ace="Verdana"><b>Palavras-chave: </b> Hipersensibilidade a    leite, condi&ccedi
l;&otilde;es patol&oacute;gicas, sinais e sintomas, lactente,    pr&eacute;-esco
lar.</font></p> <hr size="1" noshade>     ^cY#a07v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#24#20#article#137#<p>&nbsp;</p>     ^
cY#a07v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#25#21#article#137#<p>&nbsp;</p>     ^
cY#a07v86n4.htm##
00319000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008400076002001300160#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#26#22#article#137#<p><font size="3" f
ace="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#a07v86n4.htm##
00897000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704066200076002001300738#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#27#23#article#137#<p><font face="Verd
ana" size="2">A preval&ecirc;ncia da alergia &agrave; prote&iacute;na    do leit
e de vaca (APLV) &eacute; descrita entre 2 e 8%<SUP>1,2</sup>. Os resultados    
s&atilde;o conflitantes e de dif&iacute;cil compara&ccedil;&atilde;o, devido    
aos diversos crit&eacute;rios diagn&oacute;sticos e desenhos de estudo utilizado
s,    sendo maiores as preval&ecirc;ncias baseadas exclusivamente nas manifesta&
ccedil;&otilde;es    cl&iacute;nicas (em geral, percep&ccedil;&atilde;o dos pais
) do que quando se    utilizam instrumentos diagn&oacute;sticos mais objetivos, 
como o teste de desencadeamento    alimentar oral<SUP>3-5</sup></font></p>     ^
cY#a07v86n4.htm##
00748000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051300076002001300589#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#28#24#article#137#<p><font face="Verd
ana" size="2">A hist&oacute;ria natural da APLV difere da observada    para outr
as prote&iacute;nas alimentares, que ocorrem em fases mais tardias    da vida, p
or ser a primeira prote&iacute;na estranha introduzida na alimenta&ccedil;&atild
e;o    de um organismo que ainda est&aacute; em matura&ccedil;&atilde;o do mecan
ismo    de toler&acirc;ncia oral a prote&iacute;nas heter&oacute;logas, portanto
, mais    propenso ao desenvolvimento de alergias alimentares<SUP>6</sup>.</font
></p>     ^cY#a07v86n4.htm##
01185000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704095000076002001301026#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#29#25#article#137#<p><font face="Verd
ana" size="2">Assim, &eacute; preciso considerar a baixa especificidade    dos s
intomas no diagn&oacute;stico de APLV, pois tamb&eacute;m podem indicar    outra
s doen&ccedil;as, como doen&ccedil;a do refluxo gastroesof&aacute;gico,    diarr
eia infecciosa, altera&ccedil;&otilde;es anat&ocirc;micas, constipa&ccedil;&atil
de;o    org&acirc;nica, etc.<SUP>6</sup>. Ademais, na perspectiva da medicina ev
olutiva,    o consumo precoce de f&oacute;rmula l&aacute;ctea impede o contato d
o tubo digest&oacute;rio    com os agentes bioativos do leite materno, propician
do o desenvolvimento de    sintomas<SUP>7</sup>. Esses agentes contribuem para a
 matura&ccedil;&atilde;o    imunol&oacute;gica e integridade da mucosa intestina
l (dificultando a ocorr&ecirc;ncia    de APLV) e a matura&ccedil;&atilde;o da fu
n&ccedil;&atilde;o motora (dificultando    o aparecimento de sintomas por imatur
idade funcional)<SUP>7,8</sup>.</font></p>     ^cY#a07v86n4.htm##
00911000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067600076002001300752#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#30#26#article#137#<p><font face="Verd
ana" size="2">Atualmente, observa-se dificuldade no diagn&oacute;stico    da APL
V, com incid&ecirc;ncia reduzida ou elevada, resultando em preju&iacute;zo    pa
ra a nutri&ccedil;&atilde;o da crian&ccedil;a e para a qualidade de vida da    f
am&iacute;lia, especialmente nos diagn&oacute;sticos err&ocirc;neos<SUP>9</sup>.
    Portanto, s&atilde;o necess&aacute;rios estudos que utilizem crit&eacute;rio
s    mais apropriados e possam auxiliar o diagn&oacute;stico da APLV. Este estud
o    teve o objetivo de verificar a preval&ecirc;ncia de APLV em crian&ccedil;as
    com sintomas atribu&iacute;dos &agrave; ingest&atilde;o do leite de vaca.</f
ont></p>     ^cY#a07v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#31#27#article#137#<p>&nbsp;</p>     ^
cY#a07v86n4.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007400076002001300150#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#32#28#article#137#<p><font size="3" f
ace="Verdana"><b>M&eacute;todos</b></font></p>     ^cY#a07v86n4.htm##
01988000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704175300076002001301829#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#33#29#article#137#<p><font face="Verd
ana" size="2">Foram convidados a participar da pesquisa pais    de 66 crian&cced
il;as, referenciadas ao ambulat&oacute;rio de Gastroenterologia    Pedi&aacute;t
rica do Hospital das Cl&iacute;nicas (HC),&nbsp;Universidade Federal    de Perna
mbuco (UFPE), Recife (PE), com sintomas adversos relacionados &agrave;    ingest
&atilde;o do leite de vaca pela crian&ccedil;a, ou pela m&atilde;e em    amament
a&ccedil;&atilde;o ainda consumindo leite de vaca e derivados. Os sintomas    er
am cut&acirc;neos (dermatite at&oacute;pica e urtic&aacute;ria), respirat&oacute
;rios    (tosse e dispneia, rinites) e digest&oacute;rios (regurgita&ccedil;&ati
lde;o,    v&ocirc;mitos, sangramento retal, constipa&ccedil;&atilde;o, diarreia 
e proctite).    Constipa&ccedil;&atilde;o foi considerada quando a crian&ccedil;
a defecava duas    ou menos vezes por semana, com fezes endurecidas e dor &agrav
e; defeca&ccedil;&atilde;o.    O sangramento retal foi referido pelos pais como 
presen&ccedil;a de sangue em    qualquer quantidade, antes ou depois da defeca&c
cedil;&atilde;o ou junto com    as fezes. Proctite foi considerada ao exame f&ia
cute;sico pela presen&ccedil;a    de edema e eritema, com ou sem fissura, na reg
i&atilde;o perianal, ainda consumindo    leite de vaca e seus derivados. O mesmo
 paciente poderia apresentar um ou mais    sintomas gastrointestinais ou associa
&ccedil;&atilde;o destes com sintomas cut&acirc;neos    ou respirat&oacute;rios.
 Foram exclu&iacute;dos pacientes com outras doen&ccedil;as    do trato digest&o
acute;rio, alergia a m&uacute;ltiplas prote&iacute;nas, sintomas    respirat&oac
ute;rios ou dermatite at&oacute;pica isolados, em uso de antial&eacute;rgicos   
 e prematuros de muito baixo peso.</font></p>     ^cY#a07v86n4.htm##
00808000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704057300076002001300649#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#34#30#article#137#<p><font size="2" f
ace="Verdana">Ap&oacute;s assinatura do Termo de Consentimento    Livre e Esclar
ecido, foi aplicado um formul&aacute;rio, estruturado com dados    da hist&oacut
e;ria individual, para avalia&ccedil;&atilde;o de sintomas e sua    rela&ccedil;
&atilde;o com a exposi&ccedil;&atilde;o ao leite de vaca, registro    de dados d
o exame f&iacute;sico, incluindo avalia&ccedil;&atilde;o do estado    nutriciona
l e imunoglobulina E (IgE) total e espec&iacute;ficas (anticase&iacute;na,    an
ti &#946;-lactoglobulina e anti &#945;-lactoalbumina).</font></p>     ^cY#a07v86
n4.htm##
01079000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084400076002001300920#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#35#31#article#137#<p><font face="Verd
ana" size="2">O estado nutricional foi avaliado com base na    idade, peso e est
atura, conforme recomendado por Gibson<SUP>10</sup>. O peso    foi mensurado em 
uma balan&ccedil;a digital (Filizola<sup>TM</sup>) com a    crian&ccedil;a despi
da. O comprimento ou altura foi aferido com estadi&ocirc;metro    de beb&ecirc; 
nos menores de 2 anos e de parede (Tonelli<sup>&reg;</sup>) com    a crian&ccedi
l;a descal&ccedil;a, com coluna e membros inferiores alinhados.    Os &iacute;nd
ices antropom&eacute;tricos peso/idade e altura/idade foram calculados    pelo p
rograma Epi-Info vers&atilde;o 3.3.2, com base nos valores de refer&ecirc;ncia  
  do Centers for Disease Control and Prevention (CDC) 2000<SUP>11</sup>. O valor
    do ponto de corte para baixo peso e baixa estatura foi o percentil menor de 
   5.</font></p>     ^cY#a07v86n4.htm##
00935000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070000076002001300776#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#36#32#article#137#<p><font face="Verd
ana" size="2">O n&iacute;vel de IgE total e espec&iacute;ficas    foi determinad
o pelo 3gAllergy<sup>TM</sup> Specific IgE Universal Kit e    Immulite<sup>&reg;
</sup> 2000 3g, um imunoensaio por electroquimioluminesc&ecirc;ncia    com dois 
passos reacionais baseados numa tecnologia de fase l&iacute;quida e    em esfera
s revestidas. Considerou-se elevada a IgE total com n&iacute;veis acima    dos p
ontos de corte indicados pelas idades (rec&eacute;m-nascidos at&eacute;    1 m&e
circ;s: 6,1 UI/mL; 1-2 meses: at&eacute; 15 UI/mL; 3 meses a 5 anos: at&eacute; 
   60 UI/mL) e, para IgE espec&iacute;ficas, o valor igual ou acima da classe II
I    (3,5-17,5 KU/L).</font></p>     ^cY#a07v86n4.htm##
02734000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704249900076002001302575#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#37#33#article#137#<p><font face="Verd
ana" size="2">O teste de desencadeamento alimentar oral aberto    foi realizado 
para definir o diagn&oacute;stico de APLV: crian&ccedil;as e m&atilde;es,    qua
ndo ainda amamentando, foram orientadas para seguir uma dieta de exclus&atilde;o
    do leite de vaca e derivados durante pelo menos 2 semanas, utilizando f&oacu
te;rmula    de prote&iacute;na isolada de soja. Todos os pacientes realizaram a 
dieta de    exclus&atilde;o pr&eacute;-teste adequadamente. Havendo resolu&ccedi
l;&atilde;o    dos sintomas, as crian&ccedil;as eram admitidas na enfermaria de 
Cl&iacute;nica    Pedi&aacute;trica do HC/UFPE, por 24 horas, para realiza&ccedi
l;&atilde;o do    teste de desencadeamento alimentar oral aberto modificado de I
solauri &amp;    Hill<SUP>12</sup>, Sampson<SUP>13</sup> e Chapman<SUP>14</sup>,
 da seguinte    forma: 1) tempo 0: aplicou-se cerca de 2 mL de leite de vaca na 
pele do antebra&ccedil;o    esquerdo; 2) tempo 15': aplicou-se cerca de 2 mL de 
leite de vaca na regi&atilde;o    perioral; 3) a partir do tempo 30', a cada 15 
minutos, ofertou-se o leite de    vaca gradativamente, em por&ccedil;&otilde;es 
de 1, 4, 10, 20, 20, 20 e 25%    do volume total calculado (0,5 g de prote&iacut
e;na do leite de vaca sem lactose/kg),    at&eacute; o aparecimento de sintomas.
 O teste de desencadeamento foi suspenso    sempre que o sintoma apresentado pel
o paciente, referido pela fam&iacute;lia,    antes do teste de desencadeamento, 
era reproduzido, incluindo-se o paciente    no grupo APLV. Se os sintomas n&atil
de;o apareciam durante a hospitaliza&ccedil;&atilde;o,    o paciente continuava 
a consumi-lo na quantidade habitual, pr&eacute;-teste,    duas a tr&ecirc;s veze
s por dia. Foi agendada uma visita semanal de retorno    ao ambulat&oacute;rio p
ara averiguar a presen&ccedil;a de sintomas, at&eacute;    4 semanas consecutiva
s. O paciente que desenvolvia o mesmo sintoma relatado    antes do teste de dese
ncadeamento durante o per&iacute;odo de observa&ccedil;&atilde;o    foi inclu&ia
cute;do no grupo APLV ao final de 4 semanas de observa&ccedil;&atilde;o;    e o 
paciente que n&atilde;o apresentava sintomas foi inclu&iacute;do no grupo    sem
 APLV. N&atilde;o houve aparecimento de sintomas diferentes dos apresentados    
antes do teste. Estes foram contrarreferenciados para continuar a investiga&cced
il;&atilde;o,    e os primeiros foram mantidos em acompanhamento no ambulat&oacu
te;rio de Gastroenterologia    Pedi&aacute;trica do HC/UFPE.</font></p>     ^cY#
a07v86n4.htm##
00459000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022400076002001300300#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#38#34#article#137#<p><font face="Verd
ana" size="2">Este estudo foi aprovado pelo Comit&ecirc; de    &Eacute;tica em P
esquisa com Seres Humanos do Centro de Ci&ecirc;ncias da Sa&uacute;de    (CEP/CC
S) da UFPE sob nº 197/06.</font></p>     ^cY#a07v86n4.htm##
00996000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076100076002001300837#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#39#35#article#137#<p><font face="Verd
ana" size="2">As informa&ccedil;&otilde;es obtidas dos formul&aacute;rios    e d
os exames complementares de 65 pacientes foram armazenadas (codificando-se    as
 vari&aacute;veis categ&oacute;ricas) em arquivo de dados elaborado no programa 
   de estat&iacute;stica Epi-Info, vers&atilde;o 3.3.2 for Windows, no qual foi 
   realizada a an&aacute;lise estat&iacute;stica. As idades entre os grupos de  
  compara&ccedil;&atilde;o foram sumarizadas como medianas e comparadas pelo tes
te    de Mann-Whitney. As diferen&ccedil;as entre as vari&aacute;veis categ&oacu
te;ricas    foram determinadas pelo teste de qui-quadrado. Os testes estat&iacut
e;sticos    foram considerados significantes quando o valor de p <u>&lt;</u> 0,0
5.</font></p>     ^cY#a07v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#40#36#article#137#<p>&nbsp;</p>     ^
cY#a07v86n4.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007000076002001300146#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#41#37#article#137#<p><font size="3" f
ace="Verdana"><b>Resultados</b></font></p>     ^cY#a07v86n4.htm##
01097000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704086200076002001300938#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#42#38#article#137#<p><font face="Verd
ana" size="2">&Agrave; admiss&atilde;o no estudo, a idade dos    pacientes foi d
e 5 meses (P 25-75% 2-9 meses) no grupo APLV e de 7 meses (P    25-75% 4-11 mese
s) no grupo sem APLV (p = 0,05). Cerca de 50% dos pacientes    com sintomas atri
bu&iacute;dos &agrave; ingest&atilde;o de leite de vaca n&atilde;o    confirmara
m APLV no teste de desencadeamento alimentar oral. Os pacientes relatavam    in&
uacute;meros sintomas no momento da inclus&atilde;o no estudo, na maioria    dos
 casos; por&eacute;m, no teste de desencadeamento alimentar oral, 24/35 paciente
s    positivaram com apenas um sintoma, e 11/35 positivaram com dois sintomas. R
ea&ccedil;&atilde;o    tardia ocorreu em 77,1% (27/35) dos casos com teste posit
ivo, sendo 18/27 na    primeira, 3/27 na segunda e 6/27 na terceira semana de ob
serva&ccedil;&atilde;o.</font></p>     ^cY#a07v86n4.htm##
00719000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048400076002001300560#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#43#39#article#137#<p><font face="Verd
ana" size="2">Conforme se observa na <a href=/img/revistas/jped/v86n4/4a07t1.gif
>Tabela    1</a>, encontrou-se associa&ccedil;&atilde;o estatisticamente signifi
cante entre    manifesta&ccedil;&otilde;es cut&acirc;neas e teste de desencadeam
ento alimentar    oral positivo. A presen&ccedil;a de sintomas digestivos e resp
irat&oacute;rios    n&atilde;o se associou estatisticamente com a confirma&ccedi
l;&atilde;o do diagn&oacute;stico    de APLV.</font></p>     ^cY#a07v86n4.htm##
00923000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068800076002001300764#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#44#40#article#137#<p><font size="2" f
ace="Verdana">A IgE total foi elevada em 17/35 pacientes (33,8%)    do grupo APL
V e em 5/30 (16,7%) pacientes do grupo sem APLV, mas as IgE espec&iacute;ficas  
  foram elevadas apenas nos pacientes do grupo APLV: 3/35 (8,6%) para case&iacut
e;na,    3/35 (8,6%) para &#945;-lactoalbumina e 5/35 (14,2%) para &#946;-lactog
lobulina.    Destes, dois apresentavam v&ocirc;mitos e baixo ganho de peso assoc
iados &agrave;    urtic&aacute;ria, com sintomas vagais (palidez e sudorese); e 
tr&ecirc;s apresentavam    apenas urtic&aacute;ria. A <a href=#720f1 >Figura 1</
a> descreve o n&uacute;mero    de pacientes com sinais e sintomas digest&oacute;
rios nos dois grupos.    ^cY#a07v86n4.htm##
00268000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003300076002001300109#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#45#41#article#137#<BR>   &nbsp;</font
></p>     ^cY#a07v86n4.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003400076002001300110#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#46#42#article#137#<p><a name=720f1></
a></p>     ^cY#a07v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#47#43#article#137#<p>&nbsp;</p>     ^
cY#a07v86n4.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007800076002001300154#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#48#44#article#137#<p align="center"><
img src="/img/revistas/jped/v86n4/4a07f1.gif"></p>     ^cY#a07v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#49#45#article#137#<p>&nbsp;</p>     ^
cY#a07v86n4.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#50#46#article#137#<p><font size="3" f
ace="Verdana"><b>Discuss&atilde;o</b></font></p>     ^cY#a07v86n4.htm##
01407000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704117200076002001301248#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#51#47#article#137#<p><font face="Verd
ana" size="2">Em quase metade (46,8%) das crian&ccedil;as com    sintomas atribu
&iacute;dos &agrave; ingest&atilde;o do leite de vaca, a APLV    n&atilde;o foi 
confirmada pelo teste de desencadeamento alimentar oral. Os pacientes    relatav
am in&uacute;meros sintomas no momento da inclus&atilde;o no estudo;    por&eacu
te;m, no teste de desencadeamento alimentar oral, 24/35 pacientes positivaram   
 com apenas um sintoma, e 11/35 positivaram com dois sintomas, confirmando que  
  as queixas relacionadas &agrave; ingest&atilde;o de leite de vaca s&atilde;o  
  excessivas. Esse resultado evidencia que, mesmo na presen&ccedil;a de uma hist
&oacute;ria    cl&iacute;nica sugestiva de APLV, &eacute; preciso realizar inves
tiga&ccedil;&atilde;o    complementar com o teste de desencadeamento alimentar o
ral para confirmar o    diagn&oacute;stico<SUP>6,15</sup>. A predomin&acirc;ncia
 da APLV nos pacientes    estudados ocorreu naqueles de menor idade, e a distrib
ui&ccedil;&atilde;o de    frequ&ecirc;ncia dos sintomas gastrointestinais, cut&a
circ;neos e respirat&oacute;rios    foi semelhante &agrave; encontrada por Host<
SUP>16</sup>.</font></p>     ^cY#a07v86n4.htm##
01466000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704123100076002001301307#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#52#48#article#137#<p><font face="Verd
ana" size="2">A APLV ocorre no organismo que n&atilde;o desenvolveu    toler&aci
rc;ncia oral. Fatores envolvidos no estabelecimento da toler&acirc;ncia    oral 
s&atilde;o gen&eacute;tica, microbiota intestinal e idade do paciente,    al&eac
ute;m de fatores associados aos ant&iacute;genos<SUP>17</sup>. No in&iacute;cio 
   da vida, a exposi&ccedil;&atilde;o a ant&iacute;genos alimentares apresentado
s    ao sistema imune ativa os linf&oacute;citos T reguladores, resultando em su
press&atilde;o    da resposta imune e indu&ccedil;&atilde;o da toler&acirc;ncia 
oral<SUP>18</sup>.    Esse processo ocorre naturalmente na maioria das crian&cce
dil;as em aleitamento    materno exclusivo, expondo sua mucosa intestinal &agrav
e;s baixas doses de ant&iacute;genos    alimentares presentes no leite materno, 
que induzem supress&atilde;o ativa de    rea&ccedil;&otilde;es imunes pela secre
&ccedil;&atilde;o mucosa de fator de    crescimento tecidual beta (<i>transformi
ng growth factor beta</i>, TGF-beta)<SUP>18</sup>.    No entanto, a permeabilida
de intestinal aumentada possibilita o desenvolvimento    de APLV, sobretudo quan
do h&aacute; a oferta de prote&iacute;na heter&oacute;loga<SUP>19</sup>.</font><
/p>     ^cY#a07v86n4.htm##
00888000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704065300076002001300729#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#53#49#article#137#<p><font face="Verd
ana" size="2">A crian&ccedil;a em aleitamento artificial, al&eacute;m    de esta
r em contato cont&iacute;nuo com prote&iacute;nas estranhas numa fase    de perm
eabilidade intestinal vulner&aacute;vel, perde o benef&iacute;cio dos    agentes
 bioativos do leite materno para prote&ccedil;&atilde;o contra APLV<SUP>7</sup>.
    O TGF-beta, citocina presente no leite materno, participa da produ&ccedil;&a
tilde;o    de imunoglobulina A (IgA) pela mucosa intestinal e da supress&atilde;
o celular    na resposta imune; n&iacute;veis reduzidos propiciam sensibiliza&cc
edil;&atilde;o    al&eacute;rgica e APLV<SUP>20</sup>.</font></p>     ^cY#a07v86
n4.htm##
00940000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070500076002001300781#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#54#50#article#137#<p><font face="Verd
ana" size="2">A microbiota intestinal adquirida no per&iacute;odo    p&oacute;s-
natal tamb&eacute;m &eacute; necess&aacute;ria para o desenvolvimento    de tole
r&acirc;ncia oral e express&atilde;o e fun&ccedil;&atilde;o dos linf&oacute;cito
s    T reguladores<SUP>21</sup>. O aleitamento materno exclusivo &eacute; respon
s&aacute;vel    pela coloniza&ccedil;&atilde;o bacteriana pelo g&ecirc;nero bifi
dobact&eacute;ria,    que participa ativamente na toler&acirc;ncia oral<SUP>22</
sup>. Essas bact&eacute;rias    est&atilde;o reduzidas nas crian&ccedil;as que u
sam f&oacute;rmulas l&aacute;cteas    artificiais, favorecendo a ocorr&ecirc;nci
a de APLV<SUP>22,23</sup>.</font></p>     ^cY#a07v86n4.htm##
02573000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704233800076002001302414#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#55#51#article#137#<p><font face="Verd
ana" size="2">Cerca de 50% dos pacientes com sintomas atribu&iacute;dos    &agra
ve; ingest&atilde;o de leite de vaca n&atilde;o confirmaram APLV no teste    de 
desencadeamento alimentar oral. Isso chama a aten&ccedil;&atilde;o para o    fat
o de que a presen&ccedil;a de sintomas n&atilde;o implica, invariavelmente,    a
 presen&ccedil;a de doen&ccedil;a, mas pode indicar um processo de matura&ccedil
;&atilde;o    funcional em evolu&ccedil;&atilde;o, cabendo ao m&eacute;dico aval
iar a interpreta&ccedil;&atilde;o    dos pais e diferenciar entre sa&uacute;de e
 doen&ccedil;a<SUP>7,8,24</sup>.    &Eacute; natural que os pais associem a pres
en&ccedil;a de sintomas na crian&ccedil;a    de baixa idade &agrave; ingest&atil
de;o de leite de vaca, pois, na maioria dos    casos, &eacute; o &uacute;nico ou
 o principal alimento consumido em curtos intervalos    de tempo. Sintomas podem
 depender do in&iacute;cio precoce de f&oacute;rmula    l&aacute;ctea, que dific
ulta a matura&ccedil;&atilde;o da fun&ccedil;&atilde;o    motora gastrointestina
l decorrente da aus&ecirc;ncia do est&iacute;mulo dos    agentes bioativos do le
ite materno no organismo<SUP>7</sup>. Dessa forma, sintomas    no lactente saud&
aacute;vel possivelmente n&atilde;o representam doen&ccedil;a    na maioria das 
situa&ccedil;&otilde;es e podem indicar um problema de desenvolvimento    funcio
nal imaturo, aliado ao consumo de f&oacute;rmula l&aacute;ctea. Portanto,    reg
urgita&ccedil;&atilde;o pode decorrer do aumento do tempo de esvaziamento    g&a
acute;strico e maior intervalo entre as mamadas propiciado pelo uso de f&oacute;
rmulas    l&aacute;cteas; diarreia pode resultar de sobrecarga de solutos no pre
paro do    leite artificial ou alimenta&ccedil;&atilde;o excessiva a curtos inte
rvalos    de tempo; dificuldade na defeca&ccedil;&atilde;o pode indicar incoorde
na&ccedil;&atilde;o    entre press&atilde;o intra-abdominal e relaxamento do ass
oalho p&eacute;lvico    nos primeiros meses de vida; constipa&ccedil;&atilde;o p
ode iniciar com a mudan&ccedil;a    de leite materno para f&oacute;rmula l&aacut
e;ctea ou introdu&ccedil;&atilde;o    de s&oacute;lidos ou engrossantes do leite
; e nenhuma dessas situa&ccedil;&otilde;es    representa doen&ccedil;a, mas imat
uridade org&acirc;nica e/ou erro alimentar<SUP>24-27</sup>.</font></p>     ^cY#a
07v86n4.htm##
01543000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704130800076002001301384#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#56#52#article#137#<p><font face="Verd
ana" size="2">Na pr&aacute;tica, os exames laboratoriais (teste    cut&acirc;neo
, dosagem de IgE) identificam apenas sensibiliza&ccedil;&atilde;o    pela positi
vidade da IgE e poss&iacute;vel rea&ccedil;&atilde;o imediata, mediada    por Ig
E, sendo negativos nas crian&ccedil;as com sintomas gastrointestinais    e prov&
aacute;vel rea&ccedil;&atilde;o tardia, mediada por c&eacute;lulas. O    n&iacut
e;vel de IgE est&aacute; associado com persist&ecirc;ncia &agrave; APLV,    nota
damente no mecanismo IgE mediado, e seguimento do paciente na marcha at&oacute;p
ica,    com dura&ccedil;&atilde;o prolongada das manifesta&ccedil;&otilde;es cl&
iacute;nicas    da APLV e aparecimento de outras manifesta&ccedil;&otilde;es al&
eacute;rgicas    futuras<SUP>28,29</sup>. A aus&ecirc;ncia de sintomas no curto 
prazo, ainda    nos meses iniciais, indica maior probabilidade de desenvolviment
o de toler&acirc;ncia    oral cl&iacute;nica, mais comum nos mecanismos mediados
 por c&eacute;lulas<SUP>30</sup>.    Portanto, n&atilde;o se pode descartar que 
pacientes sintom&aacute;ticos, de    fato, apresentem APLV, por&eacute;m de curt
a dura&ccedil;&atilde;o, enquanto    a maturidade do sistema imune e a toler&aci
rc;ncia oral n&atilde;o s&atilde;o    alcan&ccedil;adas<SUP>28</sup>.</font></p>
     ^cY#a07v86n4.htm##
02015000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704178000076002001301856#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#57#53#article#137#<p><font face="Verd
ana" size="2">No per&iacute;odo de dieta de exclus&atilde;o    de leite de vaca,
 os pacientes que n&atilde;o estavam em aleitamento materno    exclusivo fizeram
 uso de&nbsp; f&oacute;rmula de prote&iacute;na isolada de    soja como substitu
to nos 15 dias que precederam a realiza&ccedil;&atilde;o do    teste de desencad
eamento alimentar oral. Apesar de a literatura n&atilde;o recomendar    o uso de
sse tipo de f&oacute;rmula para crian&ccedil;as menores de 6 meses com    manife
sta&ccedil;&otilde;es cl&iacute;nicas gastrointestinais, pelo risco de    o paci
ente tamb&eacute;m apresentar alergia &agrave; prote&iacute;na da soja    (10 a 
14% dos casos), as situa&ccedil;&otilde;es cl&iacute;nicas referidas cursam    c
om elevado grau de permeabilidade intestinal e gravidade de apresenta&ccedil;&at
ilde;o    cl&iacute;nica, comprometimento nutricional intenso (doen&ccedil;a gas
trointestinal    eosinof&iacute;lica, s&iacute;ndrome da enterocolite induzida p
or prote&iacute;na    alimentar, proctocolite al&eacute;rgica), o que n&atilde;o
 foi o caso de nossos    pacientes, que apresentavam sintomas isolados, sem inse
r&ccedil;&atilde;o em    nenhuma dessas situa&ccedil;&otilde;es cl&iacute;nicas 
espec&iacute;ficas<SUP>6,31-33</sup>.    Conforme consta no Consenso Brasileiro 
de Alergia Alimentar, respaldado por    sociedades m&eacute;dicas internacionais
, essa formula&ccedil;&atilde;o pode    ser utilizada na condu&ccedil;&atilde;o 
de formas cl&iacute;nicas leves, mediadas    por c&eacute;lulas<SUP>34</sup>. O 
seguimento dos pacientes com teste de desencadeamento    alimentar oral positivo
 que participaram deste estudo demonstrou resolu&ccedil;&atilde;o    de sintomas
, com evolu&ccedil;&atilde;o cl&iacute;nica favor&aacute;vel.</font></p>     ^cY
#a07v86n4.htm##
00725000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049000076002001300566#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#58#54#article#137#<p><font face="Verd
ana" size="2">O teste de desencadeamento alimentar oral continua    sendo a melh
or forma para demonstrar rela&ccedil;&atilde;o causal entre ant&iacute;genos    
alimentares e sintomas. Os resultados deste estudo corroboram a necessidade    d
o teste de desencadeamento alimentar oral para determinar, com menor margem    d
e erro, os pacientes que realmente t&ecirc;m APLV e que ser&atilde;o beneficiado
s    com dieta de exclus&atilde;o de leite de vaca.</font></p>     ^cY#a07v86n4.
htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#59#55#article#137#<p>&nbsp;</p>     ^
cY#a07v86n4.htm##
00312000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007700076002001300153#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#60#56#article#137#<p><font size="3" f
ace="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#a07v86n4.htm##
00384000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704013500078002001300213#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#61#57#article#137#1#<p><f
ont size="2" face="Verdana">1. Host A. Frequency of cow's milk allergy in    chi
ldhood. Ann Allergy Immunol. 2002;89:33-7.    ^cY#a07v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#62#58#article#137#</font></p>     ^cY
#a07v86n4.htm##
00414000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704016500078002001300243#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#63#59#article#137#2#<p><f
ont size="2" face="Verdana">2. Sicherer SH, Sampson HA. Food allergy: recent    
advances in pathophysiology and treatment. Annu Rev Med. 2009;60:261-77.    ^cY#
a07v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#64#60#article#137#</font></p>     ^cY
#a07v86n4.htm##
00460000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021100078002001300289#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#65#61#article#137#3#<p><f
ont size="2" face="Verdana">3. Rona RJ, Keil T, Summers C, Gislason D, Zuidmeer 
   L, Sodergren E, et al. The prevalence of food allergy: a meta-analysis. J All
ergy    Clin Immunol. 2007;120:638-46.    ^cY#a07v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#66#62#article#137# </font></p>     ^c
Y#a07v86n4.htm##
00514000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026500078002001300343#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#67#63#article#137#4#<p><f
ont size="2" face="Verdana">4. Aardoom HA, Hirasing RA, Rona RJ, Sanavro    FL, 
van den Heuvel EW, Leeuwenburg J. Food intolerance (food hypersensitivity)    an
d chronic complaints in children: the parents' perception. Eur J Pediatr.    199
7;156:110-2.    ^cY#a07v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#68#64#article#137#</font></p>     ^cY
#a07v86n4.htm##
00480000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023100078002001300309#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#69#65#article#137#5#<p><f
ont size="2" face="Verdana">5. Zuberbier T, Edenharter G, Worm M, Ehlers    I, R
eimann S, Hantke T, et al. Prevalence of adverse reactions to food in Germany   
 - a population study. Allergy. 2004;59:338-45</font></p>     ^cY#a07v86n4.htm##
00637000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704038800078002001300466#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#70#66#article#137#6#<p><f
ont size="2" face="Verdana">6. Boyce JA, Arshad SH, Assa'ad A, Bahna SL,    Beck
 LA, Burks AW, et al. Guidelines for the diagnosis and management of food    all
ergy. 2009. p. 119. <a href="http://www3.niaid.nih.gov/topics/foodAllergy/clinic
al/Who/comments.htm" target="_blank">http://www3.niaid.nih.gov/topics/foodAllerg
y/clinical/Who/comments.htm</a>.    Acesso: 30/03/2010.    ^cY#a07v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#71#67#article#137#</font></p>     ^cY
#a07v86n4.htm##
00461000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021200078002001300290#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#72#68#article#137#7#<p><f
ont size="2" face="Verdana">7. Goldman AS. Modulation of the gastrointestinal   
 tract of infants by human milk. Interfaces and interactions. An evolutionary   
 perspective. J Nutr. 2000;130:S426-31.    ^cY#a07v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#73#69#article#137#</font></p>     ^cY
#a07v86n4.htm##
00535000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028600078002001300364#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#74#70#article#137#8#<p><f
ont size="2" face="Verdana">8. Udall JN, Colony P, Fritze L, Pang K, Trier    JS
, Walker WA. Development of gastrointestinal mucosal barrier. II. The effect    
of natural versus artificial feeding on intestinal permeability to macromolecule
s.    Pediatr Res. 1981;15:245-9.    ^cY#a07v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#75#71#article#137#</font></p>     ^cY
#a07v86n4.htm##
00493000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024400078002001300322#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#76#72#article#137#9#<p><f
ont size="2" face="Verdana">9. Gupta RS, Kim JS, Barnathan JA, Amsden LB,    Tum
mala LS, Holl JL. Food allergy knowledge, attitudes and beliefs: focus groups   
 of parents, physicians and the general public. BMC Pediatr. 2008;8:36.    ^cY#a
07v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#77#73#article#137#</font></p>     ^cY
#a07v86n4.htm##
00447000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704019700079002001300276#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#78#74#article#137#10#<p><
font size="2" face="Verdana">10. Gibson RS. Evauation of anthropometric indices.
    In: Gibson RS. Principles of nutritional assessment. New York: Oxford Univer
sity;    1990. p. 248-61.    ^cY#a07v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#79#75#article#137#</font></p>     ^cY
#a07v86n4.htm##
00497000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704024700079002001300326#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#80#76#article#137#11#<p><
font size="2" face="Verdana">11. Centers for Disease Control and Prevention    (
CDC-US). 2000 CDC growth charts: United States. <A href=http://cdc.gov/growthcha
rts target="_blank">http://cdc.gov/growthcharts</A>.    Acesso: 18/01/2002.    ^
cY#a07v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#81#77#article#137#</font></p>     ^cY
#a07v86n4.htm##
00465000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704021500079002001300294#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#82#78#article#137#12#<p><
font size="2" face="Verdana">12. Isolauri E, Hill DJ. Guide for paediatricians  
  on the diagnosis and treatment of severe cow milk allergy and multiple food   
 protein intolerance in infancy. SHS; 1997.    ^cY#a07v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#83#79#article#137#</font></p>     ^cY
#a07v86n4.htm##
00374000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704012400079002001300203#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#84#80#article#137#13#<p><
font size="2" face="Verdana">13. Sampson HA. Update on food allergy. J Allergy  
  Clin Immunol. 2004;113:805-19.    ^cY#a07v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#85#81#article#137#</font></p>     ^cY
#a07v86n4.htm##
00457000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704020700079002001300286#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#86#82#article#137#14#<p><
font size="2" face="Verdana">14. Chapman JA, Bernstein L, Lee RE, Oppenheimer   
 J, Nickals RA, Portnoy JM et al. Food allergy: a practice parameter. Ann Allerg
y    Asthma Immunol. 2006;96:S1-68.    ^cY#a07v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#87#83#article#137#</font></p>     ^cY
#a07v86n4.htm##
00469000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704021900079002001300298#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#88#84#article#137#15#<p><
font size="2" face="Verdana">15. Nowak-Wegrzyn A, Assa'ad AH, Bahna SL,.Bock    
SA, Sicherer SH, Teuber SS, et al. Work Group report: oral food challenge testin
g.    J Allergy Clin Immunol. 2009;123:S365-83.    ^cY#a07v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#89#85#article#137#</font></p>     ^cY
#a07v86n4.htm##
00459000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704020900079002001300288#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#90#86#article#137#16#<p><
font size="2" face="Verdana">16. Host A. Cow's milk protein allergy and intolera
nce    in infancy. Some clinical, epidemiological and immunological aspects. Ped
iatr    Allergy Immunol. 1994;5:1-36.    ^cY#a07v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#91#87#article#137#</font></p>     ^cY
#a07v86n4.htm##
00416000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704016600079002001300245#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#92#88#article#137#17#<p><
font size="2" face="Verdana">17. Chehade M, Mayer L. Oral tolerance and its    r
elation to food hypersensitivities. J Allergy Clin Immunol. 2005;115:3-12.    ^c
Y#a07v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#93#89#article#137#</font></p>     ^cY
#a07v86n4.htm##
00468000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704021800079002001300297#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#94#90#article#137#18#<p><
font size="2" face="Verdana">18. Peron JP, de Oliveira AP, Rizzo LV. It takes   
 guts for tolerance: the phenomenon of oral tolerance and the regulation of auto
immune    response. Autoimmun Rev. 2009;9:1-4.    ^cY#a07v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#95#91#article#137#</font></p>     ^cY
#a07v86n4.htm##
00400000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704015000079002001300229#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#96#92#article#137#19#<p><
font size="2" face="Verdana">19. Weaver LT, Laker MF, Nelson R. Intestinal    pe
rmeability in the newborn. Arch Dis Child. 1984;59:236-41.    ^cY#a07v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#97#93#article#137#</font></p>     ^cY
#a07v86n4.htm##
00510000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026000079002001300339#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#98#94#article#137#20#<p><
font size="2" face="Verdana">20. Kalliom&auml;ki M, Ouwehand A, Arvilommi    H, 
Kero P, Isolauri E. Transforming growth factor-beta in breast milk: a potential 
   regulator of atopic disease at an early age. J Allergy Clin Immunol. 1999;104
:1251-7.    ^cY#a07v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002400076002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#99#95#article#137#    </font></p>    
 ^cY#a07v86n4.htm##
00483000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704023200080002001300312#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#100#96#article#137#21#<p>
<font size="2" face="Verdana">21. Ishikawa H, Tanaka K, Maeda Y, Aiba Y, Hata   
 A, Tsuji NM, et al. Effect of intestinal microbiota on the induction of regulat
ory    CD25+ CD4+ T cells. Clin Exp Immunol. 2008;153:127-35.    ^cY#a07v86n4.ht
m##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#101#97#article#137#</font></p>     ^c
Y#a07v86n4.htm##
00420000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704016900080002001300249#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#102#98#article#137#22#<p>
<font size="2" face="Verdana">22. Tannock GW. What immunologists should know    
about bacterial communities of the human bowel. Semin Immunol. 2007;19:94-105.  
  ^cY#a07v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#103#99#article#137#</font></p>     ^c
Y#a07v86n4.htm##
00471000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021900081002001300300#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#104#100#article#137#23#<p
><font size="2" face="Verdana">23. Bj&ouml;rkst&eacute;n B, Naaber P, Sepp E,   
 Mikelsaar M. The intestinal microflora in allergic Estonian and Swedish 2-year-
old    children. Clin Exp Allergy. 1999;29:342-6.    ^cY#a07v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#105#101#article#137#</font></p>     ^
cY#a07v86n4.htm##
00475000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022300081002001300304#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#106#102#article#137#24#<p
><font size="2" face="Verdana">24. Hyman PE, Milla PJ, Benninga MA, Davidson    
GP, Fleisher DF, Taminiau J. Childhood functional gastrointestinal disorders:   
 neonate/toddler. Gastroenterology. 2006;130:1519-26.    ^cY#a07v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#107#103#article#137#</font></p>     ^
cY#a07v86n4.htm##
00537000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028500081002001300366#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#108#104#article#137#25#<p
><font size="2" face="Verdana">25. Issenman RM, Hewson S, Pirhonen D, Taylor    
W, Tirosh A. Are chronic digestive complaints the result of abnormal dietary    
patterns? Diet and digestive complaints in children at 22 and 40 months of age. 
   Am J Dis Child. 1987;141:679-82.    ^cY#a07v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#109#105#article#137#</font></p>     ^
cY#a07v86n4.htm##
00450000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019800081002001300279#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#110#106#article#137#26#<p
><font size="2" face="Verdana">26. Douglas PS. Excessive crying and gastro-oesop
hageal    reflux disease in infants: misalignment of biology and culture. Med Hy
potheses.    2005;64:887-98.    ^cY#a07v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#111#107#article#137#</font></p>     ^
cY#a07v86n4.htm##
00498000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024600081002001300327#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#112#108#article#137#27#<p
><font size="2" face="Verdana">27. Heacock HJ, Jeffery HE, Baker JL, Page M.    
Influence of breast versus formula milk on physiological gastroesophageal reflux
    in healthy, newborn infants. J Pediatr Gastroenterol Nutr. 1992;14:41-6.    
^cY#a07v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#113#109#article#137#</font></p>     ^
cY#a07v86n4.htm##
00532000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028000081002001300361#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#114#110#article#137#28#<p
><font size="2" face="Verdana">28. Shek LP, Soderstrom L, Ahlstedt S, Beyer    K
, Sampson HA. Determination of food specific IgE levels over time can predict   
 the development of tolerance in cow's milk and hen's egg allergy. J Allergy    
Clin Immunol. 2004;114:387-91.    ^cY#a07v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#115#111#article#137#</font></p>     ^
cY#a07v86n4.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023300081002001300314#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#116#112#article#137#29#<p
><font size="2" face="Verdana">29. Jarvinen KM, Beyer K, Vila L, Chatchatee    P
, Busse PJ, Sampson HA. B-cell epitopes as a screening instrument for persistent
    cow's milk allergy. J Allergy Clin Immunol. 2002;110:293-7.    ^cY#a07v86n4.
htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#117#113#article#137#</font></p>     ^
cY#a07v86n4.htm##
00498000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024600081002001300327#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#118#114#article#137#30#<p
><font size="2" face="Verdana">30. Sicherer SH, Sampson HA. Cow's milk protein-s
pecific    IgE concentrations in two age groups of milk-allergic children and in
 children    achieving clinical tolerance. Clin Exp Allergy. 1999;29:507-12.    
^cY#a07v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#119#115#article#137#</font></p>     ^
cY#a07v86n4.htm##
00400000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704014800081002001300229#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#120#116#article#137#31#<p
><font size="2" face="Verdana">31. Bhatia J, Greer F. Use of soy protein-based  
  formulas in infant feeding. Pediatrics. 2008;121:1062-8.    ^cY#a07v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#121#117#article#137#</font></p>     ^
cY#a07v86n4.htm##
00554000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030200081002001300383#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#122#118#article#137#32#<p
><font size="2" face="Verdana">32. ESPGHAN Committee on Nutrition, Agostoni    C
, Axelsson I, Goulet O, Koletzko B, Michaelsen KG, et al. Soy protein infant    
formulae and follo-on formulae: a commentary by the ESPGHAN Committee on Nutriti
on.    J Pediatr Gastroenterol Nutr. 2006;42:352-61.    ^cY#a07v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#123#119#article#137#</font></p>     ^
cY#a07v86n4.htm##
00644000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704039200081002001300473#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#124#120#article#137#33#<p
><font size="2" face="Verdana">33. National Institute of Environmental Health   
 Sciences, National Institutes of Health. Draft NTP brief on soy infant formula.
    2010. 47p. <A href=http://ntp-server.niehs.nih.gov/?objectid=716A5EEB-F1F6-9
75E-781CA5472900FCAA target="_blank">http://ntp-server.niehs.nih.gov/?objectid=7
16A5EEB-F1F6-975E-781CA5472900FCAA</A>.    Acesso: 01/04/2010.    ^cY#a07v86n4.h
tm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#125#121#article#137#</font></p>     ^
cY#a07v86n4.htm##
00558000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030600081002001300387#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#p#126#122#article#137#34#<p
><font size="2" face="Verdana">34. Sol&eacute; D, Silva LR, Ros&aacute;rio Filho
    NA, Sarni RO, Sociedade Brasileira de Pediatria e Associa&ccedil;&atilde;o B
rasileira    de Alergia e Imunopatologia. Consenso Brasileiro sobre alergia alim
entar 2007.    Rev Bras Alerg Imunopatol. 2008;31:65-89.    ^cY#a07v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#127#123#article#137#</font></p>     ^
cY#a07v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#128#124#article#137#<p>&nbsp;</p>    
 ^cY#a07v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#129#125#article#137#<p>&nbsp;</p>    
 ^cY#a07v86n4.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018000078002001300258#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#130#126#article#137#<p><font size="2"
 face="Verdana"><a name="correspondence"></a><a href="#topo"><img src="/img/revi
stas/jped/v86n4/seta.gif" border="0"></a>    <b> Correspond&ecirc;ncia:</b>    ^
cY#a07v86n4.htm##
00286000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004900078002001300127#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#131#127#article#137#<br>   Maria das 
Gra&ccedil;as Moura Lins    ^cY#a07v86n4.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006400078002001300142#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#132#128#article#137#<BR>   Rua Cap. S
ampaio Xavier, 205/1801 - Gra&ccedil;as    ^cY#a07v86n4.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004200078002001300120#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#133#129#article#137#<BR>   CEP 52050-
210 - Recife, PE     ^cY#a07v86n4.htm##
00288000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005100078002001300129#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#134#130#article#137#<BR>   Tel.: (81)
 3427.3170, (81) 3223.5052    ^cY#a07v86n4.htm##
00326000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008900078002001300167#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#135#131#article#137#<BR>   E-mail: <A
 href=mailto:gracaml@gmail.com>gracaml@gmail.com</A></font></p>     ^cY#a07v86n4
.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010600078002001300184#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#136#132#article#137#<p><font size="2"
 face="Verdana">Artigo submetido em 26.01.2010, aceito em 19.04.2010.</font></p>
     ^cY#a07v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#137#133#article#137#<p>&nbsp;</p>    
 ^cY#a07v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#138#134#article#137#<p>&nbsp;</p>    
 ^cY#a07v86n4.htm##
00391000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704015400078002001300232#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#139#135#article#137#<p><font size="2"
 face="Verdana"> N&atilde;o foram declarados conflitos de interesse    associado
s &agrave; publica&ccedil;&atilde;o deste artigo.    ^cY#a07v86n4.htm##
00414000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704017700078002001300255#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#140#136#article#137#<br>   Apoio fina
nceiro: Conselho Nacional de Desenvolvimento Cient&iacute;fico e Tecnol&oacute;g
ico    (CNPq/PROPESQ/UFPE) sob n&uacute;mero de processo. 475291/2006-9.    ^cY#
a07v86n4.htm##
00452000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704021500078002001300293#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a07v86n4.htm#S#p#141#137#article#137#<br>   Este estud
o foi realizado no Programa de P&oacute;s-Gradua&ccedil;&atilde;o    em Sa&uacut
e;de da Crian&ccedil;a e do Adolescente, Universidade Federal de    Pernambuco (
UFPE), Recife, PE.</font></p>     ^cY#a07v86n4.htm##
00460000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770120049000910300
02000140710000200160065000900162064000500171031000300176014000500179865000900184
002001300193#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#c#142#1#art
icle#34#1#^rND^sHost^nA#Frequency of cow's milk allergy in childhood^len#Ann All
ergy Immunol#2#20020000#2002#89#33-7#20100800#a07v86n4.htm##
00541000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100018000960120
06700114030001300181065000900194064000500203031000300208014000700211865000900218
002001300227035001000240801001300250#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
7v86n4.htm#S#c#143#2#article#34#2#^rND^sSicherer^nSH#^rND^sSampson^nHA#Food alle
rgy: recent advances in pathophysiology and treatment^len#Annu Rev Med#20090000#
2009#60#261-77#20100800#a07v86n4.htm#0066-4219#Annu Rev Med##
00677000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100014000920100
01700106010001800123010001800141010001900159810000600178012005200184030002300236
06500090025906400050026803100040027301400070027786500090028400200130029303500100
0306801002300316#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#c#144#3
#article#34#3#^rND^sRona^nRJ#^rND^sKeil^nT#^rND^sSummers^nC#^rND^sGislason^nD#^r
ND^sZuidmeer^nL#^rND^sSodergren^nE#et al#The prevalence of food allergy: a meta-
analysis^len#J Allergy Clin Immunol#20070000#2007#120#638-46#20100800#a07v86n4.h
tm#0091-6749#J Allergy Clin Immunol##
00708000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100019000950100
01500114010001800129010002500147010002100172012010500193030001400298065000900312
06400050032103100040032601400060033086500090033600200130034503500100035880100140
0368#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#c#145#4#article#34#
4#^rND^sAardoom^nHA#^rND^sHirasing^nRA#^rND^sRona^nRJ#^rND^sSanavro^nFL#^rND^sva
n den Heuvel^nEW#^rND^sLeeuwenburg^nJ#Food intolerance (food hypersensitivity) a
nd chronic complaints in children: the parents' perception^len#Eur J Pediatr#199
70000#1997#156#110-2#20100800#a07v86n4.htm#0340-6199#Eur J Pediatr##
00671000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100020000960100
01400116010001600130010001700146010001600163810000600179012007600185030000800261
06500090026906400050027803100030028301400070028686500090029300200130030203500100
0315801000800325#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#c#146#5
#article#34#5#^rND^sZuberbier^nT#^rND^sEdenharter^nG#^rND^sWorm^nM#^rND^sEhlers^
nI#^rND^sReimann^nS#^rND^sHantke^nT#et al#Prevalence of adverse reactions to foo
d in Germany - a population study^len#Allergy#20040000#2004#59#338-45#20100800#a
07v86n4.htm#0105-4538#ALLERGY##
00701000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160016000770160017000930160
01700110016001600127016001500143016001600158810000600174018006400180065000900244
06400050025301400040025803700710026211000090033310900110034286500090035300200130
0362#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#c#147#6#article#34#
6#^rND^sBoyce^nJA#^rND^sArshad^nSH#^rND^sAssa'ad^nA#^rND^sBahna^nSL#^rND^sBeck^n
LA#^rND^sBurks^nAW#et al#Guidelines for the diagnosis and management of food all
ergy^len#20090000#2009#119#http://www3.niaid.nih.gov/topics/foodAllergy/clinical
/Who/comments.htm#20100330#30/03/2010#20100800#a07v86n4.htm##
00561000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770120128000950300
00700223065000900230064000500239031000400244014000800248865000900256002001300265
035001000278801000700288#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S
#c#148#7#article#34#7#^rND^sGoldman^nAS#Modulation of the gastrointestinal tract
 of infants by human milk: Interfaces and interactions. An evolutionary perspect
ive^len#J Nutr#20000000#2000#130#S426-31#20100800#a07v86n4.htm#0022-3166#J Nutr#
#
00727000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100016000930100
01600109010001400125010001600139010001700155012015000172030001200322065000900334
06400050034303100030034801400060035186500090035700200130036603500100037980100120
0389#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#c#149#8#article#34#
8#^rND^sUdall^nJN#^rND^sColony^nP#^rND^sFritze^nL#^rND^sPang^nK#^rND^sTrier^nJS#
^rND^sWalker^nWA#Development of gastrointestinal mucosal barrier: II. The effect
 of natural versus artificial feeding on intestinal permeability to macromolecul
es^len#Pediatr Res#19810000#1981#15#245-9#20100800#a07v86n4.htm#0031-3998#Pediat
r Res##
00656000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100014000930100
02000107010001700127010001800144010001500162012011000177030001200287710000200299
065000900301064000500310031000200315014000300317865000900320002001300329#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#c#150#9#article#34#9#^rND^sGupt
a^nRS#^rND^sKim^nJS#^rND^sBarnathan^nJA#^rND^sAmsden^nLB#^rND^sTummala^nLS#^rND^
sHoll^nJL#Food allergy knowledge, attitudes and beliefs: focus groups of parents
, physicians and the general public^len#BMC Pediatr#2#20080000#2008#8#36#2010080
0#a07v86n4.htm##
00530000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790120040000960160
01700136018004100153066000900194062001800203014000700221065000900228064000500237
865000900242002001300251#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S
#c#151#10#article#34#10#^rND^sGibson^nRS#Evauation of anthropometric indices^len
#^rND^sGibson^nRS#Principles of nutritional assessment^len#New York#Oxford Unive
rsity#248-61#19900000#1990#20100800#a07v86n4.htm##
00452000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170043000790180042001220370
02800164110000900192109001100201865000900212002001300221#v86n4#V:\Scielo\serial\
jped\v86n4\markup\a07v86n4.htm#S#c#152#11#article#34#11#Centers for Disease Cont
rol and Prevention#2000 CDC growth charts: United States^len#http://cdc.gov/grow
thcharts#20020118#18/01/2002#20100800#a07v86n4.htm##
00518000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160018000790160015000970180
13600112062000400248065000900252064000500261865000900266002001300275#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a07v86n4.htm#S#c#153#12#article#34#12#^rND^sIsolau
ri^nE#^rND^sHill^nDJ#Guide for paediatricians on the diagnosis and treatment of 
severe cow milk allergy and multiple food protein intolerance in infancy^len#SHS
#19970000#1997#20100800#a07v86n4.htm##
00493000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120027000970300
02300124065000900147064000500156031000400161014000700165865000900172002001300181
035001000194801002300204#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S
#c#154#13#article#34#13#^rND^sSampson^nHA#Update on food allergy^len#J Allergy C
lin Immunol#20040000#2004#113#805-19#20100800#a07v86n4.htm#0091-6749#J Allergy C
lin Immunol##
00679000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
01400116010002100130010001800151010001800169810000600187012003900193030002700232
06500090025906400050026803100030027301400060027686500090028200200130029103500100
0304801002700314#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#c#155#1
4#article#34#14#^rND^sChapman^nJA#^rND^sBernstein^nL#^rND^sLee^nRE#^rND^sOppenhe
imer^nJ#^rND^sNickals^nRA#^rND^sPortnoy^nJM#et al#Food allergy: a practice param
eter^len#Ann Allergy Asthma Immunol#20060000#2006#96#S1-68#20100800#a07v86n4.htm
#1081-1206#Ann Allergy Asthma Immunol##
00685000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790100017001020100
01600119010001500135010001900150010001700169810000600186012005100192030002300243
06500090026606400050027503100040028001400080028486500090029200200130030103500100
0314801002300324#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#c#156#1
5#article#34#15#^rND^sNowak-Wegrzyn^nA#^rND^sAssa'ad AH#^rND^sBahna^nSL#^rND^sBo
ck^nSA#^rND^sSicherer^nSH#^rND^sTeuber^nSS#et al#Work Group report: oral food ch
allenge testing^len#J Allergy Clin Immunol#20090000#2009#123#S365-83#20100800#a0
7v86n4.htm#0091-6749#J Allergy Clin Immunol##
00576000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790120116000930300
02400209065000900233064000500242031000200247014000500249865000900254002001300263
035001000276801002400286#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S
#c#157#16#article#34#16#^rND^sHost^nA#Cow's milk protein allergy and intolerance
 in infancy: Some clinical, epidemiological and immunological aspects^len#Pediat
r Allergy Immunol#19940000#1994#5#1-36#20100800#a07v86n4.htm#0905-6157#Pediatr A
llergy Immunol##
00553000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960120
06300111030002300174065000900197064000500206031000400211014000500215865000900220
002001300229035001000242801002300252#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
7v86n4.htm#S#c#158#17#article#34#17#^rND^sChehade^nM#^rND^sMayer^nL#Oral toleran
ce and its relation to food hypersensitivities^len#J Allergy Clin Immunol#200500
00#2005#115#3-12#20100800#a07v86n4.htm#0091-6749#J Allergy Clin Immunol##
00577000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100022000950100
01600117012010800133030001400241710000200255065000900257064000500266031000200271
014000400273865000900277002001300286#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
7v86n4.htm#S#c#159#18#article#34#18#^rND^sPeron^nJP#^rND^sde Oliveira^nAP#^rND^s
Rizzo^nLV#It takes guts for tolerance: the phenomenon of oral tolerance and the 
regulation of autoimmune response^len#Autoimmun Rev#2#20090000#2009#9#1-4#201008
00#a07v86n4.htm##
00547000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01600112012004300128030001500171065000900186064000500195031000300200014000700203
865000900210002001300219035001000232801001500242#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a07v86n4.htm#S#c#160#19#article#34#19#^rND^sWeaver^nLT#^rND^sLaker^nMF
#^rND^sNelson^nR#Intestinal permeability in the newborn^len#Arch Dis Child#19840
000#1984#59#236-41#20100800#a07v86n4.htm#0003-9888#Arch Dis Child##
00693000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100018000990100
01900117010001400136010001800150012010800168030002300276065000900299064000500308
031000400313014000700317865000900324002001300333035001000346801002300356#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#c#161#20#article#34#20#^rND^sKa
lliomäki^nM#^rND^sOuwehand^nA#^rND^sArvilommi^nH#^rND^sKero^nP#^rND^sIsolauri^nE
#Transforming growth factor-beta in breast milk: a potential regulator of atopic
 disease at an early age^len#J Allergy Clin Immunol#19990000#1999#104#1251-7#201
00800#a07v86n4.htm#0091-6749#J Allergy Clin Immunol##
00693000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01500113010001400128010001400142010001600156810000600172012008600178030001700264
06500090028106400050029003100040029501400070029986500090030600200130031503500100
0328801001700338#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#c#162#2
1#article#34#21#^rND^sIshikawa^nH#^rND^sTanaka^nK#^rND^sMaeda^nY#^rND^sAiba^nY#^
rND^sHata^nA#^rND^sTsuji^nNM#et al#Effect of intestinal microbiota on the induct
ion of regulatory CD25+ CD4+ T cells^len#Clin Exp Immunol#20080000#2008#153#127-
35#20100800#a07v86n4.htm#0009-9104#Clin Exp Immunol##
00529000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120082000970300
01400179065000900193064000500202031000300207014000700210865000900217002001300226
035001000239801001400249#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S
#c#163#22#article#34#22#^rND^sTannock^nGW#What immunologists should know about b
acterial communities of the human bowel^len#Semin Immunol#20070000#2007#19#94-10
5#20100800#a07v86n4.htm#1044-5323#Semin Immunol##
00621000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01400114010001900128012008300147030001700230065000900247064000500256031000300261
014000600264865000900270002001300279035001000292801001700302#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a07v86n4.htm#S#c#164#23#article#34#23#^rND^sBjörkstén^nB#^
rND^sNaaber^nP#^rND^sSepp^nE#^rND^sMikelsaar^nM#The intestinal microflora in all
ergic Estonian and Swedish 2-year-old children^len#Clin Exp Allergy#19990000#199
9#29#342-6#20100800#a07v86n4.htm#0954-7894#Clin Exp Allergy##
00673000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01900111010001900130010001900149010001800168012006900186030001700255065000900272
06400050028103100040028601400080029086500090029800200130030703500100032080100170
0330#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#c#165#24#article#34
#24#^rND^sHyman^nPE#^rND^sMilla^nPJ#^rND^sBenninga^nMA#^rND^sDavidson^nGP#^rND^s
Fleisher^nDF#^rND^sTaminiau^nJ#Childhood functional gastrointestinal disorders: 
neonate/toddler^len#Gastroenterology#20060000#2006#130#1519-26#20100800#a07v86n4
.htm#0016-5085#Gastroenterology##
00712000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01800114010001600132010001600148012014700164030001500311065000900326064000500335
031000400340014000700344865000900351002001300360035001000373801001500383#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#c#166#25#article#34#25#^rND^sIs
senman^nRM#^rND^sHewson^nS#^rND^sPirhonen^nD#^rND^sTaylor^nW#^rND^sTirosh^nA#Are
 chronic digestive complaints the result of abnormal dietary patterns: Diet and 
digestive complaints in children at 22 and 40 months of age^len#Am J Dis Child#1
9870000#1987#141#679-82#20100800#a07v86n4.htm#0002-922X#Am J Dis Child##
00556000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120107000970300
01500204065000900219064000500228031000300233014000700236865000900243002001300252
035001000265801001500275#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S
#c#167#26#article#34#26#^rND^sDouglas^nPS#Excessive crying and gastro-oesophagea
l reflux disease in infants: misalignment of biology and culture^len#Med Hypothe
ses#20050000#2005#64#887-98#20100800#a07v86n4.htm#0306-9877#Med Hypotheses##
00672000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970100
01600115010001400131012011300145030002900258065000900287064000500296031000300301
014000500304865000900309002001300318035001000331801002900341#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a07v86n4.htm#S#c#168#27#article#34#27#^rND^sHeacock^nHJ#^r
ND^sJeffery^nHE#^rND^sBaker^nJL#^rND^sPage^nM#Influence of breast versus formula
 milk on physiological gastroesophageal reflux in healthy, newborn infants^len#J
 Pediatr Gastroenterol Nutr#19920000#1992#14#41-6#20100800#a07v86n4.htm#0277-211
6#J Pediatr Gastroenterol Nutr##
00715000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100020000940100
01800114010001500132010001800147012013300165030002300298065000900321064000500330
031000400335014000700339865000900346002001300355035001000368801002300378#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#c#169#28#article#34#28#^rND^sSh
ek^nLP#^rND^sSoderstrom^nL#^rND^sAhlstedt^nS#^rND^sBeyer^nK#^rND^sSampson^nHA#De
termination of food specific IgE levels over time can predict the development of
 tolerance in cow's milk and hen's egg allergy^len#J Allergy Clin Immunol#200400
00#2004#114#387-91#20100800#a07v86n4.htm#0091-6749#J Allergy Clin Immunol##
00689000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100015000980100
01400113010002000127010001600147010001800163012008000181030002300261065000900284
06400050029303100040029801400060030286500090030800200130031703500100033080100230
0340#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#c#170#29#article#34
#29#^rND^sJarvinen^nKM#^rND^sBeyer^nK#^rND^sVila^nL#^rND^sChatchatee^nP#^rND^sBu
sse^nPJ#^rND^sSampson^nHA#B-cell epitopes as a screening instrument for persiste
nt cow's milk allergy^len#J Allergy Clin Immunol#20020000#2002#110#293-7#2010080
0#a07v86n4.htm#0091-6749#J Allergy Clin Immunol##
00624000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980120
14000116030001700256065000900273064000500282031000300287014000700290865000900297
002001300306035001000319801001700329#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
7v86n4.htm#S#c#171#30#article#34#30#^rND^sSicherer^nSH#^rND^sSampson^nHA#Cow's m
ilk protein-specific IgE concentrations in two age groups of milk-allergic child
ren and in children achieving clinical tolerance^len#Clin Exp Allergy#19990000#1
999#29#507-12#20100800#a07v86n4.htm#0954-7894#Clin Exp Allergy##
00523000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950120
05600110030001100166065000900177064000500186031000400191014000700195865000900202
002001300211035001000224801001100234#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
7v86n4.htm#S#c#172#31#article#34#31#^rND^sBhatia^nJ#^rND^sGreer^nF#Use of soy pr
otein-based formulas in infant feeding^len#Pediatrics#20080000#2008#121#1062-8#2
0100800#a07v86n4.htm#0031-4005#Pediatrics##
00747000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760110031000790100018001100100
01800128010001600146010001800162010002100180012010600201030002900307065000900336
06400050034503100030035001400070035386500090036000200130036903500100038280100290
0392#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#c#173#32#article#34
#32#ESPGHAN Committee on Nutrition#^rND^sAgostoni^nC#^rND^sAxelsson^nI#^rND^sGou
let^nO#^rND^sKoletzko^nB#^rND^sMichaelsen^nKG#Soy protein infant formulae and fo
llo-on formulae: a commentary by the ESPGHAN Committee on Nutrition^len#J Pediat
r Gastroenterol Nutr#20060000#2006#42#352-61#20100800#a07v86n4.htm#0277-2116#J P
ediatr Gastroenterol Nutr##
00595000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170083000790180042001620650
00900204064000500213014000300218037007800221110000900299109001100308865000900319
002001300328#v86n4#V:\Scielo\serial\jped\v86n4\markup\a07v86n4.htm#S#c#174#33#ar
ticle#34#33#National Institutes of Health^dNational Institute of Environmental H
ealth Sciences#Draft NTP brief on soy infant formula^len#20100000#2010#47#http:/
/ntp-server.niehs.nih.gov/?objectid=716A5EEB-F1F6-975E-781CA5472900FCAA#20100401
#01/04/2010#20100800#a07v86n4.htm##
00663000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100016000930100
02400109010001600133011008600149012005300235030002600288710000200314065000900316
064000500325031000300330014000600333865000900339002001300348#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a07v86n4.htm#S#c#175#34#article#34#34#^rND^sSolé^nD#^rND^s
Silva^nLR#^rND^sRosário Filho^nNA#^rND^sSarni^nRO#Sociedade Brasileira de Pediat
ria e Associação Brasileira de Alergia e Imunopatologia#Consenso Brasileiro sobr
e alergia alimentar 2007^lpt#Rev Bras Alerg Imunopatol#2#20080000#2008#31#65-89#
20100800#a07v86n4.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v86n4#V:\Scielo\serial\jped\v86n4\markup\a08v86n4.htm#S#o#1#1#article#1
#20110126#175459#a08v86n4.htm#108##
05028000000000649000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000210011303100030013403200020013706500090013901400110014803500100015901201310
01690120138003000100030004380100035004680100029005030700050005320700069005820700
02400651083169800675085001002373085002502383085002002408085002002428085002002448
08316920246808500100416008500230417008500220419308500180421508500210423311700080
42540720003042621120009042651110011042741140009042851130011042940580060043050020
01304365#v86n4#V:\Scielo\serial\jped\v86n4\markup\a08v86n4.htm#S#h#2#1#article#1
#oa#pt#br1.1#1#4.0#ILUS#TAB#08#JPED030#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f2
90^l294#0021-7557#Descarte de leite humano doado a Banco de Leite antes e após m
edidas para reduzir a quantidade de leite imprópria para consumo^lpt#Disposal of
 human milk donated to a human milk bank before and after measures to reduce the
 amount of milk unsuitable for consumption^len#^rND^1A01^nAna L.^sGrazziotin#^rN
D^1A02^nMaria C. B.^sGrazziotin#^rND^1A03^nLuiz A. J.^sLetti#Universidade Federa
l do Paraná^iA01^cCuritiba^sPR#UFPR^iA02^1Hospital de Clínicas^2Banco de Leite H
umano^cCuritiba^sPR#UFPR^iA03^cCuritiba^sPR#^lpt^aOBJETIVO: Avaliar as causas do
 descarte do leite humano doado, bem como o impacto das medidas adotadas para di
minuir a quantidade de leite impróprio. MÉTODOS: Realizou-se um estudo observaci
onal comparativo do tipo quasi-experimental com populações distintas de doadoras
 externas nos anos de 2006 e 2008. Utilizou-se, em 2006, um formulário simples p
ara registrar os critérios de descarte do leite doado e o diálogo com a doadora 
para encontrar o motivo das alterações do leite. Para as doadoras de 2008, aplic
ou-se um checklist de orientação detalhada da técnica de coleta e pré-estocagem.
 Seguiu-se o levantamento dos critérios de descarte após a intervenção por meio 
do mesmo formulário aplicado em 2006. Definiu-se como um "caso" todos os frascos
 de leite descartados por dia de uma mesma doadora. Os dados foram analisados pe
los cálculos de comparação de proporções para os anos de 2006 e 2008. RESULTADOS
: Vinte e quatro por cento do leite coletado foi descartado em 2006, enquanto qu
e, em 2008, apenas 10,5% do leite foi descartado. Houve redução significativa no
 descarte de leite para os itens: cheiro de cigarro; esquecimento do leite fora,
 no corpo ou na porta da geladeira; problemas com o freezer; abrir muito geladei
ra e freezer; prazo de validade vencida; e casos não identificados. Os itens pri
meira coleta sem orientação, uso de frasco não conforme, transporte do leite do 
trabalho para casa e orientação indireta apresentaram aumentos significativos de
 descarte. CONCLUSÕES: A aplicação do checklist passo a passo teve um impacto po
sitivo na redução do volume de leite doado descartado e modificou as frequências
 das causas desse descarte, eliminando algumas dessas causas.#^ddecs^i1#^tm^lpt^
kLeite humano^i1#^tm^lpt^kseleção^i1#^tm^lpt^kdoadora^i1#^tm^lpt^kanálise^i1#^le
n^aOBJECTIVE: To evaluate the causes of disposal of donated human milk and the i
mpact of the measures taken to reduce the amount of milk unsuitable for consumpt
ion. METHODS: A quasi-experimental, observational, comparative study was conduct
ed with different populations of external donors in 2006 and 2008. In 2006, a si
mple form was used to record the criteria for disposal of the donated milk. We a
lso interviewed the donors to find the reason of changes in the milk. In 2008, a
 checklist containing comprehensive guidance for milk collection and pre-storage
 was handed out to the donors. Next, we continued to survey the disposal criteri
a after the intervention using the same form administered in 2006. A case was de
fined as all bottles of milk of the same donor discarded per day. Data were anal
yzed by calculations based on comparison of proportions for 2006 and 2008. RESUL
TS: Twenty-four percent of the milk collected was discarded in 2006, while in 20
08 only 10.5% of the milk was discarded. There was significant reduction in the 
disposal of milk for the items: cigarette odor; forgetting the milk outside the 
refrigerator, inside it or on its door; problems with the freezer; frequent open
ing of the refrigerator and freezer; expiration date; and unidentified cases. Ho
wever, there was a significant increase in milk disposal for first milk collecti
on without guidance; use of inappropriate bottle; milk transportation from work 
to home; and indirect guidance. CONCLUSIONS: The use of the step-by-step checkli
st had a positive impact on the reduction of the volume of donated milk discarde
d and changed the frequency of the causes of disposal, eliminating some of these
 causes.#^ddecs^i2#^tm^len^kHuman milk^i2#^tm^len^kselection^i2#^tm^len^kdonor^i
2#^tm^len^kanalysis^i2#vancouv#11#20091217#17.12.2009#20100430#30.04.2010#Univer
sidade Federal do Paraná (UFPR)^dHospital de Clínicas#a08v86n4.htm##
05112000000000649000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000210011303100030013403200020013706500090013901400110014803500100015901201380
01690120145003070100030004520100035004820100029005170700050005460700069005960700
02400665083174000689085001002429085002502439085002002464085002002484085002002504
08317200252408500100424408500230425408500220427708500180429908500210431711700080
43380720003043461120009043491110011043581140009043691130011043780580060043890020
01304449#v86n4#V:\Scielo\serial\jped\v86n4\markup\a08v86n4.htm#S#f#3#1#article#1
#oa#pt#br1.1#1#4.0#ILUS#TAB#08#JPED030#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f2
90^l294#0021-7557#<b>Descarte de leite humano doado a Banco de Leite antes e apó
s medidas para reduzir a quantidade de leite imprópria para consumo</b>^lpt#<b>D
isposal of human milk donated to a human milk bank before and after measures to 
reduce the amount of milk unsuitable for consumption</b>^len#^rND^1A01^nAna L.^s
Grazziotin#^rND^1A02^nMaria C. B.^sGrazziotin#^rND^1A03^nLuiz A. J.^sLetti#Unive
rsidade Federal do Paraná^iA01^cCuritiba^sPR#UFPR^iA02^1Hospital de Clínicas^2Ba
nco de Leite Humano^cCuritiba^sPR#UFPR^iA03^cCuritiba^sPR#^lpt^a<b>OBJETIVO: </b
>Avaliar as causas do descarte do leite humano doado, bem como o impacto das med
idas adotadas para diminuir a quantidade de leite impróprio. <b>MÉTODOS: </b>Rea
lizou-se um estudo observacional comparativo do tipo quasi-experimental com popu
lações distintas de doadoras externas nos anos de 2006 e 2008. Utilizou-se, em 2
006, um formulário simples para registrar os critérios de descarte do leite doad
o e o diálogo com a doadora para encontrar o motivo das alterações do leite. Par
a as doadoras de 2008, aplicou-se um <i>checklist</i> de orientação detalhada da
 técnica de coleta e pré-estocagem. Seguiu-se o levantamento dos critérios de de
scarte após a intervenção por meio do mesmo formulário aplicado em 2006. Definiu
-se como um "caso" todos os frascos de leite descartados por dia de uma mesma do
adora. Os dados foram analisados pelos cálculos de comparação de proporções para
 os anos de 2006 e 2008. <b>RESULTADOS: </b>Vinte e quatro por cento do leite co
letado foi descartado em 2006, enquanto que, em 2008, apenas 10,5% do leite foi 
descartado. Houve redução significativa no descarte de leite para os itens: chei
ro de cigarro; esquecimento do leite fora, no corpo ou na porta da geladeira; pr
oblemas com o freezer; abrir muito geladeira e freezer; prazo de validade vencid
a; e casos não identificados. Os itens primeira coleta sem orientação, uso de fr
asco não conforme, transporte do leite do trabalho para casa e orientação indire
ta apresentaram aumentos significativos de descarte. <b>CONCLUSÕES: </b>A aplica
ção do <i>checklist</i> passo a passo teve um impacto positivo na redução do vol
ume de leite doado descartado e modificou as frequências das causas desse descar
te, eliminando algumas dessas causas.#^ddecs^i1#^tm^lpt^kLeite humano^i1#^tm^lpt
^kseleção^i1#^tm^lpt^kdoadora^i1#^tm^lpt^kanálise^i1#^len^a<b>OBJECTIVE: </b>To 
evaluate the causes of disposal of donated human milk and the impact of the meas
ures taken to reduce the amount of milk unsuitable for consumption. <b>METHODS: 
</b>A quasi-experimental, observational, comparative study was conducted with di
fferent populations of external donors in 2006 and 2008. In 2006, a simple form 
was used to record the criteria for disposal of the donated milk. We also interv
iewed the donors to find the reason of changes in the milk. In 2008, a checklist
 containing comprehensive guidance for milk collection and pre-storage was hande
d out to the donors. Next, we continued to survey the disposal criteria after th
e intervention using the same form administered in 2006. A case was defined as a
ll bottles of milk of the same donor discarded per day. Data were analyzed by ca
lculations based on comparison of proportions for 2006 and 2008. <b>RESULTS: </b
>Twenty-four percent of the milk collected was discarded in 2006, while in 2008 
only 10.5% of the milk was discarded. There was significant reduction in the dis
posal of milk for the items: cigarette odor; forgetting the milk outside the ref
rigerator, inside it or on its door; problems with the freezer; frequent opening
 of the refrigerator and freezer; expiration date; and unidentified cases. Howev
er, there was a significant increase in milk disposal for first milk collection 
without guidance; use of inappropriate bottle; milk transportation from work to 
home; and indirect guidance. <b>CONCLUSIONS: </b>The use of the step-by-step che
cklist had a positive impact on the reduction of the volume of donated milk disc
arded and changed the frequency of the causes of disposal, eliminating some of t
hese causes.#^ddecs^i2#^tm^len^kHuman milk^i2#^tm^len^kselection^i2#^tm^len^kdon
or^i2#^tm^len^kanalysis^i2#vancouv#11#20091217#17.12.2009#20100430#30.04.2010#Un
iversidade Federal do Paraná (UFPR)^dHospital de Clínicas#a08v86n4.htm##
05178000000000673000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000300117049000800120
15800030012803000210013103100030015203200020015506500090015701400110016603500100
01770120131001870120138003180100029004560100034004850100028005190700052005470700
07100599070002600670083170700696085001002403085002502413085002002438085002002458
08500200247808316990249808500100419708500230420708500220423008500180425208500210
42701170008042910720003042991120009043021110011043111140009043221130011043310580
06004342002001304402008008904415#v86n4#V:\Scielo\serial\jped\v86n4\markup\a08v86
n4.htm#S#l#4#1#article#1#^mjul./ago.^a2010#oa#pt#br1.1#1#4.0#ilus#tab#08#JPED030
#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f290^l294#0021-7557#Descarte de leite hu
mano doado a Banco de Leite antes e após medidas para reduzir a quantidade de le
ite imprópria para consumo^lpt#Disposal of human milk donated to a human milk ba
nk before and after measures to reduce the amount of milk unsuitable for consump
tion^len#^rND^1A01^nAna L^sGrazziotin#^rND^1A02^nMaria C. B^sGrazziotin#^rND^1A0
3^nLuiz A. J^sLetti#^iA01^1Universidade Federal do Paraná^cCuritiba^sPR#^iA02^1U
FPR^2Hospital de Clínicas^3Banco de Leite Humano^cCuritiba^sPR#^iA03^1UFPR^cCuri
tiba^sPR#^lpt^aOBJETIVO: Avaliar as causas do descarte do leite humano doado, be
m como o impacto das medidas adotadas para diminuir a quantidade de leite impróp
rio. MÉTODOS: Realizou-se um estudo observacional comparativo do tipo quasi-expe
rimental com populações distintas de doadoras externas nos anos de 2006 e 2008. 
Utilizou-se, em 2006, um formulário simples para registrar os critérios de desca
rte do leite doado e o diálogo com a doadora para encontrar o motivo das alteraç
ões do leite. Para as doadoras de 2008, aplicou-se um checklist de orientação de
talhada da técnica de coleta e pré-estocagem. Seguiu-se o levantamento dos crité
rios de descarte após a intervenção por meio do mesmo formulário aplicado em 200
6. Definiu-se como um "caso" todos os frascos de leite descartados por dia de um
a mesma doadora. Os dados foram analisados pelos cálculos de comparação de propo
rções para os anos de 2006 e 2008. RESULTADOS: Vinte e quatro por cento do leite
 coletado foi descartado em 2006, enquanto que, em 2008, apenas 10,5 por cento d
o leite foi descartado. Houve redução significativa no descarte de leite para os
 itens: cheiro de cigarro; esquecimento do leite fora, no corpo ou na porta da g
eladeira; problemas com o freezer; abrir muito geladeira e freezer; prazo de val
idade vencida; e casos não identificados. Os itens primeira coleta sem orientaçã
o, uso de frasco não conforme, transporte do leite do trabalho para casa e orien
tação indireta apresentaram aumentos significativos de descarte. CONCLUSÕES: A a
plicação do checklist passo a passo teve um impacto positivo na redução do volum
e de leite doado descartado e modificou as frequências das causas desse descarte
, eliminando algumas dessas causas.#^ddecs^i1#^tm^lpt^kLeite humano^i1#^tm^lpt^k
seleção^i1#^tm^lpt^kdoadora^i1#^tm^lpt^kanálise^i1#^len^aOBJECTIVE: To evaluate 
the causes of disposal of donated human milk and the impact of the measures take
n to reduce the amount of milk unsuitable for consumption. METHODS: A quasi-expe
rimental, observational, comparative study was conducted with different populati
ons of external donors in 2006 and 2008. In 2006, a simple form was used to reco
rd the criteria for disposal of the donated milk. We also interviewed the donors
 to find the reason of changes in the milk. In 2008, a checklist containing comp
rehensive guidance for milk collection and pre-storage was handed out to the don
ors. Next, we continued to survey the disposal criteria after the intervention u
sing the same form administered in 2006. A case was defined as all bottles of mi
lk of the same donor discarded per day. Data were analyzed by calculations based
 on comparison of proportions for 2006 and 2008. RESULTS: Twenty-four percent of
 the milk collected was discarded in 2006, while in 2008 only 10.5 percent of th
e milk was discarded. There was significant reduction in the disposal of milk fo
r the items: cigarette odor; forgetting the milk outside the refrigerator, insid
e it or on its door; problems with the freezer; frequent opening of the refriger
ator and freezer; expiration date; and unidentified cases. However, there was a 
significant increase in milk disposal for first milk collection without guidance
; use of inappropriate bottle; milk transportation from work to home; and indire
ct guidance. CONCLUSIONS: The use of the step-by-step checklist had a positive i
mpact on the reduction of the volume of donated milk discarded and changed the f
requency of the causes of disposal, eliminating some of these causes.#^ddecs^i2#
^tm^len^kHuman milk^i2#^tm^len^kselection^i2#^tm^len^kdonor^i2#^tm^len^kanalysis
^i2#vancouv#11#20091217#17.12.2009#20100430#30.04.2010#Universidade Federal do P
araná (UFPR)^dHospital de Clínicas#a08v86n4.htm#Internet^ihttp://www.scielo.br/s
cielo.php?script=sci_arttext&pid=S0021-75572010000400008##
00322000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704009000073002001300163#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#5#1#article#93#<p align="right"><font
 size="2" face="Verdana"><b>ARTIGO ORIGINAL</b></font> </p>     ^cY#a08v86n4.htm
##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#6#2#article#93#<p>&nbsp;</p>     ^cY#
a08v86n4.htm##
00438000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704020600073002001300279#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#7#3#article#93#<p><font size="4" face
="Verdana"><b>Descarte de leite humano doado a Banco de    Leite antes e ap&oacu
te;s medidas para reduzir a quantidade de leite impr&oacute;pria    para consumo
</b></font></p>     ^cY#a08v86n4.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#8#4#article#93#<p>&nbsp;</p>     ^cY#
a08v86n4.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000300070704002200073002001300095#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#9#5#article#93#<p>&nbsp;</p>     ^cY#
a08v86n4.htm##
00393000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704016000074002001300234#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#10#6#article#93#<p><font size="2" fac
e="Verdana"><b>Ana L. Grazziotin<sup>I</sup>;  Maria C. B. Grazziotin<sup>II</su
p>;  Luiz A. J. Letti<sup>III</sup></b></font></p>     ^cY#a08v86n4.htm##
00388000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704015500074002001300229#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#11#7#article#93#<p><font size="2" fac
e="Verdana"><sup>I</sup>Mestranda, Biologia Celular e Molecular,    Universidade
 Federal do Paran&aacute; (UFPR), Curitiba, PR    ^cY#a08v86n4.htm##
00592000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704035900074002001300433#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#12#8#article#93#<br>   <sup>II</sup>C
onsultora Internacional    em Lacta&ccedil;&atilde;o, International Board of Lac
tation Consultant Examiners,    Coordenadora, Banco de Leite Humano, Hospital de
 Cl&iacute;nicas, UFPR, Curitiba,    PR, Professora, Sa&uacute;de da Mulher e da
 Crian&ccedil;a, Banco de Leite Humano,    Hospital de Cl&iacute;nicas, UFPR, Cu
ritiba, PR    ^cY#a08v86n4.htm##
00372000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000300071704013900074002001300213#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#13#9#article#93#<br>   <sup>III</sup>
Professor assistente I,    Curso de Engenharia de Bioprocessos e Biotecnologia, 
UFPR, Curitiba, PR</font></p>     ^cY#a08v86n4.htm##
00367000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704013300075002001300208#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#14#10#article#93#<p><font size="2" fa
ce="Verdana"><a name="topo" id="topo"></a><a href="#correspondence">Correspond&e
circ;ncia</a></font></p>     ^cY#a08v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#15#11#article#93#<p>&nbsp;</p>     ^c
Y#a08v86n4.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004400075002001300119#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#16#12#article#93#<p>&nbsp;</p> <hr si
ze="1" noshade>     ^cY#a08v86n4.htm##
00300000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006600075002001300141#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#17#13#article#93#<p><font size="2" fa
ce="Verdana"><b>RESUMO</b></font></p>     ^cY#a08v86n4.htm##
00446000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704021200075002001300287#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#18#14#article#93#<p><font size="2" fa
ce="Verdana"> <b>OBJETIVO: </b> Avaliar as causas do descarte    do leite humano
 doado, bem como o impacto das medidas adotadas para diminuir    a quantidade de
 leite impr&oacute;prio.    ^cY#a08v86n4.htm##
01200000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704096600075002001301041#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#19#15#article#93#<br>   <b>M&Eacute;T
ODOS: </b> Realizou-se um estudo observacional comparativo do tipo    quasi-expe
rimental com popula&ccedil;&otilde;es distintas de doadoras externas    nos anos
 de 2006 e 2008. Utilizou-se, em 2006, um formul&aacute;rio simples    para regi
strar os crit&eacute;rios de descarte do leite doado e o di&aacute;logo    com a
 doadora para encontrar o motivo das altera&ccedil;&otilde;es do leite.    Para 
as doadoras de 2008, aplicou-se um <i>checklist</i> de orienta&ccedil;&atilde;o 
   detalhada da t&eacute;cnica de coleta e pr&eacute;-estocagem. Seguiu-se o lev
antamento    dos crit&eacute;rios de descarte ap&oacute;s a interven&ccedil;&ati
lde;o por    meio do mesmo formul&aacute;rio aplicado em 2006. Definiu-se como u
m "caso"    todos os frascos de leite descartados por dia de uma mesma doadora. 
Os dados    foram analisados pelos c&aacute;lculos de compara&ccedil;&atilde;o d
e propor&ccedil;&otilde;es    para os anos de 2006 e 2008.    ^cY#a08v86n4.htm##
00916000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704068200075002001300757#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#20#16#article#93#<br>   <b>RESULTADOS
: </b>Vinte e quatro por cento do leite coletado foi descartado    em 2006, enqu
anto que, em 2008, apenas 10,5% do leite foi descartado. Houve    redu&ccedil;&a
tilde;o significativa no descarte de leite para os itens: cheiro    de cigarro; 
esquecimento do leite fora, no corpo ou na porta da geladeira; problemas    com 
o freezer; abrir muito geladeira e freezer; prazo de validade vencida; e    caso
s n&atilde;o identificados. Os itens primeira coleta sem orienta&ccedil;&atilde;
o,    uso de frasco n&atilde;o conforme, transporte do leite do trabalho para ca
sa    e orienta&ccedil;&atilde;o indireta apresentaram aumentos significativos d
e    descarte.    ^cY#a08v86n4.htm##
00536000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704030200075002001300377#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#21#17#article#93#<br>   <b>CONCLUS&Ot
ilde;ES: </b> A aplica&ccedil;&atilde;o do <i>checklist</i> passo    a passo tev
e um impacto positivo na redu&ccedil;&atilde;o do volume de leite    doado desca
rtado e modificou as frequ&ecirc;ncias das causas desse descarte,    eliminando 
algumas dessas causas.</font></p>     ^cY#a08v86n4.htm##
00397000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704016300075002001300238#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#22#18#article#93#<p><font size="2" fa
ce="Verdana"><b>Palavras-chave: </b> Leite humano, sele&ccedil;&atilde;o,    doa
dora, an&aacute;lise.</font></p> <hr size="1" noshade>     ^cY#a08v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#23#19#article#93#<p>&nbsp;</p>     ^c
Y#a08v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#24#20#article#93#<p>&nbsp;</p>     ^c
Y#a08v86n4.htm##
00318000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704008400075002001300159#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#25#21#article#93#<p><font size="3" fa
ce="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#a08v86n4.htm##
01204000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704097000075002001301045#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#26#22#article#93#<p><font face="Verda
na" size="2">Uma grande preocupa&ccedil;&atilde;o dos bancos    de leite humano 
(BLH) &eacute; manter estoques de leite suficientes para atender    &agrave; dem
anda, e uma maneira de conseguir esse objetivo &eacute; por meio    da diminui&c
cedil;&atilde;o do volume descartado ap&oacute;s as an&aacute;lises    do leite 
cru nas etapas iniciais do processamento, ou seja, na triagem durante    a recep
&ccedil;&atilde;o, ap&oacute;s o degelo pelo visual e o cheiro e, finalmente,   
 pela titula&ccedil;&atilde;o da acidez do leite. O desprezo nessas etapas de   
 leite coletado de doadoras externas no domic&iacute;lio est&aacute; relacionado
    aos contaminantes ambientais, devido a falhas na t&eacute;cnica de coleta, p
r&eacute;-estocagem,    manuten&ccedil;&atilde;o da cadeia de frio, manejo do fr
asco coletor, resultando    em altera&ccedil;&otilde;es das propriedades do leit
e e tornando-o impr&oacute;prio    para o consumo.</font></p>     ^cY#a08v86n4.h
tm##
01537000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704130300075002001301378#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#27#23#article#93#<p><font face="Verda
na" size="2">O leite humano n&atilde;o possui barreira f&iacute;sica    que impe
&ccedil;a a presen&ccedil;a de microorganismos<SUP>1</SUP> e se comporta    como
 um fluido semipl&aacute;stico que pode sofrer transforma&ccedil;&otilde;es    a
 n&iacute;vel molecular<SUP>2</SUP>, &eacute; n&atilde;o est&eacute;ril (possui 
   flora sapr&oacute;fita), pode sofrer contamina&ccedil;&atilde;o prim&aacute;r
ia    (origem sangu&iacute;nea) e secund&aacute;ria (pele e ambiente) por microo
rganismos    que penetram na mama<SUP>1-3</SUP> e, embora apresente fatores bact
eriost&aacute;ticos    e bactericidas eficazes para proteg&ecirc;-lo de sua flor
a, nem sempre apresenta    a mesma efic&aacute;cia contra contaminantes externos
<SUP>1,2,4</SUP>. O controle    de qualidade inicia-se antes de retirar a primei
ra gota da mama, desde as orienta&ccedil;&otilde;es    &agrave; doadora e a manu
ten&ccedil;&atilde;o da cadeia de frio, e continua    por todas as etapas pelas 
quais o leite passa at&eacute; a distribui&ccedil;&atilde;o    aos rec&eacute;m-
nascidos e prematuros<SUP>2,3,5,6</SUP>, para os quais a qualidade    do leite h
umano &eacute; fundamental &agrave; sua sobreviv&ecirc;ncia e na prote&ccedil;&a
tilde;o    contra infec&ccedil;&otilde;es em geral<SUP>7</SUP>.</font></p>     ^
cY#a08v86n4.htm##
00843000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704060900075002001300684#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#28#24#article#93#<p><font face="Verda
na" size="2">No BLH, ap&oacute;s a recep&ccedil;&atilde;o    do leite humano ord
enhado cru (LHOC), a primeira etapa do processamento &eacute;    o registro e se
le&ccedil;&atilde;o do leite, seguida pela estocagem, degelo,    nova sele&ccedi
l;&atilde;o (por presen&ccedil;a de sujidades, cor, <i>off flavor</i>    e acide
z Dornic), reenvase, pasteuriza&ccedil;&atilde;o, resfriamento, an&aacute;lise  
  microbiol&oacute;gica e congelamento final<SUP>1,4,8</SUP>. A cada etapa, o   
 leite &eacute; avaliado, e continuam no processo aqueles aprovados em etapa    
anterior.</font></p>     ^cY#a08v86n4.htm##
00519000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704028500075002001300360#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#29#25#article#93#<p><font face="Verda
na" size="2">Considerando a relev&acirc;ncia do tema, o objetivo    do presente 
trabalho foi avaliar as causas do descarte do leite humano doado,    bem como o 
impacto das medidas adotadas para diminuir a quantidade de leite    impr&oacute;
prio.</font></p>     ^cY#a08v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#30#26#article#93#<p>&nbsp;</p>     ^c
Y#a08v86n4.htm##
00308000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007400075002001300149#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#31#27#article#93#<p><font size="3" fa
ce="Verdana"><b>M&eacute;todos</b></font></p>     ^cY#a08v86n4.htm##
00782000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704054800075002001300623#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#32#28#article#93#<p><font face="Verda
na" size="2">Realizou-se um estudo retrospectivo observacional    comparativo do
 tipo quasi-experimental no BLH do Hospital de Cl&iacute;nicas    (HC), Universi
dade Federal do Paran&aacute; (UFPR), Curitiba (PR), por meio    de levantamento
 e an&aacute;lise dos dados acerca dos leites descartados de    todas as 1.926 d
oadoras atendidas no ano de 2006 e de todas as 1.798 doadoras    de 2008 ap&oacu
te;s a ado&ccedil;&atilde;o de medidas de avalia&ccedil;&atilde;o    e orienta&c
cedil;&atilde;o direcionada.</font></p>     ^cY#a08v86n4.htm##
01323000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704108900075002001301164#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#33#29#article#93#<p><font face="Verda
na" size="2">Em janeiro de 2006, iniciou-se a investiga&ccedil;&atilde;o    sobr
e o descarte de leite. Definiu-se como um "caso" todos os frascos de leite    de
scartados por dia de uma mesma doadora. Para esse ano, um formul&aacute;rio    p
r&oacute;prio intitulado "Identifica&ccedil;&atilde;o e medidas adotadas nos    
casos de leite humano n&atilde;o-conforme" foi estabelecido para registrar os   
 crit&eacute;rios justific&aacute;veis (acidez, <i>off flavor</i>, embalagem,   
 sujidade, cor) de n&atilde;o-conformidade do leite recebido e para permitir    
a rastreabilidade, informando o nome da doadora, o volume total de leite e o    
n&uacute;mero de frascos descartados. Em cada visita domiciliar subsequente,    
informou-se o descarte do leite e procurou-se identificar por meio de di&aacute;
logo    a poss&iacute;vel falha no processo que envolve toda a coleta, desde a h
igieniza&ccedil;&atilde;o    at&eacute; a pr&eacute;-estocagem (condi&ccedil;&at
ilde;o tempor&aacute;ria    na qual o produto &eacute; mantido at&eacute; chegar
 ao BLH).</font></p>     ^cY#a08v86n4.htm##
01327000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704109300075002001301168#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#34#30#article#93#<p><font face="Verda
na" size="2">Em 2008, tendo em vista que no ano anterior persistiram    as causa
s de descarte, adotou-se a partir de janeiro um novo formul&aacute;rio    &#150;
 <i>checklist</i> (<a href=#f1>Figura 1</a>) &#150; especificando    o passo a p
asso da t&eacute;cnica de coleta, dos cuidados com o frasco coletor,    da higie
niza&ccedil;&atilde;o de m&atilde;os e mamas, do local adequado, dos    instrume
ntos usados, da pr&eacute;-estocagem, entre outros itens. Nas visitas    domicil
iares semanais, entregou-se o formul&aacute;rio a cada doadora juntamente    com
 um folheto educativo. A cada caso de descarte de leite, reportou-se &agrave;   
 doadora durante a visita domiciliar seguinte para revis&atilde;o do checklist, 
   a fim de se diagnosticar a poss&iacute;vel falha na conduta e registr&aacute;
-la    na ficha "Identifica&ccedil;&atilde;o e medidas adotadas nos casos de lei
te    humano n&atilde;o-conforme". Os dados foram analisados pelos c&aacute;lcul
os    de compara&ccedil;&atilde;o de propor&ccedil;&otilde;es para os anos de 20
06    e 2008.</font></p>     ^cY#a08v86n4.htm##
00267000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003300075002001300108#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#35#31#article#93#<p><a name="f1"></a>
</p>     ^cY#a08v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#36#32#article#93#<p>&nbsp;</p>     ^c
Y#a08v86n4.htm##
00312000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007800075002001300153#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#37#33#article#93#<p align="center"><i
mg src="/img/revistas/jped/v86n4/4a08f1.gif"></p>     ^cY#a08v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#38#34#article#93#<p>&nbsp;</p>     ^c
Y#a08v86n4.htm##
00545000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704031100075002001300386#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#39#35#article#93#<p><font face="Verda
na" size="2">Este estudo foi aprovado pelo Comit&ecirc; de &Eacute;tica em Pesqu
isa do HC-UFPR    sob n&uacute;mero 2115.010/2010-01 e pelo Certificado de Apres
enta&ccedil;&atilde;o    para Aprecia&ccedil;&atilde;o &Eacute;tica (CAAE) sob n
&uacute;mero 0313.0.208.000-10.</font></p>     ^cY#a08v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#40#36#article#93#<p>&nbsp;</p>     ^c
Y#a08v86n4.htm##
00304000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007000075002001300145#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#41#37#article#93#<p><font size="3" fa
ce="Verdana"><b>Resultados</b></font></p>     ^cY#a08v86n4.htm##
00686000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704045200075002001300527#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#42#38#article#93#<p><font face="Verda
na" size="2">Em 2006, detectaram-se 898 casos de descarte    de 741 doadoras. Em
 2008, detectaram-se 501 casos de descarte de 392 doadoras.    A causa de descar
te foi identificada em 596 (66,36%) e 415 (82,83%) casos para    2006 e 2008, re
spectivamente. Em rela&ccedil;&atilde;o ao volume total coletado,    dos 2.340 L
 de 2006, 24% foram descartados; em 2008, dos 2.029 L coletados,    10,5% foram 
descartados.</font></p>     ^cY#a08v86n4.htm##
00740000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704050600075002001300581#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#43#39#article#93#<p><font face="Verda
na" size="2">As causas do descarte foram reunidas em grupos    de acordo com a e
tapa do processo, desde a ordenha at&eacute; a chegada ao BLH    em situa&ccedil
;&otilde;es relacionadas &agrave; coleta; &agrave; pr&eacute;-estocagem;    ao t
ransporte; &agrave; orienta&ccedil;&atilde;o indireta; a outros motivos    para 
o descarte; e a casos n&atilde;o-identificados. Os dados est&atilde;o apresentad
os    na <a href=/img/revistas/jped/v86n4/4a08t1.gif>Tabela 1</a>.</font></p>   
  ^cY#a08v86n4.htm##
00942000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704070800075002001300783#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#44#40#article#93#<p><font face="Verda
na" size="2">Na an&aacute;lise comparativa das propor&ccedil;&otilde;es    dos a
nos de 2006 e 2008, observou-se redu&ccedil;&atilde;o significativa (p    &lt; 0
,05) no descarte de leite para os itens cheiro de cigarro; esquecimento    do le
ite fora, no corpo ou na porta da geladeira; problemas com o <i>freezer</i>;    
abrir muito a geladeira e o<i> freezer</i>; prazo de validade vencido e casos   
 n&atilde;o-identificados. Os itens primeira coleta sem orienta&ccedil;&atilde;o
;    uso de frasco n&atilde;o-conforme; transporte do leite do trabalho para cas
a;    e orienta&ccedil;&atilde;o indireta apresentaram aumentos significativos (
p    &lt; 0,05) de descarte.</font></p>     ^cY#a08v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#45#41#article#93#<p>&nbsp;</p>     ^c
Y#a08v86n4.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007600075002001300151#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#46#42#article#93#<p><font size="3" fa
ce="Verdana"><b>Discuss&atilde;o</b></font></p>     ^cY#a08v86n4.htm##
00682000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704044800075002001300523#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#47#43#article#93#<p><font face="Verda
na" size="2">Na literatura, encontram-se v&aacute;rios trabalhos    que relatam 
o descarte de leite doado cru em BLH pela an&aacute;lise visual,    do <i>off fl
avor </i>e teste da titula&ccedil;&atilde;o de acidez, entretanto    n&atilde;o 
se encontram relatos que investigam as causas que levam &agrave;s    altera&cced
il;&otilde;es das propriedades do leite que o tornam impr&oacute;prio    para o 
consumo.</font></p>     ^cY#a08v86n4.htm##
00900000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704066600075002001300741#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#48#44#article#93#<p><font face="Verda
na" size="2">Dentre os motivos para o descarte de leite agrupados    no item col
eta, a causa apontada como primeira coleta sem orienta&ccedil;&atilde;o    apres
entou um aumento significativo em 2008. Houve aumento de campanhas publicit&aacu
te;rias    para capta&ccedil;&atilde;o de doadoras cujas informa&ccedil;&otilde;
es eram    superficiais e n&atilde;o t&eacute;cnicas. Somam-se a isso, casos em 
que as    doadoras foram orientadas por outras institui&ccedil;&otilde;es ou por
 leigos,    e quando a visita domiciliar foi solicitada ao BLH, o estoque de lei
te j&aacute;    havia sido realizado para a doa&ccedil;&atilde;o. </font></p>   
  ^cY#a08v86n4.htm##
01029000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704079500075002001300870#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#49#45#article#93#<p><font face="Verda
na" size="2">No que diz respeito ao cheiro de cigarro, a lactose    tem propried
ades de sor&ccedil;&atilde;o de subst&acirc;ncias que se vaporizam    no ambient
e e modificam o odor natural do leite humano<SUP>2,9</SUP>, determinando    <i>o
ff flavor</i>, que &eacute; uma forma segura de identificar a ocorr&ecirc;ncia  
  de modifica&ccedil;&otilde;es f&iacute;sico-qu&iacute;micas que tornam o leite
    impr&oacute;prio ao consumo<SUP>10</SUP>. Em 2006, as doadoras relataram que
    n&atilde;o eram fumantes, mas que havia pessoas fumando no ambiente onde rea
lizavam    a ordenha. Com orienta&ccedil;&atilde;o refor&ccedil;ada para esse as
pecto,    houve uma redu&ccedil;&atilde;o significativa em 2008, n&atilde;o se e
ncontrando    casos para este item.</font></p>     ^cY#a08v86n4.htm##
01099000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704086500075002001300940#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#50#46#article#93#<p><font face="Verda
na" size="2">No grupo pr&eacute;-estocagem, os itens esquecimento    do leite fo
ra, no corpo ou na porta da geladeira; problemas com o <i>freezer</i>;    abrir 
muito a geladeira e o <i>freezer</i>; prazo de validade vencido; e armazenar    
o leite na geladeira da vizinha apresentaram redu&ccedil;&atilde;o dos casos    
em 2008. Para todos esses itens, a melhoria dos resultados foi atribu&iacute;da 
   &agrave; orienta&ccedil;&atilde;o acompanhada pelo <i>checklist</i>. Entretan
to,    para o item uso de frasco n&atilde;o-conforme, observou-se aumento dos ca
sos    como fator independente da orienta&ccedil;&atilde;o, pois, em muitas situ
a&ccedil;&otilde;es,    houve aumento do volume de leite esgotado na semana pela
 doadora, excedendo    o n&uacute;mero de frascos esterilizados fornecidos pelo 
BLH para o armazenamento.</font></p>     ^cY#a08v86n4.htm##
00976000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704074200075002001300817#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#51#47#article#93#<p><font face="Verda
na" size="2">Quanto ao transporte, algumas doadoras trabalhavam    em &aacute;re
as n&atilde;o abrangidas pela rota da coleta domiciliar e, por    isso, transpor
taram o leite esgotado na empresa para casa, situada em regi&atilde;o    atendid
a pela visita, sendo a &uacute;nica raz&atilde;o encontrada para justificar    o
 motivo de descarte no transporte. O LHOC deve obrigatoriamente ser transportado
    sob a cadeia de frio, em embalagens isot&eacute;rmicas de material liso, res
istente,    imperme&aacute;vel, de f&aacute;cil sanitiza&ccedil;&atilde;o, exclu
sivas para    esse fim, sendo que, para o leite congelado, a temperatura m&aacut
e;xima n&atilde;o    pode ultrapassar -1 ºC<SUP>1,4,8,9</SUP>.</font></p>     ^c
Y#a08v86n4.htm##
01156000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704092200075002001300997#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#52#48#article#93#<p><font face="Verda
na" size="2">Quanto &agrave; orienta&ccedil;&atilde;o indireta,    houve aumento
 no n&uacute;mero de casos de descarte de leite. O BLH do HC-UFPR    recebe leit
e coletado de nutrizes orientadas em outros hospitais, onde seus    filhos est&a
tilde;o internados. Essas doadoras realizam a coleta no domic&iacute;lio    e o 
transportam at&eacute; o hospital, e deste o leite &eacute; encaminhado    ao BL
H do HC-UFPR. Nesse fluxograma, n&atilde;o &eacute; poss&iacute;vel o contato   
 direto do BLH do HC-UFPR com as doadoras. Mesmo com as palestras de orienta&cce
dil;&atilde;o,    existe grande rotatividade de profissionais nos hospitais, per
mitindo per&iacute;odos    com t&eacute;cnicos sem o devido treinamento. &Eacute
; prov&aacute;vel ser esta    a causa para a persist&ecirc;ncia do resultado do 
descarte de leite no item    orienta&ccedil;&atilde;o indireta nos anos estudado
s.</font></p>     ^cY#a08v86n4.htm##
00897000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704066300075002001300738#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#53#49#article#93#<p><font face="Verda
na" size="2">Os casos n&atilde;o identificados retratam o    n&atilde;o-diagn&oa
cute;stico da causa do descarte ap&oacute;s a revis&atilde;o    pelo profissiona
l do BLH durante a visita domiciliar. No ano de 2006, a revis&atilde;o    foi re
alizada atrav&eacute;s de conversa informal entre o profissional e a doadora.   
 No ano de 2008, houve mudan&ccedil;a na estrat&eacute;gia de revis&atilde;o,   
 sendo acompanhada com o passo-a-passo do <i>checklist</i>. Acredita-se na intro
du&ccedil;&atilde;o    do <i>checklist</i> como a raz&atilde;o de diminui&ccedil
;&atilde;o significativa    dos casos n&atilde;o-identificados.</font></p>     ^
cY#a08v86n4.htm##
01262000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704102800075002001301103#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#54#50#article#93#<p><font face="Verda
na" size="2">Acreditamos que a introdu&ccedil;&atilde;o do    <i>checklist</i> n
a rotina de visita domiciliar resultou em mudan&ccedil;a de    comportamento nas
 doadoras, possivelmente por melhorar a rela&ccedil;&atilde;o    profissional/do
adora. Em 2006, apenas com a estrat&eacute;gia de conversa informal    com as do
adoras cujos leites foram desprezados, observou-se, em alguns casos,    constran
gimento por parte da doadora devido &agrave; informa&ccedil;&atilde;o    e por p
arte do profissional ao inform&aacute;-la. Entretanto, com a inclus&atilde;o    
do <i>checklist</i>, no ano de 2008, acompanhado da explica&ccedil;&atilde;o    
passo a passo pelo profissional, observou-se melhoria no di&aacute;logo entre   
 profissional e doadora e, ainda, o interesse manifestado pelas doadoras sobre  
  o aproveitamento do seu leite doado. Percebeu-se que o <i>checklist</i> foi   
 adotado como um documento de compromisso pelas doadoras, prezando pela qualidad
e    de seu leite ordenhado.</font></p>     ^cY#a08v86n4.htm##
01675000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704144100075002001301516#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#55#51#article#93#<p><font face="Verda
na" size="2">O leite humano da pr&oacute;pria m&atilde;e &eacute;    a primeira 
op&ccedil;&atilde;o em termos de qualidade para todos os lactentes,    e o leite
 de BLH &eacute; a segunda melhor op&ccedil;&atilde;o, pois, mesmo    com o proc
essamento,&nbsp; mant&eacute;m as propriedades nutricionais, metab&oacute;licas,
    protetoras e anti-infecciosas<SUP>2,7,11</SUP>, especialmente ao prematuro q
ue    necessita adaptar o seu metabolismo ao ambiente extrauterino ao qual foi e
xposto    precocemente. Para o desenvolvimento mais pr&oacute;ximo poss&iacute;v
el do    ambiente uterino, &eacute; necess&aacute;rio garantir a qualidade total
 do leite    do BLH, devendo ser esta a grande preocupa&ccedil;&atilde;o dos pro
fissionais    e das doadoras. Embora a pasteuriza&ccedil;&atilde;o seja um proce
sso que garante    a elimina&ccedil;&atilde;o de 99% da flora sapr&oacute;fita e
 100% da flora    patog&ecirc;nica<SUP>1,2,4,8,9</SUP>, &eacute; absolutamente n
ecess&aacute;rio    que o leite seja protegido de contamina&ccedil;&atilde;o pr&
eacute;via, a fim    de preservar os seus componentes at&eacute; a distribui&cce
dil;&atilde;o ao    rec&eacute;m-nascido internado. O recebimento de leite de qu
alidade pelo BLH    est&aacute; diretamente relacionado aos cuidados na t&eacute
;cnica e &agrave;    percep&ccedil;&atilde;o da import&acirc;ncia da doa&ccedil;
&atilde;o aos neonatos    pelas doadoras.</font></p>     ^cY#a08v86n4.htm##
01038000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704080400075002001300879#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#56#52#article#93#<p><font face="Verda
na" size="2">Encontram-se v&aacute;rios trabalhos sobre a    qualidade do leite 
humano na literatura, por&eacute;m todos direcionados &agrave;s    causas de des
carte do leite no controle interno dos BLH, quanto aos crit&eacute;rios    visua
l, <i>off flavor</i> e acidez adotados na rotina de sele&ccedil;&atilde;o    de 
LHOC. Considerando-se a aus&ecirc;ncia de refer&ecirc;ncias acerca das causas   
 do descarte do leite relacionadas &agrave;s doadoras, este trabalho evidenciou 
   a real import&acirc;ncia de realizar a rastreabilidade do leite humano desde 
   o in&iacute;cio do processo de obten&ccedil;&atilde;o, a fim de se conhecer  
  e combater os motivos que resultam nas altera&ccedil;&otilde;es do leite e oti
mizar    o aproveitamento do leite recebido.</font></p>     ^cY#a08v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#57#53#article#93#<p>&nbsp;</p>     ^c
Y#a08v86n4.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704007700075002001300152#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#58#54#article#93#<p><font size="3" fa
ce="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#a08v86n4.htm##
00568000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704032000077002001300397#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a08v86n4.htm#S#p#59#55#article#93#1#<p><fo
nt size="2" face="Verdana">1. BRASIL. Minist&eacute;rio da Sa&uacute;de.    Norm
as e Manuais T&eacute;cnicos, N117. Recomenda&ccedil;&otilde;es t&eacute;cnicas 
   para o funcionamento de Bancos de Leite Humano. 4a Ed. Bras&iacute;lia: Minis
t&eacute;rio    da Sa&uacute;de. Reimpress&atilde;o junho de 2001.    ^cY#a08v86
n4.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#60#56#article#93#</font></p>     ^cY#
a08v86n4.htm##
00400000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704015200077002001300229#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a08v86n4.htm#S#p#61#57#article#93#2#<p><fo
nt size="2" face="Verdana">2. Almeida JA. Amamenta&ccedil;&atilde;o: um    h&iac
ute;brido natureza-cultura. Rio de Janeiro: FIOCRUZ; 1999.    ^cY#a08v86n4.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#62#58#article#93#</font></p>     ^cY#
a08v86n4.htm##
00485000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704023700077002001300314#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a08v86n4.htm#S#p#63#59#article#93#3#<p><fo
nt size="2" face="Verdana">3. Mattar MJ, Kuzuhara JS, Gomes AM. Banco de    Leit
e Humano. In: Neto CM, editor. FEBRASGO - Manual de orienta&ccedil;&atilde;o    
de aleitamento materno. S&atilde;o Paulo: Ponto; 2006. p.130-8.    ^cY#a08v86n4.
htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#64#60#article#93#</font></p>     ^cY#
a08v86n4.htm##
00457000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704020900077002001300286#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a08v86n4.htm#S#p#65#61#article#93#4#<p><fo
nt size="2" face="Verdana">4. BRASIL. Minist&eacute;rio da Sa&uacute;de.    Prog
rama Nacional de Qualidade em Bancos de Leite Humano: curso de implanta&ccedil;&
atilde;o.    Bras&iacute;lia; 2003.    ^cY#a08v86n4.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#66#62#article#93#</font></p>     ^cY#
a08v86n4.htm##
00480000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704023200077002001300309#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a08v86n4.htm#S#p#67#63#article#93#5#<p><fo
nt size="2" face="Verdana">5. Almeida JA. Qualidade do leite humano coletado    
e processado em bancos de leite &#091;disserta&ccedil;&atilde;o&#093;. Vi&ccedil
;osa (MG):    Universidade Federal de Vi&ccedil;osa; 1986.    ^cY#a08v86n4.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#68#64#article#93#</font></p>     ^cY#
a08v86n4.htm##
00551000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704030300077002001300380#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a08v86n4.htm#S#p#69#65#article#93#6#<p><fo
nt size="2" face="Verdana">6. Cavalcante JL, Telles FJ. Aspectos f&iacute;sicos-
qu&iacute;micos    do leite humano ordenhado cru e congelado. In: Buss PM, Almei
da JA, Novak FR,    editores. Teses. III Congresso Brasileiro de Bancos de Leite
 Humano. Rio de    Janeiro: FIOCRUZ; 2002. p. 43.    ^cY#a08v86n4.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#70#66#article#93#</font></p>     ^cY#
a08v86n4.htm##
00389000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704014100077002001300218#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a08v86n4.htm#S#p#71#67#article#93#7#<p><fo
nt size="2" face="Verdana">7. Victora CG. Infection and disease: the impact    o
f early weaning. Food Nutr Bull. 1996;17:390-6.    ^cY#a08v86n4.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#72#68#article#93#</font></p>     ^cY#
a08v86n4.htm##
00577000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704032900077002001300406#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a08v86n4.htm#S#p#73#69#article#93#8#<p><fo
nt size="2" face="Verdana">8. BRASIL. Ag&ecirc;ncia Nacional de Vigil&acirc;ncia
    Sanit&aacute;ria. Resolu&ccedil;&atilde;o RDC nº171, de 4 de setembro de 200
6.    Disp&otilde;e sobre o regulamento t&eacute;cnico para funcionamento de BLH
.    Di&aacute;rio Oficial da Uni&atilde;o. Bras&iacute;lia, DF. 5/09/2006.    ^
cY#a08v86n4.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#74#70#article#93#</font></p>     ^cY#
a08v86n4.htm##
00550000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000200075704030200077002001300379#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a08v86n4.htm#S#p#75#71#article#93#9#<p><fo
nt size="2" face="Verdana">9. Brasil. Ag&ecirc;ncia Nacional de Vigil&acirc;ncia
    Sanit&aacute;ria. Banco de leite humano: funcionamento, preven&ccedil;&atild
e;o    e controle de riscos/Ag&ecirc;ncia Nacional de Vigil&acirc;ncia Sanit&aac
ute;ria.    Bras&iacute;lia: Anvisa; 2008. 160p.    ^cY#a08v86n4.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#76#72#article#93#</font></p>     ^cY#
a08v86n4.htm##
00448000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704019900078002001300277#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a08v86n4.htm#S#p#77#73#article#93#10#<p><f
ont size="2" face="Verdana">10. Novak FR, Junqueira AR, Dias Mde S, Almeida    J
A. Sensorial analysis of expressed human milk and its microbial load. J Pediatr 
   (Rio J). 2008;84:181-4.    ^cY#a08v86n4.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#78#74#article#93#</font></p>     ^cY#
a08v86n4.htm##
00454000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072888000300075704020500078002001300283#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a08v86n4.htm#S#p#79#75#article#93#11#<p><f
ont size="2" face="Verdana">11. Vinagre RD, Diniz EM. O leite humano e sua    im
port&acirc;ncia na nutri&ccedil;&atilde;o do rec&eacute;m-nascido prematuro.    
S&atilde;o Paulo: Atheneu; 2002.    ^cY#a08v86n4.htm##
00254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002000075002001300095#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#80#76#article#93#</font></p>     ^cY#
a08v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#81#77#article#93#<p>&nbsp;</p>     ^c
Y#a08v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#82#78#article#93#<p>&nbsp;</p>     ^c
Y#a08v86n4.htm##
00414000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704018000075002001300255#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#83#79#article#93#<p><font size="2" fa
ce="Verdana"><a name="correspondence"></a><a href="#topo"><img src="/img/revista
s/jped/v86n4/seta.gif" border="0"></a>    <b> Correspond&ecirc;ncia:</b>    ^cY#
a08v86n4.htm##
00285000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704005100075002001300126#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#84#80#article#93#<br>   Maria Celesti
na Bonzanini Grazziotin    ^cY#a08v86n4.htm##
00299000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704006500075002001300140#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#85#81#article#93#<BR>   Banco de Leit
e Humano, Hospital de Cl&iacute;nicas    ^cY#a08v86n4.htm##
00286000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704005200075002001300127#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#86#82#article#93#<BR>   Universidade 
Federal do Paran&aacute;    ^cY#a08v86n4.htm##
00283000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004900075002001300124#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#87#83#article#93#<BR>   Rua General C
arneiro, 181, Centro     ^cY#a08v86n4.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004400075002001300119#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#88#84#article#93#<BR>   CEP 80.060-90
0 - Curitiba, PR    ^cY#a08v86n4.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704003500075002001300110#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#89#85#article#93#<BR>   Tel.: (41) 33
60.1867    ^cY#a08v86n4.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704009700075002001300172#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#90#86#article#93#<BR>   E-mail: <A hr
ef=mailto:celestinabg@gmail.com>celestinabg@gmail.com</A></font></p>     ^cY#a08
v86n4.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704010600075002001300181#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#91#87#article#93#<p><font size="2" fa
ce="Verdana">Artigo submetido em 17.12.2009, aceito em 30.04.2010.</font></p>   
  ^cY#a08v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#92#88#article#93#<p>&nbsp;</p>     ^c
Y#a08v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704002200075002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#93#89#article#93#<p>&nbsp;</p>     ^c
Y#a08v86n4.htm##
00276000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704004200075002001300117#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#94#90#article#93#<p><font size="2" fa
ce="Verdana">     ^cY#a08v86n4.htm##
00361000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704012700075002001300202#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#95#91#article#93#<br>   N&atilde;o fo
ram declarados conflitos de interesse associados &agrave; publica&ccedil;&atilde
;o    deste artigo.    ^cY#a08v86n4.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704012400075002001300199#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#96#92#article#93#<br>   Apoio finance
iro: Hospital de Cl&iacute;nicas, Universidade Federal do Paran&aacute;    (UFPR
), Curitiba, PR.    ^cY#a08v86n4.htm##
00388000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000300072704015400075002001300229#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a08v86n4.htm#S#p#97#93#article#93#<br>   Estudo realiz
ado no Banco de Leite Humano, Hospital de Clinicas, Universidade    Federal do P
aran&aacute; (UFPR), Curitiba, PR.</font></p>     ^cY#a08v86n4.htm##
00483000000000217000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740170028000760180107001040630
00200211066001000213062002000223865000900243002001300252#v86n4#V:\Scielo\serial\
jped\v86n4\markup\a08v86n4.htm#S#c#98#1#article#11#1#BRASIL^dMinistério da Saúde
#Normas e Manuais Técnicos, N117. Recomendações técnicas para o funcionamento de
 Bancos de Leite Humano^lpt#4#Brasí­lia#Ministério da Saúde#20100800#a08v86n4.ht
m##
00431000000000229000450000400060000070200480000670500020005470600020005670000030
00587010002000617090008000637080003000711180002000740160019000760180047000950660
01500142062000800157065000900165064000500174865000900179002001300188#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a08v86n4.htm#S#c#99#2#article#11#2#^rND^sAlmeida^n
JA.#Amamentação: um hí­brido natureza-cultura.^lpt#Rio de Janeiro#FIOCRUZ#199900
00#1999#20100800#a08v86n4.htm##
00577000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100019000940100
01600113012002600129016001500155018005900170066001000229062000600239014000600245
065000900251064000500260865000900265002001300274#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a08v86n4.htm#S#c#100#3#article#11#3#^rND^sMattar^nMJ#^rND^sKuzuhara^nJ
S#^rND^sGomes^nAM#Banco de Leite Humano^lpt#^rED^sNeto^nCM#FEBRASGO - Manual de 
orientação de aleitamento materno^lpt#São Paulo#Ponto#130-8#20060000#2006#201008
00#a08v86n4.htm##
00453000000000217000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170028000770180084001050660
01000189065000900199064000500208865000900213002001300222#v86n4#V:\Scielo\serial\
jped\v86n4\markup\a08v86n4.htm#S#c#101#4#article#11#4#BRASIL^dMinistério da Saúd
e#Programa Nacional de Qualidade em Bancos de Leite Humano: curso de implantação
.^lpt#Brasí­lia#20030000#2003#20100800#a08v86n4.htm##
00498000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160018000770180071000950510
01200166066001100178062003100189065000900220064000500229865000900234002001300243
#v86n4#V:\Scielo\serial\jped\v86n4\markup\a08v86n4.htm#S#c#102#5#article#11#5#^r
ND^sAlmeida^nJA#Qualidade do leite humano coletado e processado em bancos de lei
te^lpt#dissertação#Viçosa^eMG#Universidade Federal de Viçosa#19860000#1986#20100
800#a08v86n4.htm##
00682000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100021000770100017000980120
07400115016001500189016001800204016001600222018001000238053005800248066001500306
062000800321014000300329065000900332064000500341865000900346002001300355#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a08v86n4.htm#S#c#103#6#article#11#6#^rND^sCava
lcante^nJL#^rND^sTelles^nFJ#Aspectos fí­sicos-quí­micos do leite humano ordenhad
o cru e congelado^lpt#^rED^sBuss^nPM#^rED^sAlmeida^nJA#^rED^sNovak^nFR#Teses^lpt
#Congresso Brasileiro de Bancos de Leite Humano^nIII^i1^i1#Rio de Janeiro#FIOCRU
Z#43#20020000#2002#20100800#a08v86n4.htm##
00501000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770120055000950300
01500150065000900165064000500174031000300179014000600182865000900188002001300197
035001000210801001500220#v86n4#V:\Scielo\serial\jped\v86n4\markup\a08v86n4.htm#S
#c#104#7#article#11#7#^rND^sVictora^nCG#Infection and disease: the impact of ear
ly weaning^len#Food Nutr Bull#19960000#1996#17#390-6#20100800#a08v86n4.htm#0379-
5721#Food Nutr Bull##
00546000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170049000770180112001260620
02400238066001300262065000900275064001000284865000900294002001300303#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a08v86n4.htm#S#c#105#8#article#11#8#BRASIL^dAgênci
a Nacional de Vigilância Sanitária#Resolução RDC nº171, de 4 de setembro de 2006
. Dispõe sobre o regulamento técnico para funcionamento de BLH^lpt#Diário Oficia
l da União#Brasília^eDF#20060905#5/09/2006#20100800#a08v86n4.htm##
00522000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170049000770180114001260660
00900240062000700249065000900256064000500265865000900270002001300279#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a08v86n4.htm#S#c#106#9#article#11#9#Brasil^dAgênci
a Nacional de Vigilância Sanitária#Banco de leite humano: funcionamento, prevenç
ão e controle de riscos/Agência Nacional de Vigilância Sanitária^lpt#Brasília#An
visa#20080000#2008#20100800#a08v86n4.htm##
00614000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100020000950100
01800115010001800133012007000151030001800221065000900239064000500248031000300253
014000600256865000900262002001300271035001000284801001800294#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a08v86n4.htm#S#c#107#10#article#11#10#^rND^sNovak^nFR#^rND
^sJunqueira^nAR#^rND^sDias Mde^nS#^rND^sAlmeida^nJA#Sensorial analysis of expres
sed human milk and its microbial load^len#J Pediatr (Rio J)#20080000#2008#84#181
-4#20100800#a08v86n4.htm#0021-7557#J Pediatr (Rio J)##
00485000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160018000790160016000970180
07600113066001000189062000800199065000900207064000500216865000900221002001300230
#v86n4#V:\Scielo\serial\jped\v86n4\markup\a08v86n4.htm#S#c#108#11#article#11#11#
^rND^sVinagre^nRD#^rND^sDiniz^nEM#O leite humano e sua importância na nutrição d
o recém-nascido prematuro^lpt#São Paulo#Atheneu#20020000#2002#20100800#a08v86n4.
htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#o#1#1#article#1
#20110126#175509#a09v86n4.htm#171##
06163000000000745000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000210011303100030013403200020013706500090013901400110014803500100015901200740
01690120074002430100036003170100045003530100040003980100035004380700080004730700
05100553070016300604070014300767070003000910070009000940070005101030083185401081
08500100293508500430294508500350298808500330302308500330305608319770308908500100
50660850039050760850032051150850031051470850029051781170008052070720003052151120
00905218111001105227114000905238113001105247058005605258060001405314058006205328
060001405390002001305404#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S
#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#09#JPED030#nd#J. Pediatr. (Rio J.)#8
6#4#20100800#^f295^l302#0021-7557#Avaliação do perfil de nascimentos e óbitos em
 hospital de referência^lpt#Assessment of the profile of births and deaths in a 
referral hospital^len#^rND^1A01^nMaria Albertina S.^sRego#^rND^1A02 A03 A04^nEli
sabeth Barboza^sFrança#^rND^1A05^nAna Paula Azevedo^sTravassos#^rND^1A06 A07^nFe
rnando C.^sBarros#UFMG^iA01^1Faculdade de Medicina^2Departamento de Pediatria^cB
elo Horizonte^sMG#University of Queensland^iA02^cBrisbane^pAustrália#UFMG^iA03^1
Faculdade de Medicina^2Departamento de Pediatria^3Programa de Pós-Graduação em C
iências da Saúde, Saúde da Criança e do Adolescente^cBelo Horizonte^sMG#UFMG^iA0
4^1Faculdade de Medicina^2Departamento de Medicina Preventiva e Social^3Programa
 de Pós-Graduação em Saúde Pública^cBelo Horizonte^sMG#UFMG^iA05^cBelo Horizonte
^sMG#University of London^iA06^1Escola de Higiene e Medicina Tropical^cLondres^p
United Kingdom#Universidade Católica de Pelotas^iA07^cPelotas^sRS#^lpt^aOBJETIVO
: Comparar indicadores perinatais em hospital universitário de Belo Horizonte (M
G). MÉTODOS: Foram comparados indicadores e resultados perinatais de nascidos vi
vos de partos únicos do Hospital de Clínicas da Universidade Federal de Minas Ge
rais, Belo Horizonte, em dois períodos, 1995-1998 e 2003-2006. Utilizou-se o tes
te do qui-quadrado e teste t de Student com nível de significância de 5% e risco
 relativo com intervalo de confiança de 95% nas análises. As informações foram o
btidas do banco de dados do Sistema Informático Perinatal (SIP)/Centro Latinoame
ricano de Perinatología (CLAP)/Organização Pan-Americana da Saúde (OPAS), do hos
pital e complementadas por consulta em prontuário. RESULTADOS: A média da idade 
das mães foi em torno de 26 anos. Verificou-se aumento médio de uma consulta de 
pré-natal, independentemente do peso ao nascer, e diminuição significativa dos p
artos cesáreos no segundo período. A idade gestacional média nos dois períodos f
oi de 38 semanas, com alta proporção de prematuros (17,0 e 16,7%, respectivament
e). A proporção de recém-nascidos < 2.500 g foi alta nos dois períodos (17,6 e 1
6,6%, respectivamente), com redução na proporção dos pequenos para a idade gesta
cional. A mortalidade neonatal precoce, excluídos os defeitos congênitos, foi de
 12,4 óbitos por 1.000 nascidos vivos no primeiro período, de 8,0 no segundo e r
eduziu significativamente para recém-nascidos com idade gestacional < 34 semanas
. CONCLUSÕES: Diferenças importantes relativas a aspectos assistenciais e result
ados perinatais foram detectadas e são compatíveis com melhoria global da saúde 
neonatal em 2003-2006. Entretanto, a persistência de eventos neonatais sensíveis
 à redução com uso de tecnologias perinatais disponíveis indica a necessidade de
 monitoramento da assistência perinatal para todos os grupos de recém-nascidos.#
^ddecs^i1#^tm^lpt^kAvaliação de serviços de saúde^i1#^tm^lpt^ksistemas de inform
ação^i1#^tm^lpt^kmortalidade neonatal^i1#^tm^lpt^kmortalidade infantil^i1#^len^a
OBJECTIVE: To compare perinatal health indicators in a referral hospital in Belo
 Horizonte, Brazil. METHODS: Perinatal results and indicators of single live bir
ths in Hospital das Clínicas of Universidade Federal de Minas Gerais (UFMG), Bel
o Horizonte, Brazil, were compared for two periods, 1995-1998 and 2003-2006. The
 chi-square test and Student's t test were applied with 5% significance level an
d 95% confidence interval. Data were obtained from the Perinatal Information Sys
tem (Sistema Informático Perinatal, SIP), Latin American Center for Perinatology
 (Centro Latinoamericano de Perinatología, CLAP), Pan American Health Organizati
on (PAHO), Hospital das Clínicas, and from medical records. RESULTS: Mothers wer
e approximately 26 years old on average. The number of prenatal appointments had
 an average increase of one appointment, regardless of birth weight, and there w
as a significant decrease in the number of caesarean deliveries in the second pe
riod. The average gestational age was 38 weeks in both periods, with a high rate
 of premature births (17.0 and 16.7%, respectively). The rate of newborns < 2,50
0 g was high in both periods (17.6 and 16.6%, respectively) with a decrease in t
he rate of newborns considered small for their gestational age. When congenital 
malformations were excluded, early neonatal mortality risk decreased from 12.4 p
er 1,000 live births in the first period to 8.0 per 1,000 live births in the sec
ond period, with considerable decrease for newborns with gestational age < 34 we
eks. CONCLUSIONS: Important differences were verified concerning health care ass
istance procedures and perinatal results, and they are compatible with the globa
l improvement in neonatal health observed in the 2003-2006 period. However, the 
persistence of unfortunate neonatal incidents that can be reduced with the use o
f available perinatal technologies reveals the need for constant monitoring of p
erinatal hospital care for all groups of newborns.#^ddecs^i2#^tm^len^kHealth ser
vices evaluation^i2#^tm^len^kinformation systems^i2#^tm^len^kneonatal mortality^
i2#^tm^len^kinfant mortality^i2#vancouv#28#20091103#03.11.2009#20100305#05.03.20
10#Fundação de Amparo à Pesquisa do Estado de Minas Gerais#EDT 1770/2003#Conselh
o Nacional de Desenvolvimento Científico e Tecnológico#403707/2004-8#a09v86n4.ht
m##
06376000000000745000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000210011303100030013403200020013706500090013901400110014803500100015901200810
01690120081002500100036003310100045003670100040004120100035004520700080004870700
05100567070016300618070014300781070003000924070009000954070005101044083189501095
08500100299008500430300008500350304308500330307808500330311108320180314408500100
51620850039051720850032052110850031052430850029052741170008053030720003053111120
00905314111001105323114000905334113001105343058005605354060007305410058006205483
060007205545002001305617#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S
#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#09#JPED030#nd#J. Pediatr. (Rio J.)#8
6#4#20100800#^f295^l302#0021-7557#<b>Avaliação do perfil de nascimentos e óbitos
 em hospital de referência</b>^lpt#<b>Assessment of the profile of births and de
aths in a referral hospital</b>^len#^rND^1A01^nMaria Albertina S.^sRego#^rND^1A0
2 A03 A04^nElisabeth Barboza^sFrança#^rND^1A05^nAna Paula Azevedo^sTravassos#^rN
D^1A06 A07^nFernando C.^sBarros#UFMG^iA01^1Faculdade de Medicina^2Departamento d
e Pediatria^cBelo Horizonte^sMG#University of Queensland^iA02^cBrisbane^pAustrál
ia#UFMG^iA03^1Faculdade de Medicina^2Departamento de Pediatria^3Programa de Pós-
Graduação em Ciências da Saúde, Saúde da Criança e do Adolescente^cBelo Horizont
e^sMG#UFMG^iA04^1Faculdade de Medicina^2Departamento de Medicina Preventiva e So
cial^3Programa de Pós-Graduação em Saúde Pública^cBelo Horizonte^sMG#UFMG^iA05^c
Belo Horizonte^sMG#University of London^iA06^1Escola de Higiene e Medicina Tropi
cal^cLondres^pUnited Kingdom#Universidade Católica de Pelotas^iA07^cPelotas^sRS#
^lpt^a<b>OBJETIVO: </b>Comparar indicadores perinatais em hospital universitário
 de Belo Horizonte (MG). <b>MÉTODOS: </b>Foram comparados indicadores e resultad
os perinatais de nascidos vivos de partos únicos do Hospital de Clínicas da Univ
ersidade Federal de Minas Gerais, Belo Horizonte, em dois períodos, 1995-1998 e 
2003-2006. Utilizou-se o teste do qui-quadrado e teste <i>t</i> de Student com n
ível de significância de 5% e risco relativo com intervalo de confiança de 95% n
as análises. As informações foram obtidas do banco de dados do Sistema Informáti
co Perinatal (SIP)/Centro Latinoamericano de Perinatología (CLAP)/Organização Pa
n-Americana da Saúde (OPAS), do hospital e complementadas por consulta em prontu
ário. <b>RESULTADOS: </b>A média da idade das mães foi em torno de 26 anos. Veri
ficou-se aumento médio de uma consulta de pré-natal, independentemente do peso a
o nascer, e diminuição significativa dos partos cesáreos no segundo período. A i
dade gestacional média nos dois períodos foi de 38 semanas, com alta proporção d
e prematuros (17,0 e 16,7%, respectivamente). A proporção de recém-nascidos &lt;
 2.500 g foi alta nos dois períodos (17,6 e 16,6%, respectivamente), com redução
 na proporção dos pequenos para a idade gestacional. A mortalidade neonatal prec
oce, excluídos os defeitos congênitos, foi de 12,4 óbitos por 1.000 nascidos viv
os no primeiro período, de 8,0 no segundo e reduziu significativamente para recé
m-nascidos com idade gestacional &lt; 34 semanas. <b>CONCLUSÕES: </b>Diferenças 
importantes relativas a aspectos assistenciais e resultados perinatais foram det
ectadas e são compatíveis com melhoria global da saúde neonatal em 2003-2006. En
tretanto, a persistência de eventos neonatais sensíveis à redução com uso de tec
nologias perinatais disponíveis indica a necessidade de monitoramento da assistê
ncia perinatal para todos os grupos de recém-nascidos.#^ddecs^i1#^tm^lpt^kAvalia
ção de serviços de saúde^i1#^tm^lpt^ksistemas de informação^i1#^tm^lpt^kmortalid
ade neonatal^i1#^tm^lpt^kmortalidade infantil^i1#^len^a<b>OBJECTIVE: </b>To comp
are perinatal health indicators in a referral hospital in Belo Horizonte, Brazil
. <b>METHODS: </b>Perinatal results and indicators of single live births in Hosp
ital das Clínicas of Universidade Federal de Minas Gerais (UFMG), Belo Horizonte
, Brazil, were compared for two periods, 1995-1998 and 2003-2006. The chi-square
 test and Student's <i>t</i> test were applied with 5% significance level and 95
% confidence interval. Data were obtained from the Perinatal Information System 
(Sistema Informático Perinatal, SIP), Latin American Center for Perinatology (Ce
ntro Latinoamericano de Perinatología, CLAP), Pan American Health Organization (
PAHO), Hospital das Clínicas, and from medical records. <b>RESULTS: </b>Mothers 
were approximately 26 years old on average. The number of prenatal appointments 
had an average increase of one appointment, regardless of birth weight, and ther
e was a significant decrease in the number of caesarean deliveries in the second
 period. The average gestational age was 38 weeks in both periods, with a high r
ate of premature births (17.0 and 16.7%, respectively). The rate of newborns &lt
; 2,500 g was high in both periods (17.6 and 16.6%, respectively) with a decreas
e in the rate of newborns considered small for their gestational age. When conge
nital malformations were excluded, early neonatal mortality risk decreased from 
12.4 per 1,000 live births in the first period to 8.0 per 1,000 live births in t
he second period, with considerable decrease for newborns with gestational age &
lt; 34 weeks. <b>CONCLUSIONS: </b>Important differences were verified concerning
 health care assistance procedures and perinatal results, and they are compatibl
e with the global improvement in neonatal health observed in the 2003-2006 perio
d. However, the persistence of unfortunate neonatal incidents that can be reduce
d with the use of available perinatal technologies reveals the need for constant
 monitoring of perinatal hospital care for all groups of newborns.#^ddecs^i2#^tm
^len^kHealth services evaluation^i2#^tm^len^kinformation systems^i2#^tm^len^kneo
natal mortality^i2#^tm^len^kinfant mortality^i2#vancouv#28#20091103#03.11.2009#2
0100305#05.03.2010#Fundação de Amparo à Pesquisa do Estado de Minas Gerais#<span
 style='font-size: 10.0pt;font-family:Verdana'>EDT 1770/2003</span>#Conselho Nac
ional de Desenvolvimento Científico e Tecnológico#<span style='font-size:10.0pt;
font-family:Verdana'>403707/2004-8</span>#a09v86n4.htm##
06370000000000769000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000300117049000800120
15800030012803000210013103100030015203200020015506500090015701400110016603500100
01770120074001870120074002610100035003350100045003700100040004150100034004550700
08200489070005300571070016500624070014500789070003200934070009200966070005301058
08318900111108500100300108500430301108500350305408500330308908500330312208320050
31550850010051600850039051700850032052090850031052410850029052721170008053010720
00305309112000905312111001105321114000905332113001105341058005605352060001405408
058006205422060001405484002001305498008008905511#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a09v86n4.htm#S#l#4#1#article#1#^mjul./ago.^a2010#oa#pt#br1.1#1#4.0#ilu
s#tab#09#JPED030#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f295^l302#0021-7557#Aval
iação do perfil de nascimentos e óbitos em hospital de referência^lpt#Assessment
 of the profile of births and deaths in a referral hospital^len#^rND^1A01^nMaria
 Albertina S^sRego#^rND^1A02 A03 A04^nElisabeth Barboza^sFrança#^rND^1A05^nAna P
aula Azevedo^sTravassos#^rND^1A06 A07^nFernando C^sBarros#^iA01^1UFMG^2Faculdade
 de Medicina^3Departamento de Pediatria^cBelo Horizonte^sMG#^iA02^1University of
 Queensland^cBrisbane^pAustrália#^iA03^1UFMG^2Faculdade de Medicina^3Departament
o de Pediatria. Programa de Pós-Graduação em Ciências da Saúde, Saúde da Criança
 e do Adolescente^cBelo Horizonte^sMG#^iA04^1UFMG^2Faculdade de Medicina^3Depart
amento de Medicina Preventiva e Social. Programa de Pós-Graduação em Saúde Públi
ca^cBelo Horizonte^sMG#^iA05^1UFMG^cBelo Horizonte^sMG#^iA06^1University of Lond
on^2Escola de Higiene e Medicina Tropical^cLondres^pUnited Kingdom#^iA07^1Univer
sidade Católica de Pelotas^cPelotas^sRS#^lpt^aOBJETIVO: Comparar indicadores per
inatais em hospital universitário de Belo Horizonte (MG). MÉTODOS: Foram compara
dos indicadores e resultados perinatais de nascidos vivos de partos únicos do Ho
spital de Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, em d
ois períodos, 1995-1998 e 2003-2006. Utilizou-se o teste do qui-quadrado e teste
 t de Student com nível de significância de 5 por cento e risco relativo com int
ervalo de confiança de 95 por cento nas análises. As informações foram obtidas d
o banco de dados do Sistema Informático Perinatal (SIP)/Centro Latinoamericano d
e Perinatología (CLAP)/Organização Pan-Americana da Saúde (OPAS), do hospital e 
complementadas por consulta em prontuário. RESULTADOS: A média da idade das mães
 foi em torno de 26 anos. Verificou-se aumento médio de uma consulta de pré-nata
l, independentemente do peso ao nascer, e diminuição significativa dos partos ce
sáreos no segundo período. A idade gestacional média nos dois períodos foi de 38
 semanas, com alta proporção de prematuros (17,0 e 16,7 por cento, respectivamen
te). A proporção de recém-nascidos < 2.500 g foi alta nos dois períodos (17,6 e 
16,6 por cento, respectivamente), com redução na proporção dos pequenos para a i
dade gestacional. A mortalidade neonatal precoce, excluídos os defeitos congênit
os, foi de 12,4 óbitos por 1.000 nascidos vivos no primeiro período, de 8,0 no s
egundo e reduziu significativamente para recém-nascidos com idade gestacional < 
34 semanas. CONCLUSÕES: Diferenças importantes relativas a aspectos assistenciai
s e resultados perinatais foram detectadas e são compatíveis com melhoria global
 da saúde neonatal em 2003-2006. Entretanto, a persistência de eventos neonatais
 sensíveis à redução com uso de tecnologias perinatais disponíveis indica a nece
ssidade de monitoramento da assistência perinatal para todos os grupos de recém-
nascidos.#^ddecs^i1#^tm^lpt^kAvaliação de serviços de saúde^i1#^tm^lpt^ksistemas
 de informação^i1#^tm^lpt^kmortalidade neonatal^i1#^tm^lpt^kmortalidade infantil
^i1#^len^aOBJECTIVE: To compare perinatal health indicators in a referral hospit
al in Belo Horizonte, Brazil. METHODS: Perinatal results and indicators of singl
e live births in Hospital das Clínicas of Universidade Federal de Minas Gerais (
UFMG), Belo Horizonte, Brazil, were compared for two periods, 1995-1998 and 2003
-2006. The chi-square test and Student's t test were applied with 5 percent sign
ificance level and 95 percent confidence interval. Data were obtained from the P
erinatal Information System (Sistema Informático Perinatal, SIP), Latin American
 Center for Perinatology (Centro Latinoamericano de Perinatología, CLAP), Pan Am
erican Health Organization (PAHO), Hospital das Clínicas, and from medical recor
ds. RESULTS: Mothers were approximately 26 years old on average. The number of p
renatal appointments had an average increase of one appointment, regardless of b
irth weight, and there was a significant decrease in the number of caesarean del
iveries in the second period. The average gestational age was 38 weeks in both p
eriods, with a high rate of premature births (17.0 and 16.7 percent, respectivel
y). The rate of newborns < 2,500 g was high in both periods (17.6 and 16.6 perce
nt, respectively) with a decrease in the rate of newborns considered small for t
heir gestational age. When congenital malformations were excluded, early neonata
l mortality risk decreased from 12.4 per 1,000 live births in the first period t
o 8.0 per 1,000 live births in the second period, with considerable decrease for
 newborns with gestational age < 34 weeks. CONCLUSIONS: Important differences we
re verified concerning health care assistance procedures and perinatal results, 
and they are compatible with the global improvement in neonatal health observed 
in the 2003-2006 period. However, the persistence of unfortunate neonatal incide
nts that can be reduced with the use of available perinatal technologies reveals
 the need for constant monitoring of perinatal hospital care for all groups of n
ewborns.#^ddecs^i2#^tm^len^kHealth services evaluation^i2#^tm^len^kinformation s
ystems^i2#^tm^len^kneonatal mortality^i2#^tm^len^kinfant mortality^i2#vancouv#28
#20091103#03.11.2009#20100305#05.03.2010#Fundação de Amparo à Pesquisa do Estado
 de Minas Gerais#EDT 1770/2003#Conselho Nacional de Desenvolvimento Científico e
 Tecnológico#403707/2004-8#a09v86n4.htm#Internet^ihttp://www.scielo.br/scielo.ph
p?script=sci_arttext&pid=S0021-75572010000400009##
00323000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704009000074002001300164#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#5#1#article#139#<p align="right"><fon
t size="2" face="Verdana"><b>ARTIGO ORIGINAL</b></font> </p>     ^cY#a09v86n4.ht
m##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#6#2#article#139#<p>&nbsp;</p>     ^cY
#a09v86n4.htm##
00392000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704015900074002001300233#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#7#3#article#139#<p><font size="4" fac
e="Verdana"><b>Avalia&ccedil;&atilde;o do perfil de nascimentos    e &oacute;bit
os em hospital de refer&ecirc;ncia</b></font></p>     ^cY#a09v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#8#4#article#139#<p>&nbsp;</p>     ^cY
#a09v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#9#5#article#139#<p>&nbsp;</p>     ^cY
#a09v86n4.htm##
00457000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704022300075002001300298#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#10#6#article#139#<p><font size="2" fa
ce="Verdana"><b>Maria Albertina S. Rego<sup>I</sup>; Elisabeth    Barboza Fran&c
cedil;a<sup>II</sup>; Ana Paula Azevedo Travassos<sup>III</sup>;    Fernando C. 
Barros<sup>IV</sup></b></font></p>     ^cY#a09v86n4.htm##
00525000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704029100075002001300366#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#11#7#article#139#<p><font size="2" fa
ce="Verdana"><sup>I</sup>Doutora, Ci&ecirc;ncias da Sa&uacute;de,    Sa&uacute;d
e da Crian&ccedil;a e do Adolescente, Universidade Federal de Minas    Gerais (U
FMG), Belo Horizonte, MG, Departamento de Pediatria, Faculdade de Medicina,    U
FMG, Belo Horizonte, MG    ^cY#a09v86n4.htm##
00730000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704049600075002001300571#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#12#8#article#139#<br>   <sup>II</sup>
P&oacute;s-doutora, University of Queensland, Brisbane, Austr&aacute;lia,    Pro
grama de P&oacute;s-Gradua&ccedil;&atilde;o em Ci&ecirc;ncias da Sa&uacute;de,  
  Sa&uacute;de da Crian&ccedil;a e do Adolescente, Departamento de Pediatria,   
 Faculdade de Medicina, UFMG, Belo Horizonte, MG, Programa de P&oacute;s-Gradua&
ccedil;&atilde;o    em Sa&uacute;de P&uacute;blica, Departamento de Medicina Pre
ventiva e Social,    Faculdade de Medicina, UFMG, Belo Horizonte, MG    ^cY#a09v
86n4.htm##
00315000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704008100075002001300156#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#13#9#article#139#<br>   <sup>III</sup
>Mestre, Estat&iacute;stica, UFMG, Belo Horizonte, MG    ^cY#a09v86n4.htm##
00565000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033000076002001300406#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#14#10#article#139#<br>   <sup>IV</sup
>P&oacute;s-Doutor, Epidemiologia da Assist&ecirc;ncia M&eacute;dica,    Escola 
de Higiene e Medicina Tropical, University of London, Londres, United    Kingdom
, P&oacute;s-Gradua&ccedil;&atilde;o, Sa&uacute;de e Comportamento, Universidade
    Cat&oacute;lica de Pelotas (UCPEL), Pelotas, RS</font></p>     ^cY#a09v86n4.
htm##
00368000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013300076002001300209#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#15#11#article#139#<p><font size="2" f
ace="Verdana"><a name="topo" id="topo"></a><a href="#correspondence">Correspond&
ecirc;ncia</a></font></p>     ^cY#a09v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#16#12#article#139#<p>&nbsp;</p>     ^
cY#a09v86n4.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#17#13#article#139#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a09v86n4.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006600076002001300142#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#18#14#article#139#<p><font size="2" f
ace="Verdana"><b>RESUMO</b></font></p>     ^cY#a09v86n4.htm##
00386000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704015100076002001300227#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#19#15#article#139#<p><font size="2" f
ace="Verdana"> <b>OBJETIVO: </b> Comparar indicadores perinatais    em hospital 
universit&aacute;rio de Belo Horizonte (MG).    ^cY#a09v86n4.htm##
01006000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077100076002001300847#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#20#16#article#139#<br>   <b>M&Eacute;
TODOS: </b> Foram comparados indicadores e resultados perinatais    de nascidos 
vivos de partos &uacute;nicos do Hospital de Cl&iacute;nicas da    Universidade 
Federal de Minas Gerais, Belo Horizonte, em dois per&iacute;odos,    1995-1998 e
 2003-2006. Utilizou-se o teste do qui-quadrado e teste <i>t</i>    de Student c
om n&iacute;vel de signific&acirc;ncia de 5% e risco relativo com    intervalo d
e confian&ccedil;a de 95% nas an&aacute;lises. As informa&ccedil;&otilde;es    f
oram obtidas do banco de dados do Sistema Inform&aacute;tico Perinatal (SIP)/Cen
tro    Latinoamericano de Perinatolog&iacute;a (CLAP)/Organiza&ccedil;&atilde;o 
Pan-Americana    da Sa&uacute;de (OPAS), do hospital e complementadas por consul
ta em prontu&aacute;rio.    ^cY#a09v86n4.htm##
01214000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704097900076002001301055#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#21#17#article#139#<br>   <b>RESULTADO
S: </b>A m&eacute;dia da idade das m&atilde;es foi em torno de 26    anos. Verif
icou-se aumento m&eacute;dio de uma consulta de pr&eacute;-natal,    independent
emente do peso ao nascer, e diminui&ccedil;&atilde;o significativa    dos partos
 ces&aacute;reos no segundo per&iacute;odo. A idade gestacional m&eacute;dia    
nos dois per&iacute;odos foi de 38 semanas, com alta propor&ccedil;&atilde;o    
de prematuros (17,0 e 16,7%, respectivamente). A propor&ccedil;&atilde;o de    r
ec&eacute;m-nascidos < 2.500 g foi alta nos dois per&iacute;odos (17,6 e 16,6%, 
   respectivamente), com redu&ccedil;&atilde;o na propor&ccedil;&atilde;o dos pe
quenos    para a idade gestacional. A mortalidade neonatal precoce, exclu&iacute
;dos os    defeitos cong&ecirc;nitos, foi de 12,4 &oacute;bitos por 1.000 nascid
os vivos    no primeiro per&iacute;odo, de 8,0 no segundo e reduziu significativ
amente para    rec&eacute;m-nascidos com idade gestacional < 34 semanas.    ^cY#
a09v86n4.htm##
00771000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053600076002001300612#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#22#18#article#139#<br>   <b>CONCLUS&O
tilde;ES: </b> Diferen&ccedil;as importantes relativas a aspectos    assistencia
is e resultados perinatais foram detectadas e s&atilde;o compat&iacute;veis    c
om melhoria global da sa&uacute;de neonatal em 2003-2006. Entretanto, a persist&
ecirc;ncia    de eventos neonatais sens&iacute;veis &agrave; redu&ccedil;&atilde
;o com uso    de tecnologias perinatais dispon&iacute;veis indica a necessidade 
de monitoramento    da assist&ecirc;ncia perinatal para todos os grupos de rec&e
acute;m-nascidos.</font></p>     ^cY#a09v86n4.htm##
00481000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024600076002001300322#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#23#19#article#139#<p><font size="2" f
ace="Verdana"><b>Palavras-chave: </b> Avalia&ccedil;&atilde;o    de servi&ccedil
;os de sa&uacute;de, sistemas de informa&ccedil;&atilde;o, mortalidade    neonat
al, mortalidade infantil.</font></p> <hr size="1" noshade>     ^cY#a09v86n4.htm#
#
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#24#20#article#139#<p>&nbsp;</p>     ^
cY#a09v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#25#21#article#139#<p>&nbsp;</p>     ^
cY#a09v86n4.htm##
00319000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008400076002001300160#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#26#22#article#139#<p><font size="3" f
ace="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#a09v86n4.htm##
01943000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704170800076002001301784#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#27#23#article#139#<p><font face="Verd
ana" size="2">A contribui&ccedil;&atilde;o crescente do componente    neonatal n
a mortalidade infantil no Brasil a partir da d&eacute;cada de 1990,    com as ca
usas perinatais representando atualmente cerca de 60% das causas dos    &oacute;
bitos infantis, real&ccedil;a a necessidade de se conhecer o perfil    de sa&uac
ute;de e a qualidade do cuidado perinatal oferecido a esse grupo populacional<SU
P>1</SUP>.    Prevalecem como fatores associados ao &oacute;bito o baixo peso ao
 nascer, a    prematuridade, a asfixia perinatal e as infec&ccedil;&otilde;es ne
onatais, decorrentes    principalmente de condi&ccedil;&otilde;es potencialmente
 control&aacute;veis    por meio de a&ccedil;&otilde;es efetivas no pr&eacute;-n
atal, parto, nascimento    e per&iacute;odo neonatal<SUP>2</SUP>. Caracter&iacut
e;sticas maternas, como    idade, escolaridade, hist&oacute;ria reprodutiva e co
ndi&ccedil;&otilde;es de    sa&uacute;de antes e durante a gesta&ccedil;&atilde;
o exercem efeitos cumulativos,    alterando as condi&ccedil;&otilde;es de parto 
e nascimento e adapta&ccedil;&atilde;o    do rec&eacute;m-nascido &agrave; vida 
extrauterina. Dentre os fatores proximais    associados a resultados neonatais d
esfavor&aacute;veis, idade gestacional tem    sido considerada fator preditor ma
is importante que o peso ao nascer, se considerada    isoladamente<SUP>3</SUP>. 
Condi&ccedil;&atilde;o socioecon&ocirc;mica desfavor&aacute;vel,    desnutri&cce
dil;&atilde;o, s&iacute;ndromes hipertensivas e infec&ccedil;&otilde;es    cr&oc
irc;nicas maternas s&atilde;o fatores importantes na cadeia causal da prematurid
ade    e da restri&ccedil;&atilde;o do crescimento fetal<SUP>4</SUP>.</font></p>
     ^cY#a09v86n4.htm##
01244000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704100900076002001301085#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#28#24#article#139#<p><font face="Verd
ana" size="2">Resultados de estudos de avalia&ccedil;&atilde;o    da assist&ecir
c;ncia ao parto e nascimento e sua influ&ecirc;ncia na mortalidade    infantil i
ndicam que, al&eacute;m do perfil de risco populacional, o desempenho    hospita
lar &eacute; um importante fator para os diferenciais encontrados nas    taxas d
e mortalidade entre os hospitais, nos pa&iacute;ses onde a maioria dos    partos
 &eacute; institucionalizada, como &eacute; o caso do Brasil<SUP>2</SUP>.    Ide
ntifica&ccedil;&atilde;o e condu&ccedil;&atilde;o das gesta&ccedil;&otilde;es   
 de risco, utiliza&ccedil;&atilde;o de corticoide em imin&ecirc;ncia de parto   
 prematuro, acompanhamento obst&eacute;trico do trabalho de parto, assist&ecirc;
ncia    pedi&aacute;trica ao nascimento e no per&iacute;odo neonatal, uso do sur
factante    para doen&ccedil;a da membrana hialina, dentre outros, reduzem os ef
eitos adversos    relacionados a baixo peso, prematuridade e asfixia neonatal<SU
P>5</SUP>.</font></p>     ^cY#a09v86n4.htm##
01395000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704116000076002001301236#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#29#25#article#139#<p><font face="Verd
ana" size="2">O monitoramento do perfil da popula&ccedil;&atilde;o    e do cuida
do perinatal no n&iacute;vel hospitalar e em rede, utilizando informa&ccedil;&at
ilde;o    confi&aacute;vel, coletada e armazenada adequadamente, e que contemple
 indicadores    essenciais &agrave; assist&ecirc;ncia perinatal b&aacute;sica, &
eacute; estrat&eacute;gia    fundamental para a implementa&ccedil;&atilde;o de i
nterven&ccedil;&otilde;es    efetivas, visando pr&aacute;ticas cl&iacute;nicas p
otencialmente melhores<SUP>6-9</SUP>.    Na Am&eacute;rica Latina, um programa i
nformatizado de dom&iacute;nio p&uacute;blico    para registro uniformizado da i
nforma&ccedil;&atilde;o perinatal de todos os    nascimentos, o Sistema Inform&a
acute;tico Perinatal (SIP)/Centro Latinoamericano    de Perinatolog&iacute;a (CL
AP)/Organiza&ccedil;&atilde;o Pan-Americana da Sa&uacute;de    (OPAS), foi desen
volvido para possibilitar a integra&ccedil;&atilde;o de estrat&eacute;gias    de
 melhoria da assist&ecirc;ncia individual &agrave;s fun&ccedil;&otilde;es    de 
vigil&acirc;ncia da sa&uacute;de perinatal no n&iacute;vel coletivo<SUP>10</SUP>
.</font></p>     ^cY#a09v86n4.htm##
01089000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704085400076002001300930#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#30#26#article#139#<p><font face="Verd
ana" size="2">Em Belo Horizonte (MG), entre 1999 e 2001, o    Hospital de Cl&iac
ute;nicas (HC), Universidade Federal de Minas Gerais (UFMG)    foi contemplado p
elo Programa Estadual de Refer&ecirc;ncia Hospitalar para aten&ccedil;&atilde;o 
   &agrave;s gestantes de risco<SUP>11</SUP>, complementando infraestrutura de  
  equipamentos e recursos humanos para o setor obst&eacute;trico e neonatal, par
alelamente    a mudan&ccedil;as da gest&atilde;o do fluxo perinatal municipal<SU
P>12</SUP>.    Nesse contexto, este estudo teve como objetivo comparar indicador
es b&aacute;sicos    da aten&ccedil;&atilde;o perinatal do HC/UFMG em dois per&i
acute;odos, 1995-1998    e 2003-2006, utilizando dados coletados a partir da imp
lementa&ccedil;&atilde;o    do SIP/CLAP para todos os nascimentos da institui&cc
edil;&atilde;o.</font></p>     ^cY#a09v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#31#27#article#139#<p>&nbsp;</p>     ^
cY#a09v86n4.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007400076002001300150#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#32#28#article#139#<p><font size="3" f
ace="Verdana"><b>M&eacute;todos</b></font></p>     ^cY#a09v86n4.htm##
00324000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008900076002001300165#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#33#29#article#139#<p><font face="Verd
ana" size="2"><b><i>Delineamento do estudo</i></b></font></p>     ^cY#a09v86n4.h
tm##
00622000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038700076002001300463#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#34#30#article#139#<p><font face="Verd
ana" size="2">Trata-se de estudo de coorte retrospectiva de    rec&eacute;m-nasc
idos vivos de partos &uacute;nicos, acompanhados desde o nascimento    at&eacute
; a alta hospitalar para casa ou &oacute;bito. As vari&aacute;veis    eram colet
adas por meio da hist&oacute;ria cl&iacute;nica perinatal do banco    de dados e
letr&ocirc;nico do SIP/CLAP.</font></p>     ^cY#a09v86n4.htm##
00721000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048600076002001300562#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#35#31#article#139#<p><font face="Verd
ana" size="2">Dentre as maternidades de Belo Horizonte com    o SIP/CLAP implant
ado, selecionou-se o HC/UFMG devido &agrave; sua inser&ccedil;&atilde;o    na sa
&uacute;de perinatal do estado de Minas Gerais como hospital de refer&ecirc;ncia
    municipal e estadual em medicina fetal e perinatal, al&eacute;m de programas
    de ensino nos n&iacute;veis de gradua&ccedil;&atilde;o e p&oacute;s-gradua&c
cedil;&atilde;o,    pesquisa e extens&atilde;o.</font></p>     ^cY#a09v86n4.htm#
#
00821000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058600076002001300662#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#36#32#article#139#<p><font face="Verd
ana" size="2">Foram considerados dois per&iacute;odos: 1995-1998    e 2003-2006.
 A sele&ccedil;&atilde;o desses per&iacute;odos deveu-se &agrave;    possibilida
de de mudan&ccedil;as no perfil populacional e assistencial do HC/UFMG,    decor
rentes da implanta&ccedil;&atilde;o do sistema de refer&ecirc;ncia hospitalar   
 no atendimento da gestante de alto risco em Minas Gerais<SUP>11</SUP> e da reor
ganiza&ccedil;&atilde;o    municipal do sistema de refer&ecirc;ncia hospitalar p
erinatal, ocorridas principalmente    entre 1999-2001<SUP>12</SUP>.</font></p>  
   ^cY#a09v86n4.htm##
01251000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704101600076002001301092#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#37#33#article#139#<p><font face="Verd
ana" size="2">O banco de dados do SIP/CLAP do HC/UFMG (HC/SIP)    foi constitu&i
acute;do a partir de coleta e registro rotineiro da informa&ccedil;&atilde;o    
cl&iacute;nica pelos m&eacute;dicos assistentes, obstetras e neonatologistas,   
 no formul&aacute;rio b&aacute;sico Hist&oacute;ria Cl&iacute;nica Perinatal    
(HCP/SIP). A HCP/SIP deve ser preenchida sequencialmente em m&oacute;dulos,    &
agrave; medida que &eacute; realizada a assist&ecirc;ncia &agrave; m&atilde;e   
 e ao rec&eacute;m-nascido nas sucessivas etapas da aten&ccedil;&atilde;o, desde
    o nascimento at&eacute; a alta hospitalar. Outras informa&ccedil;&otilde;es 
   detalhadas sobre o SIP/CLAP, as vari&aacute;veis do programa, os processament
os    espec&iacute;ficos para gera&ccedil;&atilde;o dos v&aacute;rios relat&oacu
te;rios    e sua interpreta&ccedil;&atilde;o para a tomada de decis&otilde;es en
contram-se    dispon&iacute;veis em v&aacute;rias publica&ccedil;&otilde;es do C
LAP<SUP>10</SUP>.</font></p>     ^cY#a09v86n4.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009600076002001300172#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#38#34#article#139#<p><font face="Verd
ana" size="2"><b><i>Vari&aacute;veis selecionadas</i></b></font></p>     ^cY#a09
v86n4.htm##
01287000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704105200076002001301128#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#39#35#article#139#<p><font face="Verd
ana" size="2">Foram consideradas as seguintes vari&aacute;veis    demogr&aacute;
ficas, assistenciais e de evolu&ccedil;&atilde;o da m&atilde;e    e do rec&eacut
e;m-nascido, registradas no SIP/CLAP: idade da m&atilde;e, escolaridade    da m&
atilde;e, n&uacute;mero de consultas de pr&eacute;-natal, termina&ccedil;&atilde
;o    do parto, idade gestacional, peso ao nascer, rela&ccedil;&atilde;o peso ao
 nascer/idade    gestacional, doen&ccedil;as maternas (hipertens&atilde;o, hemor
ragia, infec&ccedil;&atilde;o,    diabetes e cardiopatia), doen&ccedil;as neonat
ais (defeitos cong&ecirc;nitos,    doen&ccedil;a das membranas hialinas, infec&c
cedil;&atilde;o, hiperbilirrubinemia    e outras s&iacute;ndromes de dificuldade
 respirat&oacute;ria), escore de Apgar    com 1 e 5 minutos, dias de hospitaliza
&ccedil;&atilde;o (calculados pelas datas    de nascimento e alta/&oacute;bito) 
e alimenta&ccedil;&atilde;o do rec&eacute;m-nascido    &agrave; alta (leite mate
rno, f&oacute;rmula, leite materno e f&oacute;rmula).</font></p>     ^cY#a09v86n
4.htm##
00899000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704066400076002001300740#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#40#36#article#139#<p><font face="Verd
ana" size="2">O &oacute;bito foi classificado conforme a idade    do rec&eacute;
m-nascido: primeiro dia, menor que 7 dias (neonatal precoce) e    &oacute;bito h
ospitalar (antes da primeira alta, independentemente da idade    do rec&eacute;m
-nascido). Todos os rec&eacute;m-nascidos eram acompanhados para    registro de 
poss&iacute;vel &oacute;bito no SIP/CLAP. Os rec&eacute;m-nascidos    assistidos
 no HC/UFMG recebem alta para domic&iacute;lio, n&atilde;o sendo transferidos   
 para outros hospitais, exceto para serem submetidos &agrave; cirurgia card&iacu
te;aca,    retornando para recupera&ccedil;&atilde;o no hospital.</font></p>    
 ^cY#a09v86n4.htm##
01308000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704107300076002001301149#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#41#37#article#139#<p><font face="Verd
ana" size="2">Devido ao grande n&uacute;mero de valores ignorados    para a vari
&aacute;vel n&uacute;mero de anos estudados, a vari&aacute;vel "escolaridade"   
 foi composta a partir de tr&ecirc;s vari&aacute;veis originais: alfabetiza&cced
il;&atilde;o    (sim ou n&atilde;o), n&iacute;vel de escolaridade no sistema for
mal de educa&ccedil;&atilde;o    (nenhum, elementar, secund&aacute;rio, universi
t&aacute;rio) e n&uacute;mero    de anos de escola cursados no maior n&iacute;ve
l alcan&ccedil;ado. Foi considerada    a presen&ccedil;a de "hipertens&atilde;o"
 quando havia registro positivo de    pelo menos uma de tr&ecirc;s vari&aacute;v
eis originais: hipertens&atilde;o    pr&eacute;via, pr&eacute;-ecl&acirc;mpsia o
u ecl&acirc;mpsia na gesta&ccedil;&atilde;o    atual. O mesmo ocorreu com "infec
&ccedil;&atilde;o", que foi considerada presente    quando havia registro de inf
ec&ccedil;&atilde;o urin&aacute;ria ou infec&ccedil;&atilde;o    puerperal ou ou
tras infec&ccedil;&otilde;es ocorridas na gesta&ccedil;&atilde;o    atual.</font
></p>     ^cY#a09v86n4.htm##
01151000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704091600076002001300992#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#42#38#article#139#<p><font face="Verd
ana" size="2">Para defini&ccedil;&atilde;o da idade gestacional,    considerou-s
e como primeiro crit&eacute;rio a idade gestacional atribu&iacute;da    pelo obs
tetra, considerando ou o ultrassom precoce (antes de 20 semanas de idade    gest
acional) ou a data da &uacute;ltima menstrua&ccedil;&atilde;o registrada.    Na 
aus&ecirc;ncia dos dois, foi considerada a idade gestacional estimada pelo    pe
diatra pelo m&eacute;todo New Ballard<SUP>13</SUP>. Foram considerados rec&eacut
e;m-nascidos    pequenos para idade gestacional (PIG) aqueles com peso ao nascer
 abaixo do percentil    10, segundo a curva de crescimento intrauterino de Krame
r et al.<SUP>14</SUP>.    Para exclus&atilde;o dos partos m&uacute;ltiplos, foi 
feita consulta ao prontu&aacute;rio    no caso de n&atilde;o registro das vari&a
acute;veis originais gemelaridade e    ordem do nascimento (11% das HCP/SIP).</f
ont></p>     ^cY#a09v86n4.htm##
00497000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026200076002001300338#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#43#39#article#139#<p><font face="Verd
ana" size="2">Foi conferida no prontu&aacute;rio a data da    alta em todas as h
ist&oacute;rias cujos rec&eacute;m-nascidos evolu&iacute;ram    para &oacute;bit
o, com corre&ccedil;&atilde;o da data do &oacute;bito em 2,6%    dos casos.    ^
cY#a09v86n4.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#44#40#article#139#<BR>   An&aacute;li
se dos dados e aspectos &eacute;ticos</font></p>     ^cY#a09v86n4.htm##
01240000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704100500076002001301081#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#45#41#article#139#<p><font face="Verd
ana" size="2">Foram comparadas as vari&aacute;veis obst&eacute;tricas    e neona
tais nos dois per&iacute;odos utilizando-se o teste qui-quadrado para    vari&aa
cute;veis categ&oacute;ricas e o teste <i>t</i> de Student para compara&ccedil;&
atilde;o    de m&eacute;dias, com n&iacute;vel de signific&acirc;ncia de 5%. Par
a an&aacute;lise    dos resultados neonatais, os dados foram estratificados por 
idade gestacional.    Para an&aacute;lise dos &oacute;bitos, foram exclu&iacute;
dos os rec&eacute;m-nascidos    com defeitos cong&ecirc;nitos, por apresentarem 
determinantes em geral diferentes    dos demais &oacute;bitos<SUP>15</SUP>. Esti
mativas de riscos relativos para    ocorr&ecirc;ncia de &oacute;bito, estratific
adas por idade gestacional, foram    computadas como medida de associa&ccedil;&a
tilde;o entre &oacute;bito e per&iacute;odos    considerados, com intervalo de c
onfian&ccedil;a de 95%. O primeiro per&iacute;odo    foi tomado como refer&ecirc
;ncia.</font></p>     ^cY#a09v86n4.htm##
00627000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039200076002001300468#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#46#42#article#139#<p><font face="Verd
ana" size="2">Para o processamento dos dados e an&aacute;lises    estat&iacute;s
ticas, foram utilizadas as sa&iacute;das convencionais do programa    SIP/CLAP e
 os pacotes estat&iacute;sticos SPSS, vers&atilde;o 13.0, e Stata,    vers&atild
e;o 9.0. O estudo foi aprovado pelo Comit&ecirc; de &Eacute;tica em    Pesquisa 
da UFMG (Parecer nº ETIC 313/04).</font></p>     ^cY#a09v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#47#43#article#139#<p>&nbsp;</p>     ^
cY#a09v86n4.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007000076002001300146#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#48#44#article#139#<p><font size="3" f
ace="Verdana"><b>Resultados</b></font></p>     ^cY#a09v86n4.htm##
01253000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704101800076002001301094#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#49#45#article#139#<p><font face="Verd
ana" size="2">A <a href=/img/revistas/jped/v86n4/4a09f1.gif>Figura    1</a> apre
senta a distribui&ccedil;&atilde;o dos nascimentos no hospital de    acordo com 
a condi&ccedil;&atilde;o do rec&eacute;m-nascido (nascido vivo ou    &oacute;bit
o fetal), tipo de gravidez (&uacute;nica ou m&uacute;ltipla) e evolu&ccedil;&ati
lde;o    neonatal hospitalar para os rec&eacute;m-nascidos de partos &uacute;nic
os, com    e sem defeitos cong&ecirc;nitos (DC), em dois per&iacute;odos. Foram 
analisados    6.823 e 11.701 nascidos vivos de partos &uacute;nicos no primeiro 
e segundo    per&iacute;odo, respectivamente. Destes, 4,3% no primeiro per&iacut
e;odo e 6,1%    no segundo per&iacute;odo tinham defeitos cong&ecirc;nitos e for
am respons&aacute;veis    por grande propor&ccedil;&atilde;o de &oacute;bitos, c
om taxas de mortalidade    hospitalar muito maiores (28 e 26% no primeiro e segu
ndo per&iacute;odo, respectivamente)    que os rec&eacute;m-nascidos sem defeito
s cong&ecirc;nitos.</font></p>     ^cY#a09v86n4.htm##
00538000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030300076002001300379#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#50#46#article#139#<p><font face="Verd
ana" size="2">A distribui&ccedil;&atilde;o dos rec&eacute;m-nascidos    por sexo
 nos dois per&iacute;odos foi est&aacute;vel, com 48,9 e 49,5% de rec&eacute;m-n
ascidos    do sexo feminino em cada per&iacute;odo, respectivamente, praticament
e sem dados    ausentes.</font></p>     ^cY#a09v86n4.htm##
01720000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704148500076002001301561#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#51#47#article#139#<p><font face="Verd
ana" size="2">A <a href=/img/revistas/jped/v86n4/4a09t1.gif>Tabela    1</a> apre
senta caracter&iacute;sticas maternas, assistenciais e resultados    neonatais s
elecionados para o total dos nascidos vivos nos dois per&iacute;odos.    Verific
a-se que a idade m&eacute;dia das m&atilde;es manteve-se em torno de    26 anos.
 Houve redu&ccedil;&atilde;o da propor&ccedil;&atilde;o de m&atilde;es    abaixo
 de 20 anos, mas as m&atilde;es <u>&gt;</u> 35 anos aumentaram: eram 10,6%    no
 primeiro per&iacute;odo e 12,5% no segundo. Em rela&ccedil;&atilde;o &agrave;  
  escolaridade, observa-se concentra&ccedil;&atilde;o das m&atilde;es com 4 a   
 7 anos de estudo. Entretanto, n&atilde;o foi poss&iacute;vel avaliar o n&iacute
;vel    de escolaridade para 15,5% delas no primeiro per&iacute;odo e para 21,1%
 no    segundo. A propor&ccedil;&atilde;o de m&atilde;es com seis ou mais consul
tas    de pr&eacute;-natal alcan&ccedil;ou 73,8% no segundo per&iacute;odo, com 
aumento    m&eacute;dio de uma consulta por m&atilde;e. Houve redu&ccedil;&atild
e;o na    propor&ccedil;&atilde;o de partos ces&aacute;reos em 2003-2006, manten
do-se    est&aacute;vel a propor&ccedil;&atilde;o de aplica&ccedil;&atilde;o de 
f&oacute;rceps    nos dois per&iacute;odos. Se consideradas somente as prim&iacu
te;paras, a propor&ccedil;&atilde;o    de partos ces&aacute;reos reduziu de 42,3
% no primeiro per&iacute;odo para 33,6%    no segundo (dados n&atilde;o apresent
ados).</font></p>     ^cY#a09v86n4.htm##
01329000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704109400076002001301170#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#52#48#article#139#<p><font face="Verd
ana" size="2"> N&atilde;o houve modifica&ccedil;&atilde;o importante    tanto na
 distribui&ccedil;&atilde;o do peso ao nascer quanto da idade gestacional    ent
re os dois per&iacute;odos. A propor&ccedil;&atilde;o de rec&eacute;m-nascidos  
  de baixo peso (peso ao nascer &lt; 2.500 g) foi de 17,6% no primeiro per&iacut
e;odo    e de 16,6% no segundo. O &iacute;ndice de prematuridade (idade gestacio
nal &lt;    37 semanas) passou de 17,0% no primeiro per&iacute;odo para 16,7% no
 segundo,    mas a idade gestacional m&eacute;dia se manteve est&aacute;vel em t
orno de 38    semanas. Houve redu&ccedil;&atilde;o na propor&ccedil;&atilde;o de
 rec&eacute;m-nascidos    p&oacute;s-termo (idade gestacional <u>&gt;</u> 42 sem
anas), passando de 1,5%    no primeiro per&iacute;odo para 0,7% no segundo. Apes
ar de a propor&ccedil;&atilde;o    de rec&eacute;m-nascidos PIG ter diminu&iacut
e;do de 28,7 para 25,7% no segundo    per&iacute;odo, foi elevado (57%) o percen
tual de PIG nos rec&eacute;m-nascidos    entre 1.500 e 2.500 g (dados n&atilde;o
 apresentados).</font></p>     ^cY#a09v86n4.htm##
00875000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704064000076002001300716#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#53#49#article#139#<p><font face="Verd
ana" size="2">Resultados neonatais s&atilde;o apresentados    segundo idade gest
acional na <a href=/img/revistas/jped/v86n4/4a09t2.gif>Tabela    2</a>. O &iacut
e;ndice de doen&ccedil;as neonatais foi alto nos dois per&iacute;odos    para os
 rec&eacute;m-nascidos prematuros, mas tamb&eacute;m para as crian&ccedil;as    
pr&oacute;ximas do termo (entre 34 e 36 semanas). Chama a aten&ccedil;&atilde;o 
   o aumento importante da doen&ccedil;a da membrana hialina para todos os prema
turos,    e das infec&ccedil;&otilde;es para os rec&eacute;m-nascidos abaixo de 
32 semanas,    no segundo per&iacute;odo.</font></p>     ^cY#a09v86n4.htm##
01139000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704090400076002001300980#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#54#50#article#139#<p><font face="Verd
ana" size="2">A propor&ccedil;&atilde;o de depress&atilde;o    ao nascimento, av
aliada pelo &iacute;ndice de Apgar &lt; 7 com 1 e 5 minutos    de vida, apresent
ou redu&ccedil;&atilde;o no segundo per&iacute;odo para os    grupos de rec&eacu
te;m-nascidos com idade gestacional &lt; 34 semanas. Para    todos os rec&eacute
;m-nascidos nos dois per&iacute;odos, houve recupera&ccedil;&atilde;o    de parc
ela importante do Apgar aos 5 minutos de vida (Apgar <u>&gt;</u> 7) em    rela&c
cedil;&atilde;o ao primeiro (Apgar &lt; 7). A m&eacute;dia de tempo de    perman
&ecirc;ncia hospitalar em dias aumentou no segundo per&iacute;odo para    os rec
&eacute;m-nascidos &lt; 32 semanas e diminuiu para os outros grupos. Por    outr
o lado, o &iacute;ndice de amamenta&ccedil;&atilde;o ao peito exclusiva    aumen
tou no segundo per&iacute;odo, principalmente para os prematuros.</font></p>    
 ^cY#a09v86n4.htm##
00705000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047000076002001300546#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#55#51#article#139#<p><font face="Verd
ana" size="2">A <a href=/img/revistas/jped/v86n4/4a09t3.gif>Tabela    3</a> apre
senta as taxas de mortalidade nos dois per&iacute;odos para os nascidos    vivos
 sem defeitos cong&ecirc;nitos. Houve redu&ccedil;&atilde;o significativa    das
 taxas de mortalidade em 2003-2006 em rela&ccedil;&atilde;o a 1995-1998 para    
os rec&eacute;m-nascidos com idade gestacional &lt; 34 semanas em quase todos   
 os momentos de vida avaliados.</font></p>     ^cY#a09v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#56#52#article#139#<p>&nbsp;</p>     ^
cY#a09v86n4.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#57#53#article#139#<p><font size="3" f
ace="Verdana"><b>Discuss&atilde;o</b></font></p>     ^cY#a09v86n4.htm##
01511000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704127600076002001301352#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#58#54#article#139#<p><font face="Verd
ana" size="2">A utiliza&ccedil;&atilde;o de informa&ccedil;&atilde;o    dispon&i
acute;vel no SIP/CLAP/OPAS possibilitou avaliar a evolu&ccedil;&atilde;o    da m
orbimortalidade neonatal em hospital p&uacute;blico de refer&ecirc;ncia    terci
&aacute;ria em medicina fetal e neonatal em Minas Gerais. O alto &iacute;ndice  
  de baixo peso ao nascer e de prematuridade nos dois per&iacute;odos identifica
m    uma popula&ccedil;&atilde;o de rec&eacute;m-nascidos com condi&ccedil;&otil
de;es    de sa&uacute;de desfavor&aacute;veis, associadas &agrave;s principais c
ausas    de morbimortalidade neonatal e infantil<SUP>4</SUP>. Por outro lado, a 
compara&ccedil;&atilde;o    entre os dois per&iacute;odos indica melhoria import
ante de alguns indicadores    assistenciais e de resultados, como o aumento do n
&uacute;mero m&eacute;dio    de consultas de pr&eacute;-natal, a redu&ccedil;&at
ilde;o das taxas de ces&aacute;reas,    maior propor&ccedil;&atilde;o de rec&eac
ute;m-nascidos com alimenta&ccedil;&atilde;o    exclusiva ao peito, al&eacute;m 
de maiores &iacute;ndices de Apgar aos 5 minutos    e redu&ccedil;&atilde;o da m
ortalidade, indicando melhoria conjunta da assist&ecirc;ncia    ao pr&eacute;-na
tal, parto e per&iacute;odo neonatal.</font></p>     ^cY#a09v86n4.htm##
01546000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704131100076002001301387#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#59#55#article#139#<p><font face="Verd
ana" size="2">Bons resultados neonatais, apesar do grande aumento    do &iacute;
ndice de prematuridade, foram encontrados por Barros et al. em Pelotas,    ao co
mparar duas coortes de base populacional de rec&eacute;m-nascidos dos anos    de
 1982 e 1993<SUP>16</SUP>. Leal et al.<SUP>17</SUP>, em estudo da aten&ccedil;&a
tilde;o    peri e neonatal em maternidades do munic&iacute;pio do Rio de Janeiro
 (RJ) correspondente    ao per&iacute;odo 1991-2001, encontraram uma popula&cced
il;&atilde;o de m&atilde;es    com perfil de risco mais desfavor&aacute;vel quan
do avaliado pelo grau de escolaridade,    &iacute;ndice de gesta&ccedil;&otilde;
es em m&atilde;es adolescentes e maior    carga de doen&ccedil;as, como hiperten
s&atilde;o e infec&ccedil;&otilde;es,    no estrato correspondente &agrave;s mat
ernidades p&uacute;blicas. No entanto,    os &iacute;ndices de 14,8% para baixo 
peso ao nascer e 12,8% para prematuridade    foram menores que os &iacute;ndices
 encontrados neste estudo. O aumento da prematuridade    e dos &iacute;ndices de
 ces&aacute;reas, verificado em estudos de base populacional    no Brasil, mesmo
 em popula&ccedil;&otilde;es de baixo risco perinatal<SUP>18</SUP>,    n&atilde;
o foi observado com a mesma intensidade neste estudo de base hospitalar.</font><
/p>     ^cY#a09v86n4.htm##
01684000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704144900076002001301525#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#60#56#article#139#<p><font face="Verd
ana" size="2">As menores propor&ccedil;&otilde;es de depress&atilde;o    neonata
l medidas pelo &iacute;ndice de Apgar aos cinco minutos em rela&ccedil;&atilde;o
    ao primeiro, nos dois per&iacute;odos e em todas as faixas de peso ao nascer
,    sugerem que globalmente as demandas assistenciais pedi&aacute;tricas na sal
a    de parto foram respondidas. Tamb&eacute;m interven&ccedil;&otilde;es obst&e
acute;tricas    no pr&eacute;-natal e parto podem ter contribu&iacute;do para a 
redu&ccedil;&atilde;o    da propor&ccedil;&atilde;o de rec&eacute;m-nascidos &lt
; 34 semanas com Apgar    &lt; 7 com 1 minuto de vida no segundo per&iacute;odo,
 com melhor adapta&ccedil;&atilde;o    destes neonatos nos primeiros momentos de
 vida. Entretanto, ainda continuaram    elevados os &iacute;ndices de depress&at
ilde;o ao nascimento medidos pelo &Iacute;ndice    de Apgar no segundo per&iacut
e;odo, inclusive para os rec&eacute;m-nascidos    pr&eacute;-termos tardios e de
 termo. Por outro lado, sabe-se que a implementa&ccedil;&atilde;o    de pr&aacut
e;ticas assistenciais integradas, como utiliza&ccedil;&atilde;o de    corticoide
 antenatal e surfactante nas primeiras horas de vida p&oacute;s-natal,    dentre
 outras, s&atilde;o tecnologias dispon&iacute;veis e com evid&ecirc;ncias    cl&
iacute;nicas de redu&ccedil;&atilde;o da morbimortalidade neonatal e infantil   
 relativas &agrave; prematuridade<SUP>19,20</SUP>.</font></p>     ^cY#a09v86n4.h
tm##
00728000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049300076002001300569#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#61#57#article#139#<p><font face="Verd
ana" size="2">O aumento do &iacute;ndice de amamenta&ccedil;&atilde;o    para to
das as categorias de rec&eacute;m-nascidos prematuros sugere mudan&ccedil;as    
positivas de pr&aacute;ticas hospitalares relativas a interven&ccedil;&otilde;es
    que favorecem o aleitamento materno, reconhecidamente uma das mais important
es    estrat&eacute;gias de redu&ccedil;&atilde;o da mortalidade infantil. O HC 
tornou-se    Hospital Amigo da Crian&ccedil;a em 2008.</font></p>     ^cY#a09v86
n4.htm##
01458000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704122300076002001301299#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#62#58#article#139#<p><font face="Verd
ana" size="2">A alta preval&ecirc;ncia de doen&ccedil;as maternas    pode estar 
refletindo uma baixa qualidade do pr&eacute;-natal, mesmo considerando    a espe
cificidade da popula&ccedil;&atilde;o assistida na institui&ccedil;&atilde;o.   
 &Eacute; tamb&eacute;m relevante a alta preval&ecirc;ncia das doen&ccedil;as   
 analisadas entre os prematuros, com &iacute;ndices importantes nos rec&eacute;m
-nascidos    pr&eacute;-termos tardios, uma popula&ccedil;&atilde;o com risco pe
rinatal aumentado    quando comparada aos rec&eacute;m-nascidos a termo<SUP>15,2
1</SUP>. A doen&ccedil;a    da membrana hialina apresentou um aumento importante
 no segundo per&iacute;odo,    possivelmente em fun&ccedil;&atilde;o de mudan&cc
edil;a na abordagem diagn&oacute;stica,    com melhor utiliza&ccedil;&atilde;o d
e tecnologias perinatais como surfactante    nas primeiras horas de vida, assist
&ecirc;ncia obst&eacute;trica e neonatal    melhor qualificada na sala de parto 
e tamb&eacute;m maior sobrevida dessas crian&ccedil;as.    &Iacute;ndices altos 
tamb&eacute;m foram observados em outros centros brasileiros,    conforme estudo
 recente da Rede Brasileira de Pesquisas Neonatais<SUP>19</SUP>.</font></p>     
^cY#a09v86n4.htm##
01388000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704115300076002001301229#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#63#59#article#139#<p><font face="Verd
ana" size="2">As altas propor&ccedil;&otilde;es de nascimentos    de rec&eacute;
m-nascidos com defeitos cong&ecirc;nitos, com aumento no segundo    per&iacute;o
do, s&atilde;o maiores que em outros estudos<SUP>22</SUP>, possivelmente    pelo
 fato de o HC/UFMG ser hospital de refer&ecirc;ncia para malforma&ccedil;&otilde
;es    cong&ecirc;nitas, participante do Estudo Colaborativo Latino-Americano de
 Malforma&ccedil;&otilde;es    Cong&ecirc;nitas (ECLAMC). A propor&ccedil;&atild
e;o de 6,1% de defeitos cong&ecirc;nitos    verificados em 2003-2006 &eacute; re
lativamente semelhante &agrave; verificada    em 2004 no Hospital da Mulher da U
niversidade Estadual de Campinas (UNICAMP),    Campinas (SP)<SUP>23</SUP>. A con
tribui&ccedil;&atilde;o das malforma&ccedil;&otilde;es    cong&ecirc;nitas, atua
lmente uma importante causa de mortalidade infantil em    pa&iacute;ses em desen
volvimento como o Brasil, depende da qualidade e disponibilidade    de tratament
o m&eacute;dico e cir&uacute;rgico e tamb&eacute;m da presen&ccedil;a    e efeti
vidade de medidas de preven&ccedil;&atilde;o prim&aacute;ria<SUP>24</SUP>.</font
></p>     ^cY#a09v86n4.htm##
02177000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704194200076002001302018#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#64#60#article#139#<p><font face="Verd
ana" size="2">A redu&ccedil;&atilde;o das taxas globais de    mortalidade neonat
al no HC/UFMG no segundo per&iacute;odo, quando exclu&iacute;dos    os defeitos 
cong&ecirc;nitos, particularmente para os nascidos vivos prematuros    e de muit
o baixo peso, associada ao perfil de m&atilde;es e rec&eacute;m-nascidos    rela
tivamente est&aacute;vel, representa um resultado favor&aacute;vel possivelmente
    relacionado a melhores pr&aacute;ticas cl&iacute;nicas. A redu&ccedil;&atild
e;o    das taxas de mortalidade neonatal precoce e hospitalar dos rec&eacute;m-n
ascidos    &lt; 32 semanas alcan&ccedil;ando a metade do registrado no primeiro 
per&iacute;odo    refor&ccedil;a a import&acirc;ncia da melhoria da aten&ccedil;
&atilde;o &agrave;s    crian&ccedil;as mais imaturas. Tamb&eacute;m a queda da m
ortalidade dos rec&eacute;m-nascidos    de 32 e 33 semanas de idade gestacional,
 apesar de representarem um grupo menor    de crian&ccedil;as, representa um res
ultado importante. Entretanto, para os    prematuros tardios, entre 34 e 36 sema
nas de idade gestacional, a taxa de mortalidade    no segundo per&iacute;odo man
teve-se relativamente est&aacute;vel. Esse grupo    de crian&ccedil;as represent
ou uma parcela importante dos rec&eacute;m-nascidos    com grande carga de probl
emas e tempo m&eacute;dio de perman&ecirc;ncia hospitalar    alto (em m&eacute;d
ia 10 dias) quando comparado ao grupo de rec&eacute;m-nascidos    de termo, dema
ndando parte importante dos recursos neonatais dispon&iacute;veis.    Estes resu
ltados, semelhantes aos encontrados na coorte de nascimentos de Pelotas    de 20
04<SUP>21</SUP> e em estudo da popula&ccedil;&atilde;o de nascidos vivos    dos 
EUA e Canad&aacute; na d&eacute;cada de 1990<SUP>15</SUP>, refor&ccedil;am    a 
necessidade de monitoramento desse grupo de rec&eacute;m-nascidos com importante
    risco de doen&ccedil;as e morte no per&iacute;odo neonatal.</font></p>     ^
cY#a09v86n4.htm##
01080000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084500076002001300921#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#65#61#article#139#<p><font face="Verd
ana" size="2">Este estudo foi realizado com informa&ccedil;&atilde;o    coletada
 de hospital p&uacute;blico de refer&ecirc;ncia para gestantes e rec&eacute;m-na
scidos    de risco, e seus resultados n&atilde;o podem ser generalizados para a 
popula&ccedil;&atilde;o    geral. Os indicadores apresentados neste estudo, entr
etanto, permitem o monitoramento    temporal da sa&uacute;de perinatal dos nasci
dos vivos no HC/UFMG, com uma avalia&ccedil;&atilde;o    abrangente do risco ges
tacional. Precisam, por&eacute;m, ser complementados    com indicadores de gravi
dade de doen&ccedil;a neonatal ao nascimento, imprescind&iacute;veis    para ava
lia&ccedil;&atilde;o do risco cl&iacute;nico do rec&eacute;m-nascido    ao compa
rar resultados de diferentes servi&ccedil;os ou popula&ccedil;&otilde;es<SUP>25<
/SUP>.</font></p>     ^cY#a09v86n4.htm##
01004000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076900076002001300845#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#66#62#article#139#<p><font face="Verd
ana" size="2">Os resultados apresentados neste e em outros    estudos indicam a 
necessidade de monitoramento de toda a popula&ccedil;&atilde;o    perinatal no B
rasil, onde os &iacute;ndices de morbimortalidade perinatal ainda    s&atilde;o 
altos mesmo nas gesta&ccedil;&otilde;es potencialmente de baixo risco    perinat
al, incluindo regi&otilde;es mais desenvolvidas<SUP>26,27</SUP>. Dessa    forma,
 ressalta-se a import&acirc;ncia do registro sistematizado de informa&ccedil;&at
ilde;o    de vari&aacute;veis b&aacute;sicas do processo assistencial para toda 
a popula&ccedil;&atilde;o    de rec&eacute;m-nascidos, e n&atilde;o somente para
 os rec&eacute;m-nascidos    menores de 1.500 g ou idade gestacional menor que 3
4 semanas.</font></p>     ^cY#a09v86n4.htm##
00960000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072500076002001300801#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#67#63#article#139#<p><font face="Verd
ana" size="2">A utiliza&ccedil;&atilde;o de fonte eletr&ocirc;nica    dos dados 
de dom&iacute;nio p&uacute;blico como o SIP/CLAP representou um grande    avan&c
cedil;o neste estudo, por ser informa&ccedil;&atilde;o qualificada e com    dado
s validados<SUP>28</SUP>, a qual fundamentou a realiza&ccedil;&atilde;o    do di
agn&oacute;stico de sa&uacute;de perinatal da institui&ccedil;&atilde;o    nos d
ois per&iacute;odos estudados. A informa&ccedil;&atilde;o foi obtida no    local
 onde o cuidado era fornecido, e isso representa uma estrat&eacute;gia    fundam
ental de avalia&ccedil;&atilde;o da implementa&ccedil;&atilde;o de pr&aacute;tic
as    cl&iacute;nicas potencialmente melhores.</font></p>     ^cY#a09v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#68#64#article#139#<p>&nbsp;</p>     ^
cY#a09v86n4.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007400076002001300150#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#69#65#article#139#<p><font size="3" f
ace="Verdana"><b>Agradecimentos</b></font></p>     ^cY#a09v86n4.htm##
00413000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704017800076002001300254#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#70#66#article#139#<p><font face="Verd
ana" size="2">Os autores agradecem &agrave; Professora Emilia    Sakurai pelas s
uas sugest&otilde;es durante o desenvolvimento do trabalho.</font></p>     ^cY#a
09v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#71#67#article#139#<p>&nbsp;</p>     ^
cY#a09v86n4.htm##
00312000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007700076002001300153#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#72#68#article#139#<p><font size="3" f
ace="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#a09v86n4.htm##
00476000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022700078002001300305#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#73#69#article#139#1#<p><f
ont size="2" face="Verdana">1. UNICEF - Fundo das Na&ccedil;&otilde;es Unidas   
 para a Inf&acirc;ncia. Situa&ccedil;&atilde;o mundial da inf&acirc;ncia 2008:  
  sobreviv&ecirc;ncia infantil. Bras&iacute;lia: 2007.    ^cY#a09v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#74#70#article#139#</font></p>     ^cY
#a09v86n4.htm##
00480000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023100078002001300309#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#75#71#article#139#2#<p><f
ont size="2" face="Verdana">2. Barros AJ, Matijasevich A, Santos IS, Albernaz   
 EP, Victora CG. Neonatal mortality: description and effect of hospital of birth
    after risk adjustment. Rev Saude Publica. 2008;42:1-9.    ^cY#a09v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#76#72#article#139#</font></p>     ^cY
#a09v86n4.htm##
00421000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704017200078002001300250#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#77#73#article#139#3#<p><f
ont size="2" face="Verdana">3. McCormick MC. The contribution of low birth    we
ight to infant mortality and childhood morbidity. N Engl J Med. 1985;312:82-90. 
   ^cY#a09v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#78#74#article#139#</font></p>     ^cY
#a09v86n4.htm##
00505000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025600078002001300334#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#79#75#article#139#4#<p><f
ont size="2" face="Verdana">4. Martin RJ, Fanaroff AA, Walsh MC. Pregnancy    di
sorders and their impact on the fetus. In:Fanaroff and Martin's Neonatal-Perinat
al    Medicine: diseases of the fetus and infant. 8th edition. USA: Elsevier; 20
06.    ^cY#a09v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002400076002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#80#76#article#139#    </font></p>    
 ^cY#a09v86n4.htm##
00450000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020100078002001300279#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#81#77#article#139#5#<p><f
ont size="2" face="Verdana">5. American Academy of Pediatrics, The American    C
ollege of Obstetrics and Gynecologists. Guidelines for perinatal care. 5ª ed.   
 Washington: AAP/ACOG; 2002.    ^cY#a09v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#82#78#article#139#</font></p>     ^cY
#a09v86n4.htm##
00434000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704018500078002001300263#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#83#79#article#139#6#<p><f
ont size="2" face="Verdana">6. Barros FC, Diaz-Rossello JL. Redes multic&ecirc;n
tricas    e a qualidade da aten&ccedil;&atilde;o neonatal. J Pediatr (Rio J). 20
04;80:254-6.    ^cY#a09v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#84#80#article#139#</font></p>     ^cY
#a09v86n4.htm##
00419000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704017000078002001300248#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#85#81#article#139#7#<p><f
ont size="2" face="Verdana">7. Diaz-Rossello JL. Health services research,    ou
tcomes, and perinatal information systems. Curr Opin Pediatr. 1998;10:117-22.   
 ^cY#a09v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#86#82#article#139#</font></p>     ^cY
#a09v86n4.htm##
00415000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704016600078002001300244#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#87#83#article#139#8#<p><f
ont size="2" face="Verdana">8. Rodrigues RJ. Information systems: the key    to 
evidence-based health practice. Bull World Health Organ. 2000;78:1344-51.    ^cY
#a09v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#88#84#article#139#</font></p>     ^cY
#a09v86n4.htm##
00516000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026700078002001300345#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#89#85#article#139#9#<p><f
ont size="2" face="Verdana">9. Horbar JD, Plsek PE, Schriefer JA, Leahy K.    Ev
idence-based quality improvement in neonatal and perinatal medicine: the neonata
l    intensive care quality improvement collaborative experience. Pediatrics. 20
06;118:S57-64.    ^cY#a09v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#90#86#article#139#</font></p>     ^cY
#a09v86n4.htm##
00453000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704020300079002001300282#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#91#87#article#139#10#<p><
font size="2" face="Verdana">10. Simini F, Rubino M, Lopez R, Gonzalo-Diaz    A,
 Schwarcz R. Processamento de datos del sistema inform&aacute;tico perinatal.   
 Montevid&eacute;o: CLAP; 1996.    ^cY#a09v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#92#88#article#139#</font></p>     ^cY
#a09v86n4.htm##
00456000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704020600079002001300285#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#93#89#article#139#11#<p><
font size="2" face="Verdana">11. Brasil. Minist&eacute;rio da Sa&uacute;de.    P
ortaria nº 3018 de 19/06/1998. Di&aacute;rio Oficial da Uni&atilde;o 22 jun    1
998c. Se&ccedil;&atilde;o I, p.34.    ^cY#a09v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#94#90#article#139#</font></p>     ^cY
#a09v86n4.htm##
00530000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028000079002001300359#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#95#91#article#139#12#<p><
font size="2" face="Verdana">12. Lansky S. A gest&atilde;o da qualidade e    da 
integralidade do cuidado em sa&uacute;de da mulher e da crian&ccedil;a no    SUS
 de Belo Horizonte: a experi&ecirc;ncia da Comiss&atilde;o Perinatal. Divulg    
Saude Debate. 2006;36:10-17.    ^cY#a09v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#96#92#article#139#</font></p>     ^cY
#a09v86n4.htm##
00463000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704021300079002001300292#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#97#93#article#139#13#<p><
font size="2" face="Verdana">13. Ballard JL, Khoury JC, Wedig K, Wang L, Eilers-
Walsman    BL, Lipp R. New Ballard Score, expanded to include extremely prematur
e infants.    J Pediatr. 1991;119:417-23.    ^cY#a09v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#98#94#article#139#</font></p>     ^cY
#a09v86n4.htm##
00491000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704024100079002001300320#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#99#95#article#139#14#<p><
font size="2" face="Verdana">14. Kramer MS, Platt RW, Wen SW, Joseph KS, Allen  
  A, Abrahamowicz M, et al. A new and improved population-based Canadian referen
ce    for birth weight for gestational age. Pediatrics. 2001;108:E35.    ^cY#a09
v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#100#96#article#139#</font></p>     ^c
Y#a09v86n4.htm##
00549000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704029800080002001300378#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#101#97#article#139#15#<p>
<font size="2" face="Verdana">15. Kramer MS, Demissie K, Yang H, Platt RW,    Sa
uv&eacute; R, Liston R. The contribution of mild and moderate preterm birth    t
o infant mortality. Fetal and Infant Health Study Group of the Canadian Perinata
l    Surveillance System. JAMA. 2000;284:843-9.    ^cY#a09v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#102#98#article#139#</font></p>     ^c
Y#a09v86n4.htm##
00582000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704033100080002001300411#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#103#99#article#139#16#<p>
<font size="2" face="Verdana">16. Barros FC, Victora CG, Tomasi E, Horta B,    M
enezes AM, Cesar JA, et al. Sa&uacute;de materno-infantil em Pelotas, Rio Grande
    do Sul, Brasil: principais conclus&otilde;es da compara&ccedil;&atilde;o dos
    estudos das coortes de 1982 e 1993. Cad Saude Publica. 1996;12 Supl.1:87-92.
    ^cY#a09v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#104#100#article#139#</font></p>     ^
cY#a09v86n4.htm##
00586000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704033400081002001300415#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#105#101#article#139#17#<p
><font size="2" face="Verdana">17. Leal Mdo C, Gama SG, Campos MR, Cavalini    L
T, Garbayo LS, Brasil CL, et al. Fatores associados &agrave; morbi-mortalidade  
  perinatal em uma amostra de maternidades p&uacute;blicas e privadas do Munic&i
acute;pio    do Rio de Janeiro, 1999-2001. Cad Saude Publica. 2004;20 Supl 1:S20
-33.    ^cY#a09v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#106#102#article#139#</font></p>     ^
cY#a09v86n4.htm##
00504000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025200081002001300333#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#107#103#article#139#18#<p
><font size="2" face="Verdana">18. Barros AJ, da Silva dos Santos I, Victora    
CG, Albernaz EP, Domingues MR, Timm IK, et al. Coorte de nascimentos de Pelotas 
   2004: metodologia e descri&ccedil;&atilde;o. Rev Saude Publica. 2006;40:402-1
3.    ^cY#a09v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#108#104#article#139#</font></p>     ^
cY#a09v86n4.htm##
00540000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028800081002001300369#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#109#105#article#139#19#<p
><font size="2" face="Verdana">19. Almeida MF, Guinsburg R, Martinez FE, Procian
oy    RS, Leone CR, Marba ST, et al. Perinatal factors associated with early dea
ths    of preterm infants born in Brazilian Network on Neonatal Research centers
. J    Pediatr (Rio J). 2008;84:300-7.    ^cY#a09v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#110#106#article#139#</font></p>     ^
cY#a09v86n4.htm##
00544000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029200081002001300373#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#111#107#article#139#20#<p
><font size="2" face="Verdana">20. National Institutes of Health Consensus Devel
opment    Panel. Antenatal corticosteroids revisited: repeat courses - National 
Institutes    of Health Consensus Development Conference Statement, August 17-18
, 2000. Obstet    Gynecol. 2001;98:144-50.    ^cY#a09v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#112#108#article#139#</font></p>     ^
cY#a09v86n4.htm##
00535000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028300081002001300364#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#113#109#article#139#21#<p
><font size="2" face="Verdana">21. Santos IS, Matijasevich A, Silveira MF, Sclow
itz    JK, Barros AJ, Victora CG, et al. Associated factors and consequences of 
late    preterm births: results from the 2004 Pelotas birth cohort. Paediatr Per
inat    Epidemiol. 2008;22:350-8.    ^cY#a09v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#114#110#article#139#</font></p>     ^
cY#a09v86n4.htm##
00565000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031300081002001300394#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#115#111#article#139#22#<p
><font size="2" face="Verdana">22. Amorim MM, Vilela PC, Santos AR, Lima AL,    
Melo EF, Bernardes HF, et al. Impacto das malforma&ccedil;&otilde;es cong&ecirc;
nitas    na mortalidade perinatal e neonatal em uma maternidade-escola do Recife
. Rev    Bras Sa&uacute;de Matern Infant. 2006;6 Supl 1:S19-25.    ^cY#a09v86n4.
htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#116#112#article#139#</font></p>     ^
cY#a09v86n4.htm##
00472000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022000081002001300301#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#117#113#article#139#23#<p
><font size="2" face="Verdana">23. Luquetti DV, Koifman RJ. Quality of reporting
    on birth defects in birth certificates: case study from a Brazilian referenc
e    hospital. Cad Saude Publica. 2009;25:1721-31.    ^cY#a09v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#118#114#article#139#</font></p>     ^
cY#a09v86n4.htm##
00471000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021900081002001300300#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#119#115#article#139#24#<p
><font size="2" face="Verdana">24. Victora CG, Barros FC. Infant mortality due  
  to perinatal causes in Brazil: trends, regional patterns and possible interven
tions.    S&atilde;o Paulo Med J. 2001;119:33-42.    ^cY#a09v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#120#116#article#139#</font></p>     ^
cY#a09v86n4.htm##
00440000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018800081002001300269#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#121#117#article#139#25#<p
><font size="2" face="Verdana">25. Almeida RT, Persson J. The use of and need   
 for patient classification systems in Swedish neonatal care. Scand J Caring    
Sci. 1998;12:11-7.    ^cY#a09v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#122#118#article#139#</font></p>     ^
cY#a09v86n4.htm##
00552000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030000081002001300381#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#123#119#article#139#26#<p
><font size="2" face="Verdana">26. Barros FC, Victora CG, Barros AJ, Santos    I
S, Albernaz E, Matijasevich A, et al. The challenge of reducing neonatal mortali
ty    in middle-income countries: findings from three Brazilian birth cohorts in
 1982,    1993, and 2004. Lancet. 2005;365:847-54.    ^cY#a09v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#124#120#article#139#</font></p>     ^
cY#a09v86n4.htm##
00544000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029200081002001300373#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#125#121#article#139#27#<p
><font size="2" face="Verdana">27. de Silva AA, Coimbra LC, da Silva RA, Alves  
  MT, Lamy Filho F, Carvalho Lamy Z, et al. Perinatal health and mother-child   
 health care in the municipality of S&atilde;o Luis, Maranh&atilde;o State, Braz
il.    Cad Saude Publica. 2001;17:1413-23.    ^cY#a09v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#126#122#article#139#</font></p>     ^
cY#a09v86n4.htm##
00608000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704035600081002001300437#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#p#127#123#article#139#28#<p
><font size="2" face="Verdana">28. Rego MA, Fran&ccedil;a EB, Afonso DC. Avalia&
ccedil;&atilde;o    da qualidade da informa&ccedil;&atilde;o do Sistema de Infor
ma&ccedil;&atilde;o    Perinatal (SIP-CLAP/OPS) para monitoramento da assist&eci
rc;ncia perinatal hospitalar,    Belo Horizonte, 2004. Rev Bras Sa&uacute;de Mat
ern Infant. 2009;9:275-84.    ^cY#a09v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#128#124#article#139#</font></p>     ^
cY#a09v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#129#125#article#139#<p>&nbsp;</p>    
 ^cY#a09v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#130#126#article#139#<p>&nbsp;</p>    
 ^cY#a09v86n4.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018000078002001300258#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#131#127#article#139#<p><font size="2"
 face="Verdana"><a name="correspondence"></a><a href="#topo"><img src="/img/revi
stas/jped/v86n4/seta.gif" border="0"></a>    <b> Correspond&ecirc;ncia:</b>    ^
cY#a09v86n4.htm##
00281000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004400078002001300122#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#132#128#article#139#<br>   Maria Albe
rtina Santiago Rego    ^cY#a09v86n4.htm##
00275000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003800078002001300116#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#133#129#article#139#<BR>   Rua Henriq
ue Quick, 399    ^cY#a09v86n4.htm##
00287000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005000078002001300128#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#134#130#article#139#<BR>   CEP: 30210
-010 - Belo Horizonte, MG    ^cY#a09v86n4.htm##
00288000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005100078002001300129#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#135#131#article#139#<BR>   Tel.: (31)
 3225.0790, (31) 9982.0956    ^cY#a09v86n4.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#136#132#article#139#<BR>   Fax: (31) 
3225.0790    ^cY#a09v86n4.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010500078002001300183#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#137#133#article#139#<BR>   E-mail: <A
 href=mailto:albertin@medicina.ufmg.br>albertin@medicina.ufmg.br</A></font></p> 
    ^cY#a09v86n4.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010600078002001300184#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#138#134#article#139#<p><font size="2"
 face="Verdana">Artigo submetido em 03.11.2009, aceito em 05.03.2010.</font></p>
     ^cY#a09v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#139#135#article#139#<p>&nbsp;</p>    
 ^cY#a09v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#140#136#article#139#<p>&nbsp;</p>    
 ^cY#a09v86n4.htm##
00391000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704015400078002001300232#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#141#137#article#139#<p><font size="2"
 face="Verdana"> N&atilde;o foram declarados conflitos de interesse    associado
s &agrave; publica&ccedil;&atilde;o deste artigo.    ^cY#a09v86n4.htm##
00499000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704026200078002001300340#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#142#138#article#139#<br>   Apoio fina
nceiro: Funda&ccedil;&atilde;o de Amparo &agrave; Pesquisa do Estado    de Minas
 Gerais (FAPEMIG), nº REF: EDT 1770/2003, e Conselho Nacional de Desenvolvimento
    Cient&iacute;fico e Tecnol&oacute;gico (CNPq), Processo nº 403707/2004-8.   
 ^cY#a09v86n4.htm##
00414000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704017700078002001300255#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a09v86n4.htm#S#p#143#139#article#139#<br>   Este traba
lho foi realizado no Departamento de Pediatria da Faculdade de Medicina,    Univ
ersidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG.</font></p>     ^cY#
a09v86n4.htm##
00443000000000217000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170040000770180062001170660
01000179065000900189064000500198865000900203002001300212#v86n4#V:\Scielo\serial\
jped\v86n4\markup\a09v86n4.htm#S#c#144#1#article#28#1#Fundo das Nações Unidas pa
ra a Infância#Situação mundial da infância 2008: sobrevivência infantil^lpt#Bras
í­lia#20070000#2007#20100800#a09v86n4.htm##
00663000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100022000940100
01700116010001900133010001800152012009000170030001800260065000900278064000500287
031000300292014000400295865000900299002001300308035001000321801001800331#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#c#145#2#article#28#2#^rND^sBarr
os^nAJ#^rND^sMatijasevich^nA#^rND^sSantos^nIS#^rND^sAlbernaz^nEP#^rND^sVictora^n
CG#Neonatal mortality: description and effect of hospital of birth after risk ad
justment^len#Rev Saude Publica#20080000#2008#42#1-9#20100800#a09v86n4.htm#0034-8
910#Rev Saude Publica##
00530000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770120085000970300
01300182065000900195064000500204031000400209014000600213865000900219002001300228
035001000241801001300251#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S
#c#146#3#article#28#3#^rND^sMcCormick^nMC#The contribution of low birth weight t
o infant mortality and childhood morbidity^len#N Engl J Med#19850000#1985#312#82
-90#20100800#a09v86n4.htm#0028-4793#N Engl J Med##
00584000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100019000940100
01600113012005400129018008800183063000200271062000900273065000900282064000500291
865000900296002001300305#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S
#c#147#4#article#28#4#^rND^sMartin^nRJ#^rND^sFanaroff^nAA#^rND^sWalsh^nMC#Pregna
ncy disorders and their impact on the fetus^len#Fanaroff and Martin's Neonatal-P
erinatal Medicine: diseases of the fetus and infant^len#8#Elsevier#20060000#2006
#20100800#a09v86n4.htm##
00496000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170085000770180034001620630
00200196066001100198062000900209065000900218064000500227865000900232002001300241
#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#c#148#5#article#28#5#Th
e American College of Obstetrics and Gynecologists^dAmerican Academy of Pediatri
cs#Guidelines for perinatal care^len#5#Washington#AAP/ACOG#20020000#2002#2010080
0#a09v86n4.htm##
00546000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100024000940120
05900118030001800177065000900195064000500204031000300209014000600212865000900218
002001300227035001000240801001800250#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
9v86n4.htm#S#c#149#6#article#28#6#^rND^sBarros^nFC#^rND^sDiaz-Rossello^nJL#Redes
 multicêntricas e a qualidade da atenção neonatal^lpt#J Pediatr (Rio J)#20040000
#2004#80#254-6#20100800#a09v86n4.htm#0021-7557#J Pediatr (Rio J)##
00533000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100024000770120074001010300
01800175065000900193064000500202031000300207014000700210865000900217002001300226
035001000239801001800249#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S
#c#150#7#article#28#7#^rND^sDiaz-Rossello^nJL#Health services research, outcomes
, and perinatal information systems^len#Curr Opin Pediatr#19980000#1998#10#117-2
2#20100800#a09v86n4.htm#1040-8703#Curr Opin Pediatr##
00535000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770120067000970300
02400164065000900188064000500197031000300202014000800205865000900213002001300222
035001000235801002400245#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S
#c#151#8#article#28#8#^rND^sRodrigues^nRJ#Information systems: the key to eviden
ce-based health practice^len#Bull World Health Organ#20000000#2000#78#1344-51#20
100800#a09v86n4.htm#0042-9686#Bull World Health Organ##
00674000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100016000940100
02000110010001500130012014800145030001100293065000900304064000500313031000400318
014000700322865000900329002001300338035001000351801001100361#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a09v86n4.htm#S#c#152#9#article#28#9#^rND^sHorbar^nJD#^rND^
sPlsek^nPE#^rND^sSchriefer^nJA#^rND^sLeahy^nK#Evidence-based quality improvement
 in neonatal and perinatal medicine: the neonatal intensive care quality improve
ment collaborative experience^len#Pediatrics#20060000#2006#118#S57-64#20100800#a
09v86n4.htm#0031-4005#Pediatrics##
00557000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160016000790160016000950160
01500111016002200126016001800148018006100166066001100227062000500238065000900243
064000500252865000900257002001300266#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
9v86n4.htm#S#c#153#10#article#28#10#^rND^sSimini^nF#^rND^sRubino^nM#^rND^sLopez^
nR#^rND^sGonzalo-Diaz^nA#^rND^sSchwarcz^nR#Processamento de datos del sistema in
formático perinatal^les#Montevidéo#CLAP#19960000#1996#20100800#a09v86n4.htm##
00442000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170028000790180035001070620
02400142065000900166064001200175014000300187865000900190002001300199#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a09v86n4.htm#S#c#154#11#article#28#11#Brasil^dMini
stério da Saúde#Portaria nº 3018 de 19/06/1998^lpt#Diário Oficial da União#19980
622#22 jun 1998#34#20100800#a09v86n4.htm##
00566000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120150000950300
02000245710000200265065000900267064000500276031000300281014000600284865000900290
002001300299#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#c#155#12#ar
ticle#28#12#^rND^sLansky^nS#A gestão da qualidade e da integralidade do cuidado 
em saúde da mulher e da criança no SUS de Belo Horizonte: a experiência da Comis
são Perinatal^lpt#Divulg Saude Debate#2#20060000#2006#36#10-17#20100800#a09v86n4
.htm##
00656000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01500114010001400129010002500143010001400168012007100182030001000253065000900263
06400050027203100040027701400070028186500090028800200130029703500100031080100100
0320#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#c#156#13#article#28
#13#^rND^sBallard^nJL#^rND^sKhoury^nJC#^rND^sWedig^nK#^rND^sWang^nL#^rND^sEilers
-Walsman^nBL#^rND^sLipp^nR#New Ballard Score, expanded to include extremely prem
ature infants^len#J Pediatr#19910000#1991#119#417-23#20100800#a09v86n4.htm#0022-
3476#J Pediatr##
00696000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01400112010001700126010001500143010002200158810000600180012009600186030001100282
06500090029306400050030203100040030701400040031186500090031500200130032403500100
0337801001100347#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#c#157#1
4#article#28#14#^rND^sKramer^nMS#^rND^sPlatt^nRW#^rND^sWen^nSW#^rND^sJoseph^nKS#
^rND^sAllen^nA#^rND^sAbrahamowicz^nM#et al#A new and improved population-based C
anadian reference for birth weight for gestational age^len#Pediatrics#20010000#2
001#108#E35#20100800#a09v86n4.htm#0031-4005#Pediatrics##
00726000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
01400114010001600128010001500144010001600159012015900175030000500334065000900339
06400050034803100040035301400060035786500090036300200130037203500100038580100050
0395#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#c#158#15#article#28
#15#^rND^sKramer^nMS#^rND^sDemissie^nK#^rND^sYang^nH#^rND^sPlatt^nRW#^rND^sSauvé
^nR#^rND^sListon^nR#The contribution of mild and moderate preterm birth to infan
t mortality: Fetal and Infant Health Study Group of the Canadian Perinatal Surve
illance System^len#JAMA#20000000#2000#284#843-9#20100800#a09v86n4.htm#0098-7484#
JAMA##
00776000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
01600114010001500130010001800145010001600163810000600179012014100185030001800326
06500090034406400050035303100030035803200090036101400060037086500090037600200130
0385035001000398801001800408#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.h
tm#S#c#159#16#article#28#16#^rND^sBarros^nFC#^rND^sVictora^nCG#^rND^sTomasi^nE#^
rND^sHorta^nB#^rND^sMenezes^nAM#^rND^sCesar^nJA#et al#Saúde materno-infantil em 
Pelotas, Rio Grande do Sul, Brasil: principais conclusões da comparação dos estu
dos das coortes de 1982 e 1993^lpt#Cad Saude Publica#19960000#1996#12#^sSupl.1#8
7-92#20100800#a09v86n4.htm#0102-311X#Cad Saude Publica##
00781000000000349000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100015000970100
01700112010001900129010001800148010001700166810000600183012014600189030001800335
06500090035306400050036203100030036703200040037001400070037486500090038100200130
0390035001000403801001800413#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.h
tm#S#c#160#17#article#28#17#^rND^sLeal Mdo^nC#^rND^sGama^nSG#^rND^sCampos^nMR#^r
ND^sCavalini^nLT#^rND^sGarbayo^nLS#^rND^sBrasil^nCL#et al#Fatores associados à m
orbi-mortalidade perinatal em uma amostra de maternidades públicas e privadas do
 Município do Rio de Janeiro, 1999-2001^lpt#Cad Saude Publica#20040000#2004#20#^
s1#S20-33#20100800#a09v86n4.htm#0102-311X#Cad Saude Publica##
00663000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100029000960100
01800125010001900143010002000162010001500182810000600197012006700203030001900270
71000020028906500090029106400050030003100030030501400070030886500090031500200130
0324#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#c#161#18#article#28
#18#^rND^sBarros^nAJ#^rND^sda Silva dos Santos^nI#^rND^sVictora^nCG#^rND^sAlbern
az^nEP#^rND^sDomingues^nMR#^rND^sTimm^nIK#et al#Coorte de nascimentos de Pelotas
 2004: metodologia e descrição^lpt#Rev Saude Publica.#2#20060000#2006#40#402-13#
20100800#a09v86n4.htm##
00747000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
01900116010002000135010001600155010001600171810000600187012012500193030001800318
06500090033606400050034503100030035001400060035386500090035900200130036803500100
0381801001800391#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#c#162#1
9#article#28#19#^rND^sAlmeida^nMF#^rND^sGuinsburg^nR#^rND^sMartinez^nFE#^rND^sPr
ocianoy^nRS#^rND^sLeone^nCR#^rND^sMarba^nST#et al#Perinatal factors associated w
ith early deaths of preterm infants born in Brazilian Network on Neonatal Resear
ch centers^len#J Pediatr (Rio J)#20080000#2008#84#300-7#20100800#a09v86n4.htm#00
21-7557#J Pediatr (Rio J)##
00640000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760110058000790120151001370300
01500288065000900303064000500312031000300317014000700320865000900327002001300336
035001000349801001500359#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S
#c#163#20#article#28#20#National Institutes of Health Consensus Development Pane
l#Antenatal corticosteroids revisited: repeat courses - National Institutes of H
ealth Consensus Development Conference Statement, August 17-18, 2000^len#Obstet 
Gynecol#20010000#2001#98#144-50#20100800#a09v86n4.htm#0029-7844#Obstet Gynecol##
00751000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100022000960100
01900118010001900137010001700156010001800173810000600191012010700197030002700304
06500090033106400050034003100030034501400060034886500090035400200130036303500100
0376801002700386#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#c#164#2
1#article#28#21#^rND^sSantos^nIS#^rND^sMatijasevich^nA#^rND^sSilveira^nMF#^rND^s
Sclowitz^nJK#^rND^sBarros^nAJ#^rND^sVictora^nCG#et al#Associated factors and con
sequences of late preterm births: results from the 2004 Pelotas birth cohort^len
#Paediatr Perinat Epidemiol#20080000#2008#22#350-8#20100800#a09v86n4.htm#0269-50
22#Paediatr Perinat Epidemiol##
00716000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01700113010001500130010001500145010002000160810000600180012011200186030002900298
71000020032706500090032906400050033803100020034303200040034501400070034986500090
0356002001300365#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#c#165#2
2#article#28#22#^rND^sAmorim^nMM#^rND^sVilela^nPC#^rND^sSantos^nAR#^rND^sLima^nA
L#^rND^sMelo^nEF#^rND^sBernardes^nHF#et al#Impacto das malformações congênitas n
a mortalidade perinatal e neonatal em uma maternidade-escola do Recife^lpt#Rev B
ras Saúde Matern Infant#2#20060000#2006#6#^s1#S19-25#20100800#a09v86n4.htm##
00599000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980120
11200116030001800228065000900246064000500255031000300260014000800263865000900271
002001300280035001000293801001800303#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
9v86n4.htm#S#c#166#23#article#28#23#^rND^sLuquetti^nDV#^rND^sKoifman^nRJ#Quality
 of reporting on birth defects in birth certificates: case study from a Brazilia
n reference hospital^len#Cad Saude Publica#20090000#2009#25#1721-31#20100800#a09
v86n4.htm#0102-311X#Cad Saude Publica##
00553000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970120
10900114030001600223710000200239065000900241064000500250031000400255014000600259
865000900265002001300274#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S
#c#167#24#article#28#24#^rND^sVictora^nCG#^rND^sBarros^nFC#Infant mortality due 
to perinatal causes in Brazil: trends, regional patterns and possible interventi
ons^len#São Paulo Med J#2#20010000#2001#119#33-42#20100800#a09v86n4.htm##
00568000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970120
08400114030001900198065000900217064000500226031000300231014000500234865000900239
002001300248035001000261801001900271#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
9v86n4.htm#S#c#168#25#article#28#25#^rND^sAlmeida^nRT#^rND^sPersson^nJ#The use o
f and need for patient classification systems in Swedish neonatal care^len#Scand
 J Caring Sci#19980000#1998#12#11-7#20100800#a09v86n4.htm#0283-9318#Scand J Cari
ng Sci##
00748000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
01700114010001700131010001800148010002200166810000600188012014500194030000700339
06500090034606400050035503100040036001400070036486500090037100200130038003500100
0393801000700403#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#c#169#2
6#article#28#26#^rND^sBarros^nFC#^rND^sVictora^nCG#^rND^sBarros^nAJ#^rND^sSantos
^nIS#^rND^sAlbernaz^nE#^rND^sMatijasevich^nA#et al#The challenge of reducing neo
natal mortality in middle-income countries: findings from three Brazilian birth 
cohorts in 1982, 1993, and 2004^len#Lancet#20050000#2005#365#847-54#20100800#a09
v86n4.htm#0099-5355#Lancet##
00737000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
01900116010001600135010002000151010002300171810000600194012010600200030001800306
06500090032406400050033303100030033801400080034186500090034900200130035803500100
0371801001800381#v86n4#V:\Scielo\serial\jped\v86n4\markup\a09v86n4.htm#S#c#170#2
7#article#28#27#^rND^sde Silva^nAA#^rND^sCoimbra^nLC#^rND^sda Silva^nRA#^rND^sAl
ves^nMT#^rND^sLamy Filho^nF#^rND^sCarvalho Lamy^nZ#et al#Perinatal health and mo
ther-child health care in the municipality of São Luis, Maranhão State, Brazil^l
en#Cad Saude Publica#20010000#2001#17#1413-23#20100800#a09v86n4.htm#0102-311X#Ca
d Saude Publica##
00650000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01700111012016800128030002900296710000200325065000900327064000500336031000200341
014000700343865000900350002001300359#v86n4#V:\Scielo\serial\jped\v86n4\markup\a0
9v86n4.htm#S#c#171#28#article#28#28#^rND^sRego^nMA#^rND^sFrança^nEB#^rND^sAfonso
^nDC#Avaliação da qualidade da informação do Sistema de Informação Perinatal (SI
P-CLAP/OPS) para monitoramento da assistência perinatal hospitalar, Belo Horizon
te, 2004^lpt#Rev Bras Saúde Matern Infant#2#20090000#2009#9#275-84#20100800#a09v
86n4.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v86n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#o#1#1#article#1
#20110126#175523#a10v86n4.htm#178##
04861000000000625000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002100108
03100030012903200020013206500090013401400110014303500100015401200660016401200710
02300100038003010100036003390100036003750700047004110700083004580700086005410831
71100627085001002338085003102348085003602379085003302415085003102448083157202479
08500100405108500240406108500290408508500260411408500310414011700080417107200030
4179112000904182111001104191114000904202113001104211002001304222#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#TAB#1
0#JPED030#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f303^l310#0021-7557#Excesso de 
sódio e déficit de ferro em alimentos de transição^lpt#Excess sodium and insuffi
cient iron content in complementary foods^len#^rND^1A01 A02^nMarcia Bitar^sPorte
lla#^rND^1A03^nTania Beninga de^sMorais#^rND^1A02^nMauro Batista de^sMorais#Univ
ersidade do Estado do Pará^iA01^cBelém^sPA#Universidade Federal de São Paulo^iA0
2^1Escola Paulista de Medicina^cSão Paulo^sSP#UNIFESP^iA03^1Laboratório de Broma
tologia e Microbiologia de Alimentos^cSão Paulo^sSP#^lpt^aOBJETIVOS: Determinar,
 por análise química, a composição nutricional de macronutrientes, energia, sódi
o e ferro de alimentos preparados no domicílio para lactentes de dois estratos s
ocioeconômicos em Belém (PA). MÉTODOS: Estudo transversal com 78 lactentes (6 a 
18 meses) distribuídos em dois grupos com condição socioeconômica alta ou baixa.
 Foi realizada análise química de amostras de alimentos de transição preparados 
no domicílio para o almoço. Foi estimada a ingestão alimentar diária, com base e
m dois inquéritos alimentares de 24 horas. RESULTADOS: As análises químicas reve
laram que parcela das amostras dos alimentos apresentava baixo teor de energia e
m relação ao recomendado, tanto no estrato socioeconômico baixo (29,8%) como no 
alto (43,0%; p = 0,199). Todas as amostras analisadas, em ambos os grupos, apres
entaram quantidade de ferro abaixo do mínimo recomendado (6,0 mg/100 g). Por out
ro lado, excesso de sódio (200 mg/100 g) foi constatado em 89,2 e 31,7%, respect
ivamente, das amostras dos grupos de baixo e alto nível socioeconômico (p = 0,02
7). De acordo com os inquéritos alimentares, a estimativa da ingestão energética
 foi maior que 120% da necessidade média estimada em 86,5% dos lactentes do grup
o de nível socioeconômico baixo e em 92,7% do alto (p = 0,483). O almoço e o jan
tar forneceram 35,2±14,6 e 36,4±12,0% da energia, respectivamente, nos grupos de
 baixo e alto nível socioeconômico (p = 0,692). CONCLUSÃO: Alimentos de transiçã
o preparados no domicílio para lactentes apresentaram baixo teor de ferro. Parce
la expressiva das amostras apresentou quantidade excessiva de sódio, mais freque
ntemente nos alimentos preparados para os lactentes de baixo nível socioeconômic
o.#^ddecs^i1#^tm^lpt^kAlimentos infantis^i1#^tm^lpt^kcomposição de alimentos^i1#
^tm^lpt^kanálise de alimentos^i1#^tm^lpt^kestado nutricional^i1#^len^aOBJECTIVES
: To determine, by chemical analysis, the macronutrient, energy, sodium, and iro
n contents of homemade foods prepared for infants in two socioeconomic classes i
n Belém, state of Pará, Brazil. METHODS: Cross-sectional study of 78 infants (ag
ed 6 to 18 months) distributed into two groups according to socioeconomic status
 (high or low). Chemical analyses were performed on samples of homemade compleme
ntary foods prepared for each infant's lunch. Daily food intake was estimated on
 the basis of two 24-hour dietary intake recall. RESULTS: Chemical analyses show
ed that the energy content of some food samples was lower than recommended, both
 in the low socioeconomic status (SES) group (29.8% of samples) and in the high-
SES group (43.0%; p = 0.199). The iron content of all samples, regardless of gro
up, was lower than minimum recommended levels (6.0 mg/100 g). On the other hand,
 excessive sodium levels (200 mg/100 g) were found in 89.2 and 31.7% of samples 
in the low- and high-SES groups, respectively (p = 0.027). Dietary recalls showe
d that energy intake exceeded 120% of the Estimated Energy Requirement in 86.5% 
of infants in the low-SES group and 92.7% of those in the high-SES group (p = 0.
483). Lunch and dinner provided 35.2±14.6 and 36.4±12.0% of daily energy intake 
in the low- and high-SES groups, respectively (p = 0.692). CONCLUSION: Homemade 
complementary foods for infants were found to be low in iron. A significant port
ion of samples had excessive sodium content, most frequently those prepared for 
infants in low-SES status families.#^ddecs^i2#^tm^len^kInfant food^i2#^tm^len^kf
ood composition^i2#^tm^len^kfood analysis^i2#^tm^len^knutritional status^i2#vanc
ouv#33#20091103#03.11.2009#20100430#30.04.2010#a10v86n4.htm##
04931000000000625000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002100108
03100030012903200020013206500090013401400110014303500100015401200730016401200780
02370100038003150100036003530100036003890700047004250700083004720700086005550831
73900641085001002380085003102390085003602421085003302457085003102490083160002521
08500100412108500240413108500290415508500260418408500310421011700080424107200030
4249112000904252111001104261114000904272113001104281002001304292#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#TAB#1
0#JPED030#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f303^l310#0021-7557#<b>Excesso 
de sódio e déficit de ferro em alimentos de transição</b>^lpt#<b>Excess sodium a
nd insufficient iron content in complementary foods</b>^len#^rND^1A01 A02^nMarci
a Bitar^sPortella#^rND^1A03^nTania Beninga de^sMorais#^rND^1A02^nMauro Batista d
e^sMorais#Universidade do Estado do Pará^iA01^cBelém^sPA#Universidade Federal de
 São Paulo^iA02^1Escola Paulista de Medicina^cSão Paulo^sSP#UNIFESP^iA03^1Labora
tório de Bromatologia e Microbiologia de Alimentos^cSão Paulo^sSP#^lpt^a<b>OBJET
IVOS: </b>Determinar, por análise química, a composição nutricional de macronutr
ientes, energia, sódio e ferro de alimentos preparados no domicílio para lactent
es de dois estratos socioeconômicos em Belém (PA). <b>MÉTODOS: </b>Estudo transv
ersal com 78 lactentes (6 a 18 meses) distribuídos em dois grupos com condição s
ocioeconômica alta ou baixa. Foi realizada análise química de amostras de alimen
tos de transição preparados no domicílio para o almoço. Foi estimada a ingestão 
alimentar diária, com base em dois inquéritos alimentares de 24 horas. <b>RESULT
ADOS: </b>As análises químicas revelaram que parcela das amostras dos alimentos 
apresentava baixo teor de energia em relação ao recomendado, tanto no estrato so
cioeconômico baixo (29,8%) como no alto (43,0%; p = 0,199). Todas as amostras an
alisadas, em ambos os grupos, apresentaram quantidade de ferro abaixo do mínimo 
recomendado (6,0 mg/100 g). Por outro lado, excesso de sódio (200 mg/100 g) foi 
constatado em 89,2 e 31,7%, respectivamente, das amostras dos grupos de baixo e 
alto nível socioeconômico (p = 0,027). De acordo com os inquéritos alimentares, 
a estimativa da ingestão energética foi maior que 120% da necessidade média esti
mada em 86,5% dos lactentes do grupo de nível socioeconômico baixo e em 92,7% do
 alto (p = 0,483). O almoço e o jantar forneceram 35,2±14,6 e 36,4±12,0% da ener
gia, respectivamente, nos grupos de baixo e alto nível socioeconômico (p = 0,692
). <b>CONCLUSÃO: </b>Alimentos de transição preparados no domicílio para lactent
es apresentaram baixo teor de ferro. Parcela expressiva das amostras apresentou 
quantidade excessiva de sódio, mais frequentemente nos alimentos preparados para
 os lactentes de baixo nível socioeconômico.#^ddecs^i1#^tm^lpt^kAlimentos infant
is^i1#^tm^lpt^kcomposição de alimentos^i1#^tm^lpt^kanálise de alimentos^i1#^tm^l
pt^kestado nutricional^i1#^len^a<b>OBJECTIVES: </b>To determine, by chemical ana
lysis, the macronutrient, energy, sodium, and iron contents of homemade foods pr
epared for infants in two socioeconomic classes in Belém, state of Pará, Brazil.
 <b>METHODS: </b>Cross-sectional study of 78 infants (aged 6 to 18 months) distr
ibuted into two groups according to socioeconomic status (high or low). Chemical
 analyses were performed on samples of homemade complementary foods prepared for
 each infant's lunch. Daily food intake was estimated on the basis of two 24-hou
r dietary intake recall. <b>RESULTS: </b>Chemical analyses showed that the energ
y content of some food samples was lower than recommended, both in the low socio
economic status (SES) group (29.8% of samples) and in the high-SES group (43.0%;
 p = 0.199). The iron content of all samples, regardless of group, was lower tha
n minimum recommended levels (6.0 mg/100 g). On the other hand, excessive sodium
 levels (200 mg/100 g) were found in 89.2 and 31.7% of samples in the low- and h
igh-SES groups, respectively (p = 0.027). Dietary recalls showed that energy int
ake exceeded 120% of the Estimated Energy Requirement in 86.5% of infants in the
 low-SES group and 92.7% of those in the high-SES group (p = 0.483). Lunch and d
inner provided 35.2±14.6 and 36.4±12.0% of daily energy intake in the low- and h
igh-SES groups, respectively (p = 0.692). <b>CONCLUSION: </b>Homemade complement
ary foods for infants were found to be low in iron. A significant portion of sam
ples had excessive sodium content, most frequently those prepared for infants in
 low-SES status families.#^ddecs^i2#^tm^len^kInfant food^i2#^tm^len^kfood compos
ition^i2#^tm^len^kfood analysis^i2#^tm^len^knutritional status^i2#vancouv#33#200
91103#03.11.2009#20100430#30.04.2010#a10v86n4.htm##
05110000000000649000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000400108121000300112049000800115158000300123
03000210012603100030014703200020015006500090015201400110016103500100017201200660
01820120071002480100038003190100036003570100036003930700049004290700085004780700
08800563083177400651085001002425085003102435085003602466085003302502085003102535
08316210256608500100418708500240419708500290422108500260425008500310427611700080
43070720003043151120009043181110011043271140009043381130011043470020013043580080
08904371#v86n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#l#4#1#article#1
#^mjul./ago.^a2010#oa#pt#br1.1#1#4.0#tab#10#JPED030#nd#J. Pediatr. (Rio J.)#86#4
#20100800#^f303^l310#0021-7557#Excesso de sódio e déficit de ferro em alimentos 
de transição^lpt#Excess sodium and insufficient iron content in complementary fo
ods^len#^rND^1A01 A02^nMarcia Bitar^sPortella#^rND^1A03^nTania Beninga de^sMorai
s#^rND^1A02^nMauro Batista de^sMorais#^iA01^1Universidade do Estado do Pará^cBel
ém^sPA#^iA02^1Universidade Federal de São Paulo^2Escola Paulista de Medicina^cSã
o Paulo^sSP#^iA03^1UNIFESP^2Laboratório de Bromatologia e Microbiologia de Alime
ntos^cSão Paulo^sSP#^lpt^aOBJETIVOS: Determinar, por análise química, a composiç
ão nutricional de macronutrientes, energia, sódio e ferro de alimentos preparado
s no domicílio para lactentes de dois estratos socioeconômicos em Belém (PA). MÉ
TODOS: Estudo transversal com 78 lactentes (6 a 18 meses) distribuídos em dois g
rupos com condição socioeconômica alta ou baixa. Foi realizada análise química d
e amostras de alimentos de transição preparados no domicílio para o almoço. Foi 
estimada a ingestão alimentar diária, com base em dois inquéritos alimentares de
 24 horas. RESULTADOS: As análises químicas revelaram que parcela das amostras d
os alimentos apresentava baixo teor de energia em relação ao recomendado, tanto 
no estrato socioeconômico baixo (29,8 por cento) como no alto (43,0 por cento; p
 = 0,199). Todas as amostras analisadas, em ambos os grupos, apresentaram quanti
dade de ferro abaixo do mínimo recomendado (6,0 mg/100 g). Por outro lado, exces
so de sódio (200 mg/100 g) foi constatado em 89,2 e 31,7 por cento, respectivame
nte, das amostras dos grupos de baixo e alto nível socioeconômico (p = 0,027). D
e acordo com os inquéritos alimentares, a estimativa da ingestão energética foi 
maior que 120 por cento da necessidade média estimada em 86,5 por cento dos lact
entes do grupo de nível socioeconômico baixo e em 92,7 por cento do alto (p = 0,
483). O almoço e o jantar forneceram 35,2±14,6 e 36,4±12,0 por cento da energia,
 respectivamente, nos grupos de baixo e alto nível socioeconômico (p = 0,692). C
ONCLUSÃO: Alimentos de transição preparados no domicílio para lactentes apresent
aram baixo teor de ferro. Parcela expressiva das amostras apresentou quantidade 
excessiva de sódio, mais frequentemente nos alimentos preparados para os lactent
es de baixo nível socioeconômico.#^ddecs^i1#^tm^lpt^kAlimentos infantis^i1#^tm^l
pt^kcomposição de alimentos^i1#^tm^lpt^kanálise de alimentos^i1#^tm^lpt^kestado 
nutricional^i1#^len^aOBJECTIVES: To determine, by chemical analysis, the macronu
trient, energy, sodium, and iron contents of homemade foods prepared for infants
 in two socioeconomic classes in Belém, state of Pará, Brazil. METHODS: Cross-se
ctional study of 78 infants (aged 6 to 18 months) distributed into two groups ac
cording to socioeconomic status (high or low). Chemical analyses were performed 
on samples of homemade complementary foods prepared for each infant's lunch. Dai
ly food intake was estimated on the basis of two 24-hour dietary intake recall. 
RESULTS: Chemical analyses showed that the energy content of some food samples w
as lower than recommended, both in the low socioeconomic status (SES) group (29.
8 percent of samples) and in the high-SES group (43.0 percent; p = 0.199). The i
ron content of all samples, regardless of group, was lower than minimum recommen
ded levels (6.0 mg/100 g). On the other hand, excessive sodium levels (200 mg/10
0 g) were found in 89.2 and 31.7 percent of samples in the low- and high-SES gro
ups, respectively (p = 0.027). Dietary recalls showed that energy intake exceede
d 120 percent of the Estimated Energy Requirement in 86.5 percent of infants in 
the low-SES group and 92.7 percent of those in the high-SES group (p = 0.483). L
unch and dinner provided 35.2±14.6 and 36.4±12.0 percent of daily energy intake 
in the low- and high-SES groups, respectively (p = 0.692). CONCLUSION: Homemade 
complementary foods for infants were found to be low in iron. A significant port
ion of samples had excessive sodium content, most frequently those prepared for 
infants in low-SES status families.#^ddecs^i2#^tm^len^kInfant food^i2#^tm^len^kf
ood composition^i2#^tm^len^kfood analysis^i2#^tm^len^knutritional status^i2#vanc
ouv#33#20091103#03.11.2009#20100430#30.04.2010#a10v86n4.htm#Internet^ihttp://www
.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572010000400010##
00323000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704009000074002001300164#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#5#1#article#141#<p align="right"><fon
t size="2" face="Verdana"><b>ARTIGO ORIGINAL</b></font> </p>     ^cY#a10v86n4.ht
m##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#6#2#article#141#<p>&nbsp;</p>     ^cY
#a10v86n4.htm##
00385000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704015200074002001300226#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#7#3#article#141#<p><font size="4" fac
e="Verdana"><b>Excesso de s&oacute;dio e d&eacute;ficit de    ferro em alimentos
 de transi&ccedil;&atilde;o</b></font></p>     ^cY#a10v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#8#4#article#141#<p>&nbsp;</p>     ^cY
#a10v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#9#5#article#141#<p>&nbsp;</p>     ^cY
#a10v86n4.htm##
00407000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704017300075002001300248#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#10#6#article#141#<p><font size="2" fa
ce="Verdana"><b>Marcia Bitar Portella<sup>I</sup>; Tania Beninga    de Morais<su
p>II</sup>; Mauro Batista de Morais<sup>III</sup></b></font></p>     ^cY#a10v86n
4.htm##
00541000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704030700075002001300382#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#11#7#article#141#<p><font size="2" fa
ce="Verdana"><sup>I</sup>Professora adjunta, Disciplina de    Pediatria, Univers
idade do Estado do Par&aacute; (UEPA), Bel&eacute;m, PA, Doutora,    Ci&ecirc;nc
ias, Universidade Federal de S&atilde;o Paulo &#150; Escola Paulista de    Medic
ina (UNIFESP-EPM), S&atilde;o Paulo, SP    ^cY#a10v86n4.htm##
00413000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704017900075002001300254#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#12#8#article#141#<br>   <sup>II</sup>
Doutora, UNIFESP, S&atilde;o Paulo, SP, Coordenadora, Laborat&oacute;rio    de B
romatologia e Microbiologia de Alimentos, UNIFESP, S&atilde;o Paulo, SP    ^cY#a
10v86n4.htm##
00398000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704016400075002001300239#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#13#9#article#141#<br>   <sup>III</sup
>Professor associado, livre-docente, Disciplina de Gastroenterologia    Pedi&aac
ute;trica, UNIFESP-EPM, S&atilde;o Paulo, SP</font></p>     ^cY#a10v86n4.htm##
00368000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013300076002001300209#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#14#10#article#141#<p><font size="2" f
ace="Verdana"><a name="topo" id="topo"></a><a href="#correspondence">Correspond&
ecirc;ncia</a></font></p>     ^cY#a10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#15#11#article#141#<p>&nbsp;</p>     ^
cY#a10v86n4.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#16#12#article#141#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a10v86n4.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006600076002001300142#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#17#13#article#141#<p><font size="2" f
ace="Verdana"><b>RESUMO</b></font></p>     ^cY#a10v86n4.htm##
00559000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032400076002001300400#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#18#14#article#141#<p><font size="2" f
ace="Verdana"><b>OBJETIVOS: </b> Determinar, por an&aacute;lise    qu&iacute;mic
a, a composi&ccedil;&atilde;o nutricional de macronutrientes, energia,    s&oacu
te;dio e ferro de alimentos preparados no domic&iacute;lio para lactentes    de 
dois estratos socioecon&ocirc;micos em Bel&eacute;m (PA).    ^cY#a10v86n4.htm##
00702000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046700076002001300543#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#19#15#article#141#<br>   <b>M&Eacute;
TODOS: </b> Estudo transversal com 78 lactentes (6 a 18 meses) distribu&iacute;d
os    em dois grupos com condi&ccedil;&atilde;o socioecon&ocirc;mica alta ou bai
xa.    Foi realizada an&aacute;lise qu&iacute;mica de amostras de alimentos de t
ransi&ccedil;&atilde;o    preparados no domic&iacute;lio para o almo&ccedil;o. F
oi estimada a ingest&atilde;o    alimentar di&aacute;ria, com base em dois inqu&
eacute;ritos alimentares de 24    horas.    ^cY#a10v86n4.htm##
01299000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704106400076002001301140#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#20#16#article#141#<br>   <b>RESULTADO
S: </b>As an&aacute;lises qu&iacute;micas revelaram que parcela    das amostras 
dos alimentos apresentava baixo teor de energia em rela&ccedil;&atilde;o    ao r
ecomendado, tanto no estrato socioecon&ocirc;mico baixo (29,8%) como no    alto 
(43,0%; p = 0,199). Todas as amostras analisadas, em ambos os grupos, apresentar
am    quantidade de ferro abaixo do m&iacute;nimo recomendado (6,0 mg/100 g). Po
r    outro lado, excesso de s&oacute;dio (200 mg/100 g) foi constatado em 89,2 e
    31,7%, respectivamente, das amostras dos grupos de baixo e alto n&iacute;vel
    socioecon&ocirc;mico (p = 0,027). De acordo com os inqu&eacute;ritos aliment
ares,    a estimativa da ingest&atilde;o energ&eacute;tica foi maior que 120% da
 necessidade    m&eacute;dia estimada em 86,5% dos lactentes do grupo de n&iacut
e;vel socioecon&ocirc;mico    baixo e em 92,7% do alto (p = 0,483). O almo&ccedi
l;o e o jantar forneceram    35,2±14,6 e 36,4±12,0% da energia, respectivamente,
 nos grupos de baixo e alto    n&iacute;vel socioecon&ocirc;mico (p = 0,692).   
 ^cY#a10v86n4.htm##
00601000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036600076002001300442#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#21#17#article#141#<br>   <b>CONCLUS&A
tilde;O: </b> Alimentos de transi&ccedil;&atilde;o preparados no    domic&iacute
;lio para lactentes apresentaram baixo teor de ferro. Parcela expressiva    das 
amostras apresentou quantidade excessiva de s&oacute;dio, mais frequentemente   
 nos alimentos preparados para os lactentes de baixo n&iacute;vel socioecon&ocir
c;mico.</font></p>     ^cY#a10v86n4.htm##
00444000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020900076002001300285#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#22#18#article#141#<p><font size="2" f
ace="Verdana"><b>Palavras-chave: </b> Alimentos infantis, composi&ccedil;&atilde
;o    de alimentos, an&aacute;lise de alimentos, estado nutricional.</font></p> 
<hr size="1" noshade>     ^cY#a10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#23#19#article#141#<p>&nbsp;</p>     ^
cY#a10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#24#20#article#141#<p>&nbsp;</p>     ^
cY#a10v86n4.htm##
00319000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008400076002001300160#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#25#21#article#141#<p><font size="3" f
ace="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#a10v86n4.htm##
01341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704110600076002001301182#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#26#22#article#141#<p><font face="Verd
ana" size="2">Os h&aacute;bitos e costumes da humanidade t&ecirc;m    se modific
ado nos &uacute;ltimos anos e podem interferir na qualidade e na expectativa    
de vida. Alimenta&ccedil;&atilde;o inadequada no primeiro ano da vida pode influ
enciar    no aparecimento de doen&ccedil;as cr&ocirc;nicas n&atilde;o transmiss&
iacute;veis    na idade adulta<SUP>1</SUP>. A transi&ccedil;&atilde;o da aliment
a&ccedil;&atilde;o    do lactente representada pela introdu&ccedil;&atilde;o de 
alimentos s&oacute;lidos    em sua dieta &eacute; influenciada n&atilde;o soment
e pelas necessidades nutricionais,    mas pelos padr&otilde;es culturais de cada
 regi&atilde;o<SUP>2</SUP>. O per&iacute;odo    de transi&ccedil;&atilde;o &eacu
te; realizado muitas vezes de maneira impr&oacute;pria,    no entanto, s&atilde;
o raros os estudos sobre a composi&ccedil;&atilde;o qu&iacute;mica    de aliment
os para lactentes preparados no domic&iacute;lio<SUP>3,4</SUP>. Os    resultados
 desses estudos indicam que a quantidade de s&oacute;dio &eacute;    excessiva, 
e a de ferro, insuficiente.</font></p>     ^cY#a10v86n4.htm##
01281000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704104600076002001301122#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#27#23#article#141#<p><font face="Verd
ana" size="2">Deve ser ressaltado que o teor de s&oacute;dio    na alimenta&cced
il;&atilde;o complementar oferecida para lactentes pode determinar    um h&aacut
e;bito alimentar com prefer&ecirc;ncia por alimentos salgados e, ainda,    assoc
iar-se com maiores n&iacute;veis de press&atilde;o arterial na inf&acirc;ncia   
 e na vida adulta<SUP>5,6</SUP>. Por sua vez, a defici&ecirc;ncia de ferro ocorr
e    com elevada preval&ecirc;ncia em lactentes de varias regi&otilde;es do mund
o<SUP>7</SUP>,    sendo que os alimentos complementares deveriam ser ricos em fe
rro para prevenir    esse tipo de car&ecirc;ncia nutricional. A defici&ecirc;nci
a de ferro &eacute;    mais frequente em popula&ccedil;&otilde;es com baixo n&ia
cute;vel socioecon&ocirc;mico;    assim, &eacute; poss&iacute;vel que ocorram di
feren&ccedil;as na qualidade da    alimenta&ccedil;&atilde;o de transi&ccedil;&a
tilde;o de acordo com a classe    socioecon&ocirc;mica de uma determinada regi&a
tilde;o ou popula&ccedil;&atilde;o<SUP>8</SUP>.</font></p>     ^cY#a10v86n4.htm#
#
00841000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060600076002001300682#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#28#24#article#141#<p><font face="Verd
ana" size="2">Considerando o exposto, o objetivo do estudo    foi avaliar, por a
n&aacute;lise qu&iacute;mica, a composi&ccedil;&atilde;o de    macronutrientes, 
energia, s&oacute;dio e ferro de alimentos preparados no domic&iacute;lio    par
a o almo&ccedil;o de lactentes de dois estratos socioecon&ocirc;micos de    Bel&
eacute;m (PA), na Amaz&ocirc;nia oriental. Foi avaliado, tamb&eacute;m,    o pap
el quantitativo dos alimentos de transi&ccedil;&atilde;o como fonte de    nutrie
ntes em rela&ccedil;&atilde;o &agrave; ingest&atilde;o diet&eacute;tica    recom
endada.</font></p>     ^cY#a10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#29#25#article#141#<p>&nbsp;</p>     ^
cY#a10v86n4.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007400076002001300150#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#30#26#article#141#<p><font size="3" f
ace="Verdana"><b>M&eacute;todos</b></font></p>     ^cY#a10v86n4.htm##
01294000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704105900076002001301135#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#31#27#article#141#<p><font face="Verd
ana" size="2">   Neste estudo transversal, realizado entre junho de 2005 e setem
bro de 2006,    foram analisadas 78 amostras de alimentos de transi&ccedil;&atil
de;o preparados    em domic&iacute;lios. Na constitui&ccedil;&atilde;o desta amo
stra de conveni&ecirc;ncia,    foram obedecidos os seguintes crit&eacute;rios de
 inclus&atilde;o, considerando    o lactente para quem o alimento foi preparado:
 1) aus&ecirc;ncia de evid&ecirc;ncias    cl&iacute;nicas de doen&ccedil;as infe
cciosas agudas ou doen&ccedil;as cr&ocirc;nicas    e degenerativas; 2) idade ent
re 6 e 18 meses; 3) utiliza&ccedil;&atilde;o, na    dieta, de alimentos de trans
i&ccedil;&atilde;o preparados apenas em domic&iacute;lios    situados no munic&i
acute;pio de Bel&eacute;m. Os respons&aacute;veis assinaram    o Termo de Consen
timento Livre e Esclarecido. O projeto foi aprovado pelo Comit&ecirc;    de &Eac
ute;tica em Pesquisa da Universidade Federal de S&atilde;o Paulo &#150; Escola  
  Paulista de Medicina (UNIFESP-EPM), S&atilde;o Paulo (SP).</font></p>     ^cY#
a10v86n4.htm##
01149000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704091400076002001300990#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#32#28#article#141#<p><font face="Verd
ana" size="2">Para o c&aacute;lculo do tamanho da amostra,    o teor de ferro fo
i escolhido porque a defici&ecirc;ncia de ferro &eacute; a    principal car&ecir
c;ncia nutricional nessa faixa et&aacute;ria e por ter sido    uma das principai
s inadequa&ccedil;&otilde;es em alimentos de transi&ccedil;&atilde;o    em um es
tudo realizado previamente, sobre alimentos adaptados da refei&ccedil;&atilde;o 
   da fam&iacute;lia para o consumo por lactentes<SUP>9</SUP>. Considerou-se que
,    no estrato socioecon&ocirc;mico alto, 65% dos alimentos teriam teor inadequ
ado    de ferro e, no estrato socioecon&ocirc;mico baixo, 95%. Ou seja, diferen&
ccedil;a    de 30% entre os dois grupos, estimando-se 33 crian&ccedil;as em cada
 estrato    socioecon&ocirc;mico. Como precau&ccedil;&atilde;o, foram inclu&iacu
te;das no    estudo 78 crian&ccedil;as e respectivas amostras de alimentos.</fon
t></p>     ^cY#a10v86n4.htm##
00725000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049000076002001300566#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#33#29#article#141#<p><font face="Verd
ana" size="2">As amostras de alimentos foram coletadas de fam&iacute;lias    ate
ndidas em dois tipos de servi&ccedil;o de atendimento pedi&aacute;trico:    1) U
nidade Materno Infantil da Universidade do Estado do Par&aacute; (UEPA),    Bel&
eacute;m (PA); e 2) quatro consult&oacute;rios privados da cidade de Bel&eacute;
m.    Utilizou-se essa estrat&eacute;gia para a inclus&atilde;o de crian&ccedil;
as    de diferentes estratos socioecon&ocirc;micos.</font></p>     ^cY#a10v86n4.
htm##
00664000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042900076002001300505#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#34#30#article#141#<p><font face="Verd
ana" size="2">Ap&oacute;s a inclus&atilde;o no estudo, foram    realizados os se
guintes procedimentos: entrevista com as m&atilde;es; exame    f&iacute;sico e d
etermina&ccedil;&atilde;o do peso e estatura dos lactentes;    inqu&eacute;rito 
alimentar de 24 horas; e coleta de amostra de alimento de transi&ccedil;&atilde;
o    preparado no domic&iacute;lio para an&aacute;lise qu&iacute;mica.</font></p
>     ^cY#a10v86n4.htm##
00717000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048200076002001300558#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#35#31#article#141#<p><font face="Verd
ana" size="2">No dia da admiss&atilde;o, foi preenchido question&aacute;rio    c
om informa&ccedil;&otilde;es cl&iacute;nicas da crian&ccedil;a e de seus anteced
entes    alimentares. Para a caracteriza&ccedil;&atilde;o da condi&ccedil;&atild
e;o socioecon&ocirc;mica,    foi utilizado o Crit&eacute;rio de Classifica&ccedi
l;&atilde;o Econ&ocirc;mica    Brasil, da Associa&ccedil;&atilde;o Brasileira da
s Empresas de Pesquisa (ABEP)<SUP>10</SUP>.</font></p>     ^cY#a10v86n4.htm##
01260000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704102500076002001301101#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#36#32#article#141#<p><font face="Verd
ana" size="2">Os inqu&eacute;ritos alimentares de 24 horas    foram realizados n
o dia da admiss&atilde;o e no dia da coleta da amostra do    alimento de transi&
ccedil;&atilde;o (intervalo aproximado de duas semanas).    O c&aacute;lculo dos
 nutrientes das dietas foi realizado com o <i>software</i>    Sistema de Apoio e
 Decis&atilde;o em Nutri&ccedil;&atilde;o (NutWin). Os valores    de ingest&atil
de;o foram comparados com os valores de recomenda&ccedil;&atilde;o    diet&eacut
e;tica di&aacute;ria (<i>dietary reference intake</i>, DRI)<SUP>11</SUP>.    For
am considerados os seguintes par&acirc;metros: necessidade estimada de energia  
  (<i>estimated energy requirements,</i> EER), necessidade m&eacute;dia estimada
    (<i>estimated average requirement,</i> EAR), ingest&atilde;o diet&eacute;tic
a    recomendada (recommended dietary allowances, RDA) e ingest&atilde;o adequad
a    (<i>adequate intake,</i> AI) na depend&ecirc;ncia da vari&aacute;vel diet&e
acute;tica    considerada.</font></p>     ^cY#a10v86n4.htm##
00895000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704066000076002001300736#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#37#33#article#141#<p><font face="Verd
ana" size="2">Durante a primeira entrevista, a pesquisadora    anotava no questi
on&aacute;rio a hora do almo&ccedil;o da crian&ccedil;a, e    a visita domicilia
r obedecia esse hor&aacute;rio, sem pr&eacute;vio agendamento,    para que fosse
 coletada uma amostra de alimento preparado de acordo com os procedimentos    ha
bituais. As amostras foram analisadas em duplicata no Laborat&oacute;rio de    B
romatologia e Microbiologia de Alimentos da UNIFESP com t&eacute;cnicas padroniz
adas.    Assim, determinou-se: prote&iacute;nas, lip&iacute;dios, hidrato de car
bono,    ferro, s&oacute;dio e valor energ&eacute;tico total.</font></p>     ^cY
#a10v86n4.htm##
00936000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070100076002001300777#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#38#34#article#141#<p><font face="Verd
ana" size="2">As densidades energ&eacute;ticas das amostras    foram comparadas 
com o valor estabelecido pela Portaria nº 34 do Minist&eacute;rio    da Sa&uacut
e;de<SUP>12</SUP>, referente a alimentos de transi&ccedil;&atilde;o    para lact
entes e crian&ccedil;as de primeira inf&acirc;ncia. A quantidade de    prote&iac
ute;nas, lip&iacute;dios, ferro e s&oacute;dio das refei&ccedil;&otilde;es    en
caminhadas para an&aacute;lise qu&iacute;mica foi comparada com o valor estabele
cido    pela Diretriz 06/125 da Comiss&atilde;o da Comunidade Europeia<SUP>13</S
UP>,    referente a alimentos infantis para lactentes e crian&ccedil;as de prime
ira    inf&acirc;ncia.</font></p>     ^cY#a10v86n4.htm##
00737000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050200076002001300578#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#39#35#article#141#<p><font face="Verd
ana" size="2">Para avaliar a contribui&ccedil;&atilde;o energ&eacute;tica    dos
 macronutrientes (<i>acceptable macronutrient distribution range</i>, AMDR)<SUP>
12</SUP>,    foram utilizados os valores para a faixa de idade entre 1 e 3 anos 
(5 a 20%    do total de energia proveniente de prote&iacute;nas; 30 a 40%, de li
p&iacute;dios;    e 45 a 65%, de carboidratos), considerando a inexist&ecirc;nci
a de preconiza&ccedil;&atilde;o    para o primeiro ano de vida.</font></p>     ^
cY#a10v86n4.htm##
00625000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039000076002001300466#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#40#36#article#141#<p><font face="Verd
ana" size="2">Os escores z de peso/idade, estatura/idade e    peso/estatura fora
m calculados pelo programa de computador WHO Anthro vers&atilde;o    2.0<SUP>14<
/SUP>. O diagn&oacute;stico nutricional foi definido segundo os pontos    de cor
te apresentados em documento preliminar do Sistema de Vigil&acirc;ncia    Alimen
tar e Nutricional<SUP>15</SUP>.</font></p>     ^cY#a10v86n4.htm##
00692000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045700076002001300533#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#41#37#article#141#<p><font face="Verd
ana" size="2">Foram utilizados m&eacute;todos estat&iacute;sticos    param&eacut
e;tricos e n&atilde;o-param&eacute;tricos segundo a distribui&ccedil;&atilde;o  
  das vari&aacute;veis. Foi adotado n&iacute;vel de signific&acirc;ncia de 5%.  
  Os c&aacute;lculos foram realizados utilizando os programas Epi-Info v.6.04   
 e SigmaStat for Windows v.2.0. Os testes utilizados s&atilde;o apresentados    
com os resultados.</font></p>     ^cY#a10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#42#38#article#141#<p>&nbsp;</p>     ^
cY#a10v86n4.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007000076002001300146#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#43#39#article#141#<p><font size="3" f
ace="Verdana"><b>Resultados</b></font></p>     ^cY#a10v86n4.htm##
01631000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704139600076002001301472#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#44#40#article#141#<p><font face="Verd
ana" size="2">Das 78 crian&ccedil;as admitidas no estudo, 37    foram inclu&iacu
te;das no grupo do estrato socioecon&ocirc;mico baixo (classes    C, D e E) e 41
 no grupo do estrato socioecon&ocirc;mico alto (classes A e B).    No grupo baix
o, 19 eram meninas (51,4%), e no alto, as meninas foram 15 (36,6%;    p = 0,191;
 teste do qui-quadrado). Com rela&ccedil;&atilde;o &agrave; idade,    no estrato
 socioecon&ocirc;mico baixo, 18 crian&ccedil;as encontravam-se entre    os 6 e 1
2 meses incompletos e 20 entre 12 e 18 meses completos. No estrato socioecon&oci
rc;mico    alto, esses valores foram, respectivamente, 19 e 21 (p = 0,990; teste
 do qui-quadrado).    Os escores z, respectivamente, nos grupos de baixo e alto 
estrato socioecon&ocirc;mico,    foram: peso/idade = +0,39±0,39 e +0,99±1,35 (p 
= 0,026); peso/estatura = +0,61±0,97    e +0,65±1,12 &#091;p = 0,864, m&eacute;d
ia e desvio padr&atilde;o (DP), teste<i>    t</i> de Student para peso/idade e p
eso/estatura&#093;; e estatura/idade = +0,03    e +0,94 (mediana, teste de Mann-
Whitney; p = 0,014). Em nenhum dos dois grupos    se observou crian&ccedil;as co
m d&eacute;ficit (escore z &lt; -2,0 DP) de peso    para a idade ou estatura. D&
eacute;ficit de estatura para a idade foi observado    em 10,8% dos lactentes do
 grupo de n&iacute;vel socioecon&ocirc;mico baixo e    em 2,4% do grupo alto.</f
ont></p>     ^cY#a10v86n4.htm##
00849000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061400076002001300690#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#45#41#article#141#<p><font face="Verd
ana" size="2">Excesso de peso para a estatura (escore z &gt;    +2,0 DP) ocorreu
 em 10,8 e 16,9%, respectivamente, nos grupos de baixo e alto    n&iacute;vel so
cioecon&ocirc;mico. Quanto &agrave; idade, cinco (13,5%) das    m&atilde;es do g
rupo baixo apresentavam idade inferior a 20 anos, enquanto que    nenhuma do gru
po alto encontrava-se nessa faixa de idade (p = 0,015; teste do    qui-quadrado)
. A propor&ccedil;&atilde;o de m&atilde;es que estudaram mais de    12 anos foi 
maior no grupo alto (65,8%) do que no grupo baixo (43,2%, p = 0,017;    teste do
 qui-quadrado).</font></p>     ^cY#a10v86n4.htm##
01191000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704095600076002001301032#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#46#42#article#141#<p><font face="Verd
ana" size="2">Na <a href=/img/revistas/jped/v86n4/4a10t1.gif>Tabela    1</a>, s&
atilde;o apresentados os resultados das an&aacute;lises qu&iacute;micas    de ma
cronutrientes, energia, ferro e s&oacute;dio dos alimentos preparados para    o 
almo&ccedil;o dos lactentes segundo o estrato socioecon&ocirc;mico. Os teores   
 de &aacute;gua, prote&iacute;na, lip&iacute;dio, carboidratos e ferro foram    
semelhantes nos dois grupos. A quantidade de carboidratos nesses alimentos,    n
o n&iacute;vel socioecon&ocirc;mico baixo (10,9±4,3/100 g), foi maior do que    
no alto (9,0±4,5/100 g); entretanto, o estudo estat&iacute;stico n&atilde;o    a
tingiu signific&acirc;ncia (p = 0,078). Por sua vez, os alimentos preparados    
para as crian&ccedil;as do estrato socioecon&ocirc;mico baixo apresentaram maior
    (p = 0,005) quantidade de s&oacute;dio em rela&ccedil;&atilde;o ao grupo do 
   estrato socioecon&ocirc;mico alto.</font></p>     ^cY#a10v86n4.htm##
01439000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704120400076002001301280#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#47#43#article#141#<p><font face="Verd
ana" size="2">A <a href=/img/revistas/jped/v86n4/4a10t2.gif>Tabela    2</a> apre
senta os resultados da adequa&ccedil;&atilde;o da energia e dos nutrientes    do
 almo&ccedil;o de lactentes, segundo as an&aacute;lises qu&iacute;micas, em    r
ela&ccedil;&atilde;o ao preconizado pelo Minist&eacute;rio da Sa&uacute;de    do
 Brasil<SUP>12</SUP> e pelas Diretrizes da Comunidade Europeia<SUP>13</SUP>.    
Excesso de s&oacute;dio foi mais frequente (p = 0,027) nos alimentos do estrato 
   socioecon&ocirc;mico baixo (89,2%) do que nos alimentos do grupo do estrato  
  socioecon&ocirc;mico alto (31,7%). O conte&uacute;do de ferro foi insuficiente
    na totalidade das amostras dos dois estratos socioecon&ocirc;micos. N&atilde
;o    se observou diferen&ccedil;a, entre os grupos, quanto &agrave; propor&cced
il;&atilde;o    de alimentos com teor adequado de energia, prote&iacute;nas e li
p&iacute;dios.    Entretanto, 29,8 e 43,9% das amostras dos alimentos dos estrat
os socioecon&ocirc;micos    baixo e alto, respectivamente, apresentavam densidad
e energ&eacute;tica abaixo    dos valores m&iacute;nimos para alimentos de trans
i&ccedil;&atilde;o destinados    a lactentes.</font></p>     ^cY#a10v86n4.htm##
01068000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083300076002001300909#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#48#44#article#141#<p><font face="Verd
ana" size="2">A <a href=/img/revistas/jped/v86n4/4a10t2.gif>Tabela    2</a> most
ra, ainda, as m&eacute;dias da contribui&ccedil;&atilde;o percentual    dos macr
onutrientes das prepara&ccedil;&otilde;es em rela&ccedil;&atilde;o ao    valor e
nerg&eacute;tico total. Apenas as m&eacute;dias das contribui&ccedil;&otilde;es 
   dos carboidratos situaram-se dentro da faixa esperada. Ambos os grupos aprese
ntaram    m&eacute;dia de prote&iacute;na superior &agrave; faixa recomendada, s
endo que    os valores do grupo do estrato socioecon&ocirc;mico alto foram super
iores aos    do grupo do estrato socioecon&ocirc;mico baixo (p = 0,035). Por sua
 vez, a m&eacute;dia    da contribui&ccedil;&atilde;o dos lip&iacute;dios situou
-se abaixo do recomendado    nos estratos socioecon&ocirc;micos estudados.</font
></p>     ^cY#a10v86n4.htm##
01341000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704110600076002001301182#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#49#45#article#141#<p><font face="Verd
ana" size="2">A <a href=/img/revistas/jped/v86n4/4a10t3.gif>Tabela    3</a> most
ra os resultados da estimativa de ingest&atilde;o di&aacute;ria, com    base na 
m&eacute;dia de dois inqu&eacute;ritos alimentares de 24 horas. N&atilde;o    se
 encontrou diferen&ccedil;a estatisticamente significante na m&eacute;dia    de 
consumo ou da distribui&ccedil;&atilde;o da ingest&atilde;o em rela&ccedil;&atil
de;o    aos indicadores das DRI para prote&iacute;nas, carboidratos, lip&iacute;
dios    e ferro entre os dois grupos estudados. Ressalte-se que a maioria das cr
ian&ccedil;as    apresentava consumo dentro das expectativas. Quanto ao ferro, c
onstatou-se que    a maioria das crian&ccedil;as apresentava consumo acima da EA
R. Por sua vez,    o consumo m&eacute;dio de s&oacute;dio foi superior no estrat
o socioecon&ocirc;mico    baixo. A propor&ccedil;&atilde;o de crian&ccedil;as co
m consumo acima de 120%    da AI foi maior no estrato socioecon&ocirc;mico baixo
, mas o estudo estat&iacute;stico    n&atilde;o atingiu signific&acirc;ncia esta
t&iacute;stica (p = 0,089).</font></p>     ^cY#a10v86n4.htm##
00983000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074800076002001300824#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#50#46#article#141#<p><font face="Verd
ana" size="2">Na <a href=/img/revistas/jped/v86n4/4a10t4.gif>Tabela    4</a>, &e
acute; apresentada a contribui&ccedil;&atilde;o das refei&ccedil;&otilde;es    d
o almo&ccedil;o e do jantar em rela&ccedil;&atilde;o &agrave; ingest&atilde;o   
 di&aacute;ria total. Com rela&ccedil;&atilde;o aos nutrientes da refei&ccedil;&
atilde;o    do almo&ccedil;o em rela&ccedil;&atilde;o &agrave; ingest&atilde;o d
i&aacute;ria    total, n&atilde;o foi encontrada diferen&ccedil;a estatisticamen
te significante    entre os estratos socioecon&ocirc;micos. Constata-se que cerc
a de 35% da energia    e 75% do s&oacute;dio s&atilde;o fornecidos pelos aliment
os preparados no domic&iacute;lio    para o almo&ccedil;o e o jantar.</font></p>
     ^cY#a10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#51#47#article#141#<p>&nbsp;</p>     ^
cY#a10v86n4.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#52#48#article#141#<p><font size="3" f
ace="Verdana"><b>Discuss&atilde;o</b></font></p>     ^cY#a10v86n4.htm##
01735000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704150000076002001301576#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#53#49#article#141#<p><font face="Verd
ana" size="2">Como era de se esperar, no grupo de n&iacute;vel    socioecon&ocir
c;mico baixo, encontrou-se maior n&uacute;mero de m&atilde;es    com idade infer
ior a 20 anos e com escolaridade inferior a 12 anos de estudo.    Por sua vez, o
 peso e a estatura das crian&ccedil;as dos dois grupos foram semelhantes    para
 os indicadores peso/idade e peso/estatura, enquanto a m&eacute;dia do escore   
 z no grupo de n&iacute;vel socioecon&ocirc;mico baixo foi inferior, no entanto,
    pr&oacute;ximo do esperado (+0,03). N&atilde;o se encontrou crian&ccedil;as 
   com d&eacute;ficit de peso para a idade ou estatura (escore z inferior a -2,0
    DP) em ambos os grupos (resultados n&atilde;o mostrados). Estes dados est&at
ilde;o    em conson&acirc;ncia com as profundas transforma&ccedil;&otilde;es no 
perfil    epidemiol&oacute;gico alimentar observadas no Brasil, representadas pe
la passagem    do p&oacute;lo desnutri&ccedil;&atilde;o/infec&ccedil;&atilde;o p
ara o p&oacute;lo    obesidade/doen&ccedil;as cr&ocirc;nico-degenerativas<SUP>16
</SUP>. Assim, pode-se    considerar que os dois grupos que forneceram as amostr
as de alimentos, mesmo    sendo de conveni&ecirc;ncia, refletem o perfil socioec
on&ocirc;mico encontrado    no pa&iacute;s. Pretendia-se verificar se existiam d
iferen&ccedil;as entre as    diferentes classes socioecon&ocirc;micas no que se 
refere &agrave; composi&ccedil;&atilde;o    nutricional dos alimentos preparados
 no domic&iacute;lio.</font></p>     ^cY#a10v86n4.htm##
01769000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704153400076002001301610#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#54#50#article#141#<p><font face="Verd
ana" size="2">A diferen&ccedil;a na qualidade dos alimentos    dos diferentes gr
upos socioecon&ocirc;micos foi constatada num dos resultados    mais contundente
s deste estudo, apontado tanto pela an&aacute;lise qu&iacute;mica    dos aliment
os de transi&ccedil;&atilde;o preparados para o almo&ccedil;o como    pelos inqu
&eacute;ritos alimentares: o consumo excessivo de s&oacute;dio. Constatou-se,   
 ainda, que essa situa&ccedil;&atilde;o era pior no grupo de n&iacute;vel socioe
con&ocirc;mico    baixo. A an&aacute;lise qu&iacute;mica mostrou que apenas 10,8
 e 68,3%, respectivamente,    das amostras dos grupos de baixo e alto n&iacute;v
el socioecon&ocirc;mico apresentavam    menos de 200 mg de s&oacute;dio por 100 
gramas, conforme preconizado pela Comunidade    Europeia para alimentos industri
alizados para lactentes. Neste contexto, vale    ressaltar que esse padr&atilde;
o foi adotado considerando a inexist&ecirc;ncia    de um referencial para alimen
tos preparados no domic&iacute;lio. Esses resultados    s&atilde;o compat&iacute
;veis com as escassas informa&ccedil;&otilde;es da literatura    internacional, 
onde se encontrou tr&ecirc;s estudos, um realizado nos EUA, em    que 64% das 70
 amostras de alimentos preparados para lactentes com idade entre    3 e 14 meses
 apresentavam excesso de s&oacute;dio<SUP>17</SUP>. Os outros dois    foram real
izados na Espanha<SUP>4</SUP> e na Inglaterra<SUP>3</SUP> e constataram    exces
so de s&oacute;dio em 24 e 31% das amostras analisadas.</font></p>     ^cY#a10v8
6n4.htm##
01254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704101900076002001301095#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#55#51#article#141#<p><font face="Verd
ana" size="2">De acordo com o inqu&eacute;rito alimentar, o    consumo mediano d
i&aacute;rio de s&oacute;dio foi de 1.556 e 1.250 mg, respectivamente,    nos gr
upos de n&iacute;vel socioecon&ocirc;mico baixo e alto (p = 0,020). Quando    a 
estimativa de ingest&atilde;o de s&oacute;dio foi comparada ao recomendado,    o
s lactentes dos dois estratos apresentaram consumo acima das recomenda&ccedil;&o
tilde;es,    sendo que 51,4 e 31,7% dos estratos baixo e alto, respectivamente, 
consumiam    quantidades de s&oacute;dio acima do valor m&aacute;ximo considerad
o seguro    (<i>tolerable upper intake level</i>, UL). Na Finl&acirc;ndia, lacte
ntes aos    13 meses de vida tamb&eacute;m apresentam elevado consumo m&eacute;d
io de s&oacute;dio    (1.650 mg/dia)<SUP>18</SUP>. A &uacute;nica informa&ccedil
;&atilde;o dispon&iacute;vel    no Brasil revelou excesso de s&oacute;dio em tod
as as an&aacute;lises laboratoriais    das amostras de refei&ccedil;&otilde;es c
aseiras<SUP>9</SUP>.</font></p>     ^cY#a10v86n4.htm##
00982000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074700076002001300823#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#56#52#article#141#<p><font face="Verd
ana" size="2">Conforme se observa na <a href=/img/revistas/jped/v86n4/4a10t4.gif
>Tabela    4</a>, a contribui&ccedil;&atilde;o mediana das refei&ccedil;&otilde;
es do almo&ccedil;o    e do jantar representa, respectivamente, 73,0 e 79,2% do 
s&oacute;dio consumido    pelos grupos de baixo e alto n&iacute;vel socioecon&oc
irc;mico. Dessa maneira,    deve ser enfatizada a import&acirc;ncia da qualidade
 dos alimentos de transi&ccedil;&atilde;o    para o desenvolvimento de h&aacute;
bitos e prefer&ecirc;ncias alimentares saud&aacute;veis,    considerando que est
es s&atilde;o formados precocemente, e que estas prefer&ecirc;ncias    por alime
ntos salgados n&atilde;o sejam inatas, mas provavelmente adquiridas.</font></p> 
    ^cY#a10v86n4.htm##
00947000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071200076002001300788#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#57#53#article#141#<p><font face="Verd
ana" size="2">Se alimentos salgados forem oferecidos &agrave;    crian&ccedil;a 
regularmente, esses h&aacute;bitos podem permanecer durante a    idade adulta. P
ortanto, a interven&ccedil;&atilde;o no in&iacute;cio da vida    &eacute; import
ante para que maus h&aacute;bitos alimentares n&atilde;o sejam    adquiridos<SUP
>19,20</SUP>. Estudo que analisou o comportamento materno e as    pr&aacute;tica
s alimentares infantis com rela&ccedil;&atilde;o &agrave; ingest&atilde;o    de 
s&oacute;dio constatou que 40% das m&atilde;es, pelo menos alguma vez, salgaram 
   seus alimentos sem antes experiment&aacute;-los, e que 19% das m&atilde;es se
mpre    faziam isso<SUP>20</SUP>.</font></p>     ^cY#a10v86n4.htm##
01244000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704100900076002001301085#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#58#54#article#141#<p><font face="Verd
ana" size="2">Quantidade excessiva de s&oacute;dio na dieta    reflete o h&aacut
e;bito da popula&ccedil;&atilde;o adulta brasileira de preferir    alimentos sal
gados. Estudos realizados na popula&ccedil;&atilde;o brasileira    detectaram co
nsumo de sal elevado, mais de duas vezes o limite recomendado.    A ingest&atild
e;o de sal &eacute; fortemente influenciada pelo n&iacute;vel    socioecon&ocirc
;mico e pode, parcialmente, explicar a alta preval&ecirc;ncia    de hipertens&at
ilde;o arterial nas classes socioecon&ocirc;micas mais baixas<SUP>21,22</SUP>.  
  O excesso de s&oacute;dio na alimenta&ccedil;&atilde;o do lactente e sua rela&
ccedil;&atilde;o    com hipertens&atilde;o arterial &eacute; apontado em alguns 
estudos que demonstraram    associa&ccedil;&atilde;o entre consumo excessivo de 
s&oacute;dio no in&iacute;cio    da vida com maiores n&iacute;veis de press&atil
de;o arterial no primeiro ano    de vida<SUP>23</SUP> e na adolesc&ecirc;ncia<SU
P>5</SUP>.</font></p>     ^cY#a10v86n4.htm##
01328000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704109300076002001301169#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#59#55#article#141#<p><font face="Verd
ana" size="2">Al&eacute;m do s&oacute;dio, outro nutriente    em quantidade acim
a do recomendado &eacute; a prote&iacute;na, conforme o resultado    dos inqu&ea
cute;ritos alimentares (<a href=/img/revistas/jped/v86n4/4a10t3.gif>Tabela    3<
/a>). A an&aacute;lise qu&iacute;mica dos alimentos de transi&ccedil;&atilde;o  
  mostrou que pelo menos 95% das amostras respeitavam o conte&uacute;do m&iacute
;nimo    de prote&iacute;nas que contribu&iacute;am com mais de 20% para o valor
 energ&eacute;tico    total. O excesso de prote&iacute;nas pode levar a uma sobr
ecarga renal e hipertens&atilde;o    arterial<SUP>24</SUP>. Outra pesquisa mostr
ou a associa&ccedil;&atilde;o entre    o consumo elevado de prote&iacute;nas nos
 primeiros anos de vida e obesidade    na idade escolar e idade adulta<SUP>25</S
UP>. Outros estudos realizados no Brasil<SUP>26</SUP>    e no exterior<SUP>27</S
UP> mostraram, com base na estimativa da ingest&atilde;o    alimentar, que lacte
ntes consomem maior quantidade de prote&iacute;nas em rela&ccedil;&atilde;o    a
o recomendado.</font></p>     ^cY#a10v86n4.htm##
01815000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704158000076002001301656#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#60#56#article#141#<p><font face="Verd
ana" size="2">Quanto aos demais macronutrientes, a an&aacute;lise    qu&iacute;m
ica das amostras de alimentos de transi&ccedil;&atilde;o mostraram    ainda que,
 em rela&ccedil;&atilde;o ao valor energ&eacute;tico total, a m&eacute;dia    da
 contribui&ccedil;&atilde;o dos carboidratos encontra-se na faixa recomendada,  
  e a dos lip&iacute;dios, abaixo do recomendado. A densidade energ&eacute;tica 
   foi inferior &agrave; recomendada pela Comunidade Europeia em 70,2 e 56,1% do
s    alimentos dos grupos de baixo e alto n&iacute;vel socioecon&ocirc;mico, res
pectivamente.    Entretanto, os inqu&eacute;ritos alimentares mostraram que o co
nsumo de energia    &eacute; superior ao recomendado, o que pode ser explicado p
elo elevado consumo    de mamadeiras de leite artificial com adi&ccedil;&atilde;
o de carboidratos<SUP>28</SUP>    ou por&ccedil;&otilde;es muito grandes dos ali
mentos de transi&ccedil;&atilde;o<SUP>29</SUP>.    Outra poss&iacute;vel fonte d
e energia seria o consumo de alimentos considerados    n&atilde;o saud&aacute;ve
is, conforme constatado em pesquisa recente do Minist&eacute;rio    da Sa&uacute
;de do Brasil<SUP>30</SUP>. Alertou-se que, nas 24 horas anteriores,    71,7% do
s lactentes estudados, com idade entre 9 e 12 meses, consumiram bolachas    ou s
algadinhos, 11,6%, refrigerantes, e 8,7%, caf&eacute;<SUP>30</SUP>. A contribui&
ccedil;&atilde;o    desses alimentos n&atilde;o saud&aacute;veis na composi&cced
il;&atilde;o do    valor energ&eacute;tico total dever&aacute; ser motivo de fut
uras an&aacute;lises.</font></p>     ^cY#a10v86n4.htm##
00636000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040100076002001300477#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#61#57#article#141#<p><font face="Verd
ana" size="2">A totalidade das amostras de alimentos submetidos    &agrave; an&a
acute;lise qu&iacute;mica apresentava teor de ferro abaixo do recomendado    (6 
mg/100 g). Por sua vez, os inqu&eacute;ritos alimentares dos dois grupos    estu
dados revelaram que cerca da metade dos lactentes apresentava consumo acima    d
o RDA e outra parcela entre o EAR e o RDA.</font></p>     ^cY#a10v86n4.htm##
00768000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053300076002001300609#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#62#58#article#141#<p><font face="Verd
ana" size="2">Os alimentos de transi&ccedil;&atilde;o do almo&ccedil;o    e do j
antar foram fonte de cerca de 60% do ferro da dieta dos dois grupos estudados.  
  Esses dados s&atilde;o conflitantes com a preval&ecirc;ncia de defici&ecirc;nc
ia    de ferro nessa faixa et&aacute;ria na mesma Unidade B&aacute;sica de Sa&ua
cute;de    que atingiu 70% dos lactentes, sendo que 55% encontravam-se an&ecirc;
micos,    ou seja, no est&aacute;gio mais grave dessa car&ecirc;ncia nutricional
<SUP>31</SUP>.</font></p>     ^cY#a10v86n4.htm##
00744000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050900076002001300585#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#63#59#article#141#<p><font face="Verd
ana" size="2">O teor e a biodisponibilidade de ferro dos alimentos    de transi&
ccedil;&atilde;o devem ser motivos de mais investiga&ccedil;&otilde;es,    consi
derando sua import&acirc;ncia como fontes de ferro a partir do segundo    semest
re de vida. A grande import&acirc;ncia da biodisponibilidade do ferro    dos dif
erentes alimentos pode ser exemplificada pela pequena absor&ccedil;&atilde;o    
intestinal do ferro adicionado ao leite de vaca integral<SUP>32</SUP>.</font></p
>     ^cY#a10v86n4.htm##
01158000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704092300076002001300999#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#64#60#article#141#<p><font face="Verd
ana" size="2">Deve-se ter prud&ecirc;ncia em extrapolar as    informa&ccedil;&ot
ilde;es desta amostra de conveni&ecirc;ncia para o universo    de lactentes. Ent
retanto, os dados das popula&ccedil;&otilde;es estudadas parecem    refletir o q
ue se observa em v&aacute;rias regi&otilde;es do mundo onde a desnutri&ccedil;&a
tilde;o    deu lugar ao excesso de peso<SUP>33</SUP>, como observado em parcela 
de ambos    os grupos estudados. Por sua vez, considerando que o tamanho da amos
tra fundamentou-se    exclusivamente na preval&ecirc;ncia da car&ecirc;ncia de f
erro, &eacute; prov&aacute;vel,    em fun&ccedil;&atilde;o dos resultados obtido
s, que se o tamanho da amostra    fosse maior, poder-se-ia encontrar diferen&cce
dil;a estatisticamente significante    entre os dois grupos quanto aos carboidra
tos, tanto na an&aacute;lise laboratorial    como nos inqu&eacute;ritos alimenta
res.</font></p>     ^cY#a10v86n4.htm##
00858000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062300076002001300699#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#65#61#article#141#<p><font face="Verd
ana" size="2">Em conclus&atilde;o, os alimentos de transi&ccedil;&atilde;o    pr
eparados para o almo&ccedil;o e jantar, em ambos os grupos, s&atilde;o respons&a
acute;veis    por cerca de 35% da energia, 60% do ferro e 75% do s&oacute;dio co
nsumido diariamente.    De acordo com a an&aacute;lise qu&iacute;mica, esses ali
mentos de transi&ccedil;&atilde;o    apresentaram baixo teor de ferro. Parcela e
xpressiva das amostras apresentou    quantidade excessiva de s&oacute;dio, mais 
frequentemente nos alimentos preparados    para os lactentes de baixo n&iacute;v
el socioecon&ocirc;mico.</font></p>     ^cY#a10v86n4.htm##
00689000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045400076002001300530#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#66#62#article#141#<p><font face="Verd
ana" size="2">&Eacute; necess&aacute;rio que se desenvolvam    estrat&eacute;gia
s educacionais para o preparo de alimentos de transi&ccedil;&atilde;o    adequad
os do ponto de vista nutricional, a serem oferecidos numa fase da vida    de gra
nde import&acirc;ncia para o estabelecimento de h&aacute;bitos alimentares    sa
ud&aacute;veis e a preven&ccedil;&atilde;o de doen&ccedil;as cr&ocirc;nicas    d
a idade adulta.</font></p>     ^cY#a10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#67#63#article#141#<p>&nbsp;</p>     ^
cY#a10v86n4.htm##
00312000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007700076002001300153#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#68#64#article#141#<p><font size="3" f
ace="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#a10v86n4.htm##
00425000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704017600078002001300254#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#69#65#article#141#1#<p><f
ont size="2" face="Verdana">1. Waterland RA, Garza C. Potential mechanisms    of
 metabolic imprinting that lead to chronic disease. Am J Clin Nutr. 1999;69:179-
97.    ^cY#a10v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#70#66#article#141#</font></p>     ^cY
#a10v86n4.htm##
00549000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704030000078002001300378#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#71#67#article#141#2#<p><f
ont size="2" face="Verdana">2. Heinig MJ, Nommsen LA, Peerson JM, Lonnerdal    B
, Dewey KG. Energy and protein intakes of breast-fed and formula-fed infants    
during the first year of live and their association with growth velocity: the   
 DARLING Study. Am J Clin Nutr. 1993;58:152-61.    ^cY#a10v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#72#68#article#141#</font></p>     ^cY
#a10v86n4.htm##
00405000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704015600078002001300234#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#73#69#article#141#3#<p><f
ont size="2" face="Verdana">3. Stordy BJ, Redfern AM, Morgan JB. Healthy    eati
ng for infants- mothers' action. Acta Paediatr. 1995;84:733-41.    ^cY#a10v86n4.
htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#74#70#article#141#</font></p>     ^cY
#a10v86n4.htm##
00506000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025700078002001300335#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#75#71#article#141#4#<p><f
ont size="2" face="Verdana">4. van den Boom S, Kimber AC, Morgan JB. Nutritional
    composition of home-prepared baby meals in Madrid. Comparison with commercia
l    products in Spain and home-made meals in England. Acta Paediatr. 1997;86:57
-62.    ^cY#a10v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#76#72#article#141#</font></p>     ^cY
#a10v86n4.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022400078002001300302#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#77#73#article#141#5#<p><f
ont size="2" face="Verdana">5. Geleijnse JM, Hofman A, Witteman JC, Hazebroek   
 AA, Valkenburg HA, Grobbee DE. Long-term effects of neonatal sodium restriction
    on blood pressure. Hypertension. 1997;29:913-7.    ^cY#a10v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#78#74#article#141#</font></p>     ^cY
#a10v86n4.htm##
00449000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020000078002001300278#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#79#75#article#141#6#<p><f
ont size="2" face="Verdana">6. Singhal A, Cole TJ, Lucas A. Early nutrition    i
n preterm infants and later blood pressure: two cohorts after randomised trials.
    Lancet. 2001;357:413-9.    ^cY#a10v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#80#76#article#141#</font></p>     ^cY
#a10v86n4.htm##
00402000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704015300078002001300231#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#81#77#article#141#7#<p><f
ont size="2" face="Verdana">7. DeMaeyer EM, Adiels-Tegman M. The prevalence    o
f anaemia in the world. World Health Stat Q. 1985;38:302-16.    ^cY#a10v86n4.htm
##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#82#78#article#141#</font></p>     ^cY
#a10v86n4.htm##
00411000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704016200078002001300240#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#83#79#article#141#8#<p><f
ont size="2" face="Verdana">8. Os&oacute;rio MM. Fatores determinantes de    ane
mia em crian&ccedil;as. J Pediatr (Rio J). 2002;78:269-78</font></p>     ^cY#a10
v86n4.htm##
00535000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028600078002001300364#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#84#80#article#141#9#<p><f
ont size="2" face="Verdana">9. Ribeiro P. Composi&ccedil;&atilde;o de prepara&cc
edil;&otilde;es    culin&aacute;rias salgadas destinadas a crian&ccedil;as menor
es de 18 meses    de idade &#091;tese&#093;. S&atilde;o Paulo: Universidade Fede
ral de S&atilde;o Paulo;    2006.    ^cY#a10v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#85#81#article#141#</font></p>     ^cY
#a10v86n4.htm##
00568000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704031800079002001300397#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#86#82#article#141#10#<p><
font size="2" face="Verdana">10. ABEP &#150; Associa&ccedil;&atilde;o Brasileira
    de Empresas de Pesquisa. Crit&eacute;rio de classifica&ccedil;&atilde;o econ
&ocirc;mica    Brasil. S&atilde;o Paulo: ABEP; 2008. <A href=http://www.abep.org
/ target="_blank">http://www.abep.org/</A>.    Acesso: 05/06/2008.    ^cY#a10v86
n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#87#83#article#141#</font></p>     ^cY
#a10v86n4.htm##
00482000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704023200079002001300311#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#88#84#article#141#11#<p><
font size="2" face="Verdana">11. IOM - Institute of Medicine. Dietary reference 
   intakes for energy, carbohydrates, fiber, fat, protein and amino acid (macron
utrients).    Washington (DC): National Academy Press; 2005.    ^cY#a10v86n4.htm
##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#89#85#article#141#</font></p>     ^cY
#a10v86n4.htm##
00630000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704038000079002001300459#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#90#86#article#141#12#<p><
font size="2" face="Verdana">12. Brasil. Minist&eacute;rio da Sa&uacute;de.    S
ecretaria de Vigil&acirc;ncia Sanit&aacute;ria. Portaria nº 34, de 13 de janeiro
    de 1998. Alimentos de transi&ccedil;&atilde;o para lactentes e crian&ccedil;
as    de primeira inf&acirc;ncia. Di&aacute;rio Oficial da Rep&uacute;blica Fede
rativa    do Brasil, Bras&iacute;lia (DF); 1998.    ^cY#a10v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#91#87#article#141#</font></p>     ^cY
#a10v86n4.htm##
00486000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704023600079002001300315#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#92#88#article#141#13#<p><
font size="2" face="Verdana">13. European Communities. Commission directive    2
006/125/EC on processed cereal-based foods and baby foods for infants and young 
   children. Official Journal of the European Union; 2006 Dec 5;    ^cY#a10v86n4
.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#93#89#article#141#</font></p>     ^cY
#a10v86n4.htm##
00602000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704035200079002001300431#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#94#90#article#141#14#<p><
font size="2" face="Verdana">14. World Health Organization. Anthro - Software   
 for assessing growth and development of the world's children &#091;computer pro
gram&#093;.    Version 2.0.; 2006.&nbsp; <A href=http://www.who.int/childgrowth/
software/en/ target="_blank">http://www.who.int/childgrowth/software/en/</A>.   
 Acesso: 18/04/2008.    ^cY#a10v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#95#91#article#141#</font></p>     ^cY
#a10v86n4.htm##
00659000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704040900079002001300488#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#96#92#article#141#15#<p><
font size="2" face="Verdana">15. Brasil. Minist&eacute;rio da Sa&uacute;de    - 
Sistema de Vigil&acirc;ncia Alimentar e Nutricional - SISVAN. Coordena&ccedil;&a
tilde;o-Geral    da Pol&iacute;tica de Alimenta&ccedil;&atilde;o e Nutri&ccedil;
&atilde;o - CGPAN.&nbsp;    <A href=http://nutricao.saude.gov.br/index.php targe
t="_blank">http://nutricao.saude.gov.br/index.php</A>.    Acesso: 02/02/2009.   
 ^cY#a10v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#97#93#article#141#</font></p>     ^cY
#a10v86n4.htm##
00460000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704021000079002001300289#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#98#94#article#141#16#<p><
font size="2" face="Verdana">16. Batista Filho M, Rissin A. A transi&ccedil;&ati
lde;o    nutricional no Brasil: tend&ecirc;ncias regionais e temporais. Cad Saud
e Publica.    2003;19 Suppl 1:S181-91.    ^cY#a10v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#99#95#article#141#</font></p>     ^cY
#a10v86n4.htm##
00408000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704015700080002001300237#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#100#96#article#141#17#<p>
<font size="2" face="Verdana">17. Kerr CM Jr, Reisinger KS, Plankey FW. Sodium  
  concentration of homemade baby foods. Pediatrics. 1978;62:331-5.    ^cY#a10v86
n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#101#97#article#141#</font></p>     ^c
Y#a10v86n4.htm##
00551000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704030000080002001300380#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#102#98#article#141#18#<p>
<font size="2" face="Verdana">18. Heino T, Kallio K, Jokinen E, Lagstr&ouml;m   
 H, Sepp&auml;nen R, V&auml;lim&auml;ki I, et al. Sodium intake of 1 to 5-year-o
ld    children: the STRIP project. The Special Turku Coronary Risk Factor Interv
ention    Project. Acta Paediatr. 2000;89:406-10.    ^cY#a10v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#103#99#article#141#</font></p>     ^c
Y#a10v86n4.htm##
00426000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017400081002001300255#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#104#100#article#141#19#<p
><font size="2" face="Verdana">19. Beauchamp GK, Cowart BJ, Moran M. Development
al    changes in salt acceptability in human infants. Dev Psychobiol. 1986;19:17
-25.    ^cY#a10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#105#101#article#141#</font></p>     ^
cY#a10v86n4.htm##
00452000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020000081002001300281#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#106#102#article#141#20#<p
><font size="2" face="Verdana">20. Schaefer LJ, Kumanyika SK. Maternal variables
    related to potentially high-sodium infant-feeding practices. J Am Diet Assoc
.    1985;85:433-8</font></p>     ^cY#a10v86n4.htm##
00474000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022200081002001300303#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#107#103#article#141#21#<p
><font size="2" face="Verdana">21. Bisi Molina Mdel C, Cunha Rde S, Herkenhoff  
  LF, Mill JG. Hipertens&atilde;o arterial e consumo de sal em popula&ccedil;&at
ilde;o    urbana. Rev Saude Publica. 2003;37:743-50.    ^cY#a10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#108#104#article#141#</font></p>     ^
cY#a10v86n4.htm##
00493000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024100081002001300322#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#109#105#article#141#22#<p
><font size="2" face="Verdana">22. Sarno F, Claro RM, Levy RB, Bandoni DH, Ferre
ira    SR, Monteiro CA. Estimativa de consumo de s&oacute;dio pela popula&ccedil
;&atilde;o    brasileira, 2002-2003. Rev Saude Publica. 2009;43:219-25.    ^cY#a
10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#110#106#article#141#</font></p>     ^
cY#a10v86n4.htm##
00433000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018100081002001300262#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#111#107#article#141#23#<p
><font size="2" face="Verdana">23. Hofman A, Haebroek A, Valkenburg HA. A random
ized    trial of sodium intake and blood pressure in newborn infants. JAMA. 1983
;250:370-3.    ^cY#a10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#112#108#article#141#</font></p>     ^
cY#a10v86n4.htm##
00396000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704014400081002001300225#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#113#109#article#141#24#<p
><font size="2" face="Verdana">24. Akre J. Infant feeding. The physiological    
basis. Bull World Health Organ. 1989;67 Suppl 1:1-108.    ^cY#a10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#114#110#article#141#</font></p>     ^
cY#a10v86n4.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028100081002001300362#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#115#111#article#141#25#<p
><font size="2" face="Verdana">25. G&uuml;nther AL, Buyken AE, Kroke A. Protein 
   intake during the period of complementary feeding and early childhood and the
    association with body mass index and percentage body fat at 7 y of age. Am J
    Clin Nutr. 2007;85:1626-33.    ^cY#a10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#116#112#article#141#</font></p>     ^
cY#a10v86n4.htm##
00502000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025000081002001300331#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#117#113#article#141#26#<p
><font size="2" face="Verdana">26. Fidelis CM, Os&oacute;rio MM. Consumo aliment
ar    de macro e micronutrientes de crian&ccedil;as menores de cinco anos no Est
ado    de Pernambuco, Brasil. Rev Bras Sa&uacute;de Matern Infant. 2007;7:63-74.
    ^cY#a10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#118#114#article#141#</font></p>     ^
cY#a10v86n4.htm##
00508000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025600081002001300337#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#119#115#article#141#27#<p
><font size="2" face="Verdana">27. Fisher JO, Butte NF, Mendoza PM, Wilson TA,  
  Hodges EA, Reidy KC, et al. Overestimation of infant and toddler energy intake
    by 24-h recall compared with weighed food records. Am J Clin Nutr. 2008;88:4
07-15.    ^cY#a10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#120#116#article#141#</font></p>     ^
cY#a10v86n4.htm##
00567000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031500081002001300396#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#121#117#article#141#28#<p
><font size="2" face="Verdana">28. Morais TB, Sigulem DM. Determination of macro
nutrients,    by chemical analysis, of home-prepared milk feeding bottles and th
eir contribution    to the energy and protein requirements of infants from high 
and low socioeconomic    classes. J Am Coll Nutr. 2002; 21:284-8.    ^cY#a10v86n
4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#122#118#article#141#</font></p>     ^
cY#a10v86n4.htm##
00433000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018100081002001300262#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#123#119#article#141#29#<p
><font size="2" face="Verdana">29. Kumanyika SK, Lancaster KJ. The challenge    
of feeding children to protect against overweight.&nbsp; J Pediatr (Rio J).    2
008;84:3-6.    ^cY#a10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#124#120#article#141#</font></p>     ^
cY#a10v86n4.htm##
00528000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027600081002001300357#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#125#121#article#141#30#<p
><font size="2" face="Verdana">30. Brasil. Minist&eacute;rio da Sa&uacute;de.   
 Secretaria de Aten&ccedil;&atilde;o &agrave; Sa&uacute;de. II Pesquisa de aleit
amento    materno nas capitais brasileira e Distrito Federal. Bras&iacute;lia: E
ditora    MS; 2009. 108 p.    ^cY#a10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#126#122#article#141#</font></p>     ^
cY#a10v86n4.htm##
00550000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029800081002001300379#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#127#123#article#141#31#<p
><font size="2" face="Verdana">31. Neves MB, da Silva EM, de Morais MB. Preval&e
circ;ncia    e fatores associados &agrave; defici&ecirc;ncia de ferro em lactent
es atendidos    em um centro de sa&uacute;de-escola em Bel&eacute;m, Par&aacute;
, Brasil. Cad.    Saude Publica. 2005;21:1911-8.    ^cY#a10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#128#124#article#141#</font></p>     ^
cY#a10v86n4.htm##
00517000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026500081002001300346#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#129#125#article#141#32#<p
><font size="2" face="Verdana">32. Costa Mde L, Freitas Kde C, Amancio OM, Paes 
   AT, da Silva SM, Luz J, et al. Iron absorption from infant formula and iron-f
ortified    cow's milk: experimental model in weanling rats. J Pediatr (Rio J). 
2009;85:449-54.    ^cY#a10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#130#126#article#141#</font></p>     ^
cY#a10v86n4.htm##
00502000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025000081002001300331#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#p#131#127#article#141#33#<p
><font size="2" face="Verdana">33. Vitolo MR, Gama CM, Bortolini GA, Campagnolo 
   PD, Drachler Mde L. Some risk factors associated with overweight, stunting an
d    wasting among children under 5 years old. J Pediatr (Rio J). 2008;84:251-7.
    ^cY#a10v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#132#128#article#141#</font></p>     ^
cY#a10v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#133#129#article#141#<p>&nbsp;</p>    
 ^cY#a10v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#134#130#article#141#<p>&nbsp;</p>    
 ^cY#a10v86n4.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018000078002001300258#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#135#131#article#141#<p><font size="2"
 face="Verdana"><a name="correspondence"></a><a href="#topo"><img src="/img/revi
stas/jped/v86n4/seta.gif" border="0"></a>    <b> Correspond&ecirc;ncia:</b>    ^
cY#a10v86n4.htm##
00276000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003900078002001300117#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#136#132#article#141#<br>   Tania Beni
nga de Morais     ^cY#a10v86n4.htm##
00286000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004900078002001300127#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#137#133#article#141#<BR>   Rua Napole
&atilde;o de Barros, 889    ^cY#a10v86n4.htm##
00288000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005100078002001300129#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#138#134#article#141#<BR>   CEP 04024-
002 - S&atilde;o Paulo, SP    ^cY#a10v86n4.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003500078002001300113#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#139#135#article#141#<BR>   Tel.: (11)
 5571.1160    ^cY#a10v86n4.htm##
00326000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704008900078002001300167#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#140#136#article#141#<BR>   E-mail: <A
 href=mailto:tania.pnut@epm.br>tania.pnut@epm.br</A></font></p>     ^cY#a10v86n4
.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010600078002001300184#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#141#137#article#141#<p><font size="2"
 face="Verdana">Artigo submetido em 03.11.2009, aceito em 30.04.2010.</font></p>
     ^cY#a10v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#142#138#article#141#<p>&nbsp;</p>    
 ^cY#a10v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#143#139#article#141#<p>&nbsp;</p>    
 ^cY#a10v86n4.htm##
00391000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704015400078002001300232#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#144#140#article#141#<p><font size="2"
 face="Verdana"> N&atilde;o foram declarados conflitos de interesse    associado
s &agrave; publica&ccedil;&atilde;o deste artigo.    ^cY#a10v86n4.htm##
00421000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018400078002001300262#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a10v86n4.htm#S#p#145#141#article#141#<br>   A pesquisa
 est&aacute; vinculada &agrave; Universidade Federal de S&atilde;o    Paulo &#15
0; Escola Paulista de Medicina (UNIFESP-EPM), S&atilde;o Paulo, SP.</font></p>  
   ^cY#a10v86n4.htm##
00554000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100015000970120
07800112030001500190065000900205064000500214031000300219014000700222865000900229
002001300238035001000251801001500261#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
0v86n4.htm#S#c#146#1#article#33#1#^rND^sWaterland^nRA#^rND^sGarza^nC#Potential m
echanisms of metabolic imprinting that lead to chronic disease^len#Am J Clin Nut
r#19990000#1999#69#179-97#20100800#a10v86n4.htm#0002-9165#Am J Clin Nutr##
00726000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100018000940100
01800112010001900130010001600149012016100165030001500326065000900341064000500350
031000300355014000700358865000900365002001300374035001000387801001500397#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#c#147#2#article#33#2#^rND^sHein
ig^nMJ#^rND^sNommsen^nLA#^rND^sPeerson^nJM#^rND^sLonnerdal^nB#^rND^sDewey^nKG#En
ergy and protein intakes of breast-fed and formula-fed infants during the first 
year of live and their association with growth velocity: the DARLING Study^len#A
m J Clin Nutr#19930000#1993#58#152-61#20100800#a10v86n4.htm#0002-9165#Am J Clin 
Nutr##
00551000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100018000940100
01700112012004800129030001400177065000900191064000500200031000300205014000700208
865000900215002001300224035001000237801001400247#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a10v86n4.htm#S#c#148#3#article#33#3#^rND^sStordy^nBJ#^rND^sRedfern^nAM
#^rND^sMorgan^nJB#Healthy eating for infants- mothers' action^len#Acta Paediatr#
19950000#1995#84#733-41#20100800#a10v86n4.htm#0001-656X#Acta Paediatr##
00649000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100022000770100017000990100
01700116012014300133030001400276065000900290064000500299031000300304014000600307
865000900313002001300322035001000335801001400345#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a10v86n4.htm#S#c#149#4#article#33#4#^rND^svan den Boom^nS#^rND^sKimber
^nAC#^rND^sMorgan^nJB#Nutritional composition of home-prepared baby meals in Mad
rid: Comparison with commercial products in Spain and home-made meals in England
^len#Acta Paediatr#19970000#1997#86#57-62#20100800#a10v86n4.htm#0001-656X#Acta P
aediatr##
00669000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100016000970100
01900113010002000132010002100152010001800173012007100191030001300262065000900275
06400050028403100030028901400060029286500090029800200130030703500100032080100130
0330#v86n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#c#150#5#article#33#
5#^rND^sGeleijnse^nJM#^rND^sHofman^nA#^rND^sWitteman^nJC#^rND^sHazebroek^nAA#^rN
D^sValkenburg^nHA#^rND^sGrobbee^nDE#Long-term effects of neonatal sodium restric
tion on blood pressure^len#Hypertension#19970000#1997#29#913-7#20100800#a10v86n4
.htm#0194-911X#Hypertension##
00585000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100015000940100
01500109012010100124030000700225065000900232064000500241031000400246014000600250
865000900256002001300265035001000278801000700288#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a10v86n4.htm#S#c#151#6#article#33#6#^rND^sSinghal^nA#^rND^sCole^nTJ#^r
ND^sLucas^nA#Early nutrition in preterm infants and later blood pressure: two co
horts after randomised trials^len#Lancet#20010000#2001#357#413-9#20100800#a10v86
n4.htm#0099-5355#Lancet##
00536000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100023000960120
04300119030002000162065000900182064000500191031000300196014000700199865000900206
002001300215035001000228801002000238#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
0v86n4.htm#S#c#152#7#article#33#7#^rND^sDeMaeyer^nEM#^rND^sAdiels-Tegman^nM#The 
prevalence of anaemia in the world^len#World Health Stat Q#19850000#1985#38#302-
16#20100800#a10v86n4.htm#0379-8070#World Health Stat Q##
00500000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770120048000940300
01800142065000900160064000500169031000300174014000700177865000900184002001300193
035001000206801001800216#v86n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S
#c#153#8#article#33#8#^rND^sOsório^nMM#Fatores determinantes de anemia em crianç
as^lpt#J Pediatr (Rio J)#20020000#2002#78#269-78#20100800#a10v86n4.htm#0021-7557
#J Pediatr (Rio J)##
00522000000000241000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160017000770180101000940510
00500195046001000200050003400210045000900244044000500253865000900258002001300267
#v86n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#c#154#9#article#33#9#^r
ND^sRibeiro^nP#Composição de preparações culinárias salgadas destinadas a crianç
as menores de 18 meses de idade^lpt#tese#São Paulo#Universidade Federal de São P
aulo#20060000#2006#20100800#a10v86n4.htm##
00537000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170053000790180047001320660
01000179062000500189065000900194064000500203037002100208110000900229109001100238
865000900249002001300258#v86n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S
#c#155#10#article#33#10#ABEP - Associação Brasileira de Empresas de Pesquisa#Cri
tério de classificação econômica Brasil^lpt#São Paulo#ABEP#20080000#2008#http://
www.abep.org/#20080605#05/06/2008#20100800#a10v86n4.htm##
00514000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170022000790180109001010660
01500210062002300225065000900248064000500257865000900262002001300271#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a10v86n4.htm#S#c#156#11#article#33#11#Institute of
 Medicine#Dietary reference intakes for energy, carbohydrates, fiber, fat, prote
in and amino acid (macronutrients)^len#Washington^eDC#National Academy Press#200
50000#2005#20100800#a10v86n4.htm##
00587000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170064000790180116001430620
04900259066001300308065000900321064000500330865000900335002001300344#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a10v86n4.htm#S#c#157#12#article#33#12#Brasil^dMini
stério da Saúde. Secretaria de Vigilância Sanitária#Portaria nº 34, de 13 de jan
eiro de 1998. Alimentos de transição para lactentes e crianças de primeira infân
cia^lpt#Diário Oficial da República Federativa do Brasil#Brasília^eDF#19980000#1
998#20100800#a10v86n4.htm##
00514000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170021000790180115001000620
03900215065000900254064001100263865000900274002001300283#v86n4#V:\Scielo\serial\
jped\v86n4\markup\a10v86n4.htm#S#c#158#13#article#33#13#European Communities#Com
mission directive 2006/125/EC on processed cereal-based foods and baby foods for
 infants and young children^len#Official Journal of the European Union#20061205#
2006 Dec 5#20100800#a10v86n4.htm##
00562000000000241000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170026000790180115001050650
00900220064000500229037004400234110000900278109001100287865000900298002001300307
#v86n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#c#159#14#article#33#14#
World Health Organization#Anthro - Software for assessing growth and development
 of the world's children [computer program]. Version 2.0^len#20060000#2006#http:
//www.who.int/childgrowth/software/en/#20080418#18/04/2008#20100800#a10v86n4.htm
##
00522000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170076000790180068001550370
03900223110000900262109001100271865000900282002001300291#v86n4#V:\Scielo\serial\
jped\v86n4\markup\a10v86n4.htm#S#c#160#15#article#33#15#Brasil^dMinistério da Sa
úde - Sistema de Vigilância Alimentar e Nutricional#Coordenação-Geral da Polític
a de Alimentação e Nutrição - CGPAN^lpt#http://nutricao.saude.gov.br/index.php#2
0090202#02/02/2009#20100800#a10v86n4.htm##
00577000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100023000790100016001020120
07200118030001800190065000900208064000500217031000300222032000400225014000800229
865000900237002001300246035001000259801001800269#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a10v86n4.htm#S#c#161#16#article#33#16#^rND^sBatista Filho^nM#^rND^sRis
sin^nA#A transição nutricional no Brasil: tendências regionais e temporais^lpt#C
ad Saude Publica#20030000#2003#19#^s1#S181-91#20100800#a10v86n4.htm#0102-311X#Ca
d Saude Publica##
00550000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100020000970100
01800117012004800135030001100183065000900194064000500203031000300208014000600211
865000900217002001300226035001000239801001100249#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a10v86n4.htm#S#c#162#17#article#33#17#^rND^sKerr Jr^nCM#^rND^sReisinge
r^nKS#^rND^sPlankey^nFW#Sodium concentration of homemade baby foods^len#Pediatri
cs#19780000#1978#62#331-5#20100800#a10v86n4.htm#0031-4005#Pediatrics##
00735000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
01700110010001800127010001800145010001800163810000600181012012600187030001400313
06500090032706400050033603100030034101400070034486500090035100200130036003500100
0373801001400383#v86n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#c#163#1
8#article#33#18#^rND^sHeino^nT#^rND^sKallio^nK#^rND^sJokinen^nE#^rND^sLagström^n
H#^rND^sSeppänen^nR#^rND^sVälimäki^nI#et al#Sodium intake of 1 to 5-year-old chi
ldren: the STRIP project. The Special Turku Coronary Risk Factor Intervention Pr
oject^len#Acta Paediatr#20000000#2000#89#406-10#20100800#a10v86n4.htm#0001-656X#
Acta Paediatr##
00571000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100017000990100
01500116012006500131030001500196065000900211064000500220031000300225014000600228
865000900234002001300243035001000256801001500266#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a10v86n4.htm#S#c#164#19#article#33#19#^rND^sBeauchamp^nGK#^rND^sCowart
^nBJ#^rND^sMoran^nM#Developmental changes in salt acceptability in human infants
^len#Dev Psychobiol#19860000#1986#19#17-25#20100800#a10v86n4.htm#0012-1630#Dev P
sychobiol##
00566000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100020000980120
08300118030001600201065000900217064000500226031000300231014000600234865000900240
002001300249035001000262801001600272#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
0v86n4.htm#S#c#165#20#article#33#20#^rND^sSchaefer^nLJ#^rND^sKumanyika^nSK#Mater
nal variables related to potentially high-sodium infant-feeding practices^len#J 
Am Diet Assoc#19850000#1985#85#433-8#20100800#a10v86n4.htm#0002-8223#J Am Diet A
ssoc##
00616000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100026000790100019001050100
02100124010001500145012006200160030001800222065000900240064000500249031000300254
014000700257865000900264002001300273035001000286801001800296#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a10v86n4.htm#S#c#166#21#article#33#21#^rND^sBisi Molina Md
el^nC#^rND^sCunha Rde^nS#^rND^sHerkenhoff^nLF#^rND^sMill^nJG#Hipertensão arteria
l e consumo de sal em população urbana^lpt#Rev Saude Publica#20030000#2003#37#74
3-50#20100800#a10v86n4.htm#0034-8910#Rev Saude Publica##
00671000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100016000940100
01500110010001800125010001900143010001900162012007200181030001800253065000900271
06400050028003100030028501400070028886500090029500200130030403500100031780100180
0327#v86n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#c#167#22#article#33
#22#^rND^sSarno^nF#^rND^sClaro^nRM#^rND^sLevy^nRB#^rND^sBandoni^nDH#^rND^sFerrei
ra^nSR#^rND^sMonteiro^nCA#Estimativa de consumo de sódio pela população brasilei
ra, 2002-2003^lpt#Rev Saude Publica#20090000#2009#43#219-25#20100800#a10v86n4.ht
m#0034-8910#Rev Saude Publica##
00568000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
02100113012007800134030000500212065000900217064000500226031000400231014000600235
865000900241002001300250035001000263801000500273#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a10v86n4.htm#S#c#168#23#article#33#23#^rND^sHofman^nA#^rND^sHaebroek^n
A#^rND^sValkenburg^nHA#A randomized trial of sodium intake and blood pressure in
 newborn infants^len#JAMA#19830000#1983#250#370-3#20100800#a10v86n4.htm#0098-748
4#JAMA##
00522000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790120044000930300
02400137065000900161064000500170031000300175032000400178014000600182865000900188
002001300197035001000210801002400220#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
0v86n4.htm#S#c#169#24#article#33#24#^rND^sAkre^nJ#Infant feeding: The physiologi
cal basis^len#Bull World Health Organ#19890000#1989#67#^s1#1-108#20100800#a10v86
n4.htm#0042-9686#Bull World Health Organ##
00667000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01500114012016100129030001500290065000900305064000500314031000300319014000800322
865000900330002001300339035001000352801001500362#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a10v86n4.htm#S#c#170#25#article#33#25#^rND^sGünther^nAL#^rND^sBuyken^n
AE#^rND^sKroke^nA#Protein intake during the period of complementary feeding and 
early childhood and the association with body mass index and percentage body fat
 at 7 y of age^len#Am J Clin Nutr#20070000#2007#85#1626-33#20100800#a10v86n4.htm
#0002-9165#Am J Clin Nutr##
00570000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970120
11500114030002900229710000200258065000900260064000500269031000200274014000600276
865000900282002001300291#v86n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S
#c#171#26#article#33#26#^rND^sFidelis^nCM#^rND^sOsório^nMM#Consumo alimentar de 
macro e micronutrientes de crianças menores de cinco anos no Estado de Pernambuc
o, Brasil^lpt#Rev Bras Saúde Matern Infant#2#20070000#2007#7#63-74#20100800#a10v
86n4.htm##
00715000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960100
01800112010001700130010001700147010001600164810000600180012010500186030001500291
06500090030606400050031503100030032001400070032386500090033000200130033903500100
0352801001500362#v86n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#c#172#2
7#article#33#27#^rND^sFisher^nJO#^rND^sButte^nNF#^rND^sMendoza^nPM#^rND^sWilson^
nTA#^rND^sHodges^nEA#^rND^sReidy^nKC#et al#Overestimation of infant and toddler 
energy intake by 24-h recall compared with weighed food records^len#Am J Clin Nu
tr#20080000#2008#88#407-15#20100800#a10v86n4.htm#0002-9165#Am J Clin Nutr##
00687000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960120
21000114030001500324065000900339064000500348031000300353014000600356865000900362
002001300371035001000384801001500394#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
0v86n4.htm#S#c#173#28#article#33#28#^rND^sMorais^nTB#^rND^sSigulem^nDM#Determina
tion of macronutrients, by chemical analysis, of home-prepared milk feeding bott
les and their contribution to the energy and protein requirements of infants fro
m high and low socioeconomic classes^len#J Am Coll Nutr#20020000#2002#21#284-8#2
0100800#a10v86n4.htm#0731-5724#J Am Coll Nutr##
00554000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100020000990120
06800119030001800187065000900205064000500214031000300219014000400222865000900226
002001300235035001000248801001800258#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
0v86n4.htm#S#c#174#29#article#33#29#^rND^sKumanyika^nSK#^rND^sLancaster^nKJ#The 
challenge of feeding children to protect against overweight^lpt#J Pediatr (Rio J
)#20080000#2008#84#3-6#20100800#a10v86n4.htm#0021-7557#J Pediatr (Rio J)##
00507000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170059000790180082001380660
01000220062001100230065000900241064000500250865000900255002001300264#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a10v86n4.htm#S#c#175#30#article#33#30#Brasil^dMini
stério da Saúde. Secretaria de Atenção à Saúde#II Pesquisa de aleitamento matern
o nas capitais brasileira e Distrito Federal^lpt#Brasí­lia#Editora MS#20090000#2
009#20100800#a10v86n4.htm##
00651000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100019000950100
02000114012013500134030001800269065000900287064000500296031000300301014000700304
865000900311002001300320035001000333801001800343#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a10v86n4.htm#S#c#176#31#article#33#31#^rND^sNeves^nMB#^rND^sda Silva^n
EM#^rND^sde Morais^nMB#Prevalência e fatores associados à deficiência de ferro e
m lactentes atendidos em um centro de saúde-escola em Belém, Pará, Brasil^lpt#Ca
d Saude Publica#20050000#2005#21#1911-8#20100800#a10v86n4.htm#0102-311X#Cad Saud
e Publica##
00727000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100021000980100
01800119010001500137010001900152010001300171810000600184012010700190030001800297
06500090031506400050032403100030032901400070033286500090033900200130034803500100
0361801001800371#v86n4#V:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#c#177#3
2#article#33#32#^rND^sCosta Mde^nL#^rND^sFreitas Kde^nC#^rND^sAmancio^nOM#^rND^s
Paes^nAT#^rND^sda Silva^nSM#^rND^sLuz^nJ#et al#Iron absorption from infant formu
la and iron-fortified cow's milk: experimental model in weanling rats^len#J Pedi
atr (Rio J)#20090000#2009#85#449-54#20100800#a10v86n4.htm#0021-7557#J Pediatr (R
io J)##
00683000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960100
02000111010002100131010002200152012010400174030001800278065000900296064000500305
031000300310014000600313865000900319002001300328035001000341801001800351#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a10v86n4.htm#S#c#178#33#article#33#33#^rND^sVi
tolo^nMR#^rND^sGama^nCM#^rND^sBortolini^nGA#^rND^sCampagnolo^nPD#^rND^sDrachler 
Mde^nL#Some risk factors associated with overweight, stunting and wasting among 
children under 5 years old^len#J Pediatr (Rio J)#20080000#2008#84#251-7#20100800
#a10v86n4.htm#0021-7557#J Pediatr (Rio J)##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v86n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#o#1#1#article#1
#20110126#175533#a11v86n4.htm#169##
04726000000000637000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002100108
03100030012903200020013206500090013401400110014303500100015401200780016401200640
02420100031003060100031003370100030003680100035003980100043004330100031004760700
06900507070004900576083154400625085001002169085003102179085002502210085002202235
08316280225708500100388508500310389508500260392608500230395211700080397507200030
3983112000903986111001103995114000904006113001104015058004904026002001304075#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#h#2#1#article#1#oa#pt#br1.1
#1#4.0#TAB#11#JPED030#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f311^l316#0021-7557
#Fatores determinantes do sobrepeso em crianças menores de 4 anos de idade^lpt#D
eterminants of overweight in children under 4 years of age^len#^rND^1A01^nGilmar
 M. de^sJesus#^rND^1A02^nGraciete O.^sVieira#^rND^1A02^nTatiana O.^sVieira#^rND^
1A01^nCamila da Cruz^sMartins#^rND^1A02^nCarlos Maurício Cardeal^sMendes#^rND^1A
01^nElizia S.^sCastelão#Universidade Estadual de Feira de Santana^iA01^cFeira de
 Santana^sBA#Universidade Federal da Bahia^iA02^cSalvador^sBA#^lpt^aOBJETIVOS: D
escrever a prevalência e os fatores determinantes do sobrepeso de crianças menor
es de 4 anos de idade de Feira de Santana (BA). MÉTODOS: Estudo transversal anin
hado em uma coorte de nascidos (n = 793) em Feira de Santana. As variáveis indep
endentes foram relacionadas às características das crianças, aos fatores sociode
mográficos e reprodutivos maternos e à alimentação da criança aos 4 meses. A var
iável dependente foi o sobrepeso avaliado pelo índice peso/estatura, comparado a
o padrão do Multicentre Growth Reference Study de 2006. Adotaram-se os pontos de
 corte de normalidade -2 e +2 escore z em relação à mediana da população de refe
rência. O estudo foi aprovado pelo Comitê de Ética em Pesquisa da Universidade E
stadual de Feira de Santana, sob registro nº 096/2006. RESULTADOS: A prevalência
 de sobrepeso observada foi de 12,5%. Características associadas positivamente a
o sobrepeso: peso adequado ao nascer (razão de prevalência 2,75; IC95% 1,50-5,05
), primiparidade (razão de prevalência 1,61; IC95% 1,09-2,35) e trabalho materno
 fora de casa aos 4 meses de idade da criança (razão de prevalência 1,73; IC95% 
1,16-2,59). CONCLUSÕES: No presente estudo, peso adequado ao nascer, primiparida
de e trabalho materno aos 4 meses de vida da criança se associaram com o sobrepe
so infantil. A taxa de sobrepeso superou os resultados de outros estudos no país
, inclusive em outros municípios baianos, sinalizando para o risco de obesidade 
e seus comprometimentos a que as crianças em Feira de Santana podem estar submet
idas.#^ddecs^i1#^tm^lpt^kEstado nutricional^i1#^tm^lpt^kantropometia^i1#^tm^lpt^
ksobrepeso^i1#^len^aOBJECTIVES: To describe the prevalence of and factors associ
ated with overweight in children under 4 years of age in Feira de Santana, state
 of Bahia, Brazil. METHODS: Cross-sectional study nested within a birth cohort o
f 793 children born in Feira de Santana, Brazil. Independent variables were rela
ted to infant characteristics, social and demographic factors, maternal reproduc
tive aspects, and diet of the child at age 4 months. The dependent variable was 
nutritional status, as assessed by weight-for-height ratio compared to Multicent
re Growth Reference Study standards and obtained with the use of the software AN
THRO. Z-scores of -2 and +2 above or below the median for the reference populati
on were established as normality cutoff points. Child height and weight were mea
sured with an anthropometer and digital scales, respectively; all measurements w
ere taken in triplicate. The study was approved by the Research Ethics Committee
 of the Universidade Estadual de Feira de Santana (CEP/UEFS), under registration
 number 096/2006. RESULTS: The prevalence of overweight was 12.5%. Adequate birt
h weight (RR 2.75; 95%CI 1.50-5.05), primiparity (RR 1.61; 95%CI 1.09-2.35), and
 maternal employment outside the home at age 4 months (RR 1.73; 95%CI 1.16-2.59)
 were associated with overweight. CONCLUSIONS: In this study, adequate birth wei
ght, primiparity and maternal employment outside the home were associated with o
verweight in children. The rate of overweight found, which surpassed that report
ed by other studies conducted across the country (including Bahia), point to a r
isk of child obesity in Feira de Santana.#^ddecs^i2#^tm^len^kNutritional status^
i2#^tm^len^kanthropometry^i2#^tm^len^koverweight^i2#vancouv#26#20090427#27.04.20
09#20100407#07.04.2010#Fundação de Amparo à Pesquisa do Estado da Bahia#a11v86n4
.htm##
04796000000000637000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002100108
03100030012903200020013206500090013401400110014303500100015401200850016401200710
02490100031003200100031003510100030003820100035004120100043004470100031004900700
06900521070004900590083157200639085001002211085003102221085002502252085002202277
08316560229908500100395508500310396508500260399608500230402211700080404507200030
4053112000904056111001104065114000904076113001104085058004904096002001304145#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#f#3#1#article#1#oa#pt#br1.1
#1#4.0#TAB#11#JPED030#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f311^l316#0021-7557
#<b>Fatores determinantes do sobrepeso em crianças menores de 4 anos de idade</b
>^lpt#<b>Determinants of overweight in children under 4 years of age</b>^len#^rN
D^1A01^nGilmar M. de^sJesus#^rND^1A02^nGraciete O.^sVieira#^rND^1A02^nTatiana O.
^sVieira#^rND^1A01^nCamila da Cruz^sMartins#^rND^1A02^nCarlos Maurício Cardeal^s
Mendes#^rND^1A01^nElizia S.^sCastelão#Universidade Estadual de Feira de Santana^
iA01^cFeira de Santana^sBA#Universidade Federal da Bahia^iA02^cSalvador^sBA#^lpt
^a<b>OBJETIVOS: </b>Descrever a prevalência e os fatores determinantes do sobrep
eso de crianças menores de 4 anos de idade de Feira de Santana (BA). <b>MÉTODOS:
 </b>Estudo transversal aninhado em uma coorte de nascidos (n = 793) em Feira de
 Santana. As variáveis independentes foram relacionadas às características das c
rianças, aos fatores sociodemográficos e reprodutivos maternos e à alimentação d
a criança aos 4 meses. A variável dependente foi o sobrepeso avaliado pelo índic
e peso/estatura, comparado ao padrão do Multicentre Growth Reference Study de 20
06. Adotaram-se os pontos de corte de normalidade -2 e +2 escore z em relação à 
mediana da população de referência. O estudo foi aprovado pelo Comitê de Ética e
m Pesquisa da Universidade Estadual de Feira de Santana, sob registro nº 096/200
6. <b>RESULTADOS: </b>A prevalência de sobrepeso observada foi de 12,5%. Caracte
rísticas associadas positivamente ao sobrepeso: peso adequado ao nascer (razão d
e prevalência 2,75; IC95% 1,50-5,05), primiparidade (razão de prevalência 1,61; 
IC95% 1,09-2,35) e trabalho materno fora de casa aos 4 meses de idade da criança
 (razão de prevalência 1,73; IC95% 1,16-2,59). <b>CONCLUSÕES: </b>No presente es
tudo, peso adequado ao nascer, primiparidade e trabalho materno aos 4 meses de v
ida da criança se associaram com o sobrepeso infantil. A taxa de sobrepeso super
ou os resultados de outros estudos no país, inclusive em outros municípios baian
os, sinalizando para o risco de obesidade e seus comprometimentos a que as crian
ças em Feira de Santana podem estar submetidas.#^ddecs^i1#^tm^lpt^kEstado nutric
ional^i1#^tm^lpt^kantropometia^i1#^tm^lpt^ksobrepeso^i1#^len^a<b>OBJECTIVES: </b
>To describe the prevalence of and factors associated with overweight in childre
n under 4 years of age in Feira de Santana, state of Bahia, Brazil. <b>METHODS: 
</b>Cross-sectional study nested within a birth cohort of 793 children born in F
eira de Santana, Brazil. Independent variables were related to infant characteri
stics, social and demographic factors, maternal reproductive aspects, and diet o
f the child at age 4 months. The dependent variable was nutritional status, as a
ssessed by weight-for-height ratio compared to Multicentre Growth Reference Stud
y standards and obtained with the use of the software ANTHRO. Z-scores of -2 and
 +2 above or below the median for the reference population were established as n
ormality cutoff points. Child height and weight were measured with an anthropome
ter and digital scales, respectively; all measurements were taken in triplicate.
 The study was approved by the Research Ethics Committee of the Universidade Est
adual de Feira de Santana (CEP/UEFS), under registration number 096/2006. <b>RES
ULTS: </b>The prevalence of overweight was 12.5%. Adequate birth weight (RR 2.75
; 95%CI 1.50-5.05), primiparity (RR 1.61; 95%CI 1.09-2.35), and maternal employm
ent outside the home at age 4 months (RR 1.73; 95%CI 1.16-2.59) were associated 
with overweight. <b>CONCLUSIONS: </b>In this study, adequate birth weight, primi
parity and maternal employment outside the home were associated with overweight 
in children. The rate of overweight found, which surpassed that reported by othe
r studies conducted across the country (including Bahia), point to a risk of chi
ld obesity in Feira de Santana.#^ddecs^i2#^tm^len^kNutritional status^i2#^tm^len
^kanthropometry^i2#^tm^len^koverweight^i2#vancouv#26#20090427#27.04.2009#2010040
7#07.04.2010#Fundação de Amparo à Pesquisa do Estado da Bahia#a11v86n4.htm##
04922000000000661000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000400108121000300112049000800115158000300123
03000210012603100030014703200020015006500090015201400110016103500100017201200780
01820120064002600100031003240100030003550100029003850100035004140100043004490100
03000492070007100522070005100593083158000644085001002224085003102234085002502265
08500220229008316560231208500100396808500310397808500260400908500230403511700080
40580720003040661120009040691110011040781140009040891130011040980580049041090020
01304158008008904171#v86n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#l#4
#1#article#1#^mjul./ago.^a2010#oa#pt#br1.1#1#4.0#tab#11#JPED030#nd#J. Pediatr. (
Rio J.)#86#4#20100800#^f311^l316#0021-7557#Fatores determinantes do sobrepeso em
 crianças menores de 4 anos de idade^lpt#Determinants of overweight in children 
under 4 years of age^len#^rND^1A01^nGilmar M. de^sJesus#^rND^1A02^nGraciete O^sV
ieira#^rND^1A02^nTatiana O^sVieira#^rND^1A01^nCamila da Cruz^sMartins#^rND^1A02^
nCarlos Maurício Cardeal^sMendes#^rND^1A01^nElizia S^sCastelão#^iA01^1Universida
de Estadual de Feira de Santana^cFeira de Santana^sBA#^iA02^1Universidade Federa
l da Bahia^cSalvador^sBA#^lpt^aOBJETIVOS: Descrever a prevalência e os fatores d
eterminantes do sobrepeso de crianças menores de 4 anos de idade de Feira de San
tana (BA). MÉTODOS: Estudo transversal aninhado em uma coorte de nascidos (n = 7
93) em Feira de Santana. As variáveis independentes foram relacionadas às caract
erísticas das crianças, aos fatores sociodemográficos e reprodutivos maternos e 
à alimentação da criança aos 4 meses. A variável dependente foi o sobrepeso aval
iado pelo índice peso/estatura, comparado ao padrão do Multicentre Growth Refere
nce Study de 2006. Adotaram-se os pontos de corte de normalidade -2 e +2 escore 
z em relação à mediana da população de referência. O estudo foi aprovado pelo Co
mitê de Ética em Pesquisa da Universidade Estadual de Feira de Santana, sob regi
stro nº 096/2006. RESULTADOS: A prevalência de sobrepeso observada foi de 12,5 p
or cento. Características associadas positivamente ao sobrepeso: peso adequado a
o nascer (razão de prevalência 2,75; IC95 por cento 1,50-5,05), primiparidade (r
azão de prevalência 1,61; IC95 por cento 1,09-2,35) e trabalho materno fora de c
asa aos 4 meses de idade da criança (razão de prevalência 1,73; IC95 por cento 1
,16-2,59). CONCLUSÕES: No presente estudo, peso adequado ao nascer, primiparidad
e e trabalho materno aos 4 meses de vida da criança se associaram com o sobrepes
o infantil. A taxa de sobrepeso superou os resultados de outros estudos no país,
 inclusive em outros municípios baianos, sinalizando para o risco de obesidade e
 seus comprometimentos a que as crianças em Feira de Santana podem estar submeti
das.#^ddecs^i1#^tm^lpt^kEstado nutricional^i1#^tm^lpt^kantropometia^i1#^tm^lpt^k
sobrepeso^i1#^len^aOBJECTIVES: To describe the prevalence of and factors associa
ted with overweight in children under 4 years of age in Feira de Santana, state 
of Bahia, Brazil. METHODS: Cross-sectional study nested within a birth cohort of
 793 children born in Feira de Santana, Brazil. Independent variables were relat
ed to infant characteristics, social and demographic factors, maternal reproduct
ive aspects, and diet of the child at age 4 months. The dependent variable was n
utritional status, as assessed by weight-for-height ratio compared to Multicentr
e Growth Reference Study standards and obtained with the use of the software ANT
HRO. Z-scores of -2 and +2 above or below the median for the reference populatio
n were established as normality cutoff points. Child height and weight were meas
ured with an anthropometer and digital scales, respectively; all measurements we
re taken in triplicate. The study was approved by the Research Ethics Committee 
of the Universidade Estadual de Feira de Santana (CEP/UEFS), under registration 
number 096/2006. RESULTS: The prevalence of overweight was 12.5 percent. Adequat
e birth weight (RR 2.75; 95 percentCI 1.50-5.05), primiparity (RR 1.61; 95 perce
ntCI 1.09-2.35), and maternal employment outside the home at age 4 months (RR 1.
73; 95 percentCI 1.16-2.59) were associated with overweight. CONCLUSIONS: In thi
s study, adequate birth weight, primiparity and maternal employment outside the 
home were associated with overweight in children. The rate of overweight found, 
which surpassed that reported by other studies conducted across the country (inc
luding Bahia), point to a risk of child obesity in Feira de Santana.#^ddecs^i2#^
tm^len^kNutritional status^i2#^tm^len^kanthropometry^i2#^tm^len^koverweight^i2#v
ancouv#26#20090427#27.04.2009#20100407#07.04.2010#Fundação de Amparo à Pesquisa 
do Estado da Bahia#a11v86n4.htm#Internet^ihttp://www.scielo.br/scielo.php?script
=sci_arttext&pid=S0021-75572010000400011##
00323000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704009000074002001300164#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#5#1#article#139#<p align="right"><fon
t size="2" face="Verdana"><b>ARTIGO ORIGINAL</b></font> </p>     ^cY#a11v86n4.ht
m##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#6#2#article#139#<p>&nbsp;</p>     ^cY
#a11v86n4.htm##
00376000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704014300074002001300217#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#7#3#article#139#<p><font size="4" fac
e="Verdana"><b>Fatores determinantes do sobrepeso em crian&ccedil;as    menores 
de 4 anos de idade</b></font></p>     ^cY#a11v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#8#4#article#139#<p>&nbsp;</p>     ^cY
#a11v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#9#5#article#139#<p>&nbsp;</p>     ^cY
#a11v86n4.htm##
00523000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704028900075002001300364#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#10#6#article#139#<p><font size="2" fa
ce="Verdana"><b>Gilmar M. de Jesus<sup>I</sup>; Graciete O.    Vieira<sup>II</su
p>; Tatiana O. Vieira<sup>III</sup>; Camila da Cruz Martins<sup>I</sup>;    Carl
os Maur&iacute;cio Cardeal Mendes<sup>IV</sup>; Elizia S. Castel&atilde;o<sup>V<
/sup></b></font></p>     ^cY#a11v86n4.htm##
00392000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704015800075002001300233#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#11#7#article#139#<p> <font size="2" f
ace="Verdana"><sup>I</sup>Mestre, Sa&uacute;de Coletiva, Universidade    Estadua
l de Feira de Santana (UEFS), Feira de Santana, BA    ^cY#a11v86n4.htm##
00349000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011500075002001300190#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#12#8#article#139#<br>   <sup>II</sup>
Doutora, Medicina e Sa&uacute;de, Universidade Federal da Bahia    (UFBA), Salva
dor, BA    ^cY#a11v86n4.htm##
00317000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704008300075002001300158#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#13#9#article#139#<br>   <sup>III</sup
>Mestranda, Medicina e Sa&uacute;de, UFBA, Salvador, BA    ^cY#a11v86n4.htm##
00304000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006900076002001300145#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#14#10#article#139#<br>   <sup>IV</sup
>Doutor, Epidemiologia, UFBA, Salvador, BA    ^cY#a11v86n4.htm##
00329000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009400076002001300170#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#15#11#article#139#<br>   <sup>V</sup>
Acad&ecirc;mica, Enfermagem, UEFS, Feira de Santana, BA</font></p>     ^cY#a11v8
6n4.htm##
00368000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013300076002001300209#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#16#12#article#139#<p><font size="2" f
ace="Verdana"><a name="topo" id="topo"></a><a href="#correspondence">Correspond&
ecirc;ncia</a></font></p>     ^cY#a11v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#17#13#article#139#<p>&nbsp;</p>     ^
cY#a11v86n4.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#18#14#article#139#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a11v86n4.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006600076002001300142#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#19#15#article#139#<p><font size="2" f
ace="Verdana"><b>RESUMO</b></font></p>     ^cY#a11v86n4.htm##
00443000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020800076002001300284#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#20#16#article#139#<p><font size="2" f
ace="Verdana"> <b>OBJETIVOS: </b> Descrever a preval&ecirc;ncia    e os fatores 
determinantes do sobrepeso de crian&ccedil;as menores de 4 anos    de idade de F
eira de Santana (BA).    ^cY#a11v86n4.htm##
01076000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084100076002001300917#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#21#17#article#139#<br>   <b>M&Eacute;
TODOS: </b> Estudo transversal aninhado em uma coorte de nascidos    (n = 793) e
m Feira de Santana. As vari&aacute;veis independentes foram relacionadas    &agr
ave;s caracter&iacute;sticas das crian&ccedil;as, aos fatores sociodemogr&aacute
;ficos    e reprodutivos maternos e &agrave; alimenta&ccedil;&atilde;o da crian&
ccedil;a    aos 4 meses. A vari&aacute;vel dependente foi o sobrepeso avaliado p
elo &iacute;ndice    peso/estatura, comparado ao padr&atilde;o do Multicentre Gr
owth Reference Study    de 2006. Adotaram-se os pontos de corte de normalidade -
2 e +2 escore z em rela&ccedil;&atilde;o    &agrave; mediana da popula&ccedil;&a
tilde;o de refer&ecirc;ncia. O estudo foi    aprovado pelo Comit&ecirc; de &Eacu
te;tica em Pesquisa da Universidade Estadual    de Feira de Santana, sob registr
o nº 096/2006.    ^cY#a11v86n4.htm##
00687000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045200076002001300528#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#22#18#article#139#<br>   <b>RESULTADO
S: </b>A preval&ecirc;ncia de sobrepeso observada foi de 12,5%.    Caracter&iacu
te;sticas associadas positivamente ao sobrepeso: peso adequado    ao nascer (raz
&atilde;o de preval&ecirc;ncia 2,75; IC95% 1,50-5,05), primiparidade    (raz&ati
lde;o de preval&ecirc;ncia 1,61; IC95% 1,09-2,35) e trabalho materno    fora de 
casa aos 4 meses de idade da crian&ccedil;a (raz&atilde;o de preval&ecirc;ncia  
  1,73; IC95% 1,16-2,59).    ^cY#a11v86n4.htm##
00713000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047800076002001300554#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#23#19#article#139#<br>   <b>CONCLUS&O
tilde;ES: </b> No presente estudo, peso adequado ao nascer, primiparidade    e t
rabalho materno aos 4 meses de vida da crian&ccedil;a se associaram com o    sob
repeso infantil. A taxa de sobrepeso superou os resultados de outros estudos    
no pa&iacute;s, inclusive em outros munic&iacute;pios baianos, sinalizando para 
   o risco de obesidade e seus comprometimentos a que as crian&ccedil;as em Feir
a    de Santana podem estar submetidas.</font></p>     ^cY#a11v86n4.htm##
00381000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014600076002001300222#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#24#20#article#139#<p><font size="2" f
ace="Verdana"><b>Palavras-chave: </b> Estado nutricional, antropometia,    sobre
peso.</font></p> <hr size="1" noshade>     ^cY#a11v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#25#21#article#139#<p>&nbsp;</p>     ^
cY#a11v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#26#22#article#139#<p>&nbsp;</p>     ^
cY#a11v86n4.htm##
00319000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008400076002001300160#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#27#23#article#139#<p><font size="3" f
ace="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#a11v86n4.htm##
00925000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069000076002001300766#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#28#24#article#139#<p><font face="Verd
ana" size="2">A avalia&ccedil;&atilde;o do estado nutricional    das crian&ccedi
l;as brasileiras tem revelado transforma&ccedil;&otilde;es, apesar    de o conte
xto epidemiol&oacute;gico indicar clara conviv&ecirc;ncia do ainda    recursivo 
problema da desnutri&ccedil;&atilde;o com o avan&ccedil;o do sobrepeso    e da o
besidade. Esse panorama tem sido reportado em estudos importantes, tais    como 
o Estudo Nacional de Despesa Familiar (ENDEF), a Pesquisa Nacional sobre    Sa&u
acute;de e Nutri&ccedil;&atilde;o (National Health and Nutrition Examination    
Survey, NHANES) e a Pesquisa Nacional sobre Demografia e Sa&uacute;de (PNDS)<SUP
>1,2</SUP>.</font></p>     ^cY#a11v86n4.htm##
00897000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704066200076002001300738#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#29#25#article#139#<p><font face="Verd
ana" size="2">Assim, nos &uacute;ltimos anos, ao mesmo tempo    em que houve uma
 queda na ocorr&ecirc;ncia da desnutri&ccedil;&atilde;o em determinados    subgr
upos e regi&otilde;es do Brasil, a ascend&ecirc;ncia do sobrepeso e da    obesid
ade na popula&ccedil;&atilde;o vem se destacando como importantes problemas    d
e sa&uacute;de p&uacute;blica<SUP>3</SUP>. Estabelece-se, dessa forma, uma    co
exist&ecirc;ncia de tend&ecirc;ncias temporais entre desnutri&ccedil;&atilde;o  
  e obesidade, definindo, assim, uma das caracter&iacute;sticas marcantes do pro
cesso    de transi&ccedil;&atilde;o nutricional do pa&iacute;s.</font></p>     ^
cY#a11v86n4.htm##
00849000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061400076002001300690#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#30#26#article#139#<p><font face="Verd
ana" size="2">De acordo com as disposi&ccedil;&otilde;es da    Organiza&ccedil;&
atilde;o Mundial de Sa&uacute;de (OMS) em 1978, o acompanhamento    do crescimen
to infantil foi institu&iacute;do na d&eacute;cada de 1970, como    atividade fo
cal da assist&ecirc;ncia prim&aacute;ria &agrave; sa&uacute;de da    crian&ccedi
l;a, momento no qual se considerou a detec&ccedil;&atilde;o dos d&eacute;ficits 
   de crescimento como a forma mais adequada de diagnosticar, logo no in&iacute;
cio    da vida, os agravos &agrave; sa&uacute;de e &agrave; nutri&ccedil;&atilde
;o<SUP>2</SUP>.</font></p>     ^cY#a11v86n4.htm##
00755000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052000076002001300596#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#31#27#article#139#<p><font face="Verd
ana" size="2">Por outro lado, o ganho acelerado de peso das    crian&ccedil;as t
em sido utilizado para predizer seu risco posterior de desenvolver    obesidade.
 Por&eacute;m, n&atilde;o est&atilde;o claros que fatores influenciam    a dieta
 e o ganho de peso dessas crian&ccedil;as. Sabe-se que o consumo energ&eacute;ti
co    durante a inf&acirc;ncia determina o ganho de peso e pode influenciar o ri
sco    de desenvolver obesidade na adolesc&ecirc;ncia e idade adulta<SUP>4</SUP>
.</font></p>     ^cY#a11v86n4.htm##
00567000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033200076002001300408#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#32#28#article#139#<p><font face="Verd
ana" size="2">H&aacute; relativo consenso sobre o entendimento    das causas mul
tifatoriais do sobrepeso e da obesidade, admitindo-se que seu    desenvolvimento
 pode ser determinado por um ou pela soma de fatores gen&eacute;ticos,    ambien
tais, comportamentais e socioculturais<SUP>5,6</SUP>.</font></p>     ^cY#a11v86n
4.htm##
00738000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050300076002001300579#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#33#29#article#139#<p><font face="Verd
ana" size="2">Notadamente, diferencia&ccedil;&otilde;es geogr&aacute;ficas    ex
pressam, tamb&eacute;m, diferencia&ccedil;&otilde;es na g&ecirc;nese do sobrepes
o    e obesidade. De fato, os achados de literatura<SUP>7</SUP> apontam maior pr
eval&ecirc;ncia    de sobrepeso e obesidade em regi&otilde;es de renda mais alta
, condi&ccedil;&atilde;o    esta explicativa das diferen&ccedil;as nos panoramas
 epidemiol&oacute;gicos    entre o Nordeste e Sudeste do Brasil.</font></p>     
^cY#a11v86n4.htm##
00797000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056200076002001300638#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#34#30#article#139#<p><font face="Verd
ana" size="2">Contudo, cabe registrar que, nos &uacute;ltimos    anos, j&aacute;
 se desenha outra tend&ecirc;ncia: o aumento da ocorr&ecirc;ncia    da obesidade
 nas regi&otilde;es de renda baixa<SUP>1</SUP>. Mesmo que as maiores    taxas de
 sobrepeso, entre mulheres de 15 a 49 anos de idade e entre crian&ccedil;as    m
enores de 5 anos de idade, ainda se encontrem nas regi&otilde;es Sul e Sudeste  
  do Brasil, os resultados da &uacute;ltima PNDS em 2006, indicam menor disparid
ade    entre as regi&otilde;es<SUP>8</SUP>.</font></p>     ^cY#a11v86n4.htm##
00476000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024100076002001300317#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#35#31#article#139#<p><font face="Verd
ana" size="2">Assim, o presente estudo teve como objetivo descrever    a preval&
ecirc;ncia e os fatores associados ao sobrepeso em crian&ccedil;as    menores de
 4 anos de idade de Feira de Santana (BA).</font></p>     ^cY#a11v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#36#32#article#139#<p>&nbsp;</p>     ^
cY#a11v86n4.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007400076002001300150#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#37#33#article#139#<p><font size="3" f
ace="Verdana"><b>M&eacute;todos</b></font></p>     ^cY#a11v86n4.htm##
00566000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033100076002001300407#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#38#34#article#139#<p><font face="Verd
ana" size="2">Este &eacute; um estudo epidemiol&oacute;gico    de corte transver
sal, aninhado em uma coorte de nascidos de base populacional    em Feira de Sant
ana, no qual foi avaliada a preval&ecirc;ncia e os fatores associados    ao sobr
epeso em crian&ccedil;as menores de 4 anos de idade.</font></p>     ^cY#a11v86n4
.htm##
00550000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031500076002001300391#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#39#35#article#139#<p><font face="Verd
ana" size="2">A coorte foi composta por uma amostra de nascidos    vivos nos hos
pitais de Feira de Santana e residentes no munic&iacute;pio, cujos    nascimento
s ocorreram em 2 meses consecutivos, entre julho de 2004 e mar&ccedil;o    de 20
05, em todos os hospitais da cidade.</font></p>     ^cY#a11v86n4.htm##
01263000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704102800076002001301104#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#40#36#article#139#<p><font face="Verd
ana" size="2">A amostra desse estudo foi calculada com corre&ccedil;&atilde;o   
 para uma popula&ccedil;&atilde;o finita conforme os seguintes par&acirc;metros:
    tamanho da popula&ccedil;&atilde;o de refer&ecirc;ncia, preval&ecirc;ncia es
timada    do evento estudado, tamanho da popula&ccedil;&atilde;o, intervalo de c
onfian&ccedil;a    e precis&atilde;o preterida em torno da preval&ecirc;ncia do 
evento. Sendo assim,    tomou-se 6,0% de preval&ecirc;ncia de sobrepeso entre cr
ian&ccedil;as menores    de 5 anos de idade na Regi&atilde;o Nordeste<SUP>8</SUP
>, intervalo de confian&ccedil;a    de 95% (IC95%) e precis&atilde;o de 1,25% em
 torno da preval&ecirc;ncia estimada,    com uma popula&ccedil;&atilde;o de 977 
crian&ccedil;as seguidas na coorte. Isto    resultou em uma amostra de 573 crian
&ccedil;as. Somou-se a este n&uacute;mero,    20% de perdas presum&iacute;veis, 
resultando em 688 sujeitos. Contudo, foram    obtidos e analisados os dados refe
rentes a 793 crian&ccedil;as.</font></p>     ^cY#a11v86n4.htm##
00954000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071900076002001300795#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#41#37#article#139#<p><font face="Verd
ana" size="2">As vari&aacute;veis independentes ou preditoras    foram relaciona
das &agrave;s caracter&iacute;sticas das crian&ccedil;as (sexo    e peso ao nasc
er), aos fatores sociodemogr&aacute;ficos e reprodutivos maternos    (paridade, 
escolaridade, idade na ocasi&atilde;o do parto, realiza&ccedil;&atilde;o    de p
r&eacute;-natal e trabalho materno aos 4 meses) e &agrave; alimenta&ccedil;&atil
de;o    da crian&ccedil;a aos 4 meses (aleitamento materno exclusivo, predominan
te e    complementado e desmame). Todas as vari&aacute;veis independentes foram 
obtidas    nos bancos de dados da pesquisa original, caracterizando os dados sec
und&aacute;rios    da presente pesquisa.</font></p>     ^cY#a11v86n4.htm##
00526000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029100076002001300367#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#42#38#article#139#<p><font face="Verd
ana" size="2">A vari&aacute;vel dependente foi o estado nutricional    avaliado 
pelo &iacute;ndice peso/estatura (P/E), comparado &agrave;s novas curvas    de c
rescimento recomendadas pela OMS, a partir do Multicentre Growth Reference    St
udy de 2006.</font></p>     ^cY#a11v86n4.htm##
01049000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704081400076002001300890#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#43#39#article#139#<p><font face="Verd
ana" size="2">Por sua vez, a estatura e o peso das crian&ccedil;as    foram mens
urados em visitas domiciliares, com a utiliza&ccedil;&atilde;o de    um estadi&o
circ;metro port&aacute;til e desmont&aacute;vel de 2,16 m de altura    m&aacute;
xima e precis&atilde;o de 0,1 cm, e uma balan&ccedil;a digital com    capacidade
 m&aacute;xima de 150 kg e precis&atilde;o de 100 g, respectivamente.    Todas a
s medidas foram realizadas em triplicata &#150; obtendo-se os valores finais    
por m&eacute;dia aritm&eacute;tica &#150; pelo pr&oacute;prio pesquisador e por 
um    grupo de quatro estudantes de Educa&ccedil;&atilde;o F&iacute;sica da Univ
ersidade    Estadual de Feira de Santana (UEFS), Feira de Santana (BA), o que as
sinala os    dados prim&aacute;rios do presente estudo.</font></p>     ^cY#a11v8
6n4.htm##
01016000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704078100076002001300857#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#44#40#article#139#<p><font face="Verd
ana" size="2">Para o c&aacute;lculo do &iacute;ndice P/E, foi    utilizado o<i> 
software</i> ANTHRO9, sendo adotados como pontos de corte de    normalidade -2 e
 +2 escore z em rela&ccedil;&atilde;o &agrave; mediana da popula&ccedil;&atilde;
o    de refer&ecirc;ncia. Vale ressaltar que as novas curvas de refer&ecirc;ncia
    para o crescimento foram constru&iacute;das a partir de um estudo realizado 
   entre 1997 e 2003 &#150; com coleta de dados de aproximadamente 8.500 crian&c
cedil;as    de diferentes pa&iacute;ses (Brasil, Gana, &Iacute;ndia, Noruega, Om
&atilde;)    &#150; e representam a refer&ecirc;ncia atual de altura e massa cor
poral, estabelecendo    os beb&ecirc;s que recebem leite materno como modelo nor
mativo de crescimento.</font></p>     ^cY#a11v86n4.htm##
01033000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704079800076002001300874#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#45#41#article#139#<p><font face="Verd
ana" size="2">O atual estudo foi realizado conforme a Resolu&ccedil;&atilde;o   
 196/96 do Conselho Nacional de Sa&uacute;de, tendo seu protocolo aprovado pelo 
   Comit&ecirc; de &Eacute;tica em Pesquisa (CEP) da UEFS sob registro nº 096/20
06.    As m&atilde;es cujas crian&ccedil;as participaram da pesquisa foram infor
madas,    em linguagem acess&iacute;vel, sobre as justificativas e os objetivos 
do estudo    e aceitaram participar mediante a assinatura do Termo de Consentime
nto Livre    e Esclarecido. Durante a trajet&oacute;ria da pesquisa, as crian&cc
edil;as que    foram identificadas com altera&ccedil;&otilde;es no estado nutric
ional tiveram    seus pais e/ou respons&aacute;veis alertados e informados sobre
 os encaminhamentos    cab&iacute;veis.</font></p>     ^cY#a11v86n4.htm##
00864000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062900076002001300705#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#46#42#article#139#<p><font face="Verd
ana" size="2">O novo banco de dados foi digitado com dupla    entrada de informa
&ccedil;&otilde;es no <i>software</i> Statistical Package    for Social Sciences
 (SPSS), vers&atilde;o 10.0, e validado com o aux&iacute;lio    do pacote Valida
te do <i>software</i> Epidata. Todos os c&aacute;lculos referentes    &agrave; f
ase de an&aacute;lise bivariada dos dados da pesquisa foram realizados    no SPS
S, no qual foram calculadas as raz&otilde;es de preval&ecirc;ncia (RP),    adota
ndo-se IC95% para a signific&acirc;ncia estat&iacute;stica, por meio da    estat
&iacute;stica do qui-quadrado.</font></p>     ^cY#a11v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#47#43#article#139#<p>&nbsp;</p>     ^
cY#a11v86n4.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007000076002001300146#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#48#44#article#139#<p><font size="3" f
ace="Verdana"><b>Resultados</b></font></p>     ^cY#a11v86n4.htm##
00796000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056100076002001300637#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#49#45#article#139#<p><font face="Verd
ana" size="2">As caracter&iacute;sticas das 793 crian&ccedil;as    menores de 4 
anos de idade avaliadas s&atilde;o descritas na <a href=#379t1 >Tabela    1</a>.
 Os valores de peso e estatura variaram de 8,9 a 24,8 kg e de 73,0 a 112,2    cm
, com m&eacute;dias de 14,3 kg e 91,9 cm e desvios padr&atilde;o de 2,29 kg    e
 5,1 cm, respectivamente. Na ocasi&atilde;o da coleta de dados, as idades das   
 crian&ccedil;as estudadas variaram de 22,7 a 45,8 meses, com m&eacute;dia de   
 31,7 e desvio padr&atilde;o de 4,1 meses.</font></p>     ^cY#a11v86n4.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003600076002001300112#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#50#46#article#139#<p><a name="379t1">
</a></p>     ^cY#a11v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#51#47#article#139#<p>&nbsp;</p>     ^
cY#a11v86n4.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007800076002001300154#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#52#48#article#139#<p align="center"><
img src="/img/revistas/jped/v86n4/4a11t1.gif"></p>     ^cY#a11v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#53#49#article#139#<p>&nbsp;</p>     ^
cY#a11v86n4.htm##
00709000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047400076002001300550#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#54#50#article#139#<p><font face="Verd
ana" size="2"> A preval&ecirc;ncia total de sobrepeso encontrada    foi de 12,5%
, sendo 11,2% entre as crian&ccedil;as do sexo feminino e 13,7%    entre as do s
exo masculino; contudo, n&atilde;o houve diferen&ccedil;a estatisticamente    si
gnificante entre os sexos (p = 0,276). Isso est&aacute; descrito na <a href=/img
/revistas/jped/v86n4/4a11t2.gif>Tabela    2</a>, que cont&eacute;m todos os resu
ltados da an&aacute;lise bivariada.</font></p>     ^cY#a11v86n4.htm##
00590000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035500076002001300431#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#55#51#article#139#<p><font face="Verd
ana" size="2">Entre as crian&ccedil;as com peso adequado ao    nascer (PAN), 14,
9% apresentaram sobrepeso, comparadas &agrave;s nascidas com    peso insuficient
e ou baixo peso ao nascer. Isto indicou ocorr&ecirc;ncia de    sobrepeso quase t
r&ecirc;s vezes superior entre as nascidas com peso adequado    (p = 0,000).</fo
nt></p>     ^cY#a11v86n4.htm##
00532000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029700076002001300373#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#56#52#article#139#<p><font face="Verd
ana" size="2">Embora n&atilde;o tenha sido alcan&ccedil;ada    signific&acirc;nc
ia estat&iacute;stica, as crian&ccedil;as filhas de m&atilde;es    com maior esc
olaridade apresentaram maior preval&ecirc;ncia de sobrepeso quando    comparadas
 &agrave;s demais.</font></p>     ^cY#a11v86n4.htm##
00696000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046100076002001300537#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#57#53#article#139#<p><font face="Verd
ana" size="2">A paridade e o trabalho materno aos 4 meses de    idade das crian&
ccedil;as tamb&eacute;m se associaram positivamente com o sobrepeso    infantil.
 Nota-se que entre as crian&ccedil;as filhas de m&atilde;es prim&iacute;paras,  
  a ocorr&ecirc;ncia de sobrepeso foi 1,6 vezes maior (p = 0,014), e entre aquel
as    filhas de m&atilde;es que j&aacute; trabalhavam aos 4 meses, foi 1,7 vezes
 maior    (p = 0,008).</font></p>     ^cY#a11v86n4.htm##
00566000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033100076002001300407#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#58#54#article#139#<p><font face="Verd
ana" size="2">A idade materna no nascimento da crian&ccedil;a,    a realiza&cced
il;&atilde;o de consultas pr&eacute;-natais e a pr&aacute;tica    da amamenta&cc
edil;&atilde;o e o tipo de aleitamento materno aos 4 meses de    idade das crian
&ccedil;as n&atilde;o se associaram com o sobrepeso.</font></p>     ^cY#a11v86n4
.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#59#55#article#139#<p>&nbsp;</p>     ^
cY#a11v86n4.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#60#56#article#139#<p><font size="3" f
ace="Verdana"><b>Discuss&atilde;o</b></font></p>     ^cY#a11v86n4.htm##
00688000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045300076002001300529#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#61#57#article#139#<p><font face="Verd
ana" size="2">No presente estudo, a preval&ecirc;ncia de sobrepeso    avaliado p
elo &iacute;ndice antropom&eacute;trico P/E entre as crian&ccedil;as    (12,5%) 
foi superior &agrave; encontrada em menores de 7 anos de creches da    Prefeitur
a do munic&iacute;pio de S&atilde;o Paulo (SP) (5,0%)<SUP>10</SUP>    e entre cr
ian&ccedil;as de tr&ecirc;s creches municipais de Bras&iacute;lia    (DF) (6,1%)
<SUP>11</SUP>.</font></p>     ^cY#a11v86n4.htm##
00557000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032200076002001300398#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#62#58#article#139#<p><font face="Verd
ana" size="2">Nota-se, ainda, que a taxa de sobrepeso encontrada    foi superior
 &agrave;s reportadas pela &uacute;ltima PNDS de 2006 para o pa&iacute;s    (6,6
%) e para as Regi&otilde;es Norte (5,2%), Nordeste (6,0%), Sudeste (6,7%),    Su
l (8,8%) e Centro-Oeste (7,0%)<SUP>8</SUP>.</font></p>     ^cY#a11v86n4.htm##
01344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704110900076002001301185#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#63#59#article#139#<p><font face="Verd
ana" size="2">Com o aumento da incid&ecirc;ncia de sobrepeso    e obesidade entr
e crian&ccedil;as menores de 5 anos de idade em todo o Brasil,    fen&ocirc;meno
 que tem ocorrido com a sistem&aacute;tica diminui&ccedil;&atilde;o    das taxas
 de desnutri&ccedil;&atilde;o<SUP>8</SUP>, atenta-se para o munic&iacute;pio    
de Feira de Santana<SUP>12</SUP>, em que j&aacute; foram detectadas preval&ecirc
;ncias    de sobrepeso e de obesidade, respectivamente 9,3 e 4,4%, entre crian&c
cedil;as    de uma escola privada e de uma p&uacute;blica, com destaque para mai
ores taxas    de sobrepeso e obesidade, respectivamente, entre as crian&ccedil;a
s da escola    privada (13,4 e 7,0%), comparadas &agrave;s da escola p&uacute;bl
ica (6,5 e    2,7%). No entanto, at&eacute; o presente momento, n&atilde;o havia
 dados populacionais    dispon&iacute;veis sobre a frequ&ecirc;ncia e distribui&
ccedil;&atilde;o do    sobrepeso em crian&ccedil;as pr&eacute;-escolares no muni
c&iacute;pio que permitissem    uma compara&ccedil;&atilde;o mais apropriada dos
 resultados da atual pesquisa.</font></p>     ^cY#a11v86n4.htm##
00495000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026000076002001300336#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#64#60#article#139#<p><font face="Verd
ana" size="2">Nesta pesquisa, n&atilde;o houve diferen&ccedil;a    na preval&eci
rc;ncia de sobrepeso entre os sexos, assim como reportado entre    pr&eacute;-es
colares do munic&iacute;pio de S&atilde;o Paulo<SUP>13</SUP>.</font></p>     ^cY
#a11v86n4.htm##
00850000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061500076002001300691#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#65#61#article#139#<p><font face="Verd
ana" size="2">At&eacute; certo ponto, isso pode ser explicado    por fatores hor
monais da faixa et&aacute;ria das crian&ccedil;as, assim como    foi reportado a
nteriormente em Feira de Santana<SUP>14</SUP>. Resultado que    &eacute; distint
o do reportado por um estudo realizado em Florian&oacute;polis    (SC), em que f
oi encontrada uma preval&ecirc;ncia de 6,8% de sobrepeso em um    grupo de crian
&ccedil;as menores de 6 anos de idade, com predom&iacute;nio entre    as menores
 de 2 anos, do sexo feminino e que residiam em &aacute;reas n&atilde;o    carent
es<SUP>15</SUP>.</font></p>     ^cY#a11v86n4.htm##
01225000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704099000076002001301066#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#66#62#article#139#<p><font face="Verd
ana" size="2">Ademais, o PAN associou-se positivamente com    o sobrepeso das cr
ian&ccedil;as, conforme havia sido apontado, anteriormente,    em uma revis&atil
de;o sistem&aacute;tica<SUP>16</SUP>. Em um ponto de vista,    esse resultado po
deria ampliar a base de sustenta&ccedil;&atilde;o da hip&oacute;tese    sobre um
a associa&ccedil;&atilde;o positiva, na qual crian&ccedil;as que nascem    com m
aior peso t&ecirc;m maior probabilidade de apresentar obesidade na inf&acirc;nci
a,    e, desse modo, o baixo peso ao nascer agiria como um fator protetor. Todav
ia,    ao considerar que o PAN &eacute; um par&acirc;metro de sa&uacute;de adequ
ado,    &eacute; poss&iacute;vel que entre as crian&ccedil;as do presente estudo
 fatores    externos (como a alimenta&ccedil;&atilde;o) influenciem na express&a
tilde;o    do sobrepeso durante a inf&acirc;ncia e que haja associa&ccedil;&atil
de;o entre    o baixo peso ao nascer e o d&eacute;ficit de crescimento.</font></
p>     ^cY#a11v86n4.htm##
00696000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046100076002001300537#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#67#63#article#139#<p><font face="Verd
ana" size="2">Al&eacute;m disso, a associa&ccedil;&atilde;o    entre o peso ao n
ascer e o excesso de peso durante a inf&acirc;ncia n&atilde;o    &eacute; linear
. Assim, tanto crian&ccedil;as nascidas com baixo peso como as    nascidas com p
eso elevado t&ecirc;m probabilidade de apresentar obesidade na    inf&acirc;ncia
, mas essa probabilidade &eacute; maior para aquelas que nascem    com peso mais
 elevado<SUP>16</SUP>.</font></p>     ^cY#a11v86n4.htm##
01423000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704118800076002001301264#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#68#64#article#139#<p><font face="Verd
ana" size="2">Assim como apontado em outros estudos<SUP>10,12,17</SUP>,    obser
vou-se entre as crian&ccedil;as de Feira de Santana uma tend&ecirc;ncia    de ma
ior preval&ecirc;ncia de sobrepeso em fun&ccedil;&atilde;o de n&iacute;veis    m
ais elevados de escolaridade materna, embora isso n&atilde;o tenha alcan&ccedil;
ado    signific&acirc;ncia estat&iacute;stica. &Eacute; importante salientar que
 mulheres    com maior escolaridade podem apresentar tamb&eacute;m poder aquisit
ivo mais    elevado, com maior chance de adquirir alimentos industrializados e m
ais cal&oacute;ricos.    Assim, as condi&ccedil;&otilde;es socioecon&ocirc;micas
 podem influenciar, de    forma significativa, a ocorr&ecirc;ncia de sobrepeso/o
besidade durante a inf&acirc;ncia<SUP>17</SUP>.    Al&eacute;m de outros fatores
, tem sido revelado o aumento das preval&ecirc;ncias    de sobrepeso entre crian
&ccedil;as, em fun&ccedil;&atilde;o da sua idade, da    escolaridade materna (su
perior ao Ensino Fundamental) e qualifica&ccedil;&atilde;o    profissional de se
us pais e da renda familiar <i>per capita </i>(<u>&gt;</u>    2 sal&aacute;rios 
m&iacute;nimos)<SUP>17</SUP>.</font></p>     ^cY#a11v86n4.htm##
00676000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044100076002001300517#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#69#65#article#139#<p><font face="Verd
ana" size="2">Da mesma forma, notou-se maior ocorr&ecirc;ncia    de sobrepeso en
tre as crian&ccedil;as filhas de m&atilde;es prim&iacute;paras.    Sobre esse as
pecto, tem sido apontado na literatura que o fato de a crian&ccedil;a    ter doi
s ou mais irm&atilde;os &eacute; fator de prote&ccedil;&atilde;o para    o sobre
peso<SUP>3</SUP> ou fator de risco para o d&eacute;ficit nutricional<SUP>18</SUP
>.</font></p>     ^cY#a11v86n4.htm##
01063000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082800076002001300904#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#70#66#article#139#<p><font face="Verd
ana" size="2">De forma distinta do que foi apontado anteriormente<SUP>17</SUP>, 
   o trabalho materno aos 4 meses de idade foi fator de risco para o sobrepeso  
  entre as crian&ccedil;as do estudo. Destarte, &eacute; preciso considerar a   
 hip&oacute;tese, apontada em estudos anteriores, de que as crian&ccedil;as cuja
s    m&atilde;es j&aacute; trabalham no quarto m&ecirc;s ap&oacute;s seu nascime
nto    s&atilde;o mais precocemente desmamadas e introduzidas no consumo dos ali
mentos    da fam&iacute;lia, estando mais suscept&iacute;veis ao sobrepeso<SUP>1
9</SUP>.    Al&eacute;m disso, m&atilde;es que trabalham fora do lar t&ecirc;m u
ma tend&ecirc;ncia    de agradar os filhos com merendas, que na maioria das veze
s apresentam alto    valor cal&oacute;rico e baixo valor nutricional.</font></p>
     ^cY#a11v86n4.htm##
00872000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063700076002001300713#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#71#67#article#139#<p><font face="Verd
ana" size="2">Note-se, contudo, que, no presente estudo, n&atilde;o    houve ass
ocia&ccedil;&atilde;o positiva entre a pr&aacute;tica de amamentar,    o tipo de
 amamenta&ccedil;&atilde;o aos 4 meses e o sobrepeso das crian&ccedil;as.    Os 
resultados obtidos neste estudo coadunam com evid&ecirc;ncias que sugerem    n&a
tilde;o haver uma forte associa&ccedil;&atilde;o entre a amamenta&ccedil;&atilde
;o    e o sobrepeso na inf&acirc;ncia<SUP>20</SUP>, apesar de outros estudos pub
licados    enfatizarem os efeitos protetores do leite humano contra o desenvolvi
mento da    obesidade<SUP>21-25</SUP>.</font></p>     ^cY#a11v86n4.htm##
01138000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704090300076002001300979#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#72#68#article#139#<p><font face="Verd
ana" size="2">&Eacute; importante salientar que a influ&ecirc;ncia    da amament
a&ccedil;&atilde;o sobre o crescimento e estado nutricional de crian&ccedil;as  
  tem sido extensivamente comentada como efetiva em crian&ccedil;as at&eacute;  
  o primeiro ano de vida<SUP>21-25</SUP>. Por outro lado, foi demonstrado o efei
to    protetor contra sobrepeso e obesidade do aleitamento materno exclusivo por
 6    meses e do aleitamento materno por 24 meses ou mais entre pr&eacute;-escol
ares    de 2 a 6 anos de idade do munic&iacute;pio de S&atilde;o Paulo<SUP>13</S
UP>.    Isto inspira, portanto, a investiga&ccedil;&atilde;o sobre o consumo ali
mentar    atual das crian&ccedil;as e no percurso entre o quarto m&ecirc;s de id
ade e    a ocasi&atilde;o da coleta de dados, por volta dos 30 meses, j&aacute; 
que este    pode ter influenciado efetivamente o ganho ponderal.</font></p>     
^cY#a11v86n4.htm##
00656000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704042100076002001300497#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#73#69#article#139#<p><font face="Verd
ana" size="2">Por fim, &eacute; importante ressaltar que a    maioria dos trabal
hos realizados abordando a tem&aacute;tica do estado nutricional    e/ou crescim
ento infantil, at&eacute; pouco tempo, foi feita de acordo com curvas    de cres
cimento que n&atilde;o consideram o aleitamento materno como alimenta&ccedil;&at
ilde;o    ideal para o crescimento e desenvolvimento infantil.</font></p>     ^c
Y#a11v86n4.htm##
01025000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704079000076002001300866#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#74#70#article#139#<p><font face="Verd
ana" size="2">Neste estudo, por&eacute;m, foram utilizadas    as curvas de cresc
imento recomendadas pela OMS<SUP>9</SUP> e recentemente adotadas    pelo Minist&
eacute;rio da Sa&uacute;de. O novo padr&atilde;o de crescimento    das crian&cce
dil;as amamentadas, comparado a refer&ecirc;ncias anteriores, como    o padr&ati
lde;o do National Centers&nbsp;for Health Statistics (NCHS) de 1977    e do Cent
ers for Disease Control and Prevention&nbsp;(CDC) de 2000, resultar&aacute;    e
m um aumento das taxas de sobrepeso avaliado pelo &iacute;ndice P/E<SUP>26</SUP>
.    Portanto, a maior preval&ecirc;ncia de sobrepeso entre as crian&ccedil;as d
e    Feira de Santana, quando comparadas a diversos estudos pelo pa&iacute;s, po
de    ser devido a esse efeito.</font></p>     ^cY#a11v86n4.htm##
01271000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704103600076002001301112#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#75#71#article#139#<p><font face="Verd
ana" size="2">Conclui-se que, no presente estudo, PAN, primiparidade    e trabal
ho materno aos 4 meses de vida da crian&ccedil;a se associaram com o    sobrepes
o infantil. A taxa de sobrepeso encontrada, que superou resultados de    outros 
estudos pelo pa&iacute;s, aponta para o risco de obesidade e seus comprometiment
os,    a que as crian&ccedil;as em Feira de Santana podem estar submetidas. Apes
ar    de ter sido observada maior tend&ecirc;ncia ao sobrepeso entre as crian&cc
edil;as    filhas de m&atilde;es com maiores n&iacute;veis de escolaridade, &eac
ute; necess&aacute;rio    instituir pol&iacute;ticas de educa&ccedil;&atilde;o e
m sa&uacute;de que permeiem    os diferentes grupos sociais e, sobretudo, alcanc
em as mulheres prim&iacute;paras    e que se ausentam do lar para trabalhar, ale
rtando sobre os riscos desta afec&ccedil;&atilde;o,    bem como as medidas de pr
even&ccedil;&atilde;o para que se controle sua ascens&atilde;o    entre crian&cc
edil;as pequenas do munic&iacute;pio.</font></p>     ^cY#a11v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#76#72#article#139#<p>&nbsp;</p>     ^
cY#a11v86n4.htm##
00312000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007700076002001300153#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#77#73#article#139#<p><font size="3" f
ace="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#a11v86n4.htm##
00458000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704020900078002001300287#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#78#74#article#139#1#<p><f
ont size="2" face="Verdana">1. Batista Filho M, Rissin A. A transi&ccedil;&atild
e;o    nutricional no Brasil: tend&ecirc;ncias regionais e temporais. Cad Saude 
Publica.    2003;19 Suppl 1:S181-91.    ^cY#a11v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#79#75#article#139#</font></p>     ^cY
#a11v86n4.htm##
00412000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704016300078002001300241#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#80#76#article#139#2#<p><f
ont size="2" face="Verdana">2. Monteiro CA. A dimens&atilde;o da pobreza,    da 
desnutri&ccedil;&atilde;o e da fome no Brasil. Estud Av. 2003;17:7-20.    ^cY#a1
1v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#81#77#article#139#</font></p>     ^cY
#a11v86n4.htm##
00479000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023000078002001300308#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#82#78#article#139#3#<p><f
ont size="2" face="Verdana">3. Monteiro CA, Conde WL, Popkin BM. Is obesity    r
eplacing or adding to undernutrition? evidence from different social classes    
in Brazil. Public Health Nutr. 2002;5:105-112</font></p>     ^cY#a11v86n4.htm##
00500000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025100078002001300329#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#83#79#article#139#4#<p><f
ont size="2" face="Verdana">4. Ong KK, Emmett PM, Noble S, Ness A, Dunger    DB;
 ALSPAC Study Team. Dietary energy intake at the age of 4 months predicts    pos
tnatal weight gain and childhood body mass index. Pediatrics. 2006;117:e503-8.  
  ^cY#a11v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#84#80#article#139#</font></p>     ^cY
#a11v86n4.htm##
00417000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704016800078002001300246#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#85#81#article#139#5#<p><f
ont size="2" face="Verdana">5. Damiani D, Carvalho DP, Oliveira, RG. Obesidade  
  na Inf&acirc;ncia: um grande desafio. Pediatria Moderna. 2000;36:489-528.    ^
cY#a11v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#86#82#article#139#</font></p>     ^cY
#a11v86n4.htm##
00460000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021100078002001300289#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#87#83#article#139#6#<p><f
ont size="2" face="Verdana">6. Escriv&atilde;o MA, Oliveira FL, Taddei JA,    Lo
pez FA. Obesidade ex&oacute;gena na inf&acirc;ncia e adolesc&ecirc;ncia. J    Pe
diatr (Rio J). 2000;76 Suppl 3:305-10.    ^cY#a11v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#88#84#article#139#</font></p>     ^cY
#a11v86n4.htm##
00489000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024000078002001300318#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#89#85#article#139#7#<p><f
ont size="2" face="Verdana">7. Abrantes MM, Lamounier JA, Colosimo EA. Preval&ec
irc;ncia    de sobrepeso e obesidade em crian&ccedil;as e adolescentes das regi&
otilde;es    Sudeste e Nordeste. J Pediatr (Rio J). 2002;78:335-40.    ^cY#a11v8
6n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#90#86#article#139#</font></p>     ^cY
#a11v86n4.htm##
00446000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019700078002001300275#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#91#87#article#139#8#<p><f
ont size="2" face="Verdana">8. Brasil. Minist&eacute;rio da Sa&uacute;de.    Pes
quisa Nacional de Demografia e Sa&uacute;de da Crian&ccedil;a e da Mulher.    Br
as&iacute;lia, DF; 2008.    ^cY#a11v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#92#88#article#139#</font></p>     ^cY
#a11v86n4.htm##
00734000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704048500078002001300563#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#93#89#article#139#9#<p><f
ont size="2" face="Verdana">9. World Health Organization. Multicentre Growth    
Reference Study Group (2006). WHO Child Growth Standards: Length/height-for-age,
    weight-for-age, weight-for-length, weight-for-height and body mass index-for
-age:    Methods and development. Geneva: World Health Organization. 2006; pp 31
2. <A href=http://www.who.int/childgrowth/publications/en target="_blank">http:/
/www.who.int/childgrowth/publications/en</A>&gt;.    Acesso: 10/01/2007.    ^cY#
a11v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#94#90#article#139#</font></p>     ^cY
#a11v86n4.htm##
00581000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704033100079002001300410#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#95#91#article#139#10#<p><
font size="2" face="Verdana">10. Z&ouml;llner CC, Fisberg RM. Estado nutricional
    e sua rela&ccedil;&atilde;o com fatores biol&oacute;gicos, sociais e demogr&
aacute;ficos    de crian&ccedil;as assistidas em creches da Prefeitura do Munic&
iacute;pio de    S&atilde;o Paulo. Rev Bras Saude Matern Infant. 2006;6:319-28. 
   ^cY#a11v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#96#92#article#139#</font></p>     ^cY
#a11v86n4.htm##
00532000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704028200079002001300361#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#97#93#article#139#11#<p><
font size="2" face="Verdana">11. Tuma RC, da Costa TH, Schimitz BA. Avalia&ccedi
l;&atilde;o    antropom&eacute;trica e diet&eacute;tica de pr&eacute;-escolares 
em tr&ecirc;s    creches de Bras&iacute;lia, Distrito Federal. Rev Bras Saude Ma
tern Infant.    2005;5:419-28.    ^cY#a11v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#98#94#article#139#</font></p>     ^cY
#a11v86n4.htm##
00489000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704023900079002001300318#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#99#95#article#139#12#<p><
font size="2" face="Verdana">12. Oliveira AM, Cerqueira EM, Souza JS, Oliveira  
  AC. Sobrepeso e obesidade infantil: fatores biol&oacute;gicos e ambientais em 
   Feira de Santana, BA. Arq Bras Endocrinol Metab. 2003;47:144-50.    ^cY#a11v8
6n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#100#96#article#139#</font></p>     ^c
Y#a11v86n4.htm##
00472000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704022100080002001300301#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#101#97#article#139#13#<p>
<font size="2" face="Verdana">13. Simon VG, Souza JM, Souza SB. Aleitamento    m
aterno, alimenta&ccedil;&atilde;o complementar, sobrepeso e obesidade em pr&eacu
te;-escolares.    Rev Saude Publica. 2009;43:60-9.    ^cY#a11v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002100077002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#102#98#article#139# </font></p>     ^
cY#a11v86n4.htm##
00552000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704030100080002001300381#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#103#99#article#139#14#<p>
<font size="2" face="Verdana">14. de Oliveira AM, Cerqueira Ede M, de Oliveira  
  AC. Preval&ecirc;ncia de sobrepeso e obesidade infantil na cidade de Feira de 
   Santana-BA: detec&ccedil;&atilde;o na fam&iacute;lia x diagn&oacute;stico cl&
iacute;nico.    J Pediatr (Rio J). 2003;79:325-28.    ^cY#a11v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#104#100#article#139#</font></p>     ^
cY#a11v86n4.htm##
00454000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020200081002001300283#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#105#101#article#139#15#<p
><font size="2" face="Verdana">15. Corso AC, Botelho LJ, Zeni LA, Moreira EA.   
 Sobrepeso em crian&ccedil;as menores de 6 anos de idade em Florian&oacute;polis
,    SC. Rev Nutr. 2003;16:21-8.    ^cY#a11v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#106#102#article#139#</font></p>     ^
cY#a11v86n4.htm##
00449000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019700081002001300278#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#107#103#article#139#16#<p
><font size="2" face="Verdana">16. Martins EB, Carvalho MS. Associa&ccedil;&atil
de;o    entre peso ao nascer e o excesso de peso na inf&acirc;ncia. Cad Saude Pu
blica.    2006;22:2281-300.    ^cY#a11v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#108#104#article#139#</font></p>     ^
cY#a11v86n4.htm##
00478000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022600081002001300307#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#109#105#article#139#17#<p
><font size="2" face="Verdana">17. Drachler Mde L, Macluf SP, Leite JC, Aerts   
 DR, Giugliani ER, Horta BL. Fatores de risco para sobrepeso em crian&ccedil;as 
   no Sul do Brasil. Cad Saude Publica. 2003;19:1073-81.    ^cY#a11v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#110#106#article#139#</font></p>     ^
cY#a11v86n4.htm##
00537000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028500081002001300366#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#111#107#article#139#18#<p
><font size="2" face="Verdana">18. Fisberg RM, Marchioni DM, Cardoso MR. Estado 
   nutricional e fatores associados ao d&eacute;ficit de crescimento de crian&cc
edil;as    freq&uuml;entadoras de creches p&uacute;blicas de S&atilde;o Paulo. C
ad Saude    Publica. 2004;20:812-7.    ^cY#a11v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#112#108#article#139#</font></p>     ^
cY#a11v86n4.htm##
00421000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016900081002001300250#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#113#109#article#139#19#<p
><font size="2" face="Verdana">19. Balaban G, Silva GA. Efeito protetor do aleit
amento    materno contra a obesidade infantil. J Pediatr (Rio J). 2004;80:7-16. 
   ^cY#a11v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#114#110#article#139#</font></p>     ^
cY#a11v86n4.htm##
00489000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023700081002001300318#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#115#111#article#139#20#<p
><font size="2" face="Verdana">20. Horta BL, Bahl R, Martines JC, Victora CG.   
 Evidence on the long-term effects of breastfeeding: systematic reviews and meta
-analyses.    World Health Organization. Geneva, Switzerland; 2007.    ^cY#a11v8
6n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#116#112#article#139#</font></p>     ^
cY#a11v86n4.htm##
00455000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020300081002001300284#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#117#113#article#139#21#<p
><font size="2" face="Verdana">21. Nielsen GA, Thomsen BL, Michaelsen KF. Influe
nce    of breastfeeding and complementary food on growth between 5 and 10 months
. Acta    Pediatr. 1998;87:911-7.    ^cY#a11v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#118#114#article#139#</font></p>     ^
cY#a11v86n4.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023800081002001300319#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#119#115#article#139#22#<p
><font size="2" face="Verdana">22. Espo M, Kulmala T, Maleta K, Cullinan T,    S
alin ML, Ashorn P. Determinants of linear growth and predictors of severe stunti
ng    during infancy in rural Malawi. Acta Pediatr. 2002;91:1364-70.    ^cY#a11v
86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#120#116#article#139#</font></p>     ^
cY#a11v86n4.htm##
00552000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030000081002001300381#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#121#117#article#139#23#<p
><font size="2" face="Verdana">23. Mamabolo RL, Alberts M, Mbenyane GX, Steyn   
 NP, Nthangeni NG, Delemarre-Van De Waal HA, et al. Feeding practices and growth
    of infant from birth to 12 months in the central region of the Limpopo Provi
nce    of South Africa. Nutrition. 2004;20:327-33.    ^cY#a11v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#122#118#article#139#</font></p>     ^
cY#a11v86n4.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022100081002001300302#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#123#119#article#139#24#<p
><font size="2" face="Verdana">24. Marques RF, Lopez FA, Braga JA. O crescimento
    de crian&ccedil;as alimentadas com leite materno exclusivo nos primeiros 6 m
eses    de vida. J Pediatr (Rio J). 2004;80:99-105.    ^cY#a11v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#124#120#article#139#</font></p>     ^
cY#a11v86n4.htm##
00570000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031800081002001300399#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#125#121#article#139#25#<p
><font size="2" face="Verdana">25. Vohr BR, Poindexter BB, Dusick AM, McKinley  
  LT, Wright LL, Langer JC, et al. Beneficial effects of breast milk in the neon
atal    intensive care unit on the developmental outcome of extremely low birth 
weight    infants at 18 months of age. Pediatrics. 2006;118:e115-23.    ^cY#a11v
86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#126#122#article#139#</font></p>     ^
cY#a11v86n4.htm##
00451000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019900081002001300280#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#p#127#123#article#139#26#<p
><font size="2" face="Verdana">26. WHO Multicentre Growth Reference Study Group.
    WHO Child Growth Standards based on length/height, weight and age. Acta Paed
iatr    Suppl. 2006;95:76-85.    ^cY#a11v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#128#124#article#139#</font></p>     ^
cY#a11v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#129#125#article#139#<p>&nbsp;</p>    
 ^cY#a11v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#130#126#article#139#<p>&nbsp;</p>    
 ^cY#a11v86n4.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018000078002001300258#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#131#127#article#139#<p><font size="2"
 face="Verdana"><a name="correspondence"></a><a href="#topo"><img src="/img/revi
stas/jped/v86n4/seta.gif" border="0"></a>    <b> Correspond&ecirc;ncia:</b>    ^
cY#a11v86n4.htm##
00270000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003300078002001300111#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#132#128#article#139#<br>   Gilmar M. 
de Jesus    ^cY#a11v86n4.htm##
00281000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004400078002001300122#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#133#129#article#139#<BR>   Rua Juiz d
e Fora, 581, Caseb     ^cY#a11v86n4.htm##
00288000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005100078002001300129#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#134#130#article#139#<BR>   CEP 44040-
080 - Feira de Santana, BA    ^cY#a11v86n4.htm##
00288000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005100078002001300129#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#135#131#article#139#<BR>   Tel.: (75)
 3225.3477, (75) 8108.5104    ^cY#a11v86n4.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#136#132#article#139#<BR>   Fax: (75) 
3224.8088    ^cY#a11v86n4.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009100078002001300169#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#137#133#article#139#<BR>   E-mail: <A
 href=mailto:gilmj@yahoo.com.br>gilmj@yahoo.com.br</A></font></p>     ^cY#a11v86
n4.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010600078002001300184#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#138#134#article#139#<p><font size="2"
 face="Verdana">Artigo submetido em 27.04.2009, aceito em 07.04.2010.</font></p>
     ^cY#a11v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#139#135#article#139#<p>&nbsp;</p>    
 ^cY#a11v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#140#136#article#139#<p>&nbsp;</p>    
 ^cY#a11v86n4.htm##
00391000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704015400078002001300232#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#141#137#article#139#<p><font size="2"
 face="Verdana"> N&atilde;o foram declarados conflitos de interesse    associado
s &agrave; publica&ccedil;&atilde;o deste artigo.    ^cY#a11v86n4.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011500078002001300193#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#142#138#article#139#<br>   Apoio fina
nceiro: Funda&ccedil;&atilde;o de Amparo &agrave; Pesquisa do Estado    da Bahia
 (FAPESB).    ^cY#a11v86n4.htm##
00367000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704013000078002001300208#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a11v86n4.htm#S#p#143#139#article#139#<br>   Este estud
o foi realizado na Universidade Estadual de Feira de Santana (UEFS),    Feira de
 Santana, BA.</font></p>     ^cY#a11v86n4.htm##
00575000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100023000770100016001000120
07200116030001800188065000900206064000500215031000300220032000400223014000800227
865000900235002001300244035001000257801001800267#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a11v86n4.htm#S#c#144#1#article#26#1#^rND^sBatista Filho^nM#^rND^sRissi
n^nA#A transição nutricional no Brasil: tendências regionais e temporais^lpt#Cad
 Saude Publica#20030000#2003#19#^s1#S181-91#20100800#a11v86n4.htm#0102-311X#Cad 
Saude Publica##
00467000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770120062000960300
00900158710000200167065000900169064000500178031000300183014000500186865000900191
002001300200#v86n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#c#145#2#art
icle#26#2#^rND^sMonteiro^nCA#A dimensão da pobreza, da desnutrição e da fome no 
Brasil^lpt#Estud Av#2#20030000#2003#17#7-20#20100800#a11v86n4.htm##
00577000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100016000960100
01700112012010300129030001900232710000200251065000900253064000500262031000200267
014000800269865000900277002001300286#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
1v86n4.htm#S#c#146#3#article#26#3#^rND^sMonteiro^nCA#^rND^sConde^nWL#^rND^sPopki
n^nBM#Is obesity replacing or adding to undernutrition: evidence from different 
social classes in Brazil^len#Public Health Nutr#2#20020000#2002#5#105-112#201008
00#a11v86n4.htm##
00687000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100017000910100
01500108010001400123010001700137011001800154012011000172030001100282065000900293
06400050030203100040030701400070031186500090031800200130032703500100034080100110
0350#v86n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#c#147#4#article#26#
4#^rND^sOng^nKK#^rND^sEmmett^nPM#^rND^sNoble^nS#^rND^sNess^nA#^rND^sDunger^nDB#A
LSPAC Study Team#Dietary energy intake at the age of 4 months predicts postnatal
 weight gain and childhood body mass index^len#Pediatrics#20060000#2006#117#e503
-8#20100800#a11v86n4.htm#0031-4005#Pediatrics##
00560000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100019000940100
01900113012004500132030001800177065000900195064000500204031000300209014000800212
865000900220002001300229035001000242801001800252#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a11v86n4.htm#S#c#148#5#article#26#5#^rND^sDamiani^nD#^rND^sCarvalho^nD
P#^rND^sOliveira^nRG#Obesidade na Infância: um grande desafio^lpt#Pediatria Mode
rna#20000000#2000#36#489-528#20100800#a11v86n4.htm#0031-3920#Pediatria moderna##
00607000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100019000960100
01700115010001600132012004900148030001800197065000900215064000500224031000300229
032000400232014000700236865000900243002001300252035001000265801001800275#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#c#149#6#article#26#6#^rND^sEscr
ivão^nMA#^rND^sOliveira^nFL#^rND^sTaddei^nJA#^rND^sLopez^nFA#Obesidade exógena n
a infância e adolescência^lpt#J Pediatr (Rio J)#20000000#2000#76#^s3#305-10#2010
0800#a11v86n4.htm#0021-7557#J Pediatr (Rio J)##
00616000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100020000960100
01900116012009900135030001800234065000900252064000500261031000300266014000700269
865000900276002001300285035001000298801001800308#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a11v86n4.htm#S#c#150#7#article#26#7#^rND^sAbrantes^nMM#^rND^sLamounier
^nJA#^rND^sColosimo^nEA#Prevalência de sobrepeso e obesidade em crianças e adole
scentes das regiões Sudeste e Nordeste^lpt#J Pediatr (Rio J)#20020000#2002#78#33
5-40#20100800#a11v86n4.htm#0021-7557#J Pediatr (Rio J)##
00451000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170028000770180067001050660
01000172062000300182065000900185064000500194865000900199002001300208#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a11v86n4.htm#S#c#151#8#article#26#8#Brasil^dMinist
ério da Saúde#Pesquisa Nacional de Demografia e Saúde da Criança e da Mulher^lpt
#Brasí­lia#DF#20080000#2008#20100800#a11v86n4.htm##
00724000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170068000770180161001450660
00700306062002600313065000900339064000500348014000400353037004700357110000900404
109001100413865000900424002001300433#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
1v86n4.htm#S#c#152#9#article#26#9#World Health Organization^dMulticentre Growth 
Reference Study Group#WHO Child Growth Standards: Length/height-for-age, weight-
for-age, weight-for-length, weight-for-height and body mass index-for-age: Metho
ds and development^len#Geneva#World Health Organization#20060000#2006#312#http:/
/www.who.int/childgrowth/publications/en#20070110#10/01/2007#20100800#a11v86n4.h
tm##
00615000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970120
15800115030002900273710000200302065000900304064000500313031000200318014000700320
865000900327002001300336#v86n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S
#c#153#10#article#26#10#^rND^sZöllner^nCC#^rND^sFisberg^nRM#Estado nutricional e
 sua relação com fatores biológicos, sociais e demográficos de crianças assistid
as em creches da Prefeitura do Município de São Paulo^lpt#Rev Bras Saude Matern 
Infant#2#20060000#2006#6#319-28#20100800#a11v86n4.htm##
00590000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100019000940100
01900113012010400132030002900236710000200265065000900267064000500276031000200281
014000700283865000900290002001300299#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
1v86n4.htm#S#c#154#11#article#26#11#^rND^sTuma^nRC#^rND^sda Costa^nTH#^rND^sSchi
mitz^nBA#Avaliação antropométrica e dietética de pré-escolares em três creches d
e Brasília, Distrito Federal^lpt#Rev Bras Saude Matern Infant#2#20050000#2005#5#
419-28#20100800#a11v86n4.htm##
00682000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100020000980100
01600118010001900134012009200153030002600245065000900271064000500280031000300285
014000700288865000900295002001300304035001000317801005300327#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a11v86n4.htm#S#c#155#12#article#26#12#^rND^sOliveira^nAM#^
rND^sCerqueira^nEM#^rND^sSouza^nJS#^rND^sOliveira^nAC#Sobrepeso e obesidade infa
ntil: fatores biológicos e ambientais em Feira de Santana, BA^lpt#Arq Bras Endoc
rinol Metab#20030000#2003#47#144-50#20100800#a11v86n4.htm#0004-2730#Arquivos Bra
sileiros de Endocrinologia & Metabologia##
00597000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100016000950100
01600111012009000127030001800217065000900235064000500244031000300249014000500252
865000900257002001300266035001000279801001800289#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a11v86n4.htm#S#c#156#13#article#26#13#^rND^sSimon^nVG#^rND^sSouza^nJM#
^rND^sSouza^nSB#Aleitamento materno, alimentação complementar, sobrepeso e obesi
dade em pré-escolares^lpt#Rev Saude Publica#20090000#2009#43#60-9#20100800#a11v8
6n4.htm#0034-8910#Rev Saude Publica##
00654000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100023001010100
02200124012012600146030001800272065000900290064000500299031000300304014000700307
865000900314002001300323035001000336801001800346#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a11v86n4.htm#S#c#157#14#article#26#14#^rND^sde Oliveira^nAM#^rND^sCerq
ueira Ede^nM#^rND^sde Oliveira^nAC#Prevalência de sobrepeso e obesidade infantil
 na cidade de Feira de Santana-BA: detecção na família x diagnóstico clínico^lpt
#J Pediatr (Rio J)#20030000#2003#79#325-28#20100800#a11v86n4.htm#0021-7557#J Ped
iatr (Rio J)##
00565000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01500113010001800128012007400146030000900220710000200229065000900231064000500240
031000300245014000500248865000900253002001300262#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a11v86n4.htm#S#c#158#15#article#26#15#^rND^sCorso^nAC#^rND^sBotelho^nL
J#^rND^sZeni^nLA#^rND^sMoreira^nEA#Sobrepeso em crianças menores de 6 anos de id
ade em Florianópolis, SC^lpt#Rev Nutr#2#20030000#2003#16#21-8#20100800#a11v86n4.
htm##
00556000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970120
06800116030001800184065000900202064000500211031000300216014000900219865000900228
002001300237035001000250801001800260#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
1v86n4.htm#S#c#159#16#article#26#16#^rND^sMartins^nEB#^rND^sCarvalho^nMS#Associa
ção entre peso ao nascer e o excesso de peso na infância^lpt#Cad Saude Publica#2
0060000#2006#22#2281-300#20100800#a11v86n4.htm#0102-311X#Cad Saude Publica##
00671000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100017001010100
01600118010001600134010002000150010001600170012006600186030001800252065000900270
06400050027903100030028401400080028786500090029500200130030403500100031780100180
0327#v86n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#c#160#17#article#26
#17#^rND^sDrachler Mde^nL#^rND^sMacluf^nSP#^rND^sLeite^nJC#^rND^sAerts^nDR#^rND^
sGiugliani^nER#^rND^sHorta^nBL#Fatores de risco para sobrepeso em crianÃ§as no S
ul do Brasil^lpt#Cad Saude Publica#20030000#2003#19#1073-81#20100800#a11v86n4.ht
m#0102-311X#Cad Saude Publica##
00646000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100020000970100
01800117012013000135030001800265065000900283064000500292031000300297014000600300
865000900306002001300315035001000328801001800338#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a11v86n4.htm#S#c#161#18#article#26#18#^rND^sFisberg^nRM#^rND^sMarchion
i^nDM#^rND^sCardoso^nMR#Estado nutricional e fatores associados ao déficit de cr
escimento de crianças freqüentadoras de creches públicas de São Paulo^lpt#Cad Sa
ude Publica#20040000#2004#20#812-7#20100800#a11v86n4.htm#0102-311X#Cad Saude Pub
lica##
00551000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100016000960120
07100112030001800183065000900201064000500210031000300215014000500218865000900223
002001300232035001000245801001800255#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
1v86n4.htm#S#c#162#19#article#26#19#^rND^sBalaban^nG#^rND^sSilva^nGA#Efeito prot
etor do aleitamento materno contra a obesidade infantil^lpt#J Pediatr (Rio J)#20
040000#2004#80#7-16#20100800#a11v86n4.htm#0021-7557#J Pediatr (Rio J)##
00574000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160016000790160014000950160
01900109016001800128018009300146062002600239066000700265065000900272064000500281
865000900286002001300295#v86n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S
#c#163#20#article#26#20#^rND^sHorta^nBL#^rND^sBahl^nR#^rND^sMartines^nJC#^rND^sV
ictora^nCG#Evidence on the long-term effects of breastfeeding: systematic review
s and meta-analyses^len#World Health Organization#Geneva#20070000#2007#20100800#
a11v86n4.htm##
00595000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970100
02100115012008800136030001300224065000900237064000500246031000300251014000600254
865000900260002001300269035001000282801001300292#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a11v86n4.htm#S#c#164#21#article#26#21#^rND^sNielsen^nGA#^rND^sThomsen^
nBL#^rND^sMichaelsen^nKF#Influence of breastfeeding and complementary food on gr
owth between 5 and 10 months^len#Acta Pediatr#19980000#1998#87#911-7#20100800#a1
1v86n4.htm#0001-6640#Acta Pediatr##
00684000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100017000930100
01600110010001800126010001600144010001600160012009900176030001300275065000900288
06400050029703100030030201400080030586500090031300200130032203500100033580100130
0345#v86n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#c#165#22#article#26
#22#^rND^sEspo^nM#^rND^sKulmala^nT#^rND^sMaleta^nK#^rND^sCullinan^nT#^rND^sSalin
^nML#^rND^sAshorn^nP#Determinants of linear growth and predictors of severe stun
ting during infancy in rural Malawi^len#Acta Pediatr#20020000#2002#91#1364-70#20
100800#a11v86n4.htm#0001-6640#Acta Pediatr##
00751000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
01900115010001600134010002000150010003200170810000600202012012900208030001000337
06500090034706400050035603100030036101400070036486500090037100200130038003500100
0393801001000403#v86n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#c#166#2
3#article#26#23#^rND^sMamabolo^nRL#^rND^sAlberts^nM#^rND^sMbenyane^nGX#^rND^sSte
yn^nNP#^rND^sNthangeni^nNG#^rND^sDelemarre-Van De Waal^nHA#et al#Feeding practic
es and growth of infant from birth to 12 months in the central region of the Lim
popo Province of South Africa^len#Nutrition#20040000#2004#20#327-33#20100800#a11
v86n4.htm#0029-6600#Nutrition##
00611000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01600113012010000129030001800229065000900247064000500256031000300261014000700264
865000900271002001300280035001000293801001800303#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a11v86n4.htm#S#c#167#24#article#26#24#^rND^sMarques^nRF#^rND^sLopez^nF
A#^rND^sBraga^nJA#O crescimento de crianças alimentadas com leite materno exclus
ivo nos primeiros 6 meses de vida^lpt#J Pediatr (Rio J)#20040000#2004#80#99-105#
20100800#a11v86n4.htm#0021-7557#J Pediatr (Rio J)##
00770000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100021000940100
01700115010001900132010001700151010001700168810000600185012016100191030001100352
06500090036306400050037203100040037701400080038186500090038900200130039803500100
0411801001100421#v86n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S#c#168#2
5#article#26#25#^rND^sVohr^nBR#^rND^sPoindexter^nBB#^rND^sDusick^nAM#^rND^sMcKin
ley^nLT#^rND^sWright^nLL#^rND^sLanger^nJC#et al#Beneficial effects of breast mil
k in the neonatal intensive care unit on the developmental outcome of extremely 
low birth weight infants at 18 months of age^len#Pediatrics#20060000#2006#118#e1
15-23#20100800#a11v86n4.htm#0031-4005#Pediatrics##
00555000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760110045000790120070001240300
02000194065000900214064000500223031000300228014000600231865000900237002001300246
035001000259801002000269#v86n4#V:\Scielo\serial\jped\v86n4\markup\a11v86n4.htm#S
#c#169#26#article#26#26#WHO Multicentre Growth Reference Study Group#WHO Child G
rowth Standards based on length/height, weight and age^len#Acta Paediatr Suppl#2
0060000#2006#95#76-85#20100800#a11v86n4.htm#0803-5326#Acta Paediatr Suppl##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v86n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#o#1#1#article#1
#20110126#175543#a12v86n4.htm#180##
04705000000000649000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000210011303100030013403200020013706500090013901400110014803500100015901201070
01690120113002760100030003890100032004190100036004510100033004870700082005200700
06500602083149000667085001002157085003202167085004202199085003102241085002402272
08315460229608500100384208500260385208500360387808500340391408500230394811700080
39710720003039791120009039821110011039911140009040021130011040110580020040220020
01304042#v86n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#h#2#1#article#1
#oa#pt#br1.1#1#4.0#ILUS#TAB#12#JPED030#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f3
17^l324#0021-7557#A prática do aleitamento materno nas capitais brasileiras e Di
strito Federal: situação atual e avanços^lpt#Breastfeeding practice in the Brazi
lian capital cities and the Federal District: current status and advances^len#^r
ND^1A01^nSonia I.^sVenancio#^rND^1A01^nMaria M. L.^sEscuder#^rND^1A01^nSílvia R.
 D. M.^sSaldiva#^rND^1A02^nElsa R. J.^sGiugliani#Secretaria Estadual de Saúde de
 São Paulo^iA01^1Instituto de Saúde^cSão Paulo^sSP#Universidade Federal do Rio G
rande do Sul^iA02^cPorto Alegre^sRS#^lpt^aOBJETIVOS: Apresentar os indicadores d
e aleitamento materno (AM), obtidos na II Pesquisa de Prevalência de Aleitamento
 Materno nas Capitais Brasileiras e Distrito Federal, bem como analisar sua evol
ução no período de 1999 a 2008. MÉTODOS: Pesquisa de corte transversal, envolven
do crianças menores de 1 ano de idade que participaram da segunda fase da campan
ha de multivacinação de 2008. Foram utilizadas amostras por conglomerados, com s
orteio em dois estágios. O questionário era composto por questões fechadas, incl
uindo o consumo de leite materno, outros tipos de leite e outros alimentos no di
a anterior à pesquisa. Foram analisadas as prevalências de AM na primeira hora d
e vida; aleitamento materno exclusivo (AME) em menores de 6 meses; AM em criança
s de 9 a 12 meses; e medianas do AME e AM. A variação temporal do AM foi estabel
ecida por meio da comparação das medianas do AME e AM em 1999 e 2008. RESULTADOS
: Obtiveram-se dados de 34.366 crianças. Verificou-se que 67,7% (IC95% 66,7-68,8
) mamaram na primeira hora de vida; a prevalência do AME em crianças de 0 a 6 me
ses foi de 41% (IC95% 39,7-42,4), e do AM em crianças de 9 a 12 meses foi de 58,
7% (IC95% 56,8-60,7). Houve aumento de 30,7 dias na duração mediana do AME e de 
45,7 dias na mediana do AM. CONCLUSÃO: Houve melhora significativa da situação d
o AM na última década. Porém, ainda são necessários esforços para que o Brasil a
tinja índices de AM compatíveis com as recomendações da Organização Mundial da S
aúde.#^ddecs^i1#^tm^lpt^kAleitamento materno^i1#^tm^lpt^kaleitamento materno exc
lusivo^i1#^tm^lpt^kestudo transversal^i1#^tm^lpt^kindicadores^i1#^len^aOBJECTIVE
S: To present the breastfeeding (BF) indicators obtained in the Second Survey on
 Prevalence of Breastfeeding in the Brazilian Capitals and the Federal District 
and to analyze their evolution from 1999 to 2008. METHODS: A cross-sectional stu
dy was conducted in children younger than 1 year old who participated in the sec
ond phase of the multivaccination campaign in 2008. We used two-stage cluster sa
mpling. The questionnaire consisted of closed questions, including data on consu
mption of breast milk, other types of milk, and other foods on the day prior to 
the survey. We analyzed the prevalence of BF in the first hour of life; exclusiv
e BF in children younger than 6 months; BF in children aged 9 to 12 months; and 
medians of exclusive BF and BF. The time variation of BF was established by comp
aring the medians of exclusive BF and BF in 1999 and 2008. RESULTS: We obtained 
data from 34,366 children. We found that 67.7% (95%CI 66.7-68.8) of the children
 were breastfed in the first hour of life; the prevalence of exclusive BF in chi
ldren aged 0 to 6 months was 41% (95%CI 39.7-42.4), while the prevalence of BF i
n children aged 9 to 12 months was 58.7% (95%CI 56.8-60.7). There was an increas
e of 30.7 days in the median duration of exclusive BF and 45.7 days in the media
n of BF. CONCLUSION: There was a significant improvement in the breastfeeding pr
evalence in the last decade. However, further efforts are required so that Brazi
l can reach BF rates compatible with the recommendations of the World Health Org
anization.#^ddecs^i2#^tm^len^kBreastfeeding^i2#^tm^len^kexclusive breastfeeding^
i2#^tm^len^kcross-sectional study^i2#^tm^len^kindicators^i2#vancouv#29#20091221#
21.12.2009#20100512#12.05.2010#Ministério da Saúde#a12v86n4.htm##
04789000000000649000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000210011303100030013403200020013706500090013901400110014803500100015901201210
01690120127002900100030004170100032004470100036004790100033005150700082005480700
06500630083151800695085001002213085003202223085004202255085003102297085002402328
08315740235208500100392608500260393608500360396208500340399808500230403211700080
40550720003040631120009040661110011040751140009040861130011040950580020041060020
01304126#v86n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#f#3#1#article#1
#oa#pt#br1.1#1#4.0#ILUS#TAB#12#JPED030#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f3
17^l324#0021-7557#<b>A prática do aleitamento materno nas capitais brasileiras e
 Distrito Federal</b>: <b>situação atual e avanços</b>^lpt#<b>Breastfeeding prac
tice in the Brazilian capital cities and the Federal District</b>: <b>current st
atus and advances</b>^len#^rND^1A01^nSonia I.^sVenancio#^rND^1A01^nMaria M. L.^s
Escuder#^rND^1A01^nSílvia R. D. M.^sSaldiva#^rND^1A02^nElsa R. J.^sGiugliani#Sec
retaria Estadual de Saúde de São Paulo^iA01^1Instituto de Saúde^cSão Paulo^sSP#U
niversidade Federal do Rio Grande do Sul^iA02^cPorto Alegre^sRS#^lpt^a<b>OBJETIV
OS: </b>Apresentar os indicadores de aleitamento materno (AM), obtidos na II Pes
quisa de Prevalência de Aleitamento Materno nas Capitais Brasileiras e Distrito 
Federal, bem como analisar sua evolução no período de 1999 a 2008. <b>MÉTODOS: <
/b>Pesquisa de corte transversal, envolvendo crianças menores de 1 ano de idade 
que participaram da segunda fase da campanha de multivacinação de 2008. Foram ut
ilizadas amostras por conglomerados, com sorteio em dois estágios. O questionári
o era composto por questões fechadas, incluindo o consumo de leite materno, outr
os tipos de leite e outros alimentos no dia anterior à pesquisa. Foram analisada
s as prevalências de AM na primeira hora de vida; aleitamento materno exclusivo 
(AME) em menores de 6 meses; AM em crianças de 9 a 12 meses; e medianas do AME e
 AM. A variação temporal do AM foi estabelecida por meio da comparação das media
nas do AME e AM em 1999 e 2008. <b>RESULTADOS: </b>Obtiveram-se dados de 34.366 
crianças. Verificou-se que 67,7% (IC95% 66,7-68,8) mamaram na primeira hora de v
ida; a prevalência do AME em crianças de 0 a 6 meses foi de 41% (IC95% 39,7-42,4
), e do AM em crianças de 9 a 12 meses foi de 58,7% (IC95% 56,8-60,7). Houve aum
ento de 30,7 dias na duração mediana do AME e de 45,7 dias na mediana do AM. <b>
CONCLUSÃO: </b>Houve melhora significativa da situação do AM na última década. P
orém, ainda são necessários esforços para que o Brasil atinja índices de AM comp
atíveis com as recomendações da Organização Mundial da Saúde.#^ddecs^i1#^tm^lpt^
kAleitamento materno^i1#^tm^lpt^kaleitamento materno exclusivo^i1#^tm^lpt^kestud
o transversal^i1#^tm^lpt^kindicadores^i1#^len^a<b>OBJECTIVES: </b>To present the
 breastfeeding (BF) indicators obtained in the Second Survey on Prevalence of Br
eastfeeding in the Brazilian Capitals and the Federal District and to analyze th
eir evolution from 1999 to 2008. <b>METHODS: </b>A cross-sectional study was con
ducted in children younger than 1 year old who participated in the second phase 
of the multivaccination campaign in 2008. We used two-stage cluster sampling. Th
e questionnaire consisted of closed questions, including data on consumption of 
breast milk, other types of milk, and other foods on the day prior to the survey
. We analyzed the prevalence of BF in the first hour of life; exclusive BF in ch
ildren younger than 6 months; BF in children aged 9 to 12 months; and medians of
 exclusive BF and BF. The time variation of BF was established by comparing the 
medians of exclusive BF and BF in 1999 and 2008. <b>RESULTS: </b>We obtained dat
a from 34,366 children. We found that 67.7% (95%CI 66.7-68.8) of the children we
re breastfed in the first hour of life; the prevalence of exclusive BF in childr
en aged 0 to 6 months was 41% (95%CI 39.7-42.4), while the prevalence of BF in c
hildren aged 9 to 12 months was 58.7% (95%CI 56.8-60.7). There was an increase o
f 30.7 days in the median duration of exclusive BF and 45.7 days in the median o
f BF. <b>CONCLUSION: </b>There was a significant improvement in the breastfeedin
g prevalence in the last decade. However, further efforts are required so that B
razil can reach BF rates compatible with the recommendations of the World Health
 Organization.#^ddecs^i2#^tm^len^kBreastfeeding^i2#^tm^len^kexclusive breastfeed
ing^i2#^tm^len^kcross-sectional study^i2#^tm^len^kindicators^i2#vancouv#29#20091
221#21.12.2009#20100512#12.05.2010#Ministério da Saúde#a12v86n4.htm##
04932000000000673000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000300117049000800120
15800030012803000210013103100030015203200020015506500090015701400110016603500100
01770120107001870120113002940100029004070100031004360100035004670100032005020700
08400534070006700618083154400685085001002229085003202239085004202271085003102313
08500240234408315880236808500100395608500260396608500360399208500340402808500230
40621170008040850720003040931120009040961110011041051140009041161130011041250580
02004136002001304156008008904169#v86n4#V:\Scielo\serial\jped\v86n4\markup\a12v86
n4.htm#S#l#4#1#article#1#^mjul./ago.^a2010#oa#pt#br1.1#1#4.0#ilus#tab#12#JPED030
#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f317^l324#0021-7557#A prática do aleitam
ento materno nas capitais brasileiras e Distrito Federal: situação atual e avanç
os^lpt#Breastfeeding practice in the Brazilian capital cities and the Federal Di
strict: current status and advances^len#^rND^1A01^nSonia I^sVenancio#^rND^1A01^n
Maria M. L^sEscuder#^rND^1A01^nSílvia R. D. M^sSaldiva#^rND^1A02^nElsa R. J^sGiu
gliani#^iA01^1Secretaria Estadual de Saúde de São Paulo^2Instituto de Saúde^cSão
 Paulo^sSP#^iA02^1Universidade Federal do Rio Grande do Sul^cPorto Alegre^sRS#^l
pt^aOBJETIVOS: Apresentar os indicadores de aleitamento materno (AM), obtidos na
 II Pesquisa de Prevalência de Aleitamento Materno nas Capitais Brasileiras e Di
strito Federal, bem como analisar sua evolução no período de 1999 a 2008. MÉTODO
S: Pesquisa de corte transversal, envolvendo crianças menores de 1 ano de idade 
que participaram da segunda fase da campanha de multivacinação de 2008. Foram ut
ilizadas amostras por conglomerados, com sorteio em dois estágios. O questionári
o era composto por questões fechadas, incluindo o consumo de leite materno, outr
os tipos de leite e outros alimentos no dia anterior à pesquisa. Foram analisada
s as prevalências de AM na primeira hora de vida; aleitamento materno exclusivo 
(AME) em menores de 6 meses; AM em crianças de 9 a 12 meses; e medianas do AME e
 AM. A variação temporal do AM foi estabelecida por meio da comparação das media
nas do AME e AM em 1999 e 2008. RESULTADOS: Obtiveram-se dados de 34.366 criança
s. Verificou-se que 67,7 por cento (IC95 por cento 66,7-68,8) mamaram na primeir
a hora de vida; a prevalência do AME em crianças de 0 a 6 meses foi de 41 por ce
nto (IC95 por cento 39,7-42,4), e do AM em crianças de 9 a 12 meses foi de 58,7 
por cento (IC95 por cento 56,8-60,7). Houve aumento de 30,7 dias na duração medi
ana do AME e de 45,7 dias na mediana do AM. CONCLUSÃO: Houve melhora significati
va da situação do AM na última década. Porém, ainda são necessários esforços par
a que o Brasil atinja índices de AM compatíveis com as recomendações da Organiza
ção Mundial da Saúde.#^ddecs^i1#^tm^lpt^kAleitamento materno^i1#^tm^lpt^kaleitam
ento materno exclusivo^i1#^tm^lpt^kestudo transversal^i1#^tm^lpt^kindicadores^i1
#^len^aOBJECTIVES: To present the breastfeeding (BF) indicators obtained in the 
Second Survey on Prevalence of Breastfeeding in the Brazilian Capitals and the F
ederal District and to analyze their evolution from 1999 to 2008. METHODS: A cro
ss-sectional study was conducted in children younger than 1 year old who partici
pated in the second phase of the multivaccination campaign in 2008. We used two-
stage cluster sampling. The questionnaire consisted of closed questions, includi
ng data on consumption of breast milk, other types of milk, and other foods on t
he day prior to the survey. We analyzed the prevalence of BF in the first hour o
f life; exclusive BF in children younger than 6 months; BF in children aged 9 to
 12 months; and medians of exclusive BF and BF. The time variation of BF was est
ablished by comparing the medians of exclusive BF and BF in 1999 and 2008. RESUL
TS: We obtained data from 34,366 children. We found that 67.7 percent (95 percen
tCI 66.7-68.8) of the children were breastfed in the first hour of life; the pre
valence of exclusive BF in children aged 0 to 6 months was 41 percent (95 percen
tCI 39.7-42.4), while the prevalence of BF in children aged 9 to 12 months was 5
8.7 percent (95 percentCI 56.8-60.7). There was an increase of 30.7 days in the 
median duration of exclusive BF and 45.7 days in the median of BF. CONCLUSION: T
here was a significant improvement in the breastfeeding prevalence in the last d
ecade. However, further efforts are required so that Brazil can reach BF rates c
ompatible with the recommendations of the World Health Organization.#^ddecs^i2#^
tm^len^kBreastfeeding^i2#^tm^len^kexclusive breastfeeding^i2#^tm^len^kcross-sect
ional study^i2#^tm^len^kindicators^i2#vancouv#29#20091221#21.12.2009#20100512#12
.05.2010#Ministério da Saúde#a12v86n4.htm#Internet^ihttp://www.scielo.br/scielo.
php?script=sci_arttext&pid=S0021-75572010000400012##
00322000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704008900074002001300163#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#5#1#article#147#<p align="right"><fon
t size="2" face="Verdana"><b>ARTIGO ORIGINAL</b></font></p>     ^cY#a12v86n4.htm
##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#6#2#article#147#<p>&nbsp;</p>     ^cY
#a12v86n4.htm##
00426000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704019300074002001300267#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#7#3#article#147#<p><font size="4" fac
e="Verdana"><b>A pr&aacute;tica do aleitamento materno nas    capitais brasileir
as e Distrito Federal: situa&ccedil;&atilde;o atual e avan&ccedil;os</b></font><
/p>     ^cY#a12v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#8#4#article#147#<p>&nbsp;</p>     ^cY
#a12v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#9#5#article#147#<p>&nbsp;</p>     ^cY
#a12v86n4.htm##
00440000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704020600075002001300281#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#10#6#article#147#<p> <font size="2" f
ace="Verdana"><b>Sonia I. Venancio<sup>I</sup>; Maria M. L. Escuder<sup>II</sup>
;  S&iacute;lvia R. D. M. Saldiva<sup>III</sup>; Elsa R. J. Giugliani<sup>IV</su
p></b></font></p>     ^cY#a12v86n4.htm##
00429000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704019500075002001300270#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#11#7#article#147#<p><font size="2" fa
ce="Verdana"><sup>I</sup>Doutora, Pesquisadora, Instituto    de Sa&uacute;de, Se
cretaria Estadual de Sa&uacute;de de S&atilde;o Paulo (SES-SP),    S&atilde;o Pa
ulo, SP    ^cY#a12v86n4.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704010800075002001300183#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#12#8#article#147#<br>   <sup>II</sup>
Mestre, Pesquisadora, Instituto    de Sa&uacute;de, SES-SP, S&atilde;o Paulo, SP
    ^cY#a12v86n4.htm##
00344000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704011000075002001300185#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#13#9#article#147#<br>   <sup>III</sup
>Doutora, Pesquisadora, Instituto    de Sa&uacute;de, SES-SP, S&atilde;o Paulo, 
SP    ^cY#a12v86n4.htm##
00376000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014100076002001300217#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#14#10#article#147#<br>   <sup>IV</sup
>Doutora, Professora associada,    Universidade Federal do Rio Grande do Sul (UF
RGS), Porto Alegre, RS</font></p>     ^cY#a12v86n4.htm##
00368000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013300076002001300209#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#15#11#article#147#<p><font size="2" f
ace="Verdana"><a name="topo" id="topo"></a><a href="#correspondence">Correspond&
ecirc;ncia</a></font></p>     ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#16#12#article#147#<p>&nbsp;</p>     ^
cY#a12v86n4.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#17#13#article#147#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a12v86n4.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006600076002001300142#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#18#14#article#147#<p><font size="2" f
ace="Verdana"><b>RESUMO</b></font></p>     ^cY#a12v86n4.htm##
00549000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031400076002001300390#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#19#15#article#147#<p><font size="2" f
ace="Verdana"><b>OBJETIVOS: </b> Apresentar os indicadores    de aleitamento mat
erno (AM), obtidos na II Pesquisa de Preval&ecirc;ncia de    Aleitamento Materno
 nas Capitais Brasileiras e Distrito Federal, bem como analisar    sua evolu&cce
dil;&atilde;o no per&iacute;odo de 1999 a 2008.    ^cY#a12v86n4.htm##
01059000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082400076002001300900#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#20#16#article#147#<br>   <b>M&Eacute;
TODOS: </b> Pesquisa de corte transversal, envolvendo crian&ccedil;as    menores
 de 1 ano de idade que participaram da segunda fase da campanha de multivacina&c
cedil;&atilde;o    de 2008. Foram utilizadas amostras por conglomerados, com sor
teio em dois est&aacute;gios.    O question&aacute;rio era composto por quest&ot
ilde;es fechadas, incluindo o    consumo de leite materno, outros tipos de leite
 e outros alimentos no dia anterior    &agrave; pesquisa. Foram analisadas as pr
eval&ecirc;ncias de AM na primeira    hora de vida; aleitamento materno exclusiv
o (AME) em menores de 6 meses; AM    em crian&ccedil;as de 9 a 12 meses; e media
nas do AME e AM. A varia&ccedil;&atilde;o    temporal do AM foi estabelecida por
 meio da compara&ccedil;&atilde;o das medianas    do AME e AM em 1999 e 2008.   
 ^cY#a12v86n4.htm##
00670000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043500076002001300511#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#21#17#article#147#<br>   <b>RESULTADO
S: </b>Obtiveram-se dados de 34.366 crian&ccedil;as. Verificou-se    que 67,7% (
IC95% 66,7-68,8) mamaram na primeira hora de vida; a preval&ecirc;ncia    do AME
 em crian&ccedil;as de 0 a 6 meses foi de 41% (IC95% 39,7-42,4), e do    AM em c
rian&ccedil;as de 9 a 12 meses foi de 58,7% (IC95% 56,8-60,7). Houve    aumento 
de 30,7 dias na dura&ccedil;&atilde;o mediana do AME e de 45,7 dias    na median
a do AM.    ^cY#a12v86n4.htm##
00608000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037300076002001300449#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#22#18#article#147#<br>   <b>CONCLUS&A
tilde;O: </b> Houve melhora significativa da situa&ccedil;&atilde;o    do AM na 
&uacute;ltima d&eacute;cada. Por&eacute;m, ainda s&atilde;o necess&aacute;rios  
  esfor&ccedil;os para que o Brasil atinja &iacute;ndices de AM compat&iacute;ve
is    com as recomenda&ccedil;&otilde;es da Organiza&ccedil;&atilde;o Mundial da
 Sa&uacute;de.</font></p>     ^cY#a12v86n4.htm##
00421000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018600076002001300262#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#23#19#article#147#<p><font size="2" f
ace="Verdana"><b>Palavras-chave: </b> Aleitamento materno,    aleitamento matern
o exclusivo, estudo transversal, indicadores.</font></p> <hr size="1" noshade>  
   ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#24#20#article#147#<p>&nbsp;</p>     ^
cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#25#21#article#147#<p>&nbsp;</p>     ^
cY#a12v86n4.htm##
00319000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008400076002001300160#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#26#22#article#147#<p><font size="3" f
ace="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#a12v86n4.htm##
00874000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063900076002001300715#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#27#23#article#147#<p><font face="Verd
ana" size="2">O aleitamento materno (AM) &eacute; a estrat&eacute;gia    que mai
s previne mortes infantis<SUP>1</SUP>, al&eacute;m de promover a sa&uacute;de   
 f&iacute;sica, mental e ps&iacute;quica da crian&ccedil;a. Estima-se que a amam
enta&ccedil;&atilde;o    tem o potencial de reduzir em 13% as mortes em crian&cc
edil;as menores de 5    anos<SUP>1</SUP>, assim como em 19 a 22% as mortes neona
tais, se praticada na    primeira hora de vida<SUP>2,3</SUP>. A promo&ccedil;&at
ilde;o do AM, portanto,    deve ser inclu&iacute;da entre as a&ccedil;&otilde;es
 priorit&aacute;rias de    sa&uacute;de.</font></p>     ^cY#a12v86n4.htm##
01062000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082700076002001300903#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#28#24#article#147#<p><font face="Verd
ana" size="2">O Brasil vem investindo no incentivo ao AM desde    1981, com a in
stitui&ccedil;&atilde;o do Programa Nacional de Incentivo ao Aleitamento    Mate
rno, considerado modelo pela diversidade de a&ccedil;&otilde;es<SUP>4</SUP>.    
Gra&ccedil;as a pesquisas nacionais, &eacute; poss&iacute;vel constatar que    o
s &iacute;ndices de AM no Brasil v&ecirc;m aumentando gradativamente. Venancio  
  &amp; Monteiro<SUP>5</SUP> verificaram aumento da dura&ccedil;&atilde;o da ama
menta&ccedil;&atilde;o    entre 1974 e 1989, passando de 2,5 para 5,5 meses<SUP>
5</SUP>. Dados das Pesquisas    Nacionais sobre Demografia e Sa&uacute;de (PNDS)
 confirmaram essa tend&ecirc;ncia,    identificando aumento na mediana do AM de 
7 meses, em 1996<SUP>6</SUP>, para    14 meses, em 2006<SUP>7</SUP>.</font></p> 
    ^cY#a12v86n4.htm##
00685000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704045000076002001300526#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#29#25#article#147#<p><font face="Verd
ana" size="2">A primeira informa&ccedil;&atilde;o sobre a situa&ccedil;&atilde;o
    do aleitamento materno exclusivo (AME) no Brasil &eacute; proveniente de pes
quisa    realizada em 1986, na qual se evidenciou que apenas 3,6% das crian&cced
il;as    entre 0 e 4 meses eram amamentadas de forma exclusiva<SUP>8</SUP>. Dado
s de    2006 mostraram preval&ecirc;ncia do AME de 38,6% em menores de 6 meses<S
UP>7</SUP>.</font></p>     ^cY#a12v86n4.htm##
00641000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040600076002001300482#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#30#26#article#147#<p><font face="Verd
ana" size="2">Em 1999, realizou-se o primeiro inqu&eacute;rito    sobre preval&e
circ;ncia de AM nas capitais brasileiras e Distrito Federal (DF),    durante cam
panha nacional de vacina&ccedil;&atilde;o. Verificou-se uma preval&ecirc;ncia   
 de 35,6% de AME em menores de 4 meses e dura&ccedil;&atilde;o mediana da amamen
ta&ccedil;&atilde;o    de 10 meses<SUP>9</SUP>.</font></p>     ^cY#a12v86n4.htm#
#
00987000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075200076002001300828#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#31#27#article#147#<p><font face="Verd
ana" size="2">Em 2008, sob os ausp&iacute;cios do Minist&eacute;rio    da Sa&uac
ute;de, realizou-se a II Pesquisa Nacional de Preval&ecirc;ncia de    AM (II PPA
M)<SUP>10</SUP>, utilizando a mesma metodologia do inqu&eacute;rito    de 1999. 
A justificativa para a realiza&ccedil;&atilde;o da pesquisa foi a necessidade,  
  por parte dos gestores, de uma an&aacute;lise da evolu&ccedil;&atilde;o da sit
ua&ccedil;&atilde;o    do AM, tendo em vista as diversas a&ccedil;&otilde;es des
envolvidas no &acirc;mbito    da pol&iacute;tica nacional. O presente artigo apr
esenta os dados relativos    aos principais indicadores de AM nas capitais e DF 
e analisa sua evolu&ccedil;&atilde;o    no per&iacute;odo de 1999 a 2008.</font>
</p>     ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#32#28#article#147#<p>&nbsp;</p>     ^
cY#a12v86n4.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007400076002001300150#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#33#29#article#147#<p><font size="3" f
ace="Verdana"><b>M&eacute;todos</b></font></p>     ^cY#a12v86n4.htm##
00498000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026300076002001300339#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#34#30#article#147#<p><font face="Verd
ana" size="2">Trata-se de uma pesquisa de corte transversal,    envolvendo crian
&ccedil;as menores de 1 ano que compareceram &agrave; campanha    de multivacina
&ccedil;&atilde;o de 2008 em todas as capitais brasileiras e DF.</font></p>     
^cY#a12v86n4.htm##
00711000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047600076002001300552#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#35#31#article#147#<p><font face="Verd
ana" size="2">A capacita&ccedil;&atilde;o das Secretarias de    Sa&uacute;de dos
 estados e capitais foi feita em tr&ecirc;s oficinas de 16 horas,    que contemp
laram a prepara&ccedil;&atilde;o dos profissionais para a realiza&ccedil;&atilde
;o    de todas as etapas da pesquisa. Os participantes receberam manuais de apoi
o    contendo orienta&ccedil;&otilde;es para os coordenadores municipais, superv
isores    de campo e entrevistadores.</font></p>     ^cY#a12v86n4.htm##
01391000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704115600076002001301232#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#36#32#article#147#<p><font face="Verd
ana" size="2">O inqu&eacute;rito foi realizado adotando-se    amostras por congl
omerados, com sorteio em dois est&aacute;gios e probabilidade    proporcional ao
 tamanho dos conglomerados. No primeiro est&aacute;gio, foram    sorteados os po
stos de vacina&ccedil;&atilde;o e, no segundo, as crian&ccedil;as    em cada pos
to<SUP>11</SUP>. As amostras foram planejadas com base nas informa&ccedil;&otild
e;es    fornecidas pelos estados: n&uacute;mero de postos de vacina&ccedil;&atil
de;o    em cada capital e n&uacute;mero de crian&ccedil;as menores de 1 ano vaci
nadas    em cada posto em 2007. O tamanho amostral levou em considera&ccedil;&at
ilde;o    a preval&ecirc;ncia de AME nas capitais e DF em 1999, com acr&eacute;s
cimo de    2 a 10%, prevendo-se um aumento da preval&ecirc;ncia. Para compensar 
as perdas    de precis&atilde;o inerentes &agrave; amostra por conglomerados, ac
rescentou-se    o efeito do desenho, multiplicando-se por 1,5 a estimativa inici
al e, ainda,    uma taxa de n&atilde;o resposta de 5 a 10%. O tamanho da amostra
 desejado para    estimar o AME em menores de 6 meses foi multiplicado por 2.</f
ont></p>     ^cY#a12v86n4.htm##
01356000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704112100076002001301197#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#37#33#article#147#<p><font face="Verd
ana" size="2">O question&aacute;rio continha quest&otilde;es    fechadas sobre o
 consumo de leite materno, outros tipos de leite e outros alimentos,    incluind
o &aacute;gua, ch&aacute;s e outros l&iacute;quidos, no dia anterior    &agrave;
 pesquisa. A utiliza&ccedil;&atilde;o de dados atuais (<i>current status</i>),  
  recomendada pela Organiza&ccedil;&atilde;o Mundial da Sa&uacute;de (OMS)<SUP>1
2</SUP>,    tem por objetivo minimizar poss&iacute;veis vieses decorrentes da me
m&oacute;ria    do informante, o que &eacute; particularmente adequado para a ca
racteriza&ccedil;&atilde;o    do AME. Esse instrumento foi aplicado por entrevis
tadores previamente capacitados    a todos os acompanhantes de crian&ccedil;as m
enores de 1 ano durante a segunda    etapa da campanha de multivacina&ccedil;&at
ilde;o de 2008. As entrevistas ocorreram    durante o dia inteiro da campanha, e
 nos munic&iacute;pios onde as atividades    de vacina&ccedil;&atilde;o antecede
ram ou ultrapassaram a data prevista, orientou-se    que a coleta de dados acomp
anhasse todo o per&iacute;odo da campanha.</font></p>     ^cY#a12v86n4.htm##
00550000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031500076002001300391#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#38#34#article#147#<p><font face="Verd
ana" size="2">A digita&ccedil;&atilde;o foi de responsabilidade    dos munic&iac
ute;pios, que alimentaram um aplicativo on-line desenvolvido para    esse fim. O
s bancos de dados das capitais e DF foram posteriormente exportados    para um b
anco de dados no programa SPSS 16.0.</font></p>     ^cY#a12v86n4.htm##
01010000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077500076002001300851#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#39#35#article#147#<p><font face="Verd
ana" size="2">Foram utilizados procedimentos espec&iacute;ficos    para an&aacut
e;lise de inqu&eacute;ritos com amostragem probabil&iacute;stica    complexa. As
 estimativas de preval&ecirc;ncia consideram o erro padr&atilde;o,    determinad
o pelo delineamento amostral, e seus respectivos intervalos de confian&ccedil;a 
   de 95% (IC95%). Devido &agrave;s diferen&ccedil;as populacionais entre as cap
itais    envolvidas, cada plano representou uma fra&ccedil;&atilde;o amostral di
ferente,    representada pelo tamanho estimado da amostra sobre o n&uacute;mero 
de crian&ccedil;as    a serem vacinadas. O inverso dessa fra&ccedil;&atilde;o fo
i aplicado para o    c&aacute;lculo das preval&ecirc;ncias regionais e do conjun
to das capitais.</font></p>     ^cY#a12v86n4.htm##
01009000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077400076002001300850#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#40#36#article#147#<p><font face="Verd
ana" size="2">Foram analisados os seguintes indicadores propostos    pela OMS<SU
P>12</SUP>: AM na primeira hora de vida; AME em menores de 6 meses;    AM contin
uado; e dura&ccedil;&atilde;o mediana do AME e do AM. Foram consideradas    em A
ME as crian&ccedil;as que haviam recebido somente leite materno sem quaisquer   
 outros alimentos s&oacute;lidos ou l&iacute;quidos, inclusive &aacute;gua e    
ch&aacute;; e, em AM, as crian&ccedil;as que haviam recebido leite materno,    i
ndependentemente de outros alimentos. As medianas do AME e AM foram obtidas    m
ediante an&aacute;lise de logito, na qual s&atilde;o estimadas, por modelagem   
 estat&iacute;stica, as probabilidades do evento em estudo em fun&ccedil;&atilde
;o    da idade.</font></p>     ^cY#a12v86n4.htm##
00874000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063900076002001300715#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#41#37#article#147#<p><font face="Verd
ana" size="2">A varia&ccedil;&atilde;o temporal do AM foi estabelecida    por me
io da compara&ccedil;&atilde;o das medianas do AME e AM, tomando-se por    base 
os dados publicados da pesquisa de 1999<SUP>9</SUP> e os dados de 2008.    Foram
 calculados a diferen&ccedil;a do indicador, em dias, e o grau de evolu&ccedil;&
atilde;o    do mesmo, em porcentagem, obtido pelo c&aacute;lculo: &#091;(mediana
 2008 - mediana    1999)/mediana 1999 x 100&#093;. Considerou-se que houve mudan
&ccedil;a estatisticamente    significativa quando n&atilde;o houve sobreposi&cc
edil;&atilde;o dos respectivos    IC95%.</font></p>     ^cY#a12v86n4.htm##
00601000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036600076002001300442#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#42#38#article#147#<p><font face="Verd
ana" size="2">Testou-se, ainda, a correla&ccedil;&atilde;o    entre a situa&cced
il;&atilde;o da amamenta&ccedil;&atilde;o em 1999 e o grau    de evolu&ccedil;&a
tilde;o das medianas do AME e AM. Os resultados s&atilde;o    apresentados em gr
&aacute;ficos de correla&ccedil;&atilde;o, constru&iacute;dos    no programa SPS
S 16.0.</font></p>     ^cY#a12v86n4.htm##
00525000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029000076002001300366#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#43#39#article#147#<p><font face="Verd
ana" size="2">O protocolo de pesquisa foi aprovado pelo Comit&ecirc;    de &Eacu
te;tica do Instituto de Sa&uacute;de (Protocolo 001/2008, de 06/05/2008),    ap&
oacute;s consulta &agrave; Comiss&atilde;o Nacional de &Eacute;tica em Pesquisa 
   (CONEP).</font></p>     ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#44#40#article#147#<p>&nbsp;</p>     ^
cY#a12v86n4.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007000076002001300146#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#45#41#article#147#<p><font size="3" f
ace="Verdana"><b>Resultados</b></font></p>     ^cY#a12v86n4.htm##
00917000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068200076002001300758#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#46#42#article#147#<p><font face="Verd
ana" size="2">Foram inclu&iacute;das 34.366 crian&ccedil;as    no estudo. Verifi
cou-se leve predom&iacute;nio do sexo masculino (50,4%) e maior    concentra&cce
dil;&atilde;o de crian&ccedil;as at&eacute; os 6 meses de idade    (55,4%). A ma
ioria das m&atilde;es encontrava-se na faixa et&aacute;ria de 20    a 35 anos (7
2,2%), e o percentual de m&atilde;es com idade inferior a 20 anos    foi 17,2%; 
86,2% tinham menos de 12 anos de escolaridade e 24,9% menos de 8    anos de estu
do; 66,2% n&atilde;o estavam trabalhando fora de casa, 11,9% estavam    em licen
&ccedil;a-maternidade e 21,9% estavam trabalhando fora no momento da    entrevis
ta.</font></p>     ^cY#a12v86n4.htm##
00479000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024400076002001300320#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#47#43#article#147#<p><font face="Verd
ana" size="2">A <a href=/img/revistas/jped/v86n4/4a12t1.gif>Tabela    1</a> apre
senta os indicadores "AM na primeira hora de vida", "AME em menores    de 6 mese
s" e "AM em crian&ccedil;as de 9 a 12 meses".</font></p>     ^cY#a12v86n4.htm##
00958000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072300076002001300799#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#48#44#article#147#<p><font face="Verd
ana" size="2">Verificou-se que 67,7% das crian&ccedil;as mamaram    na primeira 
hora de vida; as Regi&otilde;es Norte, Centro-Oeste e Sul apresentaram    os mel
hores resultados (72,9, 72,0 e 71,8%, respectivamente), e na Regi&atilde;o    Su
deste, verificou-se o menor percentual de crian&ccedil;as nessa condi&ccedil;&at
ilde;o    (63,5%). Na compara&ccedil;&atilde;o entre as capitais, verificou-se m
elhor    situa&ccedil;&atilde;o em S&atilde;o Lu&iacute;s (83,5%), e pior em Sal
vador    (58,5%), chamando a aten&ccedil;&atilde;o o fato de que a maioria das c
apitais    (17) apresentou valores superiores &agrave; m&eacute;dia referente ao
 conjunto    das crian&ccedil;as analisadas.</font></p>     ^cY#a12v86n4.htm##
01042000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704080700076002001300883#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#49#45#article#147#<p><font face="Verd
ana" size="2">A preval&ecirc;ncia do AME em menores de 6 meses    foi de 41% no 
conjunto das capitais e DF; a Regi&atilde;o Norte foi a que apresentou    maior 
preval&ecirc;ncia (45,9%), seguida da Centro-Oeste (45,0%), Sul (43,9%)    e Sud
este (39,4%), com a Regi&atilde;o Nordeste apresentando a pior situa&ccedil;&ati
lde;o    (37,0%). Em rela&ccedil;&atilde;o &agrave;s capitais, Bel&eacute;m se d
estaca    com a maior preval&ecirc;ncia (56,1%), seguida de Florian&oacute;polis
 (52,4%),    Campo Grande (50,1%) e Distrito Federal (50,0%). Por outro lado, a 
menor preval&ecirc;ncia    foi identificada em Cuiab&aacute; (27,1%). Vale ressa
ltar que a maioria das    capitais (17) apresentou valores abaixo da m&eacute;di
a do conjunto das crian&ccedil;as    analisadas.</font></p>     ^cY#a12v86n4.htm
##
00920000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068500076002001300761#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#50#46#article#147#<p><font face="Verd
ana" size="2">A preval&ecirc;ncia do AM em crian&ccedil;as    de 9 a 12 meses fo
i de 58,7%. A Regi&atilde;o Norte apresentou a melhor situa&ccedil;&atilde;o    
(76,9%), seguida do Centro-Oeste (64,1%), Nordeste (59,1%) e Sudeste (51,4%),   
 com a Regi&atilde;o Sul apresentando a pior situa&ccedil;&atilde;o (49,5%).    
No tocante &agrave;s capitais, Macap&aacute; e Bel&eacute;m se destacam com    a
s maiores preval&ecirc;ncias (82,8 e 79,9%, respectivamente), e Curitiba com    
a menor (48,5%). Em 15 dos 27 locais estudados, a situa&ccedil;&atilde;o foi    
melhor que a m&eacute;dia identificada para o conjunto das crian&ccedil;as anali
sadas.</font></p>     ^cY#a12v86n4.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019500076002001300271#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#51#47#article#147#<p><font face="Verd
ana" size="2">A <a href=/img/revistas/jped/v86n4/4a12t2.gif>Tabela    2</a> apre
senta os dados comparativos sobre a dura&ccedil;&atilde;o mediana    do AME.</fo
nt></p>     ^cY#a12v86n4.htm##
01296000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704106100076002001301137#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#52#48#article#147#<p><font face="Verd
ana" size="2"> Constatou-se aumento de 1 m&ecirc;s na dura&ccedil;&atilde;o    m
ediana do AME no Brasil, passando de 23,4 dias, em 1999, para 54,1 dias, em    2
008. A compara&ccedil;&atilde;o entre as regi&otilde;es apontou aumento expressi
vo    na Regi&atilde;o Centro-Oeste (47,1 dias), seguida das Regi&otilde;es Nort
e    (42,2 dias) e Sudeste (41,9 dias). Na Regi&atilde;o Sul, verificou-se aumen
to    de menor intensidade (20,2 dias), e a Regi&atilde;o Nordeste teve o pior d
esempenho    (8,6 dias). Nesta Regi&atilde;o houve aumento da mediana do AME na 
maioria das    capitais, mas redu&ccedil;&atilde;o expressiva em Fortaleza, que 
passou de 63,6    dias (a melhor situa&ccedil;&atilde;o desse indicador em 1999)
 para 10,6 dias,    em 2008. A an&aacute;lise da evolu&ccedil;&atilde;o desse in
dicador revela que    mudan&ccedil;as favor&aacute;veis foram estatisticamente s
ignificativas em 20    capitais. Vale destacar que em Campo Grande verificou-se 
aumento de 2 meses    na dura&ccedil;&atilde;o mediana do AME.</font></p>     ^c
Y#a12v86n4.htm##
00438000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704020300076002001300279#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#53#49#article#147#<p><font face="Verd
ana" size="2">Na <a href=/img/revistas/jped/v86n4/4a12t3.gif>Tabela    3</a> s&a
tilde;o apresentadas as dura&ccedil;&otilde;es medianas do AM nas duas    pesqui
sas.</font></p>     ^cY#a12v86n4.htm##
01317000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704108200076002001301158#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#54#50#article#147#<p><font face="Verd
ana" size="2">A dura&ccedil;&atilde;o mediana do AM no Brasil    aumentou cerca 
de 1,5 m&ecirc;s, passando de 295,9 dias em 1999, para 341,6    dias em 2008. A 
Regi&atilde;o Norte, onde se verificou a maior dura&ccedil;&atilde;o    do AM na
 pesquisa de 1999, foi a &uacute;nica Regi&atilde;o na qual o aumento,    de 20,
6 dias, n&atilde;o foi estatisticamente significativo. A Regi&atilde;o    Nordes
te foi a que mais se destacou na expans&atilde;o do AM, com aumento de    cerca 
de 3 meses, seguida das Regi&otilde;es Sul (2,5 meses), Sudeste (2 meses)    e C
entro-Oeste (1,5 m&ecirc;s). Mudan&ccedil;as favor&aacute;veis, estatisticamente
    significativas, foram observadas em 14 capitais. &Eacute; interessante obser
var    que, em Bel&eacute;m, onde se obteve a maior dura&ccedil;&atilde;o median
a do    AM em 1999 (566,3 dias), foi onde se verificou a redu&ccedil;&atilde;o m
ais    expressiva em 2008, de 121 dias. A evolu&ccedil;&atilde;o mais favor&aacu
te;vel    foi observada em Macei&oacute;, que aumentou em 159 dias a mediana do 
AM.</font></p>     ^cY#a12v86n4.htm##
01094000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704085900076002001300935#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#55#51#article#147#<p><font face="Verd
ana" size="2">Na <a href=#f1>Figura 1</a> s&atilde;o apresentados    os gr&aacut
e;ficos de correla&ccedil;&atilde;o entre a situa&ccedil;&atilde;o    da amament
a&ccedil;&atilde;o em 1999 e o grau de evolu&ccedil;&atilde;o das    medianas do
 AME e AM no per&iacute;odo analisado. Verificou-se correla&ccedil;&atilde;o    
negativa entre a dura&ccedil;&atilde;o mediana de 1999 e o percentual de evolu&c
cedil;&atilde;o,    em ambos os casos. Nas capitais onde a dura&ccedil;&atilde;o
 mediana de AM era    menor em 1999, como em Macei&oacute;, S&atilde;o Paulo e P
orto Alegre, houve    maior incremento percentual e, por outro lado, em Bel&eacu
te;m, Teresina e Boa    Vista, capitais com situa&ccedil;&atilde;o mais favor&aa
cute;vel em 1999, houve,    inclusive, redu&ccedil;&atilde;o da dura&ccedil;&ati
lde;o mediana do AM.</font></p>     ^cY#a12v86n4.htm##
00268000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003300076002001300109#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#56#52#article#147#<p><a name="f1"></a
></p>     ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#57#53#article#147#<p>&nbsp;</p>     ^
cY#a12v86n4.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007800076002001300154#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#58#54#article#147#<p align="center"><
img src="/img/revistas/jped/v86n4/4a12f1.gif"></p>     ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#59#55#article#147#<p>&nbsp;</p>     ^
cY#a12v86n4.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#60#56#article#147#<p><font size="3" f
ace="Verdana"><b>Discuss&atilde;o</b></font></p>     ^cY#a12v86n4.htm##
00485000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704025000076002001300326#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#61#57#article#147#<p><font face="Verd
ana" size="2">A II PPAM possibilitou conhecer a situa&ccedil;&atilde;o    atual 
da amamenta&ccedil;&atilde;o e analisar sua evolu&ccedil;&atilde;o na    &uacute
;ltima d&eacute;cada nas capitais brasileiras e DF.</font></p>     ^cY#a12v86n4.
htm##
01063000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082800076002001300904#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#62#58#article#147#<p><font face="Verd
ana" size="2">Inicialmente, &eacute; importante ressaltar alguns    aspectos rel
acionados ao desenho da pesquisa. A realiza&ccedil;&atilde;o de    pesquisas dur
ante as campanhas de vacina&ccedil;&atilde;o tem sido uma estrat&eacute;gia    a
mplamente utilizada e recomendada no Brasil por possibilitar a obten&ccedil;&ati
lde;o    de informa&ccedil;&otilde;es em um curto per&iacute;odo e com um custo 
relativamente    baixo<SUP>13</SUP>. Al&eacute;m disso, a alta cobertura populac
ional das campanhas,    somada &agrave; utiliza&ccedil;&atilde;o de delineamento
s amostrais, como o    utilizado no presente estudo, permitem a obten&ccedil;&at
ilde;o de amostras    probabil&iacute;sticas representativas da popula&ccedil;&a
tilde;o de crian&ccedil;as    menores de 1 ano nas cidades estudadas.</font></p>
     ^cY#a12v86n4.htm##
00927000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069200076002001300768#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#63#59#article#147#<p><font face="Verd
ana" size="2">Dessa forma, no tocante &agrave; validade externa    do estudo, s&
atilde;o aspectos positivos: a alta cobertura da segunda etapa    da campanha de
 vacina&ccedil;&atilde;o de 2008 (superior a 80% em todas as capitais    e m&eac
ute;dia de 95% para o Brasil)<SUP>14</SUP> e o fato de que o perfil da    escola
ridade materna (considerada, neste estudo, como <i>proxy </i>da situa&ccedil;&at
ilde;o    socioecon&ocirc;mica) &eacute; semelhante quando se compara a amostra 
analisada    aos dados do Sistema de Informa&ccedil;&atilde;o de Nascidos Vivos 
em 2008 (86,2%    com menos de 12 anos de estudo versus 83,8%, respectivamente)<
SUP>15</SUP>.</font></p>     ^cY#a12v86n4.htm##
00939000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070400076002001300780#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#64#60#article#147#<p><font face="Verd
ana" size="2">Uma limita&ccedil;&atilde;o desta pesquisa diz    respeito &agrave
; n&atilde;o inclus&atilde;o da popula&ccedil;&atilde;o residente    em &aacute;
reas rurais e munic&iacute;pios menores<SUP>16</SUP>. Por outro lado,    vantage
ns adicionais dos inqu&eacute;ritos realizados em campanhas de vacina&ccedil;&at
ilde;o    s&atilde;o: a viabilidade de realiza&ccedil;&atilde;o em intervalos me
nores,    permitindo a avalia&ccedil;&atilde;o e o planejamento de a&ccedil;&oti
lde;es    no n&iacute;vel local, e seu potencial para a mobiliza&ccedil;&atilde;
o das    equipes de sa&uacute;de municipais e entrevistadores, geralmente recrut
ados    em universidades.</font></p>     ^cY#a12v86n4.htm##
00610000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037500076002001300451#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#65#61#article#147#<p><font face="Verd
ana" size="2">Dois outros aspectos merecem destaque. O primeiro    diz respeito 
&agrave; heterogeneidade dos indicadores entre as capitais e regi&otilde;es    d
o pa&iacute;s, refor&ccedil;ando a import&acirc;ncia das pesquisas locais;    o 
segundo refere-se aos avan&ccedil;os verificados na pr&aacute;tica da amamenta&c
cedil;&atilde;o.</font></p>     ^cY#a12v86n4.htm##
01109000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087400076002001300950#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#66#62#article#147#<p><font face="Verd
ana" size="2">O percentual de crian&ccedil;as amamentadas na    primeira hora de
 vida (67,7%) superou o encontrado na PNDS/2006 (43%) em uma    amostra de crian
&ccedil;as menores de 60 meses<SUP>7</SUP>. Essa diferen&ccedil;a    pode ser ex
plicada, pelo menos parcialmente, em fun&ccedil;&atilde;o do presente    inqu&ea
cute;rito refletir situa&ccedil;&atilde;o mais recente, de crian&ccedil;as    me
nores de 1 ano. N&atilde;o foi poss&iacute;vel avaliar a evolu&ccedil;&atilde;o 
   desse indicador, pois o inqu&eacute;rito de 1999 n&atilde;o contemplou essa  
  informa&ccedil;&atilde;o. Sua introdu&ccedil;&atilde;o na pesquisa atual deveu
-se    &agrave; recente recomenda&ccedil;&atilde;o da OMS<SUP>12</SUP> e aos rec
entes    relatos do impacto dessa pr&aacute;tica na redu&ccedil;&atilde;o da mor
talidade    neonatal<SUP>2,3</SUP>.</font></p>     ^cY#a12v86n4.htm##
01125000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704089000076002001300966#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#67#63#article#147#<p><font face="Verd
ana" size="2">A preval&ecirc;ncia de AME em crian&ccedil;as    de 0 a 6 meses (4
1%) foi muito pr&oacute;xima ao identificado na PNDS/2006 (39,8%)<SUP>7</SUP>.  
  O aumento de cerca de 1 m&ecirc;s na mediana do AME, verificado neste estudo, 
   foi mais expressivo que o verificado na compara&ccedil;&atilde;o da PNDS de  
  1996 (mediana de 1,1 m&ecirc;s) com a de 2006 (mediana de 1,4 m&ecirc;s)<SUP>7
</SUP>.    Vale ressaltar, por&eacute;m, que a compara&ccedil;&atilde;o do AME e
ntre as    PNDS de 1996 e 2006 deve ser interpretada com cautela, uma vez que os
 dados    de 1996 podem estar superestimados por problemas na coleta da informa&
ccedil;&atilde;o<SUP>8</SUP>.    Tend&ecirc;ncia crescente do AME tem sido verif
icada em diversos estudos realizados    em munic&iacute;pios brasileiros<SUP>17-
19</SUP> e em outros pa&iacute;ses<SUP>20-22</SUP>.</font></p>     ^cY#a12v86n4.
htm##
00671000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043600076002001300512#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#68#64#article#147#<p><font face="Verd
ana" size="2">O indicador AM em crian&ccedil;as de 9 a 12 meses    foi utilizado
 como indicador de continuidade do AM. A OMS recomenda, para o    c&aacute;lculo
 desse indicador, a propor&ccedil;&atilde;o de crian&ccedil;as    de 12 a 15,9 m
eses amamentadas<SUP>12</SUP>, mas como a pesquisa incluiu crian&ccedil;as    me
nores de um ano, optou-se por utilizar a faixa et&aacute;ria de 9 a 12 meses.</f
ont></p>     ^cY#a12v86n4.htm##
01103000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704086800076002001300944#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#69#65#article#147#<p><font face="Verd
ana" size="2">A continuidade do AM teve um comportamento bastante    heterog&eci
rc;neo entre as capitais e regi&otilde;es, variando de 49,5%, na    Regi&atilde;
o Sul, a 76,9%, na Norte. A mediana do AM, verificada nesta pesquisa,    de 11,2
 meses, foi inferior &agrave; encontrada na PNDS/2006 (14,0 meses)<SUP>7</SUP>; 
   por&eacute;m, a mediana do AM na &aacute;rea urbana do pa&iacute;s, verificad
a    na PNDS/2006, foi de 12,9 meses<SUP>7</SUP>, ou seja, mais pr&oacute;xima d
o    encontrado neste estudo. &Eacute; interessante observar que apesar do incre
mento    verificado na manuten&ccedil;&atilde;o do AM no pa&iacute;s, sua median
a continua    inferior &agrave; observada por P&eacute;rez-Escamilla<SUP>21</SUP
> na Bol&iacute;via    (17,5 meses), Guatemala (19,9 meses) e Peru (19,5 meses),
 na d&eacute;cada de    1990.</font></p>     ^cY#a12v86n4.htm##
01165000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704093000076002001301006#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#70#66#article#147#<p><font face="Verd
ana" size="2">A OMS recomenda amamenta&ccedil;&atilde;o exclusiva    at&eacute; 
os 6 meses e manuten&ccedil;&atilde;o do AM, juntamente com alimentos    complem
entares, por 2 anos ou mais<SUP>23</SUP>. Segundo par&acirc;metros propostos    
pela OMS<SUP>24</SUP>, os valores revelados pela pesquisa est&atilde;o longe    
do ideal. No tocante ao AME em menores de 6 meses, 23 capitais se encontram    e
m situa&ccedil;&atilde;o considerada "razo&aacute;vel" (preval&ecirc;ncias    en
tre 12 e 49%), e apenas quatro (Bel&eacute;m, Campo Grande, DF e Florian&oacute;
polis)    est&atilde;o em "boa situa&ccedil;&atilde;o" (entre 50 e 89%). Quanto 
&agrave;    dura&ccedil;&atilde;o do AM, a situa&ccedil;&atilde;o &eacute; consi
derada,    na maioria dos casos, "ruim" (mediana inferior a 17 meses) e apenas M
acap&aacute;    &eacute; classificada como "razo&aacute;vel" (mediana entre 18 e
 20 meses).</font></p>     ^cY#a12v86n4.htm##
00921000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068600076002001300762#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#71#67#article#147#<p><font face="Verd
ana" size="2">Apesar de a situa&ccedil;&atilde;o do AM estar    longe da ideal, 
os avan&ccedil;os conquistados rumo &agrave; expans&atilde;o    da pr&aacute;tic
a da amamenta&ccedil;&atilde;o no pa&iacute;s s&atilde;o ineg&aacute;veis.    Em
bora a identifica&ccedil;&atilde;o dos fatores que levaram a essa melhora    ext
rapole o escopo deste estudo, &eacute; importante, a t&iacute;tulo de contextual
iza&ccedil;&atilde;o,    apontar algumas mudan&ccedil;as no perfil socioecon&oci
rc;mico da popula&ccedil;&atilde;o    e a evolu&ccedil;&atilde;o da pol&iacute;t
ica nacional de AM, por serem fatores    que podem ter influenciado esse comport
amento.</font></p>     ^cY#a12v86n4.htm##
00597000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036200076002001300438#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#72#68#article#147#<p><font face="Verd
ana" size="2">A escolaridade materna, identificada como importante    fator asso
ciado &agrave; pr&aacute;tica de amamenta&ccedil;&atilde;o<SUP>25</SUP>,    teve
 melhora consider&aacute;vel entre 1999 e 2008, com aumento de 20,4 pontos    pe
rcentuais de m&atilde;es com escolaridade entre 8 e 11 anos completos<SUP>15</SU
P>.</font></p>     ^cY#a12v86n4.htm##
01846000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704161100076002001301687#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#73#69#article#147#<p><font face="Verd
ana" size="2">O papel dos programas e pol&iacute;ticas na expans&atilde;o    da 
pr&aacute;tica da amamenta&ccedil;&atilde;o tamb&eacute;m tem sido relatado    p
or v&aacute;rios autores<SUP>16,20-22,24</SUP>. Nesse sentido, destacam-se    no
 pa&iacute;s: a expans&atilde;o da Rede Brasileira de Bancos de Leite Humano,   
 composta atualmente por 270 unidades, a qual registrou aumento de 56% na coleta
    de leite entre 2003 e 2008, de 50% de crian&ccedil;as beneficiadas e duplica
&ccedil;&atilde;o    do n&uacute;mero de doadoras, que chegam a 113 mil<SUP>26</
SUP>; a expans&atilde;o    da Iniciativa Hospital Amigo da Crian&ccedil;a, entre
 1999 e 2008, com o credenciamento    de 52 hospitais em 2002 e 43 em 2003<SUP>2
7</SUP>; os avan&ccedil;os relacionados    &agrave; Norma Brasileira de Comercia
liza&ccedil;&atilde;o de Alimentos para    Lactentes e Crian&ccedil;as de Primei
ra Inf&acirc;ncia, Bicos, Chupetas e Mamadeiras    (NBCAL), decorrentes das muda
n&ccedil;as nessa legisla&ccedil;&atilde;o que    ocorreram em 2002 e da cria&cc
edil;&atilde;o da Lei 11.625, publicada em 2006,    visando &agrave; regulamenta
&ccedil;&atilde;o da promo&ccedil;&atilde;o comercial    e das orienta&ccedil;&o
tilde;es do uso apropriado de alimentos para crian&ccedil;as    de at&eacute; 3 
anos<SUP>28</SUP>; e, por fim, a intensa mobiliza&ccedil;&atilde;o    social pro
vocada pela comemora&ccedil;&atilde;o das Semanas Mundiais da Amamenta&ccedil;&a
tilde;o,    e a institui&ccedil;&atilde;o do Dia Nacional da Doa&ccedil;&atilde;
o de Leite    Humano, em 1º de outubro<SUP>29</SUP>.</font></p>     ^cY#a12v86n4
.htm##
01528000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704129300076002001301369#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#74#70#article#147#<p><font face="Verd
ana" size="2">A an&aacute;lise da influ&ecirc;ncia da situa&ccedil;&atilde;o    
da amamenta&ccedil;&atilde;o em 1999 sobre o comportamento dos indicadores em   
 2008 revelou claramente que houve maior incremento nas capitais com pior situa&
ccedil;&atilde;o    em 1999 e, por outro lado, avan&ccedil;os mais discretos ou 
mesmo retrocessos    em locais onde a situa&ccedil;&atilde;o era mais favor&aacu
te;vel. Os munic&iacute;pios    de Bel&eacute;m e Fortaleza, por exemplo, que em
 1999 apresentavam as maiores    medianas de AM e AME, respectivamente, n&atilde
;o s&oacute; n&atilde;o avan&ccedil;aram,    como retrocederam. Esse cen&aacute;
rio evidencia a necessidade de o Brasil investir    em novas estrat&eacute;gias 
de incentivo &agrave; amamenta&ccedil;&atilde;o    para que os seus indicadores 
atinjam patamares mais elevados. Nesse sentido,    o Minist&eacute;rio da Sa&uac
ute;de lan&ccedil;ou, em 2008, a Rede Amamenta    Brasil, visando &agrave; promo
&ccedil;&atilde;o e apoio &agrave; amamenta&ccedil;&atilde;o    na rede de aten&
ccedil;&atilde;o b&aacute;sica do pa&iacute;s. Essa estrat&eacute;gia    veio pr
eencher uma importante lacuna, haja vista as a&ccedil;&otilde;es de incentivo   
 ao AM estarem focalizadas no &acirc;mbito hospitalar.</font></p>     ^cY#a12v86
n4.htm##
00973000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704073800076002001300814#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#75#71#article#147#<p><font face="Verd
ana" size="2">Pode-se concluir que houve uma melhora significativa    da situa&c
cedil;&atilde;o do AM na &uacute;ltima d&eacute;cada, no conjunto    das capitai
s brasileiras, persistindo diferen&ccedil;as entre as regi&otilde;es    e capita
is analisadas. Por&eacute;m, ainda &eacute; necess&aacute;rio um grande    esfor
&ccedil;o para que o Brasil atinja &iacute;ndices de AM compat&iacute;veis    co
m a recomenda&ccedil;&atilde;o da OMS. Espera-se que os dados desta pesquisa    
sejam utilizados por gestores, profissionais de sa&uacute;de e pela sociedade,  
  fornecendo subs&iacute;dios para o planejamento e avalia&ccedil;&atilde;o de  
  a&ccedil;&otilde;es em prol da amamenta&ccedil;&atilde;o.</font></p>     ^cY#a
12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#76#72#article#147#<p>&nbsp;</p>     ^
cY#a12v86n4.htm##
00312000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007700076002001300153#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#77#73#article#147#<p><font size="3" f
ace="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#a12v86n4.htm##
00461000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021200078002001300290#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#78#74#article#147#1#<p><f
ont size="2" face="Verdana">1. Jones G, Steketee RW, Black RE, Bhutta ZA,    Mor
ris SS; Bellagio Child Survival Study Group. How many child deaths can we    pre
vent this year? Lancet. 2003;362:65-71.    ^cY#a12v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#79#75#article#147#</font></p>     ^cY
#a12v86n4.htm##
00474000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022500078002001300303#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#80#76#article#147#2#<p><f
ont size="2" face="Verdana">2. Edmond KM, Zandoh C, Quigley MA, Amenga-Etego    
S, Owusu-Agyei S, Kirkwood BR. Delayed breastfeeding initiation increases risk  
  of neonatal mortality. Pediatrics. 2006;117:380-6.    ^cY#a12v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#81#77#article#147#</font></p>     ^cY
#a12v86n4.htm##
00493000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024400078002001300322#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#82#78#article#147#3#<p><f
ont size="2" face="Verdana">3. Mullany LC, Katz J, Li YM, Khatry SK, LeClerq    
SC, Darmstadt GL, et al. Breast-feeding patterns, time to initiation, and mortal
ity    risk among newborns in southern Nepal. J Nutr. 2008;138:599-603.    ^cY#a
12v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#83#79#article#147#</font></p>     ^cY
#a12v86n4.htm##
00403000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704015400078002001300232#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#84#80#article#147#4#<p><f
ont size="2" face="Verdana">4. Rea MF. The Brazilian National Breastfeeding    P
rogram: a success story. Int J Gynecol Obstet. 1990;31:79-82.    ^cY#a12v86n4.ht
m##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#85#81#article#147#</font></p>     ^cY
#a12v86n4.htm##
00460000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021100078002001300289#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#86#82#article#147#5#<p><f
ont size="2" face="Verdana">5. Venancio SI, Monteiro CA. A evolu&ccedil;&atilde;
o    da pr&aacute;tica da amamenta&ccedil;&atilde;o nas d&eacute;cadas de 70 e 8
0.    Rev Bras Epidemiol. 1998;1:40-9.    ^cY#a12v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#87#83#article#147#</font></p>     ^cY
#a12v86n4.htm##
00441000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019200078002001300270#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#88#84#article#147#6#<p><f
ont size="2" face="Verdana">6. Sociedade Civil Bem-Estar Familiar no Brasil.    
Pesquisa Nacional sobre Demografia e Sa&uacute;de. Rio de Janeiro: BEMFAM; 1997.
&nbsp;    p.125-38.    ^cY#a12v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#89#85#article#147#</font></p>     ^cY
#a12v86n4.htm##
00505000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025600078002001300334#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#90#86#article#147#7#<p><f
ont size="2" face="Verdana">7. Brasil. Minist&eacute;rio da Sa&uacute;de.    Pes
quisa Nacional de Demografia e Sa&uacute;de da Crian&ccedil;a e da Mulher    &#1
50; PNDS 2006. Bras&iacute;lia: Minist&eacute;rio da Sa&uacute;de; 2009. p.195-2
12.    ^cY#a12v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#91#87#article#147#</font></p>     ^cY
#a12v86n4.htm##
00494000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024500078002001300323#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#92#88#article#147#8#<p><f
ont size="2" face="Verdana">8. Monteiro CA. O panorama da nutri&ccedil;&atilde;o
    infantil nos anos 90. Bras&iacute;lia: UNICEF; 1997. (Cadernos de Pol&iacute
;ticas    Sociais, S&eacute;rie Documentos para Discuss&atilde;o, v. 1).    ^cY#
a12v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#93#89#article#147#</font></p>     ^cY
#a12v86n4.htm##
00488000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023900078002001300317#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#94#90#article#147#9#<p><f
ont size="2" face="Verdana">9. Brasil. Minist&eacute;rio da Sa&uacute;de.    Pre
val&ecirc;ncia de Aleitamento Materno nas Capitais Brasileiras e no Distrito    
Federal. Bras&iacute;lia: Minist&eacute;rio da Sa&uacute;de; 2001.    ^cY#a12v86
n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#95#91#article#147#</font></p>     ^cY
#a12v86n4.htm##
00658000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704040800079002001300487#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#96#92#article#147#10#<p><
font size="2" face="Verdana">10. Brasil. Minist&eacute;rio da Sa&uacute;de.    S
ecretaria de Aten&ccedil;&atilde;o &agrave; Sa&uacute;de. Departamento de A&cced
il;&otilde;es    Program&aacute;ticas e Estrat&eacute;gicas. II Pesquisa de Prev
al&ecirc;ncia    de Aleitamento Materno nas Capitais Brasileiras e Distrito Fede
ral. Bras&iacute;lia:    Editora do Minist&eacute;rio da Sa&uacute;de, 2009.    
^cY#a12v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#97#93#article#147#</font></p>     ^cY
#a12v86n4.htm##
00402000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704015200079002001300231#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#98#94#article#147#11#<p><
font size="2" face="Verdana">11. Silva NN. Amostragem Probabil&iacute;stica:    
um curso introdut&oacute;rio. S&atilde;o Paulo: EDUSP, 1998.    ^cY#a12v86n4.htm
##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#99#95#article#147#</font></p>     ^cY
#a12v86n4.htm##
00502000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704025100080002001300331#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#100#96#article#147#12#<p>
<font size="2" face="Verdana">12. World Health Organization. Indicators for    a
ssessing infant and young child feeding practices: conclusions of a consensus   
 meeting held 6&#150;8 November 2007 in Washington D.C., USA. Geneva: WHO; 2008.
    ^cY#a12v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#101#97#article#147#</font></p>     ^c
Y#a12v86n4.htm##
00477000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704022600080002001300306#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#102#98#article#147#13#<p>
<font size="2" face="Verdana">13. Santos LM, Paes-Sousa R, Silva Junior JB,    V
ictora CG. National Immunization Day: a strategy to monitor health and nutrition
    indicators. Bull World Health Organ. 2008;86:474-9.    ^cY#a12v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#103#99#article#147#</font></p>     ^c
Y#a12v86n4.htm##
00536000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028400081002001300365#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#104#100#article#147#14#<p
><font size="2" face="Verdana">14. Brasil. Minist&eacute;rio da Sa&uacute;de.   
 Sistema de informa&ccedil;&atilde;o do Programa Nacional de Imuniza&ccedil;&oti
lde;es.    <A href=http://pni.datasus.gov.br target="_blank">http://pni.datasus.
gov.br</A>.    Acesso: 10/03/2010.    ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#105#101#article#147#</font></p>     ^
cY#a12v86n4.htm##
00473000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704023600078002001300314#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#106#102#article#147#<p><font size="2"
 face="Verdana">15. Brasil. Minist&eacute;rio da Sa&uacute;de.&nbsp;    Sistema 
de Informa&ccedil;&otilde;es sobre Nascidos Vivos &#150; SINASC. Situa&ccedil;&a
tilde;o    da base de dados nacional em 14/12/2009.    ^cY#a12v86n4.htm##
00448000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019600081002001300277#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#107#103#article#147#15#<B
R>   <A href=http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sinascp/cnv/nvuf.def ta
rget="_blank">http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sinascp/cnv/nvuf.def</
A>.    Acesso: 12/03/2010.    ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#108#104#article#147#</font></p>     ^
cY#a12v86n4.htm##
00470000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021800081002001300299#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#109#105#article#147#16#<p
><font size="2" face="Verdana">16. Rea MF. Reflex&otilde;es sobre a amamenta&cce
dil;&atilde;o    no Brasil: de como passamos a 10 meses de dura&ccedil;&atilde;o
. Cad Saude Publica.    2003;19 Suppl 1:S37-S45.    ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#110#106#article#147#</font></p>     ^
cY#a12v86n4.htm##
00555000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030300081002001300384#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#111#107#article#147#17#<p
><font size="2" face="Verdana">17. Brunken GS, Silva SM, Fran&ccedil;a GV, Escud
er    MM, Ven&acirc;ncio SI. Risk factors for early interruption of exclusive br
eastfeeding    and late introduction of complementary foods among infants in mid
western Brazil.    J Pediatr (Rio J). 2006;82:445-51.    ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#112#108#article#147#</font></p>     ^
cY#a12v86n4.htm##
00500000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024800081002001300329#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#113#109#article#147#18#<p
><font size="2" face="Verdana">18. Ferreira L, Parada CM, Carvalhaes MA. Tend&ec
irc;ncia    do aleitamento materno em munic&iacute;pio da regi&atilde;o centro-s
ul de estado    de S&atilde;o Paulo: 1995-1999-2004. Rev Nutr. 2007;20:265-73.  
  ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#114#110#article#147#</font></p>     ^
cY#a12v86n4.htm##
00557000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030500081002001300386#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#115#111#article#147#19#<p
><font size="2" face="Verdana">19. Albernaz E, Ara&uacute;jo CL, Tomasi E, Minte
m    G, Giugliani E, Matijasevich A, et al. Influence of breastfeeding support o
n    the tendencies of breastfeeding rates in the city of Pelotas (RS), Brazil, 
from    1982 to 2004. J Pediatr (Rio J). 2008;84:560-4.    ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#116#112#article#147#</font></p>     ^
cY#a12v86n4.htm##
00463000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021100081002001300292#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#117#113#article#147#20#<p
><font size="2" face="Verdana">20. Grummer-Strawn LM. The effect of changes    i
n population characteristics on breastfeeding trends in fifteen developing    co
untries. Int J Epidemiol. 1996;25:94-102.    ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#118#114#article#147#</font></p>     ^
cY#a12v86n4.htm##
00470000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021800081002001300299#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#119#115#article#147#21#<p
><font size="2" face="Verdana">21. P&eacute;rez-Escamilla R. Breastfeeding and  
  the nutritional transition in the Latin American and Caribbean Region: a succe
ss    story? Cad Saude Publica. 2003;19:S119-27.    ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#120#116#article#147#</font></p>     ^
cY#a12v86n4.htm##
00437000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018500081002001300266#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#121#117#article#147#22#<p
><font size="2" face="Verdana">22. Labbok MH, Wardlaw T, Blanc A, Clark D, Terre
ri    N. Trends in exclusive breastfeeding: findings from the 1990s. J Hum Lact.
 2006;22:272-6.    ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#122#118#article#147#</font></p>     ^
cY#a12v86n4.htm##
00420000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704016800081002001300249#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#123#119#article#147#23#<p
><font size="2" face="Verdana">23. World Health Organization. The optimal durati
on    of exclusive breastfeeding. Note for the Press No 7. Geneva : WHO, 2001.  
  ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#124#120#article#147#</font></p>     ^
cY#a12v86n4.htm##
00449000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019700081002001300278#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#125#121#article#147#24#<p
><font size="2" face="Verdana">24. World Health Organization. Infant and Young  
  Child Feeding: A tool for assessing breastfeeding practices, policies and prog
rams.    Geneva: WHO; 2003.    ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#126#122#article#147#</font></p>     ^
cY#a12v86n4.htm##
00486000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023400081002001300315#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#127#123#article#147#25#<p
><font size="2" face="Verdana">25. Venancio SI, Monteiro CA.&nbsp; Individual   
 and contextual determinants of exclusive breastfeeding in S&atilde;o Paulo,    
Brazil: a multilevel analysis. Public Health Nutr. 2006; 9:40-6.    ^cY#a12v86n4
.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#128#124#article#147#</font></p>     ^
cY#a12v86n4.htm##
00526000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027400081002001300355#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#129#125#article#147#26#<p
><font size="2" face="Verdana">26. FIOCRUZ. Rede de Bancos de Leite Humano.    <
A href=http://www.redeblh.fiocruz.br/cgi/cgilua.exe/sys/start.htm?sid=352 target
="_blank">http://www.redeblh.fiocruz.br/cgi/cgilua.exe/sys/start.htm?sid=352</A>
.    Acesso: 15/10/2009.    ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#130#126#article#147#</font></p>     ^
cY#a12v86n4.htm##
00662000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704041000081002001300491#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#131#127#article#147#27#<p
><font size="2" face="Verdana">27. Brasil. Minist&eacute;rio da Sa&uacute;de.   
 A Iniciativa Hospital Amigo da Crian&ccedil;a no Brasil: hist&oacute;rico, situ
a&ccedil;&atilde;o    atual, a&ccedil;&otilde;es e perspectivas. <A href=http://
portal.saude.gov.br/portal/saude/area.cfm?id_area=1460 target="_blank">http://po
rtal.saude.gov.br/portal/saude/area.cfm?id_area=1460</A>.    Acesso: 15/10/2009.
    ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#132#128#article#147#</font></p>     ^
cY#a12v86n4.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028100081002001300362#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#133#129#article#147#28#<p
><font size="2" face="Verdana">28. de F&aacute;tima Moura de Ara&uacute;jo M,   
 Rea MF, Pinheiro KA, de Abreu Soares Schmitz B. Avan&ccedil;os na norma brasile
ira    de comercializa&ccedil;&atilde;o de alimentos para idade infantil. Rev Sa
ude    Publica. 2006;40:513-20.    ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#134#130#article#147#</font></p>     ^
cY#a12v86n4.htm##
00519000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026700081002001300348#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#p#135#131#article#147#29#<p
><font size="2" face="Verdana">29. Alencar SM. A Pol&iacute;tica Nacional de    
Aleitamento Materno. In: O aleitamento materno no contexto atual. Pol&iacute;tic
as,    pr&aacute;ticas e bases cient&iacute;ficas. S&atilde;o Paulo: Sarvier; 20
08.    p. 70-101.    ^cY#a12v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#136#132#article#147#</font></p>     ^
cY#a12v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#137#133#article#147#<p>&nbsp;</p>    
 ^cY#a12v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#138#134#article#147#<p>&nbsp;</p>    
 ^cY#a12v86n4.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018000078002001300258#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#139#135#article#147#<p><font size="2"
 face="Verdana"><a name="correspondence"></a><a href="#topo"><img src="/img/revi
stas/jped/v86n4/seta.gif" border="0"></a>    <b> Correspond&ecirc;ncia:</b>    ^
cY#a12v86n4.htm##
00269000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003200078002001300110#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#140#136#article#147#<br>   Sonia I. V
enancio    ^cY#a12v86n4.htm##
00303000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704006600078002001300144#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#141#137#article#147#<BR>   Rua Santo 
Ant&ocirc;nio, 590/5º andar - Bela Vista     ^cY#a12v86n4.htm##
00288000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005100078002001300129#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#142#138#article#147#<BR>   CEP 01314-
000 - S&atilde;o Paulo, SP    ^cY#a12v86n4.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003500078002001300113#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#143#139#article#147#<BR>   Tel.: (11)
 3293.2278    ^cY#a12v86n4.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#144#140#article#147#<BR>   Fax: (11) 
3105.2772    ^cY#a12v86n4.htm##
00338000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010100078002001300179#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#145#141#article#147#<BR>   E-mail: <A
 href=mailto:soniav@isaude.sp.gov.br>soniav@isaude.sp.gov.br</A></font></p>     
^cY#a12v86n4.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010600078002001300184#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#146#142#article#147#<p><font size="2"
 face="Verdana">Artigo submetido em 21.12.2009, aceito em 12.05.2010.</font></p>
     ^cY#a12v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#147#143#article#147#<p>&nbsp;</p>    
 ^cY#a12v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#148#144#article#147#<p>&nbsp;</p>    
 ^cY#a12v86n4.htm##
00331000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009400078002001300172#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#149#145#article#147#<p><font size="2"
 face="Verdana"> Apoio financeiro: Minist&eacute;rio da Sa&uacute;de.    ^cY#a12
v86n4.htm##
00364000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704012700078002001300205#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#150#146#article#147#<br>   N&atilde;o
 foram declarados conflitos de interesse associados &agrave; publica&ccedil;&ati
lde;o    deste artigo.    ^cY#a12v86n4.htm##
00414000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704017700078002001300255#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a12v86n4.htm#S#p#151#147#article#147#<br>   Este traba
lho foi realizado no Instituto de Sa&uacute;de, Secretaria de Estado    da Sa&ua
cute;de de S&atilde;o Paulo (SES-SP), S&atilde;o Paulo, SP. </font></p>     ^cY#
a12v86n4.htm##
00645000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100019000920100
01600111010001700127010001700144011003600161012005200197030000700249065000900256
06400050026503100040027001400060027486500090028000200130028903500100030280100070
0312#v86n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#c#152#1#article#29#
1#^rND^sJones^nG#^rND^sSteketee^nRW#^rND^sBlack^nRE#^rND^sBhutta^nZA#^rND^sMorri
s^nSS#Bellagio Child Survival Study Group#How many child deaths can we prevent t
his year?^len#Lancet#20030000#2003#362#65-71#20100800#a12v86n4.htm#0099-5355#Lan
cet##
00668000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100016000940100
01800110010002200128010002100150010001900171012007400190030001100264065000900275
06400050028403100040028901400060029386500090029900200130030803500100032180100110
0331#v86n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#c#153#2#article#29#
2#^rND^sEdmond^nKM#^rND^sZandoh^nC#^rND^sQuigley^nMA#^rND^sAmenga-Etego^nS#^rND^
sOwusu-Agyei^nS#^rND^sKirkwood^nBR#Delayed breastfeeding initiation increases ri
sk of neonatal mortality^len#Pediatrics#20060000#2006#117#380-6#20100800#a12v86n
4.htm#0031-4005#Pediatrics##
00694000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100014000950100
01300109010001700122010001800139010002000157810000600177012010100183030000700284
06500090029106400050030003100040030501400080030986500090031700200130032603500100
0339801000700349#v86n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#c#154#3
#article#29#3#^rND^sMullany^nLC#^rND^sKatz^nJ#^rND^sLi^nYM#^rND^sKhatry^nSK#^rND
^sLeClerq^nSC#^rND^sDarmstadt^nGL#et al#Breast-feeding patterns, time to initiat
ion, and mortality risk among newborns in southern Nepal^len#J Nutr#20080000#200
8#138#599-603#20100800#a12v86n4.htm#0022-3166#J Nutr##
00479000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770120066000910300
02100157710000200178065000900180064000500189031000300194014000600197865000900203
002001300212#v86n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#c#155#4#art
icle#29#4#^rND^sRea^nMF#The Brazilian National Breastfeeding Program: a success 
story^len#Int J Gynecol Obstet#2#19900000#1990#31#79-82#20100800#a12v86n4.htm##
00509000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100019000960120
06400115030001900179710000200198065000900200064000500209031000200214014000500216
865000900221002001300230#v86n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S
#c#156#5#article#29#5#^rND^sVenancio^nSI#^rND^sMonteiro^nCA#A evolução da prátic
a da amamentação nas décadas de 70 e 80^lpt#Rev Bras Epidemiol#2#19980000#1998#1
#40-9#20100800#a12v86n4.htm##
00457000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170045000770180047001220660
01500169062000700184065000900191064000500200865000900205002001300214#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a12v86n4.htm#S#c#157#6#article#29#6#Sociedade Civi
l Bem-Estar Familiar no Brasil#Pesquisa Nacional sobre Demografia e Saúde^lpt#Ri
o de Janeiro#BEMFAM#19970000#1997#20100800#a12v86n4.htm##
00480000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170028000770180079001050660
01000184062002000194065000900214064000500223865000900228002001300237#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a12v86n4.htm#S#c#158#7#article#29#7#Brasil^dMinist
ério da Saúde#Pesquisa Nacional de Demografia e Saúde da Criança e da Mulher - P
NDS 2006^lpt#Brasí­lia#Ministério da Saúde#20090000#2009#20100800#a12v86n4.htm##
00427000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750160019000770180048000960660
01000144062000700154065000900161064000500170865000900175002001300184#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a12v86n4.htm#S#c#159#8#article#29#8#^rND^sMonteiro
^nCA#O panorama da nutrição infantil nos anos 90^lpt#Brasí­lia#UNICEF#19970000#1
997#20100800#a12v86n4.htm##
00487000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170028000770180086001050660
01000191062002000201065000900221064000500230865000900235002001300244#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a12v86n4.htm#S#c#160#9#article#29#9#Brasil^dMinist
ério da Saúde#Prevalência de Aleitamento Materno nas Capitais Brasileiras e no D
istrito Federal^lpt#Brasí­lia#Ministério da Saúde#20010000#2001#20100800#a12v86n
4.htm##
00595000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170111000790180098001900660
01000288062003100298065000900329064000500338865000900343002001300352#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a12v86n4.htm#S#c#161#10#article#29#10#Brasil^dMini
stério da Saúde. Secretaria de Atenção à Saúde. Departamento de Ações Programáti
cas e Estratégicas#II Pesquisa de Prevalência de Aleitamento Materno nas Capitai
s Brasileiras e Distrito Federal^lpt#Brasí­lia#Editora do Ministério da Saúde#20
090000#2009#20100800#a12v86n4.htm##
00430000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760160016000790180053000950660
01000148062000600158065000900164064000500173865000900178002001300187#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a12v86n4.htm#S#c#162#11#article#29#11#^rND^sSilva^
nNN#Amostragem Probabilística: um curso introdutório^lpt#São Paulo#EDUSP#1998000
0#1998#20100800#a12v86n4.htm##
00535000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170026000790180153001050660
00700258062000400265065000900269064000500278865000900283002001300292#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a12v86n4.htm#S#c#163#12#article#29#12#World Health
 Organization#Indicators for assessing infant and young child feeding practices:
 conclusions of a consensus meeting held 6-8 November 2007 in Washington D.C., U
SA^len#Geneva#WHO#20080000#2008#20100800#a12v86n4.htm##
00647000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100020000960100
02300116010001800139012008500157030002400242065000900266064000500275031000300280
014000600283865000900289002001300298035001000311801002400321#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a12v86n4.htm#S#c#164#13#article#29#13#^rND^sSantos^nLM#^rN
D^sPaes-Sousa^nR#^rND^sSilva Junior^nJB#^rND^sVictora^nCG#National Immunization 
Day: a strategy to monitor health and nutrition indicators^len#Bull World Health
 Organ#20080000#2008#86#474-9#20100800#a12v86n4.htm#0042-9686#Bull World Health 
Organ##
00455000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170028000790180062001070370
02600169110000900195109001100204865000900215002001300224#v86n4#V:\Scielo\serial\
jped\v86n4\markup\a12v86n4.htm#S#c#165#14#article#29#14#Brasil^dMinistério da Sa
úde#Sistema de informação do Programa Nacional de Imunizações^lpt#http://pni.dat
asus.gov.br#20100310#10/03/2010#20100800#a12v86n4.htm##
00539000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170028000790180107001070370
06500214110000900279109001100288865000900299002001300308#v86n4#V:\Scielo\serial\
jped\v86n4\markup\a12v86n4.htm#S#c#166#15#article#29#15#Brasil^dMinistério da Sa
úde#Sistema de Informações sobre Nascidos Vivos  SINASC. Situação da base de da
dos nacional em 14/12/2009^lpt#http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sinas
cp/cnv/nvuf.def#20100312#12/03/2010#20100800#a12v86n4.htm##
00552000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790120084000930300
01800177065000900195064000500204031000300209032000400212014000800216865000900224
002001300233035001000246801001800256#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
2v86n4.htm#S#c#167#16#article#29#16#^rND^sRea^nMF#Reflexões sobre a amamentação 
no Brasil: de como passamos a 10 meses de duração^lpt#Cad Saude Publica#20030000
#2003#19#^s1#S37-S45#20100800#a12v86n4.htm#0102-311X#Cad Saude Publica##
00720000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01700113010001800130010001900148012014700167030001800314065000900332064000500341
031000300346014000700349865000900356002001300365035001000378801001800388#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#c#168#17#article#29#17#^rND^sBr
unken^nGS#^rND^sSilva^nSM#^rND^sFrança^nGV#^rND^sEscuder^nMM#^rND^sVenâncio^nSI#
Risk factors for early interruption of exclusive breastfeeding and late introduc
tion of complementary foods among infants in midwestern Brazil^len#J Pediatr (Ri
o J)#20060000#2006#82#445-51#20100800#a12v86n4.htm#0021-7557#J Pediatr (Rio J)##
00580000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
02100114012011000135030000900245710000200254065000900256064000500265031000300270
014000700273865000900280002001300289#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
2v86n4.htm#S#c#169#18#article#29#18#^rND^sFerreira^nL#^rND^sParada^nCM#^rND^sCar
valhaes^nMA#Tendência do aleitamento materno em município da região centro-sul d
e estado de São Paulo: 1995-1999-2004^lpt#Rev Nutr#2#20070000#2007#20#265-73#201
00800#a12v86n4.htm##
00757000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01600114010001600130010001900146010002200165810000600187012013500193030001800328
06500090034606400050035503100030036001400060036386500090036900200130037803500100
0391801001800401#v86n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#c#170#1
9#article#29#19#^rND^sAlbernaz^nE#^rND^sAraújo^nCL#^rND^sTomasi^nE#^rND^sMintem^
nG#^rND^sGiugliani^nE#^rND^sMatijasevich^nA#et al#Influence of breastfeeding sup
port on the tendencies of breastfeeding rates in the city of Pelotas (RS), Brazi
l, from 1982 to 2004^len#J Pediatr (Rio J)#20080000#2008#84#560-4#20100800#a12v8
6n4.htm#0021-7557#J Pediatr (Rio J)##
00570000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100025000790120112001040300
01600216065000900232064000500241031000300246014000700249865000900256002001300265
035001000278801001600288#v86n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S
#c#171#20#article#29#20#^rND^sGrummer-Strawn^nLM#The effect of changes in popula
tion characteristics on breastfeeding trends in fifteen developing countries^len
#Int J Epidemiol#19960000#1996#25#94-102#20100800#a12v86n4.htm#0300-5771#Int J E
pidemiol##
00573000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100025000790120110001040300
01800214065000900232064000500241031000300246014000800249865000900257002001300266
035001000279801001800289#v86n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S
#c#172#21#article#29#21#^rND^sPérez-Escamilla^nR#Breastfeeding and the nutrition
al transition in the Latin American and Caribbean Region: a success story?^len#C
ad Saude Publica#20030000#2003#19#S119-27#20100800#a12v86n4.htm#0102-311X#Cad Sa
ude Publica##
00614000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01500113010001500128010001700143012006300160030001100223065000900234064000500243
031000300248014000600251865000900257002001300266035001000279801001100289#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#c#173#22#article#29#22#^rND^sLa
bbok^nMH#^rND^sWardlaw^nT#^rND^sBlanc^nA#^rND^sClark^nD#^rND^sTerreri^nN#Trends 
in exclusive breastfeeding: findings from the 1990s^len#J Hum Lact#20060000#2006
#22#272-6#20100800#a12v86n4.htm#0890-3344#J Hum Lact##
00459000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170026000790180077001050660
00700182062000400189065000900193064000500202865000900207002001300216#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a12v86n4.htm#S#c#174#23#article#29#23#World Health
 Organization#The optimal duration of exclusive breastfeeding. Note for the Pres
s No 7^len#Geneva#WHO#20010000#2001#20100800#a12v86n4.htm##
00486000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170026000790180104001050660
00700209062000400216065000900220064000500229865000900234002001300243#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a12v86n4.htm#S#c#175#24#article#29#24#World Health
 Organization#Infant and Young Child Feeding: A tool for assessing breastfeeding
 practices, policies and programs^len#Geneva#WHO#20030000#2003#20100800#a12v86n4
.htm##
00561000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100019000980120
11400117030001900231710000200250065000900252064000500261031000200266014000500268
865000900273002001300282#v86n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S
#c#176#25#article#29#25#^rND^sVenancio^nSI#^rND^sMonteiro^nCA#Individual and con
textual determinants of exclusive breastfeeding in São Paulo, Brazil: a multilev
el analysis^len#Public Health Nutr#2#20060000#2006#9#40-6#20100800#a12v86n4.htm#
#
00449000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170008000790180035000870370
06700122110000900189109001100198865000900209002001300218#v86n4#V:\Scielo\serial\
jped\v86n4\markup\a12v86n4.htm#S#c#177#26#article#29#26#FIOCRUZ#Rede de Bancos d
e Leite Humano^lpt#http://www.redeblh.fiocruz.br/cgi/cgilua.exe/sys/start.htm?si
d=352#20091015#15/10/2009#20100800#a12v86n4.htm##
00531000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170028000790180102001070370
06200209110000900271109001100280865000900291002001300300#v86n4#V:\Scielo\serial\
jped\v86n4\markup\a12v86n4.htm#S#c#178#27#article#29#27#Brasil^dMinistério da Sa
úde#A Iniciativa Hospital Amigo da Criança no Brasil: histórico, situação atual,
 ações e perspectivas^lpt#http://portal.saude.gov.br/portal/saude/area.cfm?id_ar
ea=1460#20091015#15/10/2009#20100800#a12v86n4.htm##
00658000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100035000790100014001140100
01900128010003300147012008400180030001800264065000900282064000500291031000300296
014000700299865000900306002001300315035001000328801001800338#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a12v86n4.htm#S#c#179#28#article#29#28#^rND^sde Fátima Mour
a de Araújo^nM#^rND^sRea^nMF#^rND^sPinheiro^nKA#^rND^sde Abreu Soares Schmitz^nB
#Avanços na norma brasileira de comercialização de alimentos para idade infantil
^lpt#Rev Saude Publica#20060000#2006#40#513-20#20100800#a12v86n4.htm#0034-8910#R
ev Saude Publica##
00503000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790120047000970180
04400144066001000188062000800198014000700206065000900213064000500222865000900227
002001300236#v86n4#V:\Scielo\serial\jped\v86n4\markup\a12v86n4.htm#S#c#180#29#ar
ticle#29#29#^rND^sAlencar^nSM#A Política Nacional de Aleitamento Materno^lpt#Pol
íticas, práticas e bases científicas^lpt#São Paulo#Sarvier#70-101#20080000#2008#
20100800#a12v86n4.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#o#1#1#article#1
#20110126#175556#a13v86n4.htm#187##
04512000000000673000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002100108
03100030012903200020013206500090013401400110014303500100015401200620016401200570
02260100041002830100048003240100039003720100052004110700053004630700101005160700
08300617070005500700083140700755085001002162085003502172085003102207085002402238
08500320226208312930229408500100358708500310359708500300362808500240365808500310
36821170008037130720003037211120009037241110011037331140009037441130011037530580
05003764060001103814002001303825#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86
n4.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#TAB#13#JPED030#nd#J. Pediatr. (Rio J.
)#86#4#20100800#^f325^l330#0021-7557#Síndrome metabólica: comparação de critério
s diagnósticos^lpt#Metabolic syndrome: comparison of diagnosis criteria^len#^rND
^1A01^nMônica de Lima Raeder^sCavali#^rND^1A02^nMaria Arlete Meil Schimith^sEscr
ivão#^rND^1A03^nRosana Sarmento^sBrasileiro#^rND^1A04^nJosé Augusto de Aguiar Ca
rrazedo^sTaddei#Universidade Estadual de Campinas^iA01^cCampinas^sSP#Universidad
e Federal de São Paulo^iA02^1Departamento de Pediatria^2Setor de Obesidade^cSão 
Paulo^sSP#Universidade Federal de São Paulo^iA03^1Escola Paulista de Medicina^cS
ão Paulo^sSP#UNIFESP^iA04^1Departamento de Pediatria^cSão Paulo^sSP#^lpt^aOBJETI
VO: Propor um critério para o diagnóstico da síndrome metabólica em adolescentes
 e verificar a sua concordância com os propostos por Jolliffe e Janssen e pela I
nternational Diabetes Federation (IDF). MÉTODO: Estudo transversal com 80 adoles
centes obesos de 14 a 19 anos. Foram realizadas avaliações antropométricas (peso
, estatura e circunferência da cintura), laboratoriais [triglicérides, high dens
ity lipoprotein cholesterol (HDLc), glicemia e insulinemia de jejum] e da pressã
o arterial. O índice HOMA-IR foi utilizado para caracterizar a resistência insul
ínica, e a presença de esteatose foi verificada pela ultrassonografia hepática. 
Análise de concordância entre os três critérios foi feita pela estatística de ka
ppa. RESULTADOS: Foram encontradas prevalências para síndrome metabólica de 13,7
5, 15 e 25%, utilizando os critérios da International Diabetes Federation, de Jo
lliffe e Janssen e da nova proposta, respectivamente. Verificou-se concordância 
quase perfeita entre Jolliffe e Janssen e a IDF (kappa = 0,94) e moderada entre 
a nova proposta e as duas anteriores (kappa = 0,46 e 0,41, respectivamente). CON
CLUSÕES: A prevalência mais alta da síndrome metabólica foi verificada pelo crit
ério proposto neste estudo, que incluiu a esteatose hepática e a resistência ins
ulínica entre os seus componentes, diagnosticando, desta forma, maior número de 
adolescentes com risco metabólico.#^ddecs^i1#^tm^lpt^kResistência insulínica^i1#
^tm^lpt^kesteatose hepática^i1#^tm^lpt^kadolescente^i1#^tm^lpt^ksíndrome metaból
ica^i1#^len^aOBJECTIVE: To propose a new criterion for the diagnosis of metaboli
c syndrome (MS) in adolescents and to check its consistency with those proposed 
by Jolliffe and Janssen and by the International Diabetes Federation (IDF). METH
OD: This is a cross-sectional study of 80 obese adolescents aged 14 to 19 years.
 Anthropometric (weight, height, and waist circumference) and laboratory (fastin
g triglycerides, HDLc, glucose, and insulin) parameters, as well as blood pressu
re were evaluated. The HOMA-IR index was used to characterize insulin resistance
, and the presence of steatosis was assessed by hepatic ultrasound. Agreement an
alyses across the three criteria were made using the kappa coefficient. RESULTS:
 The prevalence of MS was 13.5, 15, and 25% for IDF and Jolliffe and Janssen's c
riteria and the proposed method, respectively. A nearly perfect agreement betwee
n Jolliffe and Janssen's and IDF (kappa = 0.94) criteria and a moderate agreemen
t between the new criteria and the previous two (kappa = 0.46 and 0.41, respecti
vely) were observed. CONCLUSIONS: The highest prevalence of MS was observed with
 the criterion proposed in this study, which included steatosis and insulin resi
stance as parameters, thus being able to diagnose a larger number of adolescents
 at metabolic risk.#^ddecs^i2#^tm^len^kInsulin resistance^i2#^tm^len^khepatic st
eatosis^i2#^tm^len^kadolescents^i2#^tm^len^kmetabolic syndrome^i2#vancouv#31#201
00113#13.01.2010#20100310#10.03.2010#Fundo de Amparo à Pesquisa do Estado de São
 Paulo#0754490-8R#a13v86n4.htm##
04661000000000673000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002100108
03100030012903200020013206500090013401400110014303500100015401200760016401200710
02400100041003110100048003520100039004000100052004390700053004910700101005440700
08300645070005500728083144200783085001002225085003502235085003102270085002402301
08500320232508313210235708500100367808500310368808500300371908500240374908500310
37731170008038040720003038121120009038151110011038241140009038351130011038440580
05003855060006903905002001303974#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86
n4.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#TAB#13#JPED030#nd#J. Pediatr. (Rio J.
)#86#4#20100800#^f325^l330#0021-7557#<b>Síndrome metabólica</b>: <b>comparação d
e critérios diagnósticos</b>^lpt#<b>Metabolic syndrome</b>: <b>comparison of dia
gnosis criteria</b>^len#^rND^1A01^nMônica de Lima Raeder^sCavali#^rND^1A02^nMari
a Arlete Meil Schimith^sEscrivão#^rND^1A03^nRosana Sarmento^sBrasileiro#^rND^1A0
4^nJosé Augusto de Aguiar Carrazedo^sTaddei#Universidade Estadual de Campinas^iA
01^cCampinas^sSP#Universidade Federal de São Paulo^iA02^1Departamento de Pediatr
ia^2Setor de Obesidade^cSão Paulo^sSP#Universidade Federal de São Paulo^iA03^1Es
cola Paulista de Medicina^cSão Paulo^sSP#UNIFESP^iA04^1Departamento de Pediatria
^cSão Paulo^sSP#^lpt^a<b>OBJETIVO: </b>Propor um critério para o diagnóstico da 
síndrome metabólica em adolescentes e verificar a sua concordância com os propos
tos por Jolliffe e Janssen e pela International Diabetes Federation (IDF). <b>MÉ
TODO: </b>Estudo transversal com 80 adolescentes obesos de 14 a 19 anos. Foram r
ealizadas avaliações antropométricas (peso, estatura e circunferência da cintura
), laboratoriais [triglicérides, <i>high density lipoprotein cholesterol</i> (HD
Lc), glicemia e insulinemia de jejum] e da pressão arterial. O índice HOMA-IR fo
i utilizado para caracterizar a resistência insulínica, e a presença de esteatos
e foi verificada pela ultrassonografia hepática. Análise de concordância entre o
s três critérios foi feita pela estatística de kappa. <b>RESULTADOS: </b>Foram e
ncontradas prevalências para síndrome metabólica de 13,75, 15 e 25%, utilizando 
os critérios da International Diabetes Federation, de Jolliffe e Janssen e da no
va proposta, respectivamente. Verificou-se concordância quase perfeita entre Jol
liffe e Janssen e a IDF (kappa = 0,94) e moderada entre a nova proposta e as dua
s anteriores (kappa = 0,46 e 0,41, respectivamente). <b>CONCLUSÕES: </b>A preval
ência mais alta da síndrome metabólica foi verificada pelo critério proposto nes
te estudo, que incluiu a esteatose hepática e a resistência insulínica entre os 
seus componentes, diagnosticando, desta forma, maior número de adolescentes com 
risco metabólico.#^ddecs^i1#^tm^lpt^kResistência insulínica^i1#^tm^lpt^kesteatos
e hepática^i1#^tm^lpt^kadolescente^i1#^tm^lpt^ksíndrome metabólica^i1#^len^a<b>O
BJECTIVE: </b>To propose a new criterion for the diagnosis of metabolic syndrome
 (MS) in adolescents and to check its consistency with those proposed by Jolliff
e and Janssen and by the International Diabetes Federation (IDF). <b>METHOD: </b
>This is a cross-sectional study of 80 obese adolescents aged 14 to 19 years. An
thropometric (weight, height, and waist circumference) and laboratory (fasting t
riglycerides, HDLc, glucose, and insulin) parameters, as well as blood pressure 
were evaluated. The HOMA-IR index was used to characterize insulin resistance, a
nd the presence of steatosis was assessed by hepatic ultrasound. Agreement analy
ses across the three criteria were made using the kappa coefficient. <b>RESULTS:
 </b>The prevalence of MS was 13.5, 15, and 25% for IDF and Jolliffe and Janssen
's criteria and the proposed method, respectively. A nearly perfect agreement be
tween Jolliffe and Janssen's and IDF (kappa = 0.94) criteria and a moderate agre
ement between the new criteria and the previous two (kappa = 0.46 and 0.41, resp
ectively) were observed. <b>CONCLUSIONS: </b>The highest prevalence of MS was ob
served with the criterion proposed in this study, which included steatosis and i
nsulin resistance as parameters, thus being able to diagnose a larger number of 
adolescents at metabolic risk.#^ddecs^i2#^tm^len^kInsulin resistance^i2#^tm^len^
khepatic steatosis^i2#^tm^len^kadolescents^i2#^tm^len^kmetabolic syndrome^i2#van
couv#31#20100113#13.01.2010#20100310#10.03.2010#Fundo de Amparo à Pesquisa do Es
tado de São Paulo#<span style='font-size:10.0pt;font-family:Verdana'>0754490-8R<
/span>#a13v86n4.htm##
04667000000000697000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000400108121000300112049000800115158000300123
03000210012603100030014703200020015006500090015201400110016103500100017201200620
01820120057002440100041003010100048003420100039003900100052004290700055004810700
10300536070008500639070005700724083141600781085001002197085003502207085003102242
08500240227308500320229708313000232908500100362908500310363908500300367008500240
37000850031037241170008037550720003037631120009037661110011037751140009037861130
01103795058005003806060001103856002001303867008008903880#v86n4#V:\Scielo\serial\
jped\v86n4\markup\a13v86n4.htm#S#l#4#1#article#1#^mjul./ago.^a2010#oa#pt#br1.1#1
#4.0#tab#13#JPED030#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f325^l330#0021-7557#S
índrome metabólica: comparação de critérios diagnósticos^lpt#Metabolic syndrome:
 comparison of diagnosis criteria^len#^rND^1A01^nMônica de Lima Raeder^sCavali#^
rND^1A02^nMaria Arlete Meil Schimith^sEscrivão#^rND^1A03^nRosana Sarmento^sBrasi
leiro#^rND^1A04^nJosé Augusto de Aguiar Carrazedo^sTaddei#^iA01^1Universidade Es
tadual de Campinas^cCampinas^sSP#^iA02^1Universidade Federal de São Paulo^2Depar
tamento de Pediatria^3Setor de Obesidade^cSão Paulo^sSP#^iA03^1Universidade Fede
ral de São Paulo^2Escola Paulista de Medicina^cSão Paulo^sSP#^iA04^1UNIFESP^2Dep
artamento de Pediatria^cSão Paulo^sSP#^lpt^aOBJETIVO: Propor um critério para o 
diagnóstico da síndrome metabólica em adolescentes e verificar a sua concordânci
a com os propostos por Jolliffe e Janssen e pela International Diabetes Federati
on (IDF). MÉTODO: Estudo transversal com 80 adolescentes obesos de 14 a 19 anos.
 Foram realizadas avaliações antropométricas (peso, estatura e circunferência da
 cintura), laboratoriais [triglicérides, high density lipoprotein cholesterol (H
DLc), glicemia e insulinemia de jejum] e da pressão arterial. O índice HOMA-IR f
oi utilizado para caracterizar a resistência insulínica, e a presença de esteato
se foi verificada pela ultrassonografia hepática. Análise de concordância entre 
os três critérios foi feita pela estatística de kappa. RESULTADOS: Foram encontr
adas prevalências para síndrome metabólica de 13,75, 15 e 25 por cento, utilizan
do os critérios da International Diabetes Federation, de Jolliffe e Janssen e da
 nova proposta, respectivamente. Verificou-se concordância quase perfeita entre 
Jolliffe e Janssen e a IDF (kappa = 0,94) e moderada entre a nova proposta e as 
duas anteriores (kappa = 0,46 e 0,41, respectivamente). CONCLUSÕES: A prevalênci
a mais alta da síndrome metabólica foi verificada pelo critério proposto neste e
studo, que incluiu a esteatose hepática e a resistência insulínica entre os seus
 componentes, diagnosticando, desta forma, maior número de adolescentes com risc
o metabólico.#^ddecs^i1#^tm^lpt^kResistência insulínica^i1#^tm^lpt^kesteatose he
pática^i1#^tm^lpt^kadolescente^i1#^tm^lpt^ksíndrome metabólica^i1#^len^aOBJECTIV
E: To propose a new criterion for the diagnosis of metabolic syndrome (MS) in ad
olescents and to check its consistency with those proposed by Jolliffe and Janss
en and by the International Diabetes Federation (IDF). METHOD: This is a cross-s
ectional study of 80 obese adolescents aged 14 to 19 years. Anthropometric (weig
ht, height, and waist circumference) and laboratory (fasting triglycerides, HDLc
, glucose, and insulin) parameters, as well as blood pressure were evaluated. Th
e HOMA-IR index was used to characterize insulin resistance, and the presence of
 steatosis was assessed by hepatic ultrasound. Agreement analyses across the thr
ee criteria were made using the kappa coefficient. RESULTS: The prevalence of MS
 was 13.5, 15, and 25 percent for IDF and Jolliffe and Janssen's criteria and th
e proposed method, respectively. A nearly perfect agreement between Jolliffe and
 Janssen's and IDF (kappa = 0.94) criteria and a moderate agreement between the 
new criteria and the previous two (kappa = 0.46 and 0.41, respectively) were obs
erved. CONCLUSIONS: The highest prevalence of MS was observed with the criterion
 proposed in this study, which included steatosis and insulin resistance as para
meters, thus being able to diagnose a larger number of adolescents at metabolic 
risk.#^ddecs^i2#^tm^len^kInsulin resistance^i2#^tm^len^khepatic steatosis^i2#^tm
^len^kadolescents^i2#^tm^len^kmetabolic syndrome^i2#vancouv#31#20100113#13.01.20
10#20100310#10.03.2010#Fundo de Amparo à Pesquisa do Estado de São Paulo#0754490
-8R#a13v86n4.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pi
d=S0021-75572010000400013##
00323000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704009000074002001300164#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#5#1#article#152#<p align="right"><fon
t size="2" face="Verdana"><b>ARTIGO ORIGINAL</b></font> </p>     ^cY#a13v86n4.ht
m##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#6#2#article#152#<p>&nbsp;</p>     ^cY
#a13v86n4.htm##
00395000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704016200074002001300236#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#7#3#article#152#<p><font size="4" fac
e="Verdana"><b>S&iacute;ndrome metab&oacute;lica: compara&ccedil;&atilde;o    de
 crit&eacute;rios diagn&oacute;sticos</b></font></p>     ^cY#a13v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#8#4#article#152#<p>&nbsp;</p>     ^cY
#a13v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#9#5#article#152#<p>&nbsp;</p>     ^cY
#a13v86n4.htm##
00506000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704027200075002001300347#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#10#6#article#152#<p><font size="2" fa
ce="Verdana"><b>M&ocirc;nica de Lima Raeder Cavali<sup>I</sup>;    Maria Arlete 
Meil Schimith Escriv&atilde;o<sup>II</sup>; Rosana Sarmento Brasileiro<sup>III</
sup>;    Jos&eacute; Augusto de Aguiar Carrazedo Taddei<sup>IV</sup></b></font><
/p>     ^cY#a13v86n4.htm##
00366000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704013200075002001300207#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#11#7#article#152#<p><font size="2" fa
ce="Verdana"><sup>I</sup>Mestre, Pediatria, Universidade Estadual    de Campinas
 (UNICAMP), Campinas, SP    ^cY#a13v86n4.htm##
00440000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704020600075002001300281#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#12#8#article#152#<br>   <sup>II</sup>
Doutora, Pediatria, Chefe,    Setor de Obesidade, Disciplina de Nutrologia, Depa
rtamento de Pediatria, Universidade    Federal de S&atilde;o Paulo (UNIFESP), S&
atilde;o Paulo, SP    ^cY#a13v86n4.htm##
00413000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704017900075002001300254#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#13#9#article#152#<br>   <sup>III</sup
>Doutora, Nutri&ccedil;&atilde;o,    Universidade Federal de S&atilde;o Paulo &#
150; Escola Paulista de Medicina (UNIFESP-EPM),    S&atilde;o Paulo, SP    ^cY#a
13v86n4.htm##
00381000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014600076002001300222#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#14#10#article#152#<br>   <sup>IV</sup
>Professor associado, Disciplina    de Nutrologia, Departamento de Pediatria, UN
IFESP, S&atilde;o Paulo, SP</font></p>     ^cY#a13v86n4.htm##
00368000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013300076002001300209#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#15#11#article#152#<p><font size="2" f
ace="Verdana"><a name="topo" id="topo"></a><a href="#correspondence">Correspond&
ecirc;ncia</a></font></p>     ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#16#12#article#152#<p>&nbsp;</p>     ^
cY#a13v86n4.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#17#13#article#152#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a13v86n4.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006600076002001300142#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#18#14#article#152#<p><font size="2" f
ace="Verdana"><b>RESUMO</b></font></p>     ^cY#a13v86n4.htm##
00533000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029800076002001300374#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#19#15#article#152#<p><font size="2" f
ace="Verdana"> <b>OBJETIVO: </b> Propor um crit&eacute;rio    para o diagn&oacut
e;stico da s&iacute;ndrome metab&oacute;lica em adolescentes    e verificar a su
a concord&acirc;ncia com os propostos por Jolliffe e Janssen    e pela Internati
onal Diabetes Federation (IDF).    ^cY#a13v86n4.htm##
00935000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704070000076002001300776#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#20#16#article#152#<br>   <b>M&Eacute;
TODO: </b> Estudo transversal com 80 adolescentes obesos de 14 a    19 anos. For
am realizadas avalia&ccedil;&otilde;es antropom&eacute;tricas (peso,    estatura
 e circunfer&ecirc;ncia da cintura), laboratoriais &#091;triglic&eacute;rides,  
  <i>high density lipoprotein cholesterol</i> (HDLc), glicemia e insulinemia de 
   jejum&#093; e da press&atilde;o arterial. O &iacute;ndice HOMA-IR foi utiliza
do para    caracterizar a resist&ecirc;ncia insul&iacute;nica, e a presen&ccedil
;a de esteatose    foi verificada pela ultrassonografia hep&aacute;tica. An&aacu
te;lise de concord&acirc;ncia    entre os tr&ecirc;s crit&eacute;rios foi feita 
pela estat&iacute;stica de kappa.    ^cY#a13v86n4.htm##
00696000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046100076002001300537#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#21#17#article#152#<br>   <b>RESULTADO
S: </b>Foram encontradas preval&ecirc;ncias para s&iacute;ndrome    metab&oacute
;lica de 13,75, 15 e 25%, utilizando os crit&eacute;rios da International    Dia
betes Federation, de Jolliffe e Janssen e da nova proposta, respectivamente.    
Verificou-se concord&acirc;ncia quase perfeita entre Jolliffe e Janssen e a    I
DF (kappa = 0,94) e moderada entre a nova proposta e as duas anteriores (kappa  
  = 0,46 e 0,41, respectivamente).    ^cY#a13v86n4.htm##
00627000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039200076002001300468#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#22#18#article#152#<br>   <b>CONCLUS&O
tilde;ES: </b> A preval&ecirc;ncia mais alta da s&iacute;ndrome    metab&oacute;
lica foi verificada pelo crit&eacute;rio proposto neste estudo,    que incluiu a
 esteatose hep&aacute;tica e a resist&ecirc;ncia insul&iacute;nica    entre os s
eus componentes, diagnosticando, desta forma, maior n&uacute;mero    de adolesce
ntes com risco metab&oacute;lico.</font></p>     ^cY#a13v86n4.htm##
00448000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021300076002001300289#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#23#19#article#152#<p><font size="2" f
ace="Verdana"><b>Palavras-chave: </b> Resist&ecirc;ncia insul&iacute;nica,    es
teatose hep&aacute;tica, adolescente, s&iacute;ndrome metab&oacute;lica.</font><
/p> <hr size="1" noshade>     ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#24#20#article#152#<p>&nbsp;</p>     ^
cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#25#21#article#152#<p>&nbsp;</p>     ^
cY#a13v86n4.htm##
00319000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008400076002001300160#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#26#22#article#152#<p><font size="3" f
ace="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#a13v86n4.htm##
00763000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052800076002001300604#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#27#23#article#152#<p><font face="Verd
ana" size="2">A s&iacute;ndrome metab&oacute;lica (SM) &eacute;    definida como
 uma associa&ccedil;&atilde;o de situa&ccedil;&otilde;es cl&iacute;nicas    que 
inclui hipertens&atilde;o arterial, dislipidemias, altera&ccedil;&otilde;es    d
o metabolismo da glicose e obesidade, especialmente abdominal, com dep&oacute;si
tos    intra-abdominais de gordura. A SM representa um agrupamento de fatores de
 risco    para o desenvolvimento das doen&ccedil;as cardiovasculares (DCV)<SUP>1
,2</SUP>.</font></p>     ^cY#a13v86n4.htm##
00945000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071000076002001300786#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#28#24#article#152#<p><font face="Verd
ana" size="2">A preval&ecirc;ncia da SM, entre as crian&ccedil;as    e os adoles
centes, aumentou concomitantemente ao aumento do n&uacute;mero de    casos de ob
esidade e suas comorbidades<SUP>3</SUP>. An&aacute;lises de dados    do National
 Health and Nutrition Examination Survey (NHANES) III (1988-1992)    e do NHANES
 (1999-2000) constataram aumento da preval&ecirc;ncia de SM de 4,2    para 6,4% 
na popula&ccedil;&atilde;o de adolescentes americanos<SUP>4</SUP>.    Estudo rea
lizado em crian&ccedil;as e adolescentes obesos encontrou preval&ecirc;ncia    d
a SM de 38,7 e 49,7% entre aqueles que apresentavam obesidade moderada e grave, 
   respectivamente<SUP>5</SUP>.</font></p>     ^cY#a13v86n4.htm##
00823000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058800076002001300664#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#29#25#article#152#<p><font face="Verd
ana" size="2">Observa-se ampla variabilidade na preval&ecirc;ncia    da SM entre
 os diversos estudos, devido aos diferentes crit&eacute;rios diagn&oacute;sticos
    utilizados. Reinehr et al.<SUP>6</SUP> compararam a preval&ecirc;ncia da SM 
   em crian&ccedil;as e adolescentes utilizando oito diferentes defini&ccedil;&o
tilde;es.    A preval&ecirc;ncia variou de 6 a 39%, e somente 2% deles preencher
am todos    os crit&eacute;rios propostos, refor&ccedil;ando a necessidade da pa
droniza&ccedil;&atilde;o    de um crit&eacute;rio diagn&oacute;stico.</font></p>
     ^cY#a13v86n4.htm##
01203000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704096800076002001301044#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#30#26#article#152#<p><font face="Verd
ana" size="2">V&aacute;rios crit&eacute;rios para o diagn&oacute;stico    da SM 
em crian&ccedil;as e adolescentes j&aacute; foram propostos<SUP>5,7-9</SUP>,    
mas ainda n&atilde;o h&aacute; consenso na literatura sobre o mais adequado.    
As constantes mudan&ccedil;as fisiol&oacute;gicas no metabolismo e na composi&cc
edil;&atilde;o    corporal, que ocorrem nessas faixas et&aacute;rias, dificultam
 o estabelecimento    de pontos de corte espec&iacute;ficos para os par&acirc;me
tros utilizados nesse    diagn&oacute;stico. Al&eacute;m disso, faltam estudos d
e longo seguimento com    crian&ccedil;as e adolescentes, associando esses valor
es com morbidades futuras.    O crit&eacute;rio para o diagn&oacute;stico da SM,
 na inf&acirc;ncia e na adolesc&ecirc;ncia,    deve conter par&acirc;metros que 
contemplem as altera&ccedil;&otilde;es metab&oacute;licas    de ocorr&ecirc;ncia
 mais precoce na crian&ccedil;a e no adolescente.</font></p>     ^cY#a13v86n4.ht
m##
00549000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031400076002001300390#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#31#27#article#152#<p><font face="Verd
ana" size="2">Weiss et al.<SUP>5</SUP> observaram que a resist&ecirc;ncia    ins
ul&iacute;nica (RI) era fator independente para o diagn&oacute;stico da SM    em
 crian&ccedil;as e adolescentes com excesso de peso e que a preval&ecirc;ncia   
 da SM aumentava com a piora da RI.</font></p>     ^cY#a13v86n4.htm##
00781000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054600076002001300622#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#32#28#article#152#<p><font face="Verd
ana" size="2">O padr&atilde;o-ouro para a medida da RI &eacute;    o <i>clamp</i
> euglic&ecirc;mico hiperinsulin&ecirc;mico, embora ele n&atilde;o    seja utili
zado na pr&aacute;tica cl&iacute;nica<SUP>10</SUP>. O &iacute;ndice    HOMA-IR (
<i>homeostasis model assessment &#150; insulin resistance</i>) pode ser    usado
 como m&eacute;todo alternativo na avalia&ccedil;&atilde;o da RI, por apresentar
    boa correla&ccedil;&atilde;o com o <i>clamp</i> euglic&ecirc;mico hiperinsul
in&ecirc;mico<SUP>11</SUP>.</font></p>     ^cY#a13v86n4.htm##
01538000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704130300076002001301379#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#33#29#article#152#<p><font face="Verd
ana" size="2">Chan et al.<SUP>12</SUP>, a partir de revis&atilde;o    sistem&aac
ute;tica da literatura, prop&otilde;em que a doen&ccedil;a gordurosa    do f&iac
ute;gado n&atilde;o alco&oacute;lica (DGFNA) seja reconhecida como um    compone
nte da SM, por estar envolvida no contexto dos fatores de risco para    o desenv
olvimento do diabetes melito tipo 2 e da DCV precoce. Musso et al.<SUP>13</SUP> 
   verificaram associa&ccedil;&atilde;o positiva entre RI e DGFNA e tamb&eacute;
m    sugeriram a inclus&atilde;o da DGFNA nos crit&eacute;rios para o diagn&oacu
te;stico    da SM. D'&Aacute;damo et al.<SUP>14</SUP>, em estudo transversal com
 100 crian&ccedil;as    obesas e pr&eacute;-p&uacute;beres, encontraram preval&e
circ;ncia de esteatose    hep&aacute;tica de 52%. As crian&ccedil;as obesas com 
esteatose, quando comparadas    com o grupo-controle de eutr&oacute;ficas e tamb
&eacute;m com aquelas obesas    sem esteatose, apresentavam valores de HOMA-IR m
ais elevados, o que sugere haver    associa&ccedil;&atilde;o entre RI e esteatos
e. Sartorio et al.<SUP>15</SUP>,    avaliando crian&ccedil;as e adolescentes obe
sos, detectaram esteatose em 44%    deles, e o HOMA-IR tamb&eacute;m foi maior n
os obesos com esteatose, comparados    aos obesos sem esteatose.</font></p>     
^cY#a13v86n4.htm##
00636000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040100076002001300477#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#34#30#article#152#<p><font face="Verd
ana" size="2">Apesar das dificuldades para se estabelecer o    diagn&oacute;stic
o da SM, cabe ressaltar a import&acirc;ncia da identifica&ccedil;&atilde;o    de
 crian&ccedil;as e adolescentes que preencham os requisitos para esse diagn&oacu
te;stico,    pois s&atilde;o indiv&iacute;duos de maior risco metab&oacute;lico 
e devem ser    adequadamente acompanhados.</font></p>     ^cY#a13v86n4.htm##
00574000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033900076002001300415#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#35#31#article#152#<p><font face="Verd
ana" size="2">O objetivo do presente estudo &eacute; propor    um novo crit&eacu
te;rio para o diagn&oacute;stico da SM em adolescentes obesos    e verificar a s
ua concord&acirc;ncia com os propostos por Jolliffe &amp; Janssen<SUP>8</SUP>   
 e pela International Diabetes Federation (IDF)<SUP>9</SUP>.</font></p>     ^cY#
a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#36#32#article#152#<p>&nbsp;</p>     ^
cY#a13v86n4.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007400076002001300150#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#37#33#article#152#<p><font size="3" f
ace="Verdana"><b>M&eacute;todos</b></font></p>     ^cY#a13v86n4.htm##
01048000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704081300076002001300889#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#38#34#article#152#<p><font face="Verd
ana" size="2">Trata-se de um estudo transversal, realizado    em adolescentes de
 ambos os sexos, obesos &#091;&iacute;ndice de massa corporal (IMC)    &gt; P95&
#093;, na faixa et&aacute;ria de 14 a 19 anos, matriculados em quatro escolas   
 p&uacute;blicas da mesma regi&atilde;o, na cidade de S&atilde;o Paulo (SP).    
Foram exclu&iacute;dos os adolescentes com doen&ccedil;as agudas ou cr&ocirc;nic
as,    aqueles que estavam em tratamento para perda de peso e as adolescentes gr
&aacute;vidas    ou em lacta&ccedil;&atilde;o. O estudo foi aprovado pelo Comit&
ecirc; de &Eacute;tica    em Pesquisa da Universidade Federal de S&atilde;o Paul
o (UNIFESP), e os dados    somente foram coletados ap&oacute;s o consentimento d
e todos os adolescentes    e seus respons&aacute;veis.</font></p>     ^cY#a13v86
n4.htm##
01254000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704101900076002001301095#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#39#35#article#152#<p><font face="Verd
ana" size="2">Dos 2.330 adolescentes avaliados, 150 (6,43%)    foram diagnostica
dos como obesos. Entre estes, 26 (17,33%) apresentavam os crit&eacute;rios    de
 exclus&atilde;o citados acima. Dos 124 alunos restantes, 42 (33,87%) recusaram-
se    a participar do estudo, e dois (1,61%) abandonaram o projeto no decorrer d
a    fase de coleta de dados laboratoriais. Chegaram ao final do protocolo, 80 a
dolescentes    obesos (64,5% da amostra inicial). Quando comparadas as m&eacute;
dias dos valores    de IMC, estratificados por idade e sexo, da amostra analisad
a com as m&eacute;dias    dos valores de IMC dos 44 adolescentes que n&atilde;o 
participaram do estudo,    n&atilde;o foram encontradas diferen&ccedil;as signif
icantes entre os grupos,    evid&ecirc;ncia de que as perdas n&atilde;o introduz
iram vi&eacute;s de sele&ccedil;&atilde;o.    Da mesma forma, foram mantidas as 
proporcionalidades em rela&ccedil;&atilde;o    &agrave; idade, ao sexo e ao dese
nvolvimento puberal.</font></p>     ^cY#a13v86n4.htm##
01749000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704151400076002001301590#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#40#36#article#152#<p><font face="Verd
ana" size="2">Para a avalia&ccedil;&atilde;o do peso, foi usada    uma balan&cce
dil;a digital marca Kratos<sup>&reg;</sup>, modelo Linea, e para    a estatura, 
utilizou-se o antrop&ocirc;metro port&aacute;til Alturaexata<sup>&reg;</sup>,   
 ambos dispostos em superf&iacute;cie plana e firme. A medida da circunfer&ecirc
;ncia    da cintura (CC) foi feita no ponto m&eacute;dio entre a &uacute;ltima c
ostela    e a crista il&iacute;aca, utilizando-se uma fita inextens&iacute;vel. 
A medida    da press&atilde;o arterial e o diagn&oacute;stico de hipertens&atild
e;o foram    feitos de acordo com as recomenda&ccedil;&otilde;es do National Hig
h Blood Pressure    Education Program Working Group on High Blood Pressure in Ch
ildren and Adolescents<SUP>16</SUP>.    As amostras de sangue foram coletadas po
r pun&ccedil;&atilde;o venosa, ap&oacute;s    12 horas de jejum, e para as dosag
ens de glicemia, insulina e perfil lip&iacute;dico,    foram utilizadas t&eacute
;cnicas laboratoriais convencionais. Foram considerados    os pontos de corte pr
opostos pela American Heart Association (AHA)<SUP>17</SUP>    para o perfil lip&
iacute;dico. O &iacute;ndice HOMA-IR, utilizado para a classifica&ccedil;&atilde
;o    de RI, foi obtido multiplicando-se o valor da insulina plasm&aacute;tica d
e    jejum (µU/mL) pelo valor da glicemia de jejum (mmol/L) e dividindo-se esse 
produto    por 22,5<SUP>18</SUP>. Valores maiores do que 3,43 foram considerados
 indicadores    de RI<SUP>19</SUP>.</font></p>     ^cY#a13v86n4.htm##
00527000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029200076002001300368#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#41#37#article#152#<p><font face="Verd
ana" size="2">Ultrassonografia hep&aacute;tica foi realizada    pela mesma equip
e de radiologistas, com o aparelho modelo LOGIC 400 PRO-GE.    A esteatose foi c
lassificada como m&iacute;nima, moderada ou grave, segundo    Saverymutu et al.<
SUP>20</SUP>.</font></p>     ^cY#a13v86n4.htm##
01169000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704093400076002001301010#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#42#38#article#152#<p><font face="Verd
ana" size="2">A nova proposta considerou para o diagn&oacute;stico    de SM a pr
esen&ccedil;a de tr&ecirc;s ou mais dos seguintes componentes: CC    (90 cm para
 meninos e 80 cm para meninas) &#150; como sugerido pela IDF<SUP>21</SUP>    par
a a popula&ccedil;&atilde;o sul-americana, uma vez que ainda n&atilde;o existe  
  uma curva nacional espec&iacute;fica e todos os adolescentes apresentavam dese
nvolvimento    puberal <u>&gt;</u> 4, segundo os crit&eacute;rios de Tanner, hip
ertens&atilde;o    arterial<SUP>16</SUP>, hipertrigliceridemia e/ou diminui&cced
il;&atilde;o de    HDLc (<i>high density lipoprotein cholesterol</i>)<SUP>17</SU
P>, RI avaliada    pelo HOMA-IR<SUP>19</SUP> e presen&ccedil;a de esteatose<SUP>
20</SUP>. A <a href=/img/revistas/jped/v86n4/4a13t1.gif>Tabela    1</a> mostra o
s par&acirc;metros e os respectivos pontos de corte, segundo os    diferentes cr
it&eacute;rios.</font></p>     ^cY#a13v86n4.htm##
00730000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049500076002001300571#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#43#39#article#152#<p><font face="Verd
ana" size="2"> A caracteriza&ccedil;&atilde;o da amostra foi    realizada pela e
stat&iacute;stica descritiva &#091;m&eacute;dia, desvio padr&atilde;o    e inter
valo de confian&ccedil;a de 95% (IC95%)&#093;, e a an&aacute;lise de concord&aci
rc;ncia    dos tr&ecirc;s crit&eacute;rios para o diagn&oacute;stico de SM foi f
eita pela    estat&iacute;stica de kappa. Utilizou-se o programa Stata 10.0 para
 as an&aacute;lises    estat&iacute;sticas<SUP>22</SUP>.</font></p>     ^cY#a13v
86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#44#40#article#152#<p>&nbsp;</p>     ^
cY#a13v86n4.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007000076002001300146#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#45#41#article#152#<p><font size="3" f
ace="Verdana"><b>Resultados</b></font></p>     ^cY#a13v86n4.htm##
01308000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704107300076002001301149#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#46#42#article#152#<p><font face="Verd
ana" size="2">Do total de 80 adolescentes, 33 (41,25%) eram    do sexo masculino
. A m&eacute;dia de idade foi de 15,96 anos, e a m&eacute;dia    do IMC, de 32,5
3 kg/m<SUP sa>2</SUP> (<a href=#702t2 >Tabela 2</a>). Os adolescentes    do sexo
 masculino apresentaram maior peso (97,46<i> versus</i> 88,81 kg; p =    0,006) 
e maior estatura (174,05 <i>versus</i> 164,45 cm; p = 0,000) em rela&ccedil;&ati
lde;o    ao sexo feminino, embora n&atilde;o tenha havido diferen&ccedil;a signi
ficante    no IMC (p = 0,526). N&atilde;o houve diferen&ccedil;a significante en
tre as    m&eacute;dias de CC (p = 0,098), press&atilde;o arterial diast&oacute;
lica (p    = 0,336), triglic&eacute;rides (TG) (p = 0,589), HDLc (p = 0,164) e H
OMA (p    = 0,28), quando avaliadas em rela&ccedil;&atilde;o ao sexo, exceto par
a press&atilde;o    arterial sist&oacute;lica (p = 0,040). Encontrou-se esteatos
e em 16,88% da popula&ccedil;&atilde;o    estudada (<a href=#702t2 >Tabela 2</a>
), sendo mais frequente no sexo masculino    (18,18 <i>versus </i>15,91%).</font
></p>     ^cY#a13v86n4.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#47#43#article#152#<p><a name=702t2 id
=702t2 ></a></p>     ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#48#44#article#152#<p>&nbsp;</p>     ^
cY#a13v86n4.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007800076002001300154#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#49#45#article#152#<p align="center"><
img src="/img/revistas/jped/v86n4/4a13t2.gif"></p>     ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#50#46#article#152#<p>&nbsp;</p>     ^
cY#a13v86n4.htm##
00529000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704029400076002001300370#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#51#47#article#152#<p><font face="Verd
ana" size="2">A preval&ecirc;ncia da SM variou de acordo com    o crit&eacute;ri
o utilizado. O crit&eacute;rio da IDF diagnosticou a SM em 13,75%    dos adolesc
entes; o crit&eacute;rio de Jolliffe &amp; Janssen, em 15%; e a nova    proposta
, em 25% deles.</font></p>     ^cY#a13v86n4.htm##
00896000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704066100076002001300737#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#52#48#article#152#<p><font face="Verd
ana" size="2">A concord&acirc;ncia no diagn&oacute;stico da    SM pelos crit&eac
ute;rios da IDF e de Jolliffe &amp; Janssen foi quase perfeita    (kappa = 0,94;
 p &lt; 0,001). Os 11 adolescentes que tiveram o diagn&oacute;stico    de SM pel
a classifica&ccedil;&atilde;o de Jolliffe &amp; Janssen tamb&eacute;m    o tiver
am pela classifica&ccedil;&atilde;o da IDF, e somente um caso foi diagnosticado 
   apenas pela classifica&ccedil;&atilde;o de Jolliffe &amp; Janssen. Cabe ressa
ltar    que os 68 casos n&atilde;o diagnosticados pelo IDF tamb&eacute;m n&atild
e;o    o foram pelo crit&eacute;rio de Jolliffe &amp; Janssen.</font></p>     ^c
Y#a13v86n4.htm##
00760000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052500076002001300601#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#53#49#article#152#<p><font face="Verd
ana" size="2">A concord&acirc;ncia no diagn&oacute;stico da    SM pelas classifi
ca&ccedil;&otilde;es da IDF e da nova proposta foi moderada    (kappa = 0,41; p 
&lt; 0,001) (<a href=#702t3 >Tabela 3</a>). Verificou-se que,    dos 20 diagn&oa
cute;sticos da SM pela nova proposta, oito concordaram, e, em    12, houve diagn
&oacute;stico apenas pela nova proposta. Os 12 adolescentes diagnosticados    pe
la nova proposta apresentavam RI, e somente um tinha glicemia alterada (103    m
g/dL).</font></p>     ^cY#a13v86n4.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#54#50#article#152#<p><a name=702t3 id
=702t3 ></a></p>     ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#55#51#article#152#<p>&nbsp;</p>     ^
cY#a13v86n4.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007800076002001300154#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#56#52#article#152#<p align="center"><
img src="/img/revistas/jped/v86n4/4a13t3.gif"></p>     ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#57#53#article#152#<p>&nbsp;</p>     ^
cY#a13v86n4.htm##
01002000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076700076002001300843#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#58#54#article#152#<p><font face="Verd
ana" size="2">Do mesmo modo, ao serem analisados os resultados    obtidos pelas 
classifica&ccedil;&otilde;es de Jolliffe &amp; Janssen e da nova    proposta, ho
uve concord&acirc;ncia moderada no estabelecimento do diagn&oacute;stico    (kap
pa = 0,46; p &lt; 0,001) (<a href=#702t4 >Tabela 4</a>). Enquanto a classifica&c
cedil;&atilde;o    de Jolliffe &amp; Janssen estabeleceu isoladamente o diagn&oa
cute;stico em tr&ecirc;s    adolescentes, a nova proposta o fez em 11. Os 11 cas
os diagnosticados pela nova    proposta apresentavam RI. Os tr&ecirc;s adolescen
tes, que tiveram diagn&oacute;stico    de SM pelas classifica&ccedil;&otilde;es 
da IDF e de Jolliffe &amp; Janssen,    e n&atilde;o pela nova proposta, foram os
 mesmos.</font></p>     ^cY#a13v86n4.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#59#55#article#152#<p><a name=702t4 id
=702t4 ></a></p>     ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#60#56#article#152#<p>&nbsp;</p>     ^
cY#a13v86n4.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007800076002001300154#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#61#57#article#152#<p align="center"><
img src="/img/revistas/jped/v86n4/4a13t4.gif"></p>     ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#62#58#article#152#<p>&nbsp;</p>     ^
cY#a13v86n4.htm##
00391000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704015600076002001300232#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#63#59#article#152#<p><font face="Verd
ana" size="2">Entre todos os adolescentes com diagn&oacute;stico    de RI, 70% a
presentavam glicemia de jejum normal.</font></p>     ^cY#a13v86n4.htm##
00929000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069400076002001300770#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#64#60#article#152#<p><font face="Verd
ana" size="2">Quando foram analisados os resultados do ultrassom    hep&aacute;t
ico, verificou-se esteatose em 13 adolescentes, sendo que sete pertenciam    ao 
grupo com diagn&oacute;stico de SM. Importante salientar que, destes sete,    ci
nco tiveram o diagn&oacute;stico da SM somente pela nova proposta, e os outros  
  dois, pelas tr&ecirc;s classifica&ccedil;&otilde;es. Houve diferen&ccedil;a   
 significante entre as m&eacute;dias do HOMA-IR quando se considerou a presen&cc
edil;a    ou aus&ecirc;ncia de esteatose (4,68 <i>versus</i> 3,05; p = 0,001). A
 m&eacute;dia    do HOMA-IR foi significantemente mais elevada na presen&ccedil;
a de esteatose.</font></p>     ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#65#61#article#152#<p>&nbsp;</p>     ^
cY#a13v86n4.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#66#62#article#152#<p><font size="3" f
ace="Verdana"><b>Discuss&atilde;o</b></font></p>     ^cY#a13v86n4.htm##
00820000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058500076002001300661#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#67#63#article#152#<p><font face="Verd
ana" size="2">Observa-se, na literatura, grande varia&ccedil;&atilde;o    na pre
val&ecirc;ncia da SM em crian&ccedil;as e adolescentes, devido aos diferentes   
 crit&eacute;rios diagn&oacute;sticos utilizados<SUP>6,23,24</SUP>. A maioria   
 deles deriva dos crit&eacute;rios usados para o adulto, e, dessa forma, anormal
idades    que ocorrem com frequ&ecirc;ncias mais baixas na inf&acirc;ncia e na a
dolesc&ecirc;ncia,    como &eacute; o caso da glicemia alterada, podem estar inc
lu&iacute;das entre    os requisitos para esse diagn&oacute;stico.</font></p>   
  ^cY#a13v86n4.htm##
00671000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043600076002001300512#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#68#64#article#152#<p><font face="Verd
ana" size="2">No presente estudo, a preval&ecirc;ncia da SM    variou de acordo 
com o crit&eacute;rio utilizado, sendo de 13,75% para o da    IDF, 15% para o de
 Jolliffe &amp; Janssen e 25% para o da nova proposta. Outros    autores, que co
mpararam a preval&ecirc;ncia de SM usando diferentes crit&eacute;rios,    tamb&e
acute;m encontraram varia&ccedil;&otilde;es entre os valores<SUP>23,24</SUP>.</f
ont></p>     ^cY#a13v86n4.htm##
02295000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704206000076002001302136#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#69#65#article#152#<p><font face="Verd
ana" size="2">A grande concord&acirc;ncia na preval&ecirc;ncia    da SM entre os
 crit&eacute;rios de Jolliffe &amp; Janssen e da IDF pode ser    explicada pela 
utiliza&ccedil;&atilde;o dos mesmos par&acirc;metros, embora    com pontos de co
rte diferentes. A nova proposta apresentou concord&acirc;ncia    moderada com os
 crit&eacute;rios de Jolliffe &amp; Janssen e da IDF, mas fez    diagn&oacute;st
ico de SM em maior percentual de adolescentes, o que pode ser    explicado pela 
substitui&ccedil;&atilde;o da glicemia pela RI (30 adolescentes    com RI, sendo
 somente nove com glicemia <u>&gt;</u> 100 mg/dL). Weiss et al.<SUP>5</SUP>    c
hamam a aten&ccedil;&atilde;o para o fato de a glicemia de jejum alterar-se    t
ardiamente na evolu&ccedil;&atilde;o da SM nas crian&ccedil;as e nos adolescente
s.    Neste estudo, foi utilizado o ponto de corte para RI sugerido por Cuartero
<SUP>19</SUP>,    devido &agrave; RI fisiol&oacute;gica presente na adolesc&ecir
c;ncia. Invitti    et al.<SUP>25</SUP> consideraram a RI como um dos par&acirc;m
etros para a defini&ccedil;&atilde;o    da SM em crian&ccedil;as obesas e encont
raram preval&ecirc;ncia dessa s&iacute;ndrome    em 23,3%, valor muito pr&oacute
;ximo ao encontrado pela nova proposta (25%).    Ferreira et al.<SUP>26</SUP> re
alizaram um estudo transversal com 52 crian&ccedil;as    obesas de 7 a 10 anos e
 encontraram SM em 10% dos meninos e 25% das meninas.    Tamb&eacute;m observara
m que, quanto maior era o valor do HOMA-IR, maior era    o n&uacute;mero de fato
res de risco cardiovascular. Do mesmo modo, Caranti et    al.<SUP>27</SUP>, em e
studo comparativo com adolescentes obesos brasileiros    e italianos, verificara
m diferen&ccedil;as entre as duas popula&ccedil;&otilde;es    quanto &agrave; pr
eval&ecirc;ncia da SM, sendo de 23,6% para os brasileiros    e 16,5% para os ita
lianos. O HOMA-IR foi o par&acirc;metro que apresentou maior    frequ&ecirc;ncia
 de altera&ccedil;&otilde;es nos dois grupos e era mais elevado    entre os adol
escentes brasileiros.</font></p>     ^cY#a13v86n4.htm##
00774000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053900076002001300615#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#70#66#article#152#<p><font face="Verd
ana" size="2">Os pontos de corte para a hipertens&atilde;o    arterial foram dif
erentes entre os tr&ecirc;s crit&eacute;rios usados neste    estudo. A classific
a&ccedil;&atilde;o da IDF, com pontos de corte mais altos    e sem estratifica&c
cedil;&atilde;o para idade, sexo e altura, fez o diagn&oacute;stico    de hipert
ens&atilde;o arterial em menor n&uacute;mero de adolescentes (8%),    em rela&cc
edil;&atilde;o ao crit&eacute;rio de Jolliffe &amp; Janssen (13,75%)    e da nov
a proposta (23,75%).</font></p>     ^cY#a13v86n4.htm##
01134000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704089900076002001300975#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#71#67#article#152#<p><font face="Verd
ana" size="2">Encontrou-se maior preval&ecirc;ncia de altera&ccedil;&otilde;es  
  para o HDLc quando utilizado o crit&eacute;rio de Jolliffe &amp; Janssen, com 
   pontos de corte mais elevados em rela&ccedil;&atilde;o &agrave;s outras duas 
   classifica&ccedil;&otilde;es. A nova proposta baseou-se nos valores preconiza
dos    pela AHA<SUP>17</SUP>, considerados de risco para a DCV. Os TG estavam al
terados    em sete adolescentes, com somente uma discord&acirc;ncia entre as tr&
ecirc;s    classifica&ccedil;&otilde;es. Sinaiko et al.<SUP>28</SUP>, em estudo 
longitudinal    com adolescentes de 11 a 14 anos, encontraram no grupo com resis
t&ecirc;ncia    &agrave; insulina, caracterizada pelo <i>clamp</i> euglic&ecirc;
mico hiperinsulin&ecirc;mico,    valores de TG mais elevados e de HDLc mais baix
os em rela&ccedil;&atilde;o aos    encontrados neste estudo.</font></p>     ^cY#
a13v86n4.htm##
01593000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704135800076002001301434#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#72#68#article#152#<p><font face="Verd
ana" size="2">Alguns autores consideram a presen&ccedil;a da    esteatose como a
 manifesta&ccedil;&atilde;o hep&aacute;tica da RI<SUP>13,15</SUP>.    No estudo 
de Schwimmer et al.<SUP>29</SUP>, as crian&ccedil;as e os adolescentes    que ap
resentavam DGFNA tinham valores absolutos mais altos para marcadores de    risco
 cardiovascular, al&eacute;m de maior frequ&ecirc;ncia da SM. Vitola et    al.<S
UP>30</SUP> verificaram diminui&ccedil;&atilde;o de TG intra-hep&aacute;ticos,  
  pela resson&acirc;ncia magn&eacute;tica, assim como melhora da sensibilidade  
  &agrave; insulina em adolescentes obesos ap&oacute;s programa de perda de peso
.    No presente estudo, a esteatose hep&aacute;tica foi detectada pela ultrasso
nografia,    que &eacute; um m&eacute;todo de f&aacute;cil realiza&ccedil;&atild
e;o, mas,    segundo Saadeh et al.<SUP>31</SUP>, ele detecta altera&ccedil;&otil
de;es quando    j&aacute; ocorreu comprometimento do par&ecirc;nquima hep&aacute
;tico maior    do que 33%, revelado pela bi&oacute;psia. A esteatose foi encontr
ada em 13 adolescentes,    e em sete ela estava associada &agrave; RI, sugerindo
 que a esteatose deva ser    investigada na presen&ccedil;a de RI. A sua inclus&
atilde;o no diagn&oacute;stico    da SM talvez permita identificar indiv&iacute;
duos com maior risco metab&oacute;lico.</font></p>     ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#73#69#article#152#<p>&nbsp;</p>     ^
cY#a13v86n4.htm##
00312000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007700076002001300153#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#74#70#article#152#<p><font size="3" f
ace="Verdana"><b>Conclus&otilde;es</b></font></p>     ^cY#a13v86n4.htm##
01029000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704079400076002001300870#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#75#71#article#152#<p><font face="Verd
ana" size="2">A preval&ecirc;ncia da SM variou de acordo com    o crit&eacute;ri
o diagn&oacute;stico utilizado. A preval&ecirc;ncia mais alta    foi verificada 
pelo crit&eacute;rio proposto neste estudo, que incluiu a RI    e a esteatose he
p&aacute;tica entre os seus par&acirc;metros, diagnosticando,    desta forma, ma
ior n&uacute;mero de adolescentes com risco metab&oacute;lico.    A nova propost
a fez mais diagn&oacute;sticos de SM em rela&ccedil;&atilde;o    aos outros dois
 crit&eacute;rios utilizados pelo fato de usar a RI, e n&atilde;o    a glicemia,
 como par&acirc;metro de altera&ccedil;&atilde;o do metabolismo da    glicose. A
 glicemia costuma alterar-se tardiamente na evolu&ccedil;&atilde;o    da SM nas 
crian&ccedil;as e nos adolescentes.</font></p>     ^cY#a13v86n4.htm##
00730000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704049500076002001300571#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#76#72#article#152#<p><font face="Verd
ana" size="2">Cabe ressaltar a import&acirc;ncia da identifica&ccedil;&atilde;o 
   de crian&ccedil;as e adolescentes que preencham os requisitos para o diagn&oa
cute;stico    da SM, pois s&atilde;o indiv&iacute;duos de maior risco metab&oacu
te;lico e    devem ser adequadamente acompanhados. A persist&ecirc;ncia dessas a
ltera&ccedil;&otilde;es    favorecer&aacute; o desenvolvimento do diabetes melit
o tipo 2 e a ocorr&ecirc;ncia    das DCV na fase adulta.</font></p>     ^cY#a13v
86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#77#73#article#152#<p>&nbsp;</p>     ^
cY#a13v86n4.htm##
00312000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007700076002001300153#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#78#74#article#152#<p><font size="3" f
ace="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#a13v86n4.htm##
00377000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704012800078002001300206#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#79#75#article#152#1#<p><f
ont size="2" face="Verdana">1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic    
syndrome. Lancet. 2005;365:1415-28.    ^cY#a13v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#80#76#article#152#</font></p>     ^cY
#a13v86n4.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022400078002001300302#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#81#77#article#152#2#<p><f
ont size="2" face="Verdana">2. Franks PW, Hanson RL, Knowler WC, Sievers    ML, 
Bennett PH, Looker HC. Childhood obesity, other cardiovascular risk factors,    
and premature death. N Engl J Med. 2010;362:485-93.    ^cY#a13v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#82#78#article#152#</font></p>     ^cY
#a13v86n4.htm##
00459000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021000078002001300288#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#83#79#article#152#3#<p><f
ont size="2" face="Verdana">3. Ogden CL, Carroll MD, Curtin LR, McDowell    MA, 
Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United    State
s, 1999-2004. JAMA. 2006;295:1549-55.    ^cY#a13v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#84#80#article#152#</font></p>     ^cY
#a13v86n4.htm##
00447000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704019800078002001300276#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#85#81#article#152#4#<p><f
ont size="2" face="Verdana">4. Duncan GE, Li SM, Zhou XH. Prevalence and    tren
ds of a metabolic syndrome phenotype among U.S. adolescents,1999-2000. Diabetes 
   Care. 2004;27:2438-43.    ^cY#a13v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#86#82#article#152# </font></p>     ^c
Y#a13v86n4.htm##
00470000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022100078002001300299#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#87#83#article#152#5#<p><f
ont size="2" face="Verdana">5. Weiss R, Dziura J, Burgert TS, Tamborlane    WV, 
Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children    
and adolescents. N Engl J Med. 2004;350:2362-74.    ^cY#a13v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#88#84#article#152#</font></p>     ^cY
#a13v86n4.htm##
00476000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022700078002001300305#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#89#85#article#152#6#<p><f
ont size="2" face="Verdana">6. Reinehr T, de Souza G, Toschke AM, Andler    W. C
omparison of metabolic syndrome prevalence using eight different definitions:   
 a critical approach. Arch Dis Child. 2007;92:1067-72.    ^cY#a13v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#90#86#article#152#</font></p>     ^cY
#a13v86n4.htm##
00540000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704029100078002001300369#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#91#87#article#152#7#<p><f
ont size="2" face="Verdana">7. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz   
 WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from 
   the third National Health and Nutrition Examination Survey, 1988-1994. Arch  
  Pediatr Adolesc Med. 2003;157:821-7.    ^cY#a13v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#92#88#article#152#</font></p>     ^cY
#a13v86n4.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704027400078002001300352#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#93#89#article#152#8#<p><f
ont size="2" face="Verdana">8. Jolliffe CJ, Janssen I. Development of age-specif
ic    adolescent metabolic syndrome criteria that are linked to the Adult Treatm
ent    Panel III and International Diabetes Federation criteria. J Am Coll Cardi
ol.    2007;49:891-8.    ^cY#a13v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#94#90#article#152#</font></p>     ^cY
#a13v86n4.htm##
00476000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022700078002001300305#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#95#91#article#152#9#<p><f
ont size="2" face="Verdana">9. Zimmet P, Alberti KG, Kaufman F, Tajima N,    Sil
ink M, Arslanian S, et al. The metabolic syndrome in children and adolescents:  
  the IDF consensus. Diabetes Voice. 2007;52(4):29-32.    ^cY#a13v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#96#92#article#152#</font></p>     ^cY
#a13v86n4.htm##
00432000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704018200079002001300261#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#97#93#article#152#10#<p><
font size="2" face="Verdana">10. Consensus Development Conference on Insulin    
Resistance. 5-6 November 1997. American Diabetes Association. Diabetes Care.1998
;21:310-4.    ^cY#a13v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#98#94#article#152#</font></p>     ^cY
#a13v86n4.htm##
00395000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704014500079002001300224#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#99#95#article#152#11#<p><
font size="2" face="Verdana">11. Wallace TM, Levy JC, Matthews DR. Use and    ab
use of HOMA modeling. Diabetes Care. 2004;27:1487-95.    ^cY#a13v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#100#96#article#152#</font></p>     ^c
Y#a13v86n4.htm##
00513000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704026200080002001300342#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#101#97#article#152#12#<p>
<font size="2" face="Verdana">12. Chan HL, de Silva HJ, Leung NW, Lim SG, Farrel
l    GC; Asia-Pacific Working Party on NAFLD.&nbsp; How should we manage patient
s    with non-alcoholic fatty liver disease in 2007? J Gastrenterol Hepatol. 200
7;22:801-8.    ^cY#a13v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#102#98#article#152#</font></p>     ^c
Y#a13v86n4.htm##
00593000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704034200080002001300422#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#103#99#article#152#13#<p>
<font size="2" face="Verdana">13. Musso G, Gambino R, Bo S, Uberti B, Biroli    
G, Pagano G, et al. Should nonalcoholic fatty liver disease be included in the  
  definition of metabolic syndrome? A cross-sectional comparison with Adult Trea
tment    Panel III criteria in nonobese nondiabetic subjects. Diabetes Care. 200
8;31:562-8.    ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#104#100#article#152#</font></p>     ^
cY#a13v86n4.htm##
00462000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021000081002001300291#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#105#101#article#152#14#<p
><font size="2" face="Verdana">14. D'Adamo E, Santoro N, Caprio S. Metabolic    
syndrome in pediatrics: old concepts revised, new concepts discussed. Endocrinol
    Metab Clin North Am. 2009;38:549-63.    ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#106#102#article#152#</font></p>     ^
cY#a13v86n4.htm##
00481000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022900081002001300310#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#107#103#article#152#15#<p
><font size="2" face="Verdana">15. Sartorio A, Del Col A, Agosti F, Mazzilli    
G, Bellentani S, Tiribelli C, et al. Predictors of non-alcoholic fatty liver    
disease in obese children. Eur J Clin Nutr. 2007;61:877-83.    ^cY#a13v86n4.htm#
#
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#108#104#article#152#</font></p>     ^
cY#a13v86n4.htm##
00561000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030900081002001300390#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#109#105#article#152#16#<p
><font size="2" face="Verdana">16. National High Blood Pressure Education Progra
m    Working Group on High Blood Pressure in Children and Adolescents. The fourt
h    report on the diagnosis, evaluation, and treatment of high blood pressure i
n    children and adolescents. Pediatrics. 2004;114:555-76.    ^cY#a13v86n4.htm#
#
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#110#106#article#152#</font></p>     ^
cY#a13v86n4.htm##
00527000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027500081002001300356#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#111#107#article#152#17#<p
><font size="2" face="Verdana">17. Kavey RE, Daniels SR, Lauer RM, Atkins DL,   
 Hayman LL, Taubert K. American Heart Association guidelines for primary prevent
ion    of atherosclerotic cardiovascular disease beginning in childhood. Circula
tion.    2003;107:1562-6.    ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#112#108#article#152#</font></p>     ^
cY#a13v86n4.htm##
00541000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028900081002001300370#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#113#109#article#152#18#<p
><font size="2" face="Verdana">18. Matthews DR, Hosker JP, Rudenski AS, Naylor  
  BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance  
  and beta-cell function from fasting plasma glucose and insulin concentrations 
   in man. Diabetologia. 1985;28:412-9.    ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#114#110#article#152#</font></p>     ^
cY#a13v86n4.htm##
00528000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027600081002001300357#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#115#111#article#152#19#<p
><font size="2" face="Verdana">19. Cuartero BG, Lacalle CG, Lobo CJ, Vergaz    A
G, Rey CC, Villar MJ, et al. &Iacute;ndice de HOMA y QUICKI, Insulina y peptide 
   C en ni&ntilde;os sanos. Puntos de corte de riesgo cardiovascular. An Pediatr
    (Barc). 2007;66:481-9.    ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#116#112#article#152#</font></p>     ^
cY#a13v86n4.htm##
00452000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020000081002001300281#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#117#113#article#152#20#<p
><font size="2" face="Verdana">20. Saverymuttu SH, Joseph AE, Maxwell JD. Ultras
ound    scanning in the detection of hepatic fibrosis and steatosis. Br Med J (C
lin    Res Ed). 1986;292:13-5.    ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#118#114#article#152#</font></p>     ^
cY#a13v86n4.htm##
00455000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704020300081002001300284#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#119#115#article#152#21#<p
><font size="2" face="Verdana">21. Alberti KG, Zimmet P, Shaw J; IDF Epidemiolog
y    Task Force Consensus Group. The metabolic syndrome-a new world-wide definit
ion.    Lancet. 2005;366:1059-62.    ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#120#116#article#152#</font></p>     ^
cY#a13v86n4.htm##
00387000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704013500081002001300216#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#121#117#article#152#22#<p
><font size="2" face="Verdana">22. Stata Statistical Software. Release 10.0.    
College Station, TX: Stata Corporation; 2003.    ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#122#118#article#152#</font></p>     ^
cY#a13v86n4.htm##
00549000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704029700081002001300378#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#123#119#article#152#23#<p
><font size="2" face="Verdana">23. Golley RK, Magarey AM, Steinbeck KS, Baur    
LA, Daniels LA. Comparison of metabolic syndrome prevalence using six different 
   definitions in overweight pre-pubertal children enrolled in a weight manageme
nt    study. Int J Obes (Lond). 2006;30:853-60.    ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#124#120#article#152#</font></p>     ^
cY#a13v86n4.htm##
00552000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030000081002001300381#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#125#121#article#152#24#<p
><font size="2" face="Verdana">24. Sartorio A, Agosti F, De Col A, Mornati D,   
 Francescato MP, Lazzer S. Prevalence of the metabolic syndrome in Caucasian    
obese children and adolescents: comparison between three different definition   
 criteria. Diabetes Res Clin Pract. 2007;77:341-2.    ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#126#122#article#152#</font></p>     ^
cY#a13v86n4.htm##
00568000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704031600081002001300397#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#127#123#article#152#25#<p
><font size="2" face="Verdana">25. Invitti C, Maffeis C, Gilardini L, Pontiggia 
   B, Mazzilli G, Girola A, et al. Metabolic syndrome in obese Caucasian childre
n:    prevalence using WHO-derived criteria and association with nontraditional 
cardiovascular    risk factors. Int J Obes (Lond). 2006;30:627-33.    ^cY#a13v86
n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#128#124#article#152#</font></p>     ^
cY#a13v86n4.htm##
00513000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026100081002001300342#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#129#125#article#152#26#<p
><font size="2" face="Verdana">26. Ferreira AP, Oliveira CE, Fran&ccedil;a NM.  
  Metabolic syndrome and risk factors for cardiovascular disease in obese childr
en:    the relationship with insulin resistance (HOMA-IR). J Pediatr (Rio J). 20
07;83:21-6.    ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#130#126#article#152#</font></p>     ^
cY#a13v86n4.htm##
00534000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028200081002001300363#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#131#127#article#152#27#<p
><font size="2" face="Verdana">27. Caranti DA, Lazzer S, D&acirc;maso AR, Agosti
    F, Zennaro R, de Mello MT, et al. Prevalence and risk factors of metabolic s
yndrome    in Brazilian and Italian obese adolescents: a comparison study. Int J
 Clin Pract.    2008;62:1526-32.    ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#132#128#article#152#</font></p>     ^
cY#a13v86n4.htm##
00398000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704014600081002001300227#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#133#129#article#152#28#<p
><font size="2" face="Verdana">28. Sinaiko A. Obesity, insulin resistance and   
 the metabolic syndrome. J Pediatr (Rio J). 2007;83:3-4.    ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#134#130#article#152#</font></p>     ^
cY#a13v86n4.htm##
00490000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023800081002001300319#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#135#131#article#152#29#<p
><font size="2" face="Verdana">29. Schwimmer JB, Pardee PE, Lavine JE, Blumkin  
  AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatri
c    nonalcoholic fatty liver disease. Circulation. 2008;118:277-83.    ^cY#a13v
86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#136#132#article#152#</font></p>     ^
cY#a13v86n4.htm##
00529000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027700081002001300358#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#137#133#article#152#30#<p
><font size="2" face="Verdana">30. Vitola BE, Deivanayagam S, Stein RI, Mohammed
    BS, Magkos F, Kirk EP, et al. Weight loss reduces fat and improves hepatic a
nd    skeletal muscle insulin sensitivity in obese adolescents. Obesity (Silver 
Spring).    2009;17:1744-8.    ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#138#134#article#152#</font></p>     ^
cY#a13v86n4.htm##
00480000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704022800081002001300309#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#p#139#135#article#152#31#<p
><font size="2" face="Verdana">31. Saadeh S, Younossi ZM, Remer EM, Gramlich    
T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic 
   fatty liver disease. Gastroenterology. 2002;123:745-50.    ^cY#a13v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#140#136#article#152#</font></p>     ^
cY#a13v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#141#137#article#152#<p>&nbsp;</p>    
 ^cY#a13v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#142#138#article#152#<p>&nbsp;</p>    
 ^cY#a13v86n4.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018000078002001300258#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#143#139#article#152#<p><font size="2"
 face="Verdana"><a name="correspondence"></a><a href="#topo"><img src="/img/revi
stas/jped/v86n4/seta.gif" border="0"></a>    <b> Correspond&ecirc;ncia:</b>    ^
cY#a13v86n4.htm##
00294000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005700078002001300135#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#144#140#article#152#<br>   Maria Arle
te Meil Schimith Escriv&atilde;o    ^cY#a13v86n4.htm##
00342000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010500078002001300183#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#145#141#article#152#<BR>   Universida
de Federal de S&atilde;o Paulo, Disciplina de Nutrologia, Depto. de    Pediatria
    ^cY#a13v86n4.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#146#142#article#152#<BR>   Rua Loefgr
een, 1647    ^cY#a13v86n4.htm##
00288000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005100078002001300129#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#147#143#article#152#<BR>   CEP 04040-
032 - S&atilde;o Paulo, SP    ^cY#a13v86n4.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003500078002001300113#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#148#144#article#152#<BR>   Tel.: (11)
 5539.1783    ^cY#a13v86n4.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#149#145#article#152#<BR>   Fax: (11) 
5539.1783    ^cY#a13v86n4.htm##
00401000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704016400078002001300242#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#150#146#article#152#<BR>   E-mail: <A
 href=mailto:maria.arlete@uol.com.br>maria.arlete@uol.com.br</A>,    <A href=mai
lto:nutsec@yahoo.com.br>nutsec@yahoo.com.br</A></font></p>     ^cY#a13v86n4.htm#
#
00343000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010600078002001300184#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#151#147#article#152#<p><font size="2"
 face="Verdana">Artigo submetido em 13.01.2010, aceito em 10.03.2010.</font></p>
     ^cY#a13v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#152#148#article#152#<p>&nbsp;</p>    
 ^cY#a13v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#153#149#article#152#<p>&nbsp;</p>    
 ^cY#a13v86n4.htm##
00391000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704015400078002001300232#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#154#150#article#152#<p><font size="2"
 face="Verdana"> N&atilde;o foram declarados conflitos de interesse    associado
s &agrave; publica&ccedil;&atilde;o deste artigo.    ^cY#a13v86n4.htm##
00429000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019200078002001300270#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#155#151#article#152#<br>   Apoio fina
nceiro: Este trabalho faz parte de uma pesquisa financiada pela FAPESP    (Fundo
 de Amparo &agrave; Pesquisa do Estado de S&atilde;o Paulo), Processo    n° 0754
490-8R.    ^cY#a13v86n4.htm##
00424000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018700078002001300265#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a13v86n4.htm#S#p#156#152#article#152#<br>   Este traba
lho foi realizado na Disciplina de Nutrologia, Departamento de Pediatria,    Uni
versidade Federal de S&atilde;o Paulo (UNIFESP), S&atilde;o Paulo, SP.</font></p
>     ^cY#a13v86n4.htm##
00516000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100017000930100
01700110012002700127030000700154065000900161064000500170031000400175014000800179
865000900187002001300196035001000209801000700219#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a13v86n4.htm#S#c#157#1#article#31#1#^rND^sEckel^nRH#^rND^sGrundy^nSM#^
rND^sZimmet^nPZ#The metabolic syndrome^len#Lancet#20050000#2005#365#1415-28#2010
0800#a13v86n4.htm#0099-5355#Lancet##
00669000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100017000940100
01800111010001800129010001800147010001700165012007800182030001300260065000900273
06400050028203100040028701400070029186500090029800200130030703500100032080100130
0330#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#c#158#2#article#31#
2#^rND^sFranks^nPW#^rND^sHanson^nRL#^rND^sKnowler^nWC#^rND^sSievers^nML#^rND^sBe
nnett^nPH#^rND^sLooker^nHC#Childhood obesity, other cardiovascular risk factors,
 and premature death^len#N Engl J Med#20100000#2010#362#485-93#20100800#a13v86n4
.htm#0028-4793#N Engl J Med##
00647000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100018000930100
01700111010001900128010001600147010001700163012007300180030000500253065000900258
06400050026703100040027201400080027686500090028400200130029303500100030680100050
0316#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#c#159#3#article#31#
3#^rND^sOgden^nCL#^rND^sCarroll^nMD#^rND^sCurtin^nLR#^rND^sMcDowell^nMA#^rND^sTa
bak^nCJ#^rND^sFlegal^nKM#Prevalence of overweight and obesity in the United Stat
es, 1999-2004^len#JAMA#20060000#2006#295#1549-55#20100800#a13v86n4.htm#0098-7484
#JAMA##
00590000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100013000940100
01500107012009300122030001400215065000900229064000500238031000300243014000800246
865000900254002001300263035001000276801001400286#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a13v86n4.htm#S#c#160#4#article#31#4#^rND^sDuncan^nGE#^rND^sLi^nSM#^rND
^sZhou^nXH#Prevalence and trends of a metabolic syndrome phenotype among U.S. ad
olescents,1999-2000^len#Diabetes Care#20040000#2004#27#2438-43#20100800#a13v86n4
.htm#0149-5992#Diabetes Care##
00677000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100016000920100
01800108010002100126010001800147010001700165810000600182012006700188030001300255
06500090026806400050027703100040028201400080028686500090029400200130030303500100
0316801001300326#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#c#161#5
#article#31#5#^rND^sWeiss^nR#^rND^sDziura^nJ#^rND^sBurgert^nTS#^rND^sTamborlane^
nWV#^rND^sTaksali^nSE#^rND^sYeckel^nCW#et al#Obesity and the metabolic syndrome 
in children and adolescents^len#N Engl J Med#20040000#2004#350#2362-74#20100800#
a13v86n4.htm#0028-4793#N Engl J Med##
00638000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100018000940100
01800112010001600130012010300146030001500249065000900264064000500273031000300278
014000800281865000900289002001300298035001000311801001500321#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a13v86n4.htm#S#c#162#6#article#31#6#^rND^sReinehr^nT#^rND^
sde Souza^nG#^rND^sToschke^nAM#^rND^sAndler^nW#Comparison of metabolic syndrome 
prevalence using eight different definitions: a critical approach^len#Arch Dis C
hild#20070000#2007#92#1067-72#20100800#a13v86n4.htm#0003-9888#Arch Dis Child##
00727000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100018000910100
01700109010001600126010001600142012014900158030002500307065000900332064000500341
031000400346014000600350865000900356002001300365035001000378801002500388#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#c#163#7#article#31#7#^rND^sCook
^nS#^rND^sWeitzman^nM#^rND^sAuinger^nP#^rND^sNguyen^nM#^rND^sDietz^nWH#Prevalenc
e of a metabolic syndrome phenotype in adolescents: findings from the third Nati
onal Health and Nutrition Examination Survey, 1988-1994^len#Arch Pediatr Adolesc
 Med#20030000#2003#157#821-7#20100800#a13v86n4.htm#1072-4710#Arch Pediatr Adoles
c Med##
00649000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100017000960120
16700113030001800280065000900298064000500307031000300312014000600315865000900321
002001300330035001000343801001800353#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
3v86n4.htm#S#c#164#8#article#31#8#^rND^sJolliffe^nCJ#^rND^sJanssen^nI#Developmen
t of age-specific adolescent metabolic syndrome criteria that are linked to the 
Adult Treatment Panel III and International Diabetes Federation criteria^len#J A
m Coll Cardiol#20070000#2007#49#891-8#20100800#a13v86n4.htm#0735-1097#J Am Coll 
Cardiol##
00661000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100018000930100
01700111010001600128010001600144010001900160810000600179012007400185030001500259
71000020027406500090027606400050028503100030029003200020029301400060029586500090
0301002001300310#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#c#165#9
#article#31#9#^rND^sZimmet^nP#^rND^sAlberti^nKG#^rND^sKaufman^nF#^rND^sTajima^nN
#^rND^sSilink^nM#^rND^sArslanian^nS#et al#The metabolic syndrome in children and
 adolescents: the IDF consensus^len#Diabetes Voice#2#20070000#2007#52#4#29-32#20
100800#a13v86n4.htm##
00525000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760120109000790300014001880650
00900202064000500211031000300216014000600219865000900225002001300234035001000247
801001400257#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#c#166#10#ar
ticle#31#10#Consensus Development Conference on Insulin Resistance. 5-6 November
 1997: American Diabetes Association^len#Diabetes Care#19980000#1998#21#310-4#20
100800#a13v86n4.htm#0149-5992#Diabetes Care##
00541000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100015000970100
01900112012003500131030001400166065000900180064000500189031000300194014000800197
865000900205002001300214035001000227801001400237#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a13v86n4.htm#S#c#167#11#article#31#11#^rND^sWallace^nTM#^rND^sLevy^nJC
#^rND^sMatthews^nDR#Use and abuse of HOMA modeling^len#Diabetes Care#20040000#20
04#27#1487-95#20100800#a13v86n4.htm#0149-5992#Diabetes Care##
00653000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100019000940100
01600113010001400129010001800143012011900161030002400280710000200304065000900306
064000500315031000300320014000600323865000900329002001300338#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a13v86n4.htm#S#c#168#12#article#31#12#^rND^sChan^nHL#^rND^
sde Silva^nHJ#^rND^sLeung^nNW#^rND^sLim^nSG#^rND^sFarrell^nGC#Asia-Pacific Worki
ng Party on NAFLD. How should we manage patients with non-alcoholic fatty liver 
disease in 2007?^len#J Gastrenterol Hepatol.#2#20070000#2007#22#801-8#20100800#a
13v86n4.htm##
00798000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01200111010001600123010001600139010001600155810000600171012020000177030001400377
06500090039106400050040003100030040501400060040886500090041400200130042303500100
0436801001400446#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#c#169#1
3#article#31#13#^rND^sMusso^nG#^rND^sGambino^nR#^rND^sBo^nS#^rND^sUberti^nB#^rND
^sBiroli^nG#^rND^sPagano^nG#et al#Should nonalcoholic fatty liver disease be inc
luded in the definition of metabolic syndrome?: A cross-sectional comparison wit
h Adult Treatment Panel III criteria in nonobese nondiabetic subjects^len#Diabet
es Care#20080000#2008#31#562-8#20100800#a13v86n4.htm#0149-5992#Diabetes Care##
00620000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01600113012008300129030003100212065000900243064000500252031000300257014000700260
865000900267002001300276035001000289801003100299#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a13v86n4.htm#S#c#170#14#article#31#14#^rND^sD'Adamo^nE#^rND^sSantoro^n
N#^rND^sCaprio^nS#Metabolic syndrome in pediatrics: old concepts revised, new co
ncepts discussed^len#Endocrinol Metab Clin North Am#20090000#2009#38#549-63#2010
0800#a13v86n4.htm#0889-8529#Endocrinol Metab Clin North Am##
00689000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100017000970100
01600114010001800130010002000148010001900168810000600187012007000193030001600263
06500090027906400050028803100030029301400070029686500090030300200130031203500100
0325801001600335#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#c#171#1
5#article#31#15#^rND^sSartorio^nA#^rND^sDel Col^nA#^rND^sAgosti^nF#^rND^sMazzill
i^nG#^rND^sBellentani^nS#^rND^sTiribelli^nC#et al#Predictors of non-alcoholic fa
tty liver disease in obese children^len#Eur J Clin Nutr#20070000#2007#61#877-83#
20100800#a13v86n4.htm#0954-3007#Eur J Clin Nutr##
00653000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760110112000790120117001910300
01100308065000900319064000500328031000400333014000700337865000900344002001300353
035001000366801001100376#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S
#c#172#16#article#31#16#National High Blood Pressure Education Program Working G
roup on High Blood Pressure in Children and Adolescents#The fourth report on the
 diagnosis, evaluation, and treatment of high blood pressure in children and ado
lescents^len#Pediatrics#20040000#2004#114#555-76#20100800#a13v86n4.htm#0031-4005
#Pediatrics##
00717000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01600113010001700129010001700146010001700163012013000180030001200310065000900322
06400050033103100040033601400070034086500090034700200130035603500100036980100120
0379#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#c#173#17#article#31
#17#^rND^sKavey^nRE#^rND^sDaniels^nSR#^rND^sLauer^nRM#^rND^sAtkins^nDL#^rND^sHay
man^nLL#^rND^sTaubert^nK#American Heart Association guidelines for primary preve
ntion of atherosclerotic cardiovascular disease beginning in childhood^len#Circu
lation#20030000#2003#107#1562-6#20100800#a13v86n4.htm#0009-7322#Circulation##
00732000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
01900115010001700134010001900151010001700170012013800187030001300325065000900338
06400050034703100030035201400060035586500090036100200130037003500100038380100130
0393#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#c#174#18#article#31
#18#^rND^sMatthews^nDR#^rND^sHosker^nJP#^rND^sRudenski^nAS#^rND^sNaylor^nBA#^rND
^sTreacher^nDF#^rND^sTurner^nRC#Homeostasis model assessment: insulin resistance
 and beta-cell function from fasting plasma glucose and insulin concentrations i
n man^len#Diabetologia#19850000#1985#28#412-9#20100800#a13v86n4.htm#0012-186X#Di
abetologia##
00683000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
01500116010001700131010001400148010001700162810000600179012010700185030001800292
71000020031006500090031206400050032103100030032601400060032986500090033500200130
0344#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#c#175#19#article#31
#19#^rND^sCuartero^nBG#^rND^sLacalle^nCG#^rND^sLobo^nCJ#^rND^sVergaz^nAG#^rND^sR
ey^nCC#^rND^sVillar^nMJ#et al#Índice de HOMA y QUICKI, Insulina y peptide C en n
iños sanos: Puntos de corte de riesgo cardiovascular^les#An Pediatr (Barc)#2#200
70000#2007#66#481-9#20100800#a13v86n4.htm##
00602000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100017001010100
01800118012007500136030002300211065000900234064000500243031000400248014000500252
865000900257002001300266035001000279801002300289#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a13v86n4.htm#S#c#176#20#article#31#20#^rND^sSaverymuttu^nSH#^rND^sJose
ph^nAE#^rND^sMaxwell^nJD#Ultrasound scanning in the detection of hepatic fibrosi
s and steatosis^len#Br Med J (Clin Res Ed)#19860000#1986#292#13-5#20100800#a13v8
6n4.htm#0267-0623#Br Med J (Clin Res Ed)##
00600000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01400113011004400127012005500171030000700226065000900233064000500242031000400247
014000800251865000900259002001300268035001000281801000700291#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a13v86n4.htm#S#c#177#21#article#31#21#^rND^sAlberti^nKG#^r
ND^sZimmet^nP#^rND^sShaw^nJ#IDF Epidemiology Task Force Consensus Group#The meta
bolic syndrome-a new world-wide definition^len#Lancet#20050000#2005#366#1059-62#
20100800#a13v86n4.htm#0099-5355#Lancet##
00427000000000229000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170027000790180034001060660
00300140062001800143065000900161064000500170865000900175002001300184#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a13v86n4.htm#S#c#178#22#article#31#22#Stata Statis
tical Software#Release 10.0. College Station^len#TX#Stata Corporation#20030000#2
003#20100800#a13v86n4.htm##
00689000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960100
02000114010001500134010001800149012015400167030001800321710000200339065000900341
064000500350031000300355014000700358865000900365002001300374#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a13v86n4.htm#S#c#179#23#article#31#23#^rND^sGolley^nRK#^rN
D^sMagarey^nAM#^rND^sSteinbeck^nKS#^rND^sBaur^nLA#^rND^sDaniels^nLA#Comparison o
f metabolic syndrome prevalence using six different definitions in overweight pr
e-pubertal children enrolled in a weight management study^len#Int J Obes (Lond)#
2#20060000#2006#30#853-60#20100800#a13v86n4.htm##
00754000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01600113010001700129010002200146010001600168012014100184030002400325065000900349
06400050035803100030036301400060036686500090037200200130038103500100039480100240
0404#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#c#180#24#article#31
#24#^rND^sSartorio^nA#^rND^sAgosti^nF#^rND^sDe Col^nA#^rND^sMornati^nD#^rND^sFra
ncescato^nMP#^rND^sLazzer^nS#Prevalence of the metabolic syndrome in Caucasian o
bese children and adolescents: comparison between three different definition cri
teria^len#Diabetes Res Clin Pract#20070000#2007#77#341-2#20100800#a13v86n4.htm#0
168-8227#Diabetes Res Clin Pract##
00737000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100017000960100
01900113010001900132010001800151010001600169810000600185012015400191030001800345
71000020036306500090036506400050037403100030037901400070038286500090038900200130
0398#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#c#181#25#article#31
#25#^rND^sInvitti^nC#^rND^sMaffeis^nC#^rND^sGilardini^nL#^rND^sPontiggia^nB#^rND
^sMazzilli^nG#^rND^sGirola^nA#et al#Metabolic syndrome in obese Caucasian childr
en: prevalence using WHO-derived criteria and association with nontraditional ca
rdiovascular risk factors^len#Int J Obes (Lond)#2#20060000#2006#30#627-33#201008
00#a13v86n4.htm##
00651000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100019000980100
01700117012013700134030001800271065000900289064000500298031000300303014000500306
865000900311002001300320035001000333801001800343#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a13v86n4.htm#S#c#182#26#article#31#26#^rND^sFerreira^nAP#^rND^sOliveir
a^nCE#^rND^sFrança^nNM#Metabolic syndrome and risk factors for cardiovascular di
sease in obese children: the relationship with insulin resistance (HOMA-IR)^len#
J Pediatr (Rio J)#20070000#2007#83#21-6#20100800#a13v86n4.htm#0021-7557#J Pediat
r (Rio J)##
00734000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100016000970100
01700113010001600130010001700146010001900163810000600182012011700188030001700305
06500090032206400050033103100030033601400080033986500090034700200130035603500100
0369801001700379#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#c#183#2
7#article#31#27#^rND^sCaranti^nDA#^rND^sLazzer^nS#^rND^sDâmaso^nAR#^rND^sAgosti^
nF#^rND^sZennaro^nR#^rND^sde Mello^nMT#et al#Prevalence and risk factors of meta
bolic syndrome in Brazilian and Italian obese adolescents: a comparison study^le
n#Int J Clin Pract#20080000#2008#62#1526-32#20100800#a13v86n4.htm#1368-5031#Int 
J Clin Pract##
00510000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790120059000960300
01800155065000900173064000500182031000300187014000400190865000900194002001300203
035001000216801001800226#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S
#c#184#28#article#31#28#^rND^sSinaiko^nA#Obesity, insulin resistance and the met
abolic syndrome^len#J Pediatr (Rio J)#20070000#2007#83#3-4#20100800#a13v86n4.htm
#0021-7557#J Pediatr (Rio J)##
00665000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100017000990100
01700116010001800133010001400151012010500165030001200270065000900282064000500291
031000400296014000700300865000900307002001300316035001000329801001200339#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#c#185#29#article#31#29#^rND^sSc
hwimmer^nJB#^rND^sPardee^nPE#^rND^sLavine^nJE#^rND^sBlumkin^nAK#^rND^sCook^nS#Ca
rdiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic f
atty liver disease^len#Circulation#20080000#2008#118#277-83#20100800#a13v86n4.ht
m#0009-7322#Circulation##
00698000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100022000960100
01600118010001900134010001600153010001500169810000600184012011000190030002400300
71000020032406500090032606400050033503100030034001400070034386500090035000200130
0359#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#c#186#30#article#31
#30#^rND^sVitola^nBE#^rND^sDeivanayagam^nS#^rND^sStein^nRI#^rND^sMohammed^nBS#^r
ND^sMagkos^nF#^rND^sKirk^nEP#et al#Weight loss reduces fat and improves hepatic 
and skeletal muscle insulin sensitivity in obese adolescents^len#Obesity (Silver
 Spring)#2#20090000#2009#17#1744-8#20100800#a13v86n4.htm##
00689000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100019000950100
01600114010001800130010001400148010001600162810000600178012007600184030001700260
06500090027706400050028603100040029101400070029586500090030200200130031103500100
0324801001700334#v86n4#V:\Scielo\serial\jped\v86n4\markup\a13v86n4.htm#S#c#187#3
1#article#31#31#^rND^sSaadeh^nS#^rND^sYounossi^nZM#^rND^sRemer^nEM#^rND^sGramlic
h^nT#^rND^sOng^nJP#^rND^sHurley^nM#et al#The utility of radiological imaging in 
nonalcoholic fatty liver disease^len#Gastroenterology#20020000#2002#123#745-50#2
0100800#a13v86n4.htm#0016-5085#Gastroenterology##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v86n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#o#1#1#article#1
#20110126#175620#a15v86n4.htm#191##
05581000000000709000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002100108
03100030012903200020013206500090013401400110014303500100015401201110016401201090
02750100040003840100031004240100031004550100045004860100027005310100034005580700
09500592070005600687070010600743070006700849070010000916083179001016085001002806
08500230281608500210283908500250286008500330288508500210291808317390293908500100
46780850021046880850021047090850024047300850026047540850027047801170008048070720
00304815112000904818111001104827114000904838113001104847002001304858#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a15v86n4.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#T
AB#15#JPED030#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f337^l344#0021-7557#Sibilân
cia em crianças e adolescentes vizinhos a uma indústria petroquímica no Rio Gran
de do Norte, Brasil^lpt#Wheezing in children and adolescents living next to a pe
trochemical plant in Rio Grande do Norte, Brazil^len#^rND^1A01^nAna Claudia Lope
s de^sMoraes#^rND^1A02 A03^nEliane^sIgnotti#^rND^1A04^nPaulo Artaxo^sNetto#^rND^
1A03^nLudmilla da Silva Viana^sJacobson#^rND^1A05^nHermano^sCastro#^rND^1A03^nSa
ndra de Souza^sHacon#Fundação Oswaldo Cruz^iA01^1Escola Nacional de Saúde Públic
a Sérgio Arouca^cRio de Janeiro^sRJ#Universidade do Estado de Mato Grosso^iA02^c
Cáceres^sMT#Fiocruz^iA03^1ENSP^2Programa de Mestrado e Doutorado em Saúde Públic
a e Meio Ambiente^cRio de Janeiro^sRJ#Universidade de São Paulo^iA04^1Instituto 
de Física^cSão Paulo^sSP#Fiocruz^iA05^1ENSP^2Centro de Estudos de Saúde do Traba
lhador e Ecologia Humana^cRio de Janeiro^sRJ#^lpt^aOBJETIVO: Verificar a associa
ção entre relato de sibilância em crianças e adolescentes e o local de residênci
a em relação à dispersão dos poluentes atmosféricos emitidos pelo Pólo Petroquím
ico (PPQ) de Guamaré (RN). MÉTODOS: Estudo transversal de relato de sibilância e
m crianças e adolescentes de 0 a 14 anos de idade, residentes no entorno do PPQ 
de Guamaré, em 2006. Foi utilizado o questionário padronizado do International S
tudy of Asthma and Allergies in Childhood, acrescido de questões relativas ao ta
bagismo, renda, moradia e escolaridade. Concentrações diárias de PM10, PM2,5, ca
rbono grafítico, SO2, NO2, O3, benzeno, tolueno e xilenos foram medidas em uma e
stação de monitoramento fixa. As comunidades residentes na área de influência da
s emissões do PPQ foram classificadas, segundo a direção preferencial dos ventos
, em expostas e de referência. RESULTADOS: Participaram do estudo 209 crianças e
 adolescentes. As concentrações médias diárias dos poluentes monitorados mantive
ram-se abaixo dos limites estabelecidos nos padrões de qualidade do ar. A preval
ência de sibilos nos últimos 12 meses foi de 27,3%. Associações estatisticamente
 significantes com sibilos nos últimos 12 meses foram verificadas mesmo após aju
stamentos para comunidades expostas [razão de chances (odds ratio, ORajust) = 2,
01; intervalo de confiança de 95% (IC95%) 1,01-4,01], gênero masculino (ORajust 
= 2,50; IC95% 1,21-5,18) e idade de 0 a 6 anos (ORajust = 5,00; IC95% 2,41-10,39
). CONCLUSÃO: Mesmo em baixas concentrações de poluentes atmosféricos, a ocorrên
cia de sintomas respiratórios em crianças e adolescentes nas comunidades no ento
rno de um PPQ esteve associada a residência na direção preferencial dos ventos, 
mostrando-se mais vulnerável o grupo de pré-escolares do gênero masculino.#^ddec
s^i1#^tm^lpt^kSibilância^i1#^tm^lpt^kcrianças^i1#^tm^lpt^kadolescentes^i1#^tm^lp
t^kpoluição atmosférica^i1#^tm^lpt^kpetróleo^i1#^len^aOBJECTIVE: To examine the 
association between wheezing in children and adolescents and living downwind of 
the dispersion plume of atmospheric pollutants emitted by the Guamaré Petrochemi
cal Complex, in the state of Rio Grande do Norte, Brazil. METHODS: Cross-section
al study of wheezing in children and adolescents (aged 0 to 14 years) living in 
the vicinity of the Guamaré petrochemical complex in 2006. The standardized Inte
rnational Study of Asthma and Allergies in Childhood questionnaire was used, wit
h additional questions concerning tobacco use, income, living conditions, and ed
ucational achievement. Daily concentrations of PM10, PM2.5, black carbon, SO2, N
O2, O3, benzene, toluene, and xylenes were measured at a fixed monitoring statio
n. According to their position relative to wind direction, communities present i
n the area affected by plant emissions were categorized into one of two groups, 
exposed communities and reference communities. RESULTS: Two hundred and nine chi
ldren and adolescents took part in the study. Mean daily concentrations of the m
onitored pollutants were consistently below established acceptable upper limits.
 The prevalence of wheezing in the 12 months prior to study was 27.3%. After adj
ustment, statistically significant associations were found between wheezing and 
living in exposed communities (adjusted odds ratio [ORadj] 2.01; 95% confidence 
interval [95%CI] 1.01-4.01), male gender (ORadj 2.50; 95%CI 1.21-5.18), and age 
0 to 6 years (ORadj 5.00; 95%CI 2.41-10.39). CONCLUSION: Even with low levels of
 atmospheric pollutants, respiratory symptoms in children and adolescents were a
ssociated with living downwind of a petrochemical plant. Male preschoolers were 
the most vulnerable group.#^ddecs^i2#^tm^len^kWheezing^i2#^tm^len^kchildren^i2#^
tm^len^kadolescents^i2#^tm^len^kair pollution^i2#^tm^len^kpetrochemicals^i2#vanc
ouv#30#20100118#18.01.2010#20100602#02.06.2010#a15v86n4.htm##
05834000000000709000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002100108
03100030012903200020013206500090013401400110014303500100015401201180016401201160
02820100040003980100031004380100031004690100045005000100027005450100034005720700
09500606070005600701070010600757070006700863070010000930083191301030085001002943
08500230295308500210297608500250299708500330302208500210305508318550307608500100
49310850021049410850021049620850024049830850026050070850027050331170008050600720
00305068112000905071111001105080114000905091113001105100002001305111#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a15v86n4.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#T
AB#15#JPED030#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f337^l344#0021-7557#<b>Sibi
lância em crianças e adolescentes vizinhos a uma indústria petroquímica no Rio G
rande do Norte, Brasil</b>^lpt#<b>Wheezing in children and adolescents living ne
xt to a petrochemical plant in Rio Grande do Norte, Brazil</b>^len#^rND^1A01^nAn
a Claudia Lopes de^sMoraes#^rND^1A02 A03^nEliane^sIgnotti#^rND^1A04^nPaulo Artax
o^sNetto#^rND^1A03^nLudmilla da Silva Viana^sJacobson#^rND^1A05^nHermano^sCastro
#^rND^1A03^nSandra de Souza^sHacon#Fundação Oswaldo Cruz^iA01^1Escola Nacional d
e Saúde Pública Sérgio Arouca^cRio de Janeiro^sRJ#Universidade do Estado de Mato
 Grosso^iA02^cCáceres^sMT#Fiocruz^iA03^1ENSP^2Programa de Mestrado e Doutorado e
m Saúde Pública e Meio Ambiente^cRio de Janeiro^sRJ#Universidade de São Paulo^iA
04^1Instituto de Física^cSão Paulo^sSP#Fiocruz^iA05^1ENSP^2Centro de Estudos de 
Saúde do Trabalhador e Ecologia Humana^cRio de Janeiro^sRJ#^lpt^a<b>OBJETIVO: </
b>Verificar a associação entre relato de sibilância em crianças e adolescentes e
 o local de residência em relação à dispersão dos poluentes atmosféricos emitido
s pelo Pólo Petroquímico (PPQ) de Guamaré (RN). <b>MÉTODOS: </b>Estudo transvers
al de relato de sibilância em crianças e adolescentes de 0 a 14 anos de idade, r
esidentes no entorno do PPQ de Guamaré, em 2006. Foi utilizado o questionário pa
dronizado do International Study of Asthma and Allergies in Childhood, acrescido
 de questões relativas ao tabagismo, renda, moradia e escolaridade. Concentraçõe
s diárias de PM<sub>10</sub>, PM<sub>2,5</sub>, carbono grafítico, SO<sub>2</sub
>, NO<sub>2</sub>, O<sub>3</sub>, benzeno, tolueno e xilenos foram medidas em um
a estação de monitoramento fixa. As comunidades residentes na área de influência
 das emissões do PPQ foram classificadas, segundo a direção preferencial dos ven
tos, em expostas e de referência. <b>RESULTADOS: </b>Participaram do estudo 209 
crianças e adolescentes. As concentrações médias diárias dos poluentes monitorad
os mantiveram-se abaixo dos limites estabelecidos nos padrões de qualidade do ar
. A prevalência de sibilos nos últimos 12 meses foi de 27,3%. Associações estati
sticamente significantes com sibilos nos últimos 12 meses foram verificadas mesm
o após ajustamentos para comunidades expostas [razão de chances (<i>odds ratio</
i>, OR<sub>ajust</sub>) = 2,01; intervalo de confiança de 95% (IC95%) 1,01-4,01]
, gênero masculino (OR<sub>ajust</sub> = 2,50; IC95% 1,21-5,18) e idade de 0 a 6
 anos (OR<sub>ajust</sub> = 5,00; IC95% 2,41-10,39). <b>CONCLUSÃO: </b>Mesmo em 
baixas concentrações de poluentes atmosféricos, a ocorrência de sintomas respira
tórios em crianças e adolescentes nas comunidades no entorno de um PPQ esteve as
sociada a residência na direção preferencial dos ventos, mostrando-se mais vulne
rável o grupo de pré-escolares do gênero masculino.#^ddecs^i1#^tm^lpt^kSibilânci
a^i1#^tm^lpt^kcrianças^i1#^tm^lpt^kadolescentes^i1#^tm^lpt^kpoluição atmosférica
^i1#^tm^lpt^kpetróleo^i1#^len^a<b>OBJECTIVE: </b>To examine the association betw
een wheezing in children and adolescents and living downwind of the dispersion p
lume of atmospheric pollutants emitted by the Guamaré Petrochemical Complex, in 
the state of Rio Grande do Norte, Brazil. <b>METHODS: </b>Cross-sectional study 
of wheezing in children and adolescents (aged 0 to 14 years) living in the vicin
ity of the Guamaré petrochemical complex in 2006. The standardized International
 Study of Asthma and Allergies in Childhood questionnaire was used, with additio
nal questions concerning tobacco use, income, living conditions, and educational
 achievement. Daily concentrations of PM<sub>10</sub>, PM<sub>2.5</sub>, black c
arbon, SO<sub>2</sub>, NO<sub>2</sub>, O<sub>3</sub>, benzene, toluene, and xyle
nes were measured at a fixed monitoring station. According to their position rel
ative to wind direction, communities present in the area affected by plant emiss
ions were categorized into one of two groups, exposed communities and reference 
communities. <b>RESULTS: </b>Two hundred and nine children and adolescents took 
part in the study. Mean daily concentrations of the monitored pollutants were co
nsistently below established acceptable upper limits. The prevalence of wheezing
 in the 12 months prior to study was 27.3%. After adjustment, statistically sign
ificant associations were found between wheezing and living in exposed communiti
es (adjusted odds ratio [OR<sub>adj</sub>] 2.01; 95% confidence interval [95%CI]
 1.01-4.01), male gender (OR<sub>adj</sub> 2.50; 95%CI 1.21-5.18), and age 0 to 
6 years (OR<sub>adj</sub> 5.00; 95%CI 2.41-10.39). <b>CONCLUSION: </b>Even with 
low levels of atmospheric pollutants, respiratory symptoms in children and adole
scents were associated with living downwind of a petrochemical plant. Male presc
hoolers were the most vulnerable group.#^ddecs^i2#^tm^len^kWheezing^i2#^tm^len^k
children^i2#^tm^len^kadolescents^i2#^tm^len^kair pollution^i2#^tm^len^kpetrochem
icals^i2#vancouv#30#20100118#18.01.2010#20100602#02.06.2010#a15v86n4.htm##
05802000000000733000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000400108121000300112049000800115158000300123
03000210012603100030014703200020015006500090015201400110016103500100017201201110
01820120109002930100040004020100031004420100031004730100045005040100027005490100
03400576070009700610070005800707070010800765070006900873070010200942083183501044
08500100287908500230288908500210291208500250293308500330295808500210299108317740
30120850010047860850021047960850021048170850024048380850026048620850027048881170
00804915072000304923112000904926111001104935114000904946113001104955002001304966
008008904979#v86n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#l#4#1#artic
le#1#^mjul./ago.^a2010#oa#pt#br1.1#1#4.0#tab#15#JPED030#nd#J. Pediatr. (Rio J.)#
86#4#20100800#^f337^l344#0021-7557#Sibilância em crianças e adolescentes vizinho
s a uma indústria petroquímica no Rio Grande do Norte, Brasil^lpt#Wheezing in ch
ildren and adolescents living next to a petrochemical plant in Rio Grande do Nor
te, Brazil^len#^rND^1A01^nAna Claudia Lopes de^sMoraes#^rND^1A02 A03^nEliane^sIg
notti#^rND^1A04^nPaulo Artaxo^sNetto#^rND^1A03^nLudmilla da Silva Viana^sJacobso
n#^rND^1A05^nHermano^sCastro#^rND^1A03^nSandra de Souza^sHacon#^iA01^1Fundação O
swaldo Cruz^2Escola Nacional de Saúde Pública Sérgio Arouca^cRio de Janeiro^sRJ#
^iA02^1Universidade do Estado de Mato Grosso^cCáceres^sMT#^iA03^1Fiocruz^2ENSP^3
Programa de Mestrado e Doutorado em Saúde Pública e Meio Ambiente^cRio de Janeir
o^sRJ#^iA04^1Universidade de São Paulo^2Instituto de Física^cSão Paulo^sSP#^iA05
^1Fiocruz^2ENSP^3Centro de Estudos de Saúde do Trabalhador e Ecologia Humana^cRi
o de Janeiro^sRJ#^lpt^aOBJETIVO: Verificar a associação entre relato de sibilânc
ia em crianças e adolescentes e o local de residência em relação à dispersão dos
 poluentes atmosféricos emitidos pelo Pólo Petroquímico (PPQ) de Guamaré (RN). M
ÉTODOS: Estudo transversal de relato de sibilância em crianças e adolescentes de
 0 a 14 anos de idade, residentes no entorno do PPQ de Guamaré, em 2006. Foi uti
lizado o questionário padronizado do International Study of Asthma and Allergies
 in Childhood, acrescido de questões relativas ao tabagismo, renda, moradia e es
colaridade. Concentrações diárias de PM10, PM2,5, carbono grafítico, SO2, NO2, O
3, benzeno, tolueno e xilenos foram medidas em uma estação de monitoramento fixa
. As comunidades residentes na área de influência das emissões do PPQ foram clas
sificadas, segundo a direção preferencial dos ventos, em expostas e de referênci
a. RESULTADOS: Participaram do estudo 209 crianças e adolescentes. As concentraç
ões médias diárias dos poluentes monitorados mantiveram-se abaixo dos limites es
tabelecidos nos padrões de qualidade do ar. A prevalência de sibilos nos últimos
 12 meses foi de 27,3 por cento. Associações estatisticamente significantes com 
sibilos nos últimos 12 meses foram verificadas mesmo após ajustamentos para comu
nidades expostas [razão de chances (odds ratio, ORajust) = 2,01; intervalo de co
nfiança de 95 por cento (IC95 por cento) 1,01-4,01], gênero masculino (ORajust =
 2,50; IC95 por cento 1,21-5,18) e idade de 0 a 6 anos (ORajust = 5,00; IC95 por
 cento 2,41-10,39). CONCLUSÃO: Mesmo em baixas concentrações de poluentes atmosf
éricos, a ocorrência de sintomas respiratórios em crianças e adolescentes nas co
munidades no entorno de um PPQ esteve associada a residência na direção preferen
cial dos ventos, mostrando-se mais vulnerável o grupo de pré-escolares do gênero
 masculino.#^ddecs^i1#^tm^lpt^kSibilância^i1#^tm^lpt^kcrianças^i1#^tm^lpt^kadole
scentes^i1#^tm^lpt^kpoluição atmosférica^i1#^tm^lpt^kpetróleo^i1#^len^aOBJECTIVE
: To examine the association between wheezing in children and adolescents and li
ving downwind of the dispersion plume of atmospheric pollutants emitted by the G
uamaré Petrochemical Complex, in the state of Rio Grande do Norte, Brazil. METHO
DS: Cross-sectional study of wheezing in children and adolescents (aged 0 to 14 
years) living in the vicinity of the Guamaré petrochemical complex in 2006. The 
standardized International Study of Asthma and Allergies in Childhood questionna
ire was used, with additional questions concerning tobacco use, income, living c
onditions, and educational achievement. Daily concentrations of PM10, PM2.5, bla
ck carbon, SO2, NO2, O3, benzene, toluene, and xylenes were measured at a fixed 
monitoring station. According to their position relative to wind direction, comm
unities present in the area affected by plant emissions were categorized into on
e of two groups, exposed communities and reference communities. RESULTS: Two hun
dred and nine children and adolescents took part in the study. Mean daily concen
trations of the monitored pollutants were consistently below established accepta
ble upper limits. The prevalence of wheezing in the 12 months prior to study was
 27.3 percent. After adjustment, statistically significant associations were fou
nd between wheezing and living in exposed communities (adjusted odds ratio [ORad
j] 2.01; 95 percent confidence interval [95 percentCI] 1.01-4.01), male gender (
ORadj 2.50; 95 percentCI 1.21-5.18), and age 0 to 6 years (ORadj 5.00; 95 percen
tCI 2.41-10.39). CONCLUSION: Even with low levels of atmospheric pollutants, res
piratory symptoms in children and adolescents were associated with living downwi
nd of a petrochemical plant. Male preschoolers were the most vulnerable group.#^
ddecs^i2#^tm^len^kWheezing^i2#^tm^len^kchildren^i2#^tm^len^kadolescents^i2#^tm^l
en^kair pollution^i2#^tm^len^kpetrochemicals^i2#vancouv#30#20100118#18.01.2010#2
0100602#02.06.2010#a15v86n4.htm#Internet^ihttp://www.scielo.br/scielo.php?script
=sci_arttext&pid=S0021-75572010000400015##
00322000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704008900074002001300163#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#5#1#article#157#<p align="right"><fon
t size="2" face="Verdana"><b>ARTIGO ORIGINAL</b></font></p>     ^cY#a15v86n4.htm
##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#6#2#article#157#<p>&nbsp;</p>     ^cY
#a15v86n4.htm##
00432000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704019900074002001300273#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#7#3#article#157#<p><font size="4" fac
e="Verdana"><b>Sibil&acirc;ncia em crian&ccedil;as e adolescentes    vizinhos a 
uma ind&uacute;stria petroqu&iacute;mica no Rio Grande do Norte,    Brasil</b></
font></p>     ^cY#a15v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#8#4#article#157#<p>&nbsp;</p>     ^cY
#a15v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#9#5#article#157#<p>&nbsp;</p>     ^cY
#a15v86n4.htm##
00513000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704027900075002001300354#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#10#6#article#157#<p><font size="2" fa
ce="Verdana"><b>Ana Claudia Lopes de Moraes<sup>I</sup>; Eliane    Ignotti<sup>I
I</sup>; Paulo Artaxo Netto<sup>III</sup>; Ludmilla da Silva Viana    Jacobson<s
up>IV</sup>; Hermano Castro<sup>V</sup>; Sandra de Souza Hacon<sup>VI</sup></b><
/font></p>     ^cY#a15v86n4.htm##
00494000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704026000075002001300335#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#11#7#article#157#<p><font size="2" fa
ce="Verdana"><sup>I</sup>Doutoranda, Sa&uacute;de P&uacute;blica    e Meio Ambie
nte, Escola Nacional de Sa&uacute;de P&uacute;blica S&eacute;rgio    Arouca (ENS
P), Funda&ccedil;&atilde;o Oswaldo Cruz (Fiocruz), Rio de Janeiro,    RJ    ^cY#
a15v86n4.htm##
00496000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704026200075002001300337#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#12#8#article#157#<br>   <sup>II</sup>
Co-orientadora, Professora,    Epidemiologia, Universidade do Estado de Mato Gro
sso (UNEMAT), C&aacute;ceres,    MT, Programa de Mestrado e Doutorado em Sa&uacu
te;de P&uacute;blica e Meio Ambiente,    ENSP, Fiocruz, Rio de Janeiro, RJ    ^c
Y#a15v86n4.htm##
00354000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704012000075002001300195#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#13#9#article#157#<br>   <sup>III</sup
>Instituto de F&iacute;sica,    Universidade de S&atilde;o Paulo (USP), S&atilde
;o Paulo, SP    ^cY#a15v86n4.htm##
00383000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014800076002001300224#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#14#10#article#157#<br>   <sup>IV</sup
>Programa de Mestrado e Doutorado    em Sa&uacute;de P&uacute;blica e Meio Ambie
nte, ENSP, Fiocruz, Rio de Janeiro,    RJ    ^cY#a15v86n4.htm##
00366000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013100076002001300207#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#15#11#article#157#<br>   <sup>V</sup>
Centro de Estudos de Sa&uacute;de    do Trabalhador e Ecologia Humana, ENSP, Fio
cruz, Rio de Janeiro, RJ    ^cY#a15v86n4.htm##
00428000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019300076002001300269#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#16#12#article#157#<br>   <sup>VI</sup
>Orientadora, Pesquisadora    titular, Programa de Mestrado e Doutorado, Sa&uacu
te;de P&uacute;blica e Meio    Ambiente, ENSP, Fiocruz, Rio de Janeiro, RJ</font
></p>     ^cY#a15v86n4.htm##
00368000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013300076002001300209#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#17#13#article#157#<p><font size="2" f
ace="Verdana"><a name="topo" id="topo"></a><a href="#correspondence">Correspond&
ecirc;ncia</a></font></p>     ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#18#14#article#157#<p>&nbsp;</p>     ^
cY#a15v86n4.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#19#15#article#157#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a15v86n4.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006600076002001300142#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#20#16#article#157#<p><font size="2" f
ace="Verdana"><b>RESUMO</b></font></p>     ^cY#a15v86n4.htm##
00601000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704036600076002001300442#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#21#17#article#157#<p><font size="2" f
ace="Verdana"> <b>OBJETIVO: </b> Verificar a associa&ccedil;&atilde;o    entre r
elato de sibil&acirc;ncia em crian&ccedil;as e adolescentes e o local    de resi
d&ecirc;ncia em rela&ccedil;&atilde;o &agrave; dispers&atilde;o dos poluentes   
 atmosf&eacute;ricos emitidos pelo P&oacute;lo Petroqu&iacute;mico (PPQ) de Guam
ar&eacute;    (RN).    ^cY#a15v86n4.htm##
01106000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704087100076002001300947#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#22#18#article#157#<br>   <b>M&Eacute;
TODOS: </b> Estudo transversal de relato de sibil&acirc;ncia em    crian&ccedil;
as e adolescentes de 0 a 14 anos de idade, residentes no entorno    do PPQ de Gu
amar&eacute;, em 2006. Foi utilizado o question&aacute;rio padronizado    do Int
ernational Study of Asthma and Allergies in Childhood, acrescido de quest&otilde
;es    relativas ao tabagismo, renda, moradia e escolaridade. Concentra&ccedil;&
otilde;es    di&aacute;rias de PM<sub>10</sub>, PM<sub>2,5</sub>, carbono graf&i
acute;tico,    SO<sub>2</sub>, NO<sub>2</sub>, O<sub>3</sub>, benzeno, tolueno e
 xilenos foram    medidas em uma esta&ccedil;&atilde;o de monitoramento fixa. As
 comunidades residentes    na &aacute;rea de influ&ecirc;ncia das emiss&otilde;e
s do PPQ foram classificadas,    segundo a dire&ccedil;&atilde;o preferencial do
s ventos, em expostas e de refer&ecirc;ncia.    ^cY#a15v86n4.htm##
01048000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704081300076002001300889#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#23#19#article#157#<br>   <b>RESULTADO
S: </b>Participaram do estudo 209 crian&ccedil;as e adolescentes.    As concentr
a&ccedil;&otilde;es m&eacute;dias di&aacute;rias dos poluentes monitorados    ma
ntiveram-se abaixo dos limites estabelecidos nos padr&otilde;es de qualidade    
do ar. A preval&ecirc;ncia de sibilos nos &uacute;ltimos 12 meses foi de 27,3%. 
   Associa&ccedil;&otilde;es estatisticamente significantes com sibilos nos &uac
ute;ltimos    12 meses foram verificadas mesmo ap&oacute;s ajustamentos para com
unidades expostas    &#091;raz&atilde;o de chances (<i>odds ratio</i>, OR<sub>aj
ust</sub>) = 2,01; intervalo    de confian&ccedil;a de 95% (IC95%) 1,01-4,01&#09
3;, g&ecirc;nero masculino (OR<sub>ajust</sub>    = 2,50; IC95% 1,21-5,18) e ida
de de 0 a 6 anos (OR<sub>ajust</sub> = 5,00; IC95%    2,41-10,39).    ^cY#a15v86
n4.htm##
00681000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044600076002001300522#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#24#20#article#157#<br>   <b>CONCLUS&A
tilde;O: </b> Mesmo em baixas concentra&ccedil;&otilde;es de poluentes    atmosf
&eacute;ricos, a ocorr&ecirc;ncia de sintomas respirat&oacute;rios em    crian&c
cedil;as e adolescentes nas comunidades no entorno de um PPQ esteve associada   
 a resid&ecirc;ncia na dire&ccedil;&atilde;o preferencial dos ventos, mostrando-
se    mais vulner&aacute;vel o grupo de pr&eacute;-escolares do g&ecirc;nero mas
culino.</font></p>     ^cY#a15v86n4.htm##
00445000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021000076002001300286#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#25#21#article#157#<p><font size="2" f
ace="Verdana"><b>Palavras-chave: </b> Sibil&acirc;ncia, crian&ccedil;as,    adol
escentes, polui&ccedil;&atilde;o atmosf&eacute;rica, petr&oacute;leo.</font></p>
 <hr size="1" noshade>     ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#26#22#article#157#<p>&nbsp;</p>     ^
cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#27#23#article#157#<p>&nbsp;</p>     ^
cY#a15v86n4.htm##
00319000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008400076002001300160#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#28#24#article#157#<p><font size="3" f
ace="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#a15v86n4.htm##
00801000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056600076002001300642#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#29#25#article#157#<p><font face="Verd
ana" size="2">Os principais poluentes atmosf&eacute;ricos liberados    pelas ref
inarias de petr&oacute;leo s&atilde;o &oacute;xidos de enxofre e nitrog&ecirc;ni
o    (SOx e NOx), mon&oacute;xido de carbono (CO), materiais particulados (<i>pa
rticulate    matters</i>, PM) e hidrocarbonetos<SUP>1</SUP>. Esses poluentes t&e
circ;m sido    associados a efeitos &agrave; sa&uacute;de, especialmente efeitos
 respirat&oacute;rios,    em grupos mais vulner&aacute;veis, como crian&ccedil;a
s<SUP>2-5</SUP> e asm&aacute;ticos<SUP>6</SUP>.</font></p>     ^cY#a15v86n4.htm#
#
01172000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704093700076002001301013#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#30#26#article#157#<p><font face="Verd
ana" size="2">Estudos t&ecirc;m reportado associa&ccedil;&otilde;es    entre a p
roximidade de resid&ecirc;ncias a rodovias e ind&uacute;strias e desfechos    re
spirat&oacute;rios em crian&ccedil;as, incluindo sintomas como sibil&acirc;ncia 
   e exacerba&ccedil;&atilde;o de asma<SUP>7-9</SUP>. Smargiassi et al.<SUP>8</S
UP>    relataram epis&oacute;dios de eleva&ccedil;&atilde;o dos n&iacute;veis de
 di&oacute;xido    de enxofre (SO<SUB sa>2</SUB>) liberados por uma refinaria no
 Canad&aacute;,    associados com o aumento de epis&oacute;dios de asma em crian
&ccedil;as residentes    no entorno. Wichmann et al.<SUP>9</SUP> reportaram que 
crian&ccedil;as vizinhas    a uma planta petroqu&iacute;mica na Argentina aprese
ntavam maior preval&ecirc;ncia    de asma, sintomas respirat&oacute;rios e redu&
ccedil;&atilde;o da fun&ccedil;&atilde;o    pulmonar do que crian&ccedil;as de o
utras localidades.</font></p>     ^cY#a15v86n4.htm##
01092000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704085700076002001300933#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#31#27#article#157#<p><font face="Verd
ana" size="2">A identifica&ccedil;&atilde;o precoce de sibil&acirc;ncia    recor
rente &eacute; importante pela redu&ccedil;&atilde;o da fun&ccedil;&atilde;o    
pulmonar e da gravidade da express&atilde;o da doen&ccedil;a na inf&acirc;ncia, 
   que pode permanecer na idade adulta<SUP>10-12</SUP>. Para menores de 5 anos  
  de idade, o diagn&oacute;stico da asma &eacute; complexo, e a abordagem &eacut
e;    feita por meio de sintomas de sibil&acirc;ncia<SUP>13</SUP>. Sibilos nos &
uacute;ltimos    12 meses e fatores de risco associados t&ecirc;m sido utilizado
s para a avalia&ccedil;&atilde;o    de preval&ecirc;ncia de asma em estudos epid
emiol&oacute;gicos<SUP>14,15</SUP>.    Dentre os fatores ambientais associados, 
a exposi&ccedil;&atilde;o a poluentes    atmosf&eacute;ricos tem sido discutida<
SUP>6,15,16</SUP>.</font></p>     ^cY#a15v86n4.htm##
00975000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074000076002001300816#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#32#28#article#157#<p><font face="Verd
ana" size="2">Pouco se conhece a respeito dos impactos &agrave;    sa&uacute;de 
de crian&ccedil;as brasileiras residentes no entorno de unidades    da ind&uacut
e;stria petroqu&iacute;mica, tornando relevante o desenvolvimento    deste estud
o. Trata-se de um produto do projeto de pesquisa "Avalia&ccedil;&atilde;o    do 
impacto socioambiental das emiss&otilde;es atmosf&eacute;ricas e seus reflexos  
  na sa&uacute;de da comunidade no entorno", realizado atrav&eacute;s de uma par
ceria    entre o P&oacute;lo Petroqu&iacute;mico (PPQ) de Guamar&eacute; (RN), a
 Funda&ccedil;&atilde;o    Oswaldo Cruz (Fiocruz), Rio de Janeiro (RJ), e a Univ
ersidade de S&atilde;o    Paulo (USP), S&atilde;o Paulo (SP).</font></p>     ^cY
#a15v86n4.htm##
00588000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704035300076002001300429#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#33#29#article#157#<p><font face="Verd
ana" size="2">O objetivo deste estudo foi verificar a associa&ccedil;&atilde;o  
  entre relato de sibil&acirc;ncia em crian&ccedil;as e adolescentes e o local  
  de resid&ecirc;ncia em rela&ccedil;&atilde;o &agrave; pluma de dispers&atilde;
o    dos poluentes atmosf&eacute;ricos emitida pelo PPQ de Guamar&eacute;.</font
></p>     ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#34#30#article#157#<p>&nbsp;</p>     ^
cY#a15v86n4.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007400076002001300150#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#35#31#article#157#<p><font size="3" f
ace="Verdana"><b>M&eacute;todos</b></font></p>     ^cY#a15v86n4.htm##
00319000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008400076002001300160#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#36#32#article#157#<p><font face="Verd
ana" size="2"><b><i>Desenho de estudo</i></b></font></p>     ^cY#a15v86n4.htm##
00467000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023200076002001300308#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#37#33#article#157#<p><font face="Verd
ana" size="2">Estudo transversal de relato de sibil&acirc;ncia    em crian&ccedi
l;as e adolescentes residentes no entorno do PPQ de Guamar&eacute;,    no estado
 do Rio Grande do Norte, em 2006.</font></p>     ^cY#a15v86n4.htm##
00352000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704011700076002001300193#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#38#34#article#157#<p><font face="Verd
ana" size="2"><b><i>Popula&ccedil;&atilde;o e &aacute;rea de    estudo</i></b></
font></p>     ^cY#a15v86n4.htm##
00847000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061200076002001300688#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#39#35#article#157#<p><font face="Verd
ana" size="2">Foram inclu&iacute;das no estudo todas as crian&ccedil;as    e ado
lescentes de 0 at&eacute; 14 anos, 11 meses e 29 dias de idade, residentes    h&
aacute; no m&iacute;nimo 1 ano dentro de um raio de 5 km do PPQ, no ano de    20
06. Em raz&atilde;o de todos os participantes serem menores de idade, foi    nec
ess&aacute;rio o preenchimento do termo de esclarecimento livre e esclarecido   
 pelos respons&aacute;veis, concordando em participar do estudo. O projeto foi  
  aprovado pelo Comit&ecirc; de &Eacute;tica em Pesquisa da Fiocruz (protocolo  
  nº 153/06).</font></p>     ^cY#a15v86n4.htm##
00837000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060200076002001300678#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#40#36#article#157#<p><font face="Verd
ana" size="2">O raio de influ&ecirc;ncia foi definido a partir    de estudos sim
ilares levantados na literatura<SUP>1,17</SUP>. A &aacute;rea    de estudo compr
eendeu as cinco comunidades localizadas no entorno do PPQ, que    produz g&aacut
e;s de cozinha, g&aacute;s industrial, &oacute;leo diesel, querosene    de avia&
ccedil;&atilde;o, nafta e gasolina. Fez parte do universo de an&aacute;lise    u
m total de 209 crian&ccedil;as residentes nas comunidades de Lagoa Doce (A),    
Mangue Seco I (B), Mangue Seco II (C), Ponta de Salina (D) e Salina da Cruz    (
E).</font></p>     ^cY#a15v86n4.htm##
00606000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037100076002001300447#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#41#37#article#157#<p><font face="Verd
ana" size="2">O munic&iacute;pio de Guamar&eacute;, com 259    km<SUP sa>2</SUP>
, localiza-se no litoral norte do Rio Grande do Norte, a 180    km de Natal, cap
ital do estado, latitude 5° 06' 27" sul e longitude 36° 19'    13" oeste, 3 m ac
ima do n&iacute;vel do mar. Limita-se ao norte com o Oceano    Atl&acirc;ntico<S
UP>18</SUP>.</font></p>     ^cY#a15v86n4.htm##
00539000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030400076002001300380#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#42#38#article#157#<p><font face="Verd
ana" size="2">A popula&ccedil;&atilde;o estimada em 2006 foi    de 9.678 habitan
tes, sendo 49% do g&ecirc;nero feminino e 51% masculino. Destes,    56% vivem na
 &aacute;rea rural. O &iacute;ndice de desenvolvimento humano (IDH)    em 2000 e
ra de 0,645<SUP>19</SUP>.</font></p>     ^cY#a15v86n4.htm##
00566000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033100076002001300407#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#43#39#article#157#<p><font face="Verd
ana" size="2">O clima do munic&iacute;pio &eacute; quente e    semi-&aacute;rido
, com esta&ccedil;&atilde;o chuvosa de fevereiro a maio, com    m&eacute;dias an
uais de umidade relativa de 68%, precipita&ccedil;&atilde;o    pluviom&eacute;tr
ica de 711 mm e temperatura de 27,2 °C<SUP>18</SUP>.</font></p>     ^cY#a15v86n4
.htm##
00318000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008300076002001300159#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#44#40#article#157#<p><font face="Verd
ana" size="2"><b><i>Dados ambientais</i></b></font></p>     ^cY#a15v86n4.htm##
01373000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704113800076002001301214#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#45#41#article#157#<p><font face="Verd
ana" size="2">Foi instalada uma esta&ccedil;&atilde;o de monitoramento    da qua
lidade do ar com medidas cont&iacute;nuas em tempo real e uma esta&ccedil;&atild
e;o    meteorol&oacute;gica de 27 de mar&ccedil;o a 18 de julho de 2006, incluin
do    per&iacute;odos de chuvas e estiagem. Foram monitoradas as concentra&ccedi
l;&otilde;es    dos poluentes atmosf&eacute;ricos PM<SUB>10</SUB>, PM<SUB>2,5</S
UB>, carbono    graf&iacute;tico (<i>black carbon</i>, BC), SO<SUB>2</SUB>, di&o
acute;xido de    nitrog&ecirc;nio (NO<SUB>2</SUB>), oz&ocirc;nio (O<SUB>3</SUB>)
, benzeno, tolueno    e xilenos (BTX). A esta&ccedil;&atilde;o foi instalada dis
tando aproximadamente    4 km do PPQ, com a dire&ccedil;&atilde;o predominante d
o vento no sentido do    PPQ para a esta&ccedil;&atilde;o. O local de instala&cc
edil;&atilde;o da esta&ccedil;&atilde;o    baseou-se em dados hist&oacute;ricos 
dos &uacute;ltimos 5 anos da esta&ccedil;&atilde;o    meteorol&oacute;gica fixa 
implementada pela dire&ccedil;&atilde;o do PPQ e em    caracter&iacute;sticas to
pogr&aacute;ficas do local (plano e sem obst&aacute;culos).</font></p>     ^cY#a
15v86n4.htm##
00546000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031100076002001300387#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#46#42#article#157#<p><font face="Verd
ana" size="2">Considerando que o n&uacute;mero de ve&iacute;culos    na &aacute;
rea &eacute; pequeno e n&atilde;o h&aacute; outra ind&uacute;stria    na regi&at
ilde;o, as medidas de contaminantes na esta&ccedil;&atilde;o de monitoramento   
 foram atribu&iacute;das ao PPQ.</font></p>     ^cY#a15v86n4.htm##
00323000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008800076002001300164#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#47#43#article#157#<p><font face="Verd
ana" size="2"><b><i>Dados de sa&uacute;de</i></b></font></p>     ^cY#a15v86n4.ht
m##
01062000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082700076002001300903#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#48#44#article#157#<p><font face="Verd
ana" size="2">Foi utilizado o m&oacute;dulo de asma do question&aacute;rio    es
crito (QE) da Fase I do International Study of Asthma and Allergies in Childhood
    (ISAAC)<SUP>20</SUP>, padronizado internacionalmente para a identifica&ccedi
l;&atilde;o    de asma em escolares e adolescentes e validado no Brasil<SUP>21,2
2</SUP>. Recomenda-se    a utiliza&ccedil;&atilde;o do question&aacute;rio desen
volvido para o Estudo    Internacional de Sibil&acirc;ncias em Lactentes (EISL)<
SUP>23</SUP> para crian&ccedil;as    menores de 3 anos de idade. No entanto, em 
raz&atilde;o do pequeno n&uacute;mero    populacional na faixa et&aacute;ria de 
interesse, optou-se pelo question&aacute;rio    ISAAC, que valoriza principalmen
te informa&ccedil;&otilde;es relativas &agrave;    sibil&acirc;ncia.</font></p> 
    ^cY#a15v86n4.htm##
00547000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031200076002001300388#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#49#45#article#157#<p><font face="Verd
ana" size="2">Foram acrescentadas quest&otilde;es sobre renda    familiar e indi
vidual, tipo de domic&iacute;lio, escolaridade do respons&aacute;vel,    exposi&
ccedil;&atilde;o na agricultura, uso de outra fonte de energia e exposi&ccedil;&
atilde;o    domiciliar ao tabaco.</font></p>     ^cY#a15v86n4.htm##
00748000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704051300076002001300589#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#50#46#article#157#<p><font face="Verd
ana" size="2">Foram consideradas quest&otilde;es sobre sintomas    respirat&oacu
te;rios, gravidade e diagn&oacute;stico m&eacute;dico de asma.    O QE foi aplic
ado nos domic&iacute;lios por entrevistadores selecionados entre    os agentes d
e sa&uacute;de locais, sendo respondido pelos pais ou respons&aacute;veis.    O 
controle da qualidade dos dados foi feito pelo treinamento, supervis&atilde;o,  
  revis&atilde;o dos question&aacute;rios e dupla digita&ccedil;&atilde;o.</font
></p>     ^cY#a15v86n4.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009300076002001300169#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#51#47#article#157#<p><font face="Verd
ana" size="2"><b><i>Vari&aacute;veis em estudo</i></b></font></p>     ^cY#a15v86
n4.htm##
00764000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052900076002001300605#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#52#48#article#157#<p><font face="Verd
ana" size="2">Foram investigados sibilos, asma diagnosticada    ou asma alguma v
ez na vida, tosse seca noturna na aus&ecirc;ncia de infec&ccedil;&atilde;o    re
spirat&oacute;ria, frequ&ecirc;ncia de crises de sibilos nos &uacute;ltimos    1
2 meses e a frequ&ecirc;ncia de sibilos impedindo o sono, bem como vari&aacute;v
eis    demogr&aacute;ficas, socioecon&ocirc;micas, condi&ccedil;&otilde;es de mo
radia,    saneamento e exposi&ccedil;&atilde;o domiciliar a fontes de energia e 
tabagismo.</font></p>     ^cY#a15v86n4.htm##
01001000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704076600076002001300842#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#53#49#article#157#<p><font face="Verd
ana" size="2">Para a an&aacute;lise multivariada, a idade foi    categorizada em
 crian&ccedil;as de 0 a 6 anos (pr&eacute;-escolares) e de 7    a 14 anos (escol
ares e adolescentes). A &uacute;nica crian&ccedil;a negra foi    inclu&iacute;da
 no grupo dos pardos, dentre as categorias definidas para ra&ccedil;a    em pard
a e branca. O n&iacute;vel socioecon&ocirc;mico foi definido pela renda    total
 da fam&iacute;lia, categorizada em tercis de sal&aacute;rios m&iacute;nimos,   
 e pela renda <i>per capita</i> (at&eacute; R$ 45,00; de R$ 45,00 a R$ 100,00;  
  e R$ 100,00 ou mais por pessoa); a escolaridade do respons&aacute;vel foi estr
atificada    em n&atilde;o alfabetizado/alfabetizado e ensino fundamental/m&eacu
te;dio.</font></p>     ^cY#a15v86n4.htm##
01121000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704088600076002001300962#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#54#50#article#157#<p><font face="Verd
ana" size="2">As condi&ccedil;&otilde;es de exposi&ccedil;&atilde;o    domicilia
r e situa&ccedil;&atilde;o de moradia foram analisadas pelas vari&aacute;veis   
 relacionadas ao ambiente dom&eacute;stico (n&uacute;mero de c&ocirc;modos e    
quantas pessoas residem na casa), saneamento b&aacute;sico (&aacute;gua e destin
o    do lixo dom&eacute;stico) e produ&ccedil;&atilde;o agr&iacute;cola. As vari
&aacute;veis    relacionadas ao ambiente dom&eacute;stico inclu&iacute;ram a var
i&aacute;vel    n&uacute;mero de moradores por c&ocirc;modo, estratificada em at
&eacute; 2 ou    2 e mais moradores por c&ocirc;modo. As vari&aacute;veis de san
eamento foram    estratificadas em fun&ccedil;&atilde;o de as moradias possu&iac
ute;rem ou n&atilde;o    atendimento pela rede p&uacute;blica de distribui&ccedi
l;&atilde;o de &aacute;gua    e coleta de lixo.</font></p>     ^cY#a15v86n4.htm#
#
00562000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032700076002001300403#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#55#51#article#157#<p><font face="Verd
ana" size="2">Foi investigado tabagismo no domic&iacute;lio    e na gesta&ccedil
;&atilde;o, assim como o uso de outra fonte de energia para    ilumina&ccedil;&a
tilde;o. O uso de lenha para cozinhar n&atilde;o foi investigado    em raz&atild
e;o das comunidades receberem o vale-g&aacute;s.</font></p>     ^cY#a15v86n4.htm
##
01006000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077100076002001300847#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#56#52#article#157#<p><font face="Verd
ana" size="2">Em rela&ccedil;&atilde;o &agrave; exposi&ccedil;&atilde;o    ambie
ntal, as comunidades foram classificadas de acordo com sua localiza&ccedil;&atil
de;o    em rela&ccedil;&atilde;o ao PPQ e com a dire&ccedil;&atilde;o predominan
te dos    ventos. Aquelas na dire&ccedil;&atilde;o predominante dos ventos e suj
eitas    a maior influ&ecirc;ncia da pluma de origem do PPQ (A, B, C) foram clas
sificadas    como comunidades expostas (CE), e aquelas fora da dire&ccedil;&atil
de;o predominante    dos ventos, com menor influ&ecirc;ncia da pluma do PPQ (D, 
E), como comunidades    de refer&ecirc;ncia (CR). Os resultados do monitoramento
 de poluentes representam    os n&iacute;veis aproximados de exposi&ccedil;&atil
de;o das CE.</font></p>     ^cY#a15v86n4.htm##
00679000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704044400076002001300520#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#57#53#article#157#<p><font face="Verd
ana" size="2">Como <i>proxy </i>de exposi&ccedil;&atilde;o    foi utilizada a co
munidade de resid&ecirc;ncia categorizada segundo a dire&ccedil;&atilde;o    pre
ferencial dos ventos. Para avalia&ccedil;&atilde;o dos desfechos de sa&uacute;de
,    foi utilizado um per&iacute;odo recordat&oacute;rio de 12 meses, para dimin
uir    o vi&eacute;s de mem&oacute;ria e por independer da sazonalidade<SUP>15</
SUP>.</font></p>     ^cY#a15v86n4.htm##
00326000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009100076002001300167#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#58#54#article#157#<p><font face="Verd
ana" size="2"><b><i>An&aacute;lise dos dados</i></b></font></p>     ^cY#a15v86n4
.htm##
00735000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050000076002001300576#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#59#55#article#157#<p><font face="Verd
ana" size="2">Foram considerados os valores m&eacute;dios di&aacute;rios    dos 
contaminantes ambientais monitorados no per&iacute;odo do estudo e comparados   
 com padr&otilde;es de qualidade do ar estabelecidos pela Organiza&ccedil;&atild
e;o    Mundial da Sa&uacute;de (OMS)<SUP>2</SUP>, porque estes s&atilde;o mais r
&iacute;gidos    do que os padr&otilde;es da Resolu&ccedil;&atilde;o 003/1990 do
 Conselho Nacional    do Meio Ambiente (CONAMA)<SUP>24</SUP>.</font></p>     ^cY
#a15v86n4.htm##
01481000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704124600076002001301322#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#60#56#article#157#<p><font face="Verd
ana" size="2">Utilizou-se o teste do qui-quadrado para comparar    as diferen&cc
edil;as de propor&ccedil;&otilde;es da preval&ecirc;ncia de sintomas    de asma 
segundo g&ecirc;nero, ao n&iacute;vel de signific&acirc;ncia de 5%.    A respost
a afirmativa &agrave; quest&atilde;o sobre a presen&ccedil;a de sibilos    nos &
uacute;ltimos 12 meses foi utilizada como vari&aacute;vel dependente nas    an&a
acute;lises bivariada e multivariada. Para tanto, foram criadas duas categorias 
   de estudo, a saber: com sibilo no &uacute;ltimo ano (CSA) e sem sibilo no &ua
cute;ltimo    ano (SSA). Foram estimados valores de raz&atilde;o de chances (<i>
odds ratio</i>,    OR) bruta na an&aacute;lise da associa&ccedil;&atilde;o do si
ntoma de asma com    as vari&aacute;veis em estudo. Na an&aacute;lise multivaria
da, atrav&eacute;s    de regress&atilde;o log&iacute;stica, foram inclu&iacute;d
as as vari&aacute;veis    que atingiram o n&iacute;vel de signific&acirc;ncia de
 at&eacute; 20%, e foram    considerados estatisticamente significantes os model
os com intervalo de confian&ccedil;a    de 95% (IC95%). Os dados foram analisado
s no programa Statistical Package for    the Social Sciences (SPSS) vers&atilde;
o 16.0.</font></p>     ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#61#57#article#157#<p>&nbsp;</p>     ^
cY#a15v86n4.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007000076002001300146#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#62#58#article#157#<p><font size="3" f
ace="Verdana"><b>Resultados</b></font></p>     ^cY#a15v86n4.htm##
01226000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704099100076002001301067#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#63#59#article#157#<p><font face="Verd
ana" size="2">Verificaram-se valores m&eacute;dios de concentra&ccedil;&atilde;o
    de PM, BC e gases abaixo dos n&iacute;veis dos padr&otilde;es de qualidade d
o    ar estabelecidos pela OMS (<a href=/img/revistas/jped/v86n4/4a15t1.gif>Tabe
la    1</a>). As concentra&ccedil;&otilde;es m&eacute;dias di&aacute;rias de PM<
SUB>2,5</SUB>    na &aacute;rea do estudo foram de 4,9 (±2,5) µg/m<SUP sa>3</SUP
>, e de PM<SUB>10</SUB>,    9,8 (±7,7) µg/m<SUP sa>3</SUP>. As concentra&ccedil;
&otilde;es m&eacute;dias    de BC foram de 0,18 (±0,20) µg/m<SUP sa>3</SUP>. Em 
rela&ccedil;&atilde;o aos    gases, as concentra&ccedil;&otilde;es m&eacute;dias
 de O<SUB>3</SUB> foram 10,13    (±4,99 ppb), de SO<SUB>2</SUB> foram menores qu
e 2,5 µg/m<SUP sa>3</SUP>, e    de NO<SUB>2</SUB>, 5,48 (±4,75 ppb). Os valores 
m&eacute;dios de BTX foram,    respectivamente, 32,4 (±9,9) µg/m<SUP sa>3</SUP>,
 18,8 (±20,1) µg/m<SUP sa>3</SUP>    e 18,1 (±10,7) µg/m<SUP sa>3</SUP>.</font><
/p>     ^cY#a15v86n4.htm##
01462000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704122700076002001301303#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#64#60#article#157#<p><font face="Verd
ana" size="2">Foram avaliadas 209 crian&ccedil;as e adolescentes,    sendo 56% d
o g&ecirc;nero masculino; 15,6% tinham idade de 0 a 1 ano, 33,5%    de 2 a 6 ano
s, 17,2% de 7 a 9 anos e 34,0% de 10 a 14 anos. A <a href=/img/revistas/jped/v86
n4/4a15t2.gif>Tabela    2</a> re&uacute;ne as frequ&ecirc;ncias de respostas afi
rmativas &agrave;s quest&otilde;es    do ISAAC, estratificadas por g&ecirc;nero.
 A preval&ecirc;ncia de sibilos alguma    vez na vida foi 39,9% mais elevada ent
re os meninos (42,2 e 37,0%; IC95% 33,2-46,9).    A preval&ecirc;ncia de sibilos
 no &uacute;ltimo ano foi de 27,3%, tamb&eacute;m    mais elevada entre os menin
os (33,3 e 19,6%; IC95% 21,4-33,8). O diagn&oacute;stico    m&eacute;dico de asm
a (asma alguma vez na vida) foi apontado em 21,1% da popula&ccedil;&atilde;o    
de estudo, com predom&iacute;nio entre os meninos (23,1 e 18,5%; IC95% 15,7-27,2
).    Foram verificadas diferen&ccedil;as estatisticamente significantes entre o
s    g&ecirc;neros no que se refere &agrave; presen&ccedil;a de sibilos nos &uac
ute;ltimos    12 meses (qui-quadrado = 6,51; p = 0,011) e ao relato de 1 a 3 cri
ses nos &uacute;ltimos    12 meses (qui-quadrado = 7,28; p = 0,007).</font></p> 
    ^cY#a15v86n4.htm##
00856000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062100076002001300697#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#65#61#article#157#<p><font face="Verd
ana" size="2">A <a href=/img/revistas/jped/v86n4/4a15t3.gif>Tabela    3</a> apre
senta os resultados das an&aacute;lises bivariadas entre a vari&aacute;vel    de
pendente (sibilos nos &uacute;ltimos 12 meses) e vari&aacute;veis relacionadas  
  &agrave;s caracter&iacute;sticas demogr&aacute;ficas, exposi&ccedil;&otilde;es
    dom&eacute;sticas e ambientais, renda, escolaridade do respons&aacute;vel, s
aneamento    e caracter&iacute;sticas do domic&iacute;lio. A probabilidade de oc
orr&ecirc;ncia    de sibilo no &uacute;ltimo ano nas CE foi 81% maior que nas CR
, com IC95% 0,94-3,50.</font></p>     ^cY#a15v86n4.htm##
01083000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084800076002001300924#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#66#62#article#157#<p><font face="Verd
ana" size="2"> Os indiv&iacute;duos do g&ecirc;nero masculino    tiveram probabi
lidade duas vezes maior de apresentar sibilos no &uacute;ltimo    ano quando com
parados ao feminino (OR<SUB>bruta</SUB> = 2,06; IC95% 1,03-4,12).    A probabili
dade de apresentar sibilos decresceu com o aumento da idade. Em rela&ccedil;&ati
lde;o    &agrave; ra&ccedil;a, os brancos tiveram 43% menor probabilidade de apr
esentar    sibilos, embora sem signific&acirc;ncia estat&iacute;stica (p = 0,100
). Quanto    &agrave;s vari&aacute;veis relacionadas &agrave; exposi&ccedil;&ati
lde;o ao    tabagismo domiciliar e na gesta&ccedil;&atilde;o, n&atilde;o foram v
erificadas    associa&ccedil;&otilde;es estat&iacute;sticas (OR<SUB>bruta</SUB> 
= 0,98; IC95%    0,48-2,0 e OR<SUB>bruta</SUB> = 0,68; IC95% 0,25-1,78, respecti
vamente).</font></p>     ^cY#a15v86n4.htm##
00606000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037100076002001300447#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#67#63#article#157#<p><font face="Verd
ana" size="2">As vari&aacute;veis relacionadas &agrave; utiliza&ccedil;&atilde;o
    de outra fonte de energia para cozinhar ou iluminar a resid&ecirc;ncia n&ati
lde;o    apresentaram signific&acirc;ncia estat&iacute;stica, assim como a renda
 familiar,    a renda <i>per capita</i> e escolaridade do respons&aacute;vel e o
 saneamento.</font></p>     ^cY#a15v86n4.htm##
00546000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704031100076002001300387#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#68#64#article#157#<p><font face="Verd
ana" size="2">Aqueles que residem em im&oacute;vel com 2 e    mais c&ocirc;modos
 apresentaram probabilidade 86% menor de apresentar sibilos    nos &uacute;ltimo
s 12 meses do que aqueles que residem em constru&ccedil;&otilde;es    de at&eacu
te; 2 c&ocirc;modos (p = 0,000).</font></p>     ^cY#a15v86n4.htm##
00570000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704033500076002001300411#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#69#65#article#157#<p><font face="Verd
ana" size="2">Mesmo ap&oacute;s ajustamento por idade e g&ecirc;nero,    indiv&i
acute;duos residentes nas CE apresentaram probabilidade duas vezes maior    de o
corr&ecirc;ncia de sibilos nos &uacute;ltimos 12 meses do que aqueles residentes
    nas CR (OR<SUB>ajust</SUB> = 2,01; IC95% 1,01-4,01).</font></p>     ^cY#a15v
86n4.htm##
00558000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032300076002001300399#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#70#66#article#157#<p><font face="Verd
ana" size="2">O g&ecirc;nero esteve associado com sibilos nos    &uacute;ltimos 
12 meses, tendo os meninos apresentado 2,5 vezes mais sintomas    de sibil&acirc
;ncia do que as meninas (OR<SUB>ajust</SUB> = 2,5; IC95% 1,21-5,18),    ajustado
 por idade e comunidade de resid&ecirc;ncia.</font></p>     ^cY#a15v86n4.htm##
00779000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054400076002001300620#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#71#67#article#157#<p><font face="Verd
ana" size="2">Quanto &agrave; vari&aacute;vel idade, ap&oacute;s    ajustamento 
por comunidade e g&ecirc;nero, a associa&ccedil;&atilde;o se mostrou    signific
ativa (p&nbsp;&lt; 0,000). A probabilidade de apresentar sibilos nos    &uacute;
ltimos 12 meses foi 5 vezes maior entre as crian&ccedil;as de at&eacute;    6 an
os de idade (pr&eacute;-escolar) do que entre os escolares e adolescentes    (OR
<SUB>ajust</SUB> = 5,00; IC95% 2,41-10,39) (<a href=/img/revistas/jped/v86n4/4a1
5t4.gif>Tabela    4</a>).</font></p>     ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#72#68#article#157#<p>&nbsp;</p>     ^
cY#a15v86n4.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#73#69#article#157#<p><font size="3" f
ace="Verdana"><b>Discuss&atilde;o</b></font></p>     ^cY#a15v86n4.htm##
01131000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704089600076002001300972#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#74#70#article#157#<p><font face="Verd
ana" size="2">A dispers&atilde;o da pluma dos poluentes atmosf&eacute;ricos    e
mitidos pelo PPQ de Guamar&eacute; permitiu identificar um conjunto de comunidad
es    consideradas expostas a poluentes atmosf&eacute;ricos. Embora os n&iacute;
veis    ambientais dos poluentes monitorados durante todo o per&iacute;odo do es
tudo    tenham se apresentado abaixo dos limites estabelecidos como padr&otilde;
es de    qualidade do ar, sintomas respirat&oacute;rios em crian&ccedil;as e ado
lescentes    foram mais frequentes no grupo residente nas comunidades aqui class
ificadas    como expostas. Al&eacute;m da localiza&ccedil;&atilde;o da comunidad
e de resid&ecirc;ncia,    pertencer ao g&ecirc;nero masculino e ter menos de 7 a
nos de idade s&atilde;o    tamb&eacute;m fatores de risco para sintomas de sibil
&acirc;ncia na regi&atilde;o    do PPQ de Guamar&eacute;.</font></p>     ^cY#a15
v86n4.htm##
00794000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055900076002001300635#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#75#71#article#157#<p><font face="Verd
ana" size="2">As varia&ccedil;&otilde;es das concentra&ccedil;&otilde;es    m&ea
cute;dias estiveram dentro dos limites estabelecidos de qualidade do ar,    com 
pequenos e raros picos de concentra&ccedil;&atilde;o que n&atilde;o foram    suf
icientes para ultrapassar esses limites. Tendo em vista que as medidas de    efe
ito &agrave; sa&uacute;de foram coletadas em um &uacute;nico momento, n&atilde;o
    foi poss&iacute;vel estabelecer rela&ccedil;&atilde;o entre esses pequenos p
icos    e efeitos &agrave; sa&uacute;de.</font></p>     ^cY#a15v86n4.htm##
00992000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075700076002001300833#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#76#72#article#157#<p><font face="Verd
ana" size="2">Em rela&ccedil;&atilde;o &agrave; utiliza&ccedil;&atilde;o    de o
utras fontes de energia, n&atilde;o foi encontrada rela&ccedil;&atilde;o    com 
o desfecho estudado, diferente do estudo de Prietsch et al.<SUP>11</SUP>,    que
 reportou um risco 2,6 vezes maior de sibil&acirc;ncia recorrente entre aqueles 
   que utilizavam outros combust&iacute;veis no ambiente dom&eacute;stico. Da me
sma    forma, a aglomera&ccedil;&atilde;o de moradores no domic&iacute;lio n&ati
lde;o    se mostrou associada &agrave; sibil&acirc;ncia, ainda que outros autore
s tenham    verificado probabilidade 59% maior da ocorr&ecirc;ncia do desfecho e
m domic&iacute;lios    com duas ou mais pessoas por c&ocirc;modo<SUP>11</SUP>.</
font></p>     ^cY#a15v86n4.htm##
00555000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704032000076002001300396#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#77#73#article#157#<p><font face="Verd
ana" size="2">A preval&ecirc;ncia de sibil&acirc;ncia foi maior    no g&ecirc;ne
ro masculino, consistente com dados de literatura, provavelmente    devido a dif
eren&ccedil;as na fisiologia das vias a&eacute;reas e a maiores    limiares de r
esposta &agrave; metacolina<SUP>12</SUP>.</font></p>     ^cY#a15v86n4.htm##
01048000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704081300076002001300889#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#78#74#article#157#<p><font face="Verd
ana" size="2">Os resultados das medidas de poluentes atmosf&eacute;ricos    obse
rvados neste estudo mostram valores baixos de exposi&ccedil;&atilde;o, como    o
 estudo de Kalabokas et al.<SUP>1</SUP>, que verificou n&iacute;veis de BTX    c
om concentra&ccedil;&otilde;es de menor magnitude no entorno da refinaria do    
que nos centros urbanos gregos. As varia&ccedil;&otilde;es em torno das m&eacute
;dias    di&aacute;rias verificadas nos n&iacute;veis de tolueno chamam aten&cce
dil;&atilde;o,    embora em n&iacute;veis menores que os encontrados em centros 
urbanos<SUP>1,25</SUP>.    Entretanto, na atmosfera, os poluentes se apresentam 
como misturas complexas,    devendo ser considerada a possibilidade de efeitos a
ditivos, sinergistas ou    antagonistas<SUP>4,9</SUP>.</font></p>     ^cY#a15v86
n4.htm##
01063000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704082800076002001300904#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#79#75#article#157#<p><font face="Verd
ana" size="2">A localiza&ccedil;&atilde;o das comunidades em    rela&ccedil;&ati
lde;o &agrave;s unidades industriais e &agrave; dire&ccedil;&atilde;o    dos ven
tos tem sido utilizada como par&acirc;metro de exposi&ccedil;&atilde;o<SUP>17</S
UP>.    A pluma de dispers&atilde;o dos poluentes e a localiza&ccedil;&atilde;o 
da comunidade    de resid&ecirc;ncia podem explicar a maior preval&ecirc;ncia de
 sibilos no &uacute;ltimo    ano, relato de sibilo alguma vez, e tosse seca notu
rna maior nas CE do que nas    CR. Esses resultados est&atilde;o de acordo com o
utros estudos que t&ecirc;m    mostrado efeitos respirat&oacute;rios em crian&cc
edil;as, mesmo com varia&ccedil;&otilde;es    dentro dos n&iacute;veis aceit&aac
ute;veis de polui&ccedil;&atilde;o atmosf&eacute;rica<SUP>5,26</SUP>.</font></p>
     ^cY#a15v86n4.htm##
00915000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704068000076002001300756#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#80#76#article#157#<p><font face="Verd
ana" size="2">Os limites de exposi&ccedil;&atilde;o aos poluentes    atmosf&eacu
te;ricos t&ecirc;m sido discutidos, especialmente em rela&ccedil;&atilde;o    &a
grave; prote&ccedil;&atilde;o de grupos mais vulner&aacute;veis, levando a    OM
S a estabelecer limites mais restritivos de exposi&ccedil;&atilde;o humana,    e
m 2005<SUP>2</SUP>. As preval&ecirc;ncias de sintomas de sibil&acirc;ncia determ
inadas    neste estudo s&atilde;o consistentes com dados de outros estudos, que 
mostram    elevadas preval&ecirc;ncias na Am&eacute;rica Latina, especialmente n
o Brasil,    e ainda maiores nas Regi&otilde;es Norte e Nordeste<SUP>27-29</SUP>
.</font></p>     ^cY#a15v86n4.htm##
01810000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704157500076002001301651#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#81#77#article#157#<p><font face="Verd
ana" size="2">Wichmann et al.9 utilizaram o QE na determina&ccedil;&atilde;o    
de efeitos respirat&oacute;rios da exposi&ccedil;&atilde;o &agrave; polui&ccedil
;&atilde;o    petroqu&iacute;mica em 1.212 crian&ccedil;as de 6 a 12 anos, na Ar
gentina. Observaram    maiores preval&ecirc;ncias no entorno da planta petroqu&i
acute;mica do que em    &aacute;reas urbanas, mesmo quando os n&iacute;veis de e
xposi&ccedil;&atilde;o    foram similares, sugerindo que, al&eacute;m das concen
tra&ccedil;&otilde;es,    a fonte e a composi&ccedil;&atilde;o do MP poderiam es
tar relacionadas &agrave;    determina&ccedil;&atilde;o dos efeitos. Sol&eacute;
 et al.<SUP>6</SUP> aplicaram    o QE em cidades brasileiras para avaliar a rela
&ccedil;&atilde;o entre exposi&ccedil;&atilde;o    aos poluentes gasosos (O<SUB>
3</SUB>, CO, NO<SUB>2</SUB> e SO<SUB>2</SUB>),    condi&ccedil;&otilde;es socioe
con&ocirc;micas e preval&ecirc;ncia de sintomas    de asma, rinite e eczema em 1
6.209 adolescentes de 13 a 14 anos. Os resultados    foram sugestivos de rela&cc
edil;&atilde;o entre mais altas concentra&ccedil;&otilde;es    desses poluentes 
e preval&ecirc;ncia de asma, rinite e eczema, sendo o estado    socioecon&ocirc;
mico similar entre as cidades. No presente estudo, as condi&ccedil;&otilde;es   
 socioecon&ocirc;micas das comunidades tamb&eacute;m foram muito similares, pode
ndo    justificar a n&atilde;o associa&ccedil;&atilde;o dessa vari&aacute;vel co
m a    preval&ecirc;ncia de sibil&acirc;ncia, como encontrado em outros estudos<
SUP>27,30</SUP>.</font></p>     ^cY#a15v86n4.htm##
00908000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704067300076002001300749#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#82#78#article#157#<p><font face="Verd
ana" size="2">As comunidades estudadas s&atilde;o homog&ecirc;neas    em rela&cc
edil;&atilde;o aos h&aacute;bitos alimentares, estilo de vida e condi&ccedil;&ot
ilde;es    socioecon&ocirc;micas. Apresentam baixa escolaridade, elevados &iacut
e;ndices    de analfabetismo, prec&aacute;rias condi&ccedil;&otilde;es de saneam
ento e moradia,    car&ecirc;ncia de servi&ccedil;os p&uacute;blicos e de empreg
os e baixa renda    familiar, por vezes complementada por programas sociais. Ess
a homogeneidade    dificulta a distin&ccedil;&atilde;o de fatores de associa&cce
dil;&atilde;o dos    sintomas de sibil&acirc;ncia na regi&atilde;o do PPQ.</font
></p>     ^cY#a15v86n4.htm##
00798000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056300076002001300639#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#83#79#article#157#<p><font face="Verd
ana" size="2">Assume-se, enquanto limita&ccedil;&atilde;o do    estudo, o uso do
 QE do ISAAC para identifica&ccedil;&atilde;o do grupo dos sintom&aacute;ticos  
  para sibil&acirc;ncia em idades n&atilde;o validadas para a aplica&ccedil;&ati
lde;o    do mesmo. Entretanto, o QE do ISAAC foi anteriormente utilizado na aval
ia&ccedil;&atilde;o    de efeitos &agrave; sa&uacute;de da polui&ccedil;&atilde;
o atmosf&eacute;rica    em faixas et&aacute;rias e amostragem diferentes daquela
s validadas no pa&iacute;s<SUP>5,9,15</SUP>.</font></p>     ^cY#a15v86n4.htm##
01015000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704078000076002001300856#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#84#80#article#157#<p><font face="Verd
ana" size="2">O presente estudo buscou identificar sintomas    que configurem vu
lnerabilidade (especialmente sibil&acirc;ncia) e n&atilde;o    estabelecer o dia
gn&oacute;stico de asma. Sabe-se que o QE do EISL inclui maior    detalhamento d
a abordagem de sintomas e agravos respirat&oacute;rios, como sibil&acirc;ncia   
 e bronquite. Sendo assim, &eacute; prov&aacute;vel que no grupo de menores de  
  3 anos de idade, parte dos sintom&aacute;ticos n&atilde;o tenha sido detectada
    pelo instrumento utilizado. Entretanto, baseado nos resultados de Dela Bianc
a    et al.<SUP>23</SUP>, e em raz&atilde;o da ocorr&ecirc;ncia de perdas prov&a
acute;veis    em todas as comunidades, n&atilde;o h&aacute; invalida&ccedil;&ati
lde;o dos    achados.</font></p>     ^cY#a15v86n4.htm##
00698000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704046300076002001300539#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#85#81#article#157#<p><font face="Verd
ana" size="2">Os achados deste estudo refor&ccedil;am a relev&acirc;ncia    do m
onitoramento da qualidade do ar e da sa&uacute;de de grupos mais suscet&iacute;v
eis    aos efeitos da polui&ccedil;&atilde;o atmosf&eacute;rica no entorno de un
idades    industriais, tanto no &acirc;mbito da gest&atilde;o de sa&uacute;de p&
uacute;blica,    quanto da gest&atilde;o de risco e responsabilidade socioambien
tal da ind&uacute;stria.</font></p>     ^cY#a15v86n4.htm##
00722000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048700076002001300563#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#86#82#article#157#<p><font face="Verd
ana" size="2">Conclui-se que mesmo em baixas concentra&ccedil;&otilde;es    de p
oluentes atmosf&eacute;ricos, a ocorr&ecirc;ncia de sintomas respirat&oacute;rio
s    em crian&ccedil;as e adolescentes nas comunidades no entorno de um PPQ este
ve    associada &agrave;s comunidades de resid&ecirc;ncia na dire&ccedil;&atilde
;o    preferencial dos ventos, mostrando-se mais vulner&aacute;vel o grupo de pr
&eacute;-escolares    do g&ecirc;nero masculino.</font></p>     ^cY#a15v86n4.htm
##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#87#83#article#157#<p>&nbsp;</p>     ^
cY#a15v86n4.htm##
00312000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007700076002001300153#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#88#84#article#157#<p><font size="3" f
ace="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#a15v86n4.htm##
00499000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704025000078002001300328#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#89#85#article#157#1#<p><f
ont size="2" face="Verdana">1. Kalabokas PD, Hatzianestesis J, Bartzis JG,    Pa
pagiannakopolous P. Atmospheric concentrations of satured and aromatic hydrocarb
ons    around a Greek oil refinery. Atmospheric Environment. 2001;35:2545-55.   
 ^cY#a15v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#90#86#article#157#</font></p>     ^cY
#a15v86n4.htm##
00397000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704014800078002001300226#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#91#87#article#157#2#<p><f
ont size="2" face="Verdana">2. World Health Organization. WHO air quality    gui
delines - global update 2005. Bonn, Germany: WHO, 2005.    ^cY#a15v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#92#88#article#157#</font></p>     ^cY
#a15v86n4.htm##
00430000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704018100078002001300259#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#93#89#article#157#3#<p><f
ont size="2" face="Verdana">3. Trasande L, Thurston GD. The role of air pollutio
n    in asthma and other pediatric morbidities. J Allergy Clin Immunol. 2005;115
:689-99.    ^cY#a15v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#94#90#article#157#</font></p>     ^cY
#a15v86n4.htm##
00393000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704014400078002001300222#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#95#91#article#157#4#<p><f
ont size="2" face="Verdana">4. Salvi S. Health effects of ambient air pollution 
   in children. Paediatr Respir Rev. 2007;8:275-80.    ^cY#a15v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#96#92#article#157#</font></p>     ^cY
#a15v86n4.htm##
00493000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704024400078002001300322#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#97#93#article#157#5#<p><f
ont size="2" face="Verdana">5. Castro HA, Cunha MF, Mendon&ccedil;a GA, Junger  
  WL, Cunha-Cruz J, Leon AP. Effect of air pollution on lung function in schoolc
hildren    in Rio de Janeiro, Brazil. Rev Saude Publica. 2009;43:26-34.    ^cY#a
15v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#98#94#article#157#</font></p>     ^cY
#a15v86n4.htm##
00596000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704034700078002001300425#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#99#95#article#157#6#<p><f
ont size="2" face="Verdana">6. Sol&eacute; D, Camelo-Nunes IC, Wandalsen    GF, 
Pastorino AC, Jacob CM, Gonzalez C, et al. Prevalence of symptoms of asthma,    
rhinitis and atopic eczema in Brazilian adolescents related to exposure to gaseo
us    air pollutants and socioeconomic status. J Investig Allergol Clin Immunol.
 2007;17:6-13.    ^cY#a15v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#100#96#article#157#</font></p>     ^c
Y#a15v86n4.htm##
00523000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704027300079002001300352#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#101#97#article#157#7#<p><
font size="2" face="Verdana">7. Annesi-Maesano I, Moreau D, Caillaud D, Lavaud  
  F, Le Moullec Y, Taytard A, et al. Residential proximity fine particles relate
d    to allergic sensitisation and asthma in primary school children. Respir Med
.    2007;101:1721-9.    ^cY#a15v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#102#98#article#157#</font></p>     ^c
Y#a15v86n4.htm##
00554000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000200077704030400079002001300383#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#103#99#article#157#8#<p><
font size="2" face="Verdana">8. Smargiassi A, Kosatsky T, Hicks J, Plante    C, 
Armstrong B, Villeneuve PJ, et al. Risk of asthmatic episodes in children    exp
osed to sulfur dioxide stack emissions form a refinery point source in Montreal,
    Canada. Environ Health Perspect. 2009;117:653-9.    ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#104#100#article#157#</font></p>     ^
cY#a15v86n4.htm##
00506000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000200078704025500080002001300335#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#105#101#article#157#9#<p>
<font size="2" face="Verdana">9. Wichmann FA, M&uuml;ller A, Busi LE, Cianni    
N, Massolo L, Schlink U, et al. Increased asthma and respiratory symptoms in    
children exposed to petrochemical pollution. J Allergy Clin Immunol. 2009;123:63
2-8.    ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#106#102#article#157#</font></p>     ^
cY#a15v86n4.htm##
00498000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024600081002001300327#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#107#103#article#157#10#<p
><font size="2" face="Verdana">10. Chong Neto HJ, Ros&aacute;rio NA, Grupo EISL 
   Curitiba (Estudio Internacional de Sibilancias en Lactentes). Risk factors fo
r    wheezing in the first year of life. J Pedritr (Rio J). 2008;84:495-502.    
^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#108#104#article#157#</font></p>     ^
cY#a15v86n4.htm##
00525000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027300081002001300354#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#109#105#article#157#11#<p
><font size="2" face="Verdana">11. Prietsch SO, Fischer GB, C&eacute;sar JA,    
Cervo PV, Sangaletti LL, Wietzycoski CR, et al. Fatores de risco para sibil&acir
c;ncia    recorrente em menores de 13 anos no Sul do Brasil. Rev Panam Salud Pub
lica.    2006;20:331-7.    ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#110#106#article#157#</font></p>     ^
cY#a15v86n4.htm##
00504000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025200081002001300333#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#111#107#article#157#12#<p
><font size="2" face="Verdana">12. Uekert SJ, Akan G, Evans MD, Li Z, Roberg    
K, Tisler C, et al. Sex-related differences in immune development and the expres
sion    of atopy in early childhood.J Allergy Clin Immunol.&nbsp;2006;118:1375-8
1.    ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#112#108#article#157#</font></p>     ^
cY#a15v86n4.htm##
00431000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704017900081002001300260#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#113#109#article#157#13#<p
><font size="2" face="Verdana">13. Chong Neto HJ, Ros&aacute;ro NA. Wheezing    
in infancy: epidemiology, investigation, and treatment. J Pediatr (Rio J). 2010;
86:171-8.    ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#114#110#article#157#</font></p>     ^
cY#a15v86n4.htm##
00489000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023700081002001300318#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#115#111#article#157#14#<p
><font size="2" face="Verdana">14. Maia JG, Marcopito LF, Amaral AN, Tavares    
Bde F, Santos FA. Preval&ecirc;ncia de asma e sintomas asm&aacute;ticos em escol
ares    de 13 e 14 anos de idade. Rev Saude Publica. 2004;38:292-9.    ^cY#a15v8
6n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#116#112#article#157#</font></p>     ^
cY#a15v86n4.htm##
00499000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704024700081002001300328#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#117#113#article#157#15#<p
><font size="2" face="Verdana">15. Casagrande RR, Pastorino AC, Souza RG, Leone 
   C, Sol&eacute; D, Jacob CM. Preval&ecirc;ncia de asma e fatores de risco em  
  escolares da cidade de S&atilde;o Paulo. Rev Saude Publica. 2008;42:517-23.   
 ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#118#114#article#157#</font></p>     ^
cY#a15v86n4.htm##
00572000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704032000081002001300401#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#119#115#article#157#16#<p
><font size="2" face="Verdana">16. Cassol VE, Sol&eacute; D, Menna-Barreto SS,  
  Teche SP, Rizzato TM, Maldonado M, et al. Preval&ecirc;ncia de asma em adolesc
entes    urbanos de Santa Maria (RS). Projeto ISAAC &#150; International Study o
f Asthma and    Allergies in Childhood. J Bras Pneumol. 2005;31:191-6.    ^cY#a1
5v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#120#116#article#157#</font></p>     ^
cY#a15v86n4.htm##
00445000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019300081002001300274#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#121#117#article#157#17#<p
><font size="2" face="Verdana">17. Luginaah IN, Taylor SM, Elliot SJ, Eyles    J
D. A longitudinal study of the health impacts of a petroleum refinery. Soc    Sc
i Med. 2000;50:1155-66.    ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#122#118#article#157#</font></p>     ^
cY#a15v86n4.htm##
00852000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704060000081002001300681#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#123#119#article#157#18#<p
><font size="2" face="Verdana">18. MME. Minist&eacute;rio de Minas e Energia.   
 Secretaria de Geologia, Minera&ccedil;&atilde;o e Transforma&ccedil;&atilde;o  
  Mineral. CPRM- Servi&ccedil;o Geol&oacute;gico do Brasil. Projeto cadastro de 
   fontes de abastecimento por &aacute;gua subterr&acirc;nea estado do Rio Grand
e    do Norte. Diagn&oacute;stico do Munic&iacute;pio de Guamar&eacute;. Recife,
    2005. 22 p. <A href=http://www.cprm.gov.br/rehi/atlas/rgnorte/relatorios/GUA
M051.PDF target="_blank">www.cprm.gov.br/rehi/atlas/rgnorte/relatorios/GUAM051.P
DF</A>.    Acesso: 07/11/2009.    ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#124#120#article#157#</font></p>     ^
cY#a15v86n4.htm##
00507000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025500081002001300336#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#125#121#article#157#19#<p
><font size="2" face="Verdana">19. IBGE. Instituto Brasileiro de Geografia e    
Estat&iacute;stica. &#091;website&#093;. Bras&iacute;lia. <A href=http://www.ibg
e.gov.br/home target="_blank">http://www.ibge.gov.br/home</A>.    Acesso: 01/09/
2009.    ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#126#122#article#157#</font></p>     ^
cY#a15v86n4.htm##
00535000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028300081002001300364#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#127#123#article#157#20#<p
><font size="2" face="Verdana">20. ISAAC Steering Committee. &#091;website&#093;
. International    Study of Asthma and Allergies in Childhood. Nova Zel&acirc;nd
ia. <A href=http://isaac.auckland.ac.nz/ target="_blank">http://isaac.auckland.a
c.nz/</A>.    Acesso: 01/09/2009.    ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#128#124#article#157#</font></p>     ^
cY#a15v86n4.htm##
00483000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704023100081002001300312#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#129#125#article#157#21#<p
><font size="2" face="Verdana">21. Asher MI, Keil U, Anderson HR, Beasley R,    
Crane J, Martinez F. International Study of Asthma and Allergies in Childhood   
 (ISAAC): rationale and methods. Eur Respir J. 1995;8:483-91.    ^cY#a15v86n4.ht
m##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#130#126#article#157#</font></p>     ^
cY#a15v86n4.htm##
00560000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030800081002001300389#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#131#127#article#157#22#<p
><font size="2" face="Verdana">22. Sol&eacute; D, Vanna AT, Yamada E, Rizzo    M
C, Naspitz CK. International Study of Asthma and Allergies in Childhood (ISAAC) 
   written questionnaire: validation of the asthma component among Brazilian chi
ldren.    J Investig Allergol Clin Immunol. 1998;8:376-82.    ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#132#128#article#157#</font></p>     ^
cY#a15v86n4.htm##
00554000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704030200081002001300383#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#133#129#article#157#23#<p
><font size="2" face="Verdana">23. Dela Bianca AC, Wandalsen GF, Miyagi K, Camar
go    L, Cezarin D, Mallol J, et al. International Study of Wheezing in Infants 
(EISL):    validation of written questionnaire for children aged below 3 years. 
J Investing    Allergol Clin Immunol. 2009;19:35-42.    ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#134#130#article#157#</font></p>     ^
cY#a15v86n4.htm##
00598000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704034600081002001300427#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#135#131#article#157#24#<p
><font size="2" face="Verdana">24. CONAMA. Conselho Nacional do Meio Ambiente.  
  Resolu&ccedil;&atilde;o CONAMA Nº 003, de 28 de junho de 1990. Bras&iacute;lia
,    1990. <A href=http://www.mma.gov.br/port/conama/res/res90/res0390.html targ
et="_blank">http://www.mma.gov.br/port/conama/res/res90/res0390.html</A>.    Ace
sso: 07/11/2009.    ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#136#132#article#157#</font></p>     ^
cY#a15v86n4.htm##
00444000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704019200081002001300273#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#137#133#article#157#25#<p
><font size="2" face="Verdana">25. Han X, Naeher LP. A review of traffic-related
    air pollution exposure assessment studies in the developing world. Environ I
nt.    2006;32:106-20.    ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#138#134#article#157#</font></p>     ^
cY#a15v86n4.htm##
00467000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021500081002001300296#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#139#135#article#157#26#<p
><font size="2" face="Verdana">26. Moura M, Junger WL, Mendon&ccedil;a GA, de   
 Leon AP. Qualidade do ar e transtornos respirat&oacute;rios agudos em crian&cce
dil;as.    Rev Saude Publica. 2008;42:503-11.    ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#140#136#article#157#</font></p>     ^
cY#a15v86n4.htm##
00526000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027400081002001300355#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#141#137#article#157#27#<p
><font size="2" face="Verdana">27. Mallol J, Sol&eacute; D, Asher I, Clayton    
T, Stein R, Soto-Quiroz M. Prevalence of asthma symptoms in Latin America: the  
  International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Pulm
onol.    2000;30:439-44.    ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#142#138#article#157#</font></p>     ^
cY#a15v86n4.htm##
00626000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704037400081002001300455#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#143#139#article#157#28#<p
><font size="2" face="Verdana">28. Sol&eacute; D, Wandalsen GF, Camelo-Nunes    
IC, Naspitz CK; ISAAC - Brazilian Group. Prevalence of symptoms of asthma rhinit
is,    and atopic eczema among Brazilian children and adolescents identified by 
the    International Study of Asthma and Allergies in Childhood (ISAAC) &#150; P
hase 3.    J Pediatr (Rio J). 2006;82:341-6.    ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#144#140#article#157#</font></p>     ^
cY#a15v86n4.htm##
00467000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704021500081002001300296#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#145#141#article#157#29#<p
><font size="2" face="Verdana">29. Rosa AM, Ignotti E, Hacon Sde S, Castro HA.  
  Prevalence of asthma in children and adolescents in a city in the Brazilian   
 Amazon region. J Bras Pneumol. 2009;35:7-13.    ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#146#142#article#157#</font></p>     ^
cY#a15v86n4.htm##
00438000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704018600081002001300267#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#p#147#143#article#157#30#<p
><font size="2" face="Verdana">30. Fischer GB, Camargos PA, Mocelin HT. The    b
urden of asthma in children: a Latin American perspective. Pediatric Respir    R
ev. 2005;6:8-13.    ^cY#a15v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#148#144#article#157#</font></p>     ^
cY#a15v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#149#145#article#157#<p>&nbsp;</p>    
 ^cY#a15v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#150#146#article#157#<p>&nbsp;</p>    
 ^cY#a15v86n4.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018000078002001300258#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#151#147#article#157#<p><font size="2"
 face="Verdana"><a name="correspondence"></a><a href="#topo"><img src="/img/revi
stas/jped/v86n4/seta.gif" border="0"></a>    <b> Correspond&ecirc;ncia:</b>    ^
cY#a15v86n4.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004200078002001300120#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#152#148#article#157#<br>   Ana Claudi
a Lopes de Moraes    ^cY#a15v86n4.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704007400078002001300152#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#153#149#article#157#<BR>   Rua Marque
s do Paran&aacute;, 303, 3º andar, frente, Centro    ^cY#a15v86n4.htm##
00286000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004900078002001300127#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#154#150#article#157#<BR>   CEP 24033-
900 - Niter&oacute;i, RJ    ^cY#a15v86n4.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003500078002001300113#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#155#151#article#157#<BR>   Tel.: (21)
 2629.9021    ^cY#a15v86n4.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#156#152#article#157#<BR>   Fax: (21) 
2629.9021    ^cY#a15v86n4.htm##
00346000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010900078002001300187#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#157#153#article#157#<BR>   E-mail: <A
 href=mailto:anamoraes@predialnet.com.br>anamoraes@predialnet.com.br</A></font><
/p>     ^cY#a15v86n4.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010600078002001300184#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#158#154#article#157#<p><font size="2"
 face="Verdana">Artigo submetido em 18.01.2010, aceito em 02.06.2010.</font></p>
     ^cY#a15v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#159#155#article#157#<p>&nbsp;</p>    
 ^cY#a15v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#160#156#article#157#<p>&nbsp;</p>    
 ^cY#a15v86n4.htm##
00403000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704016600078002001300244#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a15v86n4.htm#S#p#161#157#article#157#<p><font size="2"
 face="Verdana"> N&atilde;o foram declarados conflitos de interesse    associado
s &agrave; publica&ccedil;&atilde;o deste artigo.</font></p>     ^cY#a15v86n4.ht
m##
00670000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100024000970100
01800121010002800139012009600167030002400263065000900287064000500296031000300301
014000800304865000900312002001300321035001000334801002400344#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a15v86n4.htm#S#c#162#1#article#30#1#^rND^sKalabokas^nPD#^r
ND^sHatzianestesis^nJ#^rND^sBartzis^nJG#^rND^sPapagiannakopolous^nP#Atmospheric 
concentrations of satured and aromatic hydrocarbons around a Greek oil refinery^
len#Atmospheric Environment#20010000#2001#35#2545-55#20100800#a15v86n4.htm#0004-
6981#ATMOSPHERIC ENVIRONMENT##
00430000000000229000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170026000770180052001030660
00500155062000400160065000900164064000500173865000900178002001300187#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a15v86n4.htm#S#c#163#2#article#30#2#World Health O
rganization#WHO air quality guidelines - global update 2005^len#Bonn#WHO#2005000
0#2005#20100800#a15v86n4.htm##
00567000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100019000950120
07200114030002300186065000900209064000500218031000400223014000700227865000900234
002001300243035001000256801002300266#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
5v86n4.htm#S#c#164#3#article#30#3#^rND^sTrasande^nL#^rND^sThurston^nGD#The role 
of air pollution in asthma and other pediatric morbidities^len#J Allergy Clin Im
munol#20050000#2005#115#689-99#20100800#a15v86n4.htm#0091-6749#J Allergy Clin Im
munol##
00469000000000253000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770120056000920300
02000148710000200168065000900170064000500179031000200184014000700186865000900193
002001300202#v86n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#c#165#4#art
icle#30#4#^rND^sSalvi^nS#Health effects of ambient air pollution in children^len
#Paediatr Respir Rev#2#20070000#2007#8#275-80#20100800#a15v86n4.htm##
00688000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100016000940100
02000110010001700130010002000147010001500167012008900182030001800271065000900289
06400050029803100030030301400060030686500090031200200130032103500100033480100180
0344#v86n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#c#166#5#article#30#
5#^rND^sCastro^nHA#^rND^sCunha^nMF#^rND^sMendonÃ§a^nGA#^rND^sJunger^nWL#^rND^sCu
nha-Cruz^nJ#^rND^sLeon^nAP#Effect of air pollution on lung function in schoolchi
ldren in Rio de Janeiro, Brazil^len#Rev Saude Publica#20090000#2009#43#26-34#201
00800#a15v86n4.htm#0034-8910#Rev Saude Publica##
00813000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100023000910100
02000114010002000134010001600154010001800170810000600188012016100194030003300355
06500090038806400050039703100030040201400050040586500090041000200130041903500100
0432801003300442#v86n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#c#167#6
#article#30#6#^rND^sSolé^nD#^rND^sCamelo-Nunes^nIC#^rND^sWandalsen^nGF#^rND^sPas
torino^nAC#^rND^sJacob^nCM#^rND^sGonzalez^nC#et al#Prevalence of symptoms of ast
hma, rhinitis and atopic eczema in Brazilian adolescents related to exposure to 
gaseous air pollutants and socioeconomic status^len#J Investig Allergol Clin Imm
unol#20070000#2007#17#6-13#20100800#a15v86n4.htm#1018-9068#J Investig Allergol C
lin Immunol##
00724000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100024000770100016001010100
01800117010001600135010002000151010001700171810000600188012011300194030001100307
06500090031806400050032703100040033201400070033686500090034300200130035203500100
0365801001100375#v86n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#c#168#7
#article#30#7#^rND^sAnnesi-Maesano^nI#^rND^sMoreau^nD#^rND^sCaillaud^nD#^rND^sLa
vaud^nF#^rND^sLe Moullec^nY#^rND^sTaytard^nA#et al#Residential proximity fine pa
rticles related to allergic sensitisation and asthma in primary school children^
len#Respir Med#20070000#2007#101#1721-9#20100800#a15v86n4.htm#0954-6111#Respir M
ed##
00768000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100018000970100
01500115010001600130010001900146010002100165810000600186012013400192030002400326
06500090035006400050035903100040036401400060036886500090037400200130038303500100
0396801002400406#v86n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#c#169#8
#article#30#8#^rND^sSmargiassi^nA#^rND^sKosatsky^nT#^rND^sHicks^nJ#^rND^sPlante^
nC#^rND^sArmstrong^nB#^rND^sVilleneuve^nPJ#et al#Risk of asthmatic episodes in c
hildren exposed to sulfur dioxide stack emissions form a refinery point source i
n Montreal, Canada^len#Environ Health Perspect#20090000#2009#117#653-9#20100800#
a15v86n4.htm#0091-6765#Environ Health Perspect##
00716000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100016000960100
01500112010001600127010001700143010001700160810000600177012009300183030002300276
06500090029906400050030803100040031301400060031786500090032300200130033203500100
0345801002300355#v86n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#c#170#9
#article#30#9#^rND^sWichmann^nFA#^rND^sMüller^nA#^rND^sBusi^nLE#^rND^sCianni^nN#
^rND^sMassolo^nL#^rND^sSchlink^nU#et al#Increased asthma and respiratory symptom
s in children exposed to petrochemical pollution^len#J Allergy Clin Immunol#2009
0000#2009#123#632-8#20100800#a15v86n4.htm#0091-6749#J Allergy Clin Immunol##
00546000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100018001000100
02700118012005600145030001800201710000200219065000900221064000500230031000300235
014000800238865000900246002001300255#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
5v86n4.htm#S#c#171#10#article#30#10#^rND^sChong Neto^nHJ#^rND^sRosário^nNA#^rND^
sGrupo Curitiba^nEISL#Risk factors for wheezing in the first year of life^len#J 
Pedritr (Rio J)#2#20080000#2008#84#495-502#20100800#a15v86n4.htm##
00725000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100018000980100
01600116010001600132010002100148010002200169810000600191012008700197030002400284
06500090030806400050031703100030032201400060032586500090033100200130034003500100
0353801002400363#v86n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#c#172#1
1#article#30#11#^rND^sPrietsch^nSO#^rND^sFischer^nGB#^rND^sCésar^nJA#^rND^sCervo
^nPV#^rND^sSangaletti^nLL#^rND^sWietzycoski^nCR#et al#Fatores de risco para sibi
lância recorrente em menores de 13 anos no Sul do Brasil^lpt#Rev Panam Salud Pub
lica#20060000#2006#20#331-7#20100800#a15v86n4.htm#1020-4989#Rev Panam Salud Publ
ica##
00673000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100014000960100
01600110010001200126010001600138010001600154810000600170012009700176030002400273
71000020029706500090029906400050030803100040031301400080031786500090032500200130
0334#v86n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#c#173#12#article#30
#12#^rND^sUekert^nSJ#^rND^sAkan^nG#^rND^sEvans^nMD#^rND^sLi^nZ#^rND^sRoberg^nK#^
rND^sTisler^nC#et al#Sex-related differences in immune development and the expre
ssion of atopy in early childhood^len#J Allergy Clin Immunol.#2#20060000#2006#11
8#1375-81#20100800#a15v86n4.htm##
00554000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100017001000120
06800117030001800185065000900203064000500212031000300217014000600220865000900226
002001300235035001000248801001800258#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
5v86n4.htm#S#c#174#13#article#30#13#^rND^sChong Neto^nHJ#^rND^sRosáro^nNA#Wheezi
ng in infancy: epidemiology, investigation, and treatment^len#J Pediatr (Rio J)#
20100000#2010#86#171-8#20100800#a15v86n4.htm#0021-7557#J Pediatr (Rio J)##
00657000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100020000940100
01700114010002100131010001700152012008300169030001800252065000900270064000500279
031000300284014000600287865000900293002001300302035001000315801001800325#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#c#175#14#article#30#14#^rND^sMa
ia^nJG#^rND^sMarcopito^nLF#^rND^sAmaral^nAN#^rND^sTavares Bde^nF#^rND^sSantos^nF
A#Prevalência de asma e sintomas asmáticos em escolares de 13 e 14 anos de idade
^lpt#Rev Saude Publica#20040000#2004#38#292-9#20100800#a15v86n4.htm#0034-8910#Re
v Saude Publica##
00678000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100020001000100
01600120010001500136010001400151010001600165012007900181030001800260065000900278
06400050028703100030029201400070029586500090030200200130031103500100032480100180
0334#v86n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#c#176#15#article#30
#15#^rND^sCasagrande^nRR#^rND^sPastorino^nAC#^rND^sSouza^nRG#^rND^sLeone^nC#^rND
^sSolé^nD#^rND^sJacob^nCM#Prevalência de asma e fatores de risco em escolares da
 cidade de São Paulo^lpt#Rev Saude Publica#20080000#2008#42#517-23#20100800#a15v
86n4.htm#0034-8910#Rev Saude Publica##
00723000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100014000960100
02400110010001600134010001800150010001900168810000600187012014200193030001500335
71000020035006500090035206400050036103100030036601400060036986500090037500200130
0384#v86n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#c#177#16#article#30
#16#^rND^sCassol^nVE#^rND^sSolé^nD#^rND^sMenna-Barreto^nSS#^rND^sTeche^nSP#^rND^
sRizzato^nTM#^rND^sMaldonado^nM#et al#Prevalência de asma em adolescentes urbano
s de Santa Maria (RS): Projeto ISAAC - International Study of Asthma and Allergi
es in Childhood^len#J Bras Pneumol#2#20050000#2005#31#191-6#20100800#a15v86n4.ht
m##
00602000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
01700115010001600132012007100148030001200219065000900231064000500240031000300245
014000800248865000900256002001300265035001000278801001200288#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a15v86n4.htm#S#c#178#17#article#30#17#^rND^sLuginaah^nIN#^
rND^sTaylor^nSM#^rND^sElliot^nSJ#^rND^sEyles^nJD#A longitudinal study of the hea
lth impacts of a petroleum refinery^len#Soc Sci Med#20000000#2000#50#1155-66#201
00800#a15v86n4.htm#0037-7856#Soc Sci Med##
00729000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170089000790180171001680660
00700339065000900346064000500355014000300360037005800363110000900421109001100430
865000900441002001300450#v86n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S
#c#179#18#article#30#18#Ministério de Minas e Energia^dSecretaria de Geologia, M
ineração e Transformação Mineral#CPRM- Serviço Geológico do Brasil. Projeto cada
stro de fontes de abastecimento por água subterrânea estado do Rio Grande do Nor
te. Diagnóstico do Município de Guamaré^lpt#Recife#20050000#2005#22#www.cprm.gov
.br/rehi/atlas/rgnorte/relatorios/GUAM051.PDF#20091107#07/11/2009#20100800#a15v8
6n4.htm##
00424000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170048000790660009001270370
02800136110000900164109001100173865000900184002001300193#v86n4#V:\Scielo\serial\
jped\v86n4\markup\a15v86n4.htm#S#c#180#19#article#30#19#Instituto Brasileiro de 
Geografia e Estatística#Brasília#http://www.ibge.gov.br/home#20090901#01/09/2009
#20100800#a15v86n4.htm##
00454000000000217000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170025000790180061001040370
02900165110000900194109001100203865000900214002001300223#v86n4#V:\Scielo\serial\
jped\v86n4\markup\a15v86n4.htm#S#c#181#20#article#30#20#ISAAC Steering Committee
#International Study of Asthma and Allergies in Childhood^len#http://isaac.auckl
and.ac.nz/#20090901#01/09/2009#20100800#a15v86n4.htm##
00677000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100014000950100
01900109010001700128010001500145010001800160012009200178030001300270065000900283
06400050029203100020029701400070029986500090030600200130031503500100032880100130
0338#v86n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#c#182#21#article#30
#21#^rND^sAsher^nMI#^rND^sKeil^nU#^rND^sAnderson^nHR#^rND^sBeasley^nR#^rND^sCran
e^nJ#^rND^sMartinez^nF#International Study of Asthma and Allergies in Childhood 
(ISAAC): rationale and methods^len#Eur Respir J#19950000#1995#8#483-91#20100800#
a15v86n4.htm#0903-1936#Eur Respir J##
00746000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100016000930100
01600109010001600125010001800141012015200159030003300311065000900344064000500353
031000200358014000700360865000900367002001300376035001000389801003300399#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#c#183#22#article#30#22#^rND^sSo
lé^nD#^rND^sVanna^nAT#^rND^sYamada^nE#^rND^sRizzo^nMC#^rND^sNaspitz^nCK#Internat
ional Study of Asthma and Allergies in Childhood (ISAAC) written questionnaire: 
validation of the asthma component among Brazilian children^len#J Investig Aller
gol Clin Immunol#19980000#1998#8#376-82#20100800#a15v86n4.htm#1018-9068#J Invest
ig Allergol Clin Immunol##
00723000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100022000790100020001010100
01600121010001700137010001700154010001600171810000600187012012300193030003400316
71000020035006500090035206400050036103100030036601400060036986500090037500200130
0384#v86n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#c#184#23#article#30
#23#^rND^sDela Bianca^nAC#^rND^sWandalsen^nGF#^rND^sMiyagi^nK#^rND^sCamargo^nL#^
rND^sCezarin^nD#^rND^sMallol^nJ#et al#International Study of Wheezing in Infants
 (EISL): validation of written questionnaire for children aged below 3 years^len
#J Investing Allergol Clin Immunol#2#20090000#2009#19#35-42#20100800#a15v86n4.ht
m##
00543000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760170035000790180052001140660
01000166065000900176064000500185037005700190110000900247109001100256865000900267
002001300276#v86n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#c#185#24#ar
ticle#30#24#Conselho Nacional do Meio Ambiente#Resolução CONAMA Nº 003, de 28 de
 junho de 1990^lpt#Brasí­lia#19900000#1990#http://www.mma.gov.br/port/conama/res
/res90/res0390.html#20061107#07/11/2009#20100800#a15v86n4.htm##
00565000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100013000790100017000920120
09800109030001200207065000900219064000500228031000300233014000700236865000900243
002001300252035001000265801001200275#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
5v86n4.htm#S#c#186#25#article#30#25#^rND^sHan^nX#^rND^sNaeher^nLP#A review of tr
affic-related air pollution exposure assessment studies in the developing world^
len#Environ Int#20060000#2006#32#106-20#20100800#a15v86n4.htm#0160-4120#Environ 
Int##
00609000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01900111010001800130012006700148030001800215065000900233064000500242031000300247
014000700250865000900257002001300266035001000279801001800289#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a15v86n4.htm#S#c#187#26#article#30#26#^rND^sMoura^nM#^rND^
sJunger^nWL#^rND^sMendonça^nGA#^rND^sde Leon^nAP#Qualidade do ar e transtornos r
espiratórios agudos em crianças^lpt#Rev Saude Publica#20080000#2008#42#503-11#20
100800#a15v86n4.htm#0034-8910#Rev Saude Publica##
00714000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100014000950100
01500109010001700124010001500141010002100156012012100177030001700298065000900315
06400050032403100030032901400070033286500090033900200130034803500100036180100170
0371#v86n4#V:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#c#188#27#article#30
#27#^rND^sMallol^nJ#^rND^sSolé^nD#^rND^sAsher^nI#^rND^sClayton^nT#^rND^sStein^nR
#^rND^sSoto-Quiroz^nM#Prevalence of asthma symptoms in Latin America: the Intern
ational Study of Asthma and Allergies in Childhood (ISAAC)^len#Pediatr Pulmonol#
20000000#2000#30#439-44#20100800#a15v86n4.htm#8755-6863#Pediatr Pulmonol##
00782000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100020000930100
02300113010001800136011002400154012019900178030001800377065000900395064000500404
031000300409014000600412865000900418002001300427035001000440801001800450#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a15v86n4.htm#S#c#189#28#article#30#28#^rND^sSo
lé^nD#^rND^sWandalsen^nGF#^rND^sCamelo-Nunes^nIC#^rND^sNaspitz^nCK#ISAAC - Brazi
lian Group#Prevalence of symptoms of asthma rhinitis, and atopic eczema among Br
azilian children and adolescents identified by the International Study of Asthma
 and Allergies in Childhood (ISAAC) - Phase 3^len#J Pediatr (Rio J)#20060000#200
6#82#341-6#20100800#a15v86n4.htm#0021-7557#J Pediatr (Rio J)##
00592000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100017000940100
01900111010001700130012009400147030001500241710000200256065000900258064000500267
031000300272014000500275865000900280002001300289#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a15v86n4.htm#S#c#190#29#article#30#29#^rND^sRosa^nAM#^rND^sIgnotti^nE#
^rND^sHacon Sde^nS#^rND^sCastro^nHA#Prevalence of asthma in children and adolesc
ents in a city in the Brazilian Amazon region^len#J Bras Pneumol#2#20090000#2009
#35#7-13#20100800#a15v86n4.htm##
00545000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100019000970100
01800116012006700134030002100201710000200222065000900224064000500233031000200238
014000500240865000900245002001300254#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
5v86n4.htm#S#c#191#30#article#30#30#^rND^sFischer^nGB#^rND^sCamargos^nPA#^rND^sM
ocelin^nHT#The burden of asthma in children: a Latin American perspective^len#Pe
diatric Respir Rev#2#20050000#2005#6#8-13#20100800#a15v86n4.htm##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v86n4#V:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#o#1#1#article#1
#20110126#175629#a16v86n4.htm#126##
03951000000000685000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002100108
03100030012903200020013206500090013401400110014303500100015401200790016401200850
02430100031003280100031003590100032003900100032004220100033004540100033004870100
03300520070011100553070009900664070002100763070010700784083100400891085001001895
08500270190508500170193208500210194908310800197008500100305008500290306008500180
30890850022031071170008031290720003031371120009031401110009031491140009031581130
00903167058006203176060001403238002001303252#v86n4#V:\Scielo\serial\jped\v86n4\m
arkup\a16v86n4.htm#S#h#2#1#article#1#sc#pt#br1.1#1#4.0#TAB#16#JPED160#nd#J. Pedi
atr. (Rio J.)#86#4#20100800#^f345^l348#0021-7557#Vitamina E no soro e colostro h
umanos em condições de jejum e pós-prandial^lpt#Vitamin E in human serum and col
ostrum under fasting and postprandial conditions^len#^rND^1A01^nRoberto^sDimenst
ein#^rND^1A01^nAna C. P.^sMedeiros#^rND^1A01^nLahyana R. F.^sCunha#^rND^1A02^nKa
therine F.^sAraújo#^rND^1A03^nJuliana C. O.^sDantas#^rND^1A03^nThamizy M. S.^sMa
cedo#^rND^1A04^nTânia L. M.^sStamford#Universidade Federal do Rio Grande do Nort
e^iA01^1Centro de Biociências^2Departamento de Bioquímica^cNatal^sRN#Universidad
e Federal do Rio Grande do Norte^iA02^1Laboratório de Bioquímica da Nutrição^cNa
tal^sRN#UFRN^iA03^cNatal^sRN#Universidade Federal de Pernambuco^iA04^1Centro de 
Ciências da Saúde^2Departamento de Nutrição^cRecife^sPE#^lpt^aOBJETIVO: Avaliar 
a concentração de alfa-tocoferol no soro e colostro maternos, seja em condições 
de jejum ou pós-prandial. MÉTODOS: Trinta parturientes saudáveis atendidas em um
a maternidade pública foram recrutadas para o estudo, e amostras de sangue, colo
stro em jejum e colostro pós-prandial foram coletadas até 12 horas pós-parto. RE
SULTADOS: A concentração sérica de alfa-tocoferol foi de 1.939,8±766,0 &#956;g/d
L. O alfa-tocoferol no colostro em jejum, 1.603,4±911,0 &#956;g/dL, e após a ref
eição, 1.515,0±890,9 &#956;g/dL, não apresentaram diferença significativa (p &gt
; 0,05). Houve correlação entre o alfa-tocoferol do colostro na condição de jeju
m e no pós-prandial (p < 0,05), mas não entre o soro e o colostro. CONCLUSÃO: A 
falta de correlação entre o alfa-tocoferol no plasma e no colostro e a correlaçã
o entre o alfa-tocoferol no colostro em jejum e no pós-prandial reforçam a hipót
ese de um mecanismo de controle na passagem desse micronutriente, independente d
o aporte dietético.#^ddecs^i1#^tm^lpt^kAlfa-tocoferol^i1#^tm^lpt^ksoro^i1#^tm^lp
t^kcolostro^i1#^len^aOBJECTIVE: To evaluate alpha-tocopherol concentrations in m
aternal serum and colostrum under fasting and postprandial conditions. METHODS: 
Thirty healthy childbearing women were recruited in a public maternity hospital,
 and samples of blood, fasting colostrum, and postprandial colostrum were collec
ted from them up to 12 hours after delivery. RESULTS: The serum alpha-tocopherol
 concentration was 1,939.8±766.0 &#956;g/dL. Alpha-tocopherol levels in fasting 
colostrum (1,603.4±911.0 &#956;g/dL) and in postprandial colostrum (1,515.0±890.
9 &#956;g/dL) did not demonstrate a statistically significant difference (p &gt;
 0.05). There was correlation between alpha-tocopherol levels in fasting and pos
tprandial colostrum (p < 0.05), but not between serum and colostrum. CONCLUSION:
 The lack of correlation between alpha-tocopherol levels in plasma and in colost
rum, and the correlation between alpha-tocopherol concentrations in fasting and 
postprandial colostrum support the existence of a mechanism that controls the tr
ansfer of this nutrient, regardless of dietary intake.#^ddecs^i2#^tm^len^kAlpha-
tocopherol^i2#^tm^len^kserum^i2#^tm^len^kcolostrum^i2#vancouv#15#20090723#23.07.
09#20091211#11.12.09#Conselho Nacional de Desenvolvimento Científico e Tecnológi
co#151899/2008-8#a16v86n4.htm##
04086000000000685000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000400090121000300094049000800097158000300105030002100108
03100030012903200020013206500090013401400110014303500100015401200860016401200920
02500100031003420100031003730100032004040100032004360100033004680100033005010100
03300534070011100567070009900678070002100777070010700798083103500905085001001940
08500270195008500170197708500210199408311110201508500100312608500290313608500180
31650850022031831170008032050720003032131120009032161110009032251140009032341130
00903243058006203252060007303314002001303387#v86n4#V:\Scielo\serial\jped\v86n4\m
arkup\a16v86n4.htm#S#f#3#1#article#1#sc#pt#br1.1#1#4.0#TAB#16#JPED160#nd#J. Pedi
atr. (Rio J.)#86#4#20100800#^f345^l348#0021-7557#<b>Vitamina E no soro e colostr
o humanos em condições de jejum e pós-prandial</b>^lpt#<b>Vitamin E in human ser
um and colostrum under fasting and postprandial conditions</b>^len#^rND^1A01^nRo
berto^sDimenstein#^rND^1A01^nAna C. P.^sMedeiros#^rND^1A01^nLahyana R. F.^sCunha
#^rND^1A02^nKatherine F.^sAraújo#^rND^1A03^nJuliana C. O.^sDantas#^rND^1A03^nTha
mizy M. S.^sMacedo#^rND^1A04^nTânia L. M.^sStamford#Universidade Federal do Rio 
Grande do Norte^iA01^1Centro de Biociências^2Departamento de Bioquímica^cNatal^s
RN#Universidade Federal do Rio Grande do Norte^iA02^1Laboratório de Bioquímica d
a Nutrição^cNatal^sRN#UFRN^iA03^cNatal^sRN#Universidade Federal de Pernambuco^iA
04^1Centro de Ciências da Saúde^2Departamento de Nutrição^cRecife^sPE#^lpt^a<b>O
BJETIVO: </b>Avaliar a concentração de alfa-tocoferol no soro e colostro materno
s, seja em condições de jejum ou pós-prandial. <b>MÉTODOS: </b>Trinta parturient
es saudáveis atendidas em uma maternidade pública foram recrutadas para o estudo
, e amostras de sangue, colostro em jejum e colostro pós-prandial foram coletada
s até 12 horas pós-parto. <b>RESULTADOS: </b>A concentração sérica de alfa-tocof
erol foi de 1.939,8±766,0 &#956;g/dL. O alfa-tocoferol no colostro em jejum, 1.6
03,4±911,0 &#956;g/dL, e após a refeição, 1.515,0±890,9 &#956;g/dL, não apresent
aram diferença significativa (p &gt; 0,05). Houve correlação entre o alfa-tocofe
rol do colostro na condição de jejum e no pós-prandial (p &lt; 0,05), mas não en
tre o soro e o colostro. <b>CONCLUSÃO: </b>A falta de correlação entre o alfa-to
coferol no plasma e no colostro e a correlação entre o alfa-tocoferol no colostr
o em jejum e no pós-prandial reforçam a hipótese de um mecanismo de controle na 
passagem desse micronutriente, independente do aporte dietético.#^ddecs^i1#^tm^l
pt^kAlfa-tocoferol^i1#^tm^lpt^ksoro^i1#^tm^lpt^kcolostro^i1#^len^a<b>OBJECTIVE: 
</b>To evaluate alpha-tocopherol concentrations in maternal serum and colostrum 
under fasting and postprandial conditions. <b>METHODS: </b>Thirty healthy childb
earing women were recruited in a public maternity hospital, and samples of blood
, fasting colostrum, and postprandial colostrum were collected from them up to 1
2 hours after delivery. <b>RESULTS: </b>The serum alpha-tocopherol concentration
 was 1,939.8±766.0 &#956;g/dL. Alpha-tocopherol levels in fasting colostrum (1,6
03.4±911.0 &#956;g/dL) and in postprandial colostrum (1,515.0±890.9 &#956;g/dL) 
did not demonstrate a statistically significant difference (p &gt; 0.05). There 
was correlation between alpha-tocopherol levels in fasting and postprandial colo
strum (p &lt; 0.05), but not between serum and colostrum. <b>CONCLUSION: </b>The
 lack of correlation between alpha-tocopherol levels in plasma and in colostrum,
 and the correlation between alpha-tocopherol concentrations in fasting and post
prandial colostrum support the existence of a mechanism that controls the transf
er of this nutrient, regardless of dietary intake.#^ddecs^i2#^tm^len^kAlpha-toco
pherol^i2#^tm^len^kserum^i2#^tm^len^kcolostrum^i2#vancouv#15#20090723#23.07.09#2
0091211#11.12.09#Conselho Nacional de Desenvolvimento Científico e Tecnológico#<
span style='font-size:10.0pt;font-family: Verdana'>151899/2008-8</span>#a16v86n4
.htm##
04084000000000709000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000400108121000300112049000800115158000300123
03000210012603100030014703200020015006500090015201400110016103500100017201200790
01820120085002610100031003460100030003770100031004070100031004380100032004690100
03200501010003200533070011300565070010100678070002300779070010900802083100400911
08500100191508500270192508500170195208500210196908310800199008500100307008500290
30800850018031090850022031271170008031490720003031571120009031601110009031691140
00903178113000903187058006203196060001403258002001303272008008903285#v86n4#V:\Sc
ielo\serial\jped\v86n4\markup\a16v86n4.htm#S#l#4#1#article#1#^mjul./ago.^a2010#s
c#pt#br1.1#1#4.0#tab#16#JPED160#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f345^l348
#0021-7557#Vitamina E no soro e colostro humanos em condições de jejum e pós-pra
ndial^lpt#Vitamin E in human serum and colostrum under fasting and postprandial 
conditions^len#^rND^1A01^nRoberto^sDimenstein#^rND^1A01^nAna C. P^sMedeiros#^rND
^1A01^nLahyana R. F^sCunha#^rND^1A02^nKatherine F^sAraújo#^rND^1A03^nJuliana C. 
O^sDantas#^rND^1A03^nThamizy M. S^sMacedo#^rND^1A04^nTânia L. M^sStamford#^iA01^
1Universidade Federal do Rio Grande do Norte^2Centro de Biociências^3Departament
o de Bioquímica^cNatal^sRN#^iA02^1Universidade Federal do Rio Grande do Norte^2L
aboratório de Bioquímica da Nutrição^cNatal^sRN#^iA03^1UFRN^cNatal^sRN#^iA04^1Un
iversidade Federal de Pernambuco^2Centro de Ciências da Saúde^3Departamento de N
utrição^cRecife^sPE#^lpt^aOBJETIVO: Avaliar a concentração de alfa-tocoferol no 
soro e colostro maternos, seja em condições de jejum ou pós-prandial. MÉTODOS: T
rinta parturientes saudáveis atendidas em uma maternidade pública foram recrutad
as para o estudo, e amostras de sangue, colostro em jejum e colostro pós-prandia
l foram coletadas até 12 horas pós-parto. RESULTADOS: A concentração sérica de a
lfa-tocoferol foi de 1.939,8±766,0 &#956;g/dL. O alfa-tocoferol no colostro em j
ejum, 1.603,4±911,0 &#956;g/dL, e após a refeição, 1.515,0±890,9 &#956;g/dL, não
 apresentaram diferença significativa (p &gt; 0,05). Houve correlação entre o al
fa-tocoferol do colostro na condição de jejum e no pós-prandial (p < 0,05), mas 
não entre o soro e o colostro. CONCLUSÃO: A falta de correlação entre o alfa-toc
oferol no plasma e no colostro e a correlação entre o alfa-tocoferol no colostro
 em jejum e no pós-prandial reforçam a hipótese de um mecanismo de controle na p
assagem desse micronutriente, independente do aporte dietético.#^ddecs^i1#^tm^lp
t^kAlfa-tocoferol^i1#^tm^lpt^ksoro^i1#^tm^lpt^kcolostro^i1#^len^aOBJECTIVE: To e
valuate alpha-tocopherol concentrations in maternal serum and colostrum under fa
sting and postprandial conditions. METHODS: Thirty healthy childbearing women we
re recruited in a public maternity hospital, and samples of blood, fasting colos
trum, and postprandial colostrum were collected from them up to 12 hours after d
elivery. RESULTS: The serum alpha-tocopherol concentration was 1,939.8±766.0 &#9
56;g/dL. Alpha-tocopherol levels in fasting colostrum (1,603.4±911.0 &#956;g/dL)
 and in postprandial colostrum (1,515.0±890.9 &#956;g/dL) did not demonstrate a 
statistically significant difference (p &gt; 0.05). There was correlation betwee
n alpha-tocopherol levels in fasting and postprandial colostrum (p < 0.05), but 
not between serum and colostrum. CONCLUSION: The lack of correlation between alp
ha-tocopherol levels in plasma and in colostrum, and the correlation between alp
ha-tocopherol concentrations in fasting and postprandial colostrum support the e
xistence of a mechanism that controls the transfer of this nutrient, regardless 
of dietary intake.#^ddecs^i2#^tm^len^kAlpha-tocopherol^i2#^tm^len^kserum^i2#^tm^
len^kcolostrum^i2#vancouv#15#20090723#23.07.09#20091211#11.12.09#Conselho Nacion
al de Desenvolvimento Científico e Tecnológico#151899/2008-8#a16v86n4.htm#Intern
et^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0021-755720100004000
16##
00340000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704010700074002001300181#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#5#1#article#107#<p align="right"><fon
t size="2" face="Verdana"><b>COMUNICA&Ccedil;&Atilde;O BREVE</b></font>  </p>   
  ^cY#a16v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#6#2#article#107#<p>&nbsp;</p>     ^cY
#a16v86n4.htm##
00391000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704015800074002001300232#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#7#3#article#107#<p><font size="4" fac
e="Verdana"><b>Vitamina E no soro e colostro humanos em condi&ccedil;&otilde;es 
   de jejum e p&oacute;s-prandial</b></font></p>     ^cY#a16v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#8#4#article#107#<p>&nbsp;</p>     ^cY
#a16v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#9#5#article#107#<p>&nbsp;</p>     ^cY
#a16v86n4.htm##
00551000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704031700075002001300392#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#10#6#article#107#<p><font size="2" fa
ce="Verdana"><b>Roberto Dimenstein<sup>I</sup>; Ana C. P.    Medeiros<sup>II</su
p>; Lahyana R. F. Cunha<sup>III</sup>; Katherine F. Ara&uacute;jo<sup>IV</sup>; 
   Juliana C. O. Dantas<sup>V</sup>; Thamizy M. S. Macedo<sup>V</sup>; T&acirc;n
ia    L. M. Stamford<sup>VI</sup></b></font></p>     ^cY#a16v86n4.htm##
00467000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704023300075002001300308#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#11#7#article#107#<p><font size="2" fa
ce="Verdana"><sup>I</sup>Doutor, Bioqu&iacute;mica, Professor    adjunto IV, Dep
artamento de Bioqu&iacute;mica, Centro de Bioci&ecirc;ncias,    Universidade Fed
eral do Rio Grande do Norte (UFRN), Natal, RN    ^cY#a16v86n4.htm##
00442000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704020800075002001300283#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#12#8#article#107#<br>   <sup>II</sup>
Farmac&ecirc;utica, Mestranda,    Curso de P&oacute;s-Gradua&ccedil;&atilde;o, B
ioqu&iacute;mica, Centro de Bioci&ecirc;ncias,    Departamento de Bioqu&iacute;m
ica, UFRN, Natal, RN    ^cY#a16v86n4.htm##
00439000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704020500075002001300280#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#13#9#article#107#<br>   <sup>III</sup
>Bi&oacute;loga, mestranda,    Curso de P&oacute;s-Gradua&ccedil;&atilde;o, Bioq
u&iacute;mica, Centro de Bioci&ecirc;ncias,    Departamento de Bioqu&iacute;mica
, UFRN, Natal, RN    ^cY#a16v86n4.htm##
00400000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704016500076002001300241#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#14#10#article#107#<br>   <sup>IV</sup
>Nutricionista, Bolsista de    apoio t&eacute;cnico, Laborat&oacute;rio de Bioqu
&iacute;mica da Nutri&ccedil;&atilde;o,    UFRN, Natal, RN    ^cY#a16v86n4.htm##
00321000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008600076002001300162#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#15#11#article#107#<br>   <sup>V</sup>
Acad&ecirc;mica, Nutri&ccedil;&atilde;o,    UFRN, Natal, RN    ^cY#a16v86n4.htm#
#
00471000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704023600076002001300312#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#16#12#article#107#<br>   <sup>VI</sup
>Doutora, Nutri&ccedil;&atilde;o,    Professora associada, Departamento de Nutri
&ccedil;&atilde;o, Centro de Ci&ecirc;ncias    da Sa&uacute;de, Universidade Fed
eral de Pernambuco (UFPE), Recife, PE</font></p>     ^cY#a16v86n4.htm##
00358000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012300076002001300199#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#17#13#article#107#<p><font size="2" f
ace="Verdana"><a name="topo"></a><a href="#correspondence">Correspond&ecirc;ncia
</a></font></p>     ^cY#a16v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#18#14#article#107#<p>&nbsp;</p>     ^
cY#a16v86n4.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#19#15#article#107#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a16v86n4.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006600076002001300142#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#20#16#article#107#<p><font size="2" f
ace="Verdana"><b>RESUMO</b></font></p>     ^cY#a16v86n4.htm##
00449000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704021400076002001300290#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#21#17#article#107#<p><font size="2" f
ace="Verdana"> <b>OBJETIVO: </b> Avaliar a concentra&ccedil;&atilde;o    de alfa
-tocoferol no soro e colostro maternos, seja em condi&ccedil;&otilde;es    de je
jum ou p&oacute;s-prandial.    ^cY#a16v86n4.htm##
00520000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704028500076002001300361#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#22#18#article#107#<br>   <b>M&Eacute;
TODOS: </b> Trinta parturientes saud&aacute;veis atendidas em uma    maternidade
 p&uacute;blica foram recrutadas para o estudo, e amostras de sangue,    colostr
o em jejum e colostro p&oacute;s-prandial foram coletadas at&eacute;    12 horas
 p&oacute;s-parto.    ^cY#a16v86n4.htm##
00755000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704052000076002001300596#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#23#19#article#107#<br>   <b>RESULTADO
S: </b>A concentra&ccedil;&atilde;o s&eacute;rica de alfa-tocoferol    foi de 1.
939,8±766,0 &#956;g/dL. O alfa-tocoferol no colostro em jejum, 1.603,4±911,0    
&#956;g/dL, e ap&oacute;s a refei&ccedil;&atilde;o, 1.515,0±890,9 &#956;g/dL,   
 n&atilde;o apresentaram diferen&ccedil;a significativa (p > 0,05). Houve correl
a&ccedil;&atilde;o    entre o alfa-tocoferol do colostro na condi&ccedil;&atilde
;o de jejum e no p&oacute;s-prandial    (p < 0,05), mas n&atilde;o entre o soro 
e o colostro.    ^cY#a16v86n4.htm##
00617000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038200076002001300458#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#24#20#article#107#<br>   <b>CONCLUS&A
tilde;O: </b> A falta de correla&ccedil;&atilde;o entre o alfa-tocoferol    no p
lasma e no colostro e a correla&ccedil;&atilde;o entre o alfa-tocoferol    no co
lostro em jejum e no p&oacute;s-prandial refor&ccedil;am a hip&oacute;tese    de
 um mecanismo de controle na passagem desse micronutriente, independente do    a
porte diet&eacute;tico.</font></p>     ^cY#a16v86n4.htm##
00368000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013300076002001300209#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#25#21#article#107#<p><font size="2" f
ace="Verdana"><b>Palavras-chave: </b> Alfa-tocoferol, soro,    colostro.</font><
/p> <hr size="1" noshade>     ^cY#a16v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#26#22#article#107#<p>&nbsp;</p>     ^
cY#a16v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#27#23#article#107#<p>&nbsp;</p>     ^
cY#a16v86n4.htm##
00319000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008400076002001300160#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#28#24#article#107#<p><font size="3" f
ace="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#a16v86n4.htm##
00770000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704053500076002001300611#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#29#25#article#107#<p><font face="Verd
ana" size="2">A vitamina E &eacute; um termo gen&eacute;rico    utilizado para d
esignar oito compostos naturais, sendo o alfa-tocoferol o que    possui maior at
ividade biol&oacute;gica<SUP>1</SUP>. Estudos epidemiol&oacute;gicos    t&ecirc;
m indicado um prov&aacute;vel envolvimento da defici&ecirc;ncia de vitamina    E
 na patog&ecirc;nese da aterosclerose, diabetes e alguns tipos de c&acirc;ncer, 
   bem como na modula&ccedil;&atilde;o da inflama&ccedil;&atilde;o e resposta im
une<SUP>2</SUP>.</font></p>     ^cY#a16v86n4.htm##
00783000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704054800076002001300624#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#30#26#article#107#<p><font face="Verd
ana" size="2">Durante a gesta&ccedil;&atilde;o, a transfer&ecirc;ncia    placent
&aacute;ria do alfa-tocoferol &eacute; limitada, e o feto apresenta baixa    con
centra&ccedil;&atilde;o circulante dessa vitamina. Ap&oacute;s o parto, o    lei
te &eacute; de extrema import&acirc;ncia para o abastecimento do alfa-tocoferol 
   ao rec&eacute;m-nascido, pois &eacute; essencial na defesa contra a toxicidad
e    do oxig&ecirc;nio e auxilia a estimular o desenvolvimento de seu sistema im
unol&oacute;gico<SUP>1</SUP>.</font></p>     ^cY#a16v86n4.htm##
00795000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704056000076002001300636#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#31#27#article#107#<p><font face="Verd
ana" size="2">Crian&ccedil;as rec&eacute;m-nascidas, especialmente    as prematu
ras, podem ser vulner&aacute;veis a desenvolver sintomas cl&iacute;nicos    tais
 como anemia hemol&iacute;tica, hemorragia intraventricular e displasia    bronc
opulmonar em consequ&ecirc;ncia da defici&ecirc;ncia do alfa-tocoferol<SUP>3</SU
P>.    Uma boa oferta dessa vitamina para os neonatos &eacute; cr&iacute;tica, e
specialmente    para aqueles de baixa renda ou cuja amamenta&ccedil;&atilde;o n&
atilde;o esteja    garantida<SUP>4</SUP>.</font></p>     ^cY#a16v86n4.htm##
00612000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704037700076002001300453#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#32#28#article#107#<p><font face="Verd
ana" size="2">O colostro possui uma alta concentra&ccedil;&atilde;o    de alfa-t
ocoferol, atingindo valores seis a sete vezes maiores quando comparado    ao lei
te maduro<SUP>5</SUP>; entretanto, o mecanismo de transfer&ecirc;ncia    do alfa
-tocoferol para a gl&acirc;ndula mam&aacute;ria n&atilde;o est&aacute;    comple
tamente entendido.</font></p>     ^cY#a16v86n4.htm##
00872000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063700076002001300713#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#33#29#article#107#<p><font face="Verd
ana" size="2">Existem evid&ecirc;ncias de que a secre&ccedil;&atilde;o    di&aac
ute;ria de alfa-tocoferol &eacute; limitada em quantidade e independente    do v
olume e teor de gordura do leite produzido<SUP>6</SUP>. Assim, devido &agrave;  
  import&acirc;ncia da vitamina E para o desenvolvimento do lactente, nosso obje
tivo    foi investigar a rela&ccedil;&atilde;o entre o alfa-tocoferol do soro e 
o presente    no colostro, bem como avaliar a influ&ecirc;ncia do momento da ref
ei&ccedil;&atilde;o    (jejum e p&oacute;s-prandial) sobre a concentra&ccedil;&a
tilde;o dessa vitamina    no colostro.</font></p>     ^cY#a16v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#34#30#article#107#<p>&nbsp;</p>     ^
cY#a16v86n4.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007400076002001300150#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#35#31#article#107#<p><font size="3" f
ace="Verdana"><b>M&eacute;todos</b></font></p>     ^cY#a16v86n4.htm##
00987000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075200076002001300828#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#36#32#article#107#<p><font face="Verd
ana" size="2">O estudo foi do tipo transversal, e a amostragem    foi obtida por
 conveni&ecirc;ncia, composta por parturientes volunt&aacute;rias,    atendidas 
na Maternidade Escola Janu&aacute;rio Cicco, Natal (RN). O tamanho    da amostra
 foi calculado usando o <i>software</i> Statcalc (Epi-Info, vers&atilde;o    3.5
.1), considerando uma m&eacute;dia de 250 partos por m&ecirc;s, e para um    n&i
acute;vel de confian&ccedil;a de 95% (IC95%), estimou-se a amostra m&iacute;nima
    de 30 sujeitos como representativa da maternidade. O estudo obteve aprova&cc
edil;&atilde;o    do Comit&ecirc; de &Eacute;tica em Pesquisa da Universidade Fe
deral do Rio Grande    do Norte (UFRN), Natal (RN) (Protocolo nº 284/09).</font>
</p>     ^cY#a16v86n4.htm##
00864000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062900076002001300705#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#37#33#article#107#<p><font face="Verd
ana" size="2">Foram inclu&iacute;das no estudo, apenas mulheres    sem patologia
s &#150; como diabetes, neoplasias, doen&ccedil;as do trato gastrointestinal    
e hep&aacute;ticas, cardiopatias, doen&ccedil;as infecciosas, s&iacute;filis    
e v&iacute;rus da imunodefici&ecirc;ncia humana (<i>human immunodeficiency virus
</i>    &#150; HIV) positivo &#150;, que tiveram partos a termo e concepto &uacu
te;nico sem m&aacute;-forma&ccedil;&atilde;o.    As m&atilde;es informaram n&ati
lde;o ter feito uso de suplementos vitam&iacute;nicos    contendo vitamina E dur
ante a gesta&ccedil;&atilde;o.</font></p>     ^cY#a16v86n4.htm##
00860000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062500076002001300701#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#38#34#article#107#<p><font face="Verd
ana" size="2">As primeiras amostras de sangue foram coletadas    em jejum, sempr
e no per&iacute;odo da manh&atilde;, seguindo-se da coleta de    2 mL de colostr
o tamb&eacute;m em jejum. Nova coleta de colostro ocorreu 3 horas    ap&oacute;s
 o desjejum. Dessa forma, foram realizadas duas coletas de colostro    por dia d
e cada paciente. Essas coletas foram realizadas at&eacute; 12 horas    p&oacute;
s-parto. O colostro foi obtido por express&atilde;o manual de uma &uacute;nica  
  mama, no in&iacute;cio e no final da mamada, para evitar flutua&ccedil;&otilde
;es    no teor de gordura.</font></p>     ^cY#a16v86n4.htm##
00867000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063200076002001300708#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#39#35#article#107#<p><font face="Verd
ana" size="2">Foram coletados 3 mL de sangue em jejum e armazenados    em tubo d
e polipropileno protegido da luz. As amostras de leite e sangue foram    transpo
rtadas sob refrigera&ccedil;&atilde;o ao laborat&oacute;rio de pesquisa    em Bi
oqu&iacute;mica da Nutri&ccedil;&atilde;o, Departamento de Bioqu&iacute;mica,   
 Centro de Bioci&ecirc;ncias, UFRN, Natal. As al&iacute;quotas de sangue foram  
  centrifugadas por 10 minutos (500 xg) para separa&ccedil;&atilde;o e remo&cced
il;&atilde;o    do soro. O leite e o soro foram armazenados a -20 ºC at&eacute; 
o momento das    an&aacute;lises.</font></p>     ^cY#a16v86n4.htm##
01232000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704099700076002001301073#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#40#36#article#107#<p><font face="Verd
ana" size="2">As amostras de leite e soro foram extra&iacute;das    segundo adap
ta&ccedil;&atilde;o do m&eacute;todo de Ortega et al.<SUP>7</SUP>.    Para o col
ostro e o soro, foram utilizadas al&iacute;quotas diferenciadas de    2 e 3 mL d
a fase hex&acirc;nica, respectivamente. Os extratos foram redissolvidos    em 50
0 &#956;L de etanol (Merck, S&atilde;o Paulo, Brasil), em grau de pureza    para
 cromatografia l&iacute;quida de alta efici&ecirc;ncia, e aplicados 20 &#956;L  
  no cromat&oacute;grafo de marca Shimadzu, com bomba LC-20 AT Shimadzu, acoplad
o    a um Detector SPD-20A Shimadzu UV-VIS e Coluna Shim-Pack CLC-ODS (M) 4,6 mm
    x 15 cm. Os dados foram processados pelo programa LC Solution (Shimadzu Corp
oration).    Para o colostro, a fase m&oacute;vel utilizada foi metanol: &aacute
;gua (97:3),    em sistema isocr&aacute;tico com fluxo de 1,5 mL/minuto e compri
mento de onda    de 292 nm. Para o soro, a fase m&oacute;vel foi metanol 100%.</
font></p>     ^cY#a16v86n4.htm##
00789000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055400076002001300630#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#41#37#article#107#<p><font face="Verd
ana" size="2">A identifica&ccedil;&atilde;o e quantifica&ccedil;&atilde;o    do 
alfa-tocoferol nas amostras foram estabelecidas por compara&ccedil;&atilde;o    
da respectiva &aacute;rea do pico obtido no cromatograma com a &aacute;rea do   
 padr&atilde;o de alfa-tocoferol (SIGMA, St. Louis, EUA). A concentra&ccedil;&at
ilde;o    do padr&atilde;o foi confirmada pelo coeficiente de extin&ccedil;&atil
de;o espec&iacute;fico    para alfa-tocoferol (E 1%, 1 cm = 75,8, a 292 nm) em e
tanol absoluto (Vetec)<SUP>8</SUP>.</font></p>     ^cY#a16v86n4.htm##
00539000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704030400076002001300380#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#42#38#article#107#<p><font face="Verd
ana" size="2">A concentra&ccedil;&atilde;o de alfa-tocoferol    no soro foi expr
essa em &#956;g/dL. Para alfa-tocoferol no soro: &lt; 499,6    (n&iacute;vel def
iciente), 499,6 a 697,7 (n&iacute;vel baixo) e &gt; 697,7 (n&iacute;vel    aceit
&aacute;vel)<SUP>9</SUP>.</font></p>     ^cY#a16v86n4.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#43#39#article#107#<p><font face="Verd
ana" size="2"><b><i>An&aacute;lise estat&iacute;stica</i></b></font></p>     ^cY
#a16v86n4.htm##
00838000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704060300076002001300679#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#44#40#article#107#<p><font face="Verd
ana" size="2">Os valores de alfa-tocoferol foram expressos    em m&eacute;dia e 
desvio padr&atilde;o. Para testar as diferen&ccedil;as entre    as m&eacute;dias
 dos dados num&eacute;ricos param&eacute;tricos, foi utilizado    o teste<i> t <
/i>de Student em amostras pareadas. As diferen&ccedil;as foram    consideradas s
ignificativas quando p &lt; 0,05. A associa&ccedil;&atilde;o entre    vari&aacut
e;veis cont&iacute;nuas (concentra&ccedil;&atilde;o de nutrientes    no leite e 
soro) foi determinada pela an&aacute;lise de correla&ccedil;&atilde;o    de Pear
son.</font></p>     ^cY#a16v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#45#41#article#107#<p>&nbsp;</p>     ^
cY#a16v86n4.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007000076002001300146#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#46#42#article#107#<p><font size="3" f
ace="Verdana"><b>Resultados</b></font></p>     ^cY#a16v86n4.htm##
00426000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704019100076002001300267#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#47#43#article#107#<p><font face="Verd
ana" size="2">Foram coletadas amostras de 30 mulheres e divididas    em tr&ecirc
;s grupos: o soro, o colostro em jejum e o colostro p&oacute;s-prandial.</font><
/p>     ^cY#a16v86n4.htm##
00709000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047400076002001300550#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#48#44#article#107#<p><font face="Verd
ana" size="2">A concentra&ccedil;&atilde;o m&eacute;dia de    alfa-tocoferol enc
ontrada no soro das mulheres foi de 1.939,8±766,0 &#956;g/dL,    considerada ade
quada de acordo com os valores de refer&ecirc;ncia. O alfa-tocoferol    no colos
tro em jejum, 1.603,4±911,0 &#956;g/dL, e ap&oacute;s a refei&ccedil;&atilde;o, 
   1.515,0±890,9 &#956;g/dL, n&atilde;o apresentaram diferen&ccedil;a estatistic
amente    significativa (p = 0,55).</font></p>     ^cY#a16v86n4.htm##
01350000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704111500076002001301191#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#49#45#article#107#<p><font face="Verd
ana" size="2">Nenhuma correla&ccedil;&atilde;o foi observada    entre o alfa-toc
oferol no plasma e no colostro, seja na condi&ccedil;&atilde;o    de jejum ou p&
oacute;s-prandial. Entretanto, foi observada uma forte correla&ccedil;&atilde;o 
   entre o alfa-tocoferol do colostro em jejum e o p&oacute;s-prandial (p = 0,00
1;    r = 0,596). Essa situa&ccedil;&atilde;o foi corroborada quando simulamos a
 correla&ccedil;&atilde;o    entre o grupo de parturientes, ao dividi-las em fun
&ccedil;&atilde;o da concentra&ccedil;&atilde;o    de alfa-tocoferol presente no
 soro. Quatorze mulheres possu&iacute;am concentra&ccedil;&atilde;o    s&eacute;
rica de alfa-tocoferol menor que 2.000 &#956;g/dL, e 16 mulheres, maior    que 2
.000 &#956;g/dL (<a href=/img/revistas/jped/v86n4/4a16t1.gif>Tabela 1</a>).    F
oi observado que a correla&ccedil;&atilde;o entre o alfa-tocoferol do colostro  
  em jejum e o p&oacute;s-prandial era mais forte (p = 0,017, r = 0,621) no grup
o    com menor alfa-tocoferol no soro do que no grupo de maior concentra&ccedil;
&atilde;o    (p = 0,029, r = 0,544).</font></p>     ^cY#a16v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#50#46#article#107#<p>&nbsp;</p>     ^
cY#a16v86n4.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#51#47#article#107#<p><font size="3" f
ace="Verdana"><b>Discuss&atilde;o</b></font></p>     ^cY#a16v86n4.htm##
00462000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704022700076002001300303#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#52#48#article#107#<p><font face="Verd
ana" size="2">A idade m&eacute;dia das participantes foi de    24 anos, onde 46,
3% tiveram parto ces&aacute;rea, 53,6% tiveram partos normais,    e 66,6% possu&
iacute;am um ou dois filhos.</font></p>     ^cY#a16v86n4.htm##
01067000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704083200076002001300908#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#53#49#article#107#<p><font face="Verd
ana" size="2">Os n&iacute;veis de alfa-tocoferol no soro indicam    um bom estad
o nutricional em vitamina E, refletindo uma alimenta&ccedil;&atilde;o    apropri
ada durante a gesta&ccedil;&atilde;o. Quando a concentra&ccedil;&atilde;o    de 
alfa-tocoferol foi comparada com a de outros estudos, apresentaram m&eacute;dias
    (1.938,1±766,6 &#956;g/dL) superiores &agrave;s encontradas em mulheres amer
icanas    (1.128,4 &#956;g/dL)<SUP>10</SUP> e de Cuba (1.029,4 &#956;g/dL)<SUP>1
1</SUP>.    Uma explica&ccedil;&atilde;o para os n&iacute;veis mais altos de alf
a-tocoferol    s&eacute;rico encontrado em nosso estudo pode ser devido ao fato 
de que a dieta    americana cont&eacute;m uma maior propor&ccedil;&atilde;o de g
ama tocoferol    em rela&ccedil;&atilde;o ao alfa-tocoferol<SUP>12</SUP>.</font>
</p>     ^cY#a16v86n4.htm##
00508000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027300076002001300349#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#54#50#article#107#<p><font face="Verd
ana" size="2">No colostro, a concentra&ccedil;&atilde;o de    alfa-tocoferol no 
leite do grupo em jejum (1.603,4±911,0 &#956;g/dL) foi semelhante    ao encontra
do em Cuba<SUP>13</SUP> e inferior ao encontrado na Alemanha<SUP>14</SUP>.</font
></p>     ^cY#a16v86n4.htm##
00718000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048300076002001300559#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#55#51#article#107#<p><font face="Verd
ana" size="2">Foi observado que o alfa-tocoferol do colostro    na condi&ccedil;
&atilde;o p&oacute;s-prandial n&atilde;o foi significativamente    diferente da 
condi&ccedil;&atilde;o em jejum, ou seja, n&atilde;o ocorreu aumento    nos n&ia
cute;veis de alfa-tocoferol ap&oacute;s o desjejum, indicando que a    passagem 
dessa vitamina &eacute; limitada<SUP>7</SUP>, ou a quantidade presente    na die
ta foi insuficiente para provocar o aumento.</font></p>     ^cY#a16v86n4.htm##
01080000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704084500076002001300921#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#56#52#article#107#<p><font face="Verd
ana" size="2">A aus&ecirc;ncia de correla&ccedil;&atilde;o    entre o alfa-tocof
erol do soro e o do colostro, seja em jejum ou no p&oacute;s-prandial,    exclui
 a exist&ecirc;ncia de mecanismos de transfer&ecirc;ncia passiva durante    a pa
ssagem da vitamina E da gl&acirc;ndula mam&aacute;ria para o leite. Provavelment
e,    devem existir mecanismos de transporte distintos dessa vitamina para a gl&
acirc;ndula    mam&aacute;ria que independem da concentra&ccedil;&atilde;o plasm
&aacute;tica<SUP>15</SUP>.    De fato, a redu&ccedil;&atilde;o de quase 10 vezes
 na concentra&ccedil;&atilde;o    do alfa-tocoferol presente no colostro, em com
para&ccedil;&atilde;o aos n&iacute;veis    presentes no leite de transi&ccedil;&
atilde;o e maduro, evidenciam outros mecanismos    de transfer&ecirc;ncia<SUP>1<
/SUP>.</font></p>     ^cY#a16v86n4.htm##
01321000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704108600076002001301162#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#57#53#article#107#<p><font face="Verd
ana" size="2">A correla&ccedil;&atilde;o significativa entre    o alfa-tocoferol
 do colostro em jejum e o p&oacute;s-prandial demonstra que,    uma vez ultrapas
sada a barreira de transporte da gl&acirc;ndula mam&aacute;ria    e sua conseque
nte secre&ccedil;&atilde;o l&aacute;ctea, n&atilde;o existir&aacute;    restri&c
cedil;&atilde;o para essa vitamina nos diferentes momentos da alimenta&ccedil;&a
tilde;o    materna. A correla&ccedil;&atilde;o mais forte encontrada no grupo co
m menores    n&iacute;veis de alfa-tocoferol s&eacute;ricos s&atilde;o compat&ia
cute;veis    com o achado de Jensen et al.<SUP>6</SUP>, que demonstrou, em vacas
, que a secre&ccedil;&atilde;o    do alfa-tocoferol do sangue para o leite segue
 a cin&eacute;tica de Michaelis-Menten    para transporte ativo atrav&eacute;s d
e membranas. Assim, diante de n&iacute;veis    s&eacute;ricos de alfa-tocoferol 
mais baixos, os receptores para lipoprote&iacute;nas    n&atilde;o est&atilde;o 
totalmente saturados, e todo alfa-tocoferol que chega    aos receptores passa ao
 leite.</font></p>     ^cY#a16v86n4.htm##
00669000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704043400076002001300510#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#58#54#article#107#<p><font face="Verd
ana" size="2">As evid&ecirc;ncias encontradas em condi&ccedil;&atilde;o    p&oac
ute;s-prandial apontam para uma limita&ccedil;&atilde;o no transporte de    alfa
-tocoferol do soro materno para o colostro, levantando a quest&atilde;o    da va
lidade de se suplementar a m&atilde;e nesse momento p&oacute;s-parto como    est
rat&eacute;gia para melhorar o estado nutricional do rec&eacute;m-nascido.</font
></p>      ^cY#a16v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#59#55#article#107#<p>&nbsp;</p>     ^
cY#a16v86n4.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007400076002001300150#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#60#56#article#107#<p><font size="3" f
ace="Verdana"><b>Agradecimentos</b></font></p>     ^cY#a16v86n4.htm##
00394000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704015900076002001300235#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#61#57#article#107#<p><font face="Verd
ana" size="2">&Agrave; Maternidade Escola Janu&aacute;rio Cicco,    por permitir
 a coleta de amostras biol&oacute;gicas.</font></p>     ^cY#a16v86n4.htm##
00378000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014300076002001300219#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#62#58#article#107#<p><font face="Verd
ana" size="2">Os dados deste artigo fazem parte do projeto    de P&oacute;s-Dout
orado do primeiro autor.</font></p>     ^cY#a16v86n4.htm##
00390000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704015500076002001300231#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#63#59#article#107#<p><font face="Verd
ana" size="2">Apoio financeiro: CNPq edital/Chamada: P&oacute;s-Doutorado    S&e
circ;nior - Processo 151899/2008-8.</font></p>      ^cY#a16v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#64#60#article#107#<p>&nbsp;</p>     ^
cY#a16v86n4.htm##
00312000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007700076002001300153#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#65#61#article#107#<p><font size="3" f
ace="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#a16v86n4.htm##
00409000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704016000078002001300238#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#p#66#62#article#107#1#<p><f
ont size="2" face="Verdana">1. Debier C, Larondelle Y. Vitamins A and E:    meta
bolism, roles and transfer to offspring. Br J Nutr. 2005;93:153-74.    ^cY#a16v8
6n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#67#63#article#107#</font></p>     ^cY
#a16v86n4.htm##
00423000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704017400078002001300252#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#p#68#64#article#107#2#<p><f
ont size="2" face="Verdana">2. Azzi A, Ricciarelli R, Zingg JM. Non-antioxidant 
   molecular functions of alpha-tocopherol (vitamin E). FEBS Lett. 2002;519:8-10
.    ^cY#a16v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002400076002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#69#65#article#107#    </font></p>    
 ^cY#a16v86n4.htm##
00608000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704035900078002001300437#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#p#70#66#article#107#3#<p><f
ont size="2" face="Verdana">3. Romeu-Nadal M, Morera-Pons S, Castellote AI,    L
&oacute;pez-Sabater MC. Determination of gamma- and alpha-tocopherols in human  
  milk by a direct high-performance liquid chromatographic method with UV-vis   
 detection and comparison with evaporative light scattering detection. J Chromat
ogr    A. 2006;1114:132-7.    ^cY#a16v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#71#67#article#107#</font></p>     ^cY
#a16v86n4.htm##
00510000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704026100078002001300339#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#p#72#68#article#107#4#<p><f
ont size="2" face="Verdana">4. Debier C, Pomeroy PP, Baret PV, Mignolet E,    La
rondelle Y. Vitamin E status and the dynamics of its transfer between mother    
and pup during lactation in grey seals (Halichoerus grypus). Can J Zool. 2002;80
:727-37.    ^cY#a16v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#73#69#article#107#</font></p>     ^cY
#a16v86n4.htm##
00430000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704018100078002001300259#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#p#74#70#article#107#5#<p><f
ont size="2" face="Verdana">5. Kelly FJ, Rodgers W, Handel J, Smith S, Hall    M
A. Time course of vitamin E repletion in the premature infant. Br J Nutr. 1990;6
3:631-8.    ^cY#a16v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#75#71#article#107#</font></p>     ^cY
#a16v86n4.htm##
00484000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023500078002001300313#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#p#76#72#article#107#6#<p><f
ont size="2" face="Verdana">6. Jensen SK, Johannsen AK, Hermansen JE. Quantitati
ve    secretion and maximal secretion capacity of retinol, beta-carotene and alp
ha-tocopherol    into cows' milk. J Dairy Res. 1999;66:511-22.    ^cY#a16v86n4.h
tm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#77#73#article#107#</font></p>     ^cY
#a16v86n4.htm##
00566000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704031700078002001300395#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#p#78#74#article#107#7#<p><f
ont size="2" face="Verdana">7. Ortega RM, L&oacute;pez-Sobaler AM, Mart&iacute;n
ez    RM, Andr&eacute;s P, Quintas ME. Influence of smoking on vitamin E status 
during    the third trimester of pregnancy and on breast-milk tocopherol concent
rations    in Spanish women. Am J Clin Nutr. 1998;68:662&#150;7.    ^cY#a16v86n4
.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#79#75#article#107#</font></p>     ^cY
#a16v86n4.htm##
00475000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704022600078002001300304#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#p#80#76#article#107#8#<p><f
ont size="2" face="Verdana">8. Nierenberg DW, Nann SL. A method for determining 
   concentrations of retinol, tocopherol, and five carotenoids in human plasma  
  and tissue samples. Am J Clin Nutr. 1992;56:417-26.    ^cY#a16v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#81#77#article#107#</font></p>     ^cY
#a16v86n4.htm##
00381000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704013200078002001300210#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#p#82#78#article#107#9#<p><f
ont size="2" face="Verdana">9. Morrissey PA, Sheehy PJ. Optimal nutrition:    vi
tamin E. Proc Nutr Soc. 1999;58:459-68.    ^cY#a16v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#83#79#article#107#</font></p>     ^cY
#a16v86n4.htm##
00527000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704027700079002001300356#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#p#84#80#article#107#10#<p><
font size="2" face="Verdana">10. Ascherio A, Stampfer M, Colditz GA, Rimm    EB,
 Litin L, Willett WC. Correlations of vitamin A in E intakes with the plasma    
concentrations of carotenoids and tocopherols among American men and women.    J
 Nutr. 1992;122:1792-801.    ^cY#a16v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#85#81#article#107#</font></p>     ^cY
#a16v86n4.htm##
00546000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704029600079002001300375#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#p#86#82#article#107#11#<p><
font size="2" face="Verdana">11. Rodrigu&eacute;z GP, Alonso DP, Sintes GS,    M
atos CM, Hernandez AC, Enr&iacute;ques YR, et al. Vitaminas antioxidantes en    
un grupo de embarazadas y reci&eacute;n nacidos durante un a&ntilde;o de estudio
.    Rev Cubana Aliment Nutr. 2002;16:85-94.    ^cY#a16v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002100076002001300097#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#87#83#article#107# </font></p>     ^c
Y#a16v86n4.htm##
00451000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704020100079002001300280#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#p#88#84#article#107#12#<p><
font size="2" face="Verdana">12. Traber MG. Vitamin E. In Present Knowledge    i
n Nutrition. 9th edition. Edited by: Bowman BA, Russell RM. Washington, D.C.:   
 ILSI Press; 2007. p. 211-19.    ^cY#a16v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#89#85#article#107#</font></p>     ^cY
#a16v86n4.htm##
00487000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704023700079002001300316#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#p#90#86#article#107#13#<p><
font size="2" face="Verdana">13. Macias C, Schweigert FJ. Changes in the concent
ration    of carotenoids, vitamin A, alpha-tocopherol and total lipids in human 
milk throughout    early lactation. Ann Nutr Metab. 2001;45:82-5.    ^cY#a16v86n
4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#91#87#article#107#</font></p>     ^cY
#a16v86n4.htm##
00511000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026100079002001300340#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#p#92#88#article#107#14#<p><
font size="2" face="Verdana">14. Schweigert FJ, Bathe K, Chen F, B&uuml;scher   
 U, Dudenhausen JW. Effect of the stage of lactation in humans on carotenoid    
levels in milk, blood plasma and plasma lipoprotein fractions. Eur J Nutr. 2004;
43:39-44.    ^cY#a16v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#93#89#article#107#</font></p>     ^cY
#a16v86n4.htm##
00472000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704022200079002001300301#v86
n4#V:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#p#94#90#article#107#15#<p><
font size="2" face="Verdana">15. de Azeredo VB, Trugo NM. Retinol, carotenoids, 
   and tocopherols in the milk of lactating adolescents and relationships with  
  plasma concentrations. Nutrition. 2008;24:133-9.    ^cY#a16v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#95#91#article#107#</font></p>     ^cY
#a16v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#96#92#article#107#<p>&nbsp;</p>     ^
cY#a16v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#97#93#article#107#<p>&nbsp;</p>     ^
cY#a16v86n4.htm##
00415000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018000076002001300256#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#98#94#article#107#<p><font size="2" f
ace="Verdana"><a name="correspondence"></a><a href="#topo"><img src="/img/revist
as/jped/v86n4/seta.gif" border="0"></a>    <b> Correspond&ecirc;ncia:</b>    ^cY
#a16v86n4.htm##
00268000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704003300076002001300109#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#99#95#article#107#<br>   Roberto Dime
nstein    ^cY#a16v86n4.htm##
00361000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704012500077002001300202#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#100#96#article#107#<BR>   Departament
o de Bioqu&iacute;mica, Centro de Bioci&ecirc;ncias, Universidade    Federal do 
Rio Grande do Norte    ^cY#a16v86n4.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704004600077002001300123#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#101#97#article#107#<BR>   Av. Senador
 Salgado Filho, 3000    ^cY#a16v86n4.htm##
00276000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704004000077002001300117#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#102#98#article#107#<BR>   CEP 59072-9
70 - Natal, RN    ^cY#a16v86n4.htm##
00282000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704004600077002001300123#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#103#99#article#107#<BR>   Tel.: (84) 
3215.3416, ramal 205    ^cY#a16v86n4.htm##
00271000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003400078002001300112#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#104#100#article#107#<BR>   Fax: (84) 
3211.9208    ^cY#a16v86n4.htm##
00328000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704009100078002001300169#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#105#101#article#107#<BR>   E-mail: <A
 href=mailto:robertod@ufrnet.br>robertod@ufrnet.br</A></font></p>     ^cY#a16v86
n4.htm##
00339000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010200078002001300180#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#106#102#article#107#<p><font size="2"
 face="Verdana">Artigo submetido em 23.07.09, aceito em 11.12.09.</font></p>    
 ^cY#a16v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#107#103#article#107#<p>&nbsp;</p>    
 ^cY#a16v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#108#104#article#107#<p>&nbsp;</p>    
 ^cY#a16v86n4.htm##
00390000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704015300078002001300231#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#109#105#article#107#<p><font size="2"
 face="Verdana">N&atilde;o foram declarados conflitos de interesse    associados
 &agrave; publica&ccedil;&atilde;o deste artigo.    ^cY#a16v86n4.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019300078002001300271#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#110#106#article#107#<br>   Apoio fina
nceiro: Conselho Nacional de Desenvolvimento Cient&iacute;fico e Tecnol&oacute;g
ico    (CNPq) edital/Chamada: P&oacute;s-doutorado S&ecirc;nior. Processo 151899
/2008-8.    ^cY#a16v86n4.htm##
00430000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704019300078002001300271#v86n4#V:\Scielo
\serial\jped\v86n4\markup\a16v86n4.htm#S#p#111#107#article#107#<br>   Este traba
lho foi desenvolvido no Departamento de Bioqu&iacute;mica, Centro    de Bioci&ec
irc;ncias, Universidade Federal do Rio Grande do Norte (UFRN), Natal,    RN.</fo
nt></p>     ^cY#a16v86n4.htm##
00533000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100020000930120
06600113030001000179065000900189064000500198031000300203014000700206865000900213
002001300222035001000235801001000245#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
6v86n4.htm#S#c#112#1#article#15#1#^rND^sDebier^nC#^rND^sLarondelle^nY#Vitamins A
 and E: metabolism, roles and transfer to offspring^len#Br J Nutr#20050000#2005#
93#153-74#20100800#a16v86n4.htm#0007-1145#Br J Nutr##
00565000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100014000770100021000910100
01600112012007200128030001000200065000900210064000500219031000400224014000500228
865000900233002001300242035001000255801001000265#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a16v86n4.htm#S#c#113#2#article#15#2#^rND^sAzzi^nA#^rND^sRicciarelli^nR
#^rND^sZingg^nJM#Non-antioxidant molecular functions of alpha-tocopherol (vitami
n E)^len#FEBS Lett#20020000#2002#519#8-10#20100800#a16v86n4.htm#0014-5793#FEBS l
ett##
00757000000000301000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100021000770100021000980100
02100119010002400140012020400164030001500368065000900383064000500392031000500397
014000600402865000900408002001300417035001000430801001500440#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a16v86n4.htm#S#c#114#3#article#15#3#^rND^sRomeu-Nadal^nM#^
rND^sMorera-Pons^nS#^rND^sCastellote^nAI#^rND^sLópez-Sabater^nMC#Determination o
f gamma- and alpha-tocopherols in human milk by a direct high-performance liquid
 chromatographic method with UV-vis detection and comparison with evaporative li
ght scattering detection^len#J Chromatogr A#20060000#2006#1114#132-7#20100800#a1
6v86n4.htm#0021-9673#J Chromatogr A##
00686000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100018000930100
01600111010001800127010002000145012012900165030001100294065000900305064000500314
031000300319014000700322865000900329002001300338035001000351801001100361#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#c#115#4#article#15#4#^rND^sDebi
er^nC#^rND^sPomeroy^nPP#^rND^sBaret^nPV#^rND^sMignolet^nE#^rND^sLarondelle^nY#Vi
tamin E status and the dynamics of its transfer between mother and pup during la
ctation in grey seals (Halichoerus grypus)^len#Can J Zool#20020000#2002#80#727-3
7#20100800#a16v86n4.htm#0008-4301#Can J Zool##
00608000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100016000770100017000930100
01600110010001500126010001500141012006300156030001000219065000900229064000500238
031000300243014000600246865000900252002001300261035001000274801001000284#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#c#116#5#article#15#5#^rND^sKell
y^nFJ#^rND^sRodgers^nW#^rND^sHandel^nJ#^rND^sSmith^nS#^rND^sHall^nMA#Time course
 of vitamin E repletion in the premature infant^len#Br J Nutr#19900000#1990#63#6
31-8#20100800#a16v86n4.htm#0007-1145#Br J Nutr##
00625000000000289000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100020000940100
02000114012012100134030001200255065000900267064000500276031000300281014000700284
865000900291002001300300035001000313801001200323#v86n4#V:\Scielo\serial\jped\v86
n4\markup\a16v86n4.htm#S#c#117#6#article#15#6#^rND^sJensen^nSK#^rND^sJohannsen^n
AK#^rND^sHermansen^nJE#Quantitative secretion and maximal secretion capacity of 
retinol, beta-carotene and alpha-tocopherol into cows' milk^len#J Dairy Res#1999
0000#1999#66#511-22#20100800#a16v86n4.htm#0022-0299#J Dairy Res##
00718000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100017000770100024000940100
02000118010001600138010001800154012014700172030001500319065000900334064000500343
031000300348014000600351865000900357002001300366035001000379801001500389#v86n4#V
:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#c#118#7#article#15#7#^rND^sOrte
ga^nRM#^rND^sLópez-Sobaler^nAM#^rND^sMartí­nez^nRM#^rND^sAndrés^nP#^rND^sQuintas
^nME#Influence of smoking on vitamin E status during the third trimester of preg
nancy and on breast-milk tocopherol concentrations in Spanish women^len#Am J Cli
n Nutr#19980000#1998#68#662-7#20100800#a16v86n4.htm#0002-9165#Am J Clin Nutr##
00601000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100021000770100015000980120
12400113030001500237065000900252064000500261031000300266014000700269865000900276
002001300285035001000298801001500308#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
6v86n4.htm#S#c#119#8#article#15#8#^rND^sNierenberg^nDW#^rND^sNann^nSL#A method f
or determining concentrations of retinol, tocopherol, and five carotenoids in hu
man plasma and tissue samples^len#Am J Clin Nutr#19920000#1992#56#417-26#2010080
0#a16v86n4.htm#0002-9165#Am J Clin Nutr##
00509000000000277000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100020000770100017000970120
03300114030001400147065000900161064000500170031000300175014000700178865000900185
002001300194035001000207801001400217#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
6v86n4.htm#S#c#120#9#article#15#9#^rND^sMorrissey^nPA#^rND^sSheehy^nPJ#Optimal n
utrition: vitamin E^len#Proc Nutr Soc#19990000#1999#58#459-68#20100800#a16v86n4.
htm#0029-6651#Proc Nutr Soc##
00714000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970100
01800115010001500133010001500148010001800163012013400181030000700315065000900322
06400050033103100040033601400090034086500090034900200130035803500100037180100070
0381#v86n4#V:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#c#121#10#article#15
#10#^rND^sAscherio^nA#^rND^sStampfer^nM#^rND^sColditz^nGA#^rND^sRimm^nEB#^rND^sL
itin^nL#^rND^sWillett^nWC#Correlations of vitamin A in E intakes with the plasma
 concentrations of carotenoids and tocopherols among American men and women^len#
J Nutr#19920000#1992#122#1792-801#20100800#a16v86n4.htm#0022-3166#J Nutr##
00690000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100020000790100017000990100
01700116010001600133010002000149010002000169810000600189012009800195030002400293
71000020031706500090031906400050032803100030033301400060033686500090034200200130
0351#v86n4#V:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S#c#122#11#article#15
#11#^rND^sRodriguéz^nGP#^rND^sAlonso^nDP#^rND^sSintes^nGS#^rND^sMatos^nCM#^rND^s
Hernandez^nAC#^rND^sEnrí­ques^nYR#et al#Vitaminas antioxidantes en un grupo de e
mbarazadas y recién nacidos durante un año de estudio^les#Rev Cubana Aliment Nut
r#2#20020000#2002#16#85-94#20100800#a16v86n4.htm##
00484000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790120014000960180
03500110063000200145066001700147062001100164065000900175064000500184014000700189
865000900196002001300205#v86n4#V:\Scielo\serial\jped\v86n4\markup\a16v86n4.htm#S
#c#123#12#article#15#12#^rND^sTraber^nMG#Vitamin E^len#Present Knowledge in Nutr
ition^len#9#Washington^eD.C.#ILSI Press#20070000#2007#211-19#20100800#a16v86n4.h
tm##
00613000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100021000950120
13500116030001500251065000900266064000500275031000300280014000500283865000900288
002001300297035001000310801001500320#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
6v86n4.htm#S#c#124#13#article#15#13#^rND^sMacias^nC#^rND^sSchweigert^nFJ#Changes
 in the concentration of carotenoids, vitamin A, alpha-tocopherol and total lipi
ds in human milk throughout early lactation^len#Ann Nutr Metab#20010000#2001#45#
82-5#20100800#a16v86n4.htm#0250-6807#Ann Nutr Metab##
00651000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100015001000100
01400115010001700129010002200146012012300168030001100291710000200302065000900304
064000500313031000300318014000600321865000900327002001300336#v86n4#V:\Scielo\ser
ial\jped\v86n4\markup\a16v86n4.htm#S#c#125#14#article#15#14#^rND^sSchweigert^nFJ
#^rND^sBathe^nK#^rND^sChen^nF#^rND^sBüscher^nU#^rND^sDudenhausen^nJW#Effect of t
he stage of lactation in humans on carotenoid levels in milk, blood plasma and p
lasma lipoprotein fractions^len#Eur J Nutr#2#20040000#2004#43#39-44#20100800#a16
v86n4.htm##
00593000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100016001000120
12400116030001000240065000900250064000500259031000300264014000600267865000900273
002001300282035001000295801001000305#v86n4#V:\Scielo\serial\jped\v86n4\markup\a1
6v86n4.htm#S#c#126#15#article#15#15#^rND^sde Azeredo^nVB#^rND^sTrugo^nNM#Retinol
, carotenoids, and tocopherols in the milk of lactating adolescents and relation
ships with plasma concentrations^len#Nutrition#20080000#2008#24#133-9#20100800#a
16v86n4.htm#0029-6600#Nutrition##
00275000000000169000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700910009000720920007000810020013000887030
00400101#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#o#1#1#article#1
#20110411#112357#a14v86n4.htm#167##
05415000000000745000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000210011303100030013403200020013706500090013901400110014803500100015901200640
01690120057002330100044002900100030003340100032003640100032003960100032004280700
06900460070011900529070004700648070004900695070003000744070012500774070008200899
08316590098108500100264008500270265008500260267708500240270308500220272708500220
27490831693027710850010044640850027044740850025045010850022045260850021045480850
02204569117000804591072000304599112000904602111001104611114000904622113001104631
060001404642002001304656#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S
#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#14#JPED030#nd#J. Pediatr. (Rio J.)#8
6#4#20100800#^f331^l336#0021-7557#Doença celíaca em familiares de primeiro grau 
de portadores^lpt#Celiac disease in first-degree relatives of patients^len#^rND^
1A01 A02^nMargarida M.^sCastro-Antunes#^rND^1A03^nRoberta^sMagalhães#^rND^1A03^n
Josemar M. M.^sNobre#^rND^1A05 A06^nBruna P.^sDuarte#^rND^1A07^nGiselia A. P.^sS
ilva#Universidade Federal de Pernambuco^iA01^1Centro de Saúde^cRecife^sPE#Instit
uto de Medicina Integral Professor Fernando Figueira^iA02^1Ambulatório de Gastro
enterologia Infantil^cRecife^sPE#Laboratório Marcelo Magalhães^iA03^cRecife^sPE#
IMIP^iA04^1Laboratório de Imunologia^cRecife^sPE#UFPE^iA05^cRecife^sPE^pBrazil#C
onselho Nacional de Desenvolvimento Científico e Tecnológico^iA06^1Programa Inst
itucional de Bolsas de Iniciação Científica#UFPE^iA07^1Centro de Ciências da Saú
de^2Departamento Materno Infantil^cRecife^sPE#^lpt^aOBJETIVO: Determinar a preva
lência da doença celíaca e descrever as alterações histológicas, manifestações c
línicas e condições associadas de um grupo de familiares de primeiro grau de cel
íacos na cidade de Recife (PE), Nordeste do Brasil. MÉTODO: O estudo foi realiza
do em ambulatórios de gastropediatria da cidade de Recife. Foram incluídos no es
tudo 174 familiares de primeiro grau submetidos à pesquisa do anticorpo antitran
sglutaminase IgA. Os familiares com sorologia positiva foram convidados a realiz
ar biópsia do intestino delgado (classificadas segundo Marsh) e avaliação do pes
o, estatura, manifestações clínicas e condições associadas à doença celíaca. For
am utilizados os testes do qui-quadrado e de Fisher para avaliar as diferenças, 
considerando-se significativo o valor de p < 0,05. RESULTADOS: O anticorpo antit
ransglutaminase IgA foi positivo em 20,1% (34/174) dos familiares (IC95% 14,6-26
,5). Não se observou diferença na positividade da sorologia quanto ao grau de pa
rentesco, nem quanto ao sexo. Vinte e dois pacientes submeteram-se a biópsia. Tr
eze apresentaram alterações histológicas grau III de Marsh; sete, grau I; e dois
, grau zero, conferindo uma prevalência presumível de 11,5%. Todos os pacientes,
 exceto um, eram sintomáticos; o único paciente sem sintomas tinha baixa estatur
a. CONCLUSÃO: A prevalência de doença celíaca nesse grupo de familiares foi elev
ada. Todos os novos casos identificados tinham sintomas ou condições associadas.
 Nesse grupo, houve uma frequência elevada de indivíduos com sorologia positiva,
 sintomatologia sugestiva de doença celíaca e sem evidência de atrofia vilositár
ia na mucosa intestinal.#^ddecs^i1#^tm^lpt^kDoença celíaca^i1#^tm^lpt^kepidemiol
ogia^i1#^tm^lpt^kdiagnóstico^i1#^tm^lpt^ksorologia^i1#^tm^lpt^kpatologia^i1#^len
^aOBJECTIVE: To determine the prevalence of celiac disease and to describe the h
istological alterations, clinical manifestations, and conditions associated with
 a group of first-degree relatives of celiac disease patients in the municipalit
y of Recife, Northeast Brazil. METHOD: The study was conducted in outpatient cli
nics of pediatric gastroenterology located in Recife. We included in the study 1
74 first-degree relatives who were screened for the anti-transglutaminase IgA an
tibody. Those relatives who had positive serological tests were invited to under
go a small intestine biopsy (classified according to Marsh). They were also eval
uated regarding weight, height, clinical symptoms and conditions associated with
 celiac disease. The chi-square test and Fisher's exact test were used to assess
 the differences with a significance level of p < 0.05. RESULTS: The anti-transg
lutaminase IgA antibody was positive for 20.1% (34/174) of the relatives (95%CI 
14.6-26.5). There was no difference in terms of positive serological tests regar
ding either degree of kinship or sex. Twenty-two patients underwent biopsy. Thir
teen had histological alterations classified as Marsh stage 3; seven had stage 1
; and two had stage zero, with a probable prevalence of 11.5%. All patients, exc
ept for one, had symptoms; the only patient with no symptoms was short. CONCLUSI
ON: Celiac disease prevalence in this group of relatives was high. All new cases
 identified were symptomatic or had associated conditions. In this group, there 
was a high frequency of individuals with positive serological tests, symptoms su
ggestive of celiac disease, and no evidence of villous atrophy in the intestinal
 mucosa.#^ddecs^i2#^tm^len^kCeliac disease^i2#^tm^len^kepidemiology^i2#^tm^len^k
diagnosis^i2#^tm^len^kserology^i2#^tm^len^kpathology^i2#vancouv#26#20100309#09.0
3.2010#20100505#05.05.2010#475120/2006-1#a14v86n4.htm##
05549000000000745000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700710003000720400003000750010006000780420
00200084120000400086038000500090038000400095121000300099049000800102158000300110
03000210011303100030013403200020013706500090013901400110014803500100015901200710
01690120064002400100044003040100030003480100032003780100032004100100032004420700
06900474070011900543070004700662070004900709070003000758070012500788070008200913
08316900099508500100268508500270269508500260272208500240274808500220277208500220
27940831724028160850010045400850027045500850025045770850022046020850021046240850
02204645117000804667072000304675112000904678111001104687114000904698113001104707
060007204718002001304790#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S
#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#14#JPED030#nd#J. Pediatr. (Rio J.)#8
6#4#20100800#^f331^l336#0021-7557#<b>Doença celíaca em familiares de primeiro gr
au de portadores</b>^lpt#<b>Celiac disease in first-degree relatives of patients
</b>^len#^rND^1A01 A02^nMargarida M.^sCastro-Antunes#^rND^1A03^nRoberta^sMagalhã
es#^rND^1A03^nJosemar M. M.^sNobre#^rND^1A05 A06^nBruna P.^sDuarte#^rND^1A07^nGi
selia A. P.^sSilva#Universidade Federal de Pernambuco^iA01^1Centro de Saúde^cRec
ife^sPE#Instituto de Medicina Integral Professor Fernando Figueira^iA02^1Ambulat
ório de Gastroenterologia Infantil^cRecife^sPE#Laboratório Marcelo Magalhães^iA0
3^cRecife^sPE#IMIP^iA04^1Laboratório de Imunologia^cRecife^sPE#UFPE^iA05^cRecife
^sPE^pBrazil#Conselho Nacional de Desenvolvimento Científico e Tecnológico^iA06^
1Programa Institucional de Bolsas de Iniciação Científica#UFPE^iA07^1Centro de C
iências da Saúde^2Departamento Materno Infantil^cRecife^sPE#^lpt^a<b>OBJETIVO: <
/b>Determinar a prevalência da doença celíaca e descrever as alterações histológ
icas, manifestações clínicas e condições associadas de um grupo de familiares de
 primeiro grau de celíacos na cidade de Recife (PE), Nordeste do Brasil. <b>MÉTO
DO: </b>O estudo foi realizado em ambulatórios de gastropediatria da cidade de R
ecife. Foram incluídos no estudo 174 familiares de primeiro grau submetidos à pe
squisa do anticorpo antitransglutaminase IgA. Os familiares com sorologia positi
va foram convidados a realizar biópsia do intestino delgado (classificadas segun
do Marsh) e avaliação do peso, estatura, manifestações clínicas e condições asso
ciadas à doença celíaca. Foram utilizados os testes do qui-quadrado e de Fisher 
para avaliar as diferenças, considerando-se significativo o valor de p &lt; 0,05
. <b>RESULTADOS: </b>O anticorpo antitransglutaminase IgA foi positivo em 20,1% 
(34/174) dos familiares (IC95% 14,6-26,5). Não se observou diferença na positivi
dade da sorologia quanto ao grau de parentesco, nem quanto ao sexo. Vinte e dois
 pacientes submeteram-se a biópsia. Treze apresentaram alterações histológicas g
rau III de Marsh; sete, grau I; e dois, grau zero, conferindo uma prevalência pr
esumível de 11,5%. Todos os pacientes, exceto um, eram sintomáticos; o único pac
iente sem sintomas tinha baixa estatura. <b>CONCLUSÃO: </b>A prevalência de doen
ça celíaca nesse grupo de familiares foi elevada. Todos os novos casos identific
ados tinham sintomas ou condições associadas. Nesse grupo, houve uma frequência 
elevada de indivíduos com sorologia positiva, sintomatologia sugestiva de doença
 celíaca e sem evidência de atrofia vilositária na mucosa intestinal.#^ddecs^i1#
^tm^lpt^kDoença celíaca^i1#^tm^lpt^kepidemiologia^i1#^tm^lpt^kdiagnóstico^i1#^tm
^lpt^ksorologia^i1#^tm^lpt^kpatologia^i1#^len^a<b>OBJECTIVE: </b>To determine th
e prevalence of celiac disease and to describe the histological alterations, cli
nical manifestations, and conditions associated with a group of first-degree rel
atives of celiac disease patients in the municipality of Recife, Northeast Brazi
l. <b>METHOD: </b>The study was conducted in outpatient clinics of pediatric gas
troenterology located in Recife. We included in the study 174 first-degree relat
ives who were screened for the anti-transglutaminase IgA antibody. Those relativ
es who had positive serological tests were invited to undergo a small intestine 
biopsy (classified according to Marsh). They were also evaluated regarding weigh
t, height, clinical symptoms and conditions associated with celiac disease. The 
chi-square test and Fisher's exact test were used to assess the differences with
 a significance level of p &lt; 0.05. <b>RESULTS: </b>The anti-transglutaminase 
IgA antibody was positive for 20.1% (34/174) of the relatives (95%CI 14.6-26.5).
 There was no difference in terms of positive serological tests regarding either
 degree of kinship or sex. Twenty-two patients underwent biopsy. Thirteen had hi
stological alterations classified as Marsh stage 3; seven had stage 1; and two h
ad stage zero, with a probable prevalence of 11.5%. All patients, except for one
, had symptoms; the only patient with no symptoms was short. <b>CONCLUSION: </b>
Celiac disease prevalence in this group of relatives was high. All new cases ide
ntified were symptomatic or had associated conditions. In this group, there was 
a high frequency of individuals with positive serological tests, symptoms sugges
tive of celiac disease, and no evidence of villous atrophy in the intestinal muc
osa.#^ddecs^i2#^tm^len^kCeliac disease^i2#^tm^len^kepidemiology^i2#^tm^len^kdiag
nosis^i2#^tm^len^kserology^i2#^tm^len^kpathology^i2#vancouv#26#20100309#09.03.20
10#20100505#05.05.2010#<span style='font-size:10.0pt;font-family:Verdana'>475120
/2006-1</span>#a14v86n4.htm##
05604000000000769000450000400060000070200480000670500020005470600020005670000020
00587010002000607090008000627080002000700640018000720710003000900400003000930010
00600096042000200102120000400104038000500108038000400113121000300117049000800120
15800030012803000210013103100030015203200020015506500090015701400110016603500100
01770120064001870120057002510100043003080100030003510100031003810100031004120100
03100443070007100474070012100545070004900666070005100715070003200766070012700798
07000840092508316860100908500100269508500270270508500260273208500240275808500220
27820850022028040831714028260850010045400850027045500850025045770850022046020850
02104624085002204645117000804667072000304675112000904678111001104687114000904698
113001104707060001404718002001304732008008904745#v86n4#V:\SciELO\serial\jped\v86
n4\markup\a14v86n4.htm#S#l#4#1#article#1#^mjul./ago.^a2010#oa#pt#br1.1#1#4.0#ilu
s#tab#14#JPED030#nd#J. Pediatr. (Rio J.)#86#4#20100800#^f331^l336#0021-7557#Doen
ça celíaca em familiares de primeiro grau de portadores^lpt#Celiac disease in fi
rst-degree relatives of patients^len#^rND^1A01 A02^nMargarida M^sCastro-Antunes#
^rND^1A03^nRoberta^sMagalhães#^rND^1A03^nJosemar M. M^sNobre#^rND^1A05 A06^nBrun
a P^sDuarte#^rND^1A07^nGiselia A. P^sSilva#^iA01^1Universidade Federal de Pernam
buco^2Centro de Saúde^cRecife^sPE#^iA02^1Instituto de Medicina Integral Professo
r Fernando Figueira^2Ambulatório de Gastroenterologia Infantil^cRecife^sPE#^iA03
^1Laboratório Marcelo Magalhães^cRecife^sPE#^iA04^1IMIP^2Laboratório de Imunolog
ia^cRecife^sPE#^iA05^1UFPE^cRecife^sPE^pBrazil#^iA06^1Conselho Nacional de Desen
volvimento Científico e Tecnológico^2Programa Institucional de Bolsas de Iniciaç
ão Científica#^iA07^1UFPE^2Centro de Ciências da Saúde^3Departamento Materno Inf
antil^cRecife^sPE#^lpt^aOBJETIVO: Determinar a prevalência da doença celíaca e d
escrever as alterações histológicas, manifestações clínicas e condições associad
as de um grupo de familiares de primeiro grau de celíacos na cidade de Recife (P
E), Nordeste do Brasil. MÉTODO: O estudo foi realizado em ambulatórios de gastro
pediatria da cidade de Recife. Foram incluídos no estudo 174 familiares de prime
iro grau submetidos à pesquisa do anticorpo antitransglutaminase IgA. Os familia
res com sorologia positiva foram convidados a realizar biópsia do intestino delg
ado (classificadas segundo Marsh) e avaliação do peso, estatura, manifestações c
línicas e condições associadas à doença celíaca. Foram utilizados os testes do q
ui-quadrado e de Fisher para avaliar as diferenças, considerando-se significativ
o o valor de p < 0,05. RESULTADOS: O anticorpo antitransglutaminase IgA foi posi
tivo em 20,1 por cento (34/174) dos familiares (IC95 por cento 14,6-26,5). Não s
e observou diferença na positividade da sorologia quanto ao grau de parentesco, 
nem quanto ao sexo. Vinte e dois pacientes submeteram-se a biópsia. Treze aprese
ntaram alterações histológicas grau III de Marsh; sete, grau I; e dois, grau zer
o, conferindo uma prevalência presumível de 11,5 por cento. Todos os pacientes, 
exceto um, eram sintomáticos; o único paciente sem sintomas tinha baixa estatura
. CONCLUSÃO: A prevalência de doença celíaca nesse grupo de familiares foi eleva
da. Todos os novos casos identificados tinham sintomas ou condições associadas. 
Nesse grupo, houve uma frequência elevada de indivíduos com sorologia positiva, 
sintomatologia sugestiva de doença celíaca e sem evidência de atrofia vilositári
a na mucosa intestinal.#^ddecs^i1#^tm^lpt^kDoença celíaca^i1#^tm^lpt^kepidemiolo
gia^i1#^tm^lpt^kdiagnóstico^i1#^tm^lpt^ksorologia^i1#^tm^lpt^kpatologia^i1#^len^
aOBJECTIVE: To determine the prevalence of celiac disease and to describe the hi
stological alterations, clinical manifestations, and conditions associated with 
a group of first-degree relatives of celiac disease patients in the municipality
 of Recife, Northeast Brazil. METHOD: The study was conducted in outpatient clin
ics of pediatric gastroenterology located in Recife. We included in the study 17
4 first-degree relatives who were screened for the anti-transglutaminase IgA ant
ibody. Those relatives who had positive serological tests were invited to underg
o a small intestine biopsy (classified according to Marsh). They were also evalu
ated regarding weight, height, clinical symptoms and conditions associated with 
celiac disease. The chi-square test and Fisher's exact test were used to assess 
the differences with a significance level of p < 0.05. RESULTS: The anti-transgl
utaminase IgA antibody was positive for 20.1 percent (34/174) of the relatives (
95 percentCI 14.6-26.5). There was no difference in terms of positive serologica
l tests regarding either degree of kinship or sex. Twenty-two patients underwent
 biopsy. Thirteen had histological alterations classified as Marsh stage 3; seve
n had stage 1; and two had stage zero, with a probable prevalence of 11.5 percen
t. All patients, except for one, had symptoms; the only patient with no symptoms
 was short. CONCLUSION: Celiac disease prevalence in this group of relatives was
 high. All new cases identified were symptomatic or had associated conditions. I
n this group, there was a high frequency of individuals with positive serologica
l tests, symptoms suggestive of celiac disease, and no evidence of villous atrop
hy in the intestinal mucosa.#^ddecs^i2#^tm^len^kCeliac disease^i2#^tm^len^kepide
miology^i2#^tm^len^kdiagnosis^i2#^tm^len^kserology^i2#^tm^len^kpathology^i2#vanc
ouv#26#20100309#09.03.2010#20100505#05.05.2010#475120/2006-1#a14v86n4.htm#Intern
et^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0021-755720100004000
14##
00323000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704009000074002001300164#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#5#1#article#137#<p align="right"><fon
t size="2" face="Verdana"><b>ARTIGO ORIGINAL</b></font> </p>     ^cY#a14v86n4.ht
m##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#6#2#article#137#<p>&nbsp;</p>     ^cY
#a14v86n4.htm##
00369000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704013600074002001300210#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#7#3#article#137#<p><font size="4" fac
e="Verdana"><b>Doen&ccedil;a cel&iacute;aca em familiares    de primeiro grau de
 portadores</b></font></p>     ^cY#a14v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#8#4#article#137#<p>&nbsp;</p>     ^cY
#a14v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000020
0058701000200060709000800062708000400070704002200074002001300096#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#9#5#article#137#<p>&nbsp;</p>     ^cY
#a14v86n4.htm##
00476000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704024200075002001300317#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#10#6#article#137#<p><font size="2" fa
ce="Verdana"><b>Margarida M. Castro-Antunes<sup>I</sup>; Roberta    Magalh&atild
e;es<sup>II</sup>; Josemar M. M. Nobre<sup>III</sup>; Bruna P. Duarte<sup>IV</su
p>;    Giselia A. P. Silva<sup>V</sup></b></font></p>     ^cY#a14v86n4.htm##
00590000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704035600075002001300431#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#11#7#article#137#<p><font size="2" fa
ce="Verdana"><sup>I</sup>P&oacute;s-Gradua&ccedil;&atilde;o,    Sa&uacute;de da 
Crian&ccedil;a e do Adolescente, Centro de Sa&uacute;de, Universidade    Federal
 de Pernambuco (UFPE), Recife, PE, Ambulat&oacute;rio de Gastroenterologia    In
fantil, Instituto de Medicina Integral Professor Fernando Figueira (IMIP),    Re
cife, PE    ^cY#a14v86n4.htm##
00317000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704008300075002001300158#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#12#8#article#137#<br>   <sup>II</sup>
Laborat&oacute;rio Marcelo Magalh&atilde;es, Recife, PE    ^cY#a14v86n4.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000200061709000800063708000400071704007900075002001300154#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#13#9#article#137#<br>   <sup>III</sup
>Laborat&oacute;rio de Imunologia, IMIP, Recife, PE    ^cY#a14v86n4.htm##
00505000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704027000076002001300346#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#14#10#article#137#<br>   <sup>IV</sup
>Acad&ecirc;mica, Curso M&eacute;dico, UFPE, Recife, PE, Brazil,    Programa Ins
titucional de Bolsas de Inicia&ccedil;&atilde;o Cient&iacute;fica    (PIBIC), Co
nselho Nacional de Desenvolvimento Cient&iacute;fico e Tecnol&oacute;gico    (CN
Pq)    ^cY#a14v86n4.htm##
00496000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704026100076002001300337#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#15#11#article#137#<br>   <sup>V</sup>
P&oacute;s-Gradua&ccedil;&atilde;o, Sa&uacute;de da Crian&ccedil;a    e do Adole
scente, Centro de Sa&uacute;de, UFPE, Recife, PE, Departamento Materno    Infant
il, Centro de Ci&ecirc;ncias da Sa&uacute;de, UFPE, Recife, PE</font></p>     ^c
Y#a14v86n4.htm##
00368000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704013300076002001300209#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#16#12#article#137#<p><font size="2" f
ace="Verdana"><a name="topo" id="topo"></a><a href="#correspondence">Correspond&
ecirc;ncia</a></font></p>     ^cY#a14v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#17#13#article#137#<p>&nbsp;</p>     ^
cY#a14v86n4.htm##
00279000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704004400076002001300120#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#18#14#article#137#<p>&nbsp;</p> <hr s
ize="1" noshade>     ^cY#a14v86n4.htm##
00301000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704006600076002001300142#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#19#15#article#137#<p><font size="2" f
ace="Verdana"><b>RESUMO</b></font></p>     ^cY#a14v86n4.htm##
00619000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704038400076002001300460#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#20#16#article#137#<p><font size="2" f
ace="Verdana"> <b>OBJETIVO: </b> Determinar a preval&ecirc;ncia    da doen&ccedi
l;a cel&iacute;aca e descrever as altera&ccedil;&otilde;es histol&oacute;gicas, 
   manifesta&ccedil;&otilde;es cl&iacute;nicas e condi&ccedil;&otilde;es associa
das    de um grupo de familiares de primeiro grau de cel&iacute;acos na cidade d
e Recife    (PE), Nordeste do Brasil.    ^cY#a14v86n4.htm##
00952000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704071700076002001300793#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#21#17#article#137#<br>   <b>M&Eacute;
TODO: </b> O estudo foi realizado em ambulat&oacute;rios de gastropediatria    d
a cidade de Recife. Foram inclu&iacute;dos no estudo 174 familiares de primeiro 
   grau submetidos &agrave; pesquisa do anticorpo antitransglutaminase IgA. Os  
  familiares com sorologia positiva foram convidados a realizar bi&oacute;psia  
  do intestino delgado (classificadas segundo Marsh) e avalia&ccedil;&atilde;o  
  do peso, estatura, manifesta&ccedil;&otilde;es cl&iacute;nicas e condi&ccedil;
&otilde;es    associadas &agrave; doen&ccedil;a cel&iacute;aca. Foram utilizados
 os testes    do qui-quadrado e de Fisher para avaliar as diferen&ccedil;as, con
siderando-se    significativo o valor de p < 0,05.    ^cY#a14v86n4.htm##
00858000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704062300076002001300699#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#22#18#article#137#<br>   <b>RESULTADO
S: </b>O anticorpo antitransglutaminase IgA foi positivo em 20,1%    (34/174) do
s familiares (IC95% 14,6-26,5). N&atilde;o se observou diferen&ccedil;a    na po
sitividade da sorologia quanto ao grau de parentesco, nem quanto ao sexo.    Vin
te e dois pacientes submeteram-se a bi&oacute;psia. Treze apresentaram altera&cc
edil;&otilde;es    histol&oacute;gicas grau III de Marsh; sete, grau I; e dois, 
grau zero, conferindo    uma preval&ecirc;ncia presum&iacute;vel de 11,5%. Todos
 os pacientes, exceto    um, eram sintom&aacute;ticos; o &uacute;nico paciente s
em sintomas tinha baixa    estatura.    ^cY#a14v86n4.htm##
00707000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047200076002001300548#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#23#19#article#137#<br>   <b>CONCLUS&A
tilde;O: </b> A preval&ecirc;ncia de doen&ccedil;a cel&iacute;aca    nesse grupo
 de familiares foi elevada. Todos os novos casos identificados tinham    sintoma
s ou condi&ccedil;&otilde;es associadas. Nesse grupo, houve uma frequ&ecirc;ncia
    elevada de indiv&iacute;duos com sorologia positiva, sintomatologia sugestiv
a    de doen&ccedil;a cel&iacute;aca e sem evid&ecirc;ncia de atrofia vilosit&aa
cute;ria    na mucosa intestinal.</font></p>     ^cY#a14v86n4.htm##
00423000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704018800076002001300264#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#24#20#article#137#<p><font size="2" f
ace="Verdana"><b>Palavras-chave: </b> Doen&ccedil;a cel&iacute;aca,    epidemiol
ogia, diagn&oacute;stico, sorologia, patologia.</font></p> <hr size="1" noshade>
     ^cY#a14v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#25#21#article#137#<p>&nbsp;</p>     ^
cY#a14v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#26#22#article#137#<p>&nbsp;</p>     ^
cY#a14v86n4.htm##
00319000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008400076002001300160#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#27#23#article#137#<p><font size="3" f
ace="Verdana"><b>Introdu&ccedil;&atilde;o</b></font></p>     ^cY#a14v86n4.htm##
00994000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075900076002001300835#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#28#24#article#137#<p><font face="Verd
ana" size="2">A doen&ccedil;a cel&iacute;aca (DC) &eacute;    determinada por al
tera&ccedil;&otilde;es inflamat&oacute;rias e autoimunes desencadeadas    pelo g
l&uacute;ten em indiv&iacute;duos geneticamente suscept&iacute;veis<SUP>1</SUP>.
    Ela acomete entre 0,5 e 1% da popula&ccedil;&atilde;o mundial, e o seu trata
mento    &eacute; a dieta de isen&ccedil;&atilde;o de gl&uacute;ten por toda a v
ida.    No Brasil, embora inicialmente tida como rara, os novos estudos sorol&oa
cute;gicos    evidenciaram que a DC est&aacute; presente em 0,15 a 1,75 % da pop
ula&ccedil;&atilde;o    geral<SUP>2-5</SUP>. Essa frequ&ecirc;ncia &eacute; seme
lhante &agrave; encontrada    na maioria dos pa&iacute;ses europeus<SUP>6</SUP>.
</font></p>     ^cY#a14v86n4.htm##
00819000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704058400076002001300660#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#29#25#article#137#<p><font face="Verd
ana" size="2">Os familiares de primeiro grau de pacientes cel&iacute;acos    com
partilham fatores de risco gen&eacute;ticos e ambientais para DC, portanto,    s
&atilde;o os indiv&iacute;duos de maior risco para desenvolver essa doen&ccedil;
a<SUP>7</SUP>.    Neles, a frequ&ecirc;ncia de DC &eacute; de 10 a 20 vezes maio
r que a da popula&ccedil;&atilde;o    geral. Por esse motivo, &eacute; consenso 
que, nesses indiv&iacute;duos, se    deva realizar busca ativa por meio de sorol
ogia, mesmo nos que se dizem assintom&aacute;ticos<SUP>8,9</SUP>.</font></p>    
 ^cY#a14v86n4.htm##
01526000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704129100076002001301367#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#30#26#article#137#<p><font face="Verd
ana" size="2">Segundo o crit&eacute;rio de 1990, da Sociedade    Europeia de Gas
troenterologia e Nutri&ccedil;&atilde;o (European Society for    Pediatric Gastr
oenterology, Hepatology and Nutrition, ESPGHAN), o diagn&oacute;stico    da DC s
e baseia na presen&ccedil;a de: atrofia vilosit&aacute;ria em bi&oacute;psia    
de intestino delgado (Marsh III), cl&iacute;nica e sorologia durante o consumo  
  de gl&uacute;ten e normaliza&ccedil;&atilde;o desses par&acirc;metros ap&oacut
e;s    a retirada dessa prote&iacute;na da dieta<SUP>10</SUP>. Contudo, utilizan
do-se    esses par&acirc;metros, s&atilde;o frequentes as situa&ccedil;&otilde;e
s de    indefini&ccedil;&atilde;o diagn&oacute;stica. Em 2005, a Sociedade Norte
-Americana    de Gastroenterologia e Nutri&ccedil;&atilde;o Pedi&aacute;trica (N
orth American    Society for Pediatric Gastroenterology, Hepatology and Nutritio
n, NASPGHAN)    publicou uma orienta&ccedil;&atilde;o diagn&oacute;stica revisan
do o crit&eacute;rio    da ESPGHAN e abordando as situa&ccedil;&otilde;es especi
ais de diagn&oacute;stico<SUP>8</SUP>.    Essa orienta&ccedil;&atilde;o recomend
a realizar sorologia em indiv&iacute;duos    de grupos de risco, mesmo que assin
tom&aacute;ticos, ap&oacute;s os 3 anos de    idade.</font></p>     ^cY#a14v86n4
.htm##
01010000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704077500076002001300851#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#31#27#article#137#<p><font face="Verd
ana" size="2">Em muitos dos familiares com sorologia positiva    para DC, n&atil
de;o se evidencia atrofia vilosit&aacute;ria na bi&oacute;psia    do intestino d
elgado. Muitos deles, al&eacute;m disso, t&ecirc;m sintomas inespec&iacute;ficos
    ou s&atilde;o assintom&aacute;ticos<SUP>11</SUP>. Embora, atualmente, altera
&ccedil;&otilde;es    inflamat&oacute;rias m&iacute;nimas (Grau I de Marsh) aind
a n&atilde;o sejam    suficientes para o diagn&oacute;stico de DC, alguns autore
s sugerem que os pacientes    em que foram evidenciadas essas altera&ccedil;&oti
lde;es, se tiverem sorologia    positiva e sintomas, deveriam ser submetidos a u
m teste com dieta de isen&ccedil;&atilde;o    de gl&uacute;ten e acompanhamento<
SUP>12,13</SUP>.</font></p>     ^cY#a14v86n4.htm##
00980000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704074500076002001300821#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#32#28#article#137#<p><font face="Verd
ana" size="2">Outro aspecto do diagn&oacute;stico &eacute;    que, no Brasil, co
mo em outros pa&iacute;ses em desenvolvimento, as enteroinfec&ccedil;&otilde;es 
   e a desnutri&ccedil;&atilde;o cr&ocirc;nica s&atilde;o muito frequentes e pod
em    determinar altera&ccedil;&otilde;es na mucosa intestinal que se confundem 
com    as da enteropatia cel&iacute;aca<SUP>14,15</SUP>. A popula&ccedil;&atilde
;o    brasileira, pela sua miscigena&ccedil;&atilde;o, tem caracter&iacute;stica
s    gen&eacute;ticas diferentes da europeia, onde a maioria dos estudos foi rea
lizada,    e, portanto, pode tamb&eacute;m ter formas de apresenta&ccedil;&atild
e;o cl&iacute;nica    e histol&oacute;gica caracter&iacute;sticas.</font></p>   
  ^cY#a14v86n4.htm##
00643000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704040800076002001300484#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#33#29#article#137#<p><font face="Verd
ana" size="2">Baseado nesses pressupostos, o objetivo desse    estudo foi determ
inar a preval&ecirc;ncia da DC e descrever as altera&ccedil;&otilde;es    histol
&oacute;gicas, manifesta&ccedil;&otilde;es cl&iacute;nicas e condi&ccedil;&otild
e;es    associadas de um grupo de familiares de primeiro grau de cel&iacute;acos
 na    cidade de Recife (PE), Nordeste do Brasil.</font></p>     ^cY#a14v86n4.ht
m##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#34#30#article#137#<p>&nbsp;</p>     ^
cY#a14v86n4.htm##
00308000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007300076002001300149#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#35#31#article#137#<p><font size="3" f
ace="Verdana"><b>M&eacute;todo</b></font></p>     ^cY#a14v86n4.htm##
00355000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704012000076002001300196#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#36#32#article#137#<p><font face="Verd
ana" size="2"><b><i>Popula&ccedil;&atilde;o, local e desenho    do estudo</i></b
></font></p>     ^cY#a14v86n4.htm##
01192000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704095700076002001301033#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#37#33#article#137#<p><font face="Verd
ana" size="2">A pesquisa foi realizada em ambulat&oacute;rios    de gastroentero
logia infantil de Recife, Nordeste do Brasil, no per&iacute;odo    de agosto de 
2007 a mar&ccedil;o de 2009. Pacientes com diagn&oacute;stico pregresso    de DC
 foram identificados como casos-&iacute;ndice, e os seus familiares de    primei
ro grau, maiores do que 18 meses, convidados a participar da pesquisa.    Consid
erou-se caso-&iacute;ndice o indiv&iacute;duo cujo diagn&oacute;stico    havia s
ido firmado conforme o crit&eacute;rio da ESPGHAN de 1990<SUP>10</SUP>,    indep
endentemente do tempo de acompanhamento. Os familiares que aceitaram participar 
   do estudo foram submetidos a coleta de 5 mL de sangue, avalia&ccedil;&atilde;
o    de peso e estatura e respondiam a um question&aacute;rio que investigava si
ntomas.    Os familiares que tiveram sorologia positiva foram convidados a subme
ter-se    a bi&oacute;psia intestinal.</font></p>     ^cY#a14v86n4.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#38#34#article#137#<p><font face="Verd
ana" size="2"><b><i>Sorologia</i></b></font></p>     ^cY#a14v86n4.htm##
00961000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072600076002001300802#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#39#35#article#137#<p><font face="Verd
ana" size="2">Tr&ecirc;s mL de sangue foram acondicionados    em tubo seco para 
realiza&ccedil;&atilde;o da sorologia. O sangue coletado foi    centrifugado, e 
o soro obtido nesse processo, armazenado em tubos Eppendorf    a -18 ºC. A pesqu
isa do anticorpo antitransglutaminase tecidual (tTG) no soro    foi feita pela t
&eacute;cnica de ELISA semi-quantitativa com <i>kit </i>comercialmente    dispon
&iacute;vel (ImmuLisa<SUP sa>TM</SUP>, IMMCO Diagnostics Inc, Buffalo,    NY, EU
A). O exame foi realizado em duplicata em duas leitoras distintas e foi    consi
derado positivo o indiv&iacute;duo cujas duas leituras foram maiores do    que 2
5 UI/mL, conforme estabelecido pelo fabricante.</font></p>     ^cY#a14v86n4.htm#
#
00327000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009200076002001300168#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#40#36#article#137#<p><font face="Verd
ana" size="2"><b><i>Bi&oacute;psia intestinal</i></b></font></p>     ^cY#a14v86n
4.htm##
00625000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704039000076002001300466#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#41#37#article#137#<p><font face="Verd
ana" size="2">Quatro a seis fragmentos de mucosa foram coletados    em bulbo e d
uodeno distal por meio de endoscopia digestiva alta. A avalia&ccedil;&atilde;o  
  histopatol&oacute;gica, realizada ap&oacute;s colora&ccedil;&atilde;o por hema
toxilina-eosina,    utilizou a classifica&ccedil;&atilde;o de Marsh para diagn&o
acute;stico de DC<SUP>16</SUP>.</font></p>     ^cY#a14v86n4.htm##
00340000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010500076002001300181#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#42#38#article#137#<p><font face="Verd
ana" size="2"><b><i>Avalia&ccedil;&atilde;o cl&iacute;nica</i></b></font></p>   
  ^cY#a14v86n4.htm##
01338000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704110300076002001301179#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#43#39#article#137#<p><font face="Verd
ana" size="2">As medidas de peso e estatura foram realizadas    pelo mesmo exami
nador e classificadas em percentis de acordo com a curva do    Centers for Disea
se Control and Prevention (CDC)<SUP>17</SUP>. O &iacute;ndice    de massa corpor
al (IMC) foi calculado utilizando a raz&atilde;o do peso pelo    quadrado da est
atura. Para pesquisa de sintomas e condi&ccedil;&otilde;es associadas,    utiliz
ou-se formul&aacute;rio com respostas fechadas. Os sinais e sintomas foram    ag
rupados em tr&ecirc;s categorias: 1) perda de peso; 2) gastrointestinais &#150; 
   dor abdominal, diarreia, constipa&ccedil;&atilde;o, distens&atilde;o abdomina
l,    flatul&ecirc;ncia, empachamento; 3) n&atilde;o gastrointestinais &#150; af
tas, dor    articular, fadiga, irritabilidade, ins&ocirc;nia, alopecia, dermatit
e. As condi&ccedil;&otilde;es    m&oacute;rbidas avaliadas foram: anemia, osteop
orose, dermatite herpetiforme,    tireoidite, convuls&atilde;o, depress&atilde;o
, doen&ccedil;as reumatol&oacute;gicas,    s&iacute;ndromes gen&eacute;ticas e n
efropatia cr&ocirc;nica.</font></p>     ^cY#a14v86n4.htm##
00335000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704010000076002001300176#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#44#40#article#137#<p><font face="Verd
ana" size="2"><b><i>An&aacute;lise estat&iacute;stica</i></b></font></p>     ^cY
#a14v86n4.htm##
00735000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704050000076002001300576#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#45#41#article#137#<p><font face="Verd
ana" size="2">As frequ&ecirc;ncias est&atilde;o descritas em    porcentagem com 
os seus respectivos intervalos de confian&ccedil;a de 95% (IC95%)    e as idades
 em mediana e percentil (P25-75%). Utilizaram-se os testes do qui-quadrado    e 
de Fisher para testar diferen&ccedil;as entre as frequ&ecirc;ncias e o teste<i> 
   t</i> para testar as diferen&ccedil;as entre as m&eacute;dias. Considerou-se 
   o valor do p &lt; 0,05 como estatisticamente significante.</font></p>     ^cY
#a14v86n4.htm##
00324000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008900076002001300165#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#46#42#article#137#<p><font face="Verd
ana" size="2"><b><i>Aspectos &eacute;ticos</i></b></font></p>     ^cY#a14v86n4.h
tm##
00786000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055100076002001300627#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#47#43#article#137#<p><font face="Verd
ana" size="2">Um Termo de Consentimento Livre e Esclarecido    foi obtido de tod
os os participantes. O estudo foi aprovado pelo Comit&ecirc;    de &Eacute;tica 
em Pesquisa em Seres Humanos do Instituto de Medicina Integral    Fernando Figue
ira (IMIP), Recife (PE), e cumpriu as determina&ccedil;&otilde;es    da Declara&
ccedil;&atilde;o de Helsinque. Os indiv&iacute;duos que tiveram diagn&oacute;sti
co    de DC ou sorologia positiva foram encaminhados para acompanhamento em ambu
lat&oacute;rio    especializado.</font></p>     ^cY#a14v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#48#44#article#137#<p>&nbsp;</p>     ^
cY#a14v86n4.htm##
00305000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007000076002001300146#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#49#45#article#137#<p><font size="3" f
ace="Verdana"><b>Resultados</b></font></p>     ^cY#a14v86n4.htm##
00989000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704075400076002001300830#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#50#46#article#137#<p><font face="Verd
ana" size="2">Foram identificados 199 familiares de 66 casos-&iacute;ndice    de
 DC, e 174 (87,4%) aceitaram participar e foram inclu&iacute;dos no estudo.    T
odas as fam&iacute;lias apresentavam apenas um indiv&iacute;duo com diagn&oacute
;stico    pr&eacute;vio de DC. Os familiares eram 78 homens (44,8%) e 96 mulhere
s (55,2%).    Quanto ao tipo de parentesco com o caso-&iacute;ndice, 49 eram pai
s, 63 m&atilde;es    e 62 irm&atilde;os. A idade dos pais variou entre 23 e 56 a
nos, mediana de 38    anos (P25-75% 33-42 anos), e a dos irm&atilde;os, de 20 me
ses a 27 anos, mediana    de 13 anos (P25-75% 8-17 anos). Observou-se predom&iac
ute;nio do sexo feminino    na popula&ccedil;&atilde;o estudada (p = 0,05).</fon
t></p>     ^cY#a14v86n4.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#51#47#article#137#<p><font face="Verd
ana" size="2"><b><i>Sorologia</i></b></font></p>     ^cY#a14v86n4.htm##
00706000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704047100076002001300547#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#52#48#article#137#<p><font face="Verd
ana" size="2">O tTG foi positivo em 35/174 dos familiares,    conferindo uma sor
opositividade de 20,1% (IC95% 14-26). Os resultados das sorologias,    segundo o
 tipo de parentesco e sexo, est&atilde;o descritos na <a href=/img/revistas/jped
/v86n4/4a14t1.gif>Tabela    1</a>. N&atilde;o se observa diferen&ccedil;a nas fr
equ&ecirc;ncias da soropositividade    da tTG quanto ao parentesco com o caso-&i
acute;ndice, nem quanto ao sexo.</font></p>     ^cY#a14v86n4.htm##
00333000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704009800076002001300174#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#53#49#article#137#<p><font face="Verd
ana" size="2"><b><i>Histologia do intestino delgado</i></b></font></p>     ^cY#a
14v86n4.htm##
00865000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704063000076002001300706#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#54#50#article#137#<p><font face="Verd
ana" size="2">Dos familiares com sorologia positiva, 22/35    (62,8%) aceitaram 
submeter-se &agrave; endoscopia com bi&oacute;psia. Dentre    eles, 20/22 (90,9%
) tiveram bi&oacute;psias alteradas, sendo sete compat&iacute;veis    com o grau
 I de Marsh e 13 com o grau III. Considerando-se como cel&iacute;aco    o pacien
te com bi&oacute;psia alterada e sintomas, observamos uma frequ&ecirc;ncia    pr
esum&iacute;vel de DC de 11,5% (IC95% 7,3-17,4). A <a href=#777f1 >Figura    1</
a> demonstra a sequ&ecirc;ncia e distribui&ccedil;&atilde;o dos resultados    da
s sorologias e bi&oacute;psias.</font></p>     ^cY#a14v86n4.htm##
00316000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704008100076002001300157#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#55#51#article#137#<p><font face="Verd
ana" size="2"><a name=777f1 id=777f1 ></a></font></p>     ^cY#a14v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#56#52#article#137#<p>&nbsp;</p>     ^
cY#a14v86n4.htm##
00313000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007800076002001300154#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#57#53#article#137#<p align="center"><
img src="/img/revistas/jped/v86n4/4a14f1.gif"></p>     ^cY#a14v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#58#54#article#137#<p>&nbsp;</p>     ^
cY#a14v86n4.htm##
00310000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007500076002001300151#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#59#55#article#137#<p><font face="Verd
ana" size="2"><b><i>Sintomas</i></b></font></p>     ^cY#a14v86n4.htm##
00956000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704072100076002001300797#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#60#56#article#137#<p><font face="Verd
ana" size="2">Um dos dois familiares com tTG positiva e bi&oacute;psia    normal
 era assintom&aacute;tico, e o outro apresentava dor e distens&atilde;o    abdom
inal, diarreia, empachamento, flatul&ecirc;ncia, constipa&ccedil;&atilde;o,    d
or articular, fadiga, irritabilidade, alopecia e doen&ccedil;a reumatol&oacute;g
ica    sem diagn&oacute;stico definido. Na <a href=/img/revistas/jped/v86n4/4a14
t2.gif>Tabela    2</a>, est&atilde;o descritos idade, parentesco, resultado da t
TG, classifica&ccedil;&atilde;o    da estatura, IMC, altera&ccedil;&otilde;es hi
stol&oacute;gicas, sintomas e condi&ccedil;&otilde;es    associadas nos 20 famil
iares que tiveram bi&oacute;psia alterada.</font></p>     ^cY#a14v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#61#57#article#137#<p>&nbsp;</p>     ^
cY#a14v86n4.htm##
00311000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007600076002001300152#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#62#58#article#137#<p><font size="3" f
ace="Verdana"><b>Discuss&atilde;o</b></font></p>     ^cY#a14v86n4.htm##
01125000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704089000076002001300966#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#63#59#article#137#<p><font face="Verd
ana" size="2">Neste estudo, observou-se uma soropreval&ecirc;ncia    de 20,1% e 
uma preval&ecirc;ncia de DC estimada em 11,5%, em familiares de pacientes    cel
&iacute;acos. Essa frequ&ecirc;ncia &eacute; elevada e semelhante &agrave;s    d
a Europa e Am&eacute;rica do Norte<SUP>13,18</SUP>. Os dois estudos brasileiros 
   em familiares que temos conhecimento at&eacute; o momento foram realizados no
    centro-sul do Brasil e encontraram a preval&ecirc;ncia m&aacute;xima de 4,8%
.    Ambos utilizaram o anticorpo antiendom&iacute;sio (<i>anti-endomysial antib
ody</i>,    EmA) para triagem inicial<SUP>19,20</SUP>. Acreditamos que a diferen
&ccedil;a    nas soropreval&ecirc;ncias entre estes e o presente estudo tenha si
do acentuada    pelo fato de que o EmA, embora mais espec&iacute;fico, &eacute; 
menos sens&iacute;vel    do que o tTG<SUP>21</SUP>.</font></p>     ^cY#a14v86n4.
htm##
00785000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704055000076002001300626#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#64#60#article#137#<p><font face="Verd
ana" size="2">Optamos pela tTG IgA como teste &uacute;nico    para triagem dos f
amiliares pela sua alta sensibilidade, baixo custo e facilidade    t&eacute;cnic
a. A maior causa de falso-negativo da tTG IgA &eacute; a defici&ecirc;ncia    de
 IgA. Na popula&ccedil;&atilde;o brasileira, a defici&ecirc;ncia de IgA ocorre  
  em cerca de 0,1%, uma das menores relatadas no mundo<SUP>22</SUP>, e mesmo con
siderando    a maior frequ&ecirc;ncia dentre cel&iacute;acos, essa possibilidade
 nesse grupo    &eacute; baixa.</font></p>     ^cY#a14v86n4.htm##
00722000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704048700076002001300563#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#65#61#article#137#<p><font face="Verd
ana" size="2">Uma das maiores limita&ccedil;&otilde;es operacionais    do estudo
 foi a dificuldade de retorno dos familiares provenientes de zonas    afastadas 
da cidade do Recife. Por esse motivo, 13/34 (37%) dos pacientes com    sorologia
 positiva n&atilde;o se submeteram a bi&oacute;psia. &Eacute; prov&aacute;vel   
 que alguns desses pacientes sejam portadores de DC e que a frequ&ecirc;ncia    
desse grupo seja ainda maior do que a observada.</font></p>     ^cY#a14v86n4.htm
##
01442000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704120700076002001301283#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#66#62#article#137#<p><font face="Verd
ana" size="2">Outro dado encontrado no estudo foi que, dentre    os 22 pacientes
 que se submeteram a bi&oacute;psia, sete tiveram altera&ccedil;&otilde;es    m&
iacute;nimas (grau I de Marsh). Nesses casos, podemos levantar a possibilidade  
  de um falso-positivo da sorologia, de a coleta do fragmento n&atilde;o ter sid
o    realizada numa &aacute;rea acometida do intestino delgado ou a DC encontrar
-se    numa fase inicial, em que ainda n&atilde;o h&aacute; atrofia vilosit&aacu
te;ria.    Nessa popula&ccedil;&atilde;o, &eacute; relevante considerar o diagn&
oacute;stico    diferencial com a enteropatia ambiental, end&ecirc;mica nessas r
egi&otilde;es,    e que pode ter apresenta&ccedil;&atilde;o cl&iacute;nica e his
tol&oacute;gica    semelhante &agrave; DC. Dados semelhantes foram encontrados n
a &Iacute;ndia,    Egito e Turquia, pa&iacute;ses onde a popula&ccedil;&atilde;o
 vive em condi&ccedil;&otilde;es    compar&aacute;veis &agrave;s do Brasil<SUP>1
4,23,24</SUP>. Nesse contexto, a    sorologia e o acompanhamento da resposta cl&
iacute;nica &agrave; dieta de isen&ccedil;&atilde;o    de gl&uacute;ten seriam i
mprescind&iacute;veis para o diagn&oacute;stico.</font></p>     ^cY#a14v86n4.htm
##
00931000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704069600076002001300772#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#67#63#article#137#<p><font face="Verd
ana" size="2">Todos os pacientes diagnosticados no estudo,    exceto um, eram si
ntom&aacute;ticos, e o que se dizia assintom&aacute;tico tinha    baixa estatura
. Possivelmente, por serem sintomas de menor intensidade e pouco    espec&iacute
;ficos, n&atilde;o os motivou a procurar diagn&oacute;stico. Embora    muitos es
tudos j&aacute; tenham demonstrado que uma parcela elevada de pacientes    com c
onstipa&ccedil;&atilde;o, dispepsia e s&iacute;ndrome do intestino irrit&aacute;
vel    s&atilde;o portadores de DC n&atilde;o diagnosticada, a suspei&ccedil;&at
ilde;o    diagn&oacute;stica nessas situa&ccedil;&otilde;es ainda &eacute; baixa
<SUP>25,26</SUP>.</font></p>     ^cY#a14v86n4.htm##
00852000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704061700076002001300693#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#68#64#article#137#<p><font face="Verd
ana" size="2">Esses dados refor&ccedil;am a necessidade de    busca ativa com so
rologia nos familiares de pacientes cel&iacute;acos, inclusive    em popula&cced
il;&otilde;es n&atilde;o europeias. Em pa&iacute;ses em desenvolvimento,    a so
rologia e o acompanhamento s&atilde;o fundamentais para diagn&oacute;stico    em
 familiares. Sugerimos ainda que, nos que tiverem bi&oacute;psia inconclusiva   
 e que sejam pouco sintom&aacute;ticos, devem ser considerados testes com dieta 
   de isen&ccedil;&atilde;o de gl&uacute;ten e novas bi&oacute;psias para avalia
&ccedil;&atilde;o.</font></p>     ^cY#a14v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#69#65#article#137#<p>&nbsp;</p>     ^
cY#a14v86n4.htm##
00309000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007400076002001300150#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#70#66#article#137#<p><font size="3" f
ace="Verdana"><b>Agradecimentos</b></font></p>     ^cY#a14v86n4.htm##
00378000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704014300076002001300219#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#71#67#article#137#<p><font face="Verd
ana" size="2">A S&eacute;rgio Santos, pela coleta de sangue,    transporte e pro
cessamento das amostras.</font></p>     ^cY#a14v86n4.htm##
00483000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704024800076002001300324#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#72#68#article#137#<p><font face="Verd
ana" size="2">&Agrave; equipe do Laborat&oacute;rio de Imunopatologia    Keizo A
sami (LIKA), Universidade Federal de Pernambuco (UFPE), pela centrifuga&ccedil;&
atilde;o    e armazenagem das amostras de sangue.</font></p>     ^cY#a14v86n4.ht
m##
00257000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002200076002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#73#69#article#137#<p>&nbsp;</p>     ^
cY#a14v86n4.htm##
00312000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704007700076002001300153#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#74#70#article#137#<p><font size="3" f
ace="Verdana"><b>Refer&ecirc;ncias</b></font></p>     ^cY#a14v86n4.htm##
00400000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704015100078002001300229#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#75#71#article#137#1#<p><f
ont size="2" face="Verdana">1. Kagnoff MF. Celiac disease: pathogenesis of    a 
model immunogenetic disease. J Clin Invest. 2007;117:41-9.    ^cY#a14v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#76#72#article#137#</font></p>     ^cY
#a14v86n4.htm##
00461000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704021200078002001300290#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#77#73#article#137#2#<p><f
ont size="2" face="Verdana">2. Gandolfi L, Pratesi R, Cordoba JC, Tauil PL,    G
asparin M, Catassi C. Prevalence of celiac disease among blood donors in Brazil.
    Am J Gastroenterol. 2000;95:689-92.    ^cY#a14v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#78#74#article#137#</font></p>     ^cY
#a14v86n4.htm##
00484000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704023500078002001300313#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#79#75#article#137#3#<p><f
ont size="2" face="Verdana">3. Crovella S, Brand&atilde;o L, Guimar&atilde;es   
 R, Filho JL, Arraes LC, Ventura A, et al. Speeding up coeliac disease diagnosis
    in the developing countries. Dig Liver Dis. 2007;39:900-2.    ^cY#a14v86n4.h
tm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#80#76#article#137#</font></p>     ^cY
#a14v86n4.htm##
00566000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704031700078002001300395#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#81#77#article#137#4#<p><f
ont size="2" face="Verdana">4. Oliveira RP, Sdepanian VL, Barreto J&Aacute;,    
Cortez AJ, Carvalho FO, Bordin JO, et al. High prevalence of celiac disease    i
n Brazilian blood donor volunteers based on screening by IgA antitissue transglu
taminase    antibody. Eur J Gastroenterol Hepatol. 2007;19:43-9.    ^cY#a14v86n4
.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#82#78#article#137#</font></p>     ^cY
#a14v86n4.htm##
00532000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028300078002001300361#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#83#79#article#137#5#<p><f
ont size="2" face="Verdana">5. Melo SB, Fernandes MI, Peres LC, Troncon LE,    G
alv&atilde;o LC. Prevalence and demografic characteristcs of celiac disease    a
mong blood donors in Ribeir&atilde;o Preto, State of S&atilde;o Paulo, Brasil.  
  Dig Dis Sci. 2006;51:1020-5.    ^cY#a14v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#84#80#article#137#</font></p>     ^cY
#a14v86n4.htm##
00387000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704013800078002001300216#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#85#81#article#137#6#<p><f
ont size="2" face="Verdana">6. Accomando S, Cataldo F. The global village    of 
celiac disease. Dig Liver Dis. 2004;36:492-8.    ^cY#a14v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#86#82#article#137#</font></p>     ^cY
#a14v86n4.htm##
00529000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704028000078002001300358#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#87#83#article#137#7#<p><f
ont size="2" face="Verdana">7. Bonamico M, Ferri M, Mariani P, Nenna R, Thanasi 
   E, Luparia RP, et al. Serologic and genetic markers of celiac disease: a sequ
ential    study in the screening of first degree relatives. J Pediatr Gastroente
rol Nutr.    2006;42:150-4.    ^cY#a14v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#88#84#article#137#</font></p>     ^cY
#a14v86n4.htm##
00599000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704035000078002001300428#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#89#85#article#137#8#<p><f
ont size="2" face="Verdana">8. Hill ID, Dirks MH, Liptak GS, Colletti RB,    Fas
ano A, Guandalini S, et al. Guideline for the diagnosis and treatment of    celi
ac disease in children: recommendations of the North American Society for    Ped
iatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol    Nu
tr. 2005;40:1-19.    ^cY#a14v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#90#86#article#137#</font></p>     ^cY
#a14v86n4.htm##
00619000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000200076704037000078002001300448#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#91#87#article#137#9#<p><f
ont size="2" face="Verdana">9. NICE. National Institute for Health and Clinical 
   Excellence - Clinical guideline 86. Coeliac disease: recognition and assessme
nt    of coeliac disease. May 2009. &#091;online&#093; <a href="http://www.nice.
org.uk/nicemedia/pdf/CG86CostReport.pdf" target="_blank">http://www.nice.org.uk/
nicemedia/pdf/CG86CostReport.pdf</a>.    ^cY#a14v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#92#88#article#137#</font></p>     ^cY
#a14v86n4.htm##
00473000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704022300079002001300302#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#93#89#article#137#10#<p><
font size="2" face="Verdana">10. Revised criteria for diagnosis of coeliac    di
sease. Report of Working Group of European Society of Paediatric Gastroenterolog
y    and Nutrition. Arch Dis Child. 1990;65:909-11.    ^cY#a14v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#94#90#article#137#</font></p>     ^cY
#a14v86n4.htm##
00556000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704030600079002001300385#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#95#91#article#137#11#<p><
font size="2" face="Verdana">11. Esteve M, Rosinach M, Fernandes-Banares F,    F
arr&eacute; C, Salas A, Alsina M, et al. Spectrum of gluten-sensitive enteropath
y    in first-degree relatives of patients with coeliac disease: clinical releva
nce    of lymphocytic enteritis. Gut. 2006;55:1739-45.    ^cY#a14v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#96#92#article#137#</font></p>     ^cY
#a14v86n4.htm##
00462000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704021200079002001300291#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#97#93#article#137#12#<p><
font size="2" face="Verdana">12. Tursi A, Brandimarte G. The symptomatic and    
histologic response to a gluten-free diet in patients with borderline enteropath
y.    J Clin Gastroenterol. 2003;36:6-7.    ^cY#a14v86n4.htm##
00255000000000145000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072704002000076002001300096#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#98#94#article#137#</font></p>     ^cY
#a14v86n4.htm##
00515000000000157000450000400060000070200480000670500020005470600020005670000030
0058701000300061709000800064708000400072888000300076704026500079002001300344#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#99#95#article#137#13#<p><
font size="2" face="Verdana">13. Fasano A, Berti I, Gerarduzzi T, Not T, Collett
i    RB, Drago S, et al. Prevalence of celiac disease in at-risk and not-at-risk
    groups in the United States: a large multicenter study. Arch Intern Med. 200
3;163:286-92.    ^cY#a14v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#100#96#article#137#</font></p>     ^c
Y#a14v86n4.htm##
00457000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704020600080002001300286#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#101#97#article#137#14#<p>
<font size="2" face="Verdana">14. Groover R, Puri AS, Aggarwal N, Sakhuja P.    
Familial prevalence among first-degree relatives of celiac disease in North    I
ndia. Dig Liver Dis. 2007;39:903-7.    ^cY#a14v86n4.htm##
00256000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073704002000077002001300097#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#102#98#article#137#</font></p>     ^c
Y#a14v86n4.htm##
00452000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000300062709000800065708000400073888000300077704020100080002001300281#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#103#99#article#137#15#<p>
<font size="2" face="Verdana">15. Cataldo F, Montalto G. Celiac disease in    th
e developing countries: a new and challenging public health problem. World    J 
Gastroenterol. 2007;13:2153-9.    ^cY#a14v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#104#100#article#137#</font></p>     ^
cY#a14v86n4.htm##
00510000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025800081002001300339#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#105#101#article#137#16#<p
><font size="2" face="Verdana">16. Marsh MN. Gluten, major histocompatibility   
 complex, and the small intestine. A molecular and immunobiologic approach to   
 the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology. 1992;102
:330-54.    ^cY#a14v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#106#102#article#137#</font></p>     ^
cY#a14v86n4.htm##
00620000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704036800081002001300449#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#107#103#article#137#17#<p
><font size="2" face="Verdana">17. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Stra
wn    LM, Flegal KM, Mei Z, et al. 2000 CDC growth charts for the United States:
 methods    and development. National Center for Health Statistics. Vital Health
 Stat. 2002;246:1-190.    <A href=http://www.cdc.gov/growthcharts target="_blank
">http://www.cdc.gov/growthcharts</A>.    ^cY#a14v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#108#104#article#137#</font></p>     ^
cY#a14v86n4.htm##
00515000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026300081002001300344#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#109#105#article#137#18#<p
><font size="2" face="Verdana">18. Dube C, Rostom A, Sy R, Cranney A, Saloojee  
  N, Garritty C, et al. The prevalence of celiac disease in average-risk and at-
risk    Western European populations: a systematic review. Gastroenterology. 200
5;128:S57-67.    ^cY#a14v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#110#106#article#137#</font></p>     ^
cY#a14v86n4.htm##
00508000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025600081002001300337#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#111#107#article#137#19#<p
><font size="2" face="Verdana">19. Kotze LM, Utiyama SR, Nishiara RM, Zeni MP,  
  de Sena MG, Amarante HM. Antiendomysium antibodies in Brazilian patients with 
   celiac disease and their first-degree relatives. Arq Gastroenterol. 2001;38:9
4-103.    ^cY#a14v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#112#108#article#137#</font></p>     ^
cY#a14v86n4.htm##
00509000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704025700081002001300338#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#113#109#article#137#20#<p
><font size="2" face="Verdana">20. Almeida PL, Gandolfi L, Modelli IC, Martins  
  Rde C, Almeida RC, Pratesi R. Prevalence of celiac disease among first degree 
   relatives of Brazilian celiac patients. Arq Gastroenterol. 2008;45:69-72</fon
t></p>     ^cY#a14v86n4.htm##
00531000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027900081002001300360#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#114#110#article#137#21#<p
><font size="2" face="Verdana">21. Biagi F, Pezzimenti D, Campanella J, Vadacca 
   GB, Corraza GR. Endomysial and tissue transglutaminase antibodies in celiac  
  sera: a comparison not influenced by previous serological testing. Scand J Gas
troenterol.    2001;36:955-8.    ^cY#a14v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#115#111#article#137#</font></p>     ^
cY#a14v86n4.htm##
00532000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028000081002001300361#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#116#112#article#137#22#<p
><font size="2" face="Verdana">22. Carneiro-Sampaio MM, Carbonare SB, Rozentraub
    RB, de Araujo MN, Riberiro MA, Porto MH. Frequency of selective IgA deficien
cy    among Brazilian blood donors and healthy pregnant women. Allergol Immunopa
thol    (Madr). 1989;17:213-6.    ^cY#a14v86n4.htm##
00258000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002100078002001300099#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#117#113#article#137# </font></p>     
^cY#a14v86n4.htm##
00537000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028500081002001300366#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#118#114#article#137#23#<p
><font size="2" face="Verdana">23. Bhatnagar S, Gupta SD, Mathur M, Phillips    
AD, Kumar R, Knutton S, et al. Celiac disease with mild to moderate histologic  
  changes is a common cause of cronic diarrhea in Indian children. J Pediat Gast
roenterol    Nutr. 2005;41:204-209.    ^cY#a14v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#119#115#article#137#</font></p>     ^
cY#a14v86n4.htm##
00518000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704026600081002001300347#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#120#116#article#137#24#<p
><font size="2" face="Verdana">24. Abu-Zekry M, Kryszak D, Diab M, Catassi C,   
 Fasano A. Prevalence of celiac disease in Egyptian children disputes the east-w
est    agriculture-dependent spread of the disease. J Pediat Gastroenterol Nutr.
 2008;47:136-40.    ^cY#a14v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#121#117#article#137#</font></p>     ^
cY#a14v86n4.htm##
00524000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704027200081002001300353#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#122#118#article#137#25#<p
><font size="2" face="Verdana">25. Usai P, Manca R, Cuomo R, Lai MA, Boi MF.    
Effect of gluten-free diet and co-morbidity of irritable bowel syndrome-type    
symptoms on health-related quality of life in adult coeliac patients. Dig Liver 
   Dis. 2007;39:824-8.    ^cY#a14v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#123#119#article#137#</font></p>     ^
cY#a14v86n4.htm##
00533000000000157000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074888000300078704028100081002001300362#v86
n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#p#124#120#article#137#26#<p
><font size="2" face="Verdana">26. Giangreco E, D'agate C, Barbera C, Puzzo    L
, Aprile G, Naso P, et al. Prevalence of celiac disease in adult patients with  
  refractory functional dyspepsia: value of routine duodenal biopsy. World J Gas
troenterol.    2008;14:6948-53.    ^cY#a14v86n4.htm##
00257000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002000078002001300098#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#125#121#article#137#</font></p>     ^
cY#a14v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#126#122#article#137#<p>&nbsp;</p>    
 ^cY#a14v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#127#123#article#137#<p>&nbsp;</p>    
 ^cY#a14v86n4.htm##
00417000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704018000078002001300258#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#128#124#article#137#<p><font size="2"
 face="Verdana"><a name="correspondence"></a><a href="#topo"><img src="/img/revi
stas/jped/v86n4/seta.gif" border="0"></a>    <b> Correspond&ecirc;ncia:</b>    ^
cY#a14v86n4.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004100078002001300119#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#129#125#article#137#<br>   Margarida 
M Castro-Antunes    ^cY#a14v86n4.htm##
00291000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704005400078002001300132#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#130#126#article#137#<BR>   Av. Beira 
Rio, 240/2402, Ilha do Retiro    ^cY#a14v86n4.htm##
00278000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704004100078002001300119#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#131#127#article#137#<BR>   CEP 50750-
400 - Recife, PE    ^cY#a14v86n4.htm##
00272000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704003500078002001300113#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#132#128#article#137#<BR>   Tel.: (81)
 3446.8660    ^cY#a14v86n4.htm##
00348000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704011100078002001300189#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#133#129#article#137#<BR>   E-mail: <A
 href=mailto:margarida.mmcastro@gmail.com>margarida.mmcastro@gmail.com</A></font
></p>     ^cY#a14v86n4.htm##
00343000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704010600078002001300184#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#134#130#article#137#<p><font size="2"
 face="Verdana">Artigo submetido em 09.03.2010, aceito em 05.05.2010.</font></p>
     ^cY#a14v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#135#131#article#137#<p>&nbsp;</p>    
 ^cY#a14v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#136#132#article#137#<p>&nbsp;</p>    
 ^cY#a14v86n4.htm##
00391000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704015400078002001300232#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#137#133#article#137#<p><font size="2"
 face="Verdana"> N&atilde;o foram declarados conflitos de interesse    associado
s &agrave; publica&ccedil;&atilde;o deste artigo.    ^cY#a14v86n4.htm##
00394000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704015700078002001300235#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#138#134#article#137#<br>   Apoio fina
nceiro: Conselho Nacional de Desenvolvimento Cient&iacute;fico e Tecnol&oacute;g
ico    (CNPq) (processo: 475120/2006-1).</font></p>     ^cY#a14v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#139#135#article#137#<p>&nbsp;</p>    
 ^cY#a14v86n4.htm##
00259000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704002200078002001300100#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#140#136#article#137#<p>&nbsp;</p>    
 ^cY#a14v86n4.htm##
00595000000000145000450000400060000070200480000670500020005470600020005670000040
0058701000400062709000800066708000400074704035800078002001300436#v86n4#V:\SciELO
\serial\jped\v86n4\markup\a14v86n4.htm#S#p#141#137#article#137#<p><font face="Ve
rdana" size="2">Este artigo sofreu altera&ccedil;&otilde;es por    solicita&cced
il;&atilde;o do editor em 2011 conforme ERRATA publicada no Volume    87 N&uacut
e;mero 1 do peri&oacute;dico. (<a href="http://www.scielo.br/pdf/jped/v87n1/v87n
01a15.pdf" target="_blank">http://www.scielo.br/pdf/jped/v87n1/v87n01a15.pdf</a>
)</font></p>     ^cY#a14v86n4.htm##
00510000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770120066000950300
01400161065000900175064000500184031000400189014000500193865000900198002001300207
035001000220801001400230#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S
#c#142#1#article#26#1#^rND^sKagnoff^nMF#Celiac disease: pathogenesis of a model 
immunogenetic disease^len#J Clin Invest#20070000#2007#117#41-9#20100800#a14v86n4
.htm#0021-9738#J Clin Invest##
00663000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100017000950100
01800112010001600130010001800146010001700164012006200181030001900243065000900262
06400050027103100030027601400070027986500090028600200130029503500100030880100190
0318#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#c#143#2#article#26#
2#^rND^sGandolfi^nL#^rND^sPratesi^nR#^rND^sCordoba^nJC#^rND^sTauil^nPL#^rND^sGas
parin^nM#^rND^sCatassi^nC#Prevalence of celiac disease among blood donors in Bra
zil^len#Am J Gastroenterol#20000000#2000#95#689-92#20100800#a14v86n4.htm#0002-92
70#Am J Gastroenterol##
00644000000000325000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100017000950100
01900112010001600131010001700147010001700164810000600181012007000187030001400257
71000020027106500090027306400050028203100030028701400060029086500090029600200130
0305#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#c#144#3#article#26#
3#^rND^sCrovella^nS#^rND^sBrandão^nL#^rND^sGuimarães^nR#^rND^sFilho^nJL#^rND^sAr
raes^nLC#^rND^sVentura^nA#et al#Speeding up coeliac disease diagnosis in the dev
eloping countries^len#Dig Liver Dis#2#20070000#2007#39#900-2#20100800#a14v86n4.h
tm##
00778000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100020000960100
01800116010001700134010001900151010001700170810000600187012013700193030002800330
06500090035806400050036703100030037201400050037586500090038000200130038903500100
0402801002800412#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#c#145#4
#article#26#4#^rND^sOliveira^nRP#^rND^sSdepanian^nVL#^rND^sBarreto^nJÁ#^rND^sCor
tez^nAJ#^rND^sCarvalho^nFO#^rND^sBordin^nJO#et al#High prevalence of celiac dise
ase in Brazilian blood donor volunteers based on screening by IgA antitissue tra
nsglutaminase antibody^len#Eur J Gastroenterol Hepatol#20070000#2007#19#43-9#201
00800#a14v86n4.htm#0954-691X#Eur J Gastroenterol Hepatol##
00685000000000313000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100020000920100
01600112010001800128010001700146012012800163030001200291065000900303064000500312
031000300317014000700320865000900327002001300336035001000349801001200359#v86n4#V
:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#c#146#5#article#26#5#^rND^sMelo
^nSB#^rND^sFernandes^nMI#^rND^sPeres^nLC#^rND^sTroncon^nLE#^rND^sGalvão^nLC#Prev
alence and demografic characteristcs of celiac disease among blood donors in Rib
eirão Preto, State of São Paulo, Brasil^lpt#Dig Dis Sci#20060000#2006#51#1020-5#
20100800#a14v86n4.htm#0163-2116#Dig Dis Sci##
00481000000000265000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100019000770100017000960120
04100113030001400154710000200168065000900170064000500179031000300184014000600187
865000900193002001300202#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S
#c#147#6#article#26#6#^rND^sAccomando^nS#^rND^sCataldo^nF#The global village of 
celiac disease^len#Dig Liver Dis#2#20040000#2004#36#492-8#20100800#a14v86n4.htm#
#
00749000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100018000770100015000950100
01700110010001500127010001700142010001800159810000600177012011500183030002900298
06500090032706400050033603100030034101400060034486500090035000200130035903500100
0372801002900382#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#c#148#7
#article#26#7#^rND^sBonamico^nM#^rND^sFerri^nM#^rND^sMariani^nP#^rND^sNenna^nR#^
rND^sThanasi^nE#^rND^sLuparia^nRP#et al#Serologic and genetic markers of celiac 
disease: a sequential study in the screening of first degree relatives^len#J Ped
iatr Gastroenterol Nutr#20060000#2006#42#150-4#20100800#a14v86n4.htm#0277-2116#J
 Pediatr Gastroenterol Nutr##
00816000000000337000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750100015000770100016000920100
01700108010001900125010001600144010002000160810000600180012018000186030002900366
06500090039506400050040403100030040901400050041286500090041700200130042603500100
0439801002900449#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#c#149#8
#article#26#8#^rND^sHill^nID#^rND^sDirks^nMH#^rND^sLiptak^nGS#^rND^sColletti^nRB
#^rND^sFasano^nA#^rND^sGuandalini^nS#et al#Guideline for the diagnosis and treat
ment of celiac disease in children: recommendations of the North American Societ
y for Pediatric Gastroenterology, Hepatology and Nutrition^len#J Pediatr Gastroe
nterol Nutr#20050000#2005#40#1-19#20100800#a14v86n4.htm#0277-2116#J Pediatr Gast
roenterol Nutr##
00535000000000217000450000400060000070200480000670500020005470600020005670000040
00587010002000627090008000647080003000721180002000750170054000770180090001311100
00900221109000900230037005600239865000900295002001300304#v86n4#V:\SciELO\serial\
jped\v86n4\markup\a14v86n4.htm#S#c#150#9#article#26#9#National Institute for Hea
lth and Clinical Excellence#Clinical guideline 86. Coeliac disease: recognition 
and assessment of coeliac disease^len#20090500#May 2009#http://www.nice.org.uk/n
icemedia/pdf/CG86CostReport.pdf#20100800#a14v86n4.htm##
00563000000000253000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760120144000790300015002230650
00900238064000500247031000300252014000700255865000900262002001300271035001000284
801001500294#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#c#151#10#ar
ticle#26#10#Revised criteria for diagnosis of coeliac disease: Report of Working
 Group of European Society of Paediatric Gastroenterology and Nutrition^len#Arch
 Dis Child#19900000#1990#65#909-11#20100800#a14v86n4.htm#0003-9888#Arch Dis Chil
d##
00744000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
02700113010001500140010001500155010001600170810000600186012014900192030000400341
06500090034506400050035403100030035901400080036286500090037000200130037903500100
0392801000400402#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#c#152#1
1#article#26#11#^rND^sEsteve^nM#^rND^sRosinach^nM#^rND^sFernandes-Banares^nF#^rN
D^sFarré^nC#^rND^sSalas^nA#^rND^sAlsina^nM#et al#Spectrum of gluten-sensitive en
teropathy in first-degree relatives of patients with coeliac disease: clinical r
elevance of lymphocytic enteritis^len#Gut#20060000#2006#55#1739-45#20100800#a14v
86n4.htm#0017-5749#Gut##
00594000000000277000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100021000940120
10600115030002100221065000900242064000500251031000300256014000400259865000900263
002001300272035001000285801002100295#v86n4#V:\SciELO\serial\jped\v86n4\markup\a1
4v86n4.htm#S#c#153#12#article#26#12#^rND^sTursi^nA#^rND^sBrandimarte^nG#The symp
tomatic and histologic response to a gluten-free diet in patients with borderlin
e enteropathy^len#J Clin Gastroenterol#20030000#2003#36#6-7#20100800#a14v86n4.ht
m#0192-0790#J Clin Gastroenterol##
00725000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100015000950100
02000110010001300130010001900143010001500162810000600177012011500183030001600298
06500090031406400050032303100040032801400070033286500090033900200130034803500100
0361801001600371#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#c#154#1
3#article#26#13#^rND^sFasano^nA#^rND^sBerti^nI#^rND^sGerarduzzi^nT#^rND^sNot^nT#
^rND^sColletti^nRB#^rND^sDrago^nS#et al#Prevalence of celiac disease in at-risk 
and not-at-risk groups in the United States: a large multicenter study^len#Arch 
Intern Med#20030000#2003#163#286-92#20100800#a14v86n4.htm#0003-9926#Arch Intern 
Med##
00583000000000289000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100015000960100
01800111010001700129012008600146030001400232710000200246065000900248064000500257
031000300262014000600265865000900271002001300280#v86n4#V:\SciELO\serial\jped\v86
n4\markup\a14v86n4.htm#S#c#155#14#article#26#14#^rND^sGroover^nR#^rND^sPuri^nAS#
^rND^sAggarwal^nN#^rND^sSakhuja^nP#Familial prevalence among first-degree relati
ves of celiac disease in North India^len#Dig Liver Dis#2#20070000#2007#39#903-7#
20100800#a14v86n4.htm##
00542000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100017000790100018000960120
09200114030002200206710000200228065000900230064000500239031000300244014000700247
865000900254002001300263#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S
#c#156#15#article#26#15#^rND^sCataldo^nF#^rND^sMontalto^nG#Celiac disease in the
 developing countries: a new and challenging public health problem^len#World J G
astroenterol#2#20070000#2007#13#2153-9#20100800#a14v86n4.htm##
00618000000000265000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790120166000950300
01700261065000900278064000500287031000400292014000700296865000900303002001300312
035001000325801001700335#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S
#c#157#16#article#26#16#^rND^sMarsh^nMN#Gluten, major histocompatibility complex
, and the small intestine: A molecular and immunobiologic approach to the spectr
um of gluten sensitivity ('celiac sprue')^len#Gastroenterology#19920000#1992#102
#330-54#20100800#a14v86n4.htm#0016-5085#Gastroenterology##
00742000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100021000790100016001000100
01400116010002500130010001700155010001300172810000600185012011300191030001900304
71000020032306500090032506400050033403100040033901400060034303700330034986500090
0382002001300391#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#c#158#1
7#article#26#17#^rND^sKuczmarski^nRJ#^rND^sOgden^nCL#^rND^sGuo^nSS#^rND^sGrummer
-Strawn^nLM#^rND^sFlegal^nKM#^rND^sMei^nZ#et al#2000 CDC growth charts for the U
nited States: methods and development. National Center for Health Statistics^len
#Vital Health Stat.#2#20020000#2002#246#1-190#http://www.cdc.gov/growthcharts.#2
0100800#a14v86n4.htm##
00724000000000337000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100016000930100
01200109010001700121010001800138010001800156810000600174012011500180030001700295
06500090031206400050032103100040032601400070033086500090033700200130034603500100
0359801001700369#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#c#159#1
8#article#26#18#^rND^sDube^nC#^rND^sRostom^nA#^rND^sSy^nR#^rND^sCranney^nA#^rND^
sSaloojee^nN#^rND^sGarritty^nC#et al#The prevalence of celiac disease in average
-risk and at-risk Western European populations: a systematic review^len#Gastroen
terology#20050000#2005#128#S57-67#20100800#a14v86n4.htm#0016-5085#Gastroenterolo
gy##
00707000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100016000790100018000950100
01900113010001500132010001800147010001900165012010500184030001800289065000900307
06400050031603100030032101400070032486500090033100200130034003500100035380100180
0363#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#c#160#19#article#26
#19#^rND^sKotze^nLM#^rND^sUtiyama^nSR#^rND^sNishiara^nRM#^rND^sZeni^nMP#^rND^sde
 Sena^nMG#^rND^sAmarante^nHM#Antiendomysium antibodies in Brazilian patients wit
h celiac disease and their first-degree relatives^len#Arq Gastroenterol#20010000
#2001#38#94-103#20100800#a14v86n4.htm#0004-2803#Arq Gastroenterol##
00697000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100018000790100018000970100
01800115010002100133010001800154010001700172012009100189030001800280065000900298
06400050030703100030031201400060031586500090032100200130033003500100034380100180
0353#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#c#161#20#article#26
#20#^rND^sAlmeida^nPL#^rND^sGandolfi^nL#^rND^sModelli^nIC#^rND^sMartins Rde^nC#^
rND^sAlmeida^nRC#^rND^sPratesi^nR#Prevalence of celiac disease among first degre
e relatives of Brazilian celiac patients^len#Arq Gastroenterol#20080000#2008#45#
69-72#20100800#a14v86n4.htm#0004-2803#Arq Gastroenterol##
00713000000000313000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100015000790100020000940100
02000114010001800134010001800152012013000170030002200300065000900322064000500331
031000300336014000600339865000900345002001300354035001000367801002200377#v86n4#V
:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#c#162#21#article#26#21#^rND^sBi
agi^nF#^rND^sPezzimenti^nD#^rND^sCampanella^nJ#^rND^sVadacca^nGB#^rND^sCorraza^n
GR#Endomysial and tissue transglutaminase antibodies in celiac sera: a compariso
n not influenced by previous serological testing^len#Scand J Gastroenterol#20010
000#2001#36#955-8#20100800#a14v86n4.htm#0036-5521#Scand J Gastroenterol##
00739000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100027000790100020001060100
02100126010002000147010001900167010001600186012009800202030002900300065000900329
06400050033803100030034301400060034686500090035200200130036103500100037480100290
0384#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#c#163#22#article#26
#22#^rND^sCarneiro-Sampaio^nMM#^rND^sCarbonare^nSB#^rND^sRozentraub^nRB#^rND^sde
 Araujo^nMN#^rND^sRiberiro^nMA#^rND^sPorto^nMH#Frequency of selective IgA defici
ency among Brazilian blood donors and healthy pregnant women^len#Allergol Immuno
pathol (Madr)#19890000#1989#17#213-6#20100800#a14v86n4.htm#0301-0546#Allergol Im
munopathol (Madr)##
00706000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100016000980100
01600114010001900130010001500149010001700164810000600181012011600187030002800303
71000020033106500090033306400050034203100030034701400080035086500090035800200130
0367#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#c#164#23#article#26
#23#^rND^sBhatnagar^nS#^rND^sGupta^nSD#^rND^sMathur^nM#^rND^sPhillips^nAD#^rND^s
Kumar^nR#^rND^sKnutton^nS#et al#Celiac disease with mild to moderate histologic 
changes is a common cause of cronic diarrhea in Indian children^len#J Pediat Gas
troenterol Nutr#2#20050000#2005#41#204-209#20100800#a14v86n4.htm##
00661000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
01400115010001700129010001600146012012100162030002800283710000200311065000900313
064000500322031000300327014000700330865000900337002001300346#v86n4#V:\SciELO\ser
ial\jped\v86n4\markup\a14v86n4.htm#S#c#165#24#article#26#24#^rND^sAbu-Zekry^nM#^
rND^sKryszak^nD#^rND^sDiab^nM#^rND^sCatassi^nC#^rND^sFasano^nA#Prevalence of cel
iac disease in Egyptian children disputes the east-west agriculture-dependent sp
read of the disease^len#J Pediat Gastroenterol Nutr#2#20080000#2008#47#136-40#20
100800#a14v86n4.htm##
00664000000000301000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100014000790100015000930100
01500108010001400123010001400137012015000151030001400301710000200315065000900317
064000500326031000300331014000600334865000900340002001300349#v86n4#V:\SciELO\ser
ial\jped\v86n4\markup\a14v86n4.htm#S#c#166#25#article#26#25#^rND^sUsai^nP#^rND^s
Manca^nR#^rND^sCuomo^nR#^rND^sLai^nMA#^rND^sBoi^nMF#Effect of gluten-free diet a
nd co-morbidity of irritable bowel syndrome-type symptoms on health-related qual
ity of life in adult coeliac patients^len#Dig Liver Dis#2#20070000#2007#39#824-8
#20100800#a14v86n4.htm##
00702000000000325000450000400060000070200480000670500020005470600020005670000040
00587010003000627090008000657080003000731180003000760100019000790100017000980100
01700115010001500132010001600147010001400163810000600177012012200183030002200305
71000020032706500090032906400050033803100030034301400080034686500090035400200130
0363#v86n4#V:\SciELO\serial\jped\v86n4\markup\a14v86n4.htm#S#c#167#26#article#26
#26#^rND^sGiangreco^nE#^rND^sD'agate^nC#^rND^sBarbera^nC#^rND^sPuzzo^nL#^rND^sAp
rile^nG#^rND^sNaso^nP#et al#Prevalence of celiac disease in adult patients with 
refractory functional dyspepsia: value of routine duodenal biopsy^len#World J Ga
stroenterol#2#20080000#2008#14#6948-53#20100800#a14v86n4.htm##
